<SEC-DOCUMENT>0001558370-24-003706.txt : 20240321
<SEC-HEADER>0001558370-24-003706.hdr.sgml : 20240321
<ACCEPTANCE-DATETIME>20240321162041
ACCESSION NUMBER:		0001558370-24-003706
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240321
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Armata Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		24771663

	BUSINESS ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066
		BUSINESS PHONE:		310-665-2928

	MAIL ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AmpliPhi Biosciences Corp
		DATE OF NAME CHANGE:	20130222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>armp-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/21/2024 5:39:04 PM -->
<!-- iXBRL Library version: 1.0.8703.18788 -->
<!-- iXBRL Service Job ID: 2e5b4ad4-9ae2-40f5-8a1c-27cb22eee160 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:armp="http://www.armatapharma.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" xs:nil="true" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_ul9qV3wcdUCnzSphGpbNgw"/><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" xs:nil="true" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_es_KXy1iHU6d1i8SNShtAg"/><ix:nonNumeric contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="Hidden_teD6KMncE0i22w8XvQgfrQ">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_awY-qMH9ckyLpRHsEO2jAA">36144706</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_nRF0d8lHNEuOXDFsaUyGeg">36122932</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" id="Hidden_H4ZU_MC1IUm4pyKZsAUYAw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" id="Hidden_5FzrqHRRckSxwzPY14KzNA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" id="Hidden_bbzUoNAPc0SY4-z24H0urw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" id="Hidden_ajDNRs2kdUyVeVQJ-vTaAw">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityCentralIndexKey" id="Tc_ZYoQRtcKfkyCr07DiomEhA_2_1">0000921114</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_j81Yf9iRy0ezxDq0RZejFA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:AmendmentFlag" id="Tc__zZJQDv_4USQGfBuetlIcg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_sL46fLP8U0Cmr7LIx9jlSg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_1t18bwPO80umxL4QF2kQLg">P2Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="armp-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_ftqcXLn_pEaX9uiZCz_1XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zg5utsGBa0WpBXEonilgjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ygs2ZPk4X0u6vTMLhKW83w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wxAcBPHiMEauon7dJRUqsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pnWhyf4Eu02IKHMaDDg0eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JojKduK3ZEKIWxJbgigbMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DWvEXjElOkq1isfN-8Jmcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OMmauNLPakaOiKtpaNXVNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_No_HAmgL8EWAhkjjyjrUKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_i7XUFu_B10mLUKIJzKfMTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_uL_pp_97UEyeShgihirvbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OUfmlLp-ykK4CLqXmY3zwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_ZFDHBJzLP0GHlHUMt2FQew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_q0GtuKNJvE-SBmuEJbJm6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_1q8OCMCB00i-LLEH5pkdLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Cx9LlceetkeHRu-h_tXn_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_sL46fLP8U0Cmr7LIx9jlSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ylEWFQLG5kiObFZVsEjhXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_NeQe2I2uKUmdVatAsYayIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_oTLYGAZfJ0aCfMIzYcDvAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_15_2020_To_6_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_MA9PVOA_T0GwtfbjiWZ8PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_v4Q6NyrSfkq9XoHpzL1dIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_3nc2z43Z7UGKrOWYMeqg2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_REZg-uX-1EKwp-ERlgSV_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_wkZ_l3MDG06ZzDCA_d-g9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A6LMOqmIk0W80NtUZ42iYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7rH9B56et06bczua6JeANw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xqoolKPjOkiiQNt83POWzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_-vi_PXcqgkGHr5XNE2CtDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_fGX9O5gmiU6OnmLCkIvOIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_1GHmaB3J8k2Q9CUoft7lLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n_Dh4or6E0Sk6Dr2xnxPkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_sBfL2nm_uUqs1c4xDma_2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_GYmMI98-LUq4vo-3aWzwDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Te5w4AY0_02NlOunnmW1LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_BOYj4BFoD02NQ0BXyjD2Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ptpXGjY7OUuRjoPo1n6BLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WMYo7GLLwEe8FdOQJ86O9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vc4GxSB8DkissaxivoExGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsInc.Member_BsIuyO6JukO_7P1mhHHqVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">armp:ArmataPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_hIBa8orrkkC3OY4OCziUrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_VjefCaiPsUS7e-BdlXj-7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_sJyIDh6BPkGLuZGEzoAROA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_W3KAPH27bUOTG34yisjgIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_C8m8rkPr3kO2_d83rkvc0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPostModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_4FazMg1MoUW2z0CAQf8ezg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_TrUOd3F28EaQGoWWyXJpuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_dpQ0qLj7T0mpc0O2hZcCzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_d5V1utBQS0W089AQBKdTBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_sJ5c5RHAEEuMXqt3TUVkIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_XmFAWm3wPEyeDD2bMVjmxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_pXWFLLYcXEmSfXZV4q_7FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_0FkAKCIhMkeJG_58ABDppQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_tyr5b_wy9ECTpratVa4vhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_RXIGKVqz6EWLhEi53nl4sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_w_tgP8EIkkGCdbFSjG9OBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_Zq7tR4QDd0qlIGHQ77DS4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_AxXerjEGLUa8RmPTJVbwoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_veV6l1wDOE6rGIRVVof-6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_pMc1sqe3X0KGAnGFAEcYPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_rcx6iUYUmUmx_O6MTosjtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_FHVNbN2hzEOd40sdvSt3oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_EWq8FVfJaUe4RYQsqoDOaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:SharesIssuableUponConversionOfConvertibleLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6Zjp426i-0Ws_0siDNehrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_om6vLPiiz0SKnHyQ-isXPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_SYddo8Ixd0SHaimuYPVT7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_nxls9YDyCkOu7B6yakefXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WsPyfLbv_Uq8yEsOaJ4xVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6DKSiFkyFkW5utHfv7wgDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_QB0XCwT_Y0acqtRcKca_zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbcT0OlsRk2u09atbDRY2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_J8WtBYCv8U2tTw_Q8rPekw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_15_2024_x3SUHrPdAUmw1TrhlAZLHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_79MM9fi5r0mpadFpZPg7sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_BXtfSrwb30eZ5SWw-b7Zuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_5dm2L74wiEGYYudTedh7mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_4KHIn5trmUGr81rnUbSvxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_kwVoHQWl5EakS1pp8Dn91w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_doi9Uq0Yh0K8BJ8ETe-s1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_l7DZ4uAjHkSVG38MOoqUEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_FHhuhYDYgkSEqnz0dDB17g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_8VpuTm72C0OqZUC8eh9aAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QOYAQImRME-BHccqHOTQxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_lPXHo7biDEeQ7_vk8pbcAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_MuuXgJmTa0iJw2pEu82wXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_mj_DWLuDI0Cq6OS1KhCggw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-29</xbrli:startDate><xbrli:endDate>2022-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_O-jDsojMjkyI7AvWBhYrOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPostModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPreModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_iZsH0I5d9UyGDhfUVO7qAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_eys6RJJzYEKEN14qoaYnug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_5gtvl7giZEGwZQOlYfq5Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QO_xn3VwYkyovdqWx605rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wizMKQKiNEejMmObIFsIeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_LCqVjfMIO06J26dfzj6dGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Fq3iw-UGaEOhlQJp0l-z4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_gq2pn8IK_0adzHKv0TJgmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_azF0LYLH0Eq4EiRxHIMZRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_HNJuosHgFUer-rys1t2UBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_TJiIyKEV50aTZhkCduAAZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_qhslJqPSVkGxmdvKQT37fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pukUqhbV7Ei-VqpNu2EWAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_4ewXEPeSJk66n83-o6k-PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TbUu3jFyVUu5rQXxMkwPXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_Vx583tTlMEyE357MszS1Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mHtBiNhPKE6hrpyOdzp9qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_hUTioPDLnkObuSOBkhrCew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tsvjujuR6UaiVETAvUn3jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_Ge-QKxFKqUWwu7oL5XxJ8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_83RZzW5ygkaAS8MPk5N2xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_czlMXp6LS0CZBIy4EFMggg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_3pWA20zXBEiKjqY55V5Qxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Wv6oSPAXP0CJ0UiTo6AKQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_yQKRGpMabkGpnWs-0mIn_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_QVyakBDhtUmt0Ago8wBrDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-13</xbrli:startDate><xbrli:endDate>2020-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg"><xbrli:measure>armp:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg"><xbrli:measure>armp:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_1k3oA3frkU6EqwnuCcyDiw"><xbrli:measure>armp:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:0pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_9306c7b5_835d_46f0_9e15_bb9b07a926f7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:3pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentType" id="Narr_0Mi1m77GB063RpBPwhB-Cw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">(Mark&#160;One)</p><a id="_0c44c818_c17a_4219_82c4_c382607a4e5d"></a><a id="Tc_Oc1Ac17lYE6lo1rtvwjaBQ_0_1"></a><a id="Tc_pL7cXCdDyECYWKfyZ4ryXg_1_0"></a><a id="Tc_6zqLbHahx0-CIsBu3apBtA_2_1"></a><a id="Tc_854vGkXMlUWsCyY_k8QMqQ_3_1"></a><a id="Tc_-9NgpXQpgkq_9f1jbHtRKg_4_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentAnnualReport" id="Tc_jrMmLRfNHUSh_ozg0Q0aSw_0_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentPeriodEndDate" id="Narr_S8wQ_5hqMEKwG8RLjuzbqg"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:CurrentFiscalYearEndDate" id="Narr_ELsvI0OkU0eKBBodSCDBSw"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentFiscalYearFocus" id="Narr_2hIgdxn8UUmtonNkUqOfnw"><b style="font-size:9pt;font-weight:bold;">2023</b></ix:nonNumeric></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">or</b></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentTransitionReport" id="Tc_XSUn2DJUlEudPnQ4dJAMeA_3_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityFileNumber" id="Narr_wDxR9oXZXEuM37HqnnP9TA"><b style="font-size:9pt;font-weight:bold;">001-37544</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityRegistrantName" id="Narr_xPkdkdeE20GNNupSWU7F6g"><b style="font-size:9pt;font-weight:bold;">ARMATA PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_d761a948_8d19_417f_a17a_5c7a20383030"></a><a id="Tc_Hr4ivvkmq0WDgocxvkoNqg_2_0"></a><a id="Tc_pcEQAs9pJ0qdt7zLDHIPvQ_2_2"></a><a id="Tc_g-0aLc7FZUGig7k5nnX1qw_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_ftKtrFtqlE2n7VeX6HTsVA_0_0"><b style="font-size:9pt;font-weight:bold;">Washington</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityTaxIdentificationNumber" id="Tc_PGqROT7gy0W3M6wObbFIHw_0_2"><b style="font-size:9pt;font-weight:bold;">91-1549568</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">incorporation and organization)</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityAddressAddressLine1" id="Narr_ao7IULcQmkenafuP5sIrfw"><b style="font-size:9pt;font-weight:bold;">5005 McConnell Avenue</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityAddressCityOrTown" id="Narr_AHVvza2nOUeIB2TidociLg"><b style="font-size:9pt;font-weight:bold;">Los Angeles</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityAddressStateOrProvince" id="Narr_D6xdyTsU3UOwRS340U6wCg"><b style="font-size:9pt;font-weight:bold;">CA</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;white-space:pre-wrap;">  </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityAddressPostalZipCode" id="Narr_sC8JVhRVXUSMZMzqO41beQ"><b style="font-size:9pt;font-weight:bold;">90066</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices, including zip code)</p></td><td style="vertical-align:top;width:50.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:CityAreaCode" id="Narr_ZGpf9pld5Eu6cyXFyoGJlQ"><b style="font-size:9pt;font-weight:bold;">310</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:LocalPhoneNumber" id="Narr_t1JKX5QHLEaTkW2-4PcSVg"><b style="font-size:9pt;font-weight:bold;">665-2928</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p></td></tr><tr><td style="vertical-align:top;width:49.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:50.14%;margin:0pt;padding:0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_2e875ddc_c1e8_42c1_8e36_2381b7e0f850"></a><a id="Tc_RUujDiWaSU6pjcFrE4oALg_0_0"></a><a id="Tc_-tpa-cFIvU-ouBaDL6aq_A_0_2"></a><a id="Tc_bc8EHoTZHEiFOQn2-vtBYQ_0_4"></a><a id="Tc_cAbLZxEjj06NEzZXDSb5Xg_1_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:10.45pt;"><td style="vertical-align:bottom;width:29.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style="height:11.75pt;"><td style="vertical-align:bottom;width:29.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:Security12bTitle" id="Narr_ttaDihYj_UOy13df_9ZItA"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric><span style="font-size:8pt;">, par value $0.01 per share</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:29.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:TradingSymbol" id="Tc_whw7u4grk06lRHZz305I1g_1_2"><span style="font-size:8pt;">ARMP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:SecurityExchangeName" id="Tc__wcVeWGvvUmPrph7mxXQgw_1_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section 12(g) of the Act: None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_O-3yJtp3BEuDAtRNQaDRJQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityVoluntaryFilers" id="Narr_9ai0PTex0UWNKVQak8NFuA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityCurrentReportingStatus" id="Narr_xWXQnaTH7U6fEzc-kfRsVw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityInteractiveDataCurrent" id="Narr_42miyy3aCEGZ6Q1hO0jQaQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;">Large accelerated filer&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Accelerated filer&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityFilerCategory" id="Narr_xmsXoCMri0Gkj378lO_MAQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntitySmallBusiness" id="Narr_Jt7hKuWldUmlGzgI_zsHkw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityEmergingGrowthCompany" id="Narr_w1aUh5le2kKexNCsjkCzAw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_n6PUqm0l6EKJaaRUEFfsWg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.24;text-indent:18pt;margin:0pt 2.9pt 5pt 0pt;"><span style="color:#231f20;font-size:8pt;">I</span><span style="font-size:8pt;">f securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_Ych_fuQhKUCymx2WNdO3Vg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.23;text-indent:18pt;margin:0pt 2.85pt 0pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.23;text-indent:18pt;margin:0pt 2.85pt 0pt 0pt;"><span style="font-size:4pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:EntityShellCompany" id="Narr_dBBdK9QrckeahzXgvXZBVw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">As of June&#160;30, 2023, the aggregate market value of voting stock held by non-affiliates of the Registrant, based on the closing price of the Common Stock on June&#160;30, 2023 (the last business day of the Registrant&#8217;s most recently completed second quarter) as quoted on the NYSE American, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2023_J8WtBYCv8U2tTw_Q8rPekw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_UQ4BW9kuJ0uCi2RTDlXJPA">12.5</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt;">As of March 15, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_15_2024_x3SUHrPdAUmw1TrhlAZLHg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_u-lKavz7gEeS9XOwNk5qUw">36,148,539</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Document Incorporated by Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2023, are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><a id="_3706c823_5ee7_46ff_bfbd_5eca7335d5a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 9pt 0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 9pt 0pt;">ARMATA PHARMACEUTICALS, INC. </p><a id="Item12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page&#160;No.</b></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTI_129284"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUSINESS_806208"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUSINESS_806208"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6 </p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_490547"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_490547"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">44</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUNRESOLVEDSTAFFCOMMENTS_454967"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUNRESOLVEDSTAFFCOMMENTS_454967"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">63</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">63</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item3LEGALPROCEEDINGS_563299"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item3LEGALPROCEEDINGS_563299"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MINESAFETYDISCLOSURES_516138"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MINESAFETYDISCLOSURES_516138"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTII_630154"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">65</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">66</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">66</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">76</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">76</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsAndProcedures"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsAndProcedures"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">102</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOTHERINFORMATION_104987"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOTHERINFORMATION_104987"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">103</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIII_156407"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11EXECUTIVECOMPENSATION_44857"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11EXECUTIVECOMPENSATION_44857"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_12._"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_12._"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PRINCIPALACCOUNTANTFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIV_519682"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15EXHIBITS_865142"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15EXHIBITS_865142"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">104</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_988645"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_988645"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">109</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9pt;" href="#SIGNATURES_275590"><span style="font-style:normal;font-weight:normal;">Signatures</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;">and Power of Attorney</span></a></p></td><td style="vertical-align:bottom;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;">110</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3ba23400_13cb_4e93_8108_b5962def9b44"></a><a id="FLS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K (this &#8220;Annual Report&#8221;) and certain information incorporated herein by reference contain forward-looking statements, which are provided under the &#8220;safe harbor&#8221; protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding anticipated operating losses, capital requirements and needs for additional funds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital when needed and to continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our clinical development plans, including planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our research and development plans, including our clinical development plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to select combinations of phages to formulate our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our development of bacteriophage-based therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential use of bacteriophages to treat bacterial infections; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential future of antibiotic resistance;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivity to antibiotics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned development strategy, presenting data to regulatory agencies and defining planned clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture and secure sufficient quantities of our product candidates for clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drug product candidates to be supplied by us for clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for bacteriophage technology being uniquely positioned to address the global threat of antibiotic resistance; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our anticipated regulatory pathways for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the activities to be performed by specific parties in connection with clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pursuit of additional indications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to leverage the experience of our management team and to attract and retain management and other key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the capacities and performance of our suppliers, manufacturers, contract research organizations (&#8220;CROs&#8221;) and other third parties over whom we have limited control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to staff and maintain our Marina del Rey production facility under fully compliant current Good Manufacturing Practices (&#8220;cGMP&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the actions of our competitors and success of competing drugs or other therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations with respect to future growth and investments in our infrastructure, and our ability to effectively manage any such growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and potential growth of the markets for any of our product candidates, and our ability to capture share in or impact the size of those markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the benefits of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential market growth and market and industry trends;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining collaborations with third parties including our partnerships with the Cystic Fibrosis Foundation (&#8220;CFF&#8221;), and the U.S. Department of Defense (the &#8220;DoD&#8221;); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential future collaborations with third parties and the potential markets and market opportunities for product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve our vision, including improvements through engineering and success of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to meet anticipated milestones in the development and testing of the relevant product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to be a leader in the development of phage-based therapeutics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected use of proceeds from the $16.3 million DoD grant; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of government regulation and regulatory developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates regarding future expenses, revenues, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding future planned expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve and maintain effective internal control over financial reporting in accordance with Section&#160;404 of the Sarbanes-Oxley Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of any of our products and product candidates; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect our intellectual property, including pending and issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to operate our business without infringing the intellectual property rights of others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance our clinical development programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the ongoing conflict between the Ukraine and Russia and the recent and potential future bank failures or other geopolitical events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">statements of belief and any statement of assumptions underlying any of the foregoing. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions. These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section entitled &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain. Given these uncertainties, you should not place undue reliance on any of the forward-looking statements included in this Annual Report. In addition, this Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report includes trademarks and registered trademarks of Armata Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As used in this Annual Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Armata Pharmaceuticals, Inc. and its wholly owned subsidiaries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_65dad61f_1a7b_43d2_b240_031cce312fe3"></a><a id="PARTI_129284"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1BUSINESS_806208"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;&#160;BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Overview </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We see bacteriophages as an alternative to antibiotics and an essential response to growing bacterial resistance to current classes of antibiotics. Bacteriophages or &#8220;phages&#8221; have a powerful and highly differentiated mechanism of action that enables binding to and killing of targeted bacteria while preserving the human microbiome. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as <i style="font-style:italic;">C. difficile</i>. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or &#8220;superbug&#8221; strains of bacteria. We are a leading developer of phage therapeutics and are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. We are completing two critical Phase 2 trials to ensure a pathway towards pivotal Phase 3 trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally-occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific host-engineered current good manufacturing practice (&#8220;cGMP&#8221;) manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for advanced development. We are advancing two lead candidates to address both chronic and acute bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for&#160;<i style="font-style:italic;">Pseudomonas aeruginosa </i>(<i style="font-style:italic;">&#8220;P. aeruginosa&#8221;</i>). On October 14, 2020, we received the approval to proceed from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for our Investigational New Drug (&#8220;IND&#8221;) application for AP-PA02. In the first quarter of 2023, Armata announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis (&#8220;CF&#8221;) and chronic pulmonary&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>infection. Data indicated that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetcs (PK) findings confirm AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum and exposure achievement relatively consistent across patient subjects. Additionally, bacterial levels of <i style="font-style:italic;">P. aeruginosa </i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. In addition, a correlation was seen between increasing phage dose and reduction in the bacterial load supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled antibiotics. This study was supported by the Cystic Fibrosis Foundation (&#8220;CFF&#8221;), which granted Armata a Therapeutics Development Award of $5.0 million. Following these promising Phase 1b/2a results of favorable safety and tolerability profile and plausible mechanism of action, an additional confirmatory Phase 2 trial was initiated in patients with similar chronic pulmonary infections due to <i style="font-style:italic;">Pseudomonas aeruginosa</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (&#8220;NCFB&#8221;). We initiated a Phase 2 trial (&#8220;Tailwind&#8221;) in NCFB in 2022 and reported first patient dosing in the first quarter of 2023. The &#8220;Tailwind&#8221; study is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 phage therapeutic in subjects with NCFB and chronic pulmonary <i style="font-style:italic;">Pseudomonas aeruginosa</i><span style="white-space:pre-wrap;"> infection.  We are actively accelerating enrollment and increasing phage dosing with the goal of defining a safe and promising biologic correlation for a Phase 3 definitive trial in 2025 which will evaluate phage as an alternative to antibiotics in chronic pulmonary infections.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In parallel, we have an acute bacterial infection clinical development plan focused on <i style="font-style:italic;">Staphylococcus aureus </i>bacteremia, a difficult-to-treat and often life-threatening infection that can result in high morbidity and mortality and for which bacterial resistance to antibiotics is growing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are advancing a phage product candidate for<i style="font-style:italic;">&#160;Staphylococcus aureus</i>&#160;(<i style="font-style:italic;">&#8220;S. aureus&#8221;</i>) for the treatment of complicated&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia, AP-SA02. On June 15, 2020, we entered into an agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we expect to receive a $15.0 million&#160;grant and entered into a three-year program administered by the U.S Department of Defense (the &#8220;DoD&#8221;) through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. The grant is being used to partially fund a Phase 1/2, multi-center, randomized, double-blind, placebo-controlled dose escalation study that will assess the safety, tolerability, and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia. On November 17, 2021, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-SA02. We are focused on accelerating enrollment of the Phase 2a segment of the &#8220;diSArm&#8221; study, evaluating safety with higher intravenous doses, which is possible due to the high purity of Armata&#8217;s phage product candidates. We are committed to developing a definitive efficacy trial in 2025 focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilize of broad-spectrum antibiotics and their detrimental impact on the normal human microbiome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On August 1, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-SA02, in a second indication, prosthetic joint infections (&#8220;PJI&#8221;). We had planned to initiate a Phase 1b/2a trial in 2023, however in light of the growing concerns of both PJI and wound infections, we are revising the protocol to include both indications. Driven by data from the bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic joint infections and/or wound infections caused by&#160;<i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We remain committed to conducting randomized controlled clinical trials required for FDA approval in order to move toward the commercialization of its phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent </b><b style="font-family:'Times New Roman;font-weight:bold;">Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="color:#231f20;font-style:italic;">2024 Credit Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, we entered into a credit and security agreement (the &#8220;2024 Credit Agreement&#8221;) for a loan in an aggregate amount of $35.0 million with Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) </span>(collectively, &#8220;Innoviva&#8221;), our <span style="font-family:'Times New Roman;">principal stockholder and a related party. The 2024 loan bears interest at an annual rate of 14% and matures on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by our domestic subsidiaries, and the loan is secured by substantially all of our assets. Concurrently with the execution of the 2024 loan, we amended certain provisions of the Convertible Loan and Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2023 Credit Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;">On July 10, 2023, we entered into a credit and security agreement (the &#8220;2023 Credit Agreement&#8221;) for a loan in an aggregate amount of $25.0 million with Innoviva. This loan bears interest at an annual rate of 14% and matures on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the loan is guaranteed by our domestic subsidiaries, and the loan is secured by substantially all of our assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">2023 Convertible Credit Agreement </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:135.42pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">On January 10, 2023, we entered into a secured convertible credit and security agreement (the &#8220;Convertible Credit Agreement&#8221;) with Innoviva, which was amended in July 2023. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30.0 million, which bears interest at a rate of 8.0% per annum, and matures on January 10, 2025. Repayment of this loan is guaranteed by our domestic subsidiaries and foreign material subsidiaries, and the convertible loan is secured by substantially all of our assets and the subsidiary guarantors. The Convertible Credit Agreement provides for various conversion and repayment options, including the conversion of principal and accrued interest into the shares of common stock upon a Qualified Financing (as defined below) and we have an option to repay the loan prior to maturity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The Convertible Credit Agreement provides that if there is a financing from new investors of at least $30.0 million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of common stock, at a price per share equal to a 15.0% discount to the lowest price per share for common stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required us to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which we originally filed on February 13, 2023 and which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of common stock at a price per share equal to the greater of book value or market value per share of common stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart summarizes the status of our phage product candidate development programs and partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20231231x10k003.jpg" alt="Graphic" style="display:inline-block;height:135.42pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:476.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy </b></p><a id="_Hlk159345934"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to demonstrate the safety, tolerability and definitive efficacy of multiple phage products in randomized controlled clinical trials required for FDA approval and to support commercialization in both acute and chronic indications of high unmet medical need, including bacterial infections caused by multidrug-resistant and difficult-to-treat pathogens. Our fully integrated product development capabilities from bench to clinic enable the discovery of optimal phage product candidates, and include the effective adaptation of phages to uniquely engineered host cells, essential for efficient process development and resulting in improved purity, stability, and manufacturability, to power rigorous clinical trials. Our microbiological surveillance and synthetic biology capabilities drive long-term product life cycle management. We intend to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance clinical trials of AP-PA02 in patients with CF </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and NCFB, both chronic pulmonary </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infections, as an alternative to inhaled antibiotics.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:214.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Develop bacteriophage therapeutics, including AP-PA03, for the treatment of other antibiotic-resistant and difficult-to-treat </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infections such as acute bacterial pneumonia. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Advance clinical trials of AP-SA02 in patients with bacteremia due to acute infection with </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">, including MRSA, as an alternative to antibiotics or to significantly limit duration of  antibiotic use.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Develop AP-SA02 for the treatment of other antibiotic-resistant and difficult-to-treat </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infections such as PJI and wound infections.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Need for New Anti-Infective Therapies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The introduction of penicillin in the early 1940s marked the start of the antibiotic discovery era, during which more than 20 new classes of antibiotic were marketed over a period of three decades. The first case of the &#8220;superbug&#8221;, Methicillin-resistant <i style="font-style:italic;">S. aureus</i> (&#8220;MRSA&#8221;), in the United States occurred in 1968. A void in the discovery of new classes of antibiotics lasting approximately 30&#160;years drove the emergence and spread of antibiotic-resistant bacteria, including vancomycin-resistant <i style="font-style:italic;">enterococci</i> (&#8220;VRE&#8221;), and pandrug-resistant strains of <i style="font-style:italic;">Acinetobacter baumannii</i>, <i style="font-style:italic;">P. aeruginosa</i>, <i style="font-style:italic;">Escherichia coli</i> and <i style="font-style:italic;">Klebsiella pneumoniae</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20231231x10k004.jpg" alt="Graphic" style="display:inline-block;height:210.85pt;left:0.31%;padding-bottom:2.15pt;position:relative;top:0pt;width:453.6pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The dramatic and continuous emergence of antibiotic-resistant bacteria, and the lack of novel next generation antibiotics in the pipeline, has prompted calls to action from many of the world&#8217;s major health bodies such as the U.S. Centers for Disease Control and Prevention (the &#8220;CDC&#8221;), and the World Health Organization (the &#8220;WHO&#8221;), who warn of an &#8220;antibiotic cliff&#8221; and a &#8220;post-antibiotic era.&#8221; A growing list of infections&#160;&#8211; such as pneumonia, tuberculosis, bacteremia/septicemia, gonorrhea, and foodborne diseases&#160;&#8211; are becoming harder, and sometimes impossible, to treat as antibiotics become less effective. In 2009, the European Antimicrobial Resistance Surveillance System concluded that &#8220;the loss of effective antimicrobial therapy increasingly threatens the delivery of crucial health services in hospitals and in the community.&#8221; This conclusion was reinforced by The Antimicrobial Availability Task Force of the Infectious Diseases Society of America (the &#8220;IDSA&#8221;), and the European Centre for Disease Prevention and Control in conjunction with the European Medicines Agency (the &#8220;EMA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The IDSA and the WHO regard antimicrobial resistance as one of the greatest threats to human health worldwide. The Review on Antimicrobial Resistance, a global project commissioned by the British government and the Wellcome Trust, reports that at least 700,000 people die each&#160;year of drug resistance in illnesses that include bacterial infections. The report predicts that, by 2050, 10 million lives a&#160;year worldwide (more people than currently die from cancer) and a cumulative $100 trillion of economic output are at risk due to the rise of drug-resistant infections. The CDC estimates </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that at least 2 million people in the United States develop infections due to resistant bacteria resulting in more than 23,000 deaths each&#160;year. A 2018 study from the Washington University School of Medicine indicated that the number of deaths would be between 153,113 and 162,044, which suggests that the CDC estimates may be dramatic underestimations. It is estimated that 50% of hospital-acquired infections are resistant to first-line anti-infective therapies. The cumulative annual healthcare costs for treating drug-resistant bacterial infections in the United States alone is calculated at $21 billion to $34 billion, with over 8 million additional hospital&#160;days. It is for these reasons that we believe there is a critical and pressing need to develop new and novel antibacterial therapies to combat the rise in antibiotic-resistance bacteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Increased public funding as well as foundation funding will be essential to bring new approaches forward through full cycle development. Definitive clinical trials to test promising novel therapeutics as alternatives to classic antibiotics must be funded in order to combat the growing issue of drug-resistant bacterial infections across the globe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Infective Therapeutics Market </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market opportunity for antibiotics is large, with the market estimated to exceed $58 billion in annual sales globally by 2027. Almost one in every five deaths worldwide occurs as a result of infection and, according to the WHO, many bacterial infections will become difficult or impossible to cure as the efficacy of current standard-of-care antibiotics wanes. Despite the advances in antimicrobial and vaccine development, infectious diseases still remain the third-leading cause of death in the United States and the second-leading cause of death worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of new antibiotics approved by the FDA and other global regulatory authorities has declined consistently over the last two decades. A recent review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21, and there are fewer than 30 under development in clinical trials against pathogens considered critical by WHO such as&#160;Pseudomonas aeruginosa This is compared with more than 2,000 new product candidates in the drug pipeline for cancer. Historically, the success rate from Phase 1 to marketing approval is only one in five for infectious disease products. We, therefore, believe there is a need for new approaches to treat serious and life-threatening bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Hospital-acquired (nosocomial) infections are a major healthcare problem throughout the world, affecting developed countries as well as resource-poor countries. The WHO reports that hospital-acquired infections are among the major causes of death and increased morbidity among hospitalized patients. In the US alone, the CDC estimates that hospital-acquired infections account for ~1.7 million infections and 99,000 associated deaths each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compounding the above situations is the alarming and continuing rise in the prevalence of multidrug-resistant bacterial infections. This, coupled with the lack of new antibiotics in current discovery and development pipelines, has generated a significant clinical management problem worldwide, leading to increases in morbidity and mortality due to these antibiotic-resistant bacteria as well as increases in healthcare costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bacteriophage therapy has the potential to be an alternative to antibiotics in treating bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bacteriophage Therapy </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bacteriophages, also known as phages, are ubiquitous viruses, found wherever bacteria exist. It is estimated there are more bacteriophages than every other organism on Earth combined. Phages are natural predators of bacteria, and the name &#8220;bacteriophage&#8221; translates as &#8220;eaters of bacteria&#8221;. Phages infect and rapidly kill the bacterial host by multiplying inside and then bursting through the cell membrane in order to release the next generation of phages into the surrounding environment, ready to infect and kill additional nearby target bacterial cells until the bacteria have been eliminated. When there are no target bacteria left for the phages to infect, the phages are removed through the body&#8217;s natural clearance processes. In contrast to broad-spectrum antibiotics, phages are highly targeted to specific bacteria, and do not attack the normal human microbiome on the skin, the gut or other areas critical to maintaining our defenses against more opportunistic infections like <i style="font-style:italic;">C. difficile</i>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:214.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:214.65pt;width:430.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages have the potential to provide both an alternative to, and/or a synergistic approach with, antibiotic therapy. Phages offer several differentiating attributes compared to classic antibiotics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Highly specific/selective bactericidal agents, sparing the microbiome. Since each strain of phage specifically binds and kills only a particular bacterial host, phages may be a precision tool to reduce or eliminate specific strains of harmful bacteria without exposing patients to risks of eliminating the beneficial bacteria of our microbiomes through the use of current standard of care antibiotics. Such risks could include serious opportunistic infections such as </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Clostridium difficile</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infection and VRE infection.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No known toxicities associated with chemical structures. Antibiotic use is often associated with toxicities (e.g. kidneys, bone marrow, hearing). Phages are highly unlikely to carry structural features or be metabolized by the body to produce structural elements that confer chemical toxicities associated with small molecules.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Distinct mechanism of bactericidal action. Since phages use different mechanisms of action, their activity is independent of antibiotic resistance and as such could provide much needed therapy for multi-drug resistant infections.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Replication competent. It is possible that phage replication at the site of infection facilitates effective dosing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">High potential for added functionality through genetic engineering. Phage genomes can be modified to confer benefits that address limitations, if any, that are observed during clinical development. Traits such as host range, burst size and biofilm disruption can be improved. These potential improvements help to assure phage therapeutics efficacy in difficult settings and over time as new isolates emerge.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages were discovered in 1915 at the Pasteur Institute and were shown to kill bacteria taken from patients suffering from dysentery. Furthermore, it was noted that phage numbers rose as patients recovered from infection, suggesting a direct association. Throughout the pre-antibiotic era, phages were widely used as an effective therapeutic agent to combat a variety of bacterial infections. However, phage use was displaced by the common use of broad-spectrum antibiotics in the early 1940s, with antibiotics being seen for many&#160;years as the superior treatment to combat bacterial disease, particularly in Western medicine. This attitude persisted until the development of the wide-ranging, and in some cases total, resistance to antibiotics seen within the last 10&#160;years. We believe that the continuing emergence of antibiotic-resistant bacteria provides the opportunity to revitalize phage use.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are hundreds of cases published in the scientific and medical literature describing the use of phage therapy in human medicine over more than 90&#160;years, mostly in the former Soviet Union and Eastern Europe. Phage therapy is still commonly used today in Russia, Poland and Georgia, with numerous reports of success in treating serious infectious diseases caused by many pathogenic bacterial species. However, the safety and effectiveness of these therapies have not been conclusively established due to the lack of randomized controlled clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Recently, Western medicine has seen a rise in the clinical evaluation of phages. In the United Kingdom, two early-stage clinical trials of <i style="font-style:italic;">P. aeruginosa</i> phage cocktails showed no adverse effects in patients. One study (Phase 1/2a) demonstrated efficacy in a small trial of 12 patients with chronic multidrug-resistant <i style="font-style:italic;">P. aeruginosa</i> otitis treated with a cocktail of six natural phages. Since 2016, there have been a number of &#8220;compassionate use&#8221; cases in which patients suffering from various serious or life-threatening infections have been treated with phage therapy under physician-sponsored Emergency Investigational New Drug Applications with high rates of success and no adverse effects attributable to the therapy. Most notable was the well-documented case in 2016 of Tom Patterson, whose disseminated multidrug-resistant <i style="font-style:italic;">Acinetobacter baumannii</i> infection was successfully treated with phage-based therapeutic cocktails administered intravenously and intraperitoneally. An 82-year-old male with an aortic graft (heart implant) infected with pandrug-resistant <i style="font-style:italic;">P. aeruginosa</i> was successfully treated with a single application of phage, marking Yale University&#8217;s first case using phage therapy under Emergency IND. By early 2019, Yale University had treated more than half-a-dozen compassionate use cases, the majority individuals with CF with antibiotic-resistant lung infection. In 2018, a 15-year-old CF patient with a disseminated <i style="font-style:italic;">Mycobacterium abscessus</i> lung infection was treated intravenously with a three-phage cocktail following lung transplantation. That patient&#8217;s case represents another milestone for phage therapy &#8211; the first person to be treated with genetically modified phages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A consistent takeaway from these early phage therapy uses, and from the more recent clinical trials and compassionate use cases, is that phage therapy is generally well tolerated, with generally no reports of serious adverse events when administered by inhalation. Intravenous use of phage has been more limited due to bacterial cell wall and other contaminants in the final phage product. Phages have previously received approvals for use in cleaning food facilities and as a food additive for human consumption by the FDA and the EMA, and as agricultural bacterial pest treatments by the United States Department of Agriculture. Phages have met the criteria to be considered as &#8220;generally recognized as safe&#8221;, or &#8220;GRAS&#8221;, in the food and food contact surface categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the growing problem of antimicrobial resistance, we believe it is essential that phage safety and efficacy be demonstrated by conducting rigorous well-powered clinical trials required for FDA approval, in order to move toward commercialization of phage therapy as an alternative to traditional antibiotics and to bring a potential solution to all patients suffering from drug-resistant bacterial infections. Armata has been focused on enhancing the overall quality of its manufactured phages through engineering and adaptation to maximize production titers while ensuring high level of purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Target Markets and Medical Need</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pulmonary Bacterial Infections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P. aeruginosa</i> is consistently recognized by the CDC, and other public health agencies, as among the most dangerous and difficult-to-treat pathogens associated with significant impacts on health, quality of life, and economic burden. Regular standard-of-care antibiotics treatments often fail to completely eradicate the pathogen, and the problem is further complicated by rising rates of antibiotic resistance due to a growing number of multidrug-resistant isolates emerging, particularly with long term use. <i style="font-style:italic;">P. aeruginosa</i> is particularly problematic for CF patients given that their already compromised immune system leads to chronic infections. In addition to CF lung infections, <i style="font-style:italic;">P. aeruginosa</i> is responsible for other respiratory infections with high unmet medical need, including NCFB and hospitalized pneumonia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">P. aeruginosa Infection is a Major Cause of Morbidity and Mortality in Cystic Fibrosis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CF is a genetic disease caused by mutations in the CF transmembrane conductance regulator (&#8220;CFTR&#8221;) gene. CF affects over 40,000 people in the United States (105,000 people worldwide) with approximately 1,000 new diagnoses per&#160;year. Dysfunction of the CFTR gene leads to dysfunction in multiple organs, but particularly the lungs, where a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">failure of hydration of airway secretions results in thick mucus, chronic inflammation, airway remodeling, and recurrent infections. Lung function continues to decline over time, punctuated by pulmonary exacerbations with increased cough, shortness of breath, and infections that result in rapid declines in lung function. For these reasons, CF remains the most common fatal hereditary lung disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outcomes for people with CF have improved significantly in recent&#160;years through early screening, the development and use of CFTR modulators, and other therapies. However, people with CF still suffer significant morbidity and mortality due to pulmonary infection with <i style="font-style:italic;">P. aeruginosa</i>. Chronic <i style="font-style:italic;">P. aeruginosa</i> infections occur in 45% of CF patients by age 40, and are strongly associated with worsening lung function, frequent pulmonary exacerbations, and increased mortality. In 2022, the median predicted survival age was 68&#160;years. Although many patients with chronic <i style="font-style:italic;">P. aeruginosa</i> benefit from routine suppressive inhaled antibiotic therapy, large numbers of CF patients still experience clinical deterioration despite these treatments, hence the need for more effective therapies, ideally with a different mechanism of action compared to traditional antibiotics, for the treatment of chronic <i style="font-style:italic;">P. aeruginosa</i> infection. GlobalData projects that total antibiotic sales in the CF market will exceed $900 million in the United States in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Cystic Fibrosis Bronchiectasis</i></p><a id="_Hlk63201476"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NCFB is a chronic respiratory disease affecting more than 100,000 people in the United States and 200,000 people in Europe, characterized by recurrent respiratory infections that lead to a vicious cycle of impaired mucociliary clearance, chronic infection, bronchial inflammation, and progressive lung function loss. <i style="font-style:italic;">P. aeruginosa</i> is the most prevalent pathogen responsible for these recurrent infections. It is found in approximately 30% of cases and is associated with enhanced disease progression, including poorer lung function and lower quality of life, more frequent exacerbations, 7-fold increase in hospitalizations, and 3-fold increase in death. NCFB patients frequently become chronically colonized with multidrug-resistant strains of <i style="font-style:italic;">P. aeruginosa</i> because of the need for repeated courses of antibiotic treatment. There are currently no approved inhaled antibiotics for the treatment of NCFB patients with chronic <i style="font-style:italic;">P. aeruginosa</i> respiratory infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Hospitalized </i><i style="font-style:italic;">Pneumonia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Hospital-acquired pneumonia and ventilated-associated pneumonia is one of the most common causes of death among all hospital&#8208;acquired infections, with approximately 300,000 hospitalizations each year in the United States due to <i style="font-style:italic;">Pseudomonas</i>. Infection with <i style="font-style:italic;">Pseudomonas</i> results in mortality rates ranging as high as 35&#8208;50%, drives considerable healthcare costs (in excess of $40,000 per patient), and accounts for around 50% of all intensive care unit antibiotics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Staphylococcus aureus Infections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Bacteremia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Bacteremia is a bacterial infection of the bloodstream. A common diagnosis, the CDC estimates that up to 1.7 million people in the U.S. develop bacteremia each year. <i style="font-style:italic;">S. aureus</i> is the most commonly identified pathogen in both hospital- and community-acquired bloodstream infections. Annually in the U.S. there are approximately 200,000 hospitalizations for <i style="font-style:italic;">S. aureus</i> bacteremia (&#8220;SAB&#8221;). Despite conventional antibiotics, mortality in SAB results in the death of up to 40% of all cases and 57% of patients over the age of 85. Patients with comorbidities such as alcoholism, malignancy, diabetes, end-stage renal disease requiring hemodialysis, and immunosuppression are at even higher risk for death when SAB develops. Age-adjusted mortality assessments show that SAB mortality is higher than that of AIDS, tuberculosis, or viral hepatitis, and comparable to mortality rates for breast or prostate cancer. Outcomes are even poorer for SAB due to methicillin-resistant <i style="font-style:italic;">S. aureus</i> (&#8220;MRSA&#8221;), classified as a serious threat to global health by the CDC and a high priority threat by the WHO, with higher rates of complications and increased mortality as compared to methicillin-susceptible <i style="font-style:italic;">S. aureus</i> (&#8220;MSSA&#8221;). Average hospital costs to patients with nosocomial SAB ranges between $40,000 (MSSA) and $114,000 (MRSA). Treatment failures are common in SAB, with highest rates due to MRSA. These failures can be attributed in part to poor penetration of some tissues by antibiotics, slow onset of bactericidal effects, emerging resistance patterns, and biofilm formation. While biofilms can render traditional antibiotics ineffective, phages may have the ability to penetrate the biofilm allowing rapid and efficient infection of the host and amplification at the site of infection. Daptomycin (approved in 2005; based on clinical cure rates of less than 50%) and vancomycin are the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:58.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">only two antibiotics with label indications in the U.S. for the treatment of SAB, and the emergence of drug-resistant <i style="font-style:italic;">S.&#160;aureus</i> isolates, including to these two standard of care drugs, represents a major threat in terms of increasing morbidity, mortality and health care utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prosthetic Joint Infection and Wound Infection</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total number of prosthetic joint infection (&#8220;PJI&#8221;)-related revision surgeries is expected to more than double from 70,000 in 2020 to 144,000 in 2040 in the United States and European Union Five (France, Germany, Italy, Spain, and the United Kingdom), at an annual growth rate of 5.6% due to a growing elderly population. The United States is the largest market for PJI, accounting for 61% of PJI-related revision surgery in 2020 (estimated to be 71% by 2040), each estimated to cost $150,000. <i style="font-style:italic;">S. aureus</i> PJI infections are among the most commonly observed, accounting for up to 47% of all infections. PJI caused by biofilm-forming bacteria, such as <i style="font-style:italic;">S. aureus</i>, is challenging to treat and requires both surgery and long-term antibiotic use. Lack of efficacy against biofilms is a common cause of re-infection or treatment failure in PJI. Moreover, growing antibiotic resistance complicates treatment strategies and antibiotic choice for the treatment of PJI. Phage therapy has been successful in patients who have failed conventional antibiotic treatment, including two 2020 case studies in which phages were administered by intravenous or intraarticular routes and shown to be generally well tolerated. Similarly, secondary and tertiary wound infections due to <i style="font-style:italic;">S. aureus </i>are a growing issue worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Platform Technologies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Synthetic Phage Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Phages, natural predators of bacteria, have been in an uninterrupted battle for millions of&#160;years&#160;&#8211; evolving to kill or evade. These powerful natural well-adapted phages can be purposely engineered to be more efficient killers. The use of synthetic biology tools enables us to precisely engineer natural phages in ways that further improve their pharmacological properties and antimicrobial activity. Attributes of engineered phages can include expanded host range, improved potency which is a fundamental drug property that can translate into improved clinical efficacy, and importantly, biofilm disruption, which is a critical aspect of serious infections that needs to be addressed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:89.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:86.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:53.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Phage Discovery and Phenotyping:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Development of synthetic phage products that target a specific pathogen begins with the isolation of powerful natural phages from environmental and clinical samples. Our large library of multidrug-resistant pathogens and microbiome targets aids in the identification of the optimal phage candidates for downstream engineering.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:45pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Bioinformatics Powers Engineering:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We employ next-generation sequencing, proprietary sequencing databases and software, bioinformatics, and comparative genomics, for the analyses of our phages.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20231231x10k008.jpg" alt="Graphic" style="display:inline-block;height:52.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:42pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Engineering Host and Phage to Confer Desirable Properties:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depending on the target pathogen, identified natural phages are engineered to enable desirable phenotypes such as wide host range, payload expression, biofilm degradation, resistance prevention, and bioactive peptide display. Engineered phages are evaluated both in vitro and in vivo to determine pharmacological and toxicological parameters to confirm their potential in the clinic.</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="armp-20231231x10k009.jpg" alt="Graphic" style="display:inline-block;height:58.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:43.8pt;"/></p></td><td colspan="2" style="vertical-align:middle;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Formulation Development and Chemistry, Manufacturing, and Controls:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have developed and acquired highly skilled process development and phage manufacturing expertise to manage our proprietary platforms with proven capabilities from the bench to clinic. Our research and development facilities are equipped with cGMP compliant manufacturing suites enabling the production, </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:9.83%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:86.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">purification, testing and release of reproducible batches of phage clinical trial material exhibiting high purity and high titer designed to be tolerated for both intravenous and inhaled administration.</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:89.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preclinical and Clinical Development Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are committed to developing novel phage therapies, with drug development expertise and product development capabilities that span bench to clinic, including in-house phage-specific cGMP manufacturing. Our phage discovery platform in which we screen panels of clinically-relevant isolates against our extensive phage library utilizing proprietary methods that identify phage combinations with superior attributes, together with our phage-specific cGMP compliant manufacturing facilities, uniquely enables us to efficiently identify optimal product candidates. Our microbiological surveillance and synthetic biology capabilities drive long-term product life cycle management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our therapeutic phage candidates aim to address areas of significant unmet medical need, by targeting key drug-resistant bacteria, including those on the WHO&#8217;s global priority pathogens list, and the priority pathogens list issued by the CDC. The long-term potential for phage therapy is broad reaching, including potential use as front-line therapy. However, first indications will be as adjunct therapy in indications with high unmet need, which demands careful patient population selection to assure that a treatment effect with the phage cocktail can be observed over and above the efficacy of standard-of-care antibiotics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i>, two bacterial pathogens known to have significant morbidity and mortality despite standard-of-care antibiotic usage. <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i> are causative agents for difficult-to-treat infections: <i style="font-style:italic;">P. aeruginosa</i>, with its mucoid and multidrug-resistant strains, is a dominant culprit in chronic respiratory infections in CF and NCFB patients as well as acute pneumonia in hospitalized patients; <i style="font-style:italic;">S. aureus</i>, with its heteroresistant and MRSA strains, has been implicated in systemic (e.g., bacteremia) as well as prosthetic-related and wound infections. By advancing randomized controlled clinical trials using <i style="font-style:italic;">P. aeruginosa</i> and <i style="font-style:italic;">S. aureus</i> natural phage cocktails, Armata will gain experience treating site-specific as well as systemic infections. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pseudomonas aeruginosa Phage Product Candidate, AP-PA02</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Historical Background </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-PA02 was developed as a next-generation replacement for AP-PA01 (previously known as AB-PA01). A total of 10 patients with serious or life-threatening <i style="font-style:italic;">P. aeruginosa</i> infections not responding to antibiotic therapy were treated with AP-PA01, along with antibiotics, under single-patient expanded access programs in the United States (authorized under Emergency INDs by the FDA) and in Australia (authorized under the Special Access Scheme by the Australian Therapeutic Goods Administration). The treated patients&#8217; infections included bacteremia, native and prosthetic valve endocarditis, recurrent pneumonia (CF, post-transplant), ventilated-associated pneumonia, prosthetic joint infection, ventricular assist device infection, and septicemia due to burns. Investigators concluded that intravenous and nebulized administration of AP-PA01 was well-tolerated with no treatment-related serious adverse events. One of these cases was published in August 2019, in the peer-reviewed journal Infection, after AP-PA01 was used to successfully treat a CF patient who had developed a multidrug-resistant <i style="font-style:italic;">P. aeruginosa</i> infection. Another success with AP-PA01, used to treat a 77-year-old with ventilated-associated pneumonia and empyema, was published in November 2019, in the American Journal of Respiratory and Critical Care Medicine. We no longer offer AP-PA01 through any expanded access program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2018, we held a Type B pre-IND meeting with the U.S. FDA regarding a proposed Phase 1/2 clinical study of AP-PA01 for the treatment of <i style="font-style:italic;">P. aeruginosa</i> respiratory infections (ventilated-associated pneumonia). Feedback from the FDA in September 2018 included: agreement on product specifications, manufacturing and analytical plan, and a stability program. Furthermore, the FDA noted that preclinical toxicology studies are not required for AP-PA01 to enter clinical development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human exposure through treatment of single patients with AP-PA01 under the expanded access program has been helpful in demonstrating the promise and safety of phage therapy. Feedback from the pre-IND meeting has been insightful for the regulatory path required for phage therapeutics in general, and specifically for a phage product candidate intended for respiratory infection. We, therefore, have leveraged our experiences with AP-PA01 to derive a development plan for the next-generation product candidate, AP-PA02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Development of AP-PA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-PA02 is one example of the novel candidates to emerge from our robust research and development capabilities, and significantly improves upon our original <i style="font-style:italic;">P. aeruginosa</i> phage product candidate, AP-PA01. The phages that comprise AP-PA02 were selected with desired attributes for a product candidate targeting <i style="font-style:italic;">P. aeruginosa </i>lung infections. Different methods were deployed, including microbiological, bioinformatics and comparative genomics, in order to identify optimal attributes for the product candidate. Susceptibility, killing kinetics, and biofilm eradication, was assessed using <i style="font-style:italic;">P. aeruginosa</i> isolates from CF patients to determine antimicrobial activity and potency of AP-PA02. Viability in relevant biological fluids, and compatibility with current standard of care therapies for CF patients, was verified to confirm suitability of AP-PA02 for clinical use in this patient population. Immune stimulation was assessed to assure the lack of inflammatory impact by AP-PA02. Animal studies were conducted to provide insight into safe and efficacious dose levels that would support the expectation of pharmacological activity (i.e., antimicrobial potential of phage) in the lung compartment following an inhaled route of administration. In parallel, we initiated manufacturing feasibility and process optimization efforts with the goal of achieving high-quality phage product free of endotoxin and host cell proteins whilst maintaining adequate phage titers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-PA02 is comprised of a cocktail of adapted natural <i style="font-style:italic;">P. aeruginosa</i> phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility (i.e., the phages don&#8217;t interfere with one another) and cooperativity (i.e., the phages work together for a better outcome), and further characterized by being highly potent and having a broad host range and overlap. Prior to initiating the SWARM-<i style="font-style:italic;">P.a.</i> trial (described below), our clinical isolate screening and phage collections yielded a three-phage AP-PA02 cocktail with compelling host-range coverage. We subsequently modified AP-PA02 to include additional phage genera that increase potency and broaden coverage of strains of <i style="font-style:italic;">P. aeruginosa</i> found in CF patients. The optimized five-phage AP-PA02 cocktail provided coverage against at least 90% of tested CF clinical isolates and has shown superior <i style="font-style:italic;">in vitro</i> potency as well as improved efficacy in an animal model of infection. The improvements in AP-PA02 reflect our core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="armp-20231231x10k010.jpg" alt="Graphic" style="display:inline-block;height:176.45pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:223.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical highlights of AP-PA02 include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significantly reduced </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> biofilm mass </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Persistence of active phage particles in the lung;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Limited systemic and off-target organ distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Significantly decreased mortality in a murine model of acute </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">P. aeruginosa</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> lung infection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Components are stable in blood and sputum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Not antagonistic with tobramycin nor aztreonam; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Components maintain activity in the presence of other CF therapies.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk94759422"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We developed AP-PA02 as a sterile liquid formulation, suitable for delivery by inhalation. Clinical trial material of AP-PA02 is currently manufactured under cGMP at our production facility in Marina del Rey, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development of AP-PA02 in Cystic Fibrosis</i>:<i style="font-style:italic;"> </i><i style="font-style:italic;">Completed Phase 1b/2a Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 14, 2020, Armata received approval for the study to proceed from the FDA for its IND to initiate the &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical trial to evaluate the safety, tolerability and phage recovery profile of AP-PA02 administered by inhalation in subjects with cystic fibrosis and chronic pulmonary <i style="font-style:italic;">Pseudomonas aeruginosa</i> infection. Primary Endpoints (SAD and MAD) included incidence and severity of treatment-emergent, adverse events. Secondary Endpoints (MAD) included changes in <i style="font-style:italic;">P. aeruginosa</i> colony-forming units. We looked at clinical parameters as a part of exploratory endpoints for the SAD and MAD cohorts. The SWARM-<i style="font-style:italic;">P.a.</i> study was supported by a $5 million Therapeutics Development Award from the CFF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the first quarter of 2023, Armata announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetcs (PK) findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum and exposure achievement relatively consistent across patient subjects. Additionally, bacterial levels of <i style="font-style:italic;">P. aeruginosa </i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Additive Clinical Indication for Our AP-PA02 P. aeruginosa Phage Product Candidate: Ensuring Patient Population for Definitive Phase 3 Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">With positive outcomes from the first clinical study, SWARM-<i style="font-style:italic;">P.a.</i>, we initiated a follow-on Phase 2 study investigating the efficacy of AP-PA02 in NCFB patients chronically infected with <i style="font-style:italic;">P. aeruginosa. </i>Screening <i style="font-style:italic;">P. aeruginosa</i> isolates from people diagnosed with NCFB revealed that the five-phage AP-PA02 cocktail offers broad coverage and robust potency in this indication as well. On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, NCFB. The Company initiated a Phase 2 trial (&#8220;Tailwind&#8221;) in NCFB in late 2022 and reported first patient dosing in the first quarter of 2023. The &#8220;Tailwind&#8221; study is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 phage therapeutic in subjects with NCFB and chronic pulmonary&#160;<i style="font-style:italic;">Pseudomonas aeruginosa</i>&#160;infection. Throughout 2023, the Company worked closely with clinical sites to rapidly expand enrollment to position the Phase 2 trial for completion in 2024 and have data available to support a pivotal trial in 2025. Enrollment of the Phase 2 trial is ongoing, with AP-PA02 continuing to demonstrate a favorable safety and tolerability profile, and insights from blinded data of the relationship between phage dose and microbiological impact on <i style="font-style:italic;">P. aeruginosa&#160;</i>confirms the findings in the cystic fibrosis SWARM-<i style="font-style:italic;">P.a.</i> Phase 2a trial. We are carefully evaluating the impact of AP-PA02 on <i style="font-style:italic;">P. aeruginosa&#160;</i>in patients not taking antibiotics in order to confirm the independent impact of phage treatment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">AP-PA03 for Antibiotic-Resistant and Difficult-to-Treat Acute Bacterial Pneumonia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conversely and representing the different physiology of acute pneumonia lung infections as compared to chronic CF and NCFB respiratory infections, a novel cocktail is in development for the clinical indication of acute hospitalized pneumonia. We have deployed our extensive <i style="font-style:italic;">P. aeruginosa</i> clinical isolate collection and phage library to identify a candidate phage cocktail, AP-PA03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Staphylococcus aureus Phage Product Candidate, AP-SA02</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Historical Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-SA02 was developed as a more advanced version of AP-SA01 (previously known as AB-SA01).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The therapeutic potential of AP-SA01 has been demonstrated through:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Efficacy in murine methicillin-resistant and methicillin-susceptible </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> pneumonia models, and sheep sinus biofilm model.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Demonstration of safety and tolerability in two completed investigator-initiated Phase 1 studies (topical administration: intact skin of healthy adults; intrasinal administration: patients suffering from </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-derived chronic rhinosinusitis).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AP-SA01 was provided for use under single-patient expanded access programs in the United States (Emergency INDs, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per the Food and Drug Administration</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) or Australia (Special Access Scheme, per the Australian Therapeutic Goods Administration). A total of 18 patients with serious or life-threatening </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> infections (including bacteremia, endocarditis, ventricular-assist device infection, prosthetic joint infection) not responding to standard-of-care antibiotic therapy were treated with AP-SA01. AP-SA01 was administered intravenously, with most patients treated for 14&#160;days, every 12 hours as an adjunct to antibiotic therapy. Investigators concluded that intravenous administration of AP-SA01 was well-tolerated with no </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment-related serious adverse events.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We no longer offer AP-SA01 through any expanded access program.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human exposure through treatment of single patients with AP-SA01 under the expanded access program has been helpful in demonstrating the promise of phage therapy and warrants further study to support safety and efficacy through randomized controlled trials required to support registration. Feedback from a Type B pre-IND meeting with the FDA in August&#160;2018 has been insightful for the regulatory path required for phage therapeutics in general, and specifically for a phage product candidate intended for systemic delivery. We therefore have leveraged our experiences with AP-SA01 to derive a development plan for AP-SA02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Optimization: Development of AP-SA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AP-SA02 is a novel biologic product candidate comprised of a cocktail of adapted natural lytic phages that target the problematic pathogen, <i style="font-style:italic;">S. aureus</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical highlights of AP-SA02 include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potent antimicrobial activity against approximately 95% of </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> clinical isolates tested, including drug-resistant isolates (MRSA: methicillin-resistant </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and VRSA: vancomycin-resistant </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unique mechanism of action offers independent or synergistic benefit with standard of care antibiotics; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Component phages are stable and retain infectivity after exposure to relevant biological fluids; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Penetrates pre-existing </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">S. aureus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> biofilms.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have developed AP-SA02 as a sterile solution, suitable for delivery by intravenous administration. Clinical trial material of AP-SA02 is currently manufactured under cGMP at our production facility in Marina del Rey, California to support the required regulatory filing(s)&#160;for clinical entry in the United States and ex-U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development of AP-SA02 in Bacteremia</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 17, 2021, Armata received approval for the study to proceed from the FDA for its IND to initiate the &#8220;diSArm&#8221; study &#8211; a Phase 1b/2a, randomized, double&#8208;blind, placebo&#8208;controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP&#8208;SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to <i style="font-style:italic;">Staphylococcus aureus</i>. The objectives of this study are to: (i)&#160;demonstrate safety and tolerability of multiple different dose levels of AP-SA02; (ii)&#160;evaluate optimal dosing through safety, pharmacokinetics and microbial efficacy; and (iii)&#160;explore efficacy through evaluation of key meaningful endpoints. The study is being conducted at sites in the United States and also at sites abroad in Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase 1b/2a study is partially funded by a $15.0 million&#160;award from the DoD through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3&#160;million to $16.3&#160;million and extend the term into the second half of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Data from this Phase 1b/2a study will be invaluable for a follow-on trial that is being designed to demonstrate efficacy of AP-SA02 in treating <i style="font-style:italic;">S. aureus</i> bacteremia. We anticipate findings from the Phase 1b/2a study will provide the basis for constructing a robust trial strategy for registration which can be the basis for an End-of-Phase-2 meeting with the FDA that enables us to obtain agreement on a path to approval in late 2024, early 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Additional Clinical Indications for AP-SA02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Improved patient outcomes are needed for other <i style="font-style:italic;">Staphylococcal</i> infections, in settings such as PJI and wound infections, for which antimicrobial resistance is a growing concern. We believe AP-SA02 could also have a meaningful impact in these indications, particularly infections caused by methicillin-resistant <i style="font-style:italic;">S. aureus</i> (&#8220;MRSA&#8221;). On August 1, 2022, we announced that we had received from the FDA the approval to proceed for our IND application for AP-SA02, in a second indication, PJI. We had planned to initiate a Phase 1b/2a trial in 2023; however, in light of the growing concerns of both PJI and wound infection, we are revising the protocol to include both indications, which will assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing debridement, antibiotics, and implant retention for the treatment of periprosthetic joint infections and/or wound infections caused by&#160;<i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Discovery Research</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to developing our more advanced pipeline programs described above, we continue phage discovery efforts by screening other interesting bacterial targets against our phage library in order to further expand our pipeline. <i style="font-style:italic;">Klebsiella pneumoniae</i> phage, for example, is a potentially important addition to treatment options for serious lung infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Furthermore, our team of microbiologists and synthetic biologists hunt for natural phages and evaluate the suitability of these natural phages for engineering and adaptation using our synthetic phage platform. These powerful natural well-adapted phages can be purposely engineered to be more efficient killers. The use of synthetic biology tools enables us to precisely engineer natural phages in ways that further improve their pharmacological properties and antimicrobial activity. Attributes of engineered phages can include expanded host range, improved potency which is a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fundamental drug property that can translate into improved clinical efficacy, and importantly, biofilm disruption, which is a critical aspect of serious infections that needs to be addressed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently produce clinical quantities of each of our bacteriophage product candidates at our cGMP-compliant manufacturing facility in Marina del Rey, California. This facility has approximately 35,500 square feet of laboratory and office space, including 3,000 square feet of cGMP laboratory space, designed to produce clinical quantities of each of our product candidates and to perform in-house Quality Control (&#8220;QC&#8221;) testing. We operate in-house process development activities through to the production, purification, formulation, and release of our therapeutic phage cocktails for use in human clinical trials. Our facility is licensed by the California Department of Public Health for drug manufacturing and is subject to periodic, unannounced inspections for compliance with cGMP and other state and federal laws and regulations. The facility is subject to periodic inspections by the City of Los Angeles and Los Angeles County for fire hazard and waste management and is in compliance with all applicable regulations. Our facility is staffed with an independent Quality Unit and Manufacturing and Facilities personnel trained under cGMPs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current formulations for our <i style="font-style:italic;">P. aeruginosa </i>and <i style="font-style:italic;">S. aureus</i> phage product candidates are intended for inhaled and intravenous delivery, both requiring our drug products to be sterile. Our Marina del Rey facility is capable of manufacturing sterile drug products, utilizing ISO-certified cleanrooms and ISO 5-certified biological safety cabinets. The facility also houses an ISO 5-certified closed system isolator. We may further optimize future formulations of our product candidates which may or may not require assurance of sterility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For our manufacturing facility we have been able to access and hire highly skilled process development and phage manufacturing expertise and believe that we have control of our proprietary platform from phage identification through final product fill and finish and release. Manufacturing campaigns are managed by a specialist team of our internal staff, which is designed to promote compliance with the technical aspects and regulatory requirements of the manufacturing process. We have developed a cGMP-compliant manufacturing process that utilizes both industry standard and proprietary methods for the manufacture of our product candidates. Our process is designed to be scalable to meet our clinical study needs, and to fulfill the requirements of regulators for human studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although our facility is capable of manufacturing our phage product candidates, we rely on, and may continue to rely on, third-party contract manufacturers for the manufacture of certain raw materials, components, or packaging of the product candidates that may be developed for clinical testing, as well as for commercialization. We are constructing the new manufacturing facility in Los Angeles, California and plan to move manufacturing processes to this new facility in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our goal is to protect the proprietary technology that we believe is important to our business, including to obtain, maintain and enforce patent protection for our product candidates, formulations, processes, methods and any other proprietary technologies, preserve our trade secrets and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the United States and abroad. However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We also rely on trademarks, trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. We also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary processes and know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we currently and will in the future rely on trade secret </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">protection and contractual obligations with third parties to protect our interests and to develop and maintain our competitive position. To this end, we require all of our employees, consultants, advisors and other contractors to enter into agreements with contractual obligations that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success in preserving market exclusivity for our product candidates relies on patent protection, including extensions to this where appropriate, and on data exclusivity relating to an approved biologic. This may be extended by orphan drug and/or pediatric use protection where appropriate. Once any regulatory period of data exclusivity expires, depending on the status of our patent coverage, we may not be able to prevent others from marketing and selling biosimilar versions of our product candidates. We are also dependent upon the diligence of our appointed agents in national jurisdictions, acting for and on our behalf, which manage the prosecution of pending domestic and foreign patent applications and maintain granted domestic and foreign patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries and patent application filings, we cannot be certain of the priority of inventions covered by pending patent applications. Accordingly, we may not have been the first to invent the subject matter disclosed in some of our patent applications or the first to file patent applications covering such subject matter, and we may have to participate in interference proceedings or derivation proceedings declared by the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) to determine priority of invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Bacteriophage Patent Portfolio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we owned or had exclusive license rights to a total of 151 patents and applications: 13 U.S. patents, 10 U.S. patent applications, 73 foreign patents, and 55 foreign patent applications, with nominal expiration on various dates between 2024 and 2044. Patent term adjustments or patent term extensions could result in later expiration dates. We believe these patents and applications cover our lead phage therapeutic programs and use thereof, synthetic phage and methods of manufacture thereof, beneficial effects of bacteriophage treatment - including treatment and prevention of bacteria-associated cancers, bacteriophage combinations, the sequential use of bacteriophages in combination with conventional antibiotics, genetic sequence variations, methods to reduce antibiotic resistance, methods to treat bacterial biofilms, methods to design therapeutic combination panels of bacteriophage, disinfection methods using bacteriophages, and bacteriophage mutants having increased bacterial host spectra.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drugs is highly competitive. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions all seeking to develop novel treatment modalities for bacterial infections. Many of our competitors have significantly greater financial, product development, manufacturing and marketing resources than us. Large pharmaceutical companies have extensive experience in clinical development and obtaining regulatory approval for drug products. In addition, many universities and private and public research institutes are active in antibacterial research, some in direct competition with us. We also may compete with these organizations to recruit scientists and clinical development personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to compete successfully will depend largely on our ability to leverage our collective experience in drug discovery, development and commercialization to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover and develop medicines that are differentiated from other products in the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent and/or proprietary protection for our products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain required regulatory approvals;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain a commercial partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize our drugs, if approved; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain high-quality research, development and commercial personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key factors affecting the success of any approved product include its efficacy, safety profile, drug interactions, method of administration, pricing, reimbursement and level of promotional activity relative to those of competing drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The majority of phage companies are focused on aspects outside of human health such as agriculture, food, environmental, veterinary, biocontrol, manufacturing, and diagnostics. There are a handful of small biotechnology companies developing bacteriophage products to treat human diseases. To our knowledge, several biotechnology companies in the United States and Europe, including Adaptive Phage Therapeutics, BiomX Inc., Intralytix, Inc., Locus Biosciences, Inc., TechnoPhage, SA, Felix Biotechnology, as well as academic institutions, have discovery stage or clinical programs utilizing naturally occurring phages or synthetic biology approaches to genetically modify bacteriophages to remove or input genes to improve therapeutic properties such as increases to the bacterial host range to infect a larger number of bacterial strains and decrease the need for using multiple phages in a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our bacteriophage programs may compete with or be synergistic with currently approved antibiotics, and experimental approaches such as novel antibiotics, antimicrobial peptides, antimicrobial vaccines, metals, antisense, monoclonal antibodies and possibly microbiome manipulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have full worldwide commercial rights to all of our phage-based product candidates to treat drug-resistant bacterial infections, including our product candidates: AP-PA02 and AP-PA03 for the treatment of <i style="font-style:italic;">P. aeruginosa</i> infections, and AP-SA02 for the treatment of <i style="font-style:italic;">S. aureus</i> infections. We believe we can maximize the value of our company by retaining substantial global commercialization rights to these product candidates and, where appropriate, entering into partnerships to develop and commercialize these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not yet established a sales, marketing or product distribution infrastructure because our lead candidates are still in early clinical development. Subject to receiving marketing approvals or earlier, we intend to either partner the commercial rights to our products with existing companies that have the wherewithal and resources to commercialize building the necessary marketing and sales infrastructure to market and sell our current product candidates. We also intend to explore the use of a variety of distribution agreements and commercial partnerships in those territories where we do not establish a sales force for any of our product candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Material Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strategic Alliances and Research Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MTEC Grant</i><span style="display:inline-block;width:101.74pt;"></span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, we entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we received a $15.0 million grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. The MTEC funds are used to partially fund a Phase 1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of the Company's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated <i style="font-style:italic;">Staphylococcus aureus</i> bacteremia infections. The MTEC Agreement specifies that the grant is paid to the Company over the term of the award through a cost reimbursable model, based on agreed-upon cost share percentages, and the grant money received is not refundable to MTEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through October 30, 2024. The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CFF Therapeutics Development Award</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with CFF, pursuant to which the Company received a Therapeutics Development Award of $5.0 million (the &#8220;CFF Award&#8221;). The CFF Award has funded a portion of the Company&#8217;s Phase 1b/2a clinical trial of the <i style="font-style:italic;">Pseudomonas aeruginosa</i> (&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;) phage candidate, AP-PA02, as a treatment for airway infections in people with cystic fibrosis (&#8220;CF&#8221;).&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the Award was paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The final milestone was achieved in the fourth quarter of 2023 and the milestone payment was received in the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other product (as defined in the Award Agreement), for a period of 360 days (an &#8220;Interruption&#8221;) and fails to resume the development of the product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amended and Restated Research Collaboration and Option to License Agreement with Merck </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Amended and Restated Research and Option to License Agreement (the &#8220;Research and Option Agreement&#8221;), entered into by and between us and Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;), we were engaged in generating broad host range synthetic bacteriophage candidate(s) targeting an undisclosed infectious disease agent(s), pursuant to the criteria set forth in the research plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We granted to Merck an exclusive, worldwide license in our patent rights, and our interest in any joint patent rights, with the right to grant and authorize sublicenses, for any and all uses of any product candidates, or products, developed through the research plans set forth in the Research and Option Agreement in a specific field of use. Further, in exchange for milestone payments associated with product development and regulatory achievements and royalty payments based on net sales of products developed, we granted to Merck an exclusive, worldwide license, with the right to grant and authorize sublicenses, in our background intellectual property and know-how, solely to make, have made, use, import, offer to sell and sell (but not genetically modify) the product candidates, or products, developed through the research plans set forth in the Research and Option Agreement in the specific field of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2022, Armata received a notice of termination, which became effective on March 14, 2023, in accordance with Section 8.2.1 of the Research and Option Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">License Agreement with United Kingdom Secretary of State for the Department of Health</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2011, upon completion of our acquisition of Biocontrol&#160;Ltd., we assumed a license agreement entered into in March&#160;2007 between Biocontrol&#160;Ltd. and the Health Protection Agency, Centre for Emergency Preparedness and Response, to use certain intellectual property rights to develop treatments for bacterial biofilm infections. The agreement was subsequently assigned to the United Kingdom Secretary of State for the Department of Health (&#8220;DoH&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the license agreement, we have obtained exclusive rights to a patent portfolio related to the use of bacteriophages combined with biofilm-disrupting agents in treating biofilm infections. In consideration for the exclusive license, we may be required to pay to the DoH certain milestone payments in the aggregate of up to &#163;10,000 per product, as well as single digit&#160;percentage royalty on net sales of products incorporating licensed intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The license agreement will remain in effect until the expiration of the last patent exclusively licensed under the license agreement. If we default on any milestone or royalty payments, or upon breach by us of certain other terms of the license agreement, the DoH may either terminate the license agreement immediately upon written notice or modify the license to be non-exclusive upon 30&#160;days&#8217; written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066. On October 28, 2021, we entered into a lease for 56,300 square feet of office, research and development and manufacturing space under a non-cancellable lease (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022, and the total lease term is for&#160;16 years&#160;and runs through 2038. Office space and research laboratories have been fully occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 sq. ft.) expected to be fully constructed in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a facility located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease 35,500 square feet of office, research and development and manufacturing space. The lease expires on December 31, 2031. The facility includes approximately 3,000 square feet of cGMP laboratory space, which currently serves to produce clinical quantities of our phage product candidates for ongoing human trials and to perform in-house QC testing. As we move our manufacturing into the McConnell facility by mid-2024, we are actively seeking a sub-tenant at the Glencoe location to take over the remaining term of the 4503 Glencoe Avenue lease.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our facilities are adequate for our current and long-term needs. Additionally, we believe the newly constructed McConnell facility, offering expanded manufacturing capacity, will allow us to pursue contract manufacturing opportunities for phage and other advanced biologics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we are a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business. We intend to vigorously defend our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this Annual Report, we are not subject to any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products such as those we are developing. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety, efficacy, purity, and/or potency must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority where the product is intended to be marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States Product Development Process</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable FDA requirements at any time during the product development process or approval process, or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory practice requirements (&#8220;GLP&#8221;) or other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND application, which must be granted before human clinical trials may begin in the United States or internationally if submitting results to the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (&#8220;GCPs&#8221;) and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use or uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a Biologics License Application (&#8220;BLA&#8221;) for a new biological product;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with the FDA&#8217;s cGMP regulations, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential FDA inspection of the nonclinical study sites and clinical trial sites that generated the data in support of the BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA&#8217;s approval of the BLA, which must occur before a biological product can be marketed or sold in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources even when approvals are inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The strategies, nature, and technologies of bacteriophage products are different from those of conventional antibiotic therapy products. From the regulatory requirements established to ensure the safety, efficacy and quality of bacteriophage preparations, there are several major points to consider during the development, manufacturing, characterization, preclinical study and clinical trial of bacteriophage products. The major issues include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phage preparation design (single agent versus phage mixes and wild-type phage versus genetically engineered phage);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Proof of concept in development of phage products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Selectivity of bacteriophage replication and targeting to specific species of bacteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relevant animal models in preclinical studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety and efficacy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies and IND</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before testing any compounds with potential therapeutic value in humans, the biological product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product biology, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the biological product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices described in 21 CFR Part&#160;58 (GLP). The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND application. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be certain that submission of an IND application will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by the sponsor. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject inclusion and exclusion criteria and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA. Clinical trials must be conducted in accordance with GCP requirements. Further, each clinical trial must be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee if conducted outside of the United States, at or servicing each institution at which the clinical trial will be conducted. An IRB or ethics committee is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB or ethics committee also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. We intend to use third-party CROs to administer and conduct our planned clinical trials and will rely upon such CROs, as well as medical institutions, clinical investigators and consultants, to conduct our trials in accordance with our clinical protocols. The failure by any of such third parties to meet expected timelines, adhere to our protocols or meet regulatory standards could adversely impact the subject product development program and we remain legally responsible for compliance with applicable laws and regulations governing the conduct of these clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The product candidate is initially introduced into healthy human subjects and tested primarily for safety and dosage tolerance. Absorption, metabolism, distribution and excretion may also be tested.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA and other regulatory authorities for approval of a marketing application.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Post-approval studies, or Phase 4 clinical trials, may be requested by the FDA as a condition of approval and are conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted annually to the FDA and written safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggest that there may be a significant risk for human subjects. The FDA or the sponsor or, if used, the sponsor&#8217;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB or ethics committee can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s or ethics committee&#8217;s requirements or if the pharmaceutical product has been associated with unexpected serious harm to patients. Suspension of a clinical trial due to safety risks attributed to the investigational product will result in termination of the trial and possibly others that are underway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or other impurities with the use of biological products, the Public Health Service Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Review and Approval Processes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to obtain approval to market a biological product in the United States, a BLA that provides data establishing to the FDA&#8217;s satisfaction the safety and effectiveness of the investigational product candidate for the proposed indication must be submitted to the FDA. The application includes all data available from nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s manufacture and composition, and proposed labeling, among other things. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. After the BLA is accepted for filing, the FDA reviews it to determine, among other things, whether the proposed product is safe and effective for its intended use, has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency, and purity. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10&#160;months from the filing date in which to complete its initial review of an original BLA and respond to the applicant, and six&#160;months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will conduct a preapproval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel product candidates or those that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA may ultimately decide that the BLA does not satisfy the criteria for approval. If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation for a biologic must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the rare disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven&#160;years from the date of such approval. Additionally, the sponsor can benefit from certain financial incentives, including opportunities for grant funding towards clinical trial costs, research and development tax credits, and user fee waivers. If the same drug has already been approved, the proposed drug needs to demonstrate clinical superiority to obtain orphan exclusivity for the same indication, such as by means of greater effectiveness, greater safety or providing a major contribution to patient care, or in instances of drug supply issues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven&#160;years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Information</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60&#160;days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Special FDA Expedited Review and Approval Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including Fast Track designation, Limited Population, accelerated approval and priority review, that are intended to expedite the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs and biological products to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug or biological product qualifies as a qualified infectious disease product under the Generating Antibiotic Incentives Now Act. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapies based on efficacy or safety factors. We intend to request Fast Track designation for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review, accelerated approval, and, as of 2018, for antibacterial and antifungal therapies, approval under the Limited Population Pathway. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or if there is a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefits, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The limited population pathway for antibacterial and antifungal drugs or biologics (&#8220;LPAD&#8221;) may enable the streamlined development of safe and effective medicines that overcome the unmet needs of a limited population of patients with serious bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a condition of approval, the FDA may require a sponsor of a drug or biological product receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biological product may be subject to accelerated withdrawal procedures. In addition, the FDA currently requires as a condition for accelerated approval and approval under LPAD pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Approval under LPAD is for a limited population of patients; labeling statements for the limited use of the product are removed when supplemental data substantiates expansion of the patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Eligibility for a drug or biologic product to be licensed under LPAD includes treatment of a serious or life-threatening infection in a limited population of patients with unmet medical need. FDA also considers the severity, rarity or prevalence of the infection and the lack of alternative treatment in the limited population the therapeutic is intended for. It is possible for qualifying therapies to complete a streamlined clinical program to demonstrate substantial evidence of effectiveness and safety in the limited population. Drugs or biological products approved under LPAD can also receive fast track and breakthrough designations as well as accelerated and priority review of the marketing application. LPAD-required limitations of labeling are removed when supplemental data demonstrating a favorable benefit-risk profile in a broader population corroborates label expansion. We intend to request approval under LPAD in the BLA for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor can also request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the biological product or drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biological products designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. We intend to request &#8220;breakthrough therapy&#8221; designation for our product candidates if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maintaining substantial compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of new products continues after approval, particularly with respect to cGMP. We may rely on third parties for the production of commercial quantities of any products that we may commercialize. We and third-party manufacturers of our products are required to comply with applicable requirements in the cGMPs, including quality control and quality assurance and maintenance of records and documentation. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP and other FDA requirements. Other post-approval requirements applicable to biological products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements, by us or our suppliers, may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their facilities with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Labeling, Marketing and Promotion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the labeling, marketing and promotion of drugs and biological products, including direct-to-consumer advertising, promotional activities involving the internet, and industry-sponsored scientific and educational activities. While doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a product that are consistent with FDA approval, and the company is allowed to actively market a product only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term Restoration and Extension</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States (&#8220;U.S.&#8221;), the base term is 20&#160;years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the USPTO. Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND, and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biologics Price Competition and Innovation Act of 2009: Biosimilars and Interchangeable Biologic Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009 amended the Public Health Service Act to create an abbreviated approval pathway for two types of &#8220;generic&#8221; biologics &#8212; biosimilars and interchangeable biologic products, and provides for a twelve-year data exclusivity period for the first approved biological product, or reference product, against which a biosimilar or interchangeable application is evaluated; however, if pediatric clinical trials are performed and accepted by the FDA, the twelve-year data exclusivity period will be extended for an additional six months. A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1)&#160;analytical studies showing that the biosimilar product is highly similar to the reference product; (2)&#160;animal studies (including toxicity); and (3)&#160;one or more clinical trials to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An application for a biosimilar product may not be submitted until four&#160;years after the date on which the reference product was first approved. The first approved interchangeable biologic product will be granted an exclusivity period of up to one&#160;year after it is first commercially marketed, but the exclusivity period may be shortened under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is a type of marketing exclusivity available in the United States under the Best Pharmaceuticals for Children Act, which provides for an additional six months of marketing exclusivity and may be available if a sponsor conducts clinical trials in children in response to a written request from the FDA (the &#8220;Written Request&#8221;). If the Written Request does not include clinical trials in neonates, the FDA is required to include its rationale for not requesting those clinical trials. The FDA may request studies on approved or unapproved indications in separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Diagnostics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may employ companion diagnostics to help us to more accurately identify patients within a particular bacterial strain, both during our clinical trials and in connection with the commercialization of our product candidates that we are developing or may in the future develop. Companion diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">medical devices by the FDA and, as such, require either clearance or approval prior to commercialization. The level of risk combined with available controls to mitigate risk determines whether a companion diagnostic device requires Premarket Approval Application approval or is cleared through the 510(k)&#160;premarket notification process. For a novel therapeutic product for which a companion diagnostic device is essential for the safe and effective use of the product, the companion diagnostic device should be developed and approved or 510(k)-cleared contemporaneously with the therapeutic. The use of the companion diagnostic device will be stipulated in the labeling of the therapeutic product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other U.S. Healthcare Laws and Compliance Requirements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA restrictions on the marketing of pharmaceutical products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our business or financial arrangements and relationships through which we market, sell and distribute the products, if any, for which we obtain approval. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs&#894; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalties laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent&#894; making, using or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government&#894; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#894; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Affordable Care Act (the &#8220;ACA&#8221;), including the provision commonly referred to as the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement, we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines, imprisonment and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims Act as well as under the false claims laws of several states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our arrangements with physicians and other healthcare providers, some of whom receive stock options as compensation for services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Additional Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Foreign Corrupt Practices Act</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Healthcare Reform</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March&#160;2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part&#160;D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part&#160;D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs; imposed a new federal excise tax on the sale of certain medical devices; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established the Center for Medicare Innovation at the Centers for Medicare and Medicaid to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been a number of significant changes to the ACA. On October&#160;13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October&#160;25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. In January&#160;2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a&#160;year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January&#160;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal&#160;year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer sponsored insurance plan, the annual fee imposed on certain health insurance providers based on market share, and the medical device exercise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January&#160;1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; Congress will likely consider other legislation to replace or modify elements of the Affordable Care Act. We continue to evaluate the effect that the Affordable Care Act and its possible repeal, replacement or further modification could have on our business. It is uncertain the extent to which any such changes may impact our business or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal&#160;year that will remain in effect through 2027 unless additional Congressional action is taken. Further, on January&#160;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Regulation Outside of the United States</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials of drug products as well as the approval, manufacture and distribution of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain countries outside of the United States have a regulatory process similar to the U.S. process that requires the submission of a clinical trial application (&#8220;CTA&#8221;) much like the IND prior to the commencement of human clinical trials. In the European Union, for example, CTA must be submitted for each clinical trial to the national health authority and an independent ethics committee in each country in which the trial is to be conducted, much like the FDA and an IRB, respectively. Clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the Clinical Trials Directive (and corresponding national laws of the member states) and further detailed in applicable guidance documents. Once the CTA is approved in accordance with a country&#8217;s requirements, the clinical trial may proceed. A similar process to the one described for the European Union is required in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Israel for initiation of clinical trials. The requirements and process governing the conduct of clinical trials vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Approval Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market our products, we must obtain a marketing approval for each product and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing in comparison to the testing carried out for the U.S. approval. The time required to obtain approval in foreign countries may differ substantially from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The regulatory approval process outside the United States generally is subject to all of the same risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To obtain marketing approval of a medicinal product under the European Union regulatory system, an applicant must submit a marketing authorization application (&#8220;MAA&#8221;), under either a centralized or a decentralized procedure. The decentralized procedure is based on a collaboration among the member states selected by the applicant. In essence, the applicant chooses a &#8216;lead&#8217; member state that will carry out the scientific assessment of the MAA and review the product information. The other member states must recognize the outcome of such assessment and review except in case of a &#8220;serious potential risk to public health.&#8221; The decentralized procedure results in the grant of a national marketing authorization in each selected country. That procedure is available for all medicinal products unless they fall into the mandatory scope of the centralized procedure. In practice, it is used for over-the-counter, not highly innovative products, generic products and, increasingly, for biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for certain medicinal products, including for medicinal products produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMPs&#8221;) and products with a new active substance and indicated for the treatment of certain diseases. For products with a new active substance and indicated for the treatment of other diseases, products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure is optional.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure, the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;), the main scientific committee established at the EMA, is responsible for conducting the scientific assessment of the future medicinal product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. The maximum timeframe for the evaluation of an MAA is 210&#160;days, excluding clock stops. The European Commission grants or refuses the marketing authorization, following a procedure that involves representatives of the member states. The European Commission&#8217;s decision is in accordance with the CHMP scientific assessment except in very rare cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Regulation (EC) 1394/2007, specific rules&#160;apply to ATMPs, a category that is comprised of gene therapy medical products, somatic cell therapy medicinal products, and tissue-engineered medicinal products. Those rules&#160;have triggered the adoption of guidelines on manufacturing, clinical trials and pharmacovigilance that adapt the general regulatory requirements to the specific characteristics of ATMPs. Regulation (EC) 1394/2007 introduced a &#8220;hospital exemption.&#8221; which authorizes hospitals to develop ATMP for their internal use without having obtained a marketing authorization and to complying with European Union pharmaceutical law. The hospital exemption, which is in essence a compounded ATMP, has been transposed in all Member States, sometimes in such a way that the ATMPs under the hospital exemption are competitive alternatives to ATMPs with marketing authorization. The broad use of the hospital exemption by national hospitals led the European Commission to discuss with the Member States a more reasonable application of the hospital exemption that would not undermine the common legal regime for ATMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Marketing authorization is valid for five&#160;years in principle and the marketing authorization may be renewed after five&#160;years on the basis of a re-evaluation of the risk-benefit balance by the EMA or the competent authority of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six&#160;months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional renewal. Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid (the so-called sunset clause).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Countries other than the United States have adopted a specific legal regime to support the development and marketing of drugs and biologics for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, in the European Union, Regulation 141/2000 organizes the grant of orphan drug designations to promote the development of products that are intended for the diagnosis, prevention or treatment of life threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Economic Area (the European Union, plus Iceland, Liechtenstein and Norway) (or where it is unlikely that the development of the medicine would generate sufficient return to justify the investment) and for which no satisfactory method of diagnosis, prevention or treatment has been authorized or, if a method exists, the product would be of significant benefit to those affected. The EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) examines if the orphan criteria are met and gives opinions thereon, and the orphan status is granted by the European Commission. The meeting of the criteria for orphan designation is examined again by the COMP at the time of approval of the medicinal product, which typically occurs several&#160;years after the grant of the orphan designation. If the criteria for orphan designation are no longer met at that time, the European Commission withdraws the orphan status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, orphan drug designation entitles the sponsor to financial incentives such as reduction of fees or fee waivers and to ten&#160;years of market exclusivity granted following medicinal product approval. Market exclusivity precludes the EMA or a national regulatory authority from validating another MAA, and the European Commission or a national regulatory authority from granting another marketing authorization, for the same or similar medicinal product and the same therapeutic indication, for that time period. This 10-year period may be reduced to six&#160;years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. The orphan exclusivity may be lost vis-&#224;-vis another medicinal product in cases the manufacturer is unable to assure sufficient quantity of the medicinal product to meet patient needs or if that other product is proved to be clinically superior to the approved orphan product. A drug is clinically superior if it is safer, more effective or makes a major contribution to patient care. Orphan drug designation must be requested before submitting a MAA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, and it does not afford any regulatory exclusivity until a marketing authorization is granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expedited Development and Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mechanisms are in place in many jurisdictions that allow an earlier approval of the drug so that it reaches patients with unmet medical needs earlier. The European Union, for example, has instituted several expedited approval mechanisms including two mechanisms that are specific to the centralized procedure:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accelerated approval: the EMA may reduce the maximum timeframe for the evaluation of an MAA from 210&#160;days to 150&#160;days when the future medicinal product is of major interest from the point of view of public health, in particular from the viewpoint of therapeutic innovation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conditional marketing authorization: as part of its marketing authorization process, the European Commission may grant marketing authorizations on the basis of less complete data than is normally required.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, all the following requirements are met:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk/benefit balance of the medicinal product is positive&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is likely that the applicant will be in a position to provide the comprehensive clinical data&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unmet medical needs will be addressed&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data is still required.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The granting of a conditional marketing authorization is typically restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete preclinical or quality data may however be accepted if duly justified and only in the case of a product intended to be used in emergency situations in response to public health threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conditional marketing authorizations are valid for one&#160;year, on a renewable basis. The conditions to which approval is subject will typically require the holder to complete ongoing trials or to conduct new trials with a view to confirming that the risk/benefit balance is positive and to collect pharmacovigilance data. Once the conditions to which the marketing authorization is subject are fulfilled, the conditional marketing authorization is transformed into a regular marketing authorization. If, however, the conditions are not fulfilled within the timeframe set by the EMA, the conditional marketing authorization ceases to be renewed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The EMA has also implemented the so-called &#8220;PRIME&#8221; (PRIority MEdicines) status in order support the development and accelerate the approval of complex innovative medicinal products addressing an unmet medical need. PRIME status enables early dialogue with the relevant EMA scientific committees and, possibly, some payors and thus reinforces the EMA&#8217;s scientific and regulatory support. It also opens accelerated assessment of the MAA as PRIME status, is normally reserved for medicinal products that may benefit from accelerated assessment, i.e., medicines of major interest from a public health perspective, in particular from a therapeutic innovation perspective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, all medicinal products (i.e., decentralized and centralized procedures) may benefit from an MAA &#8220;under exceptional circumstances.&#8221; This marketing authorization is close to the conditional marketing authorization as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the grant of a marketing authorization. However, unlike the conditional marketing authorization, the applicant does not have to provide the missing data and will never have to. The risk/benefit of the medicinal product is reviewed annually. As a result, although the MAA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk/benefit balance of the medicinal product is reviewed annually and the marketing authorization is withdrawn in case the risk/benefit ratio is no longer favorable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatrics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mandatory testing in the pediatric population is required in more and more jurisdictions. The European Union has enacted a complex and very stringent system that has inspired other jurisdictions, including the United States and Switzerland. Any application for approval of (i)&#160;a medicinal product containing a new active substance or (ii)&#160;a new therapeutic indication, pharmaceutical form or route of administration of an already authorized medicinal product that contains an active substance still protected by a supplementary protection certificate (&#8220;SPC&#8221;) or a patent that qualifies for an SPC, must include pediatric data. Otherwise, the application is not validated by the competent regulatory authority. The submission of pediatric data is mandatory in those cases, even if the application concerns adult use. Submission of pediatric data is not required or fully required if the EMA granted, respectively, a full or partial waiver to pediatric development. Moreover, that submission can be postponed if the EMA grants a deferral in order not to delay the submission of the MAA for the adult population.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pediatric data are generated through the implementation of a pediatric investigation plan (&#8220;PIP&#8221;) that is proposed by the company after completion of the PK studies in adults and agreed upon by the EMA, typically after some modifications. The PIP lists all the studies to conduct and measures to take in order to prove the safety and efficacy of the future medicinal product when used in children. The EMA may agree to modify the PIP at the company&#8217;s request. The scope of the PIP is the adult therapeutic indication or the condition of which the adult application is part or even the mechanism of action of the active substance, at the EMA&#8217;s quasi-discretion. This very broad discretion enables the EMA to require companies to develop children indications that are different from the adult indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Completion of a PIP renders the company eligible for a pediatric reward, which can be six-month extension of the term of the SPC or, in the cases of orphan medicinal products, two additional&#160;years of market exclusivity. The reward is subject, among other conditions, to the PIP being fully completed, to the pediatric medicinal product being approved in all the member states, and to the results of the pediatric studies being mentioned, in one way or another (for example, the approval of a pediatric indication), in the summary of product characteristics of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Marketing Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many countries impose post-marketing requirements similar to those imposed in the United States, in particular safety monitoring or pharmacovigilance. In the European Union, pharmacovigilance data are the basis for the competent regulatory authorities imposing the conduct of post-approval safety or efficacy study, including on off-label use. Non-compliance with those requirements can result in significant financial penalties as well as the suspension or withdrawal of the marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Supplementary Protection Certificate and Regulatory Exclusivities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some countries other than the United States, some of our patents may be eligible for limited patent term extension, depending upon the timing, duration and specifics of the regulatory approval of our product candidates and any future product candidates. Furthermore, authorized drugs and biologics may benefit from regulatory exclusivities (in additional to patent protection resulting from patents).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the European Union, Regulation (EC) 469/2009 institutes a SPC. An SPC is an extension of the term of a patent that compensates for the patent protection lost because of the legal requirements to conduct safety and efficacy tests and to obtain a marketing authorization before placing a medicinal product on the market. An SPC may be applied for any active substance that is protected by a &#8220;basic patent&#8221; (a patent chosen by the patent holder, which can be a product, process or application patent) and has not been placed on the market as a medicinal product before having obtained a marketing authorization in accordance with European Union pharmaceutical law. The term of the SPC is maximum five&#160;years, and the combined patent and SPC protection may not exceed fifteen&#160;years from the date of the first marketing authorization in the European Economic Area (&#8220;EEA&#8221;). SPC rights are restricted by both the basic patent and the marketing authorization, i.e., the SPC grants the same rights as those conferred by the basic patent but limited to the active substance covered by the marketing authorization (and any use as medicinal product approved afterwards).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While SPC are regulated at the European level, they are granted by the national patent offices. The grant of an SPC requires a basic patent granted by the national patent office and a marketing authorization, which is the first marketing authorization for the active substance as a medicinal product in the country. Furthermore, no SPC must have already been granted to the active substance, and the application for the SPC must be filed with the national patent office within six&#160;months of the first marketing authorization in the EEA or the grant of the basic patent, whichever is the latest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the future, we may apply for an SPC for one or more of our currently owned or licensed European patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant MAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in the European Union, medicinal products may benefit from the following regulatory exclusivities: data exclusivity, market protection, market exclusivity, and pediatric reward.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A medicinal product that contains a new active substance (reference medicinal product) is granted eight&#160;years of data exclusivity followed by two&#160;years of market protection. Data exclusivity prevents other companies from referring to the non-clinical and clinical data in marketing authorization dossier of the reference medicinal product for submission of generic MAA purposes, and market protection prevents other companies from placing generics on the market. Pursuant to the concept of global marketing authorization, any further development of that medicinal product (e.g., new indication, new form, change to the active substance) by the marketing authorization holder does not trigger any new or additional protection. The authorization of any new development is considered as &#8220;falling&#8221; into the initial marketing authorization with regard to regulatory protection; hence, the new development only benefits from the regulatory protection that remains when it is authorized. The only exception is a new therapeutic indication that is considered as bringing a significant clinical benefit in comparison to the existing therapies. Such new indication will add one-year of market protection to the global marketing authorization, provided that it is authorized within the first eight&#160;years of authorization (i.e., during the data exclusivity period). Moreover, a new therapeutic indication of a &#8220;well-established substance&#8221; benefits from one-year data exclusivity but limited to the non-clinical and clinical data supporting the new indication. Any active substance approved for at least ten&#160;years in the EEA qualifies as well-established substance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biosimilars may be approved through an abbreviated approval pathway after the expiration of the eight-year data exclusivity period and may be marketed after the 10- or 11-year market protection period. The approval of biosimilars requires the applicant to demonstrate similarity between the biosimilar and the biological medicinal product and to submit the non-clinical and clinical data defined by the EMA. The biosimilar legal regime has been mainly developed through EMA&#8217;s scientific guidelines applicable to categories of biological active substances. Unlike in the United States, interchangeability is regulated by each member state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Market exclusivity is a regulatory protection exclusively afforded to medicinal products with an orphan status. Market exclusivity precludes the EMA or a national regulatory authority from validating another MAA, and the European Commission or a national regulatory authority from granting another marketing authorization, for a same or similar medicinal product and a same therapeutic indication, for a period of ten&#160;years from approval (see above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pediatric reward is another regulatory exclusivity. Completion of a PIP renders the company eligible for a pediatric reward, which can be six-month extension of the term of the SPC or, in the cases of orphan medicinal products, two additional years of market exclusivity (see above). In case a PIP is completed on a voluntary basis, i.e., for an approved medicinal product that is not or no longer protected by an SPC or a basic patent, the pediatric reward takes the form of a &#8220;pediatric use marketing authorization&#8221;. That special authorization does not fall into the global marketing authorization and thus benefits from eight years of data exclusivity followed by two or three years of market protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Healthcare Laws and Compliance Requirements Outside of the United States</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is mainly governed by the national anti-bribery laws of the member states, such as the UK Bribery Act 2010, or national anti-kickback provisions (France, Belgium, etc.). Infringement of these laws could result in substantial fines and imprisonment. In certain member states, payments made to physicians must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Much like the U.S. Foreign Corrupt Practices Act, to which we are subject, that prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity, similar rules&#160;apply to many other countries worldwide such as France (Loi Sapin) or the United Kingdom (UK Bribery Act). It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pricing and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although none of our product candidates has been commercialized for any indication, if they are approved for marketing, commercial success of our product candidates will depend, in part, upon the availability of third-party reimbursement from payors at the federal, state and private levels. Third-party payors include government healthcare programs, such as Medicare and Medicaid, private health insurers and managed-care plans. We anticipate third-party payors will provide reimbursement for our products. However, these third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost effectiveness of our products. Our product candidates may not be considered cost effective. It is time consuming and expensive for us to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 1, 2024, we had 66 full-time employees. Of the 66 full-time employees, 54 were engaged in research and development activities and 12 employees were engaged in finance, legal, human resources, facilities and general management. We have no collective bargaining agreements with our employees, we have not experienced any work stoppages&#160;and we believe our relations with our employees are good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Our human resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and prospective employees. The principal purposes of our incentive plans are to attract, retain and motivate selected employees, consultants, advisors and directors through the granting of stock-based compensation awards and cash-based performance awards, as applicable. We provide a comprehensive benefits package to help employees manage their health, well-being, finances, and life outside of work, including health insurance, dental and vision insurance, life insurance, accidental death and dismemberment issuance, short-term and long-term disability insurance, paid sick leave, a defined contribution plan, an employee stock purchase plan, a flexible spending account program, and paid vacation time. We value the health, safety, and wellbeing of our employees and their families.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Diversity and Inclusion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are committed to our continued efforts to increase diversity and foster an inclusive work environment. We recruit the best qualified employees regardless of gender, ethnicity, or other protected traits and it is our policy to fully comply with all laws (domestic and foreign) applicable to discrimination in the workplace. Our diversity, equity and inclusion principles are also reflected in our employee training and policies. We continue to enhance our diversity, equity and inclusion policies that are guided by our executive leadership team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="color:#500050;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Health, Safety and Well-Being </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Protecting the health, safety and well-being of colleagues and, all of whom are essential to delivering our business objectives, is an integral part of how we operate. In response to the COVID-19 pandemic in 2020, we instituted a&#160;remote work protocol to help ensure the safety of our employees, our community, and to adhere to federal, state, and local requirements and the CDC recommendations of social distancing and limited public exposure in connection with the COVID-19 pandemic.&#160;We did not implement any furlough, layoff, or salary reductions during this time. These precautions have been instrumental in protecting our workforce and helping ensure continued development of our pipeline. We continue to evaluate our pandemic preparedness and response procedures and the advisability of continuing operations based on federal, state and local guidance, evolving data concerning the pandemic and the best interests of our employees, third parties with whom we collaborate, and our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Compensation and Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our commitment to pay equity for all colleagues is rooted in our core values and our intention is to continue to build a diverse and inclusive workforce. We are committed to equitable pay practices for employees based on role, education, experience, performance, and location and Armata conducts pay equity reviews on an annual basis. We believe that we must offer and maintain market competitive compensation and benefit programs for our employees in order to attract and retain qualified personnel. In addition to cash compensation, we provide equity compensation, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and employee assistance programs. We also have a defined contribution plan in the United States, enabling eligible employees to contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#500050;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate History and Reorganization </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our company was created as a result of a business combination of Armata (formerly known as AmpliPhi) with C3J that became effective on May 9, 2019. Immediately prior to the closing of the Merger, AmpliPhi changed its name to Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">C3J&#8217;s predecessor, C3 Jian,&#160;Inc., was incorporated under the laws of the State of California on November&#160;4, 2005. On February&#160;26, 2016, as part of a reorganization transaction, C3 Jian,&#160;Inc. merged with a wholly-owned subsidiary of C3J, and as part of this process, C3 Jian,&#160;Inc. was converted to a limited liability company organized under the laws of the State of California named C3 Jian,&#160;LLC. Prior to the Merger, C3J was privately held and was financed principally through a series of equity financings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AmpliPhi was incorporated under the laws of the State of Washington in March&#160;1989 as a wholly-owned subsidiary of Immunex Corporation and began operations as an independent company in 1992 as Targeted Genetics Corporation. In January&#160;2011, AmpliPhi completed the acquisition of Biocontrol Ltd, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. In November&#160;2012, AmpliPhi completed the acquisition of Special Phage Holdings Pty Ltd, a company based in Australia, with the goal of continuing research addressing the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">All periodic and current reports and other filings that we are required to file with the Securities and Exchange Commission (&#8220;SEC&#8221;), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant Section 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge from the SEC&#8217;s website (www.sec.gov) or through our Investor Relations website at https://investor.armatapharma.com. Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066, and our telephone number is +1 (310) 665-2928. We maintain a website at https://www.armatapharma.com, to which we regularly post copies of our press releases as well as additional information about us. The information on our website is not incorporated by reference into this Annual Report </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">on Form 10-K or in any other report or document we submit to the SEC, and any references to our website are intended to be inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:58.4pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_6245bd47_7b53_4a62_bd02_bbe9e5279a86"></a><a id="Item1ARiskFactors_490547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report and in our other public filings in evaluating our business. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties.&#160;Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, climate change, extreme weather and natural disasters. If known or unknown risks or uncertainties materialize, our business, financial condition, results of operations, cash flows, access to liquidity and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. The following discussion of risk factors contains forward-looking statements, as discussed in the Special Note Regarding&#160;</i>Forward-Looking Statements<i style="font-style:italic;">&#160;section in this Annual Report on Form 10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Summary of Risk Factors </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Below is a summary of the principal factors that make an investment in our common Stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making an investment decision regarding our common stock.</p><div style="margin-top:6pt;"><a id="_Hlk159848488"></a></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need substantial additional financing to develop our product candidates and implement our operating plans, including to support one or more pivotal trials in 2025 and beyond. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the Department of Defense and related entity standards could impact our ongoing and future development financing awards from the U.S. government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results from preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Innoviva, our principal stockholder, beneficially owns greater than 50% of our outstanding shares of common stock, which causes us to be deemed a &#8220;controlled company&#8221; under the rules of the New York Stock Exchange (the &#8220;NYSE&#8221;). In addition, Innoviva&#8217;s interests in our business may be different than our other stockholders.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Need for Additional Capital</b></p><a id="_Hlk159942136"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">The audited consolidated financial statements and accompanying notes thereto included disclosures that our recurring losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern. Our financial statements as of December 31, 2023 and December 31, 2022 were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2023, we had unrestricted cash and cash equivalents of $13.5 million, and we have had recurring losses from operations and negative operating cash flows since inception. In March 2024, we received an additional loan from Innoviva of $35.0 million. Our outstanding loans mature in January 2025 and in June 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">We will need to raise additional capital to support our operations and product development activities. Our ability to raise additional capital via equity or debt financing may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. We may also seek funds through arrangements with collaborators, grant agencies or others that may require us to relinquish rights to the product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to secure additional funds when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;">While we believe that our existing resources will be sufficient to fund our planned operations into fiscal year 2024, we cannot provide assurances that our estimates will be accurate, that our plans will not change or that changed circumstances will not result in the depletion of our capital resources more rapidly than we currently anticipate. Our future funding requirements will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and cost of our clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and when we receive future Australian tax rebates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent applications, claims, patents and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of lawsuits involving us or our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk159942157"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical trials and activities associated with discovery research are costly. We do not expect to generate any revenue from the commercial sales of our product candidates in the near term, and we expect to continue to have significant losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our ability to generate meaningful revenue and achieve profitability depends on successfully completing the development of, and obtaining the regulatory approvals necessary to, commercialize our product candidates. If any of our product candidates fail in clinical trials or if any of our product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our ability to generate future revenues from product sales depends heavily on our success in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and preclinical and clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a sustainable, scalable, reproducible, and transferable manufacturing process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either by establishing a sales force, marketing and distribution infrastructure, or by collaborating with a partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing additional internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and validating new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or other foreign regulatory authorities to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, our accumulated deficit was $308.8 million and we expect to incur losses for the foreseeable future. We have devoted, and will continue to devote for the foreseeable future, substantially all of our resources to research and development of our product candidates. Additional information regarding our results of operations may be found in our consolidated financial statements included in Item 8 in the Annual Report and in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Item 7 in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the Department of Defense and related entity standards could impact our ongoing and future development financing awards from the U.S. government. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">       On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium (&#8220;MTEC Agreement&#8221;), pursuant to which we received a </span>$15.0 million grant and have entered into a three-year program administered by the DoD through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total grant by $1.3 million to $16.3 million and extend the term into the third quarter of 2024. We plan to use the grant to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose-escalation clinical study of Armata&#8217;s therapeutic phage-based candidate, AP-SA02, for the treatment of <i style="font-style:italic;">S. aureus</i>&#160;bacteremia. As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and may result in the termination of our government contracts, including the MTEC Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;background:#ffffff;margin:0pt;">Government contracts and grants normally contain additional requirements that may increase our costs of doing business and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tracking of contract costs and maintenance of effective controls over tracking of such costs; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion and submission of periodic reporting packages;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">mandatory financial audits and potential liability for failing such audits; and  </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs, and environmental compliance requirements. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      While we believe we are in compliance with all requirements under the MTEC Agreement, potential failure to maintain such compliance could result in reduction of the grant or termination of the contract, which could in turn negatively impact our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b> </p><a id="_Hlk159942384"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are developing our product candidates with bacteriophage and synthetic phage technology. We have not, nor to our knowledge has any other company, received regulatory approval from the FDA or equivalent foreign agencies for a pharmaceutical drug based on this approach. While<i style="font-style:italic;"> in vitro</i> studies have characterized the behavior of bacteriophages in cell cultures and there exists a body of literature regarding the use of phage therapy in humans, the safety and efficacy of phage therapy in humans has not been extensively studied in well-controlled modern clinical trials. Most of the prior research on phage-based therapy was conducted in the former Soviet Union prior to and immediately after World War II </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and lacked appropriate control group design or lacked control groups at all. Furthermore, the standard of care has changed substantially during the ensuing decades since those studies were performed, diminishing the relevance of prior claims of improved cure rates. We cannot be certain that our approach will lead to the development of approvable or marketable drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developing phage-based therapies on a commercial scale will also require developing new manufacturing processes and techniques. We and our third-party collaborators may experience delays in developing manufacturing capabilities for our product candidates and may not be able to do so at the scale required to efficiently conduct the clinical trials required to obtain regulatory approval of our product candidates, or to manufacture commercial quantities of our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of drugs based on these approaches, which could lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Results from preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Preclinical studies, including studies of our product candidates in animal disease models, may not accurately predict the result of human clinical trials of those product candidates. In particular, promising animal studies suggesting the efficacy of prototype phage products in the treatment of bacterial infections, such as<i style="font-style:italic;">&#160;P. aeruginosa&#160;</i>and<i style="font-style:italic;">&#160;S. aureus,</i> may not predict the ability of these products to treat similar infections in humans. Despite promising data in our completed Phase 1 clinical trials, our phage technology may be found not to be safe or efficacious in treating bacterial infections alone or in combination with other agents, when studied in later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we have used our bacteriophage technology in the area of targeted medicine under single-patient expanded access guidelines, which permit the use of phage therapy outside of clinical trials, in the United States and Australia. Despite prior single-patient expanded access successes, no assurance can be given that we will have similar single-patient expanded access treatment successes in the future. Single-patient expanded access is a term that is used to refer to the use of an investigational drug or therapy outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow single-patient expanded access on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs. In some countries, such as Australia, the treating physician can administer treatment under single-patient expanded access guidelines without pre-approval from the applicable regulatory authority.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To satisfy FDA or foreign regulatory approval standards for the commercial sale of our product candidates, we must demonstrate in adequate and controlled clinical trials that our product candidates are safe and effective. Success in early clinical trials, including Phase 1 and Phase 2 trials, or in our single-patient expanded access program does not ensure that later clinical trials will be successful. Our initial results from early stage clinical trials or our single-patient expanded access program also may not be confirmed by later analysis or subsequent larger clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials and most product candidates that commence clinical trials are never approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Delays in our ability to commence or enroll patients for our clinical trials could result in us not meeting anticipated clinical milestones and could materially impact our product development costs and delay regulatory approval of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates. Planned clinical trials may not be commenced or completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the development of manufacturing capabilities for our product candidates to enable their consistent production at clinical trial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures in our internal manufacturing operations that result in our inability to consistently and timely produce bacteriophages in sufficient quantities to support our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of financial resources to commence and complete our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with clinical investigators on study design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on trial design or in obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining clinical materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected patient recruitment for participation in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by clinical trial sites, other third parties, or us to adhere to clinical trial agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable clinical trial agreement terms with prospective sites or obtaining institutional review board approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse safety events experienced during our clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Completion of clinical trials depends, among other things, on our ability to enroll a sufficient number of patients, which is a function of many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the therapeutic endpoints chosen for evaluation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived benefit of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the clinical trial&#8217;s therapeutic endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators and sites with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition for patients from clinical trials for other treatments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Difficulties in enrolling patients in our clinical trials, could increase the costs or affect the timing or outcome of these clinical trials. This is particularly true with respect to diseases with relatively small patient populations. If we do not successfully commence or complete our clinical trials on schedule, the price of our common stock may decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are developing novel manufacturing processes for our product candidates at our current facility in Marina Del Rey, California. We are constructing the new manufacturing facility in Los Angeles, California and plan to move manufacturing processes to this new facility in the second half of 2024. The manufacturing processes for our product candidates, and the scale-up of such processes for clinical trials, are novel, and there can be no assurance that we will be able to complete this work in a timely manner, if at all. The manufacture of our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. If we were to encounter any of these difficulties, our ability to provide our products to patients in our clinical trials or to commercially launch a product would be jeopardized. Any delay or interruption could postpone the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program, and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any delay in the development or scale up of these manufacturing processes could delay the start of clinical trials and harm our business. In the event our facility in Los Angeles, California, does not receive a satisfactory cGMP inspection for the manufacture of our product candidates, we may need to fund additional modifications to our manufacturing process, conduct additional validation studies, or find alternative manufacturing facilities, any of which would result in significant cost to us as well as a delay of up to several&#160;years in obtaining approval for such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facility will be subject to ongoing periodic inspection by the FDA&#160;for compliance with cGMP regulations. Compliance with these regulations and standards is complex and costly, and there can be no assurance that we will be able to comply. Any failure to comply with applicable regulations could result in sanctions being imposed (including fines, injunctions and civil penalties), failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if we fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize our products in the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">We need FDA approval prior to marketing our product candidates in the United States. If we fail to obtain FDA approval to market our product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">This regulatory review and approval process, which includes evaluation of pre-clinical studies and clinical trials of our product candidates as well as the evaluation of our manufacturing processes, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals, including approval for an Investigational New Drug application (&#8220;IND application&#8221;), for any of our product candidates currently under development, other than for our product candidates AP-PA02 and AP-SA02, for which we received FDA clearance of our respective IND applications. Moreover, approvals that we obtain may not cover all of the clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">The FDA has substantial discretion in the approval process and may either refuse to consider any of our applications for substantive review or may form the opinion after review of our data that one or more of our applications are insufficient to approve our product candidates. If the FDA does not consider or approve any of our applications, it may require that we conduct additional clinical, pre-clinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We completed an investigator-sponsored clinical trial of AP-SA01 at the University of Adelaide in Australia for CRS in December&#160;2016. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the study must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study population must also adequately represent the U.S. population, and the data must be applicable to the United States population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, such studies would be subject to the applicable local laws and FDA acceptance of the data would be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. Further, with respect to AP-SA01, we have changed the product formulation to AP-SA02 and any work related to AP-SA01 may not be relevant to the FDA or other international regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities, preclinical studies, clinical trials and the anticipated manufacturing and marketing of our product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in Europe and elsewhere. There can be no assurance that our manufacturing facilities will satisfy the requirements of the FDA or comparable foreign authorities. We require the approval of the relevant regulatory authorities before we may commence commercial sales of our product candidates in a given market. The regulatory approval process is expensive and time-consuming, and the timing of receipt of regulatory approval is difficult to predict. Our product candidates could require a significantly longer time to gain regulatory approval than expected, or may never gain approval. We cannot be certain that, even after expending substantial time and financial resources, we will obtain regulatory approval for any of our product candidates. A delay or denial of regulatory approval could delay or prevent our ability to generate product revenues and to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in regulatory approval policies during the development period of any of our product candidates, changes in, or the enactment of, additional regulations or statutes, or changes in regulatory review practices for a submitted product application may cause a delay in obtaining approval or result in the rejection of an application for regulatory approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory approval, if obtained, may be made subject to limitations on the indicated uses for which we may market a product. These limitations could adversely affect our potential product revenues. Regulatory approval may also require costly post-marketing follow-up studies. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to the product will be subject to extensive ongoing regulatory requirements. Furthermore, for any marketed product, its manufacturer and its manufacturing facilities will be subject to continual review and periodic inspections by the FDA or other regulatory authorities. Failure to comply with applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls, product seizures, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials and to obtain materials or supplies necessary to conduct trials or to manufacture our product candidates, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use third parties, such as clinical research organizations, to assist in conducting our clinical trials and for many aspects of our manufacturing process development of our product candidates. However, we may face delays outside of our control if these parties do not perform their obligations in a timely or competent fashion or if we are forced to change service providers. This risk is heightened for clinical trials conducted outside of the United States, where it may be more difficult to ensure that clinical trials are conducted in compliance with FDA requirements. Any third party that we hire to conduct clinical trials may also provide services to our competitors, which could compromise the performance of their obligations to us. If we experience significant delays in the progress of our clinical trials and in our plans to submit Biologics License Applications, the commercial prospects for product candidates could be harmed and our ability to generate product revenue would be delayed or prevented.</p><a id="_Hlk159942565"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Our business operations and current and future arrangements with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we market, sell, and distribute our product candidates, if approved. Such laws include, but are not limited to, the U.S. Anti-Kickback Statute, U.S. civil and criminal false claims laws, the U.S. federal Beneficiary Inducement Statute, HIPAA, and state and local laws and regulations. Some of these laws may apply differently to, and may have different requirements for, and effects on, our business, rendering compliance complex and possibly burdensome. We cannot predict how future changes to these laws may impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties; damages; fines; exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other jurisdictions; integrity oversight and reporting obligations to resolve allegations of non-compliance; disgorgement; individual imprisonment; contractual damages; reputational harm; diminished profits; and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Furthermore, defending against any of these actions can be costly, time-consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any actions that may be brought against us, our business may be impaired.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk159942636"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face potential liability related to the privacy of health information we may obtain from the patients in our clinical trials if we fail to comply with privacy laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Most healthcare providers are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, if we receive sensitive personally identifiable information, including health information, we may be subject to state laws requiring notification of affected individuals and state regulators if a breach of personal information occurs, which is a broader class of information than the health information protected by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">We cannot assure you that we, our CROs, our clinical trial sites, and our clinical trial principal investigators with access to personally identifiable and other sensitive or confidential information relating to the patients in our clinical trials will not breach contractual obligations, or that we or they will not experience data security breaches or attempts thereof. This could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations as discussed above, which could in turn adversely affect our business, financial condition, results of operations, and prospects. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage, and transmission of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which could have a material adverse effect on our business, financial condition, results of operations, or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, many jurisdictions have established their own data security and privacy frameworks. In the United States, there are a broad variety of data protection laws that are either currently in place or under way and a wide range of enforcement agencies at both the state and federal levels have the authority to review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission (&#8220;FTC&#8221;), and state Attorneys General have been aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which went into effect on January 1, 2020, provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. There also is the threat of consumer class actions related to these laws and the overall protection of personal data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, the CCPA was amended by the California Privacy Rights Act, which significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations, which could result in increased privacy and information security enforcement. The majority of the provisions went into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in, or are being considered by, other states. The enactment of such laws in other states could result in potentially conflicting requirements, which would make compliance challenging and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FTC and many state attorneys general continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. We may also be subject to new state laws governing the privacy of consumer health data, including information concerning individual health conditions and treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>The data privacy laws in the European Union (the &#8220;EU&#8221;) have also been significantly reformed. The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the General Data Protection Regulation, (EU) 2016/679 (the &#8220;GDPR&#8221;). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR has expanded the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial patients and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the European Economic Area should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information or impose substantial fines for violations of the GDPR, which can be up to 4% of global revenues or &#8364;20 million, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own additional laws and regulations limiting the processing of personal data, including genetic, biometric, or health data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.33;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Furthermore, since the United Kingdom is no longer part of the EU, its data protection regulatory regime will be independent of the EU. From January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, which, together with the amended United Kingdom Data Protection Act 2018, retains the GDPR in UK national law. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. In addition, the longer term economic, legal, political, regulatory, and social framework to be put in place between the United Kingdom and the EU has had, and may continue to have, a material and adverse effect on global economic conditions and the stability of global financial markets and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which could materially and adversely affect our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability. To protect our proprietary positions, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>The patent application and prosecution process is expensive and time-consuming. We, our current licensees, or any future licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We or our current licensees, or any future licensors or licensees may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with our best interests. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and/or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. For example, European patent law currently restricts the patentability of methods of treatment of the human body more than United States law does. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#8239;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in derivation, ex-parte reexamination, or inter partes review proceedings in the USPTO or similar proceedings elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">result in loss of exclusivity or freedom to operate, a patent being held unenforceable, and/or in one or more patent claims being narrowed or invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in several areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties prior to beginning research or disclosing proprietary information. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Despite these efforts and the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information due to our reliance on third parties, increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The development and commercialization of new drug products is highly competitive. We face competition from major multi-national pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies and generic drug companies with respect to our current and future product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of drug-resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, more effectively marketed and sold or less costly than our product candidates, which could render our product candidates non-competitive and obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our competitors obtain marketing approval from the FDA, the EMA or other comparable regulatory authorities for their product candidates more rapidly than we do, it could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the United States, the FDA has issued several &#8220;interchangeability&#8221; designations for biosimilar products, and is expected to continue doing so in the future. These designations could &#8211; subject to state law requirements &#8211; enable pharmacies to substitute biosimilars for innovator biological products. Given </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the importance of biologic products to our clinical-stage pipeline, such regulation could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of our competitors have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do as an organization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain approval from the FDA, the EMA or other comparable regulatory agencies for their product candidates more rapidly than we may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA or the EMA, or our competitors establish a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Additional drugs may become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>reduced resources of our management to pursue our business strategy;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>decreased demand for any product candidates or products that we may develop;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>injury to our reputation and significant negative media attention;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>withdrawal of clinical trial participants;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>initiation of investigations by regulators;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>product recalls, withdrawals or labeling, marketing or promotional restrictions;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>significant costs to defend the resulting litigation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>substantial monetary awards paid to clinical trial participants or patients;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>loss of revenue; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inability to commercialize any drugs that we may develop.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently hold product liability insurance coverage in an amount that may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential advantages or disadvantages over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of the product, both in absolute terms and relative to alternative treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party coverage or reimbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our product candidates receive regulatory approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate product revenues sufficient to attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact profits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The continuing efforts of governments, pharmaceutical benefit management organizations, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect the price, market access, and total revenues of our products. These organizations, together with governments, have increasingly imposed utilization management tools favoring the use of generic products. As these practices expand, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. In addition, we have experienced and expect to continue to experience increased competitive activity, which has resulted in lower overall prices for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together, &#8220;PPACA&#8221;) and other legislative or regulatory requirements or potential legislative or regulatory actions regarding healthcare and insurance matters, along with the trend toward managed healthcare in the U.S., could adversely influence the purchase of healthcare products and reduce demand and prices for our products. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures will continue and may increase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">More recently, presidential administrations and the U.S. Congress have taken actions in an effort to modify or replace PPACA and to implement or pass other reforms to the healthcare system, including proposed legislation related to the pricing of pharmaceuticals. There is uncertainty with respect to any potential changes that may be proposed and what the impact, if any, will be on our business, including the impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by PPACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect that additional state and federal healthcare reform measures will be considered and potentially adopted, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures and may adversely affect our operating results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk159946225"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may be subject to government price controls that may affect our revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There has been heightened governmental scrutiny in the United States and abroad of pharmaceutical pricing practices considering the rising cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the former Trump Administration&#8217;s budget proposal for fiscal year 2020 contained further drug price control measures that could be enacted during the 2020 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#8239;D plans to negotiate the price of certain drugs under Medicare Part&#8239;B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. The former Trump Administration also released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for &#8220;certain high-cost prescriptions drugs&#8221; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. While some of these and other measures may require additional authorization to become effective, members of Congress and the Biden Administration have indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. For example, the recently enacted Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside of the United States, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</p><a id="_Hlk159939126"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Innoviva, our principal </span><span style="font-style:italic;font-weight:bold;">stockholder</span><span style="font-style:italic;font-weight:bold;">, beneficially owns greater than 50% of our outstanding shares of common stock, which causes us to be deemed a &#8220;controlled company&#8221; under the rules of NYSE. In addition, Innoviva&#8217;s interests in our business may be different than our other </span><span style="font-style:italic;font-weight:bold;">stockholder</span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, Innoviva owns 69.5% of our outstanding shares and 19,364,647 warrants to purchase shares of our common stock. If Innoviva were to exercise the warrants held by them, they would hold approximately 80.1% of our issued and outstanding shares of common stock. As a result, Innoviva owns more than 50% of our outstanding shares, and as such, we are a &#8220;controlled company&#8221; under the rules of the NYSE. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and, as such, may elect to be exempt from certain corporate governance requirements, including requirements that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_5"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a majority of the board of directors consist of independent directors;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_6"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the board of directors maintain a nominating and corporate governance comprised solely of independent directors and with a written charter addressing the committee&#8217;s purpose and responsibilities; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_7"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the board of directors maintain a compensation committee comprised solely of independent directors and with a written charter addressing the committee&#8217;s purpose and responsibilities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a &#8220;controlled company,&#8221; we may elect to rely on some or all of these exemptions, however, we do not intend to take advantage of any of these exemptions. Despite the fact we do not intend to take advantage of these exemptions, our status as a controlled company could make our common stock less attractive to some investors or otherwise harm our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Innoviva&#8217;s large ownership stake may allow it to exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including amendments to our articles of incorporation, adoption of measures that could delay or prevent a change in control or impede a merger, takeover, or other business combination involving us, and approval of other major corporate transactions. In addition, Innoviva&#8217;s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price. Accordingly, our stockholders other than Innoviva may be unable to influence management and exercise control over our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk159939175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The price of our securities has been volatile and may continue to be so. Between January 1, 2023 and December 31, 2023, the high and low sales prices of our common stock as reported on The New York Stock Exchange American varied between $1.10 and $4.35 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies&#8217; operating performance, in particular during the last several years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, we had outstanding common warrants to purchase an aggregate of 19,365,847 shares of our common stock at a weighted-average exercise price of $3.59 per share. We also have outstanding options to exercise 3,165,216 shares of our common stock at a weighted-average exercise price of $5.04 per share. To the extent any of our outstanding warrants or options are exercised, additional shares of our common stock will be issued which will result in dilution to our security holders and could also have an adverse effect on the market price of our common stock.</p><a id="_Hlk159942188"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations, and/or require us to relinquish rights to our technologies or product candidates</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Until such time, if ever, that we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, and strategic collaboration and licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, licensing or assigning our intellectual property rights, declaring dividends, and possibly other restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our Common Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">Attempting to secure additional financing may also divert our management from our day-to-day activities, which could impair or delay our ability to develop our product candidates. Furthermore, if, in the future, one or more banks or financial institutions enter receivership or become insolvent in response to financial conditions affecting the banking </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">system or financial markets, our ability to access our existing cash, cash equivalents, and marketable securities may be threatened and could have a material impact on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:10pt 0pt 0pt 0pt;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts. Alternatively, we could be required to seek collaborators for our product candidates at an earlier stage than would otherwise be desirable or on terms that are less favorable than might otherwise be available. We might need to relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development and commercialization ourselves, or to license our intellectual property to others who could develop products that will compete with our products. Any of these actions could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk159939219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises, political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine&#160;</span>and Israel and Palestine<span style="background:#ffffff;">) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory&#160;cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. It is not possible to predict the short- and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices,&#160;cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Additionally, the operations of our suppliers and manufacturers may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises, and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Any public health crises may affect our operations and those of third parties on which we rely, including our business partners and suppliers. The COVID-19 pandemic has had an adverse impact on the global economy, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking or might have to take again in the future to manage the pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Without limiting the foregoing, we have experienced and/or may in the future experience:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties enrolling patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or disruptions to the conduct of preclinical programs and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">constraints on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse impacts on our workforce and/or key employees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></td></tr></table><a id="_Hlk159939240"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operations could be disrupted by failure of our information systems or&#160;cyber-attacks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations could be disrupted if our information systems fail, if we are unsuccessful in implementing necessary upgrades or if we are subject to&#160;cyber-attacks. Our business depends on the efficient and uninterrupted operation of our computer and communications systems and networks, hardware and software systems and our other information technology. We collect and maintain information, which includes confidential and proprietary information as well as personal information regarding our employees, in digital form. Data maintained in digital form is subject to risk of&#160;cyber-attacks, which are increasing in frequency and sophistication.&#160;Cyber-attacks could include the deployment of harmful malware, viruses, worms, and other means to affect service reliability and threaten data confidentiality, integrity and availability. Despite our efforts to monitor and safeguard our systems to prevent data compromise, the possibility of a future data compromise cannot be eliminated entirely, and risks associated with intrusion, tampering, and theft remain. A failure of our systems, or an inability to successfully expand the capacity of these systems, or an inability to successfully integrate new technologies into our existing systems could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#160;The Company&#8217;s and its vendors&#8217; sophisticated information technology operations are spread across multiple, sometimes inconsistent, platforms, which pose difficulties in maintaining data integrity across systems. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction of confidential information stored in the Company&#8217;s systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential information could result in financial, legal, business and reputational harm to the Company and could have a material adverse effect on our business, financial condition, results of operations, cash flows and stock price.</p><a id="_99563c6f_47f2_459e_ad30_e303a776c3a5"></a><a id="Item1BUNRESOLVEDSTAFFCOMMENTS_454967"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_f40c9cd7_9e5e_4fb6_8048_1737f827dbc3"></a><a id="Item1CCybersecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Item&#160;1C.&#160;&#160;&#160;</b><b style="font-weight:bold;">Cybersecurity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include operational risks, intellectual property or trade secret theft, improper disclosure of confidential information, fraud, extortion, harm to employees or customers, and violation of data privacy or security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity risks related to our business, technical operations, privacy, and compliance issues are identified and addressed through a multi-faceted approach including third-party assessments, internal information technology (&#8220;IT&#8221;) </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">audits, and IT security reviews. To defend, detect, and respond to cybersecurity incidents, we perform cybersecurity reviews of systems and applications; audits of applicable data policies; vulnerability assessments and penetration testing using external third-party tools to test security control; security incident and event management; continuous monitoring, and threat intelligence gathering; conduct employee training; and implement appropriate changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We leverage third-party expertise to audit and test our cybersecurity program and perform employee awareness training. These include periodic reviews of cybersecurity threats and related controls, including review of periodic penetration testing conducted by independent third parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We maintain a cyber liability insurance plan underwritten by multiple insurance companies, which provides protection against certain potential losses arising from cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, including as a result of previously identified cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cybersecurity Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors and management. Our Board of Directors delegated oversight of Cybersecurity to the Audit Committee. Our board members receive reports and presentations on data privacy and security, which address relevant cybersecurity issues, and which can span a wide range of topics, including but not limited to, recent developments, evolving standards, vulnerability assessments, review of risks from third parties such as service providers and suppliers, and the current threat environment. These updates are presented by IT third-party experts, finance, and legal departments. Our board members also engage in ad hoc conversations with management on cybersecurity-related news events and updates to our cybersecurity risk management and strategy programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Audit Committee&#8217;s cybersecurity-related oversight includes the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Receiving notice of, and providing guidance with respect to, material cybersecurity incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing our risks and cybersecurity programs and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overseeing our management and mitigation of cybersecurity risks and potential breach incidents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing reports and key metrics on the Company&#8217;s cybersecurity and related risk management programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the progress of major technology-related proposals, plans, projects and architecture decisions to ensure that these projects and decisions support our overall business strategy.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our management engages with third-party experts who have significant IT expertise and broad cybersecurity experience, including in cybersecurity threat management, cybersecurity training and education, incident response, cyber forensics, insider threats, business continuity and disaster recovery, and regulatory compliance. Such individuals have significant prior work experience in various roles involving IT security, auditing, compliance, systems, and programming. These individuals are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents and design. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_72d39c6f_0542_43c6_ba70_6528752b34a7"></a><a id="Item2Properties"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;PROPERTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066. On October 28, 2021, we entered into a lease for approximately 56,300 sq. ft. of office, research and development and manufacturing space under a non-cancellable lease (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022, and the total lease term is for&#160;16 years&#160;and runs through 2038. Office space and research laboratories have been fully occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 sq. ft.) expected to be fully constructed and occupied in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a property located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease 35,500 square feet of laboratory and office space. The lease expires on December 31, 2031. The facility includes 19,500 square feet of BSL2 laboratory space dedicated to phage product development. The facility includes approximately 3,000 square feet of cGMP laboratory space, designed to produce clinical quantities of our phage product candidates for human trials and to perform in-house QC testing. We are actively seeking a sub-tenant to take over the remaining term of the lease from mid-2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that our existing office and laboratory space is sufficient to meet our needs for the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_ae11df6a_00ca_4756_9d13_fd690e121962"></a><a id="Item3LEGALPROCEEDINGS_563299"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject us to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</p><a id="_2ace9d0a_48da_449d_98b4_562def9020bc"></a><a id="Item4MINESAFETYDISCLOSURES_516138"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_ce69eb0d_99ac_4fe1_84da_5c9b721bd9aa"></a><a id="PARTII_630154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our common stock is traded on the NYSE American under the symbol &#8220;ARMP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;15, 2024, there were 73 holders of record of our common stock. As of such date, there were 36,148,539 shares of our common stock outstanding.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</p><a id="_Hlk159860319"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.4pt;margin:0pt 0pt 10pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans: See Part III, Item 12 of this Form 10-K for additional information required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_59c2faf3_00c4_4816_afe3_140f2b8b52bf"></a><a id="Item6SELECTEDFINANCIALDATA_873680"></a><a id="Item6Reserved"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;[Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None. </p><a id="_8cc78fa7_b7bd_415d_88b8_ebda1a16ac2d"></a><a id="Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes contained elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">. Some of the information contained in this discussion and analysis are set forth elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to risks described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report </i><i style="font-style:italic;">on Form 10-K</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-indent:16.2pt;margin:0pt 4pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We see bacteriophages as an alternative to antibiotics and an essential response to growing bacterial resistance to current classes of antibiotics. Bacteriophages or &#8220;phages&#8221; have a powerful and highly differentiated mechanism of action that enables binding to and killing of targeted bacteria while uniquely preserving the human microbiome. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as <i style="font-style:italic;">C. difficile</i>. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad- spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or &#8220;superbug&#8221; strains of bacteria. We are a leading developer of phage therapeutics and are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. We are completing two critical Phase 2 trials to ensure a pathway towards pivotal Phase 3 trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific host-engineered </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">current good manufacturing practice (&#8220;cGMP&#8221;) manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for advanced development. We are uniquely advancing two lead candidates to address both chronic and acute bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for&#160;Pseudomonas aeruginosa (&#8220;P. aeruginosa&#8221;). On October 14, 2020, we received the approval to proceed from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for our Investigational New Drug (&#8220;IND&#8221;) application for AP-PA02. In the first quarter of 2023, we announced positive topline results from the completed &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis (&#8220;CF&#8221;) and chronic pulmonary&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>infection. Data indicate that AP-PA02 was well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetics (PK) findings confirm AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending doses resulting in a proportional increase in exposure as measured in induced sputum and exposure achievement relatively consistent across patient subjects. Additionally, bacterial levels of <i style="font-style:italic;">P. aeruginosa </i>in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. In addition, a correlation was seen between increasing phage dose and reduction in the bacterial load supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled antibiotics. This study is supported by the Cystic Fibrosis Foundation (&#8220;CFF&#8221;), which granted us a Therapeutics Development Award of $5.0 million. Following the promising Phase 1b/2a results of favorable safety and tolerability profile and plausible mechanism of action, an additional confirmatory Phase 2 trial was initiated in NCFB patients with similar chronic pulmonary infections due to <i style="font-style:italic;">Pseudomonas aeruginosa</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On February 22, 2022, we announced that we had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (&#8220;NCFB&#8221;). We initiated a Phase 2 trial (&#8220;Tailwind&#8221;) in NCFB in 2022 and reported first patient dosing in the first quarter of 2023. The &#8220;Tailwind&#8221; study is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 phage therapeutic in subjects with NCFB and chronic pulmonary <i style="font-style:italic;">Pseudomonas aeruginosa</i><span style="white-space:pre-wrap;"> infection.  We are actively accelerating enrollment and increasing phage dosing with the goal of defining a safe and promising biologic correlation for a Phase 3 definitive trial in 2025 which will evaluate phage as an alternative to antibiotics in chronic pulmonary infections.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">In parallel, we have an acute bacterial infection clinical development plan focused on <i style="font-style:italic;">Staphylococcus aureus </i>bacteremia, a difficult-to-treat and often life-threatening human infections that can result in high morbidity and mortality and for which bacterial resistance to antibiotics is growing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">A key advantage of our phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate for <i style="font-style:italic;">Staphylococcus aureus</i> (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;); this has enabled us to pursue treatment of complicated <i style="font-style:italic;">S. aureus</i> bacteremia, where repetitive intravenous dosing is required. On June 15, 2020, we entered into an agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we expect to receive a $15.0 million&#160;grant and entered into a three-year program administered by the U.S Department of Defense (the &#8220;DoD&#8221;) through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the second half of 2024. The grant is being used to partially fund a Phase 1/2, multi-center, randomized, double-blind, placebo- controlled dose escalation study that will assess the safety, tolerability, and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia. On November 17, 2021, we announced that we had received from the FDA the approval to proceed for our IND application for AP-SA02. We are focused on accelerating enrollment of the Phase 2a segment of the &#8220;diSArm&#8221; study, evaluating safety with higher intravenous doses, which is possible due to the high purity of our phage product candidates. We are committed to developing a definitive efficacy trial in 2025 focused on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilize of broad-spectrum antibiotics and their detrimental impact of the normal human microbiome.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:138pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On August 1, 2022, we announced that we had received from the FDA the approval to proceed for our IND application for AP-SA02, in a second indication, prosthetic joint infections (&#8220;PJI&#8221;). We had planned to initiate a Phase 1b/2a trial in 2023, however in light of the growing concerns of both PJI and wound infection, we are revising the protocol to include both indications. Driven by data from the bacteremia study, and with sufficient funding, we may in the future initiate a Phase 1b/2a trial to assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing treatment of periprosthetic joint infections and/or wound infections caused by&#160;<i style="font-style:italic;">S. aureus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We remain committed to conducting randomized controlled clinical trials required for FDA approval in order to move toward the commercialization of its phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart summarizes the status of our phage product candidate development programs and partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><img src="armp-20231231x10k011.jpg" alt="Graphic" style="display:inline-block;height:137.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">We have incurred net losses since our inception and our operations to date have been primarily limited to research and development and raising capital. As of December 31, 2023, we had an accumulated deficit of $308.8 million. We currently expect to use our existing cash and cash equivalents for the focused research and development of our current product candidates and for working capital and other general corporate purposes. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and seeking to obtain regulatory approval of our product candidates. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates. We may also use a portion of our existing cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our existing cash and cash equivalents together with the $35.0 million loan proceeds received in March 2024 will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through one or more other public or private equity offerings, debt financings, collaboration, strategic financing, grants or government contract awards, licensing arrangements or other sources. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and potential disruptions to, and volatility in, financial markets in the United States and worldwide. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of assets, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations and result in a loss of investment by our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">2024 Credit Agreement</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, we entered into a credit and security agreement (the &#8220;2024 Credit Agreement&#8221;) for a loan in an aggregate amount of $35.0 million with Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) (collectively, &#8220;Innoviva&#8221;), our principal stockholder and a related party. The 2024 loan bears interest at an annual rate of 14% and matures on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by our domestic subsidiaries, and the loan is secured by substantially all of our assets </span>and our subsidiary guarantors<span style="font-family:'Times New Roman;">. Concurrently with the execution of the 2024 loan, we amended certain provisions of the Convertible Loan and Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">2023 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">On July 10, 2023, we entered into the Credit Agreement with Innoviva,. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25.0 million (the &#8220;Loan&#8221;) at an interest rate of 14.0% per annum and has a maturity date of January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by our domestic subsidiaries, and the Loan is secured by substantially all of our assets and our subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from our operating budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Loan was initially recognized at fair value of $21.2 million and subsequently accounted for at the amortized cost net of debt issuance costs and debt discount. We amortized $0.9 million of debt issuance costs and debt discount during the year ended December 31, 2023 using the effective interest method. The Loan&#8217;s annual effective interest rate was 27.3% as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="color:#231f20;font-style:italic;">2023 Convertible Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 10, 2023, we entered into the Convertible Credit Agreement with Innoviva. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30.0 million (the &#8220;Convertible Loan&#8221;) which bears interest at a rate of 8.0% per annum, and was scheduled to mature on January 10, 2024. Concurrently with the execution of the Credit Agreement, we amended certain provisions of the Convertible Credit Agreement, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Repayment of the Convertible Loan is guaranteed by our domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of our assets and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The Convertible Credit Agreement provides that if there is a financing from new investors of at least $30.0 million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of, and all accrued and unpaid interest on, the Convertible Loan shall be converted into shares of our common stock at a price per share equal to a 15.0% discount to the lowest price per share for common stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of common stock immediately prior to the consummation of a Qualified Financing event). The Convertible Credit Agreement also required us to file a registration statement (the &#8220;Registration Statement&#8221;) for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which we originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of common stock at a price per share equal to the greater of book value or market value per share of common stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On July 10, 2023, in connection with the Credit Agreement with Innoviva, we amended the terms of the Convertible Loan, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. We concluded that the amendment is an extinguishment for accounting purposes. We recognized a $1.8 million gain as the change in fair value of the convertible debt before the extinguishment date, July 10, 2023. We estimated fair value of the combined Loan and the Convertible Loan before and after modification and recognized an extinguishment loss of $3.9 million in the consolidated statements of operations for the year ended December 31, 2023. We recognized a $23.6 million loss as the change in fair value of the Convertible Loan from July 10, 2023 to December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of years ended December 31, 2023 and 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022 (dollars in thousands):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,529</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,508</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (979)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17.8%)</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,247)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.6%)</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,649</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,437</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,212</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.6%</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42,454</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,965</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">7.0%</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40,890)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,946)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,944)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">10.7%</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 179</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,626)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,626)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of convertible debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,845)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,845)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on convertible debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,863)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,863)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other (expense) income, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,155)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,184)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (69,045)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36,917)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,128)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">87.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">*Not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized $4.5 million and $5.5 million of grant revenue for the years ended December 31, 2023 and 2022, respectively, which represents MTEC&#8217;s share of the clinical development costs incurred for our AP-SA02 program for the treatment of&#160;<i style="font-style:italic;">Staphylococcus aureus</i>&#160;bacteremia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The following table summarizes our research and development expenses for the years ended December 31, 2023 and 2022 (dollars in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">External costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Clinical trial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,982</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (813)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(7.5%)</p></td></tr><tr><td style="vertical-align:middle;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development costs, including consulting, laboratory supplies and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,665</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,963</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 702</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">17.7%</p></td></tr><tr><td style="vertical-align:middle;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,758</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (111)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.8%)</p></td></tr><tr><td style="vertical-align:middle;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Internal costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Personnel-related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,665</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,638</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,973)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(17.0%)</p></td></tr><tr><td style="vertical-align:middle;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Facilities and overhead costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,621</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9.7%</p></td></tr><tr><td style="vertical-align:middle;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total research and development expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,247)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(3.6%)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Research and development expenses decreased by $1.2 million, from $35.0 million for the year ended December 31, 2022 to $33.8 million for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trial costs decreased by $0.8 million, from $10.8 million for the year ended December 31, 2022, to $9.9 million for the year ended December 31, 2023. The decrease is primarily due to a decrease in clinical trial expenses for AP-PA02 Cystic Fibrosis study and AP-SA02 Prosthetic Joint Infection study, offset by an increase in clinical trial expenses for AP-PA02 Non-Cystic Fibrosis Bronchiectasis study and AP-SA02 Bacteremia study, based on the progress of our clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other external research and development costs increased by $0.7 million from $4.0 million for the year ended December 31, 2022 to $4.7 million for the year ended December 31, 2023. We recognized $0.3 million and $1.0 million credits to research and development expenses related to the CFF grant for the years ended December 31, 2023 and 2022, respectively. Our spending on laboratory supplies decreased by $1.4 million, which was partially offset by a $1.2 million increase in consulting expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our external research and development expenses by project for the years ended December 31, 2023 and 2022 were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:17.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:54.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:17.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:middle;width:54.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Project name </b></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-PA02</p></td><td style="vertical-align:middle;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-Cystic Fibrosis Bronchiectasis</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,922</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,709</p></td></tr><tr><td style="vertical-align:middle;width:17.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-PA02</p></td><td style="vertical-align:middle;width:54.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cystic Fibrosis</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,692</p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,483</p></td></tr><tr><td style="vertical-align:middle;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-SA02</p></td><td style="vertical-align:middle;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bacteremia</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,789</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,254</p></td></tr><tr><td style="vertical-align:middle;width:17.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AP-SA02</p></td><td style="vertical-align:middle;width:54.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prosthetic Joint Infection</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">202</p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">560</p></td></tr><tr><td style="vertical-align:middle;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:54.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expenses not allocated by projects*</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.35%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,042</p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.56%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,752</p></td></tr><tr><td style="vertical-align:middle;width:17.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:54.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total external costs</p></td><td style="vertical-align:bottom;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;$</p></td><td style="vertical-align:middle;width:10.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14,647</p></td><td style="vertical-align:middle;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;$</p></td><td style="vertical-align:middle;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14,758</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expenses not allocated by projects include consultants, lab supplies and outsource service expenses </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Personnel-related costs, including employee payroll and related expenses, decreased by $2.0 million, from $11.6 million for the year ended December 31, 2022 to $9.7 million for the year ended December 31, 2023, largely due to a decrease in payroll and related taxes of $0.9 million and recruiting expenses of $0.3 million, as well as employee stock-based compensation expenses decrease of $0.8 million, which was primarily due to the full vesting of awards issued in prior periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Facilities and overheads increased by $0.8 million from $8.6 million for the year ended December 31, 2022 to $9.4 million for the year ended December 31, 2023, largely as a result of an increase in lease expense of $1.0 million, an increase of $0.2 million related to laboratory equipment maintenance costs, partially offset by a decrease of $0.4 million in expensed noncapitalizable lab equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $11.6 million and $7.4 million for the years ended December 31, 2023 and 2022, respectively. The increase of $4.2 million is primarily related to an increase of $3.7 million in legal, accounting and other consulting expenses, <span style="background:#ffffff;">a one-time expense of $0.5 million related to the prepaid financing costs</span>, an increase of $0.3 million in other facilities and overhead expenses, an increase of $0.2 million in leases and recruiting expenses, and a net decrease in personnel-related costs of $0.6 million, including a stock-based compensation expense decrease of $1.3 million, related to the full vesting of awards issued in prior periods and a reversal of expense related to certain equity awards modifications, offset by a $0.7 million increase in severance costs payable to two former employees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest income for the years ended December 31, 2023 and 2022 was $0.2 million and less than $0.1 million, respectively, which was related to interest income earned on our cash, cash equivalents and restricted cash balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized interest expense of $2.6 million for the year ended December 31, 2023, which relates to the interest and the amortization of debt discount and issuance costs for the Loan received from Innoviva in July 2023. Interest expense is accrued at each period end and is payable at the Loan maturity in January 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Fair Value of Convertible Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized a fair value of the convertible debt loss for the year ended December 31, 2023 of $21.9 million. The Convertible Loan received is accounted at fair value using a weighted probability of various settlement scenarios of the Convertible Loan during its term discounted to each reporting date. Conversion option scenarios are valued using an option pricing model with significant assumptions and estimates such as volatility, expected term and risk-free interest rates. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible Debt</i>&#8221;, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loss on Convertible Debt Extinguishment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognized a loss on convertible debt extinguishment for the year ended December 31, 2023 of $3.9 million which relates to the amendment to the Convertible Loan on July 10, 2023.The loss amount was estimated as a difference between the fair value of the Convertible Loan before and after modification. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible Debt</i>&#8221;, in our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liquidity, Capital Resources and Financial Condition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses since our inception and have negative operating cash flows. Our cash and cash equivalents of $13.5 million as of December 31, 2023, together with the loan proceeds of $35.0 million received in March 2024, will not be sufficient to fund our operations for the next 12 months from the date of this Annual Report. We plan to control our expenses and to raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and grant arrangements. These circumstances raise substantial doubt about our ability to continue as a going concern. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. We may not be able to secure additional financing in a timely manner or on favorable terms, if at all<b style="font-weight:bold;">.</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2024, we received a $35.0 million loan from Innoviva, which matures in June 2025 and bears interest at a rate of 14% per year. Principal and accrued interest are payable at maturity and may be prepaid at the Company&#8217;s option. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> During the year ended December 31, 2023, we received from Innoviva the Convertible Loan in the aggregate amount of $30.0 million and the Loan in the aggregate amount of $25.0 million from Innoviva. The Convertible Loan and the Loan mature in January 2025, and principal and accrued interest are payable at maturity. The Convertible Loan provides for various conversion and repayment options, including the conversion of principal and accrued interest into shares of our common stock upon a Qualified Financing and our option to repay the Convertible loan prior to maturity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Future Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital in the future to continue to fund our operations. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and cost of our clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of completing the construction and improvements of our leased premises to be used as our new headquarters. We expect to incur $5.4 million of additional expenses by mid-2024, which may increase or decrease as we complete the construction by mid 2024;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting and enforcing any patent applications, claims, patents and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of potential lawsuits involving us or our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek to raise capital through a variety of sources, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the public equity market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">private equity or debt financings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborative arrangements, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">government grants; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic financings. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">Any additional fundraising efforts may divert our management team from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on acceptable terms. If we are unable to secure additional funds on a timely basis or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 12pt 18pt;">certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations, increase a risk of insolvency and loss of investment by our stockholders. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities could result in dilution to our existing stockholders. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our sources and uses of cash for the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (47,423)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (32,481)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,134)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,211)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,988</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,016</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,569)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Net cash used in operating activities was $47.4&#160;million and $32.5 million for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities in the year ended December 31, 2023 was primarily due to our net loss for the period of $69.0 million, adjusted by non-cash net expenses of $31.3 million and a net change of $9.7 million in our net operating assets and liabilities. The non-cash items consist of $21.8 million related to a loss from change in fair value of convertible debt, $3.9 million related to the Convertible Loan extinguishment loss, $2.6 million of non-cash interest expense on the Loan, $1.0 million related to depreciation and amortization expense, $1.0 million related to change in right-of-use asset, $0.9 million related to stock-based compensation expense. The changes in our net operating assets and liabilities were primarily due to a decrease of $13.5 million in operating lease liability, mainly related to payments for our new leased facility construction, which we expect to complete by mid-2024, and rent payments, a decrease of $1.1 million in accrued compensation, partially offset by a decrease of $4.8 million in prepaid expenses and other assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities in the year ended December 31, 2022 was primarily due to our net loss for the period of $36.9 million, adjusted by non-cash net expenses of $4.0 million and a net change of $0.4 million in our net operating assets and liabilities. The non-cash amounts consisted of $3.1 million related to stock-based compensation expense and $0.9 million related to depreciation and amortization expense. The changes in our net operating assets and liabilities were primarily due to an increase of $3.6 million in operating lease liability, an increase of $0.8 million in accrued compensation, an increase of $3.7 million in accounts payable and accrued liabilities, partially offset by an increase of $7.7 million in prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows Used in Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $8.1 million and $2.2 million for the years ended December 31, 2023 and 2022, respectively, which is mostly attributable to purchases of laboratory and manufacturing equipment acquired for our new manufacturing facility. We expect our spending for property and equipment to decrease as our manufacturing facility will be ready by mid-2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash Flows from Financing Activities</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2023 was $54.0 million, which consisted primarily of net proceeds from issuance of convertible debt of $29.1 million and net proceeds from issuance of long-term debt of $24.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#160;Cash provided by financing activities for the year ended December 31, 2022 was $44.0 million, which consisted primarily of proceeds from the sale of common stock, net of offering costs of $44.4 million, proceeds from the exercise of stock options of $0.1 million, offset by payment of deferred offering costs of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we did not have any off-balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-indent:18pt;margin:0pt;"><span style="font-size:11.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-indent:18pt;margin:0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements as of December 31, 2023 and December 31, 2022, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates and assumptions could occur in the future. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Although our significant accounting policies are described in more detail in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, to our consolidated financial statements included in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt;"><span style="font-size:11.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services) and in process research and development expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We record accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, we accrue the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Judgments and estimates are made in determining the accrued balances at the end of the reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Estimate of the Convertible Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2023, we entered into the Convertible Credit Agreement with Innoviva, which was amended in July 2023. The Convertible Loan includes various conversion and repayment options, including the conversion of principal and accrued interest into shares of our common stock upon a Qualified Financing and our option to repay the Convertible Loan prior to maturity. Refer to Note 7, &#8220;<i style="font-style:italic;">Convertible Debt</i>&#8221;, in the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional details.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for the Convertible Loan at fair value and changes in fair value are included in other income (expense) in the consolidated statements of operations in each reporting period. We estimate the fair value using a weighted probability of various settlement scenarios during the Convertible Loan term discounted to each reporting date. To estimate the fair value of the conversion option scenarios, we use an option pricing model with assumptions, such as volatility, expected term and risk-free interest rates. Changes in the fair value of our common stock and probabilities of scenarios significantly impact the fair value of the Convertible Loan. We expect to continue making these estimates until the Convertible Loan conversion or its maturity in January 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we estimated the fair value of the Convertible Loan to be $58.6 million. For the year ended December 31, 2023, we recognized a change in fair value loss of $21.8 million in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Refer to Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies</i>&#8221;, of the notes to the consolidated financial statements contained elsewhere in this Annual Report on Form 10-K.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><a id="_88666b08_f91c_4dc6_9efc_63c5bdbd4cff"></a><a id="Item7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><a id="_4b5141d4_e34f_4ecc_a53d_0031b3bc0a40"></a><a id="Item8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_881c9b0c_3f18_4327_9505_0966956b863d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ARMATA PHARMACEUTICALS, INC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS</p><a id="_Hlk5121034"></a><a id="_Hlk128402546"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORT_OF_INDEPENDENT_AUDITORS"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (Ernst &amp; Young, LLP; San Diego, CA; PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:AuditorFirmId" id="Narr_S7O8UBKuJUm1wYZFcD_KYQ">42</ix:nonNumeric>) </p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_283036"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11pt;text-indent:-11pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11pt;text-indent:-11pt;margin:0pt;"><a href="#ConsolidatedStatementsofStockholdersDef"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; </span><span style="font-style:normal;font-weight:normal;">(Deficit)</span><span style="font-style:normal;font-weight:normal;"> Equity for the&#160;Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_487236"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:93.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_9"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements for the&#160;Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3452478d_acd0_47a5_8875_5d77533843db"></a><a id="REPORT_OF_INDEPENDENT_AUDITORS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Report of Independ</b><b style="font-weight:bold;">ent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">The Board of Directors and Stockholders of Armata Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Armata Pharmaceuticals, Inc. (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders&#8217; (deficit) equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Company&#8217;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-left:-0.25pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Accrued clinical trial expenses and related research and development costs</span></p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-size:10pt;font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">During 2023, the Company incurred $33.8 million for research and development costs and as of December 31, 2023, the Company recorded $3.0 million for accrued clinical trial expenses. As described in Note 3 of the consolidated financial statements, the Company records accruals for estimated ongoing research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. The Company accrues for the estimated ongoing clinical trial site costs based on patient enrollment and progress of the trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">Auditing management's accounting for accrued clinical trial expenses and related research and development costs is especially challenging as evaluating the progress or stage of completion of the activities under the Company's research and development agreements is dependent upon a high volume of data from third-party service providers and internal clinical personnel, which is tracked in spreadsheets and other end user computing programs.</span></p></td></tr><tr><td style="vertical-align:top;width:15.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><i style="font-size:10pt;font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81.89%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-size:10pt;">To test the completeness of the Company's accrued clinical trial expenses and related research and development costs, we obtained supporting evidence of the research and development activities performed for significant clinical trials. To assess the appropriate measurement of accrued clinical trial expenses and related research and development costs, our audit procedures included, among others, obtaining and inspecting significant agreements and agreement amendments, evaluating the Company's documentation of trial timelines and future projections of trial progress, confirming amounts incurred to-date with third-party service providers, and testing a sample of transactions and comparing the costs against related invoices and contracts. We also tested a sample of subsequent payments to evaluate the completeness of the accrued expenses and compared the results to the current year accrual.</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:AuditorName" id="Narr_Q1rp7hCmwEq2gB3JHSyJ6g">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company's auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="dei:AuditorLocation" id="Narr_ILKMJoKr4ku-H1HpBYzwtw">San Diego, California</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">March 21, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_070b6a25_d5ef_4102_8bca_7531f900fc11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"> Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedBalanceSheets_283036"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Bala</b><b style="font-weight:bold;">nce Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_12127a33_72b6_43c7_ad5e_da119baa9625"></a><a id="Tc_-ZJnC8eFMka4IqWyfwProA_1_2"></a><a id="Tc_LYbfmVj-I02BC74F92XNXw_1_5"></a><a id="Tc_tswkZkevhkug7eB05MVQoA_3_0"></a><a id="Tc_tqVl9aM8rkyVmKJ0PCwHjQ_4_0"></a><a id="Tc_mNE7i1OQE0CEB723Q8Ic4Q_5_0"></a><a id="Tc_ov-Q1bFKVU2dkAx-i-jD7g_5_2"></a><a id="Tc_mjboSZcjsEuyn-aV-IdQoQ_5_5"></a><a id="Tc_UCvM5NJf6EW8xEwp7lqL-Q_6_0"></a><a id="Tc_0MpkOZRXTU-oC4kpH0mmcQ_7_0"></a><a id="Tc_bT4-pAcoLUG-U9BoYj0n5Q_8_0"></a><a id="Tc_pbUeHbjAnE6zDjILyeLoxg_9_0"></a><a id="Tc_WxOK0KD-CESiyQKtvLD5Sg_10_0"></a><a id="Tc_o-NKvvY93E-zLSjl5D-07g_11_0"></a><a id="Tc_qwtTNuicREuuq4z6_IRY8g_12_0"></a><a id="Tc_qH4ZWOFeJE-sqxT7N9zO8Q_13_0"></a><a id="Tc_ksUGKJdfC0OTGfdtL_HIfw_14_0"></a><a id="Tc_jplaQ6zpP0-MyAw7XXnzpg_15_0"></a><a id="Tc_VYXvwPehQ0y-ghwK8n_wqA_15_2"></a><a id="Tc_IPjipW771kKREoln3g7fUg_15_5"></a><a id="Tc_4GKnSg8IQ0qV0pmD6q65oQ_17_0"></a><a id="Tc_Gki8DxMohk6GEalA_1ABNg_18_0"></a><a id="Tc_lkb0KzkoakOXfChMW89QTw_19_0"></a><a id="Tc_CujlJxiyckOSOb9g-s3Ccg_19_2"></a><a id="Tc_dru3eUIxQ0CAtFxhNC98iQ_19_5"></a><a id="Tc__8uOb0ODbk-75QPLCcNh_A_20_0"></a><a id="Tc_VGFRbFhwX0C1dvD6k7Nqyg_21_0"></a><a id="Tc_5JeuXxFch0SsNv9AoJxb1w_22_0"></a><a id="Tc_Q46sYUN-7UeD46y_3S6XYw_22_6"></a><a id="Tc_rdrSaSO2Q0OGKZn4ssESgA_23_0"></a><a id="Tc_e7mxXUVB30G1xHhYf3pUiw_24_0"></a><a id="Tc_edgaFUuFSE-vukF2Bt_SAQ_25_0"></a><a id="Tc_BfBJkEqTVUSRT3Dhila4-A_25_6"></a><a id="Tc_D4cEGhVti0mOHEc8H43QbQ_26_0"></a><a id="Tc_VlMkmFtxj0eupJTEQuB_AQ_26_6"></a><a id="Tc_NWAV1h-NnEGVJc8uMQ7EMA_27_0"></a><a id="Tc_v1xdOk2PTkGlj_HJ0WEOqw_28_0"></a><a id="Tc_IN8nzUmYzk6CxZP2cDJLMA_30_0"></a><a id="Tc_tydoYOgnIkOkBAfU9zEZKw_31_0"></a><a id="Tc_zNer6I0QNUO8fgomkbcEbQ_32_0"></a><a id="Tc_904ZZK4OoE2cDlLA-clLuw_33_0"></a><a id="Tc_ZogfMbSmRU6hrqyKqTy7ww_34_0"></a><a id="Tc_l_-oqUoI3EOOxPaJmEPXlg_35_0"></a><a id="Tc_SA9MKtpy9UaUS0PdFagi6g_36_0"></a><a id="Tc_yveDjC6ePkSOZ6kDT93y0A_36_2"></a><a id="Tc_tDOyQaI1t0qnZ8f8bvgSTg_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HwJolcMe4kC95OpuPE-EIA_5_3">13,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1guyLgwUbEK93D_fifA0rQ_5_6">14,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_MJ2kK-n4OE-jTf8tDPthvg_6_3">2,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_QNrhSnbaKUCScPYclix7Lg_6_6">3,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_RDY0wp7Tb0CRWpVMlIbHbg_7_3">3,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_PjJD-89i70eCFFOaXdgKgw_7_6">8,531</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_R5aeKtq9uEK_jZN7ZRBSbA_8_3">19,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_9LqzIeDCmECJopjX_4tThw_8_6">27,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_mI30TSs0qEmLQHOddPvgOA_9_3">5,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_3ZzJLbNRAEKEOXGN75Mq-w_9_6">5,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_OYm-VQnhUkqfcll4SQchFw_10_3">12,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_jD_4EyKJ90SUFbiBrgUxdA_10_6">3,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_KSHz9m2EVUiU_ukO7hPAow_11_3">44,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_HYYkNRIykkyxQYZ2dQKX0A_11_6">43,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_J2ADdtSVNESPP6VEM8EOWw_12_3">10,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_sCT54DBGI0evn7Hj5OgUFQ_12_6">10,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_EBdGj06VWUai_OWJfqgNNg_13_3">3,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_tRr6PwvYL0CWO5ieM4uhNA_13_6">3,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_jsLS4Z1IL0eg_HQtYbFjgA_14_3">2,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_w9eFLGJJwE2J-JWPJ4jWng_14_6">2,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_p_G9HI7dE0Oq36H1Pn4rXQ_15_3">98,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_p00RJ6wdyE2a_Ug25jnzWw_15_6">95,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; (deficit) equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc__1P0PCGVME6QnFnrVjTIdQ_19_3">5,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_6-NGHdo310e8y_Z_0oo6UA_19_6">6,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="Tc_uKpy37Pd3k6VuqU6T4GfIQ_20_3">768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="Tc_c2VV8jB9B0SEdpncFSkGZw_20_6">1,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_HeIouCtNUk2w_8Z9blrH7w_21_3">9,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_WpR_cLZT10uZwAiefZgDNA_21_6">17,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_yCqioTM5BUmHLADsrzfdcg_22_3">523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_aAWqNydpo06ztfoCUUXNOQ_23_3">16,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_3kQDxd8JvUO_rTEAL78VfA_23_6">24,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_IrnblRI1NkKp6eL1VB9H1Q_24_3">28,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_qz7HhLetm02lDlJAv-veoQ_24_6">31,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_r_xL0yl1IUW0C-h-IKLZ7g_25_3">58,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="Tc_gPjQJw2tyk-ZuWhuEd9sUQ_26_3">23,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_KLKw88lnzUS-Me_wZGuFpw_27_3">3,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_hEo75vfPGk-Ttmvp6Fvxiw_27_6">3,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_yFFMbkWDy0uOEW1Xc0XVmQ_28_3">130,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_r5ih07YY3UiJ2nw08XakOw_28_6">59,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and contingencies (Note 12)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; (deficit) equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_5ee0RZ4FvkShTfAb33a2UQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bU2je1C1LE2MWDP8CV89Xw">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_QMMj2u40PkCc5uMaMmvF6Q"><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ZPdagx63akyLhaWCYF-rew">217,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_lcUOkxT_Rka8eLtd42bDNQ"><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_GscygrkL0k6jHyljJvvkWQ">36,122,932</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_3LaYvntUV0-hd1zZ11j38Q"><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_MMyB1hqmZ0GWCVmToBdhoQ">36,144,706</ix:nonFraction></ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_nRF0d8lHNEuOXDFsaUyGeg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_awY-qMH9ckyLpRHsEO2jAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2023 and 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_k5HOoJbbvkmzuGtP6YrMDw_32_3">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__y1a4qPexU6E7L_i1zEUgA_32_6">361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_QhUQ-x1NDki52DJ-7oL9MQ_33_3">276,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_zsvwN6zEB0mq7_NnMIwHrQ_33_6">275,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_5QVwu-3vvUG0NQJh7NasBQ_34_3">308,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_iCOtdQWQFE2HxMfay4e_TQ_34_6">239,774</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:69.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total stockholders&#8217; (deficit) equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i0JyosD9J0KL-rVoPA1b1A_35_3">32,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NQjxGggYdkSWeqFt3HREqQ_35_6">36,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; (deficit) equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ewvTBi5jpUWiPFCAnBrjCQ_36_3">98,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_obY7LVToz0-jOcNEzs4tnQ_36_6">95,834</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4c34f9e7_f042_4f42_852f_720e54a2c8ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedStatementsofOperations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_28f4c26f_02db_4010_9135_ccfe0a531feb"></a><a id="_75c98eb6_37a3_4b01_97f9_afb013b06870"></a><a id="Tc_p2RVSRRxo0qsJb4R-bRTuA_1_2"></a><a id="Tc_3casDdCvaEuX5cmX13NK0Q_2_2"></a><a id="Tc_EWzT26netkqtHMe5gfUDZQ_3_2"></a><a id="Tc_u0s-Eqx1AkGccex6ZcL8eg_3_5"></a><a id="Tc_vEDZRlDFiUKU6daXogKYcw_5_0"></a><a id="Tc_xylH78_p2ES47QRwwwxVTA_5_2"></a><a id="Tc_J3fnCmgftkuf0geAzD85qg_5_5"></a><a id="Tc_ljnelcFcFUaGN-FkuvEIvg_6_0"></a><a id="Tc_DwomXOP-Mku90xNoDNjM4A_7_0"></a><a id="Tc_AtFk9PxQqUS0D2pXgKopuw_8_0"></a><a id="Tc_R1Crmus_XU65KlHF-yUEaQ_9_0"></a><a id="Tc__oFFIRfVS0aLjEiKWo4cYw_10_0"></a><a id="Tc_Wp4eRhAnmUOKO5meldXTRw_11_0"></a><a id="Tc_hLQ41sGgQkKEGK8HJclBfg_12_0"></a><a id="Tc_Xq_v7sWCUUWssJhMAosGiA_13_0"></a><a id="Tc_H6y4Ak1wikqxkSLfHRjPYg_13_6"></a><a id="Tc_Ft61WyanGUi860CJUxGXzw_14_0"></a><a id="Tc_62xEBsQ7x0G_BL1YR1iNBw_14_6"></a><a id="Tc_39t6ejVQr0iNoGHWyUcprA_15_0"></a><a id="Tc_0C8V88qrgU-9W4d4sYfRcA_15_6"></a><a id="Tc_Sy53dALbVkyrtJhL19gfWQ_16_0"></a><a id="Tc_NNZgrtyx-U2MBx_ty3wpDg_17_0"></a><a id="Tc_PrNGtoUrXEOstGFIDf_CHw_17_2"></a><a id="Tc_f6eDPJsm20ex6p36TArt3A_17_5"></a><a id="Tc_r3AzrJLQ_0mVz4g4StC7sg_18_0"></a><a id="Tc_gdlAP5AiUUeqKNrFvd4Hnw_19_0"></a><a id="Tc_KUbNCA-z2UikQcmUVFRxDQ_19_2"></a><a id="Tc_Fi4z4KgTHUGWjmcM-UPdBA_19_5"></a><a id="Tc_FtGFfqp0gEeaO19RUz92Ng_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_kErPigWsr0GY9VTyq_3SsQ_5_3">4,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_q4NmdBToHk6W65EQz_fm2A_5_6">5,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_n2vRtSotEk6RueR0ihkgCg_7_3">33,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_dhLwg6m-gEutbtZlPvELBg_7_6">35,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Iwh99PikH0a1SIn0u-ENAQ_8_3">11,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_jP-Bt5E0eEWEbO0XcS25gw_8_6">7,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_zLwHR6BdqECj1WBv7ZMgLg_9_3">45,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_6YhBgeVl6ECmOc0YBvW-2w_9_6">42,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_4EWa8k8PK0atFNg-2nCzag_10_3">40,890</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Qrgkf8UbZkyyHeFmn-ei8g_10_6">36,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_0g9OvhyVUkeSHp8igxWybA_12_3">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_NzfejvYxAUKSkjZD1wLDpA_12_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_NaABziuv0Eual17Cc7_pbw_13_3">2,626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of convertible debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="3" id="Tc_3zXyYgrmfECRhwL06dIEZw_14_3">21,845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on convertible debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_omhqtJc5MUe5LaMhEHtgjw_15_3">3,863</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other (expense) income, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_04V-AS5NIEWJcorHC3Qwgw_16_3">28,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_ZqlB71iXC0uB9nYx8fsWLg_16_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0j-B70OzE0WUtLx2skJ6AQ_17_3">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dvuU2fZsz0-SoYVJnBcUiw_17_6">36,917</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ikhzAcZbsU2r8UF9hoUdIQ_19_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ikhzAcZbsU2r8UF9hoUdIQ_19_3_2">1.91</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_pzJPjzFnAUqsZafVqDkM6Q_19_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_pzJPjzFnAUqsZafVqDkM6Q_19_6_2">1.08</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_1Y4Irtaye06BF2_u_CN8nQ_20_3"><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_1Y4Irtaye06BF2_u_CN8nQ_20_3_2">36,075,555</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_M3vajBIUTk6M1GbMnqJazA_20_6"><ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_M3vajBIUTk6M1GbMnqJazA_20_6_2">34,294,124</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd3fc609_1236_43eb_99b6_30a1d0ba2886"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="ConsolidatedStatementsofStockholdersDef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c02c31bb_de02_4d30_8738_bddb48aec784"></a><a id="Tc_exL3Z56otUeGzusB3_9quA_1_2"></a><a id="Tc_mfuhVYfTlkayhVrkAZAlNQ_2_2"></a><a id="Tc_It-J1k_BVk--VVbLE4DHnQ_3_7"></a><a id="Tc_YCdINYfrv0ewpypaN7eE3Q_3_13"></a><a id="Tc_4Sux7n1jU0KxWuOeS4Gl4Q_4_7"></a><a id="Tc_WgkZJO9edEG5sAPomjlong_4_10"></a><a id="Tc_oPO73n3zqk2raSouWGAEdQ_4_13"></a><a id="Tc_gCxdvrPRkEWVutlw7F8lfw_5_2"></a><a id="Tc_c0k7O19dxES634qSlAM2Vw_5_4"></a><a id="Tc_JCpiE7irQUqdtx5bai42yg_5_7"></a><a id="Tc_NtL2NnL6ykaYqCpJ4Sft2A_5_10"></a><a id="Tc_DENPj1_9r0u-z_pLD1mBmA_5_13"></a><a id="Tc_2rg8DO5-5UaFjgjyF7zPIg_6_0"></a><a id="Tc_wGiaWcC2HUiA1xYQbiK_Yw_6_4"></a><a id="Tc_2wCm6d3cTUiZTT38LSH5wA_6_7"></a><a id="Tc_e92idJFGeEiBze5he4zhSw_6_10"></a><a id="Tc_UuhhnGuQz0Wwyz-1JrkOTA_6_13"></a><a id="Tc_HDSqVhR8I0WlIDYF6FfTZg_7_0"></a><a id="Tc_anXJqiuFBUa-0eTQizmZrw_7_11"></a><a id="Tc_8Gkv8738Y0-_DDychQp8cQ_8_0"></a><a id="Tc_vUy3guFXt0yt3eaD0f5RTQ_8_5"></a><a id="Tc_lydb-M__SkSdXWKCQwOuHw_8_11"></a><a id="Tc_ZFwFisw_hE2F0OKj9M1UHA_9_0"></a><a id="Tc_LNBz-4oTjEOA2vzySUA0Pg_9_5"></a><a id="Tc_3FtsY4rev06F6goOU1zqrA_9_8"></a><a id="Tc_S547Rzz9ekSW-r6FLjX21g_9_11"></a><a id="Tc_n81xyFJVSEWnxYSNUEoa8A_9_14"></a><a id="Tc_ATFcxOFIXUa6wV4sUi6xyQ_10_0"></a><a id="Tc_q4_NjGmvPEaKfW9BhOP_7w_10_5"></a><a id="Tc_zcpjPfJLp0u2EE8umpm0Jg_10_11"></a><a id="Tc_LmICTAJj-kKXFxr7CA19Dw_11_0"></a><a id="Tc_NflDeKCA9kCjRuDTapJfFw_11_2"></a><a id="Tc_nIO32IzF0kW-2_c_FaT1kA_11_5"></a><a id="Tc_NOpX4CTNXkG_Y06YeTVayg_11_11"></a><a id="Tc_8WgR5X3qbEOYCDWDS92m4w_12_0"></a><a id="Tc_O-k7Hmx8U0GhjX6Q_MUftw_12_2"></a><a id="Tc_YSAF0ftZNEiUxrozgmP9NA_12_5"></a><a id="Tc_EhQh9HRO40ecmPkJWdQKhg_12_8"></a><a id="Tc_H73KLoHrFUKrsDso7ZCk9Q_13_0"></a><a id="Tc_apBH1dYl1EOqORAL7L6sTw_14_0"></a><a id="Tc_bRbuhiNUEUOk_IO2Q5ZzZg_14_5"></a><a id="Tc_0sWGOp2LsEmNlVNaf-4LwQ_14_11"></a><a id="Tc_0pA4R9Fn-kGX6r-upJeiWQ_15_0"></a><a id="Tc_ZRf654t5Zk-VS7O6CjT7-A_15_5"></a><a id="Tc_N8KBbR1tL06TPDd-djzSPg_15_8"></a><a id="Tc_fZ9Oz1BLJUKw9S_n9jrDJA_15_11"></a><a id="Tc_WOw6UZEo0kKVrSN1h-Y3XA_15_14"></a><a id="Tc_hLJSq80whkygOWfUOKFhLA_16_0"></a><a id="Tc_jgPe_2WY-k2WMKKmYNzS4A_16_5"></a><a id="Tc_wNa-y29xx0y7NVwsowgbEg_16_11"></a><a id="Tc_Fbn_4HY_vU-mQle9lZLUKQ_17_0"></a><a id="Tc_CRuheisFIEO056v_rYpozA_17_5"></a><a id="Tc_k8qdndPxK0-nFcRO4g404Q_17_8"></a><a id="Tc_1qpoWE4BakGfKmGqo7jCgA_17_11"></a><a id="Tc_ggJNu5aM0UG-u1S9athHow_17_14"></a><a id="Tc_WuytjxFsJ0yLQdTtuFYNTg_18_0"></a><a id="Tc_FVipPE3FwEur_B-TgH0VNA_18_2"></a><a id="Tc__286TlFKz0-b3RnzcFfavg_18_5"></a><a id="Tc_L2wB_I33Tk-j65-_j8L5Xg_18_11"></a><a id="Tc_8JgPLu8twkSEjam406nXeA_19_0"></a><a id="Tc_f94Sf_Sp-UWexVCYJEoZYg_19_2"></a><a id="Tc_OB36FQuChkiczCQZ__4PFA_19_5"></a><a id="Tc_G7-36PMxRUGSWLgLqlPQDg_19_8"></a><a id="Tc_O3qVIe3AGUeKANitQic8EA_20_0"></a><a id="Tc_S6Cllr4DE0GGcPsgYP7fvA_20_4"></a><a id="Tc_oSBnOjO4OUywgkLdITUCmQ_20_7"></a><a id="Tc_qDRp1440iESLuLfFLk2Cfg_20_10"></a><a id="Tc_m3qlpgUGVkacpIfzKrsUlg_20_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:61.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; (Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8YaGWH-6YES3TIYeN1jWGQ_6_2">27,112,299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HbspwTHot0yYZGfLI-ncFA_6_5">271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DWvEXjElOkq1isfN-8Jmcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LVOxuVOA9k-L3XJFHYb4Mg_6_8">227,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JojKduK3ZEKIWxJbgigbMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5IYMloMuU0SGRR4HYEAQSQ_6_11">202,857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jTMhnvK-FEKzxlLCVpi6fg_6_14">25,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of common stock, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_Bu6NiW9FpkuB74Fe42MeIg_7_2">9,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_hidDlrU-4kG5yaFF6d7DZA_7_5">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_sQxrdgFbTU6aeHE98s3x3w_7_8">44,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_sXIN8F-je0WKCGykmvhbdw_7_14">44,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholdings for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g" decimals="INF" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_ulFG2lXrNkORXDLVEJuXnA_8_2">5,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ" decimals="-3" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_7MsBDwV8OkyYK3xRgv28-g_8_8">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_t7XfR_qUhkS-xYn8va9PJA_8_14">21</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeiture of restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_m1rTOAkXlU6CRXafab8b0Q_9_2">369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_8qG-ATfQNEeHw0f_uaiWMg_10_2">38,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XQHQ4KzOSUe9zh11KHnwvA_10_8">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_6FSqAb6pVE6B8SuRWCjsJw_10_14">125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_7XjsNR0PbUSwv4ywpAXApg_11_8">3,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_s1fS0AF9RUSb1CVKh172ng_11_14">3,105</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vc4GxSB8DkissaxivoExGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_36gsRjvdtkSV2M5byWBg2A_12_11">36,917</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_82qH6W3gLk6Y8-4XFPvg8w_12_14">36,917</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_HpFM7r_rV0m_oF2955bcSw_13_2">36,144,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_m2jZFKh4Bki_E-snbi9zlQ_13_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pnWhyf4Eu02IKHMaDDg0eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mHdHfelzxUaOOlXMFEW3qQ_13_8">275,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wxAcBPHiMEauon7dJRUqsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ApkrQuHBoEaw1JRexENq7A_13_11">239,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__x5v_fHcF0-YWaC-QgULxw_13_14">36,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Withholdings for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ" decimals="INF" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_xC5Z8gpVskuupHDUfOCAOA_14_2">25,933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA" decimals="-3" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_JZXmuA9YUk6IhxMUUNleTw_14_8">43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="3" id="Tc_gkviz6yiBEa3SAXFPW_hIQ_14_14">43</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeiture of restricted stock awards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_ORr_cfWDUkiAuoosWzyrNw_15_2">27,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_siOgJjO-gEOOBPN_TCqH0Q_16_2">1,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_2u7zxwSnu0igooU_U17w1w_16_8">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_UX3QbH0wzEee09FgmBv3og_16_14">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_v-bvUdah2UK8eO-t8ikMCg_17_2">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_adbrhKGO2EKX6F3XbES2jg_18_8">938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_V9nxxsIXTUe0xHiW2dcC7Q_18_14">938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:36.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WMYo7GLLwEe8FdOQJ86O9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Dbx97IZhUUe_9KQGt_aLTg_19_11">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ztBOi0ZRBkCZumyyxaAZbA_19_14">69,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:36.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_T9fMsaJZx0q1t4k687pIZA_20_2">36,122,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QRv2kKoNcEiKYBUQnw2t0w_20_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ygs2ZPk4X0u6vTMLhKW83w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Q4DKz-9cIUSrPiQVLTht3g_20_8">276,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zg5utsGBa0WpBXEonilgjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SUN0NAlQAECL_Ut9x6UR8A_20_11">308,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HEJPaaMswkussmk01ZAe1A_20_14">32,065</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ee06be75_7e39_4562_96b4_ff76820e6aad"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Armata Pharmaceuticals, Inc. </b></p><a id="StatementsofCashFlows_487236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_89b7a427_a54b_4827_8b6a_8a98dd47cd7d"></a><a id="Tc_489d-bWnQUOqX2yKg0Q5uA_1_2"></a><a id="Tc_BUSFpRHqSEecxVdf3-KEeA_2_2"></a><a id="Tc_zN0GVMFhukyrh0YcY9GdeQ_2_5"></a><a id="Tc_Y-KIT8RGrUqqPTtFvBIw2A_3_0"></a><a id="Tc_Fx7-lYQuIEiXFjqVVatLtQ_4_0"></a><a id="Tc_5u4JYLfRkE2gxvTc9f08mQ_4_2"></a><a id="Tc_7BaQlEO_OUG1gI3tc0rc_A_4_5"></a><a id="Tc_pX_s34QRokiSlapemIgSeA_5_0"></a><a id="Tc_KlU6DgXzKk-7qA2O97ROFQ_6_0"></a><a id="Tc_QqqMbNiGzkOA_Kdrf2iyUw_7_0"></a><a id="Tc_K6qzc6uz_kCg_zgbgD6eYg_8_0"></a><a id="Tc_HLqFg7Gib0GpzdcoL06IhQ_8_6"></a><a id="Tc_BJ44Ufaip0CcZdfpWe4JYg_9_0"></a><a id="Tc_1v9znj_eJECNBCbU0a_xKg_9_6"></a><a id="Tc_AYafcKWFo0SWK-Zb2IOXcw_10_0"></a><a id="Tc_QKFd6xyWIEW7aVG8ItbXYw_10_6"></a><a id="Tc_3Kt1MXoFJ0ialEWDLgP-lw_11_0"></a><a id="Tc_Vi2OyWanRUCpIZhLGNftUA_11_6"></a><a id="Tc_11tlWxy4jUmPXGF_5c_ldw_12_0"></a><a id="Tc_jMbt3MuB90-4y94TXqDTjA_12_6"></a><a id="Tc_HTfncP2pKEOaIbh9-HrqJw_13_0"></a><a id="Tc_Lazegn1O00-IBCHV4fe-zg_13_6"></a><a id="Tc_7mI4aAWiqkOko031yTk-ug_14_0"></a><a id="Tc_fkLQ2izK3USW68xl-7o66A_14_3"></a><a id="Tc_TAR5gcJxME2UASA4f4tYXg_15_0"></a><a id="Tc_tEgtPLpqmE-CiYYRlj4Lig_16_0"></a><a id="Tc_bRJgkbJXdkKdRUjSr-oRrg_17_0"></a><a id="Tc_zTWOf2rRnUWQhDCVjN1g6Q_18_0"></a><a id="Tc_RHZy9sPiA06SCiH49C8ESA_19_0"></a><a id="Tc_6uzGWhLE70S_N6xo8y3UAA_20_0"></a><a id="Tc_xTO6ORDXYky8GmgAVrcjew_21_0"></a><a id="Tc_IUv2kFvWuE6sh5WG3c0_3A_22_0"></a><a id="Tc_eEHNtWYW6EWl_QqKNBEETA_22_6"></a><a id="Tc_kCY7zUF43EyBU7iASyzRcg_23_0"></a><a id="Tc_o0i3YHg400Ov36CRrb6kLw_24_0"></a><a id="Tc_nAXJTdAPVkeoAHK7eCAv5A_25_0"></a><a id="Tc_fn9USN9wsUCFtfb33hpnBg_25_6"></a><a id="Tc__WIPSTEK4Eey7TnbtoWl4g_26_0"></a><a id="Tc_2KeMDcPl5Uied7Ief4TFAw_26_6"></a><a id="Tc_KbnZ8dHohkumEMc2MNtbjQ_27_0"></a><a id="Tc_8HUTzhl4xEedv-MSTedmRA_27_3"></a><a id="Tc_B_PgHKu2O0CCH0uEUtvsZg_28_0"></a><a id="Tc_k-btSkA4N0ahEGiLcsF18w_28_3"></a><a id="Tc_XXokXgoWNUCvH9hUDJG37A_29_0"></a><a id="Tc_JPUXhqhQ00yKnphmnzQX0Q_29_6"></a><a id="Tc_92EEMYvtm0ydFyI45ttmwA_30_0"></a><a id="Tc_OOehp8grI0i9Xos0WvzWtg_31_0"></a><a id="Tc_ocUYyyMRV0SzZrSM8iBLvg_32_0"></a><a id="Tc_eDiaojXtHkCHl84Ti_aujw_33_0"></a><a id="Tc_2cIfDUoXEk2eTVXJGC6hFg_34_0"></a><a id="Tc_axXkrCAD6UOBGJPjSjJZHA_34_2"></a><a id="Tc_rAjf03Alo0iMhVN51U-Dmw_34_5"></a><a id="Tc_8iTUkC9m6ky5y5RDosLe6A_35_0"></a><a id="Tc_TDs0pilLRUi3LlZV2d3X1A_36_0"></a><a id="Tc_2ct6LiBRVkakVNPetNKVag_36_2"></a><a id="Tc_9gll9Z0Q7ky9HPtuDaGn6Q_36_5"></a><a id="Tc_Tyi5TJTk6USRUE_TKTh3ag_37_0"></a><a id="Tc_oev5q7l0XkGwINJ0oanHMA_37_2"></a><a id="Tc_5WMfcPMwYEGsz2IRjmwA_A_37_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_aNnkUMzjd0uIW_RNq9NB9w_4_3">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_I924XYNp2kmq_C2Y9R0iTg_4_6">36,917</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_xT_0YYMlbUqbjummqZW4nA_6_3">972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_h7NBVp9NDUm7xXrNH5STkQ_6_6">892</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ksAvlh9hwE66YEmR6XN2PQ_7_3">938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_88G3I7-suEm7g6otEGbmtw_7_6">3,105</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of convertible debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="3" id="Tc_CfHZc2OUyU6xbhucf3nlFw_8_3">21,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashExpense" scale="3" id="Tc_czPYShq-uU6u5F9IgvseCw_9_3">2,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:NoncashInterestIncome" scale="3" id="Tc_jWWOEXo4-Uavi2cKk4pUpg_10_3">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on convertible debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_XGDSNkiM_E6z6DhS12m3KQ_11_3">3,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_gbMxU_pYSkSHWInZoJXCmw_12_3">1,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss from disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="3" id="Tc_MaPepDEVj0CTqK15WYkaDg_13_3">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_GdV25Ri7bkWqS0hxYdpYSw_15_3">4,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_1QqztPN-W0yF9FrErAV43Q_15_6">7,662</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_aD9MvyY-10OMy4QGZMqXKA_16_3">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_u2olmD4iukymydwnHp4x6g_16_6">3,665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" sign="-" scale="3" id="Tc_MXWfU-_pG0qhkPG9TI_23g_17_3">1,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="3" id="Tc_iOB-Iin4_kOAogaf6HFXpw_17_6">793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_4pKTl-ji-ku6hxvEoL4Q9A_18_3">13,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_VXn7sMCNVkeHwTo-GcSAXw_18_6">3,643</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_2932icMxkkaPgT2btTnihQ_19_3">47,423</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_oZan2Pxhu0-phN15p8qWFw_19_6">32,481</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_n-rBRyRin0GYNZGothVvVw_21_3">8,144</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_M5x0caPGNk2IjBYTgUDTUg_21_6">2,211</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_IO6J3CEEEk6qb3OyyloCew_22_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr style="height:10.85pt;"><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_jpuunE7H_0exAeL30Kpznw_23_3">8,134</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_tnbpim781EO6kGR9EF1a0w_23_6">2,211</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of convertible debt, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="Tc_MCIenzzxeEqMKpKIcNraAw_25_3">29,101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of long-term debt, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" id="Tc_Qby56i_fCEu8E-pqDSsNCA_26_3">24,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment of deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_ADt_QaL96UKMwltpkGwqUw_27_6">500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sale of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_z-Aqbli8KUqFkupJ8WwMMw_28_6">44,391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments for taxes related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_4rrN0q6L1kKvfTI5g_ndWw_29_3">43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="3" id="Tc_wQyvzBBCaEySw_ggPQ-whA_30_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="3" id="Tc_pM2AQLpZ00KE9umU_0hhFQ_30_6">125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_iDaTT3g-20KJOFtU5TUK_A_31_3">53,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_asQU-OAL8EW8trLgWs7x5A_31_6">44,016</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_tYN6DDdsEkG5f-7oUTxxSQ_32_3">1,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_TsBGJ368TU-YO6_Qu8Gq7w_32_6">9,324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_9HTepAQdoUCNd8Qz_7jsNw_33_3">20,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6u3dsKFlXUKglBAT6rJvyg_33_6">11,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_rKJbHAkfYk-Y9F9H7G6mPQ_34_3">19,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_7Kla8Uns0kq5cl-xBtJKSg_34_6">20,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use asset obtained in exchange for operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_bl8Og0tqb0aSPhwBni-09w_36_3">2,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_BWXvE5cdVUuhCEUSr_eAGA_36_6">8,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContributionOfProperty" scale="3" id="Tc_Z79sOTG7n0uZymS9Bf4Drg_37_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContributionOfProperty" scale="3" id="Tc_fK1Pkbw-jUumc-LdKOxUaA_37_6">78</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_77c3e9c4_5a12_4585_8f5f_9f1e80029717"></a><a id="Tc_cv4lKcfp2EWyvlOJqcZLRQ_1_2"></a><a id="Tc_GKovNYJuGkiq_DuUqOzfZw_2_2"></a><a id="Tc_BYau9DpIDkmJFOjCVsLi-A_2_5"></a><a id="Tc_weJu5zor0kSGhWztTZZURw_3_0"></a><a id="Tc_l5GcHHtTA0WBKYMVJwBfsw_3_2"></a><a id="Tc_ZbMi0Xvhy0iDgl1OMOsXhQ_3_5"></a><a id="Tc_Cci6MXFpoEuJzsqQ1mAM-g_4_0"></a><a id="Tc_Q-yvyX0ZyUKK1ThXkZenlQ_5_0"></a><a id="Tc_WTiD8T44MEyd-uXMiKpMYQ_5_2"></a><a id="Tc_YWsZouSd9EO9dgsTeQyHdQ_5_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gT3cngBAXEeCqBGFSbEMHA_3_3">13,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_WrBiyC6bT02-utD2vSj1_w_3_6">14,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_1UF43Ml_CEaVTPcYWkJI1w_4_3">5,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_DdawSWriz0q_l6uvZ-E3CQ_4_6">5,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_MkKGqpq0lkeHAOGmmb4nuQ_5_3">19,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_W1NWOAxB3U-rlKXZfCWxFw_5_6">20,812</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_56e053f6_1177_4f51_9d07_ef1d055a4752"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc. </p><a id="NotestoConsolidatedFinancialStatements_9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_L5IxKZ12R0Wsxj4x-PNmNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;) together with its subsidiaries (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on </span>the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Armata&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VzI-WDpzmUOnyjPxPd0PDQ">0.01</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s principal stockholder, <span style="font-family:'Times New Roman;">Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of </span>Innoviva Inc. (&#8220;Innoviva&#8221;), owns <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsInc.Member_BsIuyO6JukO_7P1mhHHqVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_XPriai903EOLPJF5e8edAg">69.4</ix:nonFraction>% of the Company&#8217;s outstanding equity as of December 31, 2023. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_sBfL2nm_uUqs1c4xDma_2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="Narr_dCCbzYbAaE-oTxGvoHrWDA"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="Narr_4pZ4S3_zn0iQ40xA2207YA">90.0</ix:nonFraction></ix:nonFraction> million in total debt financing from <span style="font-family:'Times New Roman;">Innoviva SO</span> during 2023 and in March 2024. Innoviva designees represent <ix:nonFraction unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfDirectors" scale="0" id="Narr_MfUBRp8OMEiinZHHqWF-eQ">three</ix:nonFraction> out of <ix:nonFraction unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfBoardDirectors" scale="0" id="Narr_4BNVsMLvIU-JJP7WUWJTAw">eight</ix:nonFraction> Board of Directors seats during the year ended December 31, 2023, and cannot vote or take any action by written consent with respect to any shares of common stock held by Innoviva SO that represent, in the aggregate, more than <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_3pWA20zXBEiKjqY55V5Qxw" decimals="3" format="ixt:numdotdecimal" name="armp:CommonStockVotingPercentageHeldPercentage" scale="-2" id="Narr_iyXPyFzyJU-6Ac0Ge-fnVw">49.5</ix:nonFraction>% of the total number of shares of the Company&#8217;s Common Stock for voting on the matters related to election or removal of the Company&#8217;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the board of the Company in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#8217;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#8220;FDA&#8221;) of any of the Company&#8217;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_dp-fShiMP0eBXRBEZFPHiw" continuedAt="Tb_dp-fShiMP0eBXRBEZFPHiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_8NWxce0Ea0uNdlku7lfLyg">308.8</ix:nonFraction> million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_Q9qL4FoZFEGfELB3LF3RSQ">13.5</ix:nonFraction> million as of December 31, 2023, together with a $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_J6LoZnvwmU-H0xXce8EnYg">35.0</ix:nonFraction> million loan received from Innoviva in March 2024, will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent Financing:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2024 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, the Company entered into a credit and security agreement (the &#8220;2024 Credit Agreement&#8221;) for a loan in an aggregate amount of </span><span style="font-family:'Times New Roman;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_mhkULyAqIUy-ctHnvhuM8g">35.0</ix:nonFraction></span><span style="font-family:'Times New Roman;"> million with Innoviva SO. The 2024 loan bears interest at an annual rate of </span><span style="font-family:'Times New Roman;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_qeD66OwnvEuWTQPqoYpIsA">14</ix:nonFraction>%</span><span style="font-family:'Times New Roman;"> and matures on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets </span><span style="background:#ffffff;">of the Company and the subsidiary guarantors</span><span style="font-family:'Times New Roman;">. Concurrently with the execution of the 2024 loan, we amended certain provisions of the Convertible Loan and Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dp-fShiMP0eBXRBEZFPHiw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 10, 2023, the Company entered into a credit and security agreement (the &#8220;Credit Agreement&#8221;) for a loan in an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_oQtaqTSKUkeL3zVheLOvJA">25.0</ix:nonFraction> million (the &#8220;Loan&#8221;) with Innoviva SO. The Loan bears interest at an annual rate of <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_6jLt2qL8N0CeY4Y694yEHg">14</ix:nonFraction>% and matures on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. See Note 8, <i style="font-style:italic;">&#8220;Long Term debt&#8221;</i>, for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Convertible Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company entered into a secured convertible credit and security agreement (the &#8220;Convertible Credit Agreement&#8221;) with Innoviva SO. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_I-tnsCmT-EmD8pGs_iJ3KQ">30.0</ix:nonFraction> million (the &#8220;Convertible Loan&#8221;), which bears interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_-FyhnJzJAUibj5jsOT0RKQ">8.0</ix:nonFraction>% per annum and was scheduled to mature on January 10, 2024. Concurrently with the execution of the Credit Agreement, the Company amended certain provisions of the Convertible Credit Agreement to, among other changes, extend the term of the Convertible Loan to January 10, 2025. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The Convertible Credit Agreement provides for various conversion and repayment options, including the conversion of principal and accrued interest into the shares of the Company&#8217;s Common Stock upon a Qualified Financing (as defined below) and the Company&#8217;s option to repay the loan prior to maturity. See Note 7, </span><i style="font-style:italic;">&#8220;Convertible debt&#8221;</i>, for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_lZo5xR6ftEaEDlhWMPxviA" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_wDsCt_VBFk217ghwrRdpgg" continuedAt="Tb_wDsCt_VBFk217ghwrRdpgg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont1" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont2"><ix:continuation id="Tb_wDsCt_VBFk217ghwrRdpgg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:UseOfEstimates" id="Tb_HeWgQQd_Y0SCs3pSgprThw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_n0dEE8M36EeYqJzxIdMiyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The Company operates and manages its business as </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_gOsnGYsqFUyz-mk5KNXVlQ">one</ix:nonFraction></span><span style="background:#ffffff;"> reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. The long-lived assets of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="Narr_LAmyUUOAgEWWv14sjDdXjg">12.4</ix:nonFraction></span><span style="background:#ffffff;"> million, which represents </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw" decimals="3" format="ixt:numdotdecimal" name="armp:PercentageOfLongLivedAssetsInGeographicalLocation" scale="-2" id="Narr_mEEFsKnvSEiaEEHnJWaPbg">98.8</ix:nonFraction>%</span><span style="background:#ffffff;"> of the Company&#8217;s total long-lived assets, are maintained in the United States.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_lIyZUHbfsEuOmYh8-hUqfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_nXZCqhPWlU6hb5hAL6tjnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_w1Ultbpcs0WQkmEZ-BKuAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of <ix:nonFraction unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" scale="0" id="Narr_mUjp_UPVPkOot9xi17Y2KA">two</ix:nonFraction> irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_YTy8lB1a3k6c4kBMT61S6Q" continuedAt="Tb_YTy8lB1a3k6c4kBMT61S6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, convertible debt and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Convertible debt is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fe638ad4_b564_4471_9b69_ba5c657bb7a7"></a><a id="Tc_FozHHaxsrkm22_ew9-ouTw_1_2"></a><a id="Tc_ahNGHFht80WQkNgT2ZNHCA_2_0"></a><a id="Tc_D5WNA_zA0k6HMQhD3lQHbw_2_2"></a><a id="Tc_W-nxX8QWkkO0hfYdreTkuA_3_0"></a><a id="Tc_ZV5T9QjqNEONBJqNRv89gg_3_2"></a><a id="Tc_bGyVlj-QlEuTlhbojkE2xw_4_0"></a><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont2" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont3"><ix:continuation id="Tb_YTy8lB1a3k6c4kBMT61S6Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:PropertyAndEquipmentUsefulLifeTableTextBlock" id="Tb_YIRC0XMeq0KRLZ25s0_Vcw" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_lW6jZ9UquEKGNZUEVUTOlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_aSKXF4vFXk2HV-zlZwLzyg">5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_REZg-uX-1EKwp-ERlgSV_Q" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_P4ZB37EvNkWOcE5lV8YlHQ">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_v4Q6NyrSfkq9XoHpzL1dIw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_EDIpSZXuqEyVTDw-Haydyg">3</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_3nc2z43Z7UGKrOWYMeqg2w" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_zCoxQqko30CUZXADKRF0wQ">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_A6oWH4USHUyexNBiBGQMUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;padding-top:8pt;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_nKyLOtfPKke6twSYZ5qRlw"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_8PyNJFWSnkm-YgDz0RqYpw">No</ix:nonFraction></ix:nonFraction> impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2023 or 2022. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_YY4dDxIND0mIm5qBVzaNbQ" continuedAt="Tb_YY4dDxIND0mIm5qBVzaNbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">  IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2023 and 2022, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont3" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont4"><ix:continuation id="Tb_YY4dDxIND0mIm5qBVzaNbQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a result of the quantitative analysis. Consequently, <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="Narr_JkjSjdtfzEOsjpcXvYz2Zg"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="3" id="Narr_TIduGVW8PkuW1PmPnjJFYA">no</ix:nonFraction></ix:nonFraction> impairment loss was recognized as of December 31, 2023 and 2022. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_xHrSl4y0q0qb6mbDnWz3rg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Narr_k6OtbhePZEqrvOYXbZ97zw"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Narr_qmBDKq_BWEiipoW_ojxt_w">no</ix:nonFraction></ix:nonFraction> impairment as of December 31, 2023 and 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_-2C0UMoWFky6ovvkIvEsZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_Otstt6lBRkWGpdf0kSoiNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_gS2tYVl-WEmZgRZMMSY68A" continuedAt="Tb_gS2tYVl-WEmZgRZMMSY68A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont4" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont5"><ix:continuation id="Tb_gS2tYVl-WEmZgRZMMSY68A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:GrantsAndAwardsPolicyTextBlock" id="Tb_2GhINmvQFUmbbky4mxe7cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the Company recognized as other receivables in its consolidated balance sheets $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_GYmMI98-LUq4vo-3aWzwDQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="Narr_Q0vQhMi9t0yX9geUmCprvQ">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Te5w4AY0_02NlOunnmW1LA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="Narr_fV0HC6WXjk6T7Bv66hOBAw">1.9</ix:nonFraction> million, respectively, related to invoiced grant amounts that have not been received. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_yLl7iKPewkK9Iav3QO6FVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_s3S2nmIbA0KPQqQAsiZnyQ" continuedAt="Tb_s3S2nmIbA0KPQqQAsiZnyQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont5" continuedAt="Tb_lZo5xR6ftEaEDlhWMPxviA_cont6"><ix:continuation id="Tb_s3S2nmIbA0KPQqQAsiZnyQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_4XwBZOwRxESRRKFd3aUbNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2023 and 2022, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_alnktxrIB0We0KClP0-P0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_MSRPOu_IgEWkfiePea5CfA" continuedAt="Tb_MSRPOu_IgEWkfiePea5CfA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments</i><span style="color:#212529;background:#ffffff;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203;&#160;</i>(&#8220;ASU 2020-06&#8221;)<i style="font-style:italic;">.</i>&#160;&#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lZo5xR6ftEaEDlhWMPxviA_cont6"><ix:continuation id="Tb_MSRPOu_IgEWkfiePea5CfA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">contracts that may be settled in cash or shares impact the diluted earnings per share computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_HIQsz7pArkWZksAD9bAUKA" continuedAt="Tb_HIQsz7pArkWZksAD9bAUKA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents include investments in a money market fund of <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Narr__riT5gd9bU-on919MpslWw">zero</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="Narr_BB3H78SZMUOfEYLG43BO4Q">0.5</ix:nonFraction> million as of December 31, 2023 and 2022, respectively, which are carried at fair value and represent Level 1 financial instruments under the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company&#8217;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9a672f74_4a29_46c2_a8a2_b07c1adb739f"></a><a id="Tc_3Ru0SRJgWUusFtvp7mgJJg_1_1"></a><a id="Tc_qEaTz_1yBk69LckSRyPhSg_1_4"></a><a id="Tc__KbeivMl0Uaju3xpuYx0NQ_2_0"></a><a id="Tc_eQwClr84aUK9W5aSOBb3Pw_2_1"></a><a id="Tc_FKbQwMBMaU-d0AErMvrG2Q_2_2"></a><a id="Tc_Li9VhO7MIU2zWvo1p7WUHg_2_4"></a><a id="Tc_ZNKA2nmOZEaBO89R2juyvg_2_5"></a><a id="Tc_nwnUznhzD0GU2N_zwNZIgQ_3_0"></a><a id="Tc_uOFDypXhcU-uNzlUSeJwCw_3_5"></a><a id="Tc_KIOdJe2bD0Cp5pJQiU3gGQ_4_0"></a><a id="Tc_14rqpB_q0U2RDTLnVp2HMA_4_2"></a><a id="Tc_fXK7zZLAokeuXG48q4Jt-g_5_0"></a><a id="Tc_ef65timi0E-4rdwg0Z-H9w_6_0"></a><a id="Tc_RhEep6ovfk69d1MlRrG9ew_6_5"></a><a id="Tc_VLLA0CJJskmLcpDR6e2SpQ_7_0"></a><a id="Tc_sS2jWKDSaEyi0cwDqlxiHw_7_5"></a><a id="Tc_bQslwY-FREKIzuMl0c8f9g_8_0"></a><a id="Tc_Cv9hSUcs5UKyjw2EXNF6Kw_8_1"></a><a id="Tc_CC3vTksU-0i0jUk-oneTew_8_2"></a><a id="Tc_GFYPDEzLI0G97l94y7_3JA_8_4"></a><ix:continuation id="Tb_HIQsz7pArkWZksAD9bAUKA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">models with assumptions and estimates such as volatility, expected term and risk-free interest rates. Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company estimated fair value of its Convertible Loan using the following inputs.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_1MMPp0Q__0afmeehCm6CPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:21.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_FfCrkkswzEyIOb4f4Y5BlQ">21.01</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_Ge-QKxFKqUWwu7oL5XxJ8Q" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_N9SFlfHskUSxx-CM-02CGg">45.88</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_Vx583tTlMEyE357MszS1Mw" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_yT5JWTAchEKAurhbONU-SQ">0</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_83RZzW5ygkaAS8MPk5N2xQ" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_fvKnd7F3lkGRRaLS-agdYw">85</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_4ewXEPeSJk66n83-o6k-PQ" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_soj4pzDVLUiS1kNFJ4EwgA">101.1</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_hUTioPDLnkObuSOBkhrCew" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_Nc1mCOW-gUqq6nDI9CGckQ">123.6</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TbUu3jFyVUu5rQXxMkwPXg" decimals="1" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_96nBpaTRT0KTcJJxKRuX7A">0.2</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tsvjujuR6UaiVETAvUn3jg" decimals="1" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_VAiClTdxBEyMjA5YEmkhuA">1.5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pukUqhbV7Ei-VqpNu2EWAQ" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_H4QHojlvIUatjSbGeSUpYA">4.62</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mHtBiNhPKE6hrpyOdzp9qA" decimals="2" format="ixt:numdotdecimal" name="armp:DebtInstrumentMeasurementInputForPeriod" scale="0" id="Narr_w4R4zivZU0ak1lrsrdpWFg">5.39</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_2AeqMltGfkeSv8O4BgfkGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Post Modification</b></p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net proceeds from issuance of the Convertible Loan  (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_XyWKsMBtGkaymYEAHn5zUw_3_2">29,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q" decimals="-3" format="ixt:numdotdecimal" name="armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" scale="3" id="Tc_d84T2QZGM027gkA8c4Adiw_4_5">35,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" sign="-" scale="3" id="Tc_DtOParW_lkSmcazU-TfpFQ_5_2">1,757</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="Tc_8kQ1wRIKnUaitrQjIHen2w_5_5">23,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Convertible Loan exchanged  (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q" decimals="-3" format="ixt:numdotdecimal" name="armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" sign="-" scale="3" id="Tc_z1Maa7XXgkOc_thYe0Pxtw_6_2">31,332</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_P38hzPsmtU-Ay6ZG3sC1nA_7_2">3,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_C8m8rkPr3kO2_d83rkvc0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_LpPI_VfHSkSmZ8KY66nD6A_8_5">58,633</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the determination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7).</p></ix:nonNumeric></ix:continuation><a id="Tc_ac8Dh2b_HkCyqYws-gEogA_1_2"></a><a id="Tc_Sr4b8QISqE26_yGLDRZU2g_1_4"></a><a id="Tc_ZzyCzz6gPUi8Ha-5BtkH3Q_2_0"></a><a id="Tc_yfz6q58lIUyu2wXjOQPGYQ_3_0"></a><a id="Tc_bZtV1WBsv0yf2H_-vhiKTA_4_0"></a><a id="Tc_EAoexGypUkOkfW6s1syIXw_4_2"></a><a id="Tc_p0OZr7dhmUalo-Z8X2GrPA_5_0"></a><a id="Tc_sCF3H38M6kSUdK-OoDR3wg_5_4"></a><a id="Tc_kj1KszmTE0Wbo36uaerBMA_6_0"></a><a id="Tc_ErgyKB11skaEgYlwNCEDNQ_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_lLOoxg9SYEarGooqc63O5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities at December 31, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_wJnX5QmyJ0qK8srs4UINvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_rcx6iUYUmUmx_O6MTosjtg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ChIov5RWiEmN8wnbAiWDkg_2_2">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_om6vLPiiz0SKnHyQ-isXPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sjbMgpG9d0Gnkj9aWT1vgw_2_4">3,352,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_FHVNbN2hzEOd40sdvSt3oQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ulsiy61NkkmBQb_GFIDbQg_3_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_nxls9YDyCkOu7B6yakefXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_d3QF1u17U0GGwixMihMh0g_3_4">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_SYddo8Ixd0SHaimuYPVT7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_X5sd5uUDc0m_hpWbp8mW6Q_4_4">99,666</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_EWq8FVfJaUe4RYQsqoDOaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FtIzoj8MQEm7neXCovi5zg_5_2">21,293,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_pMc1sqe3X0KGAnGFAEcYPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_avijUnDlbU2f6Njnz-kGaQ_6_2">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6Zjp426i-0Ws_0siDNehrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LnHJPBReA0ebBGF-8oj9Vg_6_4">20,549,338</ix:nonFraction></p></td></tr><tr style="height:15.35pt;"><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L7-Yo3Wmqk2VbMGTfyU4jA_7_2">44,024,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_uHBrT1WRe0W9CvV2oahT7Q_7_4">24,031,807</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c461030e_4a8d_4a1c_bda3_93b6310da40d"></a><a id="Tc_T58xtmH_gkaqfQJJlFocww_1_2"></a><a id="Tc_DY1mnBXgU02XFVAm2DC4Nw_1_5"></a><a id="Tc_UyfzzeQz6ESUoyP4teI4bA_2_0"></a><a id="Tc_px0FNtwaTEaYrxM2KbwcmA_2_2"></a><a id="Tc_FnZ1J6Wly0KrZ5jJWRQ09A_2_5"></a><a id="Tc_jkUA3-h27ECDGFbpfsh7rg_3_0"></a><a id="Tc_hFBECpO2k0amuKI-wTxCKQ_4_0"></a><a id="Tc_WqoVro4IVUGQ1FViRjh0rw_5_0"></a><a id="Tc_ydYltfCGc06osQpo4HVKAw_6_0"></a><a id="Tc_xAEivLIYdUSsG9WgFpzWCw_7_0"></a><a id="Tc_iwYo9obUsUS_iEHDoo1LIA_8_0"></a><a id="Tc_stmRfz1qvUqUL-vS0UDwfw_8_2"></a><a id="Tc_EWmp_OwL-k2uO3F_zQz9pg_8_5"></a><a id="_05669ac6_6adc_4aed_967d_07caa7dc71d3"></a><a id="Tc_EUf9vnhcKkiJ428R8NfJ-Q_1_2"></a><a id="Tc_rfpIRf8IoU-BwDKeroJV2w_1_5"></a><a id="Tc_br40oRUDJkOyClJmmAZvdg_2_0"></a><a id="Tc_7XzQZLSApkSeTcSAPmyHwA_2_2"></a><a id="Tc_Sv4IPNAhWEWw2TNFJaZjGA_2_5"></a><a id="Tc_9OSTXeECqUaMYGuB48_dtg_3_0"></a><a id="Tc_6OXhMWLLlk22LpCt_B2bXQ_4_2"></a><a id="Tc_pbVGMhaLPkC5cK_1Qak9Jg_4_5"></a><a id="_ee72c2ad_c890_4967_bd69_0688a3782b8b"></a><a id="Tc_YnmbHYZsmU6a3ET1hA0zHg_1_2"></a><a id="Tc_w6FLgfgfpUWRbRk3lSFE3A_1_5"></a><a id="Tc_cpiS6pLo_EGI6SKtO_42bg_2_0"></a><a id="Tc_VKI-892X-Uirl3ka3I3NlQ_2_2"></a><a id="Tc_KiYSrbX3rUmnK6Xm6eHTZg_2_5"></a><a id="Tc_tlKeHm97MEO2lgje43G4IA_3_0"></a><a id="Tc_VRGLmRtZ5k6F77vLM0_UNg_4_0"></a><a id="Tc_PMPeb8cgP0-md2G2kRMy6w_5_2"></a><a id="Tc_9KGn0lMa8EmArnapElLXuQ_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_h78xaErIU0GWpsbPpg0z9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_meUu0WB0FkSC_QjRoV_sKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_wkZ_l3MDG06ZzDCA_d-g9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sZc4w4GCQEGIQv1WSEnqwQ_2_3">19,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_-vi_PXcqgkGHr5XNE2CtDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8npSlT3q3ky1HlLMkFEnyA_2_6">10,007</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xqoolKPjOkiiQNt83POWzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0mSIUllSpEGJ9cFb2mIDew_3_3">817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n_Dh4or6E0Sk6Dr2xnxPkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_vGGN-RKk00aB3oV1rBpqjA_3_6">817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A6LMOqmIk0W80NtUZ42iYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_J0CCIWiv_EOIQNyXU9X9lA_4_3">438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_fGX9O5gmiU6OnmLCkIvOIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_f8_2gsIBdkSBR0r7l8p5gg_4_6">449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7rH9B56et06bczua6JeANw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_CzvQVTucWk-bF56W6AVZbg_5_3">3,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_1GHmaB3J8k2Q9CUoft7lLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GofmZfpVUUelUTPUJlht_g_5_6">3,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YLGHTiNLCUyuFPVfB8HBWA_6_3">24,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_EXZyHkfmNE6kYYLV-A7ehA_6_6">14,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_EZrS6XB6UECNbaRFHT0fLg_7_3">11,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_FY_FGoxjAUyRvYqDUX9wtw_7_6">11,103</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_S_3WG2Exd0eGSKIkGIbA4g_8_3">12,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_zGut-b3y4kGhQB2zPgQCDQ_8_6">3,617</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_EkUuJ6cYNkKt7LcFT37ITw"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_DTy1WO_fnEKDxbnzmV9i6w">1.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_UophDDJE-EmNW6l_DrCG3g">0.9</ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, respectively. Property and equipment not in use was $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-5" format="ixt:numdotdecimal" name="armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" scale="6" id="Narr_HpJkJA4dM0iehEDMot1NtQ">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-5" format="ixt:numdotdecimal" name="armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" scale="6" id="Narr_ucs7I0c58kax5yBxockfZQ">1.0</ix:nonFraction> million as of December 31, 2023 and 2022, respectively, and are included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tenant improvement allowance receivable (Note 12)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="armp:TenantImprovementReceivableCurrent" scale="3" id="Tc_rWCCYAzSOkyvCgQT7EHbgw_2_3">1,835</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="armp:TenantImprovementReceivableCurrent" scale="3" id="Tc_KreKgAG9bES9mhfvQRsFTA_2_6">6,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant and award receivable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="armp:GrantAndAwardReceivableCurrent" scale="3" id="Tc_I2EdQsIZHkimkupidC4qwA_3_3">1,528</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="armp:GrantAndAwardReceivableCurrent" scale="3" id="Tc_RMeRtgYXGkur2RLbPQwNOA_3_6">1,936</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_ibK1zzq4fEuz7vqSY8W4zA_4_3">3,363</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_ALpNsBNPMUG7E18muUR8lQ_4_6">8,531</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Payable and Accrued Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_kri3--87jUOh5lx5jDdrQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_bm1f63X8PUWSPYmtvNtcUw_2_3">1,585</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_sLvnH_xCak2oOy1rPBvehQ_2_6">1,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="armp:AccruedLiabilitiesClinicalTrial" scale="3" id="Tc_PW1zF8Z49E2GH7bvfqL8Bw_3_3">3,021</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="armp:AccruedLiabilitiesClinicalTrial" scale="3" id="Tc_V-R20RMprk-MMbZ44krzFg_3_6">2,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="Tc_bzShjxBIx0CxFSvtr8aNbA_4_3">1,083</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="3" id="Tc_LIFj1k_L_kCjhzyMITvc1g_4_6">1,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_ahLfU21lR06rMUUbHH92sQ_5_3">5,689</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_TixAidWwoEKs1d_MiVkPAw_5_6">6,034</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:ConvertibleDebtDisclosureTextBlock" id="Tb_zMKvBapKlEmCvLyKZ2UwbQ" continuedAt="Tb_zMKvBapKlEmCvLyKZ2UwbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Convertible Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company received the Convertible Loan in the aggregated amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_Uc5OB2Q4P0W_ZHrGn2e1Ig">30.0</ix:nonFraction>&#160;million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_6rKSJtAAHkaGL8-TTvHF8w">8.0</ix:nonFraction>% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Credit Agreement with Innoviva to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;The Convertible Credit Agreement provides that if there is a financing from new investors of at least $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_mj_DWLuDI0Cq6OS1KhCggw" decimals="-5" format="ixt:numdotdecimal" name="armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark" scale="6" id="Narr_vhTOgLBQYkSE_RngOs6GDg">30.0</ix:nonFraction>&#160;million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zMKvBapKlEmCvLyKZ2UwbQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Loan shall be converted into shares of the Company&#8217;s Common Stock, at a price per share equal to a&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_czlMXp6LS0CZBIy4EFMggg" decimals="4" format="ixt:numdotdecimal" name="armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice" scale="-2" id="Narr_LiKjvvIJHkmHByuCIODHgA">15.0</ix:nonFraction>% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was market value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_IcliGnlNJk-Qxez13-t0wA">1.52</ix:nonFraction>&#160;(as may be appropriately adjusted for any stock split, combination or similar act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, <i style="font-style:italic;">Distinguish Liabilities from Equity</i>, due to the fact that the Convertible Loan will predominately be settled with the Company&#8217;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 10, 2023, in connection with the Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g" decimals="-5" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="6" id="Narr_Akpnq0rFa026DeZWNRNS2w">1.8</ix:nonFraction>&#160;million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_4jIr2Fq13kSjIoBSSzDRRQ">3.9</ix:nonFraction>&#160;million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_O-jDsojMjkyI7AvWBhYrOw" decimals="-5" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseFairValueOfLiabilities" scale="6" id="Narr_Om_uwqDlc0eYbI4mS6ZMLA">23.6</ix:nonFraction>&#160;million loss as the change in fair value of the Convertible Loan from July 10, 2023 to December 31, 2023.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:LongTermDebtTextBlock" id="Tb_DxBbFZ6NhUeSHBUGk_Sziw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Long-Term Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">On July 10, 2023, the Company entered into the Credit Agreement with Innoviva. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_iwZviXkaDEmYVNgqmKdKiA">25.0</ix:nonFraction>&#160;million at an interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_5QBVBpbumE61yaOpfjYUVw">14.0</ix:nonFraction>% per annum and has a maturity date of January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Loan was initially recognized at fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="Narr_tUxFfqcQM0iq5gu7lhZTaw">21.2</ix:nonFraction>&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_rNefiGGW7E2_oHbRpd8YOQ">3.8</ix:nonFraction> million. Debt issuance costs and debt discount in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="Narr_vF0w3byII06yq-1P8XcoiQ">0.9</ix:nonFraction>&#160;million were amortized to interest expense using the effective interest method during the year ended December 31, 2023 . The Loan&#8217;s annual effective interest rate was&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_TrUOd3F28EaQGoWWyXJpuQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_htFcvQ944k-ApGS_LfJszQ">27.31</ix:nonFraction>% as of December 31, 2023. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_vk7qhJae0E6NlIpxlgYP1g">2.6</ix:nonFraction> million interest expense for the year ended December 31, 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_D-wCcyU-Rkae7U5CRpx6HA" continuedAt="Tb_D-wCcyU-Rkae7U5CRpx6HA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Investment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">February 2022 Private Placement</i></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0b1d0c7b_3568_45e7_9e5d_385277645f19"></a><a id="Tc_DIpJKnIWNkuSNcvWRnI-4A_1_0"></a><a id="Tc_dVujcCMFcUGhoLha3VJfMw_1_2"></a><a id="Tc_prsfgPaKzke7Ixc2Qw-7jw_1_4"></a><a id="Tc_VuALH5FqLUe9znYsNpuzFA_1_7"></a><a id="Tc_uUIEdnfZ502WRO8WdeFIfg_2_0"></a><a id="Tc_0scALq6XyE-OyO151aBLKw_2_4"></a><a id="Tc_EH166xaZ5k6Q233007REXA_3_4"></a><a id="Tc_tquaT9OPEE-HkxZ9IRuRnA_4_4"></a><a id="Tc_K4oaiQNsD0ey_QBBh2-57Q_5_4"></a><a id="Tc_yqr56YJ_XEen_tS-zxuqjA_6_4"></a><a id="Tc_vOrbM7bc0k6bVYm1vNmkMg_7_4"></a><a id="Tc_uUhz8zDD7E-UhS9x8lvpnA_8_4"></a><a id="Tc_NvolGsxYRk2JYGOadn3CyQ_9_4"></a><a id="Tc_1iOhVEpBkEmZQtTjEK-7cQ_9_7"></a><a id="Tc_KbtpnnoBp0Kao6zwpX9kuQ_1_2"></a><a id="Tc_lkZ-vl4LakKHRVkMisrCiw_1_4"></a><a id="Tc_RpACIW5Blk2LsfCNN8IzNw_2_0"></a><a id="Tc_2xQbcmMYqkuYHXzTXqPlUg_3_0"></a><a id="Tc_OHVU8WJ4DkG0TYi_bn5avw_4_0"></a><a id="Tc_YMFwmNPZEUWzojB5T6Y2vA_5_0"></a><a id="Tc_G_yR_zBpwkq-q4q4-lL-Xw_6_0"></a><a id="Tc_ai_JWiWCJ0yLUW5-JskVeQ_7_0"></a><a id="Tc_21xVSkSNdE2kNdsiL19o5Q_7_4"></a><a id="Tc_uFJdoF4X3k-9wdTExCWRXg_8_0"></a><ix:continuation id="Tb_D-wCcyU-Rkae7U5CRpx6HA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On February 9, 2022, the Company entered into the February 2022 Securities Purchase Agreement to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_ftqcXLn_pEaX9uiZCz_1XQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_n6ackrKCXE6eVoRhWZUGbA">9,000,000</ix:nonFraction>&#160;newly issued shares of the Company&#8217;s Common Stock, at a price of&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BofIdizhzEisdyhJU1HUhw">5.00</ix:nonFraction>&#160;per share, and warrants to purchase up to&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_H2xAt9MD_EyvlSuL8SXigg">4,500,000</ix:nonFraction>&#160;additional shares of Common Stock, with an exercise price of&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1o1WLoiM_0WLlhC8I9H1Zg">5.00</ix:nonFraction>&#160;per share. The stock purchases occurred in&#160;<ix:nonFraction unitRef="Unit_Standard_tranche_1k3oA3frkU6EqwnuCcyDiw" contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfTranches" scale="0" id="Narr_joYSyJHOV0q9eWoHYns8pg">two</ix:nonFraction>&#160;tranches. On February 9, 2022, Innoviva purchased&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Cki5zso_nUWxHFLElwJbqg">3,614,792</ix:nonFraction>&#160;shares of Common Stock and warrants to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_AxXerjEGLUa8RmPTJVbwoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KZQt-CdA1Um6W_MJi7M1sw">1,807,396</ix:nonFraction>&#160;shares of Common Stock for an aggregate purchase price of approximately&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_vIlMNi1TF0K0V_v18d3IEA">18.1</ix:nonFraction>&#160;million. On March 31, 2022, upon the Company&#8217;s stockholders voting in favor of the transaction, Innoviva purchased&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_OfJfSDlG7k2G-n0I5Vx7zA">5,385,208</ix:nonFraction>&#160;shares of Common Stock and warrants to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_Zq7tR4QDd0qlIGHQ77DS4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_0sGrVV-hAEmcBYR4QZYq0Q">2,692,604</ix:nonFraction>&#160;shares of Common Stock for an aggregate purchase price of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_tAaUeDMgY0OkzCdUv_zG2Q">26.9</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Warrants issued to Innoviva expire in five years&#160;from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_5OKBdTgKlE2K5IiOBqK8nA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 31, 2023 and 2022, outstanding Common Stock warrants to purchase shares of Common Stock, all classified as equity financial instruments, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_d5V1utBQS0W089AQBKdTBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_JvuGaIs3CEq0WQJSB7269g_2_2">1,183,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_veV6l1wDOE6rGIRVVof-6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_EI7KV1sTGUyYBgSSRIJL3g_2_5">5.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_79MM9fi5r0mpadFpZPg7sg" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_znkQz7hVs06ZkGEyIuKQIg_2_7">October 16, 2023</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_zd4PRgGtTkGC5QCkUXgU1Q_3_0">993,139</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_tyr5b_wy9ECTpratVa4vhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_iDGGw3rt-EGfulG_dgQ7vw_3_2">993,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_5VAX9kPDj0aPN7RJc-8LeQ_3_5">2.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_kwVoHQWl5EakS1pp8Dn91w" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_6O93pFdzgUiX8nUzDrvldQ_3_7">February 11, 2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_9seWtEuGBEO3mZGgbO3JNg_4_0">7,717,661</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_RXIGKVqz6EWLhEi53nl4sw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_dt1alc3ECEmDkSTMSLr8-w_4_2">7,717,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_mSMgxEhSm0GPfARC5d9onQ_4_5">2.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_doi9Uq0Yh0K8BJ8ETe-s1g" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_oHRMHkbJeEW-dFGoUnicgg_4_7">March 27, 2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_LrzTQGPJN0mfr0GCiGNXow_5_0">1,867,912</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_XmFAWm3wPEyeDD2bMVjmxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_YP6QY2qP5EuP5c3ntrlFuw_5_2">1,867,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_vtknHfSyTUGRincWFwkL1g_5_5">3.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_BXtfSrwb30eZ5SWw-b7Zuw" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_fDGKZlEou0CMJRE1ZmI1rw_5_7">January 26, 2026</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_PHXk1HBpJkC4esqlmO3qhQ_6_0">4,285,935</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_pXWFLLYcXEmSfXZV4q_7FQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_UrnDtQepMUGmpu1ZyWmTjA_6_2">4,285,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_mjqmC8fSw0CF3h4oBmj9HQ_6_5">3.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_5dm2L74wiEGYYudTedh7mQ" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_VVkzE7tYxEKzziCPAUi4VQ_6_7">March 16, 2026</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_GgtpLLzxIUeH26JlVN_krQ_7_0">1,807,396</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_w_tgP8EIkkGCdbFSjG9OBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_NT-wpB0PdU67vXjlA8RLag_7_2">1,807,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_-g6KCRVWwUqWgBKi4PhXeA_7_5">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_l7DZ4uAjHkSVG38MOoqUEw" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_Z3FEsqYFdEStJl8cqykxlQ_7_7">February 8, 2027</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_7axIpjJJHkiYH4oM0HmVtQ_8_0">2,692,604</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_0FkAKCIhMkeJG_58ABDppQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_h854TUdSWUSF_XRbhd-klQ_8_2">2,692,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_KPOYFyNQq0aN_Q7-NUE-IQ_8_5">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_4KHIn5trmUGr81rnUbSvxA" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_QAkTh9UgR0K1Sd_tI8IAfw_8_7">March 30, 2027</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_f3jAI87UzUCJHhbylLyfqQ_9_0">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_sJ5c5RHAEEuMXqt3TUVkIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_m4K4dzV9LE6gPTB-GOlMaQ_9_2">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_UWNkIu1tr0-ScPKmLsUJdQ_9_5">1,680.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__csDiGg9PkiKsCh00y4kjg_10_0">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_89ivu3M3akiKpdKWQvAVpQ_10_2">20,549,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023 and 2022, the Company had reserved shares of its Common Stock for future issuance as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="Tb_KK9zb-CsCE-P83n-eGO1MQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zYfBI2uqX0m-Th9isM8V6A_2_2">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_AwZe2QpP9kqefDPx4AEC6w_2_4">3,352,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_1q8OCMCB00i-LLEH5pkdLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_-m5xQmxm4E-vtteZZEx-SA_3_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Cx9LlceetkeHRu-h_tXn_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_40RI5WwSmU-2ObuJoaY0sw_3_4">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" scale="0" id="Tc_w7AAPtcEy0-YC6FINVeLGw_4_2">9,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" scale="0" id="Tc_sUL1ED2IcUCUZj7ycGiPlw_4_4">9,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_i7XUFu_B10mLUKIJzKfMTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_6NpVz9clRECxLky1vk9aYA_5_2">2,368,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_uL_pp_97UEyeShgihirvbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_ZOiBnQW0zEuyzAFXhF4T_A_5_4">570,570</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_DIkP-9UNNkWSBLEIktbJZQ_6_2">19,365,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Q6HSe5cfmkSe8AMtjGQWxg_6_4">20,549,338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="armp:SharesIssuableUponConversionOfConvertibleDebt" scale="0" id="Tc_pjZ5n3ztjESlQQ3WTymJRA_7_2">21,293,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_PtIXlQWHCUGy8oZ4q1jYFA_8_2">46,402,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ldzxS32sVEKmJFrUi5IXgA_8_4">24,512,459</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_zU7XkKRP5E6ClmuUqrnt3w" continuedAt="Tb_zU7XkKRP5E6ClmuUqrnt3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_ZFDHBJzLP0GHlHUMt2FQew" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_orqEdv7ij0emLZwNIwJ1Rw">ten years</ix:nonNumeric>, the exercise price is the Company&#8217;s closing price at the date of grant and the vesting period is usually <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_q0GtuKNJvE-SBmuEJbJm6w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_6kE8Pe4kek-zgrcjgwxvCA">four years</ix:nonNumeric><span style="white-space:pre-wrap;">. The Company also granted RSUs under the 2016 Plan that vest over four years.  </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_bD7Lw7Z5hEqwB5LQLYktIg_1_2"></a><a id="Tc_fGtCL4V16U6mHqAphOBYBg_2_7"></a><a id="Tc_Oa4-ex6upUCBjscyXYIa9Q_3_7"></a><a id="Tc_-X80LzGIrUeWZpVRaSxgKw_4_4"></a><a id="Tc_iXPXZ6asOEaA2rnl5sfZDA_4_7"></a><a id="Tc_BDnXyr93ik2VTBSBDRqIkg_5_4"></a><a id="Tc_lbdqOcjs_0KLheiISrwOfA_5_7"></a><a id="Tc_4_qgozwrgk2YRqEE6bzr8Q_5_9"></a><a id="Tc_su9nD8kvd0SEOCY7uxbI0A_6_4"></a><a id="Tc_wrFvHKLJGUWEkzN0jUVZng_6_7"></a><a id="Tc_iqBm0qnp3USbDdvd5tebNA_6_9"></a><a id="Tc_4OZfZu8q60e_0lcMxITXBQ_7_2"></a><a id="Tc_NS7RmtXpg06XntnM3K6LCQ_7_4"></a><a id="Tc_SPLlB3sFsEewJsir5hUypA_7_7"></a><a id="Tc_j6zOZb6MSUGZGBaQetiReA_7_9"></a><a id="Tc_HQMT8bf-bEGs6npOw8SzGQ_8_0"></a><a id="Tc_hxlO1d0bgkmXbsuZvdd_Ww_8_4"></a><a id="Tc_Tr0Gx5tjekCUTxhmUdAngA_8_9"></a><a id="Tc_0IDGpBbHU0ueSgh45JN-4w_8_10"></a><a id="Tc_P4-0tH0gL0C2a2g8NHztCA_9_0"></a><a id="Tc_p8CeBQm02UyzDHGiIXleqg_9_4"></a><a id="Tc_-dUOd0CPTEy5p33amBqpzQ_9_9"></a><a id="Tc_eS546Gx__EW3C4EBtNCvjQ_9_10"></a><a id="Tc_rO-02nOLYUCys9pB3DI0nw_10_0"></a><a id="Tc_SM---LYsS0eRjoYOHIE7vg_10_4"></a><a id="Tc_volS8nkRiUagBggoXooWuA_10_9"></a><a id="Tc_jv-IlOVC10G5lEie6HSkkA_11_0"></a><a id="Tc_5pUo3kkf6kuJjBsIZIUXkA_11_4"></a><a id="Tc_zA0xHcZRTk2WMtjy9zSi9g_11_9"></a><a id="Tc_C0VELKI5E0mf6wVom46_Yw_12_0"></a><a id="Tc_Uj7pwROScUWiueUo9lynkw_12_4"></a><a id="Tc_seAMU74Kzkuyo0bbY6uT8Q_12_9"></a><a id="Tc_nXDKAmrboUKo38H9wWMQSw_13_0"></a><a id="Tc_1ePT64-doUKG8Xkygahcag_13_4"></a><a id="Tc_cuqQd0KOsUuyQutdnSnIUQ_13_9"></a><a id="Tc_A5NLk_zFJUC0fFc5RasfXw_14_0"></a><a id="Tc_mcFkyfguzEmgibifmmqQxQ_14_4"></a><a id="Tc_aH-95UgOYEu2YPe8f6vM_Q_14_9"></a><a id="Tc_jnlHh3I-FUel4GoKuRqXAQ_1_4"></a><a id="Tc_UezDsSGwtEymHGifOVD6VA_2_4"></a><a id="Tc_VmN_yzNljU202wzkO5ng_w_3_2"></a><a id="Tc_OEUM7qcTTkG7U8QM27-Vwg_3_4"></a><a id="Tc_wGlzrrrxskGrAOU4kr82iQ_4_0"></a><a id="Tc_bPt8fA43_0W4-4UN_ZmdGA_4_4"></a><a id="Tc_yc9BzVEdHUOGuqlMXEe4hQ_5_0"></a><a id="Tc_gVLA21qdpUWQmAA9rj7RhA_5_4"></a><a id="Tc_BxUTo39jgkGBXTTkS0fCLA_6_0"></a><a id="Tc_U0Hp6C8kq0qNiMF2PYbcXg_6_4"></a><a id="Tc_VKuQYyvjYU2rpmPsjbFX8Q_7_0"></a><a id="Tc_56VhGvNL-kqZ-jepnzV-tg_7_4"></a><a id="Tc_Kwo-ub-HOkyBC2czFc2raA_8_0"></a><a id="Tc_05xUnKTxZEG8JzybUnXXjA_8_4"></a><ix:continuation id="Tb_zU7XkKRP5E6ClmuUqrnt3w_cont1" continuedAt="Tb_zU7XkKRP5E6ClmuUqrnt3w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OMmauNLPakaOiKtpaNXVNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_ADJ3Op8lUkK5YLFNB-xx1g">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_No_HAmgL8EWAhkjjyjrUKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_BoP6md_oj0Ornq2OxsoUbw">2,368,160</ix:nonFraction> shares available for issuance under the 2016 Plan. The increase as of January 1, 2024 was <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OUfmlLp-ykK4CLqXmY3zwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_xmi8Gzc7GUGT46MSqZsNZw">1,807,235</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has issued restricted stock awards (&#8220;RSAs&#8221;) under certain legacy option plans that generally vested&#160;<span style="-sec-ix-hidden:Hidden_1t18bwPO80umxL4QF2kQLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>&#160;to&#160;<ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ylEWFQLG5kiObFZVsEjhXw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_6iKiBLlDxEu8YWFWQQgWoA">four years</ix:nonNumeric>&#160;based on service conditions. As of December 31, 2023, all RSAs were fully vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to its 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_Xh2cXAws6UaeUm5E472HaQ">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s Common Stock outstanding on December 31st of the preceding calendar year and <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Rp0IDHWw3kGGWBS-ki5OiA">30,000</ix:nonFraction> shares, subject to the ability of the Company&#8217;s Board of Directors to take action to reduce the size of the increase in any given year. There were <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_PngyjB_YzEy9gqMKIHrQxQ">no</ix:nonFraction> awards issued under ESPP. As of December 31, 2023, the Company had reserved <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_dpQ0qLj7T0mpc0O2hZcCzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_0hkEPHUXhk6W4bIVh2RWLA">9,748</ix:nonFraction> shares for future grants under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option activities during the year ended December 31, 2023 are presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ZZlf1kNE-kao-JJNQCiE6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kQzNgNE_tEuqf-CBzGGysQ_8_2">3,352,803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_2CNYLpxqFEqwXdl_K36u_w_8_5">5.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Din5Q_Jbok2ItwJKnm45Gg_8_7"> 7.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_rmQMefdMYkGuh9X2b9Etow_9_2">330,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__XINCCIoi06tbigC_eOUQg_9_5">2.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EJcqOO8huUCzYaYb9NzReQ_10_2">1,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_sQOVZ9liCEqUMPzutx2rZw_10_5">3.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Tc_d62utLWZiEmbpCp9Pwuhzw_10_10">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_N9_zPNpkckKRdJxT2Wycmg_11_2">516,353</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_S9o79hA3e0WqcshNNbI_dg_11_5">4.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" scale="3" id="Tc_Sl_i8ox0JUe5N_-_rOuqfQ_11_10">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_7df3xEfKkE2CHuef5qClgw_12_2">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_BtKTfwrAN02c-N8TMP9Y2Q_12_5">5.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_DygDbwI4z0Kwf7Q5m0eUxg_12_7"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_Q1BIsiykOkegTYNa5DGOlA_12_10">429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_7r7RV0nLd0SzCLxo6fT6YQ_13_2">3,165,216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ugV-sVRYr0-xmd7QQf45ug_13_5">5.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_dgEQIwJcz0mMPPvikbUB0w_13_7"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="Tc_iDnG6_ttkEml3QCbpcIAMA_13_10">429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_DG2gu5WW5Eq5xXXfGt88Kg_14_2">2,176,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_r7r8JOABk0mHBdPBLDFuxw_14_5">4.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_VkHJbPMTe0OUKkPqfL9OZw_14_7"> 4.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_k5LO2e3wGE6y3GYYkzaV_A_14_10">115</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The aggregate intrinsic value of options at December 31, 2023 is based on the Company&#8217;s closing stock price on that date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_a59dCoSHRUe2d884bvy41w">3.24</ix:nonFraction> per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted average grant date fair value of the options granted during 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_mynwKHdNtUeXHeTtVnhWCQ">1.97</ix:nonFraction>. The fair value of vested options during the year ended December 31, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_SjJ_5BjVG0aGMGtsqJgMSA">5.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2023 are presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" id="Tb_uZFiB-Sj8US6hMK4J_hwmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_x0dFNI1ebkq5FMnu6fUwrg_4_2">129,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_gQU__jUQX02Wpc1jR-3H7Q_4_5">27.11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc__g9LUa06cECgd9u-H2uYlQ_5_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_PImw2S_umEWmeHkRrUL7vA_5_5">2.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_H6NNFkX3wUenDfwsddK3Cg_6_2">27,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_azJnZWUGGUO7cATXSq2Stg_6_5">39.53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_Rui5c_9pekSjD4U2ooMugw_7_2">102,325</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_0HaE7FcDUEW54ZV4cBcaTQ_7_5">23.79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_mq5uDVAVJEiyFcGbm5-eCw_8_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_JeBfx5Wgp0azqYrhKaCbPQ_8_5">2.39</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_zE4rcCyt6USmgXwWa_MEqg_1_3"></a><a id="Tc_L_mOsxQi906xWTyDicjg9w_2_3"></a><a id="Tc_ipjROFsjDEGipCjTANHjyQ_2_5"></a><a id="Tc_EgMr_owjnk2FlwJPtM9YTg_3_0"></a><a id="Tc_Kd7W0sy4o0yT8LpZbVxhwg_3_3"></a><a id="Tc_JWhiZ9BkjUOfFGg-RmGGJA_3_5"></a><a id="Tc_Ej7hARDpaES-azvjo9UrfA_4_0"></a><a id="Tc_yKolPMZViU6nMufd7bGKgA_4_3"></a><a id="Tc_LLV9m5UPiUep6EwYDsKOAQ_4_5"></a><a id="Tc_Y2tGUXlWoE682rdhaVaTOQ_5_0"></a><a id="Tc_1hrKBRXA70GFqe8vvfQ6rg_5_3"></a><a id="Tc_4HDRFUa_UU--FCRwCobheA_5_5"></a><a id="Tc_xnxvKQOg_0WZlnMGpT10dA_6_0"></a><a id="_f074185f_e17f_4a1f_988d_541112e782df"></a><a id="Tc_mKDjsVhwMkGj5EiFoIh9wA_1_2"></a><a id="Tc_lS1hNAExnkG3X8GS61sh6g_2_2"></a><a id="Tc_wWjjW3mAlUqhRsCATeJ6wQ_2_5"></a><a id="Tc_Wee4Ofugq0CxyYokJjURHg_3_0"></a><a id="Tc_5sK0dbTZm0qy6H9YI1hdAA_3_2"></a><a id="Tc_L_kv7c0DfEiIFKrqH_Bf2g_3_5"></a><a id="Tc_geWsiTbVSEKm5ndNj9qkig_4_0"></a><a id="Tc_nJCFFP3LfkG9spllR1j7Aw_5_0"></a><a id="Tc_ZStL8azH1UunTneWcP4X8w_5_2"></a><a id="Tc_zskNYNn0L0qqUx4cez9Zow_5_5"></a><ix:continuation id="Tb_zU7XkKRP5E6ClmuUqrnt3w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_GuAAXAp3_Ua3LqS0uUE38A">1.8</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, restricted stock awards and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_4FazMg1MoUW2z0CAQf8ezg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_5tXGh2cg80m3coZGwMBV1g">1.7</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"><span style="font-size:7.35pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The assumptions used to estimate the options fair value were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_4D-uspOQ_0K_54ON_zQtRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.54% - <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_5gtvl7giZEGwZQOlYfq5Ow" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_wmevCVvk9UKiacX-ZqxERA">5.54</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_LCqVjfMIO06J26dfzj6dGQ" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_NJQlOint00mhWRIRLmYCnQ">2.65</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_azF0LYLH0Eq4EiRxHIMZRQ" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_Pk-aMLBeBEagx_rqRP6OYw">4.20</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_iZsH0I5d9UyGDhfUVO7qAw" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_FxHaeDdYs0OQzlxelQvRhw">75.40</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QO_xn3VwYkyovdqWx605rg" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_-ZlQ9wpc-0aaMsIzKeEzXw">116.96</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Fq3iw-UGaEOhlQJp0l-z4Q" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_xk7RIQuCKU2e6snPfN498g">81.81</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_HNJuosHgFUer-rys1t2UBg" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_z2zf3yRJI0WSyu3eHEEOZA">85.86</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_eys6RJJzYEKEN14qoaYnug" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_gynRtPP0UU-PXMOh_mgDTg">0.12</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wizMKQKiNEejMmObIFsIeA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_W0_SmUKaPEGMRXDWkQ_u4Q">7.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_gq2pn8IK_0adzHKv0TJgmg" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_1nTCTdY41kWSmv5Pm8XXCA">5.50</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_TJiIyKEV50aTZhkCduAAZQ" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_bHfAGpyx50aXNvHtL53GMg">7.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ" decimals="0" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Tc_UT6Tic0SjkuXfvYEnhKA5w_6_3">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_qhslJqPSVkGxmdvKQT37fQ" decimals="0" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Tc_b_8ZlXNgAk-Zxf4gIuE6Dg_6_5">0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2023, in connection with the resignation of its former chief executive officer, the Company amended the terms of certain of his awards. As a result, the Company reversed $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w" decimals="-5" format="ixt:numdotdecimal" name="armp:ShareBasedPaymentArrangementExpenseReversed" scale="6" id="Narr_JE3xAa8veUqSKllIulsTqA">0.6</ix:nonFraction>&#160;million previously recognized stock-based compensation expense related to his forfeited and unvested awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#8217;s consolidated statements of operations for the periods presented (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_2RzU8_6c60-X3sc7XkLEaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WsPyfLbv_Uq8yEsOaJ4xVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cI7k62InlkyAGp83-NW7mQ_3_3">1,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_QB0XCwT_Y0acqtRcKca_zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_OrMvXroCSkiqc8P99sTIaA_3_6">1,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6DKSiFkyFkW5utHfv7wgDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_0J1uDvFoDUG0Pt8SW5njIw_4_3">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbcT0OlsRk2u09atbDRY2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_SsfYU5BWg0Ce-ZEIteZY-Q_4_6">1,311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U06PJdHxRk-Rnwp3oJjskA_5_3">938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aez6if4rJUuf5SVzPOwFtQ_5_6">3,105</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_ac7c0bc8_d329_4b2e_bcf6_7b2aded6afe5"></a><a id="Tc_K6gBpaAkykKRs2JVmbF98A_1_2"></a><a id="Tc_u8UY3O9ROkyPkMu2nMXc6g_2_2"></a><a id="Tc_jJv-AcFRNk-_DUZCK8UF-w_2_5"></a><a id="Tc_gUMF_rbJ5UCJPZokKPUtqg_3_0"></a><a id="Tc_Ol2YdcOEaEOv0IDu9sFLPA_3_2"></a><a id="Tc_-BeH7MvuSU-rjpZSHsFhUA_3_5"></a><a id="Tc_Hn4cf7FWu0iOG6RQgSRl6Q_4_0"></a><a id="Tc_nY6OO8jwIkO7pWLWJIr_nA_5_0"></a><a id="Tc_J0pFkfKxnEmalq_VOFRjgw_5_2"></a><a id="Tc_Q2DZsH67HUqW95wrpd2-aw_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_LeXJkQ3T-UCGccyCxiNfVQ" continuedAt="Tb_LeXJkQ3T-UCGccyCxiNfVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_bchizV5oC0yJr1vlBQgdRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_xnODQD3KD0iTaAlpfa3G8A_3_3">68,182</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_QVVFfOD7b0SMcitnUv7tvA_3_6">32,228</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_o9QZ1Q8BoUKj4oLwd8pJjA_4_3">863</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_e9ev-dLbXEa9vBC4bywm5g_4_6">4,689</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_IGTj6ZCUyke5hg4PFWhw3A_5_3">69,045</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_gOlv_B-13U2wT9ZcWOCKPg_5_6">36,917</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_BQAahEPCvkOaSNZfkCDpCg" continuedAt="Tb_BQAahEPCvkOaSNZfkCDpCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_93feb81e_e9f7_43b4_a217_ce93452f0d22"></a><a id="Tc_XzxWWbHNNkyIgoLWT4DU6w_1_2"></a><a id="Tc_4nklMNFAKU2WQzrmpsx0Cw_2_2"></a><a id="Tc_TIhA3f_YBUiHKSFOrggpXQ_2_5"></a><a id="Tc_QD8IdO_ce06RDJpBXQkhWQ_3_0"></a><a id="Tc_CnFml4A5UEqBhKHDtAF-pA_4_0"></a><a id="Tc_IGvuQY-s7Eqnu--0c9LrCQ_4_2"></a><a id="Tc_S_X54VfWAEOFGH0g1xoTxw_4_5"></a><a id="Tc_B9gC71rWWUauWT9cBgAbFw_5_0"></a><a id="Tc_fbGXa2XD2kq4KuYOb_3f5Q_6_0"></a><a id="Tc_WuMd4ciOhEOVDxDT1zRnQg_7_0"></a><a id="Tc_VCHHeLDEkEmhcL1YNMA1JA_8_0"></a><a id="Tc_tAtyhV1l3k-ICBkkv52qTQ_9_0"></a><a id="Tc_cMPrs3ano0icGEz_92dXtg_10_0"></a><a id="Tc_iMGmQ4dEX0eVQRre_jDniQ_11_0"></a><a id="Tc_l0n7FMdK8UCI3DjOGYSUDg_12_0"></a><a id="Tc__HYIBNC34E20JvEIqZmM9w_14_0"></a><a id="Tc_G8ZiPwCHe023-Z62s_DTkg_15_0"></a><a id="Tc_rwAe2ct5w0-MD7726e195Q_16_0"></a><a id="Tc_gB40oQNRlkOIH-9CulW9Lw_17_0"></a><a id="Tc_qa5fo6YBn06K5hgG8GoBOA_17_6"></a><a id="Tc_F6wphUGPN0m1k9N6FvFm5Q_18_0"></a><a id="Tc_wXzg_A8qREWQ9B94N8bEKQ_19_0"></a><a id="Tc_ai0LoKBZdUC4tbqZV7MNCw_19_2"></a><a id="Tc_3ZHi36YDXkerb4bZrneYZg_19_5"></a><ix:continuation id="Tb_LeXJkQ3T-UCGccyCxiNfVQ_cont1" continuedAt="Tb_LeXJkQ3T-UCGccyCxiNfVQ_cont2"><ix:continuation id="Tb_BQAahEPCvkOaSNZfkCDpCg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_w4N46GNWd0OIYvyfOOE6HQ_4_3">46,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_BApsfpcOZUOZsMI0olA8zA_4_6">42,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_3h6uzoGPlEWTgt7GdaAmiQ_5_3">21,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_liUauk4bl0W5xitDnnOoEA_5_6">19,103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_4Y6bIWiMqU6xXHy7N20Dxw_6_3">2,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_cjWwGM78gUWaBdWxzHVBLA_6_6">3,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" id="Tc__TTlAuA_9UCx-anwwhxhrA_7_3">856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" id="Tc_YiphiFVp3EOdDD6Ir8xKrg_7_6">929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="armp:DeferredTaxAssetLeaseObligation" scale="0" id="Tc_YJW4Sg1YSEiodXcnTCjiNw_8_3">13,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="armp:DeferredTaxAssetLeaseObligation" scale="0" id="Tc_4GOeTRZc9Emn8-kabmmPHA_8_6">13,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_IBBA5UOsm0O8yaiFz1QRDA_9_3">1,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_4IgqeCTT5UKz_o7pcSMAtg_9_6">1,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_1wcA_W7AoUyUvulGlKVV6A_10_3">86,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_8g2_d_o3yEa4yLsbU-fFcA_10_6">80,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_fS5L0G9AxkWpDkzKflFU2w_11_3">75,166</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_HDAgU5xm4UGi-MghDixlvg_11_6">68,818</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="Tc_RmXfWRVvkE-6UNKvV_EMBA_12_3">11,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" id="Tc_ETJXSkZB50-STNOCP_VaIw_12_6">12,043</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="armp:DeferredTaxLiabilitiesRightOfUseAsset" scale="0" id="Tc_QMnFoWsaEEmI7_uquhULhA_15_3">11,510</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="armp:DeferredTaxLiabilitiesRightOfUseAsset" scale="0" id="Tc_m3w3ElQaFESzMlvl4AhqoQ_15_6">12,043</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="Tc_JNkj3inayEer3J42pxx_XQ_16_3">3,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="Tc_oJd85LUEEEKiZ2tN69lakA_16_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="0" id="Tc_OWDAIzd53k63sEd1xsRRIw_17_3">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_cu7RORLe-0y0pCMZ_SJxKA_18_3">14,678</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_CBRjMdqz3Eq8Zk5YLLgNmg_18_6">15,120</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="Tc_BraSibnmYU-CZkZKm3gLgw_19_3">3,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="Tc_xubY7l4pIU2HcJIPe2RM3Q_19_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards at December&#160;31, 2023 are $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ptpXGjY7OUuRjoPo1n6BLg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_upf7NmSQMU-DqYz3G8_IYA">167.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_BOYj4BFoD02NQ0BXyjD2Vw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_8SL2Dgihf0yyqOwvEAX9vw">118.9</ix:nonFraction> million for federal and state income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2028, respectively. The federal net operating loss carryforwards generated after 2017 of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-5" format="ixt:numdotdecimal" name="armp:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_p3ticoh-QEWGPXRedpft0w">113.1</ix:nonFraction> million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#8217;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_BkWosntCZUC6bp5OOQmiHw">6.3</ix:nonFraction> million during the year ending December 31, 2023:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_2rts5phxuUuxja-znn-6pA" continuedAt="Tb_2rts5phxuUuxja-znn-6pA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Qs9N6w-yNUKDaj8gswvQnA_1_2"></a><a id="Tc_v5KcQ69bF0KlVD6iJh_wSQ_2_2"></a><a id="Tc_MOgIktfyG0-IfQmjJoYm9A_2_4"></a><a id="Tc_PHL7dpRMEEuGc9e6gryHsA_3_0"></a><a id="Tc_yVOoK79nAk2MiLCoGFY9Tw_3_3"></a><a id="Tc_9zlFYagb_ESeUtAT0zjR-w_3_5"></a><a id="Tc_womRJ2nznUeXJfgNAEglYg_4_0"></a><a id="Tc_NFGN35rmCUavv9XyfFi5dw_5_0"></a><a id="Tc_9R25sOtgcUSxjHKF6-O1nQ_5_3"></a><a id="Tc_bGGeDrfnzUCGRDzmIJQ-lg_5_5"></a><a id="Tc_nVatxfgtFUqTS-FcjipW1g_6_0"></a><a id="Tc_RPVhZl1d1keILrDL9p5XCw_6_3"></a><a id="Tc_zjR-HYSquEqvui1oVMmq6A_6_5"></a><a id="Tc_SghVrDzG-UOdDDejMqAUYw_7_0"></a><a id="Tc_Ssy4vgbXUk25pmr301EmfA_7_3"></a><a id="Tc_-9ALisHpm0qIADDcsQCPLw_7_5"></a><a id="Tc_UfYDBbs06US3n8Mhkf9jGg_8_0"></a><a id="Tc_eZhGkzBR-0q4usAGJkd6mA_8_3"></a><a id="Tc_BwV7_hBd1UmgoTZG6xXglQ_8_5"></a><a id="Tc_HEnhoAIVDUuyrLtqJAAp8A_9_0"></a><a id="Tc_-v2pbItNYEatJ3smhpFJBQ_9_3"></a><a id="Tc_QGDCfznE7kO27irdJwLKqw_9_5"></a><a id="Tc_ADvKzosRW0eKHLGXL2CFQg_10_0"></a><a id="Tc_-wQ6f6rzUkWpaJ3fn0no4A_10_3"></a><a id="Tc_ipMlav75xUyQY2Da7au7uA_10_5"></a><a id="Tc_eb9V8UKc90Sct7xjymJWrw_11_0"></a><a id="Tc_kHFYiPQz20C5Awmtbxn-ew_11_3"></a><a id="Tc_8HtAQFfx9Easu3WKglPJDQ_11_5"></a><a id="Tc_GS4pO2xBHk2wALmFSEJjCA_12_0"></a><a id="Tc__ZjpZwlR0kW7hLCSYQDbXg_12_3"></a><a id="Tc_eafg_cejG0GBoq9R94DYzA_12_5"></a><a id="_c5dc44b1_2200_44f7_b30d_f5c657ffbdea"></a><a id="_c5dc44b1_2200_44f7_b30d_f5c657ffbdea_2"></a><a id="_c5dc44b1_2200_44f7_b30d_f5c657ffbdea_3"></a><a id="_2242f5ce_7d96_4f3b_8e91_1a74cabf5540"></a><a id="_2242f5ce_7d96_4f3b_8e91_1a74cabf5540_2"></a><a id="_2242f5ce_7d96_4f3b_8e91_1a74cabf5540_3"></a><ix:continuation id="Tb_LeXJkQ3T-UCGccyCxiNfVQ_cont2"><ix:continuation id="Tb_2rts5phxuUuxja-znn-6pA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_oOcnS8p5AkCPIpbLNfPUuw_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_sq59wBoaUUK-Ie2Xaf8itw_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_61A09QBsREyfFPbesCyrAw_5_2">2.9</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_iStdUXlIJkiTfwNhxNULPw_5_4">7.3</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_DUACe0bo4EuXkMaO9MwVbQ_6_2">1.6</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_KuqTckBfuU6GI3YLMcNylA_6_4">0.2</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_tveWsydA3UaKiH88q5dbCw_7_2">9.3</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_fpJEKgHWmke7iJu-cP_WfQ_7_4">28.6</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" sign="-" scale="-2" id="Tc_7iUfD1FT1UGVf_VEXbXMOA_8_2">1.2</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" scale="-2" id="Tc_ZBoa1PlXmky0JK_MvRE4IA_8_4">0.0</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_gt2wEz84CkKqPSkA6JEoCQ_9_2">3.3</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_3QwFt-FP-EeY-ZjdJ-uprA_9_4">0.0</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value adjustment on convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" sign="-" scale="-2" id="Tc_asEgsXJzfUquLHkVnLVMNQ_10_2">6.6</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" scale="-2" id="Tc_K1RVTeIivU-O2d7DA0GoyQ_10_4">0.0</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="armp:IncomeTaxRateReconciliationPermanentDifferences1" sign="-" scale="-2" id="Tc_CRk97ZvfXk-3tK9AcPAoDw_11_2">1.9</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="armp:IncomeTaxRateReconciliationPermanentDifferences1" scale="-2" id="Tc_8OQ1f8XvokqBfIcXzLrBoA_11_4">0.5</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_k4t0Qwkk30u4xv1une-ZNA_12_2">0.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_fKVQE8rBv0q4N3bD3UHUyQ_12_4">0.0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2023, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2019 or to California state income tax examinations for tax years ended on or before December 31, 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not have a liability for unrecognized tax benefits at December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2023 and 2022, the Company has no accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes have not been provided for undistributed earnings of the Company&#8217;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_uIkFw4EnvECztjdgQV6ssA" continuedAt="Tb_uIkFw4EnvECztjdgQV6ssA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced on January&#160;1, 2012 and in April 2020, the Company amended the lease (&#8220;2020 Lease Amendment&#8221;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA" decimals="-5" format="ixt:numdotdecimal" name="armp:OperatingLeaseBaseRent" scale="6" id="Narr_l6gfYzCbaEqz0KcE0hRyLg">1.9</ix:nonFraction>&#160;million, and base rent increases by&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA" decimals="4" format="ixt:numdotdecimal" name="armp:AnnualIncreaseInRentPercentage" scale="-2" id="Narr_pp5PuOONlEC83TvvVsc37w">3</ix:nonFraction>% annually and will be $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA" decimals="-5" format="ixt:numdotdecimal" name="armp:OperatingLeaseBaseRentEndOfLeaseTerm" scale="6" id="Narr_gGttgN8k1k2Aerxv9m5lSA">2.5</ix:nonFraction>&#160;million by the end of the amended term. In addition, the Company received a&#160;<ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA" format="ixt-sec:durwordsen" name="armp:LeaseAndRentalAbatementCreditPeriod" id="Narr_1ufPUiN1yEmUwGN9-_7l1Q">six-month</ix:nonNumeric>&#160;rent abatement in 2020. In accordance with authoritative guidance, the Company re-measured the lease liability in April 2020 to be&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_QzD3XIogpku7YAA2HRlqbQ">11.7</ix:nonFraction>&#160;million <span style="background:#ffffff;">using an</span> incremental borrowing rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_P6YR06LqgUma7ssdHbDoag">12.89</ix:nonFraction>% and related&#160;right of use asset was&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_bEwGKMT4zEu9QjLLpY4h2Q">11.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with the Company&#8217;s execution of the 2020 Lease Amendment, an irrevocable letter of credit in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_MjNOJztpO0yiBsNBQMsdsg">1.2</ix:nonFraction>&#160;million was delivered to the landlord. Starting on February 1, 2022, and each&#160;year thereafter, the letter of credit will be reduced by&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ" decimals="2" format="ixt:numdotdecimal" name="armp:AnnualReductionOfStandbyLetterOfCredit" scale="-2" id="Narr_fxSPU-EPO0KxVvGXeYiPaw">20</ix:nonFraction>% of the then outstanding amount. As of December 31, 2023, the letter of credit was $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_hIBa8orrkkC3OY4OCziUrg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_KkULLBxvjk2dqOFmEbf36Q">0.7</ix:nonFraction>&#160;million.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_62072325_f91c_46c2_8c74_647672f0b308"></a><a id="Tc_HRtgGdqJjU2cI8oSsoLnUA_1_2"></a><a id="Tc_vzhOYLlbxUekpYQ-tu9SsA_2_2"></a><a id="Tc_IClLhOpG20Gx2HA8xgOPAw_3_0"></a><a id="Tc_hdmARJMeK0ebvBVUJBjzfQ_3_2"></a><a id="Tc_8jR4wKUWNU-joCEKXV8oIw_4_0"></a><a id="Tc_RcaEZ9WucU6-KA6mhE-ssQ_5_0"></a><a id="Tc_gNEtkbCA-02xfs-BKNyZdQ_6_0"></a><a id="Tc_2ZPY9ZKXMEKyDsDP2wcAHg_7_0"></a><a id="Tc_wD4oSh57gkGDxFn6LkWbcQ_8_0"></a><a id="Tc_qS-kKQT37kqKk3w2wvdOEA_9_0"></a><a id="Tc_zXpbkZREfkGSf6f9Rj9UKg_10_0"></a><a id="Tc_Vs5YLPABY06imaU-VRJoYQ_11_0"></a><a id="Tc_eCtK7SyJIUSe_CtKX51C-w_12_0"></a><a id="Tc_8t4r2YjVE0i06v3w9tzWLw_13_0"></a><a id="Tc_JEKfVAUEeUCYEi1LZKwcpA_14_0"></a><a id="Tc_TxWIkFjaBEiTp9x6jYgwLw_14_2"></a><ix:continuation id="Tb_uIkFw4EnvECztjdgQV6ssA_cont1" continuedAt="Tb_uIkFw4EnvECztjdgQV6ssA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, California (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for&#160;</span><ix:nonNumeric contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="Narr_43AsfAWYvUq4ec08l7hf0A"><span style="background:#ffffff;">16 years</span></ix:nonNumeric><span style="background:#ffffff;">&#160;and runs through 2038. Monthly rent for 2022 and 2023 are fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw" decimals="-4" format="ixt:numdotdecimal" name="armp:BaseAnnualRentToBePaidYearThree" scale="6" id="Narr_LhkVSvCGvUqNoPj4sLAbIA">0.25</ix:nonFraction></span><span style="background:#ffffff;">&#160;million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw" decimals="-5" format="ixt:numdotdecimal" name="armp:MaximumAllowanceForTenantImprovementsReceivable" scale="6" id="Narr_0spqDFJ_dUe6e9o-7V47Pw">7.3</ix:nonFraction></span><span style="background:#ffffff;"> million, of which the Company received </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw" decimals="-5" format="ixt:numdotdecimal" name="armp:ProceedsFromTenantAllowances" scale="6" id="Narr_cDTcRFFGv0mDlW5U1f6sjg">5.4</ix:nonFraction></span><span style="background:#ffffff;"> million during the year ended December 31, 2023. The Company is responsible for construction costs over such allowance. Out of pocket expenses to be incurred by the Company are considered noncash lease payments, and included in the lease liability and the right-of-use asset when the amount can be reasonably estimated. As of November 16, 2022, the Company finalized the budget to complete the construction of the 2021 Lease. Accordingly, the Company re-measured the lease liability and related right-of-use asset as of November 30, 2022, using an incremental borrowing rate of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_11_30_2022_sJyIDh6BPkGLuZGEzoAROA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_MS0IBZaglUyAl1EpScpDLA">11.8</ix:nonFraction>%</span><span style="background:#ffffff;">. The re-measured lease liability of the 2021 Lease as of November 16, 2022 was&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_MORI1LzvSkm0f9FUfOgvmA">37.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million, and the related right of use asset was&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_2x912IcoJE-3E-hD_QC_dw">33.8</ix:nonFraction></span><span style="background:#ffffff;">&#160;million</span>. During the year ended December 31, 2023, the budget was modified and the Company re-measured the lease liability. As a result, the lease liability and related right-of-use asset increased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_W3KAPH27bUOTG34yisjgIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="Narr_bqaMoVGCP06pl9dbPOiV8A">2.7</ix:nonFraction>&#160;million, using an incremental borrowing rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_VjefCaiPsUS7e-BdlXj-7g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_pI6NwauBr0e0W5Sef2z-0g">14.27</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the total amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="Narr_09EYEYQGW0qUA7R6xtUD6w">5.0</ix:nonFraction>&#160;million to the landlord in 2022. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb__HwMVQt_SUGZlReAe5S9uQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_VNSN0z3W6U6oJE3R_mpH0w_3_3">9,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_ABFMPcHiGEGohesU_WRFPw_4_3">5,307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_Z1eFkDbSNkOELn5OVd0k-A_5_3">5,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_ilZZ8XOg306JTWvID1X4Kw_6_3">5,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_rDs1qGKMok6Led2AMMYRWQ_7_3">5,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_enWczY-igUqx00DSujairg_8_3">43,181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_sU_pF9Nj30SDrbAWB9y7_w_9_3">75,179</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plus: estimated short-term variable lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="armp:ShortTermVariableLeasePaymentAmount" scale="3" id="Tc_r6P5bZpnI0e_8Vmw6OsV5Q_10_3">5,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_ixMNj6j_fkiMwTfsR6798Q_11_3">31,729</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_lESde4s8DUyDm4U9J1CYZg_12_3">38,064</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_5AGGTjvh6k2uxnvrm7X4Sw_13_3">9,481</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ddaWr_7ewEybxJK--Xyemw_14_3">28,583</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#222222;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_yqnLNrq0lkyp24QOLRnD5g">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_Q7B2Sxz7_0KL0kbhhqTUTw">6.3</ix:nonFraction> million for the years ended December 31, 2023 and 2022, respectively. Total cash payments for operating leases as included in the consolidated statements&#160;of cash flows during the&#160;years ended December 31, 2023 and 2022 were $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_5XYN55ifbEqzC3R8cB3keA">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_gjUM4bBtCEmuwBAYuLnMjA">2.7</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uIkFw4EnvECztjdgQV6ssA_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="armp:AwardTextBlock" id="Tb_pniofC5Gc0u7y_RvLAAJZw" continuedAt="Tb_pniofC5Gc0u7y_RvLAAJZw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Grants and Awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MTEC Grant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_6_15_2020_To_6_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_MA9PVOA_T0GwtfbjiWZ8PQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_KHtbM5MY00CXZmt1pd_YjA">15.0</ix:nonFraction> million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A" decimals="-5" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" scale="6" id="Narr_teRIoIVhRE-xv6Mdt_e2aw">1.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_rfXfATVMjUij8rSKfGTRWg">16.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of </span>the Company's<span style="background:#ffffff;"> therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;</span><i style="font-style:italic;background:#ffffff;">Staphylococcus aureus</i><span style="background:#ffffff;">&#160;bacteremia infections. The MTEC Agreement specifies that the grant is paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through October 30, 2024.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_NeQe2I2uKUmdVatAsYayIg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_2eTMhhGH7USUgKaruyEXMA">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_oTLYGAZfJ0aCfMIzYcDvAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_GFA39qi0d02vgl0asrqh9A">5.5</ix:nonFraction> million in grant revenue from the MTEC Agreement during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_FHhuhYDYgkSEqnz0dDB17g" decimals="-5" format="ixt:numdotdecimal" name="armp:UnbilledAwardReceivable" scale="6" id="Narr_wdKqkaY25E695sXaLyc1BQ">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_8VpuTm72C0OqZUC8eh9aAg" decimals="-5" format="ixt:numdotdecimal" name="armp:UnbilledAwardReceivable" scale="6" id="Narr_iun91xu4HE6PvvF20M9G-A">1.9</ix:nonFraction>&#160;million as awards receivable from MTEC, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with Cystic Fibrosis Foundation (&#8220;CFF&#8221;), pursuant to which the Company received a Therapeutics Development Award of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QOYAQImRME-BHccqHOTQxA" decimals="-5" format="ixt:numdotdecimal" name="armp:ThresholdDevelopmentAward" scale="6" id="Narr_nNjZaAyRgUK4U3_R1baM_Q">5.0</ix:nonFraction> million (the &#8220;CFF Award&#8221;). The CFF Award has funded a portion of the Company&#8217;s Phase 1b/2a clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa </i>(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;)<i style="font-style:italic;"> </i>phage candidate, AP-PA02, as a treatment for<i style="font-style:italic;"> </i>airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The CFF Award is payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The first payment under the Award Agreement, in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_yQKRGpMabkGpnWs-0mIn_g" decimals="-5" format="ixt:numdotdecimal" name="armp:AwardReceivable" scale="6" id="Narr_KiaaWRpTRkKD9Or07vkcmg">1.0</ix:nonFraction> million, became due upon signing the Award Agreement and was received in April 2020. The last milestone in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Wv6oSPAXP0CJ0UiTo6AKQA" decimals="-5" format="ixt:numdotdecimal" name="armp:AwardReceivable" scale="6" id="Narr_d6TouCqvLU-BSD1Kpi0WAQ">0.3</ix:nonFraction> million was achieved in December 2023 and was received in January 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of <ix:nonNumeric contextRef="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_QVyakBDhtUmt0Ago8wBrDA" format="ixt-sec:durwordsen" name="armp:AwardAgreementInterruptionPeriod" id="Narr_HeehXC6TxkSNDZEIkj7djg">360 days</ix:nonNumeric> (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_pniofC5Gc0u7y_RvLAAJZw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_lPXHo7biDEeQ7_vk8pbcAQ" decimals="-5" format="ixt:numdotdecimal" name="armp:ResearchAndDevelopmentBenefit" scale="6" id="Narr_0HeIiKgQt0SUUkzjbRniGg">0.3</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_MuuXgJmTa0iJw2pEu82wXw" decimals="-5" format="ixt:numdotdecimal" name="armp:ResearchAndDevelopmentBenefit" scale="6" id="Narr_oaq6l1JOjEas7bVhMU-bnw">1.0</ix:nonFraction> million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_x6SMmGWp2EeARuROBbPitQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Employee Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#8217;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $<ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_U1wfrjz0M0yjmitzHMOSwg">0.2</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg" contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_j2fVdGA4Z0aZCpWx1PEgzg">zero</ix:nonFraction> to the 401(k)&#160;plan for the&#160;years ended December 31, 2023 and 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_630042d4_4310_44b6_bf4a_9f4a67c69ac4"></a><a id="Item9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_32434add_2271_4a7e_a0a1_50b9350dba28"></a><a id="Item9AControlsAndProcedures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Vice President, Corporate Controller), to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Our management, under the supervision and with the participation of our Chief Executive Officer and our Vice President, Corporate Controller, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on such evaluation, our Chief Executive Officer (principal executive officer) and our Vice President, Corporate Controller (principal financial officer) have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15(d)&#160;-15(f)&#160;as a process designed by, or under the supervision of, our Chief Executive Officer and Vice President, Corporate Controller to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013) (the &#8220;2013 Framework&#8221;). In adopting the 2013 Framework, management assessed the applicability of the principles within each component of internal control and determined whether or not they have been adequately addressed within the current system of internal control and adequately documented. Based on this assessment, management, under the supervision and with the participation of our Chief Executive Officer and Vice President, Corporate Controller, concluded that, as of December&#160;31, 2023, our internal control over financial reporting was effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">This Annual Report on Form&#160;10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. We were not required to have, nor have we, engaged our independent registered public accounting firm to perform an audit of internal control over financial reporting as we are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">There were no changes in our internal control over financial reporting identified in management&#8217;s evaluation pursuant to Rules 13a-15(f) or 15d-15(f) of the Exchange Act during our fourth fiscal quarter ended December&#160;31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_62ce9f3a_4f4c_4472_9751_0103935c323e"></a><a id="Item9BOTHERINFORMATION_104987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trading Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_fZaPi8HP90aSsvtSj3MBsw">N</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_6ltz8xwErEyCM8VmZXZm4Q">o</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_nkHY5MRF90CIXmxzws1HtA">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_rR3ogs6PTku9xk4rIvyhVg">e</ix:nonNumeric> of the Company&#8217;s directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company&#8217;s fiscal quarter ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0b125339_ac13_436e_ad88_53fcbda87450"></a><a id="Item9CDISCLOSUREREGARDINGFOREIGNJURISDIC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_295f9798_5900_4550_9968_46bd9a973305"></a><a id="PARTIII_156407"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this item will be contained in our definitive proxy statement on Schedule 14A to be filed with the Securities and Exchange Commission in connection with our 2024 annual meeting of stockholders (the &#8220;2024 Proxy Statement&#8221;), which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated in this report by reference. To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 10.</p><a id="_0836a934_6d3c_4951_aa61_39ecd3f929e8"></a><a id="Item11EXECUTIVECOMPENSATION_44857"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;EXECUTIVE COMPENSATION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"> The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 11.</p><a id="_Item_12._"></a><a id="_a468e4e0_a8fb_48ca_bc9c_027ac462cbb2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a093ef75_8ec8_4a52_acf5_aac559403e33"></a><a id="Item13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 13.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_294b182e_ab09_4a2c_8f28_ef98d1b95427"></a><a id="Item14PRINCIPALACCOUNTANTFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement, which we expect to file not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K. To the extent that we do not file the 2024 Proxy Statement by such date, we will file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 14.</p><a id="_266c4357_730a_44a4_9131_4097e435e24d"></a><a id="PARTIV_519682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15EXHIBITS_865142"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;&#160;&#160;EXHIBITS<span style="font-style:italic;">,</span> FINANCIAL STATEMENT SCHEDULES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(a)(1) Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our Financial Statements are listed in the &#8220;Index to Audited Consolidated Financial Statements&#8221; of Armata Pharmaceuticals, Inc. in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(a)(2) Financial Statement Schedules</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">All financial statement schedules have been omitted because they are not required, not applicable, or the required information is included in the consolidated financial statements or notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/><span style="font-style:italic;font-weight:bold;">(a)(3) Exhibits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following exhibits are filed herewith or incorporated herein by reference:<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:3.25pt;"><td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Document</b></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417021763/v464998_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-37544), filed with the SEC on April 24, 2017</span></a>).</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420418058340/tv505699_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on November 8, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on May 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit 3.5 to the Quarterly Report on Form 10-Q (File No. 001-37544), filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Merger, dated as of May 9, 2019 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on May 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the registrant, dated as of December 10, 2019 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on December 11, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.8</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Bylaws of the registrant (December 10, 2019) (incorporated herein by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on December 11, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.9</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Bylaws of the registrant (February 24, 2020) (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on February 26, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.10</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-37544), filed with the SEC on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits 3.1 through 3.8. </p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417023433/v465550_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-217563), filed on May 1, 2017).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420415017285/v404997_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant issued to purchasers in March 2015 private placement (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 19, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Shares of Common Stock issued in connection with the Company&#8217;s acquisition of certain assets of Novolytics Limited in February 2016 (incorporated by reference to Exhibit 4.13 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 30, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420417023490/v465628_ex4-18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Common Stock issued to purchasers in May 2017 (incorporated by reference to Exhibit 4.18 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217169)).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000110465920008032/tm206157d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 29, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated January 26, 2021, by and between the Company and Innoviva (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 27, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 27, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Company&#8217;s securities registered under Section 12 of the Exchange Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Targeted Genetics Corporation 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement under AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420414022834/v372120_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Grant Notice and Stock Option Agreement under AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 30, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419030481/tv523249_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Armata Pharmaceuticals, Inc.  2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s Registration Statement on Form S-8, filed with the SEC on June 10, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex109f4c5b2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Armata Pharmaceuticals, Inc.  2016 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.9 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex1010ab7df.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Armata Pharmaceuticals, Inc.  2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420416076070/v429155_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnity Agreement with the Company&#8217;s Directors and Executive Officers (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 19, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10<b style="font-weight:bold;">+</b></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000114420419025292/tv521048_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director Appointment Letter (incorporated by reference to Exhibit 10.4 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 10, 2019).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex10116c3c2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research Collaboration and Option to License Agreement, effective as of May 24, 2017, by and between Synthetic Genomics, Inc. and Merck Sharp &amp; Dohme Corp. (incorporated herein by reference to Exhibit 10.12 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12*</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex10121c63f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated as of February 14, 2018, by and between C3J Therapeutics, Inc., Synthetic Genomics, Inc. and Synthetic Genomics Vaccines, Inc., as amended by Amendment to Asset Purchase Agreement, made and entered into as of December 20, 2018 (incorporated herein by reference to Exhibit 10.12 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920020186/tm207916d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated February&#160;12, 2020, by and between the Registrant and&#160;Innoviva,&#160;Inc.&#160;(incorporated herein by reference to Exhibit&#160;4.1 to the Current Report on&#160;Form&#160;8-K&#160;(File No.&#160;001-37544), filed with the SEC on February&#160;13, 2020).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465921007895/tm214248d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated January&#160;26, 2021, by and between the Registrant and Innoviva Strategic Opportunities LLC (incorporated herein by reference to Exhibit&#160;10.3 to the Current Report on Form&#160;8-K (File No.&#160;001-37544), filed with the SEC on January&#160;27, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15*</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837020006601/armp-20200331ex101b108a8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated as of March 10, 2020, by and between Armata Pharmaceuticals, Inc. and the Cystic Fibrosis Foundation (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921131905/tm2131430d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Registration Rights Agreement, dated October 28, 2021, by and among the Company, Innoviva, and CFF (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 29, 2021)</span></a><span style="background:#ffffff;">.</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921133195/tm2131735d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Lease Agreement, dated October 28, 2021, by and between the Company and 5005 McConnell Avenue, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 2, 2021</span></a><span style="background:#ffffff;">).</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837020006601/armp-20200331ex103beba44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment and First Amendment of Office Lease, dated as of April 2020, by and among Armata Pharmaceuticals, Inc., C3 Jian, Inc. and Marina Business Center, LLC (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922020354/tm226408d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Investor Rights Agreement, dated February 9, 2022, by and among the Company and Innoviva (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922020354/tm226408d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Registration Rights Agreement, dated February 9, 2022, by and among the Company and Innoviva (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 11, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465922038851/tm2210607d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Advisory Agreement, dated March 28, 2022, between the Company and Mr. Martin (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 25, 2022).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923002496/tm232848d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Secured Convertible Credit and Security Agreement, dated January 10, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923019627/tm236045d1_ex4-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of February 9, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 4.21 to the Company&#8217;s Registration Statement on Form S-3, filed with the SEC on February 13, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Security Convertible Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter of Employment, by and between the Company and Dr. Deborah Birx (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 11, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27+</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465923082362/tm2321631d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation and Release Agreement, dated as of July 14, 2023, by and between the Company and Brian Varnum (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 19, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex10d28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated August 30, 2023, by and between the Company and Richard Rychlik.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit and Security Agreement, dated March 4, 2024, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">First Amendment to Credit and Security Agreement, dated March 4, 2024,  by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/921114/000110465924030475/tm247888d1_8k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Secured Convertible Credit and Security Agreement, dated March 4, 2024, by and among the Company and Innoviva Strategic Opportunities, LLC (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Company.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#POWEROFATTORNEY_42904"><span style="font-style:normal;font-weight:normal;">Power of Attorney (contained on the signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="armp-20231231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Armata Pharmaceuticals, Inc. Policy for the Recovery of Erroneously Awarded Compensation, adopted on October 2, 2023.</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">+&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan or arrangement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">*&#160;&#160;&#160;&#160;&#160;Indicates that certain identified information in the exhibit has been omitted because it is both (i) not material, and (ii) would likely cause competitive harm if publicly disclosed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e507f2b4_abcc_4685_8b68_e381ea9be8b4"></a><a id="Item16Form10KSummary_988645"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"> Item&#160;16.&#160;&#160;&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d4432ec2_0b26_4b5e_a1c7_69c34b18bf11"></a><a id="SIGNATURES_275590"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARMATA PHARMACEUTICALS, INC. </p></td></tr><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 21, 2024</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.08%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx </p></td></tr><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Deborah Birx, M.D. </p></td></tr><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="POWEROFATTORNEY_42904"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES AND POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Deborah Birx, and Richard Rychlik, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx </p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx, M.D. </p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:16.3pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard Rychlik </p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President, Corporate Controller</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Rychlik</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jules Haimovitz</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jules Haimovitz</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Odysseas D. Kostas, M.D</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Odysseas D. Kostas, M.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robin Kramer </p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of the Board of Directors</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robin Kramer </p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joseph M. Patti, Ph.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joseph M. Patti, Ph.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Todd C. Peterson, Ph.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Todd C. Peterson, Ph.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Sarah J. Schlesinger, M.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2024</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sarah J. Schlesinger, M.D.</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>armp-20231231xex4d9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF COMMON STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following description of our common stock, certain provisions of our articles of incorporation and bylaws, and certain provisions of Washington law are summaries. The following description is not complete and is subject to and qualified in its entirety by our articles of incorporation and bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of March 15, 2020, our articles of incorporation authorize us to issue 217,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The holders of our common stock are entitled to the following rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our common stock is entitled to one vote for each share held on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Rights and Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Holders of our common stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Provisions of Our Articles of Incorporation, Our Bylaws and Washington Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Provisions in our articles of incorporation, our bylaws and under Washington law may delay or prevent an acquisition of us or a change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. These provisions include a requirement for the vote of stockholders holding at least two-thirds of all shares of our issued and outstanding capital stock to approve certain changes to our articles of incorporation or certain business combinations. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. Additionally, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other things, prohibits a target corporation, with certain exceptions, from engaging</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in certain &#8220;significant business transactions&#8221; for a period of five&#160;years after the share acquisition by an &#8220;acquiring person&#8221;, unless (a)&#160;the significant business transaction is approved by a majority of the members of the target corporation&#8217;s board of directors prior to the time of acquisition or (b)&#160;the significant business transaction was approved by both the majority of the members of the target corporation&#8217;s board of directors and approved at a stockholder meeting by at least two-thirds of the outstanding voting shares (excluding the acquiring person&#8217;s shares or shares over which the acquiring person has voting control) at or subsequent to the acquiring person&#8217;s share acquisition. An &#8220;acquiring person&#8221; is defined as a person or group of persons which beneficially owns 10% or more of the voting securities of the target corporation. Such significant business transactions may include, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring person;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any termination of 5% or more of the employees of the target corporation as a result of the acquiring person&#8217;s acquisition of 10% or more of the shares; or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allowing the acquiring person to receive any disproportionate benefit as a stockholder.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After the five-year period, a significant business transaction may take place as long as it complies with certain fair price provisions of the statute or is approved by a majority of the votes entitled to be counted within each voting group entitled to vote separately on the transaction (excluding the acquiring person&#8217;s shares or shares over which the acquiring person has voting control) at an annual or special meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NYSE American Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our common stock is listed on the NYSE American exchange under the symbol &#8220;ARMP.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royall Street, Canton, MA 02021.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>armp-20231231xex10d28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.28</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 2pt 0pt;"><font style="font-size:12pt;"><img src="armp-20231231xex10d28001.jpg" alt="Graphic" style="display:inline-block;height:71.39pt;width:124.91pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">Armata Pharmaceuticals, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">4503 Glencoe Avenue </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><font style="font-size:12pt;">Marina del Rey, CA 90292</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">August 30, 2023 </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Dear Richard:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4.3pt 0pt;"><font style="font-size:12pt;">We are pleased to confirm our offer of employment with Armata Pharmaceuticals, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:12pt;">&#8221;) in the position of Vice President, Corporate Controller, effective September 5, 2023 (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">&#8221;), on the terms set forth in this letter agreement (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.25pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Position</b><font style="font-size:12pt;">. As Vice President, Corporate Controller, you will be responsible for managing the financial affairs of the Company and you will report directly to the Chief Executive Officer of the Company. You agree to devote your full business time and attention to your work for the Company. Except upon the prior written consent of the Board of the Directors of the Company (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:12pt;">&#8221;), you will not, during your employment with the Company, (i) accept or maintain any other employment, or (ii) engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might interfere with your duties and responsibilities as a Company employee or create a conflict of interest with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.25pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Salary</b><font style="font-size:12pt;">. Effective as of September 5, 2023, your base salary will be paid at the annualized rate of $290,000 per year on the Company&#8217;s regular payroll dates and subject to approved deductions and required withholdings. Your salary will be reviewed from time to time by the Boardor its compensation committee and may be adjusted in the sole discretion of the Board or its compensation committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0.25pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-size:12pt;font-weight:bold;">Bonus</b><font style="font-size:12pt;">. You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established by the Board or its compensation committee and provided to you. Your annual target performance bonus will initially be equal to 30% of your base salary, although the amount of any payment will be dependent upon actual performance as determined by the Board or its compensation committee. You must be employed by the Company through the last day of the fiscal year for which bonuses are paid in order to be eligible to receive a bonus. Your annual performance bonus, if any, shall be paid to you on or before March 15 of the year following the year to which it relates. Your annual target performance bonus percentage is subject to modification from time to time in the discretion of the Board or its compensation committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 10.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Equity Award</b><font style="font-size:12pt;">. As soon as practicable following the Effective Date, you will be granted an option under the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u><font style="font-size:12pt;">&#8221;) to purchase 50,000 shares of the Company&#8217;s common stock (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option</u><font style="font-size:12pt;">&#8221;). The Option shall vest over time conditioned upon your continuous service to the Company in equal annual installments on the first four anniversaries of the date of grant. The exercise price of the Option shall be the fair market value of the Company&#8217;s common stock on thedate of grant in accordance with the Plan and shall be subject to the terms and conditions of the Plan, stock option grant notice and option agreement to be entered into between you and theCompany.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Benefits</b><font style="font-size:12pt;">. You will be eligible to participate in the benefits made generally available by the Company to its senior executives, in accordance with the benefit plans established by the Company, and as may be amended from time to time in the Company&#8217;s sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:12pt;font-weight:bold;">At-Will Employment</b><font style="font-size:12pt;">. The Company is an &#8220;at-will&#8221; employer. Accordingly, either you or the Company may terminate the employment relationship at any time, with or without advance notice, and with or without cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-size:12pt;font-weight:bold;">Termination</b><font style="font-size:12pt;">. Upon any termination of your employment, you will be deemed to have resigned, and you hereby resign, from all offices and directorships, if any, then held by you with the Company or any subsidiary. In the event of termination of your employment with the Company, regardless of the reasons for such termination, the Company shall pay your base salary and accrued but unused vacation up to and through the date of termination, less applicable payroll and tax withholdings (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Severance</b><font style="font-size:12pt;">. You shall be eligible for the severance benefits described in this Section</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-size:12pt;">In the event (i) the Company terminates your employment without Cause (as defined below and other than due to your death or disability), or (ii) you terminate your employment for Good Reason (as defined below), and provided in either case of (i) or (ii) such termination or resignation constitutes a &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation from Service</u><font style="font-size:12pt;">&#8221;) (such termination or resignation, an &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Involuntary Termination</u><font style="font-size:12pt;">&#8221;) and such Involuntary Termination does not occur during the CiC Protection Period (as defined below), then, in addition to the Accrued Obligations, subject to your obligations in Section 8(c) below, you shall be entitled to receive an amount equal to six (6) months of your then current base salary (ignoring any decrease in base salary that forms the basis for Good Reason), less all applicable withholdings and deductions, paid on the schedule described in Section 8(c) below (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Pay</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><font style="font-size:12pt;">In the event that you experience an Involuntary Termination during the period (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CiC Protection Period</u><font style="font-size:12pt;">&#8221;) commencing one (1) month prior to the consummation of the first Change in Control (as defined in Section 9 below) to occur following the Effective Date and ending on the date that is twelve (12) months immediately following the consummation of such Change in Control, then, in addition to the Accrued Obligations and subject to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 10.9pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4.34pt 0pt;"><font style="font-size:12pt;">obligations set forth in Section 8(c) below, you shall be entitled to the following payments and benefits (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CiC Severance Pay</u><font style="font-size:12pt;">&#8221;): (i) an amount equal to twelve (12) months of your then- current base salary, less all applicable withholdings and deductions, paid on the schedule described in Section 8(c), and (ii) to the extent permitted by applicable law without any penalty to you or the Company and subject to your timely election of COBRA continuation coverage under the Company&#8217;s group health plan, on the first regularly scheduled payroll date of each month for a period of twelve (12) months (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Period</u><font style="font-size:12pt;">&#8221;), the Company will pay, directly to or on your behalf, an amount equal to the monthly COBRA premium cost for your coverage thereunder; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that the payments pursuant to this clause (ii) shall cease earlier than the expiration of the COBRA Period in the event that, during the COBRA Period, (x) you become eligible to receive any health benefits, including through a spouse&#8217;s employer or (y) you are no longer eligible for benefits under COBRA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.3pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-size:12pt;">The Severance Pay or CiC Severance Pay, as applicable, is conditioned upon (i) your continuing to comply with your obligations under your PIIA (as defined in Section 11) during the period of time in which you are receiving the Severance Pay or CiC Severance Pay, as applicable; (ii) your delivering to the Company an executed separation agreement and general release of claims in favor of the Company (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u><font style="font-size:12pt;">&#8221;), in a form provided by the Company, within the time period set forth therein, which becomes effective in accordance with its terms, which shall be no later than sixty (60) days following your Separation from Service. The Severance Pay or CiC Severance Pay, as applicable, will be paid in equal installments on the Company&#8217;s regular payroll schedule over the period outlined above following the date of your Separation from Service; provided, however, that no payments will be made prior to the sixtieth (60</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) day following your Separation from Service. On the sixtieth (60</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) day following your Separation from Service, the Company will pay you in a lump sum the amount of the Severance Pay that you would have received on or prior to such date under the original schedule but for the delay while waiting for the sixtieth (60</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) day, with the balance of the Severance Pay being paid as originally scheduled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.3pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">d.</font></font><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="font-size:12pt;">&#8221; for purposes of your Severance Pay means (i) your gross negligence or willful failure substantially to perform your duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) your commission of any act of fraud, embezzlement or dishonesty against the Company or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (iii) your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv) your willful breach of any of your obligations under any written agreement or covenant with the Company, including without limitation this Agreement and your PIIA (as defined below).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0.3pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">e.</font></font><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:12pt;">&#8221; for purposes of your Severance Pay means the occurrence at any time of any of the following without your prior written consent: (i) a material reduction in your authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (ii) a material reduction in your base salary; or (iii) any willful failure or willful breach by the Company of any of its material obligations under</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 10.9pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">this Agreement. For purposes of this subsection, no act, or failure to act, on the Company&#8217;s part shall be deemed &#8220;willful&#8221; unless done, or omitted to be done, by the Company not in good faith and without reasonable belief that the Company&#8217;s act, or failure to act, was in the best interest of the Company. In order to terminate your employment under this Agreement for Good Reason, you must (1) provide written notice to the Company within ninety (90) days of the first occurrence of the events described above, (2) allow the Company at least thirty (30) days from such receipt of such written notice to cure such event, and (3) if such event is not reasonably cured within such period, resign from all position you then hold with the Company effective not later than the one- hundred eightieth (180</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) day after the initial occurrence of such event.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Change in Control Acceleration</b><font style="font-size:12pt;">. Notwithstanding any other provision contained herein, if your Involuntary Termination occurs during the CiC Protection Period, then the vesting of all of your outstanding equity awards (including the Option) that are subject to time-based vesting requirements shall accelerate in full such that all such equity awards shall be deemed fully vested as of the date of such Involuntary Termination (or Change in Control, if later). For purposes of this Agreement, the term &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:12pt;">&#8221; shall have the meaning ascribed to such term in the Plan, except that Innoviva, Inc. and each of its majority-owned subsidiaries and affiliates shall be considered Legacy Investors (as defined in the Plan) for purposes of determining whether or not a Change in Control has occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-size:12pt;font-weight:bold;">Taxes</b><font style="font-size:12pt;">. All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings (if any) and any other withholdings required by any applicable jurisdiction or authorized by you.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u><font style="font-size:12pt;">. The Severance Pay provided in this Agreement is intended to qualify for an exemption from application of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u><font style="font-size:12pt;">&#8221;) and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u><font style="font-size:12pt;">&#8221;) or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. Each installment of Severance Pay is a separate &#8220;payment&#8221; for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), and the Severance Pay is intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and you are, upon Separation from Service, a &#8220;specified employee&#8221; for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the Severance Pay shall be delayed until the earlier of (i) six (6) months and one day after your Separation from Service, or (ii) your death. Except to the minimum extent that payments must be delayed because you are a &#8220;specified employee&#8221;, all amounts of Severance Pay will be paid as soon as practicable in accordance with the schedule provided herein and in accordance with the Company&#8217;s normal payroll practices.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 280G</u><font style="font-size:12pt;">. If any payment or benefit you will or may receive from the Company or otherwise (a &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">280G Payment</u><font style="font-size:12pt;">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 11pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">imposed by Section 4999 of the Code (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u><font style="font-size:12pt;">&#8221;), then any such 280G Payment pursuant to this Agreement or otherwise (a &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u><font style="font-size:12pt;">&#8221;) shall be equal to the Reduced Amount. The &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduced Amount</u><font style="font-size:12pt;">&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction Method</u><font style="font-size:12pt;">&#8221;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Reduction Method</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Unless you and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 10(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 10.9pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this this Section 10(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this this Section 10(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-size:12pt;font-weight:bold;">Other</b><font style="font-size:12pt;">. As a condition of your commencement of employment hereunder, you must execute and deliver to the Company the Proprietary Information and Invention Assignment Agreement delivered to you under separate cover (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PIIA</u><font style="font-size:12pt;">&#8221;), which (among other provisions) prohibits any unauthorized use or disclosure of Company proprietary, confidential or trade secret information. The parties hereto acknowledge and agree that this Agreement and the PIIA shall be considered separate contracts, and the PIIA will survive the termination of this Agreement for any reason.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-size:12pt;font-weight:bold;">Entire Agreement</b><font style="font-size:12pt;">. This Agreement, together with your PIIA, sets forth our entire agreement and understanding regarding the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral. This Agreement may not be modified in any way except in a writing signed by the Company&#8217;s Chief Executive Offer (or another duly authorized officer of the Company) upon due authorization by the Board or its compensation committee and you. It shall be governed by California law, without regard to principles of conflicts of laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">(Signatures are on the following page)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sincerely,</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Deborah Birx</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Deborah Birx, M.D.</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ACCEPTED AND AGREED:</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Richard Rychlik</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8/31/2023</font></p></td></tr><tr><td style="vertical-align:top;width:48.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Richard Rychlik</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">[Signature Page to R. Rychlik Employment Agreement]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>armp-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subsidiaries of Armata Pharmaceuticals, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following companies are direct or indirect wholly owned subsidiaries of Armata Pharmaceuticals, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.48%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">C3J Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="color:#231f20;">C3&#160;Jian,&#160;LLC&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States </p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Biocontrol Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United Kingdom</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">AmpliPhi Australia Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Special Phage Holdings Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Special Phage Services Pty Ltd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>armp-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consent of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements of Armata Pharmaceuticals, Inc.: &#160; &#160; &#160; &#160; &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><a name="_Hlk97981794"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-1 Nos. 333-213421, 333-217169, 333-217680, and 333-226959),</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-3 Nos. 333-237533, 333-237534, 333-256104, 333-263936, 333-264961 and 333-269726),</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-203455) pertaining to the AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan and AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-212183, 333-217563, 333-223987, 333-275580, and 333-276657) pertaining to the Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan and Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan,</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-221564 and 333-232058) pertaining to the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan, as amended, Armata Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan, C3J Jian, Inc. Amended 2006 Stock Option Plan and C3J Therapeutics, Inc. 2016 Stock Plan, and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-250034) pertaining to the Inducement Restricted Stock Unit Award (October 2020);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of our report dated March 21, 2024, with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Armata Pharmaceuticals, Inc. for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 180pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">San Diego, California </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 21, 2024</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>armp-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, Deborah Birx, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Armata Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March 21, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>armp-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, Richard Rychlik, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Armata Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt -1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.75pt;text-indent:-37.75pt;margin:0pt 0pt 0pt -1pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.75pt;text-indent:-36.75pt;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:37.25pt;text-indent:-37.25pt;margin:0pt 0pt 0pt 37pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March 21, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard Rychlik</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Rychlik</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President, Corporate Controller </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>armp-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the annual report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Deborah Birx, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(1)&#160;&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 21, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">M</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Deborah Birx  </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deborah Birx  </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>armp-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the</p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the annual report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Richard Rychlik, Vice President, Corporate Controller of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter&#160;63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(1)&#160;&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:26pt;text-indent:-26pt;margin:0pt 0pt 0pt 55pt;">(2)&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 21, 2024</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard Rychlik </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard Rychlik </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vice President, Corporate Controller</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>10
<FILENAME>armp-20231231xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/21/2024 05:39:42 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 97</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Execution Copy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARMATA PHARMACEUTICALS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">POLICY FOR THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><b style="font-size:12pt;font-weight:bold;">Purpose</b><font style="font-size:12pt;">. The purpose of this Policy is to describe the circumstances in which Executives will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each current and future Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:12pt;"> pursuant to which such Executive will agree to be bound by the terms and comply with this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><b style="font-size:12pt;font-weight:bold;">Administration</b><font style="font-size:12pt;">. This Policy shall be administered by the Committee. Any determinations made by the Committee shall be final and binding on all affected individuals and their beneficiaries, heirs, executors, administrators, or other legal representatives. The Committee shall have full power and authority to (i) administer and interpret this Policy; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy; and (iii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations. Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual, the Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Committee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><b style="font-size:12pt;font-weight:bold;">Definitions</b><font style="font-size:12pt;">. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Accounting Restatement</font><font style="font-size:12pt;">&#8221; shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a &#8220;Big R&#8221; restatement), or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;little r&#8221; restatement).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-size:12pt;">&#8221; shall mean the Board of Directors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Clawback Eligible Incentive Compensation</font><font style="font-size:12pt;">&#8221; shall mean, in connection with an Accounting Restatement and with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-based Compensation (whether or not such individual is serving as an Executive Officer at the time the Erroneously Awarded Compensation is required to be repaid to the Company Group), all Incentive-based Compensation Received by such Executive (i) on or after the Effective Date, (ii) after beginning service as an Executive Officer, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the applicable Clawback Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Clawback Period</font><font style="font-size:12pt;">&#8221; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-size:12pt;">&#8221; shall mean the Compensation Committee of the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221; shall mean Armata Pharmaceuticals, Inc., a Washington corporation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company Group</font><font style="font-size:12pt;">&#8221; shall mean the Company, together with each of its direct and indirect subsidiaries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-size:12pt;">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:12pt;">&#8221; shall mean October 2, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(j)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Erroneously Awarded Compensation</font><font style="font-size:12pt;">&#8221; shall mean, with respect to each Executive in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(k)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Executive</font><font style="font-size:12pt;">&#8221; shall mean any current or former Executive Officer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(l)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Executive Officer</font><font style="font-size:12pt;">&#8221; shall mean each individual who is designated as an &#8220;officer&#8221; of the Company in accordance with 17 C.F.R. 240.16a-1(f). Identification of an Executive Officer for purposes of this Policy would include at a minimum executive officers identified pursuant to 17 C.F.R. 240.16a-1(b). The determination as to an individual&#8217;s status as an Executive Officer shall be made by the Committee and such determination shall be final, conclusive and binding on such individual and all other interested persons.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(m)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Financial Reporting Measures</font><font style="font-size:12pt;">&#8221; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall for purposes of this Policy be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(n)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Incentive-based Compensation</font><font style="font-size:12pt;">&#8221; shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(o)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">NYSE</font><font style="font-size:12pt;">&#8221; shall mean the New York Stock Exchange.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(p)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-size:12pt;">&#8221; shall mean this Armata Pharmaceuticals, Inc. Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended and/or restated from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(q)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Received</font><font style="font-size:12pt;">&#8221; shall, with respect to any Incentive-based Compensation, mean actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 6pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Compensation award is attained, even if payment or grant of the Incentive-based Compensation occurs after the end of that period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(r)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restatement Date</font><font style="font-size:12pt;">&#8221; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(s)</font></font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">SEC</font><font style="font-size:12pt;">&#8221; shall mean the U.S. Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 5.95pt;"><font style="display:inline-block;text-indent:0pt;width:30.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><b style="font-size:12pt;font-weight:bold;">Repayment of Erroneously Awarded Compensation</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">In the event of an Accounting Restatement, the Committee shall promptly (and in all events within ninety (90) days after the Restatement Date) determine the amount of any Erroneously Awarded Compensation for each Executive in connection with such Accounting Restatement and shall promptly thereafter provide each Executive with a written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable. For Incentive-based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-based Compensation was Received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to NYSE).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously Awarded Compensation based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery. To the extent that the Committee determines that any method of recovery (other than repayment by the Executive in a lump sum in cash or property) is appropriate, the Company shall offer to enter into a repayment agreement (in a form reasonable acceptable to the Committee) with the Executive. If the Executive accepts such offer and signs the repayment agreement within thirty (30) days after such offer is extended, the Company shall countersign such repayment agreement. If the Executive fails to sign the repayment agreement within thirty (30) days after such offer is extended, the Executive will be required to repay the Erroneously Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously Awarded Compensation) on or prior to the date that is one hundred twenty (120) days following the Restatement Date. For the avoidance of doubt, except as set forth in Section 4(d) below, in no event may the Company Group accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive&#8217;s obligations hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">To the extent that an Executive fails to repay all Erroneously Awarded Compensation to the Company Group when due (as determined in accordance with Section 4(b) above), the Company shall, or shall cause one or more other members of the Company Group to, take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">from the applicable Executive. The applicable Executive shall be required to reimburse the Company Group for any and all expenses reasonably incurred (including legal fees) by the Company Group in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section 4(b) or 4(c) above if the following conditions are met and the Committee determines that recovery would be impracticable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:12pt;">The direct expenses paid to a third party to assist in enforcing the Policy against an Executive would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempts and provided such documentation to NYSE;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:12pt;">Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to NYSE, that recovery would result in such a violation and a copy of the opinion is provided to NYSE; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:12pt;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><b style="font-size:12pt;font-weight:bold;">Reporting and Disclosure</b><font style="font-size:12pt;">. The Company shall file all disclosures with respect to this Policy in accordance with the requirement of the federal securities laws, including the disclosure required by the applicable SEC filings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><b style="font-size:12pt;font-weight:bold;">Indemnification Prohibition</b><font style="font-size:12pt;">. No member of the Company Group shall be permitted to indemnify any Executive against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company Group&#8217;s enforcement of its rights under this Policy. Further, no member of the Company Group shall enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company Group&#8217;s right to recovery of any Erroneously Awarded Compensation and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-size:12pt;font-weight:bold;">Interpretation</b><font style="font-size:12pt;">. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith). The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly. If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict. If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><b style="font-size:12pt;font-weight:bold;">Effective Date</b><font style="font-size:12pt;">. This Policy shall be effective as of the date it was adopted by the Committee, as set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><b style="font-size:12pt;font-weight:bold;">Amendment</b><font style="font-size:12pt;">; </font><b style="font-size:12pt;font-weight:bold;">Termination</b><font style="font-size:12pt;">. The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed. The Committee may terminate this Policy at any time. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><b style="font-size:12pt;font-weight:bold;">Other Recoupment Rights</b><font style="font-size:12pt;">; </font><b style="font-size:12pt;font-weight:bold;">No Additional Payments</b><font style="font-size:12pt;">. The Committee intends that this Policy will be applied to the fullest extent of the law. The Committee may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require an Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company Group under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company Group. Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of doubt, this Policy applies to all Incentive-based Compensation that is Received on or after the Effective Date, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Executive&#8217;s compensation became effective, including, without limitation, Incentive-based Compensation Received under the Armata Pharmaceuticals, Inc. 2016 Equity Incentive Plan and any successor plan thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-size:12pt;font-weight:bold;">Successors</b><font style="font-size:12pt;">. This Policy shall be binding and enforceable against all Executives and their beneficiaries, heirs, executors, administrators, or other legal representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">*</font></font><font style="font-size:12pt;">*</font><font style="display:inline-block;width:30pt;"></font><font style="font-size:12pt;">*</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy was adopted by the Committee as of November 9, 2023.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>armp-20231231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 [P# 2(  A$! Q$!_\0
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MAC:[MC@R0R1[2@;;GE0#5BW_ &C_ !#K\/CKQIHTR3^$= T>'[-9^4A2>^=
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M )]XO^^!0 G]HVO_ #\P_P#?P4?VC:_\_,/_ '\%+]AMO^?>+_O@4&QML?\
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M/_?P4?VC:_\ /S#_ -_!2_8;;_GWB_[X%'V&V_Y]XO\ O@4 )_:-K_S\P_\
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M$JEP4((('H:\$\;C_A5?B'7]+T.UCLX/%6G11Z=;VZ!(TO580D*!P/DD5O\
M@!KV32_#]MX5\%V^CVBA;>RLQ F!C.U,$_4G)_&N6KAXTXQFG=2V^[7[GH=M
M'%2JSE3<;.._K?3[UK]PWPAXSL_%WAC3];C5K.&]1I$BN64. K$'.#CMVIOC
M'QUIO@OPM=:[<L;FVA "I;,K-*Q. JY(&<GUKPCPYH%CXDTKX+V&I6RW=G(+
M\R02#Y7 #$!AW&0..AQ4'CCPUI>FZ+\4-)MM/MXM,L=1TZXM+01CR[=Y%4.8
MUZ+D$]/4^M>BL!1]MRN3M?:W3GY=[GE/,JZP_.HJ]M[]>3GO:VWS/HG1]?\
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MXHQ_M;"_S?@S] J*_/\ '_!1CQC_ -"EH?\ X$3TX?\ !1;Q@?\ F4]#_P#
MB>G_ &9B>WXH7]K83^9_<S[^HKX"'_!13Q@?^93T/_P(GIW_  \3\8?]"GH?
M_@1/1_9F)[?B@_M?"?S/[F??=%? H_X*(^+S_P RIH?_ ($3TX?\%#_%Y/\
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MY@OYG]S/LO6/^0;-]!_.K47^K7Z"OB>X_;C\3W4+1-X:TC:W7]_-4R_MT>*
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M>)_Y]2^YGD*]:D7I7K@_9'^+ /\ R*A_\&%K_P#'*</V2?BP/^94/_@PM?\
MXY5?6\/_ ,_%]Z)^I8G_ )]2^YGD@Z4\=*]:'[)7Q7Q_R*A_\#[7_P".4\?L
MF?%;_H53_P"!]K_\<IK%X?\ Y^1^]$_4L5_SZE]S_P CR4=:>O6O61^R=\5<
M_P#(JG_P/MO_ (Y3Q^R?\51_S*I_\#[;_P".4_K>'_Y^1^]"^I8K_GU+[G_D
M>3#K3UKU<?LH?%3/_(K'_P #[;_XY3Q^RE\4Q_S*Q_\  ^V_^.4_K>'_ .?D
M?O1+P6*_Y]2^Y_Y'E"TY:]4D_99^*%O&TDGA@J@ZG[=;'_VI4J_LJ_%(C/\
MPBYP?^GZV_\ CE5];P__ #\C]Z$\%BO^?4ON?^1Y2O2GCI7JH_96^*(_YE<_
M^!UM_P#'*</V5_BC_P!"N?\ P.MO_CE/ZYAO^?D?O0OJ.*_Y]2^Y_P"1Y93Q
MUKU/_AEGXH?]"P?_  .MO_CE.'[+?Q/S_P BP?\ P.MO_CE/ZYAO^?D?O1+P
M.*_Y]2_\!?\ D>64^O4O^&7/B?\ ]"P?_ ZV_P#CE._X9=^)W_0L'_P.MO\
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M]79?\_?P_P""+_6B/_/G\?\ @'Z39^OY49^OY5^;8U_5"/\ D*7_ /X%R_\
MQ5.&O:H?^8I?_P#@7)_\51_J[+_G[^'_  0_UHC_ ,^?Q_X!^D6?K^5&?K^5
M?F\->U0?\Q2__P# N3_XJGC7M4S_ ,A2_P#_  +D_P#BJ?\ JY+_ )^_A_P1
M?ZTQ_P"?/X_\ _1[/U_*C/U_*OSC_M[5/^@I?_\ @7)_\53AKNI_]!.^_P#
MN3_XJC_5R7_/W\/^"+_6F/\ SY_'_@'Z-9^OY49^OY5^<W]O:G_T$[[_ ,"Y
M/_BJ<->U/'_(3OO_  +D_P#BJ/\ 5R7_ #]_#_@B_P!:H_\ /G\?^ ?HOGZ_
ME1GZ_E7YU#7M3/\ S$[[_P "Y/\ XJGKKNI_]!.^_P# N3_XJG_JW+_G[^'_
M  0_UJC_ ,^?Q_X!^B6?K^5&:_.X:[J>?^0G??\ @7)_\56KX9\=ZSX8UVSU
M."_NI7MY QCEN'977NI!..12EPW-)N-2[]/^"5'BF#DE*E9>O_ /OVBN)3XQ
M>%8?#NEZQ?ZO!86U^FZ/SB>H^\O ."#6]X9\7Z/XQLGN]&OXM0MD?RVDBS@-
MZ<@5\I.A5@FY1:2TV/LH8BC4:C":;>MKZV-BHY[B.VC+RNL:#NQP*PO%?C;3
MO",NEP7KNL^IW'V6V"1E@7QWQT%5_#>HZ9XQ6ZN8;F2]^S3O;2B1"BHX/( /
M;WKE3<N90UY;7\K[7]3N=/V:A*KHI7MYVWMZ=2S>^-M.M"0GG7#8SB)/\<9_
M"LR3XD1Q99M+NA$OWGRH"_7L/XN_\/N,]/'I%C$"%M8L>Z UD:1=Z3XF:^BB
MTV:$6<Y@=I[8PAF'4H>,CGK6;IUY)RB]O(Z(UL'!J,X-W\_\A-.^(&CZ@44S
M/;.[;%$Z$ MSQN&1G@G&>.^*Z)'61 RL&4C((.0:XO7?AQ#>AFLI C."CK,Q
M.5/!^;!SP6.UPP)/:JGA5Y?#WBI/#\NKI-(T#W1L5MY&")NPFR0G:B@#&P#K
MS44GB'+EE"_FC7$0P2I^TI5.5]GW[(]!K/O?^0C8?[S_ ,A6A6?>_P#(1L/]
MY_Y"NH\PT***3/.* #%&* <TM "8'I12T4 )BEHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D/2EI#TH _(#]HK_ )+KXX_["DG\EKTP?$&Y
M^&GP^^"VKQ1BYLS%J4%[9O\ <NK=I4$D;#OD?KBOI;Q/^PIX(^(OB75?$NH:
MWX@M[W4KIYY8K:: 1JV<84-$3C@=2:SS_P $Y?A^0 ?$7B@@= ;BWP/_ "#7
MTJQN'E"$9/;R\K'R;P&*C4G*"6NVOG<X+5[SPQ\)=1^#=[I^HQS>$+R?49+>
MZ/\ R[P7"J &]XRQ!_W:\8M?V6/%B>+)8-7B&F>$8G:6;Q69(WLOLV<B5'W8
M<D8PO7/%?4O_  [F^'^ #XA\4$#H#<6^!_Y!IW_#NKP!L"?\)%XHV#^'[3;X
M_+R:F&,HT_AGKZ>;?ZE5,#7JOWJ:LMM?)+MMH?.%IXWO?AS\ [1O#4]G=VLO
MBR\@CN-2TN"Y\V)8%V,$E5@A( /'/.*O_L\>)_$?C'Q?XXU*UM+6]\0R>')T
MMK:TTV!(Y)!C:OD*HC;)/0CGO7T#_P .Z_ &,?\ "0^)\=<?:+?'_HFG)_P3
MN\ QG*^(?%"GU6XMQ_*&K>+PKC)7U?6Q"P6,4HNVBZ7/&O$B^-+CX$^+HOBA
MH=IX>2!HIM%_T.'3IIKO.-HBAVB0;<Y)4X]:^8!U-?H*W_!/'P$^-WB+Q0^.
MFZYMSC\X:!_P3O\   _YC_B7_O\ V_\ \9K2CC\/23UW[*R,:V6XJJT[;*VK
MN_T/S['6I%ZU^@/_  [Q\ ?]![Q+_P!_[?\ ^,TH_P"">?@$?\Q[Q+_W_M__
M (S71_:F&[O[CF_LC%=E]Y\ KVJ1>M??@_X)Z^ 1_P Q[Q+_ -_[?_XS2C_@
MGQX"'_,=\2?]_P"W_P#C-5_:F&[O[A?V/B^R^\^!5Z4\=*^^/^'?7@(?\QWQ
M)_W_ +?_ .,T[_AWYX#_ .@[XD_[_P!O_P#&:?\ :N&[O[B?[&Q?9?>? Z]*
MD7M7WJ/^"?W@,?\ ,=\1_P#?^W_^,U!>_L$^!K2)&77/$1)=5YFM^Y_ZXT_[
M5PW=_<3_ &+B^R^\^%5Z5(.U?> _8#\"C_F.>(_^_P!;_P#QFE_X8%\"C_F.
M>(O^_P!;_P#QFG_:V%[O[A?V+B^R^\^$EIPZU]V#]@?P,/\ F.>(O^_UO_\
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M[N]<6UK%]G+$^7'&K'<XR0#P"<E3P, AOO5T?A&SU_>+C4KUUMOF"VTBJSR
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MJ3X ^ )O$%UK3^&K9]1N5N%>1GD*@7"[9]J;MB>8/O;0-W4\ULWGPQ\,WR:
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M]B5?YU^)G_K#1_D?X'Z?9'J*HZP1]FCY'^M3^=?FHOQP^(9_YG;7?_ UJ?\
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MZU9Z1I\T.O77V^UNY[YX[F-(3B K&(R/X,CYAG=7TH0&!!&0>QH"A5    X
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M !7^9\L+VJ1>M?4H_8@A'_,Y2_\ @M7_ ..TX?L11#_F<9?_  6K_P#':?\
M;&"_G_!_Y"_L/,/^??XQ_P SY;7I3U[5]1C]B6$?\SC+_P""Y?\ XY2C]B>$
M?\SA+_X+E_\ CE/^V,%_/^#_ ,B?[#S#_GW^,?\ ,^7QUJ1>E?3P_8IA'_,X
M2_\ @N7_ ..4X?L61#_F;Y?_  7+_P#'*K^V<#_/^#_R%_868?\ /O\ &/\
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MC_CU3_KJO\Z +PZ4M(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6?>_\ (1L/]Y_Y"M"L^]_Y"-A_O/\ R% &A7B7
MQ2U&#P-\<?!WC#6$GA\.QZ1?Z;-?Q6TDR03/)"Z*^Q6*A@C8)&,KCKBO;:0C
M- 'QWX6\/^+I-'T/38K[Q/X7TR_L_$FN-'IJM:RN[7*R6GF'861MLA(3*D\@
M@C(K#E^*/C36I9UN?$GB6S\7+HNB76DZ/96[I!->RX,RRH(\'< =Z.0%7+
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M[?<?\]3^0H^WW'_/4_D*KT4 -TV]G2T $A WMV']XU:^WW'_ #U/Y"L[3_\
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M5D^)?A]XI^($>L:UJ%G;:7J MXK;2](DN%EVHDJROYLB_*&<J!QD 5[/11+
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M'_D/_53./^?/_DT?_DC[8/6BOBT?\%&)C_S3^+_P<'_XS3A_P45F/_-/XO\
MP<-_\9H_MC _\_/P?^0_]4\Y_P"?/_DT?_DC[0HKXP_X>)S?]"!%_P"#=O\
MXS2C_@HC-_T($7_@W/\ \9I?VS@?^?GX/_(?^J6<_P#/C_R:'_R1]G45\9C_
M (*'S'_F08O_  ;M_P#&:7_AX;+_ -"#'_X-S_\ &:7]LX'_ )^?@_\ (?\
MJCG7_/C_ ,FA_P#)'V717QM_P\,E_P"A!C_\&Y_^,TX?\%"9C_S(47_@W/\
M\9H_MK ?\_/P?^0_]4,Z_P"?'_DT/_DC['HKXY_X>$2_]"%'_P"#<_\ QFG#
M_@H+*?\ F0X__!L?_C-+^VL!_P _/P?^0_\ 4_._^?'_ )-#_P"2/L2BOCP?
M\% YC_S(D?\ X-C_ /&:4?\ !0*4_P#,B1_^#8__ !FC^V\!_P _/PE_D/\
MU.SO_GQ_Y-#_ .2/L*BOC\?M_P I_P"9%C_\&Q_^,TH_;]E/_,BQ_P#@V/\
M\9I?VW@/^?GX2_R'_J=GG_/C_P FA_\ )'UOJ'_'G+]/ZU.OW1]*^/Y_V]I9
MX63_ (0>-=PZ_P!JD_\ M&I1^WS+@?\ %#1_^#4__&:/[<R__GY^$O\ (?\
MJ;GG_/C_ ,FA_P#)'UY17R(/V^93_P R-'_X-3_\9I?^&]Y?^A&C_P#!J?\
MXS2_MS+_ /GY^$O\A_ZF9[_SX_\ )H?_ "1]=45\C?\ #>TO_0CQ_P#@U/\
M\9I?^&])?^A'C_\ !J?_ (S1_;N7_P#/S\)?Y!_J7GO_ $#_ /DT/_DCZXHK
MY'_X;TE_Z$>/_P &I_\ C-+_ ,-Y2_\ 0D1_^#4__&:/[=R__GY^$O\ (?\
MJ7GW_0/_ .30_P#DCZWHKY)'[>,I_P"9(C_\&I_^,TH_;PE/_,D1_P#@U/\
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M;HE/_,E1_P#@T/\ \:IW_#<TI_YDJ/\ \&A_^-4?V]EW_/S\)?Y#_P!2,_\
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MC_\ !F?_ (U2_P##;$I_YDV/_P &9_\ C5+_ %@RW_G[^$O\@_U%XA_Z!O\
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M%_\ BJEX:O\ \^W]S+68X+_G_#_P*/\ F><KVI]>C#]FWXIC_F0-<_[\+_\
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M_P 54O"8G_GW+[G_ )%K-<O_ .@B'_@<?\S@%ZTY>M=\/V??B4#_ ,B/K/\
MWY7_ .*IX_9^^)7_ $)&L_\ ?E?_ (JCZIB?^?<ON?\ D4LUR_\ Z"(?^!Q_
MS. H'6O0/^&?OB3_ -"1K/\ WY7_ .*H_P"&?OB3_P!"1K'_ 'Y7_P"*I?5,
M3_S[E]S_ ,BEFN7_ /01#_P./^9P:]:6N^'P ^) _P"9)UC_ +\K_P#%4O\
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M .*IP^!7Q"'_ #)NK?\ ?I?_ (JI>#Q/_/J7_@+_ ,BO[7RW_H)I_P#@<?\
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MAR+2W5]6O+S'_JWA_91J^VE:7-]E?93;^U;H]C]%_P#A,_#?_0?T?_P80?\
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M+_GE'_WP*<L$6/\ 51_]\"E_K//_ )\K[_\ @%?\0XI?]!3_ / ?_MC]5/\
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M;/?LMN?,BE,3\,W3<I /?CUK<FU*SMIHH9KRVAFE8+'').BLY(R H)R3CL*
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M5TXZ:]GML?F!<,'NYV4Y5I'(/J"QQ2+7Z@_\,0_!K_H5I_\ P;7?_P <I?\
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M^.5%=_L>?":&-2GAN<$NH_Y"=STS_P!=*7^K^+_FC][_ ,BUQUEB^Q/[H_\
MR1^<B]JE7I7Z/?\ #'/PE'_,M3_^#2Y_^.4H_8[^$P_YEJ?_ ,&ES_\ '*E\
M/8O^:/WO_(M<>99_)4^Z/_R1^<:5*O2OT8_X8]^$P_YEJ?\ \&=S_P#'*7_A
MC_X3_P#0MS_^#.Y_^+J7P[BW]J/WO_(T7'N5_P E3[H__)'YTI4BU^B?_#(/
MPH'_ #+<_P#X,[G_ .+I1^R'\*1_S+D__@SN?_BZE\.8M_:C][_R+7'^5_\
M/NI]T?\ Y(_.\=*?7Z'?\,B_"H?\RY-_X,[G_P"+I?\ AD;X5_\ 0N3?^#*Y
M_P#BZ7^KF,_FC][_ ,BUX@95_P ^ZGW1_P#DC\\Z>O:OT)_X9(^%G_0NS_\
M@RN?_BZ7_ADGX6?]"[-_X,KG_P"+J?\ 5O&?S1^]_P"17_$0LJ_Y]U/NC_\
M)'Y[TY>E?H/_ ,,E?"W_ *%V?_P97'_Q= _9,^%H_P"9=F_\&5S_ /%TO]6L
M9_-'[W_D7_Q$/*?^?=3[H_\ R9^?2T\=*_0/_ADSX6_]"[-_X,KC_P"+I?\
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M>%;KPM9ZGXD7P_X?M)->N+N(MI,T8#-*KM\S8VD@Q$DL ",<U]IT4 ?*.J_
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M&P$P9'XJ76?V?=3U(:W#'J=FECJLMS>W%JROMDNMY-K(>.BJQW<$DQ18QMY
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>armp-20231231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F XP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /,/VB_^2:M_P!A/3__ $JCKTX5
MYC^T7_R35O\ L)Z?_P"E4=>G"N*'^]5/\,?SD>S6_P"1;0_QU/RIBT5S/Q)\
M6R>!/ VL:_%;+>26,/FK [;0_(&">W6O%K?]ICQFGAF#Q1<_#II/#+C<;VWO
M<_+NV[L8R!D8R0![U-?'4,-/DJ-WM?1-Z=]$7@<EQF8TO;8=+EORZRC&\K7L
MKM7?H?1]%>#>-_VFI-+@\(3^&M$76H_$<3-"D\QB=9 X3R\8(SDD=:T?!G[0
MEU=^.(/"/C'PS-X3UFY_X]2\HDBF)S@9P.N" 1D$\=:S6985U/9\VNG1VUU6
MMK:F[X>S*-#V[IZ6;M>/-:+M)\M^;1K70]HHKYVL?VCO&GB#6M>LO#_@)-9C
MTBX:*=H;S# !F"G!').P\#->C?!KXQV/Q?T>\N(+.73=0L9!%=V4K;C&3G:0
MV!D'![ Y!&*JCF&'KS5.#U=[735[;V;5G8C&9#C\#2=:M!<L;7M*+:YMKI-M
M7Z71Z'7FEN,?M%7/OX97_P!*:]+KS6W_ .3BKG_L65_]*:TQ/_+O_$OU.;+M
MJ_\ U[E^:/2J***[3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T4F:,
MT +129HS0 M%)FC- "T4F:6@ HHHH **** "BBB@ HHHH ***3- "T4F:,T
M+129HS0 M%)FC- "T4F:6@ HHHH ***3- "T4F:,T +129HS0 M%)FC- "T4
MF:6@ HHHH **** "BBB@#S#]HO\ Y)JW_83T_P#]*HZ].%>8_M%_\DU;_L)Z
M?_Z51UZ<*XH?[U4_PQ_.1[-;_D6T/\=3\J9YW^T-_P D7\5_]>G_ +,M>"^
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MVW_QNO2Z*/J='S_\"E_F']K8KO'_ , A_P#(GFG_  J?7_\ HIGB7_OFV_\
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MGU__ **9XE_[YMO_ (W7I=%'U.CY_P#@4O\ ,/[6Q7>/_@$/_D3S3_A4^O\
M_13/$O\ WS;?_&Z/^%3Z_P#]%,\2_P#?-M_\;KTNBCZG1\__  *7^8?VMBN\
M?_ (?_(GEUU\-/&6G6[W&D?$;5+C4(QNBAU6W@EMI#_=<*BL >F0>*Z?X9^-
M6\>^$K?4YK;[%?))):WEL#D13QL4D4'N,CCV(KJ37E_[/?\ R*VO?]C#J/\
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M:9K]BKQV]]$)!'(1NC/1E..X((_"OCRP\#^+[W]F]M:MO%SIX<C6:230/**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]=._])Z@^$7P8G^%'B/Q--;:G'/H>J2B6WL%B*M;D,<<YP?E.WH.%%3^ _\
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MDN?_ (FL34/BE\-M6NGN;WPM?7=P_+33^&97=OJ3'DU[7BC%1*AB)JTIQ?\
MV[_]L:4\9@:3O3HS3\JEO_;#PS_A8'PL_P"A-N?_  EI?_C=.A^('PC,R+=>
M'(],A8[?M.H>'7@A4]MSM'@?C7N.*BO+."_M9;:YA2XMY5*212KN5U/!!!ZB
MH^JU>DH_^ ?_ &QT+,\,]'"I_P"#?_M#GH?A[X/N88YH?#NBRQ2*&1TLXBK
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M?#S_ +&6W_\ 14M>E"N*C_&J^J_(]C%_[GAO27_I3%HHHKM/'"BBB@ HHHH
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M27Q*UV T=C/)*.VT'/<MQCN,Y%=!H7P_T;XC_M->-],\0VAN8%5YBL<C1E9
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MC1_PN3P+_P!#=HW_ (&I_C6K_P ('X:_Z%_2O_ *+_XFC_A _#7_ $+^E?\
M@%%_\34VQ?>/W/\ S-+Y7_+4^^/^1E?\+D\"_P#0W:-_X&I_C1_PN3P+_P!#
M=HW_ (&I_C6I_P ('X:_Z%_2O_ *+_XFN&^$>GZ7XOT;6+G4M"T>26WUF\LX
M_+TZ%0(HY,(.%YP.]92J8F,XTVXW=^CZ?/S.F%'+IT9UU&=HV3UCUO;[/D=+
M_P +D\"_]#=HW_@:G^-'_"Y/ O\ T-VC?^!J?XUJ_P#"!^&O^A?TK_P"B_\
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MD>5J=WI=/HT^G<^:O#WP0\6KX5^(NO:\(YO%WB:QF@CT^WD!5-QS@MG&20H
M!P .M7/"GP3OE_9SU/0=2\/6W_"4,ETUNL@C,H<R%HB).W;O[5]%4E<\<JH1
M[[-:];N[?J=M3B?'5%9I+WXS5DU;D5E%6?PV^?F>=?L_Z#K/A;X6Z5I&NVTM
MIJ%F9(S%*X?";R5P02,8(^E>BFEI#7IT:2H4XTD[J*M]Q\[B\3+&8BIB9I)S
M;;2VNW?0\Y^"/_(&\2_]C)J7_H\U7_9P_P"246'_ %]7G_I3)5CX(_\ (&\2
M_P#8R:E_Z/-5_P!G#_DE%A_U]7G_ *4R5Y>&^.C_ (9?G$^CS#^'C/\ KY3_
M /2:AZ?1117M'R(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %#7O^0'J'_7O)_Z":X[X ?\D9\(?]@]/ZUV.O?\@/4/^O>3_P!!-<=\
M /\ DC/A#_L'I_6N&7^]Q_PO\XGLP_Y%=3_KY#_TF9Z!1117<>,%%%% !111
M0 4444 %%%% !1110 4444 %%%% "&O+OV?/^1;\0_\ 8Q:C_P"C:]1->7?L
M^?\ (M^(?^QBU'_T;7#5_P!YI>DOT/9P_P#R+\1ZP_\ ;CU*BBBNX\8****
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M@9ZJ!@#@D]!77ZIH>G:Y'&FH6-M?)&=R+<Q+(%.,9&1QQ49\-:2ULEN=,LS
MD@E6(P*55P,!@,=< #-<<Z51SE.+WM8]>EBJ$:4*4X7LVWYOIUV6FEOGJ>9Z
M_P#%#5;JPNX(+:"U:[6>QMS!,9+B&X4K&7('&TR/M7OG:>^!WO@:^&J:%]M4
ML4GN)BA:5I,HLC(K GID(&P.!GBM-=#TY;F:X%A;"XF97DE$*[G92"I)QDD$
M @]L59MK:&S@2&")(84&U(XU"JH] !TI4J-2,^><KAB<5AZE%4J-/E=[WO\
MA^7W7TN2TAI:0UVGD'G/P1_Y WB7_L9-2_\ 1YJO^SA_R2BP_P"OJ\_]*9*L
M?!'_ ) WB7_L9-2_]'FJ_P"SA_R2BP_Z^KS_ -*9*\7#?'1_PR_.)]=F'\/&
M?]?*?_I-0]/HHHKVCY$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;]N:+C?O97N[:VV.LHKS>&T^+,$2QG4O"%P5&/-DLKI6;W($F!^%/\GXL?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKWZ)]>M_+3;KL83I86$N7E;U:Z=.6]KM7^))6NWT0O\ PFG_ $T_6C_A-/\
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M64]]JUQ;Z=/%YGAV/0; ,RYAPH621L'^(;A@9ZBO1_\ AAR7_H<5_P#!>?\
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M,I.Z7+.RU;>Z=VV]=EMHCR^W^+L,MIH%OJ,%U>K:Z]+K6H.Q0O<[MNU0>.<
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MJ7NK):V[)*VUM-C!T[XEZ/K6E^*-8NTU"'2['1+3P[;9N8WU"8/*2\A+<,V
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M;M?R5N!\*_&JQ\-W'BJ"-]:M[+5[I+N&]M?L_P!LC92Q*N'!0@[CTZ5CZ_\
M%D:UX?\ $-FPOI]0U74H;DWMW*K-]FB0B.-MH + L3D#%>K?\,.2_P#0XK_X
M+S_\<H_X8<E_Z'%?_!>?_CE)X'-G#DY-->JZW\_-E1SCA:-5UE6]YVUY9_9M
M;[/]U:;:'GFD_&+2++Q#X=N9M+N?[/TC1#IL:HL3R)<$$FX17RI.XD@-ZUD_
M%#XJKX^;0A"MZHTZT:WDDOG1I)G+EMYV #D8["O6?^&')?\ H<5_\%Y_^.4?
M\,.2_P#0XK_X+S_\<I2P&;2INFX:/SCY>?D.GG/"].M'$1K>]';2?6]_L];L
M^;O[2?\ O4?VD_\ >KZ1_P"&')?^AQ7_ ,%Y_P#CE'_##DO_ $.*_P#@O/\
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M_P :/^$FT?\ Z"ME_P"!"?XUS?\ PI+P%_T*.D?^ JT?\*2\!?\ 0HZ1_P"
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M^!"?XUSC?!3P&[%F\):26)R2;5>32?\ "DO 7_0HZ1_X"K1H/WCI/^$FT?\
MZ"ME_P"!"?XT?\)-H_\ T%;+_P "$_QKF_\ A27@+_H4=(_\!5H_X4EX"_Z%
M'2/_  %6C0/>.D_X2;1_^@K9?^!"?XT?\)-H_P#T%;+_ ,"$_P :YO\ X4EX
M"_Z%'2/_  %6C_A27@+_ *%'2/\ P%6C0/>.D_X2;1_^@K9?^!"?XT?\)-H_
M_05LO_ A/\:YO_A27@+_ *%'2/\ P%6C_A27@+_H4=(_\!5HT#WCI/\ A)M'
M_P"@K9?^!"?XT?\ "3:/_P!!6R_\"$_QKF_^%)> O^A1TC_P%6C_ (4EX"_Z
M%'2/_ 5:- ]XZ3_A)M'_ .@K9?\ @0G^-'_"3:/_ -!6R_\  A/\:YO_ (4E
MX"_Z%'2/_ 5:/^%)> O^A1TC_P !5HT#WCIX-?TRZF2*'4;265SA42=2Q/L
M:C\2Z9?:QHT]KIVJ2:-=OC9>Q1+(T>#DX5N#GI6/I7PG\':'J,%_I_AK3;.\
M@;?%/#;JKH<8R#^-=7VI:=!ZO<\+\&VOC+5_&7BBPN_B!=K:>'KN!&)LH +A
M&02-N^7Y>,CBNKTKX[Z-JFI62?V?J=MI&H7'V6QUJXM]MK<RY("J<Y&2#@D
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M4444 %%%% !1110 4444 %%%% !1110 4444 %)3)YX[:%Y9I%BB0%F=SA5
M[DGI7F5[\6;[Q;=RZ9\/--&MRHWERZY=933;<]\/UE8?W4_.MZ5&=6_*M%N^
MB]6<];$4Z%N9ZO9+5OT1ZAQ17E\7P5N]35;K7_&WB*\U8G<9K"[^R0QGTCB4
M$ #WR?6H?[9\;?"S(UF&7QOX;3_F)V40&H6Z^LL(XE _O)S[5O\ 5X3TI5$W
MVVOZ7W^=F<WUJ</>K4W&/?1V]4MOE==V=[XK\':3XVTP:?K-J;NS$@E,0D9
M2.F=I&1ST/%:MM;16=O%!!&L4,2A$C0855 P !Z8K+\+>,-&\::8FH:+J$.H
M6K<%HFY0_P!UAU4^QYK9KCE&4'RR5FCNA*,TIP=T^HAZ&LNT_P"0PW_7,_S%
M:AY!K/MK>1-3:0H0A0C=[Y%835VCJIM)2]#1HHHK4P"BBB@ HHHH *0]*6D/
M2@#XR^.>CFZ^*NOR;<[I(^W_ $S6N$_X1\_W?TKZ"^)GAO[;XXU2?;G>Z_\
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MY(F5"I*+BTK?\/Y_WF<KX"ATK2M%\466H75Q83:K:QVD<T-L9MJ;]SY (ZX
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M3[&"9 /S,<\L:R_A';OHDGB?7]6LWN-%DM&\X.,1SW/FK)&GNV[MV!.:N_\
M"(_['Z5(?#$AA$)+F$'<(\G:#ZXZ9]ZM.KSJ<EM=KYI+K?30R;PZHRHP=E))
M/;9-RTLE9W>_IV/+-8M;O7M6O-2O6,MW=RM-*Y[L3G\NU=IX@\0VMY\.=+T2
MRBF34VM8K/49W& 887=HT4]P6?)_W16W_P (C_L?I1_PB/\ L?I7+"E4AS6^
MUN>C4QM"K[/FV@TTNFFWR6_JD5[C7]"1H]>ADO)M<CT-=(M].D@Q%;OY1B:3
MS,X*[2QV@=6I=*\2Z+9ZSI$6;J#2[3PTVBK<"(N]O,X)DE5,_-RQ'N#[5/\
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MXB:BMS:Y#Q^&]-=DLH_3S6^],?KA?8UZ;8V-OIMI%:VD$=M;1+MCAA0*B#T
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M?[,L98\8S)N_05O4U(Q&,"G5W4X*$5%=#RJM1U9N;ZA1116AD%%%% !1110
M4444 %%%% !1110 4444 >8_!P?\5!\1SW_X2*7G_MFE>G5YC\'/^0_\1_\
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M:_\ 7Y>?^E,E>BGI7G7P!_Y)K:_]?EY_Z4R52V9/VD>C4445)04444 %%%%
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M&9KF7_=C7)_'I7%_#/Q]X9\,6-IX:G_M70YY)I9(!X@M?LQF,DC.0K?</WL
M9SQ72Z'X-\+_  JL+K5)9 MPPW7>L:E+YEQ,?=SSSV5?P%.TSQ%X1^,.CW-D
M4AU.WY$ME>PE)  2-VQ@"!D'##\\U6EB-;G: @C(Y%+7EA\)^+/AF?-\*73>
M(]!3EM!U*;]]$OI;SG]%?\ZZ;P9\3M%\:226L,DEAJ\'%QI5\GE7,1[Y4]1[
MC(J;%)]&=;1112*"BBB@ HHHH **** "BBB@ HHHH **** "BL?Q5XNTCP5I
M,FI:S>QV-JG 9SR['HJJ.68^@YK@T\2?$#X@8?P_IT/A#1GP4U#6HS)=RK_>
M2 <+QTWG\*Z:>'G47/M'N]O^#\KG)5Q,*4N17<NRU?\ P/5V1ZF3Q7"_#?2;
MS2]<\=2W=M+;QWFMM/;M(N!+'Y$0W+ZC((_ UF#X)-J6U]>\9>)-7F!)_=WG
MV2/GT2(#'YT^3X!^'2AV:CXA@;^^FMW&?U8BNB*H0C*'M+W[1\[]6OR.6;Q%
M249^RMR]Y>5NB:_$]+HKS"3X<^,/#@\SPUXYNKI5 "V/B&);F-@.WF+AQ^M2
M:7\79M(U.#2/'6E'POJ$[>7!>!_,L+EO1)OX3_LM@UD\,Y*]&2EZ;_<_TN;+
M%J#2KQ</-[?>M%\['I=%("& (.0>XI:XSO"BBB@ HHK/\0:E_8VA:CJ& WV2
MVDGP>^U2W]*:3D[(F344VS"\:_$W1/ QB@NY9+O5+CBVTJQ3S;J<]MJ#G'N<
M#WKE/^$8\8?%#$GBBZ?PIX>?D:%ILO\ I4Z^D\X^Z#W5/Q-9OA*2R^&WP@N?
MB)J<*ZCXAU"R74[R\DYDD>4 I"K'[J#<J@#CC-?/GAV;XG?M!^(M1GL-:FB-
MLH>3%V]O;P!B=J*$[\'MGCDU]-A<$FISA)14-'-]_P"ZNGJ]=K6/DL9CVI4X
M5(N3FKJ$>W]Y[OT6F][[GVSX=\,Z5X3TN/3]'L(-.LH^D4";1GU/<GW/-:E?
M$OPN^+WB[X7?$>/PWXCO;F\L?M@L[RVNY#*868@!T8\]P?0BO9?VH?C+?_#K
M2K#2-#F%OK&I!G:YQEH(5X)7/&XDX![8/M7+6RK$+$QHJ7-SZI]^[9V8?.<,
M\).NXN*IZ./5/HD>Z;A2U\&2>$/BC:^ T\>MK.H+II N!_Q,9//$9;B79G&W
M.#]#G&*^A_V8_C#>_$K0+[3]:D6;6=+*;IP,&>)L[6('\0((/X'O1BLJEAZ3
MK4ZBFHNSMT88/.8XFM&A5IN$I*\;]4>C>-/AUH7CR"-=4M/]*AYM[^W8Q7-N
MW9HY!R/IT]JXW^U/&_PKXU2*;QSX93_E_M8P-1ME_P"FD8XE _O+SZBNL^(_
MQ+TCX7:/!J>LBX-O-,(%%M'O;<03TR..#4OP\^(6E?$WP^=9T<3BT$SP?Z1'
ML;<N,\9Z<UQP=:-'GG#FI[:[7\GT?I\[G=45"==PISY:MKZ;V\ULUZ_)HN^%
M?&.C>-M,6_T6_BO[<G#&,_,C?W64\J?8BMJO)?B+I5OX!\9^&_&&DQBTGO\
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M7-C<%"86N)&6/8VY/+RW[O:>1MQBNKHH5:HM%)_?VV!T*3=W!?<NN_WG/1^
MM#BU>74DLRMQ,")E$K^5*2NPL\>=K,5X+$$FCPWX!T+PE.\^E6(MIGB$!D,C
MNWE*250%B<*I)P!P*Z&BDZM1JSD[>HU0I)\RBK^G<PO'7_(D^(/^P?<?^BFK
M(^"__))O"'_8+M__ $ 5K^/"%\$>(23@#3K@DG_KDU9/P94K\)_"(((/]EV_
M!_W!70O]U?\ B7Y,Y7_OB_PO\T=G1117$>@%><Z[\2=2U76+O0?!.F+JVH6S
M^5=ZE<DI8V3]U9NKN/[J_C7<ZW=266C7]Q$0)8K>212?4*2/Y5QOP'LHK3X3
M>'&C7#W%O]IF;N\CL69B>Y)-4MKDO5V&^'OA';QZE'K7BB^D\5:^OS)/=J!;
MVQ](8?NK]3DUZ!TI:0TF[C22/%O#N@WGQ2\0ZYJ]]XDNH'TG5;G3K:R@@CV6
MHC;Y9$W!OG*X.\C([8K2USX-0Z?IGVFU\4ZMI_\ 9X>YBN7$<LD!Y=RK%0V&
M.25)(.>E<YX&\=Z;X0\<^(;1X[N?[?>3)*MK;22;+M;B;;&0!]YXBK?1:Z+X
MF?$_3'\.S:3+;ZK83:AMB+7&G2H%@WKY[G(^ZL>XD_2M-;Z&2Y;:G7_"WQ%=
M>+?A]H6KWKK)=7=LLDCJFP,>1G;VSC.*?XR^'.B>.8XVU"W:.^AYM]0M6,5S
M ?5)!S^!X]JH?!=47X7^'O*7;#]G)C&,?)O;;^F*[:H>CT-%JM3RIM>\8?"M
M3_;L3^+_  U&.=6LX\7ML@[S1#AP!U9>?45Z5I.JV>NZ;;:A87"75G<QB6*:
M,Y5U/0BK3 ,I!&0>"#7F_P #HUL])\3:?$-EG8>(;ZWMHNT<>\,%'MEC^=&Z
MN+9V/2:***DL**** "BBB@ HHHH **** "N?\<^-+'P%X=GU:^#R!2(X;>(9
MDN)6X2)!W9CQ705Y3H\7_"S/BO>ZQ,/-T'PI(;+3T/*2WQ'[Z;WV A!Z$FNJ
MA3C)N<_ACJ_T7S?^9QXFK*"4*?Q2=EY=W\E]^BZEKP5\/+W5]5C\7^-PEYX@
M<;K33B=UMI2'HD8Z&3'WG/.>E>EY&<9Y]*.U>%:-=MH?[5OB."6>0P7^C).@
MFO!CY0"=J>V&X[ $]#6T5+&.<F[<JNETLFM%VW,)2A@%3BE?GE9OK=IZOOM8
M[#Q3\4+SPW\6O"_A5["W_LW689#]MDFVN)!G"JOY=>N>.E<;\>M<NO&7BWP[
M\--%NGANKV9;O49K>0QRV\*\C!X!R,G'^R*X'XD_%%_%FF>#_B$NCS:6NC>(
M);0,%64SQ 9R'Z#[I&/7.#Q5_P (7NIZ'\.O&_QAU"18==U56_LSST\Y(8RV
MV/;U(!)Q@X&%YXKW*6#]@J=9I*2]VW>=VEWV6OR/G*V/^LRJ4%)N#]Z^UJ:B
MF^V[TU[GU#9VXL[2" 2/*(D5/,D.6; QDGN35?6]#L/$>F3Z=J=I%?64Z[9(
M)EW*P_SWK!^'_B6?4? WAJ]UV\M!J>HVT;DQGRUE=AG"J>^,<#WKHY]1M;6Y
M@MYKF&*><D11/( TA'7:#R?PKYF49TZC75/IY'U\)PJTT^C2T?GT9Y7I=Y??
M!/7K/1-4NI;_ ,$:A*(=-U&Y<M)ITI^[;RL>J'HCGIT->NUE>*/#=AXOT"^T
M?4X1/97D1BD7N,]"/0@X(/8BN1^#>OWUSI6H>'-9E,VN>'+C[!/*W6>+&89O
M^!)C\0:Z:EL13=;[2W\^S_1_)]6<E*^%JJA]B7P^5MX_=JOFNB/0Z***X#T@
MK \?_P#(B>(_^P=<?^BFK?K \?\ _(B>(_\ L'7'_HIJUI?Q(^J,:_\ "EZ,
MR?A_I-EKOPA\+V.H6L5Y9RZ1:"2"90R-B)",@^X%0>(;_P '_ [PU?ZPMA::
M5$X \JTC"/<R '8@ ZGK].34?A7Q-9>#?@=H.M:BSK966B6TLFQ=S$>4@  ]
M22!7Q?\ $3XF7WQB\917>LW@TK2Q)Y<$>UI$LXB>6VCEG(ZGN>.!7T&"P%3&
MUJEVU33=_/R2[GS&/S*EE^'I\J3JN*MY:;M]OZ[G1?"WPMJ_QU^,$NMW496T
M6\%_?SC[L:ALI$I]3@*/8$UTW[:__)0= _[!1_\ 1S5Z%X!^.GPD^&_AJWT?
M2;ZY2"(;I)6LI-\S_P 3L<<D_ITKC?VSM%GO;_POXFA4OIDUH;3S I^5BWF+
MGTR"<?0U[5&M4GF5/G@X02:C=6Z'@UL/2IY35]G44YMJ4VG?K_7XGJ^I ?\
M#*SC'_,L+_Z(%>#?LJ:\WAC4/&^JB+SQ8Z&UUY.[;O*/NQGM737G[0OAN?\
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M&-WGVU:V_P :]+I.*[%B$TE4@I6TN[WM\FC@>%:DW2J.*>ME:U^NZ=KGFO\
MPL/QU_T3&\_\&UM_C1_PL/QU_P!$QO/_  ;6W^->E#!%&*/;T_\ GU'[Y?\
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MD3GAMH)Y!Z5]!BIQ--TJ4(/HY?H:82HJU:I4751_46BBBO-/5"BBB@ HHHH
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MU\+WNI:A;-97.MZE<:K]ED&'A25OD5O?: ?QH6S![H[^BBBI+"BBB@ HHHH
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MS\(;>;7+G6- UK4O"NH79W71TYD,-PW]]XG!4M[C!JO_ ,*T\5?]%+UC_P
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M "J_15*36B9+C%ZM"  #':EHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.>*\3^(7@*W\*_$3P1K0\$/K_@W3M+O;*73=*L$N3:7DIA*3_9OXMRQR1F0
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MDDGDDDG)-:E%% !1110 4F*** %HHHH **** "BBB@ HHHH *2BB@ Q2T44
M)38H4@C6.-%CC48"J, ?A110 ^DQ110 M(RAE((R#P1110!0\/\ A_3O"VBV
M6D:3:1V.FV<0AM[:(?+&@Z*/:K^*** %I*** %KC_&OPC\(?$2\M;OQ!H<%_
M>6T;0Q7.YXI5C8Y:/>C*2A/.TDCVHHH Z+1-#T_PUI%II>DV4&G:;:1B*"TM
M8Q''$@Z*JC@"KU%% "4M%% !2444 +3!$@E,@11(0%+8Y('09HHH ?28HHH
M6BBB@ I,444 +1110 4444 %)BBB@ HQ110 M%%% "8I:** $HQ110 M)110
+ M%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>armp-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N UX# 2(  A$! Q$!_\0
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M@J"2..>>U 'IU%>0:I^TYX1TW5]*3SY9-%O(;J5M4%O-M7R?+.5&SYT(<DR
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M9%F9 <Q-QDO@')Y/-5/B)\#KGQ7XJT"XTZ^ALM#BMH[;5K)E.;I;9O-LPN.
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MKS;XX?$!?!GPWUF32]1BC\0RHMEIT<9$DINI"$C 0<DY8=N.M=#\,=-U[2/
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M1110 4444 %%%(3@4 +15>]O4LK4SN1Y8*@G/'+ 9_6G+=1-;>>7"0X+;V.
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M^=RH&YN3R>>:U***1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.>,?%T'
M@VUBN[UE2UED$2MGYO,ZA<=\@'IZ5T"N)8PR,"K#(8<@BO//B?\ !NP^+4=E
M9ZY<W$FG6EP+E(TE*$. 1E2FT@\\$DXK.\*_#SQ?X)\902OX\N=6\%10-&=/
MUA4DG!P=O[[ )P<<D]!0SHC"$XOWK-=^OIYG-?M#>#_%(TI?$&EZS+;Z1HDH
MU"\TJWF*+=1J<R<<$$+\P^;&0>,G->-_$7XVW?Q96'2_#5ZR^$%B5(Q%N5I\
M #,C$Y.,'CI]:T/VI?C_ &=O_:O@N*]E>%[J&VD?8"D\?#L-^,%4S@D<DX'8
MUX*?%.D^$_ &GC2FGT^^NY#)&JIP DN)58Y!&<$ CTKU\-2Y%[62OO;Y=3Q\
M54^L+ZNI*-I13?3W[V3MKT[>IZAH'@^TDO3:-()+U8Q.\9/S!2<!L?45J>(X
M['P=%8-)"LRRW*VSHK@.A..<'KU%1ZU\2?!?P_\ #FI^*["^CUB^NRMNL<9_
M>-*J850&^Z@/)(R.>YKYIF^,=UKWB!+B_M$D#ZA!=/>32MYZA&7Y0P*JH(&.
MG0#TKU+MTW5CJD?,PC&.,A@JUU)O6RNTN]F?4[>'- F\6KI4_G0:L\9D6%I3
M^]0C!(&3QP?2G>#?#R:+IVJ-JMLVFP0W$FV:XDPKH.C\].,#WK(74+OQ9\0-
M&\=:')9KI:PKI]V+X&.:*1I#\JC'WPIP/7-;'QKU/4;KP9<VUI=Z?91S1F.<
MZ@I9BK' "A>ASCM0YNR3=EU\B53;G)05VG9)+?L)HNM6^JWNK-<100:) @>U
MU))1Y<Z<[L'VQ^E0Z1;>$/'0&NZK:6=Q%$BQ^?=/B%PH(R03CH"3GWK!DOA\
M*O@C!9:U?)?74,;;(X!A) 2<)&<<XR/F]J^4;OQ!K=UIC/>7%[!HL\CM#"B%
M868@!F4?=)XY[\FL)S]_3X>IZ.%P_M*:4GRU'K&^B;[+K>^BM\]SU'Q;XXT6
M\\3^*XO#JQV.G2-'';"R_P!7B/*,4&. W!/IS6+!K.FZ2-(B@:;4DM+R":1I
MNPW[B.,87!/ZYS7J7[+?@7PQ<^&KS6;Z.UU"5;IK>"*<I( %4$$J.<'((SZG
M@U6^(/P<\0P^*=7_ .$3TOS_  WJ%FKC[(?^/4KD^6<G.=V2/8^QK*;7):"[
M_P!?>>OAZLX8E+%2::4;V:W5E>_5<M[*ZOW/.-)UO4Y_B#=7<UU;H&M9AY1)
M1HXW89/M]WJ:[N+5M7T7Q#/%F F_T4" H""D)<MN]LD#KR<=JSO$7PMU+P?X
M>U?Q5K@ABOM0TJ.S32HX?.FA')=I)%X4_=-+X"T37_&XTJV6TFNTFNK$WMU:
M!L06L>U1N8@@ *7Z]\]:BK4FVFMM_N-L'0PD:<N=Z_!TZ]=^F[[KJ:'@CX,Z
MIXPTRW\1)JLUG+,LMO*"^0,/M8CO_"#CI6EJ/@R^\):GI?@O39YM9T^^W3W=
M[+;^6Z _ZSH3SRN.]>V?%WXDZ?\ #73;21;9)VN;@6UM;1' QU9L*,X5<D\>
ME:?AW5-$\8V5GK=A<Q7D$BDQSP=3ST]1SV-:>S;CS2Z]3R_[2:Q#Y(K351MH
MM[6\DW=?(X.T^$6BZ+9O!IVG)&C[?WJ.S;P,D<-TZDGWKF/#.EZKK7B&^M6\
M.FPTFSF:!KVZ?:TV.A1<<@\'.<=:]&UOQ3JUQJ>I:1I6BSV11 8M<O,&T'R[
MBQ&=S8((^HKSOX%_%9?%<^N:#XJUNRU*\^U&"U,KA#=IG;\B="O';FNJG%P@
M[(\/$8AUJZ=23;=]7U^;.BG\%6MRD@MVBF"##>6ZOCZXZ5Q>M:9=>#&.L:<U
MQ%<6P+H;=L-GV].W2O3O$?PP\,7UG]@L(3H4,K![@Z8! ]PH/W6(&<5YIXJ\
M=#PIJ3Z0/#=[;^']/:."75KF3Y K# 92W+\XR<U2O-6BQ<ZHSC*JKI-=7KY:
M;>I[%^RN=)\::AJ>O^(1(GCN>X\ZX=90N8L$1HH Z* <^I.>O3ZPC540!<X'
M3)S7YZ>&O$+>"O'>C:Y:3E;8RIYA1PJR1-C()/&",'FOO[1[U;VT1U8,& (8
M'@BO#Q6'5%IQV9]7A<:\6Y.6_P"G3[MB_117GGQ?\:7?A.P@6W<V\<ZL9+A/
MOH!Z<'_&N&,>9V1Z&^B.@\5>/-)\)1D7<^^YQE;:+ES]?3\:\)U/]KJRTO76
M>>[M$LHV\MK,*S'KR=X!Y'?L/2O$=>^,ZW=U<MI^GW=WEY(U$R2>=.1D%Q\N
M!A@1SZ'.*XWX5:EI'B:YG7Q3JMWI9C60B2U$?^C*H!&Q6R>>1@@Y.-N"*B5>
ME!\L-7^'X?UZ'N4LLJ<CJ5HM+MUOZ6?]=S]#_!7Q)T/QU:)+IUVAE89,)8;O
MP]:ZJOS]\#:!I7A[6(?%%DFMVFC7,QA2\+F:5U0MN;8K%BYQD\ * /Q^V? N
MJR7MA$KWYU*-XEFAN' #.A P21UX(Y]Z4*D*E^7==/U]&<>+P<\*T]XOKY]5
MI?;8ZFBBBJ//$9@HR:\3^-/[1$'@*631M'A6]UYEX,H/DP\=3W8^P[]:W/C[
M\4&^&W@R6YM<'4KEA;V@;H'/\6.^!DXKY)\,:5/JMTU_J$TMU<S'>TDS%F.2
M?6O3PN&4U[2IL>/C<6Z;]E3^)FKJ/B'QKX^<RZOK%R59MRI&_EJGLH7 Q5&^
M^&_F:+=EHOM$SQMA7.06/3.>O/KFO2](TV*)%PA '' Z5M"VM0J[PFUAQ@XR
M :]%U$O=BM#SH49-J<Y:GSY\.O@M<:;;37%[=)/NE*Q6SJ&"1J3\I; .>?P]
M*]*MO =I"3^X52W.,].*[E8;2"/()#,<D'@$]>M3AX)77(4.K9.&Z>V?K6<9
MN*48G55BJ\W4GNSQ;1K+[1X_U70+O2DMTMH!=6DO_/1"0"1SSR3VX_&NC?P!
M9_:VNC H "\A?0G-8_C:T\4:Y\2M+U;PY;0PQ6<3VLT[, 7A<]\CG++D#I@=
M1FO3]+O?MFGQBY16D7*L,!7# X.X9X(-1"I/5/N=.)H47R3@DKI72[K37UM?
MYGS]XITG6I/'.GW6GZ"9K&Q$J2R@;E4,G\1[=L@ X!SSTK:\<:+I6G>%WN[\
M_8%<K%A206=N%4%<$COFO<K:U@A1T4*#(Q=E.-SDG//^>U>+_'O7] OM,T/P
MQ(C3^;JUJC_(Q 19,OM88).T$94\=\4>T<$VNO\ PQ5.C2KU*<9*RCIIO:[?
MZGE^H_LV76E1VES8:JUS'-.'DCD0;65F7 &.O?.:Z_Q/;ZYX/\(+>VMW<1W!
M>*)HX[AD!8MMX&>>O%?0-O:6-]IMM+9>7<6VQ'@\ILJ5'*X/Y5Y3\3/#/B_7
M);63388)M(L[M;B:+A?]6=QP#]_! _(C!S0Y<L7RK5ETFZM:FZS3C%WL]GY.
MW<\Y\0^-O&MAXX\/SP7>K7$MA'-Y<TDKLL6\(#S_  C Z$_6KD]GXTF\4+XQ
MG\6WMM>LGD('G*R?>R%#9XYP0!QT'2O?='TV.XTLS7D<<4LOSW"@Y0D@<@GM
MBO+?%L>A^,?B#X1\,VUX7M[5Y;BY*.4$@3 CC((PWS8_[Y]ZAN,4VU>[7Z(U
MHJ56<8.3C&*=VM=-9=?N.4^(WCOXD:[JWA]+B\U'5!879NXKJ,%60E&7=\F-
MO#'TKK+72M;\4V4;:CJ-[.QPY2:X9\9YX/?ZU[##X?BLYI'&W=*?FP.  .E+
M!H\5FBPHIPI.,KP!D\?X5M&48-N*W/,JJ5:$82?P^NNMSQY/ =S8HOEW,PVC
M:,2'H>H_&I-+\0>,?AW-Y^CZM/&%X"3.74#.<;3Q^=>PW.G1QV^\$,.@ (.3
M7,:UIL;H< #(P1T[5LJL9Z21PRH3A[T9:GL7P7^/]E\0]FEZB8[/7E0L8P<+
M,!P2OO[5[$#D9%?GE>SWG@W7(-9TMVANK>0."IQD=P:^OO 'Q3N_B9X5TZ\\
M.6BN]Q$#/?7!_P!&@?HRKWD8'/"\#N<\5Y6+PZI-3ALSV,#BG63A/XD;7QB^
M(_\ PJKP-/X@^S0W12ZMK8)<3F&,&:=(MS.%8@#?DX!Z5S?A']I#PWKF@>%K
M_5P^A2^(%F^R^9^\MV:-I0=LH&"&6%G7(!VD9 )Q73^+?ATWC/P8-#O];O!<
MBZ@O%U&..,2)+%,LJ;4*E=H9 ,$'CJ3UKSE/V.O"(U.QNY=1U.X$$S74R3&(
MFXG>2>21RVS<@=KF4E(RJ_=XXKSCU3HI/VC_  W'J>E0O9ZM#IU_:7=\-3N+
M)HH(X(%1VD8M@["K@AL56O\ ]J'P:NB7=U83S7-[#!=S?99873RC;PI,_G,
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MCN1@WSG:L,FX[% .<KN(R3C&?;G%2@HINZO_ %^IZ$Z-5SG%6?LVUTZ7VO\
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M\]K%#:OM;S=OR*VT9.6 W'&,$X/%?:?[.R:K87%SIFI2R2V]I;G[#YO+B E
MH)[@%6P3R1BOES]EOQ)#X$\2M8WVE311W\[I]HDB!\K:HX]5QDGW&:^Q/AW,
M]S\1-?D*ML6W6-6QP<,O?\ZK#8;V<74O\CR<VQGM&J"6BZ]_/UWZ^5D>I4V1
MMJ$TZH;G_4M]*V/FF?'?[66MG4/'>D::97\N" RM'_#DDX/^?:N5T>^2SA7
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M418D5$4(BC"JHP /04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9C\JW6-FNISO+Z3Z'Q5'^SM.&)>^N'.>,*!BI$_9SE92&O;HY().!ZU]H?\
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M>"=6&IZ3$V<G KHZ^3DK.Q]FG=7"BBBI&%%%% !1110 4444 %%%% !1110
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MKGQ%?V-.52/1&V"P:Q->%&3^)G,6<%GJ=M)HWABUBU1Y;/;<7\S,B(K XP.
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M['$K"!$4=B<TN(TC"'D"JU^;BPG>"YB>"93AHY%*D50DOO>NQ1N::(UFN4
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M@6.F(<!8F*F;&"<D<]#TZ5]<5\>?M@> ]5M+U?$*Z:UYI;29DN8N?*/0!QU
M/KTS0XRG&4:?Q=/Z]#NP,J4,1%UOA%\"W9^,'@34O!-W>W&H1RPF?36NL2/:
M2H,H-^<X[<^I%>6? +QY<?"KXK6C71:&TGE.GZA$W&T%MN3[JP!_ U[K^R5X
M9UZ71+._FLOL.@I<M=6TLP >X!C9?E Y*Y.03Z<5Y1^UQX$7PA\4Y=1M8_*M
M-9C%V-HP!*.)/S.&_$U\YF=&I15/$W]Z._\ 7X?,_3N&L7A\75Q.3R_A5$W'
MUM9V]5KZH^]E8,H8$$$9!'>EKSOX >-1X]^%.AZB[[[N*+[+<^HDC^4Y^HP?
MQKT2O?IS56"G'9GY9BL//"5YX>IO%M/Y!1116AS!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !115;4=1MM)LY+J[E6&",99V--)MV0F[:
MLLUDZQXJTK00?MM[%$W]S.6_(<UY7XF^,']KZA_9MEJ-OH=JP):YN7VNRCJ?
M]D?K5C0HOA[8RI)J'B"UU6]<H<SR'82WW<#OGWS7H+"."YJM_1+7_(XGB5-V
MIV]6QGQ-\>1^-O!FL>']#2Z2XU"$V_VLQ9"*W#8 .3E<CMUKR3X/_"/4/A=X
MLB\0?8[G6)HHGCCB>W,2J6XW9Y[9'XU]'V_Q$\%62F.#5].@"*6V(0O .#@8
MYY&.*<WQ<\'(6SX@L_E8(<,3@D$CMZ USSPM&I451T&VMKN7Z:'JT,UQN%PT
M\)2Q"C"?Q)*.NEMW=[>9BK\6KRU/^G>'+J!>[(Q./S45KZ5\5=!U)@C3M:2'
M^&X7;^O2L^[^//@.WAD>77K9U1#)@ MO ;;QQR<CI7)>*/C%\)[V!S=W$4\V
MY4S;1$2 L,YR.P[]:[HX=U-/8R7I?]3Q)8B-/7VT?G8]IM[N&ZC#PR+(AY#*
M<@U-7R?%\:M!\-ZP@T#7)VM'=@$N4^3 .!N[<_@:]V\%?$ZR\2QQQR%8KAAD
M+NRKCU4]ZRQ& JT%SM.WI8O#X^CB&XQDKKL[G=44U6#C(.13J\T]$**** "H
MW<BGGI4$IIH"-[HC^%3]15>2\C'WH%:B0\FJ,YY-:I"9))=6)^_:D?[IJM*^
MCM]Z.5/IFJT[5GSMUKHC'S,VEV+\EMH<G_+U-']1_P#6JK)HNDS?<U<)_OJ/
M_K5DW#=:K6WV5KV(7LP@ML_.Y]/2MTI+529FX0>Z-36]-F\.>&[N:TU.(->E
M(4D=<+M.<_B16'I7P_U":R1TN;24D?\ /3G^52?'+5+:Z\,:)'83Q3P27PP8
M6# !4;CCZURMK*\=M& S+QV-;474<.:^K\CFE2A*?+T1U%S\/=<496W20?[$
MHK*N?!&O1YSILQ_W<&LQM6O(?]7=SI_NR$?UIO\ PF.N6_\ J]5NEQ_TU)_G
M77&59=5^)F\-3?<CN_#FKPD[].N1_P!LS61=65W#G?;3)_O1D5N#XH>)K4_+
MJC/CM)$C?TIX^-?B*'_6"RN1_P!-(/\  BNB-6NOLI_/_@&$L%![2_ XR9BF
M<@@^XJE+)GO7H#_'2[;BZT'2[@=\(1_/-02?&+0;@?Z9X)L7]2A7_P")KHCB
M*JWI?BCFEE[>T_P//U22ZG2&%#)+(P5449+$]!7T7\,/A;;^$;2.^OD6?6)!
MEF(R(!_=7W]36?\ "IO#'C"6;5].\-+IDUE($65CD;B.< '' ]N]>I5Y&88^
M53]S%./<[,'@%1E[2H[OH%%%%> >T%%%% !1110 5\5:U\8O#GP>_P""@GC^
M[\1R:@EO>>"]+BB^P:?/>$L)Y3RL2,5X[FOM6O$?#7PFU_2_VO?&GQ$GC@'A
MO5?#%CI5LZR@RF>*9W<%.PPPY[T >%?"#X\^%Y/VEOVG/B3"]\WAK3/#6AW<
MOGV<EO.RPP7&X"*4*V21@9 !S722_M+_ !M\)>"M!^*OC#P;X1M/AEJDEK)<
M:58W=R=:TRUN6013R.P\J0J'4LBJI&>O!KIM8_9FU?QG\6_V@[S5I8K+PS\0
M?#>FZ-8W<,@>9)(H)DD9D[!6=2.>:Y*Z^$GQT^)/PK\/?!_QEI/AO3_#EE]B
MMM5\6VFIM--J%K:LA CMM@*22B-0Q+8&6('(P =[J'[3&K>'9?CO::O8:>+_
M ,"1Q7ND1P*X^VVMQ;[K<R MDL90\9V[0=O&*YS0_P!KSQ!XH^$'P7U33='T
MX>._''B%/#^H:9,DGDV,D#2C47";]X$8@<J"QQN4G=WF_:!_9P\6>//CIX7U
M[PT;(>%=3M;33/%T=Q-LD-O:WT-W"Z#^-CL>/']UV]:9\,?V8/$/@_\ :S\2
M^+;P6;?#JWFOM7\.6ZR;IH=2U!8?MKE?X "DP'J)C0!V'[=Y4?L@?%3=]W^Q
MWSGTWKFOG+P3!\,YOC/\!V^ Z67]N1L3XLD\.9%H+#[(?,%WM^0OYA&T'YMU
M?6?[47P\U?XL?L_>./"&@I#)K&KZ>;:V6XD$:%RRGECT& :[+P+X6MO"?AC2
MK&.RM;2Y@LX89S;1JH9U0 \@#/(H ^)OA[\2OC)X"\%_&/6_ GA+PU?^&?#7
MBO6M3OYM>O)A<ZFJ,))8;1(AB-D1?OR$@LV O!)^B/$_Q8\?^*_A]X*\2?#7
M3_"FG6'B#34U.YU?QM?R1V]@'2-HX?*BP\KMO;YMRJ-G?(JAX*^#'B70O@G\
M7_#%U%;#5?$VHZ[<Z>JS@HR7:%8=S?PDD\^E>4^*OV7_ !T=-^"\L_A70?B-
MIWA;PLNB:EX.UO4C!:1WFV/_ $M#M9)"-I3#*> "/8 ZFP_; \2CX":MXAN_
M#NC3>/-/\3KX/^S6=\QTF:]>=8HYUF(+" APQ_BP,=33/!GQ\^,/AWXQ>,?#
MGQ1'@%?#_A7PZ/$5Y<>&+>]^T31,'"A#+*55@T9RK+R""#UQX_\ $+X,Z_\
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MV\N2,<FM>T@N)L>7!*_^ZA-=VGQB2#BS\,Z9;>F5S_("G-\9];D_U5MI]O\
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M[G1'5WZ'C/[-ESI&M1>,?$6A?9-.L-6N8IK;0[1ES91)%L1Y47Y4DEP6*CH
MH/(-<=X!E\?>*(/A_P#VAX[\20_\)+H6I7VH^1'#&8);=U\@1$Q'R\AOFSDO
M@],U]16EG#!GRH4BSUV*!G\JT8($7;A ,# XZ5PRCI:YV)GQ_K7Q'\=S^$K;
M6K2\GL-?O/#'AUI+^"R0R"6;51#.V"O>,L2IX&2<"OH#X+WFO6?CWXF>%-5U
M>_U[3M"OK)M-OM4"FX,<]L))(RZJH<*X.#C(W8["O3(;6/ 'EKC@8VUHV\(4
MDA0"W4XZUS-6ZFZUZ%B%:O0+5>%.E7X$Q6$F;Q1/$,"I*0# I:YS8*^??VE-
M:O;N.YT[31YD\%L54 ]'?O\ @O\ .OH*OESXB7L]YXKU%XY2HDN'4@8R0.!@
MGZ5Z> A>HY=D>7F%3DHV[GS!9>#WC@M@8P^[.\G@#D\T[3_AR-1O5LK?8GGM
MP&SS@=<^AKUY=!!@;9<2<N=D9 XSG/)[5;_X1J5(8U8 /D!#&/F7&.![GUKZ
M+F=MSXY)7V/./#/PLTQ?$LFFZQ.+.%(V'FH0-Y'('L>:YC4_!%M9W%Y]C;<L
M$C+&Q7(9.QYQ7M,N@BRFN)I-P\G+.LV .^.?SYKD;II?%$IL-(A-W%(@W3,I
M51D':1^7?UKS\35BH.,G=R5DO\CV,OH59UHU:<;*#3<GLO6^AYQ9^%6DM"[Q
MN79\!BHVD YR!_\ 7J]'\/UEA::%AY^TL-B\'USFO4)X+#PA9V>G7Y,DVS )
M3=LY[<Y(S@"M*&QAU$D6\T,RKC<MN 2N>1_,9_*M:-:*C&G*7O)*ZZF.*P\Y
M3G7A!JFV[/6UK]SR_P +^"[2P>4ZA9^>Q4J40'.2>*FA\&%%E:.#$>6+"3/R
MCIP>W:OHO1/",/AF W-K<*VJ7< #3L4VVX)^8X.<N%!QQUQ69X@\?:%H5V=-
MEE'F7D)8H]HI;#DJ#+(,EB-IP0%]6S0ZZ@^;H83I1A!.H['@R>!X&A,:P[G5
MMS[LC=N^G2NMU_P<T5A:6Z71OH8T#QHH PW0 ^O>NKO;>PTV6VM6GAMVN)/D
MD60D-@#(;T'(Z^OO6W;^&B[1%(5X& L8/#=,\#C.*TYTWOL8K9Q1E^!=7NXK
M6TM9K1+9[2,;7CXSST(]:^J/ VKC5-(B8G)VU\[P>'9;2V6Z>&95Y"2,#LXX
M('O7K'P?U M \)/W37G8Z*E34ET/H,NG)-QD>FG4+5;L6IN81=$9$!D&\C_=
MZU)<7$5I \T\J0PH-SR2,%51ZDGI7S3XDAU;PW\;_B%KL.B75Y<-I\+Z9):Z
M$\US*RVKAA!>G<D1!XVE&R>.]<NX^+/COX;:_8ZS)K<EO%HVKQ16KV*(^I.9
M0MKYA,2ON$;D@*$W;02.N?"/H#[!!R,CI0S!5)8@ <DGM7@7P^\6^/->NOB#
M9S7<LT?A2&XTNVFCAB/VZ\;,\3C"]8X7@0KTW,V1Q7$V]G\89-(O(]4UKQ!K
M$,L$4#V=S86R+*MQIC/.28X5;*7 "K@C;DJ=V: /JNWU&TO(T>"ZAG1R55HY
M P8CJ 1UJ07,)* 2H2Y*K\P^8CJ!Z]#^5?$OA#X+^.K.W\-0P6#:1KVF7-IJ
MEO+:6SVUAO3265%D3)PS2!XI3GDE#QQ5S3/#WQ&UJ+P?XE3PM?:?_P (FTVI
M_P!G7KNEQYUUJ,CS(BJ")62W4IU _>G% 'VG134;>H;!&1G!ZTZ@ HHHH **
M** "BBB@ KAOC&"?!K8[3QD_K7<UR_Q+LC?>#=051DHHD ^AS71AW:K%ONC&
MLKTY+R/)_#UG;Z5>Z;<L<1.X5RP!P>W%>0_'KX/KIEYJNNVLID0R>?\ 9\9.
M6;G!].<U[/X9MFU.W6:5F(C547\!S6W?K;2P+:7T'VI,Y5>=Z^X/;Z5U8F$:
MUU4Z77IYF>68JIE\TZ>SLWY^1\Z?!GPM<:+=Z+K$ZM&-2NXBD29XC+X)(]S^
M@]Z]B?2+JUUV[U/Y8-Q8^3G"2#D$'Z@FNCFE=M)D33HSIPMAO C3Y@J]CZC&
M>*XG4/B&MOXJTOPY-"BS7D0:2\\P?N]P) P. 3QWXR*<.104;;+_ (+_ !-,
M54K8VLYP7_#+_@'.0_&K1(1'IUMH!F$4ORI<," P. V7.,^YQ6K!<WOBKQ;I
M#:I9+:6TA_<0QRH[.Y !8["=J*N?SKH;CX6:5KUC]N416%S$6<7P (VCJ7!X
M8?6L+PIX/MKV>XF36-)MY!F+R-'EV23@'/.[!0'^Z!^-5SW7-8WY:,US1OIW
MN_NZ?A]VYYW^TXVJRZU%'-8K#8P?ZB=,MYJG@@D=,%?T%:?[._BF74]6N-'E
MF#6:6JM%;RS97@X*(IZ_*Q/']VO:_%/PV/CG1AI<URT.ERM')*\17SXRH(90
M&P,'Y3GL0>.:RO!'P.TWP!J6Y66>UMF9[:>50&F<GY%8YYVCKZG'%>8J$?;J
MLY=+_P"2^?Z?,]KZ_"6!>&<=M%_G_7<M:_X92_L?L.HZ+#KC1RB-HW50XCY"
MNK<%2N #_P#6KE/!_P $D\!^(=2U5WMFTR?;+"TS!IK?#,2J8SDE3MS[FO3M
M922XTJ/4)%+2J</MXR#P2*J>)WM]-T6S%Q+F!P %3EF;J !WZ8P*TG-223^S
MJCR*-6M"+A#[6C^1796U[?)+#)#$RY(QC<N.%]<5R?B^%K;5+96X;8IQ_P "
M.*]"TZ:YNDA,5N(G<#$;@_NU]6/J?0<#WKSWQ?-)>>*?*D \R-EB(4\<<G^=
M>GAJG-=7O9,\.O2Y&G;J>W^"7+Z)#G^[705B>$8?)T:$'^Z*VZ\F?Q,]:.R"
MDZTM%040R)5.5,5HD9J"2/-4F!E31=35&:+(-;$L>*IS0^E;19)B3P]:H30]
M:W9H<U1F@]JZ8R)L8$\&*R[ZR%Q&48<5TDT%4)[?KQ71&1+5SFIY+'3- FM1
M8L^HM*&2Y!X5>./Y_G45_I5WIUO:R7D!A6Y3?$20=P_IU%;-S9K(.1FLVZBF
MNKZS;4)IKBRMR%\L-RJ9&0OX5O%V>ADU8Q9H<U1F@Q73RVL?B#Q)-::%;R-;
MD9C20X/ YZUDW,!BF>&13'*C%2K#!!':NB,[B,":WZ\50FMJ[>P\&:KK3#[)
M92.A_C8;5_,UMI\+;/3E$NO:W;V8ZF& [F_,_P!!5NO".C>HK:79X]-;^U3Z
M7X.U?Q#+LT[3;B[]61#L'U8\#\Z]8;5_!OASC3-&?5;A>D]X<+GUP?\  5E:
MO\4=?OHS%;RQZ=!T$=J@7 ^M;1G6G\$;>O\ EN<E3$T:?6_H9=K\ [BVA^T^
M(M8LM%M^I4R!F^G89^F:Z70_'GA;X86,EEH]WJ>NG^[(Y6!3_L@]/P%><7TD
M]]*9;B:2>0]7D8L?UJA);^U;?5?:JU>=UV6B_P _Q/-J9A/_ )=1M^)[GX<_
M:$T;4&$6K6\NER$X$@'F1_CCD?E7I>FZQ8ZS;K/87D%Y$>CPR!A^E?'$EM[9
MHM+BZTN<36=Q+:RC^.%RI_2N>ME%&>M)\OXH5+-:L-*BYOP9]IT5\O:-\;?%
M>C;5DN8]0C'\-RF3^8P:[C1_VE+1]JZKH\\![R6KB0?D<']37D5,JQ,/A7-Z
M'JT\TP\]W;U/::*XG3/C+X1U0*%U9+9S_!<HT9'XD8_6NIL-;T_50#9WMO=9
MY_=2!OY5YLZ-6G\<6OD>A"M3J?!)/YEVBBBL38**** "BBB@ HHHH **** "
MBD)QUJKJ&K66DPB6]NX;6(]'F<*#^=-)O1 6Z*X75OC=X+TC<)-;BG<?P6JM
M*3_WR,5PVM_M3Z;%N32-&NKMNTETXB7\AN/\JZH82O4^&#_+\R'.*ZGN=5-1
MU6RTBW:>^NX+.%>3)/($4?B:^6-<_:"\8:UN6":'2XCVM8_F'_ CDUP>H7M_
MK<_G:A>3WLO]Z>0MCZ9Z5Z5/*IO6I*WXF3K+HCZ0\5?M(Z!I.^'2(Y-9N!QO
M4%(0?]X\G\!^-<W)\=-$\:Z9_9WB73[ZPB?[TFGS$J?J!@D>W->(Q6G3BKD5
MI[5Z4<#0II<M[KK?4QE-S5I;'J\/PJT+Q(AE\+>)K:Z)Y%M=?)(/;'7]*P=8
M^&WB#P[EKO396B'_ "V@'F)CZCI^.*Y*"W*,K+E6'1AP17:>'_B'XDT+:L&I
M2RQ#_EG<?O%_6MO:8BGM+F7GO]Z_R/.G@*$]ER^A@I 0<$8-6HH?:O0(?B'H
M^NX7Q#X=B=SUN;+Y6^N#C^=7$\&>&->&[1=<^S2GI;W8_3G!_G2^N)?Q(M?B
MOP.5Y?./PN_X'GT4/M5R*&NFO_ASK6E@LUK]IB'26V;>"/Y_I66+1XGVNA5O
M[K#!JE6A-7B[F7LI0TDK$4,-;WAOPY<>(;];>$;4',DIZ(/\?:C1- ;5DN7%
MS#;1VR>9(\I/3V K0;XMZ;X7L!9>'M*FU"7^*XG/EJ[>IZD_I7%6JRUC25W^
M1U4X05I5'9?F1ZSI\_@36K)I3!<[F,D2'^(*>X_*LR22;7-5N;J>%8A*^[RT
M' K/N=5UKQOK,%_JD,$)A4HBP)C"DYP2>3756UMM4#%9JZ2<_B+TDVH_"-M+
M00J%48%:,473%$4/M5V&#%8RD;QB$,6!5V**DBAZ5=AA]JY92.B,1T,57HHZ
M;%%5V&&N:4CIC$=!%TJ]&F!3(H\"IJY9.YND%%%%24(>AKYGUJU>;6M5BRH)
MN)!\P!.=QQC-?3!Z5X9KFF&W^(&I6S [)F\]0.,@C/\ //Y5ZF!E9S7D>5F$
M.>"]3CQH6V"#8RS!6PJG!9,9YQ^%22:0SQ;GN,2.0Q/W6!XXQ79KI"P+O10\
MAZ8!)/XU#+IV"2$W9!?:!TX'%>A[4\3ZOV1YMX]@DM_"NI, TDLDBJ[%PI &
M,G=P./TJ[X*T^-_#NG&T">0806F7">:PX.?IZ>U=U=:"E]9R6@DREQ"2WEC#
M1DC&,_G^5>;Z1>3?"Z_&C>()(3IX0R6]U!&QSAN00% ]"1VQU->?.NJ595)?
M"U;TU_4]NAA7B<(Z$%[ZES6ZM6_0Q-/M-'\-^*M1_P"$LMDNI;K?+#/#AY%5
MF.X;"!G [YX /-=2/ACICW^GW>DO;Z!OB\Q(ENDE^T1,2H 9N-PXRJY SQZU
MV6HVGAGQ#I:-<SV=PCQ-*LCD JF#DJ.OK^58OP6:]O=,O+=F:ZT>TD!L)YX5
M!(9F9L+V.>>OY=*XUR0J*#LT[M/JNNIZ\I5:M"5:-XRBE&2?PM:K1/KY?,\\
M\<_%>+P]J>H:%I]K)%?PR&$S3%56)P0"6!Z@@Y'M@USN@>%_$'BMM5G.E_\
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M9[XS[4_XFZ%/8WMOX@L%_?6Y'F =U]:D\/:A_:MC:7%I%%*(U*'/RX8]0_\
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MUU4(>QBHIWU..M-U9.35C&DMJJR6Q]*Z'6[S3YQIL%A9O;2I'MN9'.0S>O\
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MNDT:PL-0T2_O;B_6TG@0-% P&93_ )X_&G6]MI;^&[N\FO#%J*.!#; <./\
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M]6<WUBG]G7T1Z;17F1\5>/+?YI=!211U"H?Z-3H/B]/92;-8T2XL_5X\G]&
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M00>8OP_O&."<3:D_0=3Q4;?&;PO!=B"S^&-DS=FNKV1LGTY_"E]0P2^S-_\
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M.P'W[M_*OG!8/B1873/9>)-)TE"^[RHM211Z $?Q8]ZH7/\ PFJJ1=_$S2(
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MC;6/]G9P<XZ_6HU_:!ULJ"OA+PM%@@,6T\#\1D^E:?5,'_SZ?_@1S?VAC?\
MG['_ ,!?^9])7/[:NDJQ$&A3R#<P!:4#( ^4].Y_*L^3]M"XF<_9/"S./*&%
M,C,?,SSR!]T#/;)]J^?V_:*\7I$SVNDZ! FTE&CTY>QQZU2/[1_Q*,;O_:=I
M;,C;6B@L(U['D9!]*KZKA%_RY^^3_P B7CL9+_E]]T%^K/HF7]J/QOJ<LO\
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MQ/5OT5_Q2\CDM6\.VM]K5U<V&E"SM6^['( 6#=_;W]LU6M/ "ZCJ6^"'<TC
M2>8ORQIQN+'H!P>37<:58MK$TMG<I(FI(NYPZ;5=,*2X SW../:N@TC46\,V
M\]J+>TG>60 PM&99$*G.XJ,D_P JWCBJ;I<Z=EY_UN<D\!6CB/92C=[^[K=>
M7DS#\-^#HK*ZFAFNC=74JPI:":VD200M,F^2/>H&T1ECN[8JEXOFN==OEM8D
M\NS@E/E(SM(2I'+LY)/0#CM7:OJFM2VMZ\=ZT@F5I_)D+8;;RR=,KD*1^(X.
M,58TOQI9ZV(18-IMA>%<?V?J$(FC# $95DVMD$ E22#ZK4?6*<9*+>KU6O\
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MZVHKX;U[]M;QQJ)9=.L]+TB,]"L33./Q8X_\=KSW5_C?\0O%TABF\1ZC-O\
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M1*I)0I&[;AQA3WXH \"TG6_'?PVN-*673M:UNP,NN:SIDACDD*R%;A!9R\9
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MF2QKZC R:X3Q=9?"GPYIE]J5YI<-U8W5D(+DZ>'EAEBC:& !MK;-Z[H@"?F
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M+R-1')'>1S/)=3<@HWRJL:GLV6SD< &O2_$&M0^%M$N;^ZB:=H(&D2(,%,S
M<*">Y.!^-<YJ5S+?*UMK?@T7MY=1+Y!LF\R-P2#L>4@&,J1DGIQD>E7R56_:
M4[=K/;\R(U:-O95T^]UNNF]OZL<=<>'K+Q+XDB^Q:9=:-83I#"0+6,$RD$R
M*W1452&8?>+ @UZ9IWA"RTK1WT^TC12Z.'G:) TA;/+ #!Z].E7O#^@V'AZP
M2WL[6.R4@%XHY&D4-C& QY('3H/I6!XGU_5=-\4VEOI,#ZD)+1FN;0SK$D.&
M'ER!F!P2=ZD=P,]JF,5)VLE_7?\ S*J59)?$VEW_  TU2MY'G-O\ %M-)N#:
M:[>:9KEW%NFBBP(W?: J_+C'W?U)Q65\%YM+^&$VKVGB2%M,U+;$$DFM@NY
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M6-8QPH  VH. *ZVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME)R=V=T8J.B+=%9NK^(;#0Y].AO9Q#)J%R+2V7!.^4JS!?R5ORK2J2@HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>armp-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !' #H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** *>
ML:S8>'],N=1U.]@T_3[9#)-=74@CCC4=2S'@"OFSQK^VC>6^K>'1X#^&^L>-
M=!U74AIT6MR3)I\%Y)L=]MF)@#/Q&WS85#C 8YKS?XZ:#H?QS_;IL/A-X_U/
M7)/"C>&8]4TK2]/U!K:V-\DK%S(J_?)1<C/3;5+XW>#?"/P?\7R:3>_"M/%E
MH+5;G2-2U?6KV:>8JF'CB+,<2JW 5,-M88'6M8Q74PE-]#ZW^&7QL\+_ !4^
MTVVF7$^GZ[9<7_A_5H3:ZC9-Z20MSC_:&5/8FN]K\\OVE_@?X6^&'[-L/QDN
M8O$?A#XG:=IT!T^+3]?NG-G>S%0(1YC,Q123E#QA37W1\,M2NM9^''A:_OIC
M<WMUI=K-/,W5W:)2S'ZDDU,DEJBXR;T9TM%%%0:!1110!^?7[5/C+2? ?[5L
M^N.)[CQ=I5KH>IZ+IMI;22W-_"DUPE]'&%!SB!V)^@J3XA:UH7[1/BF7QQI>
MK^.+OP_?6D5MIT5IX+O+F*W1#ES&ZL ',@W9 # @#/%?:7Q%^$OA/XK::EGX
MFT>&_P#*.Z"Z4F*YMF[-%,A#QGW4BOR/^-GQW@_9Z^*OBKPM\(?BOXL31=0N
M7L=?6XT^.86TBG;)+:RY7?,,%2X"D]V)YKH@^;;<Y9KEU>Q[I^TA^T/X7\?^
M&]$\):WJFL-9>$=-O7UO5-7T6>TCN-8%F8K*!P00LCL[O@G@@5]]_!U73X2^
M"UD4JXT:S#*PP0?)3K7SI^QA\%/@_P"*?AGH'C70[O4O'A1I%BNO$RX-M<*Q
M$A%K_JTDSR7.YCUW'-?704*    . !VJ)M;(TII_$Q:***R-@HHHH YGXEZW
MJGAOX?>(=3T32[C6M9MK&62RT^U7=)/-M.Q0/=L5^8/P+^ ?C'7?#'Q2L;K0
M9]9OM$TK4;6WO?(5O/U9KV.=XD)ZN#'C\?>OMWXE?MH>#?!'C3P%H^FWECXA
ML=?UN?1M2O[.Z##2'CPA:4#.,2NBG=C&<U<_9'!33?BDI[>/=8_]&+6T6XQV
M.>24Y)7/'O\ @G#;>*-$F^($6H:?=#PUKNIW&L6=RR8CM;H3O#<6Q]&^1&Q]
M:^W*^'/AE^TII_P#^'?A'3+BP.HW7BKQ_JMB^'VBSM3?R+)=.<?=5GC'. 2W
M6OL7P?X[\/?$"PN;[PWK-GKEG;74EE+<6,HDC6:,X=-PXR#4SO>Y=-KE2-ZB
MBBLS4*^:_P!KSXQ>(?"T,/A?P5K2Z#K,.FW7B/6-66!)VT_3;9#C"/\ +OFE
MVQKG_:/:OI2OGO2OV:[GQOI?Q+NOB#<B+6_&U^B3'3)=WV;2[>0?9K5'9>A5
M2S\<F1JJ-D[LB=VK(^!XO@A\2I+V\B\/>$M)\3Z[IG@RW36X]'"P37W]H%IR
MEVDIRUPN P>(@@A#@CBOI#]A/X\:'\-?@_JNF?%G6U\(>.)-<N[N]T_6X9+>
MX;=LP^UE^;.T_=S7V_9:-8:=<W%Q:V<%O<W 0331QA7E"+M3<0,G X&>@J6X
MT^UO'5Y[:&=E^ZTD88CZ9K1U.96:,XT^5W3/QOA\!?&+XGZ=\5YM*\'ZA+X%
M<WTMGK-U&MJDUDET]UY41FPVR1\.Q1=S;54$5[C\(?'?C'X%^+;K7H;W2+;P
M%<6ND^*=1\+>'[#R[%-,O8Q;RW4+-F0- \<3.,X(+'%?I))#'-$T4B*\3*59
M&&00>H(]*\\UOX#^&-<\8V^O20- B:!<>&I=,@"I:SV4K*Q1D _A(.,8QN-/
MVE]&B?9-:IGH4$\=S#'-$ZR12*'1U.0P(R"#Z5)7FW[/O@KQ)\-OAQ;>$_$=
MY%J7]BSRV6FWR2%Y)[!6_P!&,N1Q($(4CG[N>]>DUBSH3N@HHHI#"BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>armp-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ #H# 2(  A$! Q$!_\0
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M;MJ[]-]D<YXEL=(\6RW7Q%^$>H"+7]*;??V$2%!<IU),9ZY&?8X/>O;?A/\
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,-:=GHT%%%%69'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>armp-20231231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& #@# 2(  A$! Q$!_\0
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F)=J*J+UPHP***@L=1110 4444 -2-8]VU0NXY.!C)]:*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>armp-20231231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. #H# 2(  A$! Q$!_\0
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FN3-]GSU*+@*I/KC/O7844U0IIWL)XW$23CS;]K+\@HHHK<X3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>armp-20231231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %A ;\# 2(  A$! Q$!_\0
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M$WC/]GKP'K6M> M&U'5;W3(YKF[GA8O*Y+98G=UXKU7_ (8P^"7_ $3;0?\
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MWDW)-+O,B2M(%D5XR5"(5(!-'MJG\S^\/9P['H__  QA\$O^B;:#_P!^&_\
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ML#IH;QQ\3(+B"Q4AOWB%BY'7E5'S8'(Q7V#_ ,*I\%_]"EH7_@L@_P#B*/\
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MO?\ 8UWG_I"U?4D?W%^@H =1110 4444 %%%% !1110 4444 %%%% !1110
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M]E?ZW<ZC;Z9\2-)MK(7]Z9C;P&?29/+0L?E0.\A"]!SZ5]]1$,F0<@Y(([T
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M?LO?]C7>?^D+5]21_<7Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45@^.?&-EX!\*:CKVH!WMK./>4B&6<D@*H]R2!7F_P]_:"F^+,=S:>
M'-!>'583F5K^=1;PQG@.2OS,<Y^55[=1UH Z3Q[\=O"/PXURVTG6;V5+R51(
MRP0M((4/1GQTSCH,GVJ>UT^]^)(BO-7C:R\--B2WTDGY[L=5>X(_A/41#C^_
MG[HX?QK^RY:?$#78=:UCQ'>/J+X%XT-NBI*HP L:_P   &,G<?6O:]/L(=+L
M+:SMUV6]O&L4:YSA5  'Y"@#)\->!/#W@Z2ZDT31[33'N3NF:WC"E_;Z>W2M
MZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-#'<1/%*BR1NI5D<9
M# \$$=Q6-I?@;PYH>@SZ)IV@:7I^C3[_ #=.M;***WDW##;HU4*<CKD<UN44
M 9-AX2T/2]%ET>RT?3[329599+""UC2!PPPP,8&T@CKD<UF-\+/!CZ;IVGMX
M1T)K#3I#+96ITR'RK5R<EHDVX0D@'*@'BNIHH YL?#7PB(M2C'A;11'J<RW%
M\G]GPXNY0VX/*-OSL&Y#-DYYJ2\^'WA?4+VYN[KPWI%S=W)B:>>:PB>24Q8\
MHLQ7+%,#;G[N!C%=!10!R5Q\)/ UW'?1S>#/#TR7TJSW:R:5 PN)!DAY 4^=
MAN;!.2-Q]:ZFWMXK2WB@@B2&")0D<<:A510,  #H .U244 %?,W_  4=_P"3
M1/&7_7:P_P#2R&OIFOF;_@H[_P FB>,O^NUA_P"ED-=&'_C0]495?X<O0Z_]
MC#_DUSX;?]@>/_T)J]JKQ7]C#_DUSX;?]@>/_P!":O:JBM_$EZLJ'P+T.9^)
M.O\ AOPOX'U?5/%P@;P[;P[KQ+BV-PCKD +Y05C(22 % ))( &:\V^#%Q\'[
M4>&]3\$^"=+\'S^*8+B6RE@\/QZ=-,8B1+$^U RR *S;&P2JL?X3C:_:?-M_
MPI+Q"DUOK=S=2>1'81^&YA#J/VTS(+8V[GA7$NPY/& <@CBOFSX&_ Z3X2_'
M_P"'%]\2/B=XE\9>+=7L-2N/#VAZG)&L>ESO%YMV)421M\A228>8N$)!'4K6
M19]T44G05\SZ;^V=9WWC+3T?1UB\(ZEXZN/A[9ZAYQ-Q)?Q1%O/* ;?):56B
M'.X8#'@X !],T5S/Q&\?Z;\,O!6K>)=4$LEMI]M)<?9[==TTY1"WEQK_ !,0
MIP/J3@ FN4^#_P <M/\ '_P-\'_$37WL?"\.OV45UY-S>*L43/DB,2/MW' /
MIG!XH \J_:O_ .3B/V7O^QKO/_2%J^I(_N+]!7R!^T=XW\/>+/VC/V9(]%UW
M3=6DA\57;2)8WD<S(#9, 2%8X'%?7\?W%^@H =1110 4444 %%%% !1110 4
M444 %%%% !1110 445B>)/&6C^%('?4K^"WE$9D2W,@\Z4#LB9RQ)X '4F@#
M!^)D,7BNUC\%K&L\NKKFZ9AD6UJK O+_ +Q.%3_:.?X34_PX^$OAWX66UW%H
M=M(CW3!IIYY-\C@9VKGL!D\#UJWX(T2ZM8;G5]60#6]482W"YR+=!_JX%/H@
M//JQ<]ZZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *^9O^"CO_)HGC+_KM8?^ED-?3-?,W_!1W_DT3QE_
MUVL/_2R&NC#_ ,:'JC*K_#EZ'7_L8?\ )KGPV_[ \?\ Z$U>U5XK^QA_R:Y\
M-O\ L#Q_^A-7M516_B2]65#X%Z'D_P"U1JV@Z/\  3Q;)XE\+WGC71YX([.3
M0=/SY]Z\TR11(A!!5O,="&'*D9'(%?%O[$O@&V\"_M":??']GOXA>&+[4XKB
MW;Q7XUU)KR/3T$+N4C_<( TA54W,2<' /)!^POVQK+0+_P#9R\81^*/$^H^#
M] 6*&2[U;24+W<:K/&P2(#DN[!4'^]7Q1^Q;XI^'>O?M(^%K?PY\6/BYXOU-
M(KV9=.\5PL=.8+;NK&0E^&&XE3@C<H'!(K(L_3[J*^,]$_8V\0V/BS0]%EEM
M%\(:)\3;GXB6VII/^]>)XV,=F8L9\P3.07R%V+D?,<#[,I: /F[XH?"?XJ_&
MKP7JDEUKEKX%UJ"WU;3[32=-$.HVM_#,FR&226:,-#(R;D)7.U9&YYP+'P1_
M9=M(?V7? _PU^+FFZ;XQET6&-VM+N%)(+>50ZHJ%<;MBNRASR0QS7T310!\,
M_&/X ?#KX-_M)_LUW7@KP=I/AFYO?%%U%<2Z=!Y;2HMFY"MSR 3FON2/[B_0
M5\M_M7_\G$?LO?\ 8UWG_I"U?4D?W%^@H =1110 4444 %%%% !1110 4444
M %%%% !1110 AZ5\H_$OX(>(?BM\7=3UC0[Z-M+CN(K9[V>3;]G=%4.L8'+!
M#Z?Q$CJ#7T/XVUNZMX[71M)<+K>J%HX'QD6\8_UDY'H@(QZLRCO6SH6BVOAW
M2+73;)"EM;($0$Y8^I8]V)R2>Y)- %NWC,,$:,YD*J 6;J<#K4E%% !1110
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M S_+/%=W7&_$0_VS_9?AA.3J\W^E8[6D>'F_[Z^2/_MI0!YO^R]XTU;XB_\
M"1:WKT7GZBC0VL=^$V*8@"?*4#@8;YCCKN&>@KWJJ]C86VF6ZP6EO%:P+TB@
M0(H^@'%6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^9O^"CO_)HGC+_ *[6'_I9#7TS7S-_P4=_
MY-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\ L8?\FN?#;_L#Q_\ H35[57BO
M[&'_ ":Y\-O^P/'_ .A-7M516_B2]65#X%Z'C?[7WA_3_%7[/?BO2=4FUZ.S
MNHX8V@\+IOU*[;SDVVUNIX+RMB/GC#'/&:^-OV)_A7JG@[X\:#/XJT+XN^#Y
M+=;E='A\6ZB+[2;S_1Y%,+;8T$<HC+.@Y!$;8Z#/VS^T]+ID7P4U_P#M8WR6
MSFWCCGTS48M/N8)FGC6*:*YE98XF1RKAF('RX.<X/R%^Q;XQT_Q;\=Y_M/CS
MXG?%*QTZ>YL-'U_6(57P^EWY#-*JLKMYDPB$@5R I4L0!N6LBS]$*6DZ"O'K
M']J;P7J'C:/P_$]V()?$4WA*'5VB M)=6BA\Z2U5MV[( 9=VW:75E!SU /8J
M*\O^/'[06B? #P]%JNK:1KNO&022FT\/Z>UW-'!& 99Y,85(TW+EF(^\,9YQ
MU7PX^(FB?%7P%H?C#P_<-<Z+K-JEW:RR1E&*MV93R""""/4&@#Y__:O_ .3B
M/V7O^QKO/_2%J^I(_N+]!7RU^U:P;]H?]E['/_%5WG_I"U?4L?W%^@H =111
M0 4444 %%%% !1110 4444 %%%% "&N.\(#_ (2#Q-KGB-OF@#_V78GMY43'
MS7'^]+N'TC6KWC[7)M%\.SBR8?VK=LMG9(>IGD.U#CT7)8^RFM3P_HMOX=T2
MQTRUSY%I"L*D]6P,9/N>I]S0!H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\S?\ !1W_ )-$
M\9?]=K#_ -+(:^F:^9O^"CO_ ":)XR_Z[6'_ *60UT8?^-#U1E5_AR]#K_V,
M/^37/AM_V!X__0FKVJO%?V,/^37/AM_V!X__ $)J]JJ*W\27JRH? O0\F_:7
M\9V'AKX1>)HGT#2_&M_-;QV\7AG4KB&.*\::5(D$OF' C#.&9CT"D]LU\]?L
MQWOBG1OB;X3TGQ[\'O GAA([>YM/#^J>"]2AE&G/Y3RRQ- LK%1(@DS*O?:&
MSN!'HG[2G['_ ,"OBEXAN/B#\5E\B6"SCM7O[K5VLK>&&/<5'! ZLQR:^??V
M6Y/V8/#'[4N@:3\#-%UW5=:FAN[:\\1I=7!TR"(6[2&,F3_6EB@ P,9P<G&*
MR+/T;/2OS\T#]G/QO#XC\*>$)M(O4.A?&F[\;2ZO)&3:RZ48VFCF$OW2[LXB
M\O.X.&R,#-?H'1B@#YH^-WQYUR]^%5]9Z5\+_B$][K-[=Z%-%::,)+JVM5&R
M2\1=^TJRL1%N(RW)&%.=GP_\'/#_ ,9/V</!_AB31_%OPQT.P$9LM(M[]].U
M.VCA\R*-9FC)/S*=Y4DY+*3R*]^Q2T ?G]\1/V:] ^!G[3'[.%YH^O\ BO6)
M+_Q-<PR)XAUN6_1 MF[ HKCY3SR1VK[_ (_N+]!7RW^U?_R<1^R]_P!C7>?^
MD+5]21_<7Z"@!U%%% !1110 4444 %%%% !1110 4UV"(68A5 R23TK*\5>+
M-)\%:--JNLWD=C8Q$ R29Y)Z  <DGT%<7:^(K;XU#R-(N&?P?'@7]VN4:\?
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M)!I!UO[!I^F33-+:B18RT;!=KD,P&T'/;J0*\ML_V@8M3^-VFZOHNMZEXC\
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M\?8TNF6<]I):R6L,EM(2SPM&I1B3DDKC!YY^M60,#% 'YO?M!>"/V@[+XR_
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MX'_\)J7_ .+H_P"%;?M6_P#16O __A-2_P#Q=?4]% 'RQ_PK;]JW_HK7@?\
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M9$4<G,3E<QLV&RN, $9KW>WMX[2".&%%CBC4(B*,!0!@ ?A0!)1110 4444
M>,?M7_&'5/A!\&/%^K>&HXKCQ19:-=:A;";F.W2-.9G'< D!5_B8@=,D=O\
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MP9?:%I5U+>R:EJMUK5]<O&L2R7,[ OLC7B- %5509P%ZDYH ]-HHHH ****
M/G+]H7XF^,_ 7Q\^!>BZ1K-O;^&O%>M3:?J-A]B5II!'"9,^<6. 21P%!X^]
MSBL+XZZU\:_!7QS^'%]X<\7:=?\ A[Q#XDBTA_!"::I;[!Y9DN+M[@_.614=
MFQM5<H!NYW>B?&;X W_Q8^(WP]\50^*$T8^"KY]1L[3^SA.)Y738XD8R+\NW
M@ #@G/-8WC/]G3QSXK^+[>-+3XR:GH%@1%;+H=CH]NR):*ZL\*S.2Z^85RS#
M!/R_W%P >_"EI ,"EH **** /G/]N;XG>,OA#\)K#Q'X.UBWTJ<:U86-R);)
M9WECGG2,[&9L(0">2K9SVZUD?M*?M,W/@CXHZ?\ #_3-3D\-V=IHLGBGQ1XF
MATYK^73--241((H@I7>[YS(X*HH)VL3QZ+^TQ\!9_P!HKP/;>%_^$B_X1VRC
MOH-0DF2R%S([PR"2,#+J -PYZY]JPOBK^RI;_$_Q%=^(SXCET?Q!JWA2X\'Z
MU<VUFLD5Y8S-N)1&;]U(K%BK98#=@@XH ]D\(7MIJ7A71[NPU1]<L;BTBE@U
M)V5FNHV0%925 4[@0> !ST%:]8G@GPAIWP_\':'X9TA'CTK1[*'3[5)&W,(H
MD")D]SA1DUMT %%%% 'G?QQT7QIK_@R6V\%^,K+P%=+OEN==N[);MH8E0G"H
MQ"#+ ;F;HH.!D@CYC^&G[0OQ1\3^'OV:/"OBZY_L;Q/\0YM6N=4U.UMECG>P
MLX7D@=$92L;3!H&)V_=S@+GCZ6^/?PLU[XP^"AX=T7QI/X)26=9+N[MK".[>
MXB7GR2LA"A&.-W!W ;3P3GC[']F/4C:>"=2UOX@:AXD\=^$M3NM1T_Q+?V,2
M@K<0F"2W:W0JOEF,CA2#N4-ZB@"[^QQ\9-6^.OP"T+Q1KRQ#6O/N["[DA38D
MSV]P\/F!>VX(K$#@$G'&*]MKA_@K\(]&^!GPUT?P9H;2RV6GB1FGN,>9/+)(
MTLLC8XRSNQP.!D <"NXH **** .>\?:?XBU7PI?67A;5;;0];N (X=3N[?[0
MMJ"P#2"+(#N%SM4D#=C/&17@?[+7Q)^(5OX+\>#XE:M'XM_L;Q3<:'H6MVUF
MMM)K*(5C^6-?E/[W<NX<#:^20A->Z_$WPOK'C3P/JVAZ%XCE\):E?1&!-9M[
M<32VRG[S1J2!NQD ]LYZBO)O ?[)<=CX2?P_\1/&.H_$RQ@G@FTR.>$:6NF^
M5'(@$0M64Y82L"2>1B@!?V+OBWXG^,OP^\6:UXMFMWU.V\6ZIIL<-JH$5O!#
M(J)$AP"P'/S'D]37T!7C7[,G[,FA_LQ>&]?TG1KZXU'^U]5FU.2:X+ HKGY(
M@"S#" D;NK9R:]EH **** "BBB@ HHHH *^9O^"CO_)HGC+_ *[6'_I9#7TS
M7S-_P4=_Y-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\ L8?\FN?#;_L#Q_\
MH35[57BO[&'_ ":Y\-O^P/'_ .A-7M516_B2]65#X%Z!1116184444 %%%%
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M "BBB@ KYF_X*._\FB>,O^NUA_Z60U],U\S?\%'?^31/&7_7:P_]+(:Z,/\
MQH>J,JO\.7H=?^QA_P FN?#;_L#Q_P#H35[57BO[&'_)KGPV_P"P/'_Z$U>U
M5%;^)+U94/@7H%%%%9%A1110 4444 %%0"]MR<">,G.,!A4] !1110 4444
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MGC+_ *[6'_I9#7TS7S-_P4=_Y-$\9?\ 7:P_]+(:Z,/_ !H>J,JO\.7H=?\
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MJ*6KS6]M$ZR+&NV-0[ED3=+)N8X[9-7?$/[+R^,_$7B_4_$'BV_OT\4^%O\
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M?C'Q]^T=X>^R7UG:^$-3^'MGXECT>:%S(C7$X!#2!L%P0H#;<!<X&236U/\
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M4444 %?,W_!1W_DT3QE_UVL/_2R&OIFOF;_@H[_R:)XR_P"NUA_Z60UT8?\
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M< XR>XZUUW@WXAZ/XJL(UCU;3YM5@LH+N_L[>X5GM?,0,"ZYRH/."?2OE?\
M:$\/7_CP?$WQ3X9\.:S#82?"_4O"SVRZ3-%/J.H3R*;2%(=F]_) D&\#:OGX
M!^]BOXE-_+\0;6ZT/P'JVM1?\*=O]%73I])NK6VN[PO#+'8RR;%"%E248)!&
M2!@L,@'UQH7Q$\+^)[6_N=(\0Z9J=O8#-W+:7<<BP#!/SD'Y> 3SZ4NC?$+P
MQXBLIKO2_$&F:C:PHTDDUK=QR(BK]XD@\ 9&:^'?$'@K4)K+XJRW^E^)Y]+U
MCX;Z-:P7%KHC6H-Q#<3YMH(&4<1[XAY#DNREE^;-:6HZ1=?$33OBMJ^CZ3K
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M .UC:Q>%=:U"XU;7["7281HT\C7FRVLXO,@&SYPKP2C<N<;<YP03#\2=(DU
M?M>)9>$-:FE\5>'K*WT9XO#]S_I\XT]XG6,B+YF$S)GT/)Z9 !]D6>OSW'Q"
MU32_[7T:6SM=/@F_LV)R=0AD9WS)(-V!$RA0O .0W)XJ;3OB+X6U>WU.>Q\1
M:7=P:8,WTD-W&ZVHP3^\(/R]#U]*^3-3\*^)/'OC3XIQ^&=,U72=5U_X3V.F
M66JW>G3V:2Z@INLQM,Z+^\ EB!R<@'_9XTO$FHKX[^#>O:QI?P/U2U\3VNAV
M&BZAI^MZ1/"/+CNHB88HE*F[C@S-,/+X8(%!^?% 'L/QN^.J>%/@%XQ\?> [
MS1?$T^A6[3#-UYEN60KO1FCR=P5L@<=LD=:];LIFN;2&5@ SHK''3D U\*^-
MO"GB)/AG^U=:QZ/XFUJX\1K82Z7/+I$@FU-FL((BT<<<8!^=&7 &5"_-TS7W
M'H4PN=%L)55T62WC8+(A1@"HZJP!!]B,B@"]1110 5\S?\%'?^31/&7_ %VL
M/_2R&OIFOF;_ (*._P#)HGC+_KM8?^ED-=&'_C0]495?X<O0Z_\ 8P_Y-<^&
MW_8'C_\ 0FKVJO%?V,/^37/AM_V!X_\ T)J]JJ*W\27JRH? O0****R+"BBB
M@ HHI#P* ,[1?$>E^(OMW]EZA;W_ -ANI+&Z^SR!_)G3&^)L=&7(R#R,UHXK
MY17]HOQAI7A;Q+J6HV$,>GZ1X^U'0-3U?0])EO/L%C @9+A[=7WOEBJNXSMW
M9Q78:#\9-<^)&L>&O"WA[7]"CU._\,MXEFUZSMVO+2:,W(@B$$9="5)W%BS9
M7 &,G@ ]IO?%FC:;X@TW0KK5+2WUG4ED>SL))E6:X6,;G*)G+!1R2.E:M?&^
MD_$Z[^)_Q7_9\\1ZMIMKIOB"RO?%^DZ@L3_N//LX'@E:-R,^4S1%AGH#SR*K
M_P##1?C[Q!9^)-&&L:<LEY\/-0\3VFMZ18-Y%K=6\BHR6LDCD746'P)=H!*A
MAN!P #[0!!&1R#17R-X8^+?CW3_!?PY\%Z%+)K?BB[\#V_B)]0&FK-\K+%'#
M&R-<)D;BV]]Q)XX&<CZ5^'^M:YK/@'0]3\4Z0N@>(9K*.74=,299EMI]O[Q%
M=20P#9P1VQ0!TF*YZ_\ B'X9TOQ/9>';S7;"VUR];;;:?+<*LTK;2VU5)R3M
M!..N 3VKP6Q_:%\4S>%?AO\ $@?V?>^#?&6MVNDR:-% PNK&*[G:"VF6;>0[
M*_E^8A0##-@_)\UC]FGPY>ZIX]^--SXAOK37X[+QV_DI<:<@:*XCT^Q\N9&+
M-M*HQ4 #CD@\D4 >\Z]XWT#PO<10:OK-AILTJ[TCN[E(F9<XR Q&11K&AZ/X
MZT>V%RB7MIOCN[:XAD(:-UY26.13E2/4'D$CD$BO ?BA'+XW_:HT6/3_  G:
M^+)? GAV6\:.::&)8[O4',4(=I >!%;3G R?WH.#Q7IW[.OPNO\ X._"?3/#
M6J:A!J.H1SW5W.UHI6VA:>XDG,,"GD11^9L4''"C@=  >E 8KC_BO\+-$^,O
M@RZ\+>(OM;:-=LK7$-G<M;M*%.0I9>=N0#@=P*Y#QE\:+Q-?\5Z;X<AL19>#
MK07GB'6M3=EMK9C%YPM4"\M)Y6'8DA45TSN+8KSM?VL=<U#POIMG!I6G6?CE
M_#UKKE_ILCR7!AFNU9[2QBA0>;-,ZK\Q "IP3]X"@#Z9TK3QI6F6MFLT]R+>
M)8A-<R;Y7P,99NY/<U:Q7@&C_&?XC^*?''B'PMIGA/18M3T;3]&N+S[1J4A2
MUGNAON(9&$>"\<8)4+G=D$E<UGW7[3&O1:7XB,6D:=+J+^.(/!GAV-)I"EY(
M3$+EY#MX$.;C++P3"10![IXS\&:5X]T&72-8ADEM'DCF4PS/#)'+&XDCD1T(
M965U5@0>HIGA?P=:^%X0JW=]J5Q@J+K4K@SRA2<[03T&?0=AG.!7A'CC]ISQ
M%IA\7:GH.CZ9<V'ASQ'!X7BTB]GD34-8NW:)6,(13Y:@S KE6++&[?*,&M+7
M/BMK*_&?Q):7>DZ;%9^ _")URZU&/6KE;>.>X#8@FC$84C;;2N'97*KM( +$
M4 ?0=+7RS'^UWK&B>#?AWXK\3:#;:?IFM^'[WQ#JMG \CW-O;10(Z/$"!NW3
M36\"AL%VE!&!U[G1_B_XNT_XE^"_#?BC0["SE\6Z;>W\=A93M)<:2;=8F*W#
MG".#YJH67 #X W [J /;,48KYP\(_M2ZE/X*U3Q%X@T.&)[>[&D+HEE*?[0C
MUE[CRDTMXWQF3!C;S>$99-PPHW'K?!GQ*\9W_P :)_!6M:=H_D6N@KK=]<Z;
M/)(;.2:;R[>U.X#<2(IVWX7(4844 >Q<9HKY1\1_M$:[X9T;XV^/H/#^GS-X
M6U2V\+:<IUJY>#4IE=0P6/R]J2"6Z2/Y$RS*P+$*IKUOP;\3?$&O?&#6/"EW
MIEI%8:=H5KJ4\T3L9;>XGED6.&0'C+)$TF!RHP#G- 'J>*.*\&\)_''Q?XEU
MG7]!FT'2K/Q#H?C6+0KBU2[DD2?3FMXKAKF)M@.]8IMV& 7*$9R17!:U\>O%
M-C\+_C+\0-*TNPM-<M=>7PMH$9OKF_MM3N895M4*1-L5-T\S1_(!DQL6R #0
M!]4:YHMMXBTFYTZ\\PVEPNR58I6C9ER,KN4@@'H<'H34]A86VEV5O9V=O%:V
MEO&L4,$*!$C11A551P    !7SUIWQ)^*.C>*+SX;VMEH'BSQ/H_A:VU*XU>6
M[EMH9+J69HU\Y=C>6&6*9@%+$X'W1T)OVF-:NO"VC>/K#1[,^!]4U^TT33K>
M:1_[0U6.>[6U%W"H&U%W,TBHV2T:%B5R!0!]&TF* <C-+0!PNC_!S0M!U6[N
M;&;4H+*ZGEN9=)^WR-9-+*YDD81,3C<Y9BH.W+'CDUW( %+10 F*,4M% "8I
M:** "BBB@ I,4M% "48I:* $HQ2T4 )BEHHH **** "OF;_@H[_R:)XR_P"N
MUA_Z60U],U\S?\%'?^31/&7_ %VL/_2R&NC#_P :'JC*K_#EZ'7_ +&'_)KG
MPV_[ \?_ *$U>U5\W_![P_\ &GX2?#+PYX.B\*^$-3CT:T6U6[;Q#/&90"3N
M*_93CKTR:['_ (2;XV_]"/X/_P#"FG_^1*=2'-.336_="A*T4FCU^BO(/^$F
M^-O_ $(_@_\ \*:?_P"1*/\ A)OC;_T(_@__ ,*:?_Y$K/V;[K[T7SKL>OT5
MY!_PDWQM_P"A'\'_ /A33_\ R)1_PDWQM_Z$?P?_ .%-/_\ (E'LWW7WH.==
MCU^D/->0_P#"3?&W_H1_!_\ X4T__P B4?\ "3?&W_H1_!__ (4T_P#\B4>S
M?=?>@YUV)= _9PT7PR^ISZ=X@\1VU]?:U=:\UXM['OCNKA0LV!Y>PH0H^1U8
M @$<@&IH/V;_  EI4'A@Z$;_ ,-ZCX=@GM;+4]+G"W!AG?S)XY-ZLLBR28D(
M93AP"NVJG_"3?&W_ *$?P?\ ^%-/_P#(E'_"3?&W_H1_!_\ X4T__P B4>S?
M=?>@YUV+&H?LU>$-0U/P?=9U"W@\,17T5K8Q7 \FX^V(R733[E+2-(&;+;@<
ML3U.:HZ!^RKX/T&31S]KUJ_BTOP[/X4A@O+[>C:9+M_<, HR%"*%;AL 9+5-
M_P )-\;?^A'\'_\ A33_ /R)1_PDWQM_Z$?P?_X4T_\ \B4>S?=?>@YUV*FK
M?LH>%-4T#P?8IJWB/3=1\*6OV#3->T[4S;Z@EJ51#;M(J[7C*QQ_*5ZJ#][)
M/K>AZ+:^'M'M-,LQ)]FM8Q&AED:1R!W9F)+,>I)Y))->7_\ "3?&W_H1_!__
M (4T_P#\B4?\)-\;?^A'\'_^%-/_ /(E'LWW7WH.==C2\-?L]>%O"E[;_83?
M?V-9ZB^KV.@2SAK"RNW+,9(DV[E^9W8(6**S$JH(&+OPT^#=A\,-9\4:E8ZW
MK.HR>([]M3OHM2GBDC-R41#(@6-2OR1HN,XPHXSS6!_PDWQM_P"A'\'_ /A3
M3_\ R)1_PDWQM_Z$?P?_ .%-/_\ (E'LWW7WH.==C>^'_P &=/\ A[XQ\6>)
MK?6=9U34_$TL4VH'4YXI$+1)LCV!8UVA4&T#.,=LDFNL\-: /#6D+8"_O=2
MEFE^T:A-YLQ\R1I-I; ^5=VU1CA54<XS7FO_  DWQM_Z$?P?_P"%-/\ _(E'
M_"3?&W_H1_!__A33_P#R)1[-]U]Z#G78L>)?V;/"OBJR\?6%W<ZK'I?C9_.U
M73X+L+"9_*CB:5/E)5BD2 @DJ=N=M:!^!&@0^*[W7K*[U33+C4;.WLM2@LKH
M)'?) I2(R':75@IV[HV0D  YQ6/_ ,)-\;?^A'\'_P#A33__ ")1_P )-\;?
M^A'\'_\ A33_ /R)1[-]U]Z#G78[OPAX!TOP5=^(;JP\Y[G7=1.IWLUQ)O9I
M/+CB50<<(J1(JKV ]S7$Z;^S7X6T2+PVUM)J5Q+X<U*[U;3Q<WG'GS^<75R%
MY7=<2'/WLD$DXJ+_ (2;XV_]"/X/_P#"FG_^1*/^$F^-O_0C^#__  II_P#Y
M$H]F^Z^]!SKL>6Z%\+?B-<?$6V\:QV-WH7C.\N+>761J,&G7FDE5V1RI;S*?
MM2)Y*L$ (RQRR\D5['J_[/?AG6X_B''=7&J,GCID.KJMWC*K#'#Y:?+\JF.)
M5(.>&?&-QK._X27XV_\ 0C^#_P#PII__ )$H_P"$F^-O_0C^#_\ PII__D2C
MV;[K[T'.NQL>-?@!X1^(&JZA>ZU;7%P+W0QX?:U2;RX8K83><#&H'RN'"'<#
M_P LTX^45&OP#\/3G5;G4KO5=8UK4K:&RGUN[N]MXMO%()$AC:-46)-Z[B$4
M;CRQ) QE_P#"3?&W_H1_!_\ X4T__P B4?\ "3?&W_H1_!__ (4T_P#\B4>S
M?=?>@YUV+%]^S?X:U.RN/M-]JTNLSZW;>(7UW[1&+PWMN@CA?B,1X6-1'MV8
M*YR">:Z/PA\)]$\%>,?$_B>P>\DU7Q&+7[?)<SF0.8(]D9 QQP3[9)QC.*Y3
M_A)OC;_T(_@__P *:?\ ^1*/^$F^-O\ T(_@_P#\*:?_ .1*/9ONOO0<Z[%W
M1_V<_"NCZ!I6C+)J5U8Z=X@/B5$N;K?YMV9I9P9/E^91+,S@=<JA).T5U7AK
MX=Z7X6\5>*?$-H]S)J/B.XBN+UIY=R@QPI"BH,#:H5!QSR6/<UQ'_"3?&W_H
M1_!__A33_P#R)1_PDWQM_P"A'\'_ /A33_\ R)1[-]U]Z#G78[30OACX?\.>
M-O$WBVRLRNO>(F@-]=.Y;<(HEB14'1!M0$XZGKG QR%A^S-X3T[P-X6\*1SZ
MJVF^'-636K)Y+L-*;A'D=2[;<,-TKMT!W8;.X9J+_A)OC;_T(_@__P *:?\
M^1*/^$F^-O\ T(_@_P#\*:?_ .1*/9ONOO0<Z['<^'?A]I/AGQ%XEUNU6:34
M/$$T$M[)/)OXAA6&.->.$"J3CGEV/>N6\*?L[^%/"=SH!B-_?V/AQWDT'3+^
MX$EKI18,N84"C)5795:0NR*2%(S6?_PDWQM_Z$?P?_X4T_\ \B4?\)-\;?\
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>armp-20231231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $4 \L# 2(  A$! Q$!_\0
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MEM9:G!-(WT56)-;#>(])775T4ZI9#66B\]=.-PGV@Q]-XCSNV^^,4 :-%%%
M!1110 4444 %%%% !1110 4444 %%%<OKOQ2\&>%]1?3]9\7:#I-^@#-:WVI
MPPRJ",@E68$9% '4456TW4[/6;&&]T^[@OK.9=T5Q;2"2.0>JLI((^E6: "B
MBL_7/$.E^&;$WNL:E9Z39AUC^T7TZ0Q[B<*-S$#)/04 :%%9UGXCTG4-5N],
MM=4LKG4K14>XLX;A'FA5QE"Z Y4,.02.:T: "BL[0_$>D^)K1[K1]4L]6MDD
M:)IK&X29%<=5+*2 1W%:- !14-Y>6^G6<]W=SQVMK!&TLL\SA$C11EF9CP
M"23TJ/3-4LM;T^"_TZ[@O[&X4/#<VLJR1R*>A5E)!'N* +5%%% !116%>^._
M#6G3:E#=^(=*M9=,19+Z.:]B1K1&("M*"WR DC!;&<T ;M%9%YXOT'3M+L]3
MN];TZUTV]9$M;R:[C2&=G&4".3ABPY !.>U9VN?%+P9X8U*33]9\7:#I-_&
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MEIUR]K=0AOO!9$(.#Z4 >!2_M%>-H_A]J.E&XL?^$OM_&2>#5UX0 6Y+L_\
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M/MQ7IOA/]G;PAX0\0:;K,"ZGJ-YI:-'IPU349;J.R5A@B%')"<$CBH(?V9_
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M/)<1.,,69R3NQW]A7=>$/"MAX'\,:;H&E(Z:=I\*P0+(^]@@Z9)ZT ;%%%%
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ME1&R>60X_B^7UKE+#]DOX?Z9>:9<6T.JQ_V7>K?Z?$=2E:*SE5P_[I"2%!8
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M //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\
M?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I_
M_/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?
MH4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_
M +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT
M?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_
M8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C
M;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?
MV)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;
M_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6
M_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_
MG1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?
MSK)O-'L4N;(+9P -*0P$8Y&QJM_V)I__ #XV_P#WZ% %OSH_[Z_G1YT?]]?S
MJI_8FG_\^-O_ -^A1_8FG_\ /C;_ /?H4 6_.C_OK^='G1_WU_.JG]B:?_SX
MV_\ WZ%']B:?_P ^-O\ ]^A0!;\Z/^^OYT>='_?7\ZJ?V)I__/C;_P#?H4?V
M)I__ #XV_P#WZ% %OSH_[Z_G1YT?]]?SJI_8FG_\^-O_ -^A1_8FG_\ /C;_
M /?H4 6_.C_OK^='G1_WU_.JG]B:?_SXV_\ WZ%']B:?_P ^-O\ ]^A0!;\Z
M/^^OYT>='_?7\ZJ?V)I__/C;_P#?H4?V)I__ #XV_P#WZ% %OSH_[Z_G1YT?
M]]?SJI_8FG_\^-O_ -^A1_8FG_\ /C;_ /?H4 6_.C_OK^='G1_WU_.LJ71[
M$:G;H+. *8I"5\L8)!7'\ZM?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_
M8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C
M;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?
MV)I__/C;_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;
M_P#?H4 6_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6
M_.C_ +Z_G1YT?]]?SJI_8FG_ //C;_\ ?H4?V)I__/C;_P#?H4 6_.C_ +Z_
MG1YT?]]?SJI_8FG_ //C;_\ ?H52UK2+&+2[ETLX$<+PRQ@$<T ;'G1_WU_.
MCSH_[Z_G53^Q-/\ ^?&W_P"_0H_L33_^?&W_ ._0H M^='_?7\Z/.C_OK^=5
M/[$T_P#Y\;?_ +]"C^Q-/_Y\;?\ []"@"WYT?]]?SH\Z/^^OYU4_L33_ /GQ
MM_\ OT*/[$T__GQM_P#OT* +?G1_WU_.CSH_[Z_G53^Q-/\ ^?&W_P"_0H_L
M33_^?&W_ ._0H M^='_?7\Z/.C_OK^=5/[$T_P#Y\;?_ +]"C^Q-/_Y\;?\
M[]"@"WYT?]]?SH\Z/^^OYU4_L33_ /GQM_\ OT*/[$T__GQM_P#OT* +?G1_
MWU_.CSH_[Z_G53^Q-/\ ^?&W_P"_0H_L33_^?&W_ ._0H M^='_?7\Z/.C/\
M:_G5&?1=/$$A%E;@A3SY8]*@TG1[&72[-WLX&=H4)8Q@DG:* -7SH_[Z_G1Y
MT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\Z
MJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\
MSXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4
M?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I_P#S
MXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z%
M %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z
M_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\
M?7\ZJ?V)I_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)
MI_\ SXV__?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV_
M_?H4?V)I_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H4?V)I
M_P#SXV__ 'Z% %OSH_[Z_G1YT?\ ?7\ZJ?V)I_\ SXV__?H55L-'L7:ZW6<#
M;9B!F,<# XH U?.C_OK^='G1_P!]?SJI_8FG_P#/C;_]^A1_8FG_ //C;_\
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M.X\1%WL1#K&M6<LB[SQI]N%PGW?O$H!CIR>:ZYTL/1=II+5][N-TM?-KFO\
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M%% !1110 4444 1W'_'O+_NG^55]&_Y ]C_UPC_]!%6+C_CWE_W3_*J^C?\
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MW_X&+_\ $TH_;ATP_P#,J7?_ (&+_P#$T?V5C/\ GW^*_P Q?VS@/^?GX/\
MR/IRBOF/_AN#3?\ H5+O_P #%_\ B:=_PV_IO_0JW?\ X&+_ /$T_P"RL9_S
M[_%?YA_;. _Y^?@_\CZ:HKYF'[;NFG_F5;K_ ,"U_P#B:/\ AMS33_S*MU_X
M%K_\31_96-_Y]_BO\P_MG ?\_/P?^1]*W'_'O+_NG^55]&_Y ]C_ -<(_P#T
M$5\XR_ML:;)&Z_\ "+70W C/VM?_ (FF6/[:.G6EE;P'PO=,8HU3(NUYP,?W
M:/[*QO\ S[_%?YA_;6 _Y^_@_P#(^G:*^:1^VQII_P"96NO_  +7_P")I?\
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MK@:'XK'B[3/@+XDM_$:/]H@MY%G?3;>YZ^8D'D!L!OF52^ <8Z"N7URW\?\
MB#X:-X9N_ /B.2^EU^77)M0_LZ?#L\90IL\OCDYSG\*ZVHRLDE';L<47.%W*
M3EOW\O1ZG$?$[6M3U36X8;_QU/X^CMXAY.H2SW4JINY9%^T ,.@SQBN2':NH
M'PC\=8_Y$OQ#_P""J?\ ^(IX^$GCGC_BC/$/_@JG_P#B*[X2A%637X'F3A4D
MVW%_B<N.M/'6NH'PE\<Y_P"1,\0?^"N?_P"(IX^$WCC/_(F^(/\ P5S_ /Q%
M:*I#NB/9S_E9RZT\=*Z=?A/XX_Z$WQ!_X*Y__B*D'PG\;X_Y$WQ!_P""N?\
M^(I^TAW1+IS_ )6<L.M/7K73CX3^-\_\B;X@_P#!7/\ _$4\?"CQOG_D3M?_
M /!7/_\ $T_:0[H3IS_E9S"]*>.E=,/A3XVQ_P B=K__ (*Y_P#XFI!\*?&V
M/^1.U_\ \%D__P 35>TAW1/LI_RO[CF5[4]>M=,OPJ\;<?\ %'Z__P""R?\
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M?\C!9I3;MR2^Y=-^I^B=%?GEK_QJ^/FBZ?I6J6OQ$TK7]$U*[%A%JNDV=K)
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M[W_D'^L&%_EE]R_S/T7HK\ZA^U?\5"?^1J/_ (+[7_XU3Q^U;\5#_P S2?\
MP7VO_P :I_V)B?YH_>_\A?ZPX7^67W+_ #/T2HK\[Q^U9\4\?\C2?_!?:_\
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M9\'_ "2^Y?\ R1]Q45\/C]H[XB'_ )F(_P#@%;__ !NE_P"&C?B)_P!#$?\
MP"M__C='^KV*_FC][_R#_6?!_P DON7_ ,D?;]%?$(_:-^(A/_(PG_P"M_\
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MW]G_ /C5'U_#?SHEY=B_^?;/F"GCK7T[_P ._/'/_0?\/?\ ?V?_ .-4X?\
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M/^TL)_S\1+RK&_\ /IGS^.E.7I7T,/V(_&/_ $&M#_[^3?\ QNE'[$GC ?\
M,:T/_OY-_P#&ZK^TL)_S\0O[*QO_ #Z9\\TX=*^A?^&)/&'_ $&M#_[^3?\
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MU6]?RX+<03IO;!.-S7( X!ZFNBEA*E:#J1M8YJV-I4)JG.]_)'Z!45\>:O\
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MPS;WL! DC6.60#(!'S+<$'@CH:/[*Q-[:?>']M82U[O[C[BHKX/'[>7CT_\
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MUK9T^QATNPMK*V3R[>WB6&-,D[54  9/L*[JF-A9NG'5ZZ]+JSMKUUW1YU+
M3NE5E[L5;3JE*ZOITTV9YIXZUSQ!JOPX\81ZOX9.AP)IDQCF-_'<>8<=,)R.
M.<FL/2;37=;M/!VN:QI-OX?T+PQ9?;C=FZ6:>Y46^  %'R(1\Q!/:O8M:T>U
M\0:3=Z;?1F6SNXFAE0,5+*1@C(Y%4]4\):9K'A=O#US S:4T*6YA61E)C7&%
MW Y_A'?FHIXN$(<O+;7I?1-6=KO?U-:N"J3GSN=[+K;5IW5[+:]MCYPTO7H-
M&'ASQQ+!J,.L3:O-=:I++I\R0_9;@[ /-*["%41D<]SBO5?AVL%Q\3/B>UT$
M>87%M&3)R1#Y1P/]WK7H&J^'-/UO0)]%O+<2Z;-#Y#PY(RF,8R.1TK U#X2>
M&]2ECEDMKF*9+5+-I;:\FA:6%1A5D*L-_''S9K>>,I5HR4DTVK=]+IKMYHYJ
M> K4)1<6I)-/JKOE<7WWT?WG%?!I-;7X36TF@VVGW5S%J-VMK_:<CI&MOYKY
MV,JL?O <=.O-:/P!G:&S\4Z=>PF#7H=8EGU*-2#")9%7'E$?P[4'7G.:ZV_^
M&?A^_ATZ,6LMD-/B,%LUA<R6S1QG&5S&P)''>M#PQX1TKP=9RVVE6OD+-(9I
MI&=I))7/5G=B68^Y-95L52J1J66LG?;S[WU^[<VH8.K2G2N](*V^^EM%;37S
M>AX)_P % ?\ D@$G_83MO_9J^+?V2?\ DXGP1_U^-_Z*>OO3]L3X?:_\3OA%
M_87AJP_M+59;^&1+?SHXLJNXL=TC*O ]Z^0OAS^S#\=_AGXTTKQ-IG@>VGO]
M.D\V*.[U*T:)CM*_,%N%)&">A%=>#J06%E!R2;ON_(X<?3J/&0J1BVE;9-]2
M'X:ZG\,?@AX@D\5V'Q!O_%NH6UK/%;Z/;:)+9K</)&R 2/(Q&P;LGZ \XQ6]
M'KGA_P ):1\'[=? GAK4Y_$ELK:G=:A8K))(K73)A3_"V"?GY/ '05Q*_L5?
M&8'_ )$W_P JEE_\>KM+[]GWX]:DO@U9? UFH\*Q+%9;-1M?W@$IE'F_Z1R=
MQQ\NWC\Z[I.BW?VB??5=G;:W5GGP5=)KV37;W7W5][]$;Z?"SPU\.K/QKJ]L
MGA47">)YM&L!XQ\R:TMH(T20A45&W2'?C+=%4'O6'JGAOP-?ZSXPO-#CT6_)
M\#SWUS!IH,MI9:@LT2LUOYB@H,$D<# 8@5T2?#/]H&?4O$<VI?#C1-9T_7KS
M^T+K2-0N[9[5+CH)(P+H.IQQG?R.#FD_X5E^T,WB_P#MQ_ NE/#_ &<='_L<
MW-F+ 61','EBX!V\ _>SD9S6<9J]W45_\2\C:5-M65)V_P +\]3&^#/@[0-6
M\-?"66_T:QNWO_$E_;WCRVZ,T\2PJ51R1\P!Y / -&G^*_#VI_"3Q)XJ_P"%
M>^&(;[0-5M[33HUM#Y?ERAA^_&[]^0%ZOW.:ZJ/P+^T!;S^'#:?#?0=/M?#]
M[)?:?96MS;I#&TD81D(^U99>"W)W;F/S8P!R=A^SQ\<+#P/K/A5/!5L=/U6[
MAO)Y6U"U\U7CSM"GS\ ?,<Y!^HJU.G)WE46Z^UTN[]>QDX5(Q48TWL_LO?E2
M73N;E[X+\+)=7WCS_A'+$I;^#;'7UT%$(LFO)Y&C),8_Y9KLSL&!DTGP[T+P
M]\5(/!/BR[\-:1I=VGB8:+?6=A;".TO83")%)AY4,-Q!QU'7MB>R^%_[0%CJ
M.E72>"[!HK+18] DLI+RU>WO+1"Q"S(;CYB2W52O08Q5O_A7/QYAU7P[<V/P
M_P!'TFPT&Y-Y::18W5LEH9CPTC@W)=B1QDOT'&*.>-K>T5^_-TMM_7Z#4)73
M=*5NJY7J[WOM_7S.3FN=#^(/@+XD(/"6BZ')X;,,^FW.F6_ESA3,8RDKYS)D
M=SW_  QT6N^%8-%^)WCJ32/"/AMK6UFM8(;S7GCATVQW1AF40G"N[8XQDC!.
M#FLO1O@)\;=%TKQ380^#+5H?$:*EVTE_;%D"R;QY>)QCD]\\5UD_@;XZZC>:
M[)JGPZT/5[/6)X[J;3KVY@:WCF1 BR1XN@RG:,'YCFM'.";Y:D;?XO\ #Y^3
M,8TZDDN>E*_^'_%Y>:_I'EW[0N@:?I-_X5OK*TTBTFU325N;H:#G[%)()9$W
MQ @8!"C@#&<]>I\J3M7T/X]^"/QK^(HTC^TO!-A;?V7;FTM_L-W:Q 0[RRH5
M\\KA<D# ''7)YKEU_9)^*X_YE3_RHVG_ ,=KT,/B:,*:C.I&_JCS<3A:]2JY
M0I2M_A?8\F3I4R5ZNO[)GQ6'_,J_^5&T_P#CM2K^R?\ %4=?"W_E1M/_ ([7
M4L7A_P#GY'[T<;P6*_Y]2_\  7_D>4IUJ9*]1_X97^**3+$?#&'8%@/[0M>0
M,9_Y:^XJ=?V5/BD/^97_ /*A:_\ QVK6,PW_ #\C]Z)>!Q7_ #ZE_P" O_(\
MM3I4B]*]37]ECXH#_F6/_*A:_P#QVGC]EGXH#_F6/_*A:_\ QVJ6,PW_ #]C
M]Z,_J.+_ .?4O_ 7_D>5KTJ5>M>HC]EKXGC_ )EC_P G[7_X[3Q^R[\3@?\
MD6?_ "?M?_CM/ZYAO^?L?O1/U#%_\^I?^ O_ "/+EZ5*M>GC]E[XFC_F6?\
MR?M?_CM/7]F#XF#_ )EK_P G[;_X[5?7,-_S]C]Z$\!B_P#GS+_P%_Y'F"]*
M>.E>GC]F+XEC_F6O_)^V_P#CE.'[,GQ+Q_R+?_D_;?\ QRG]=PO_ #]C]Z_S
M)^H8O_GS+_P%_P"1YDO:GCK7IJ_LR_$H8_XIO_R>MO\ XY3A^S/\2<_\BW_Y
M/6W_ ,<JEC<+_P _8_>O\R?J&,_Y\R_\!?\ D>:#I4@ZUZ4/V:?B1C_D7/\
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M_P#H(JQ<?\>\O^Z?Y57T;_D#V/\ UPC_ /010!<HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEIWWKS_KNW\A5VJ6
MG?>O/^N[?R% %VOF75_&.O1?L\>-[]=;ODU>V\93V,-R+IA-%'_;21)$K9R!
MY;! O]U@.AKZ:KCYOA%X.N/%'_"0R:#;-JINDOVDRWEO<HH5+AHL[&E50H$A
M4L-JX/ P >?6GQN\1GQHT-W8:4GAUO%LWA2)8C*;MF6W:59V8G:!N784 /!W
M;A]VL71/VD?$-MI6B:MXGLM"L;#7_#M]K=E]EDG;[(ULT(V3MM+.'68-\B J
MPV#?D/7M+_#[P\S[_P"RK<2#46U</@Y%X5*&;K][:2*X_P"'W[.7@WP+X.30
MGTRWU1I-/;3;NXF1@MQ$[;Y (RQ$8=_G8)C<WS')YH XC3?V@_%^J,FCV^CZ
M>->/BV+PV9]0MKBRB$+V'VO[1Y#%I R D>66P^T?.F[*QCXK_$7PYJWQ4-Y=
M:'KJZ1XDTK1=+LC:R6D<7VJWL&.Z16=BH-T['(9MV<$+A1ZYH/P@\'^&I!+I
MVAPPS_VA_:IG=WEE>[\GR/.9W8LS^5\F23Q5NZ^&WAJ^U?4-3GTF*2\U"2WF
MNG+OMFD@*&&1DSM+KY:8;&<(HS@8H \=O?VBO$=M?_\ "-)IEI<>)XM?O=&F
MN[.PN;FW*6]I#<^:MNC>82PN(EV[\+\[9. I?+^T3XKL/[1O-7\*V^A:?H'@
MW_A+=<M;EI)+U2K7*O;0QC ^86Y978Y P"A+?)ZQJ?PH\)ZO]H:XT:(33Z@=
M5>XA=X9A=&$0M,LB,&5C$H0E2,KP>":OZ9X$\/Z-.9K+2+6WD:QCTQBJ<-:Q
MERD1'0J#(Y_X$<T >)VO[0OC6'PI)J-_X5B22^_LF'3;V2UN+6T6YOKI;?RG
M\SYI%B$B2>8FT."1M0X)ZKX W.MSZ]\58]?EMI;^#Q1Y>;)G\C8+&T*E%?E,
M@[BF3@DC<W4]5:_!?P59Z!>Z)'H,!TJ\2.*2VDDD=52-MT:1EF)C5& 90A4*
M0",$5L>$? N@^!+6[M]!TV+38[N<W5SY9):>8J%:5V8DLY"C+$DG&22: -ZB
MBB@ HHHH **** *$VJ>5*R>5G:<9W?\ UJ9_;'_3'_Q[_P"M52\_X^I?]ZN.
M\:>,+S0-1T;2M*TY-1U;56E\E)YO)B18PI=F;!/&X< $FLZE2-*/-+;_ #T-
MZ%">)J*G3WUZI:)7;N]-$KG>?VQ_TQ_\>_\ K4?VQ_TQ_P#'O_K5Y?%\2KW0
MVUF+Q9I<6D/I]I]L6XM[CS;:=-VT!7*@ABV!M(!.:OZ'\4-$OO!FF>(=1U"R
MTNWO4SB6X7:K=TSQDCH?0UA'%49.W-9[ZZ;.W4[9Y9BX1YN2ZNDFO>3;5U:U
M[Z=MNIZ#_;'_ $Q_\>_^M1_;'_3'_P >_P#K5S*^+-&?2H=375+0Z?,XCCNA
M,OELQ.  V<9S5-/'FB7NB:GJ6FZG::C#I\3R3&WE#A=JDX..G2MG5IK[2[G*
ML+7>T'O;9[[6]3LO[8_Z8_\ CW_UJ/[8_P"F/_CW_P!:N$\&_$'3?%%G81O>
M646MSVJ74VFPW >2$,H;!'7(!&>*V/\ A)=*_L=-6_M"W_LU\;;KS!Y9RVT8
M/NW'UI0K4YQYHRT'5PE>C-TYP:=[;=]K=[VT[]#H_P"V/^F/_CW_ -:C^V/^
MF/\ X]_]:N"T[Q_:RS^))=0>WTW2])O!9+>33!1(P16?.<8P6 ]\&MC2?%.C
MZ[ITE_I^IVMY919WSPRAD3 R<GMQ1&M3GHI?T@J82O2UE!VTUZ:I-*^U[/;<
MZ7^V/^F/_CW_ -:C^V/^F/\ X]_]:N4T3QKH'B26:+2M8LM0DA&9%MYE<H/4
MX[4W2O'/A[7=1>PT[6K&]O4!+003JSC'7@&FJM-VM):[:[B>%KQYDZ;7+OH]
M/7L=;_;'_3'_ ,>_^M1_;'_3'_Q[_P"M7(R>.O#L6LC2'UNQ74RVP6AG7S-W
MIC/7VI=1\<^'M(U1--O=:L;6_? 6VEG57.>G!-'MJ:5^9=M^H+"XAM)4W=J^
MSV[^GF=;_;'_ $Q_\>_^M1_;'_3'_P >_P#K5BIJ=I)J,E@MQ&U['&LSP!OG
M5"2 Q'H2#^59-YX^\-Z?IT5_<ZY8P64LC11SR3J$=E.& /<@]:;J0BKN21$*
M%6H[0@V_)/KM]YV']L?],?\ Q[_ZU']L?],?_'O_ *U8]A?VVJ6<5W9SQW5K
M,NZ.:)@RL/4$5DW_ ([\.Z5JJZ9>:W8VVH,0!;2SJKY/08S1*I"*4I-),4*%
M6I)PA!MK=).Z.N_MC_IC_P"/?_6H_MC_ *8_^/?_ %JPWU>RCU.+3FNHA?RQ
M&9+<L-[(#@L!Z9/6L^X\;Z!:HSS:Q9Q*L[VS,\P $J+N=/J!R10ZD([M#C0J
MS^&#?R9UG]L?],?_ ![_ .M1_;'_ $Q_\>_^M7%7/Q(\*V<%I-/X@TZ&*[7?
M SW"@2+G&1SR/>M:?6]/MIK&&6\A26^)%JA<9F(&3M]>.:2JTY;27W]]BI8:
MO"W-!J]^CZ;_ '=>QO\ ]L?],?\ Q[_ZU']L?],?_'O_ *U<Q=^+-&L!?FYU
M2U@%AL^U&24+Y.[[N[TSCBI-"\2:5XGM6N=)U"WU&!6VF2VD#@'T.*:J0;Y4
MU<ET*L8>T<'R][.VNJU\T='_ &Q_TQ_\>_\ K4?VQ_TQ_P#'O_K5G45H8&C_
M &Q_TQ_\>_\ K4?VQ_TQ_P#'O_K5G44 :/\ ;'_3'_Q[_P"M1_;'_3'_ ,>_
M^M6=10!H_P!L?],?_'O_ *U']L?],?\ Q[_ZU9U% $]YJFZXLSY6-LI/WO\
M8;VJU_;'_3'_ ,>_^M6-<_Z^U_ZZ'_T$U8H T?[8_P"F/_CW_P!:C^V/^F/_
M (]_]:LZB@#1_MC_ *8_^/?_ %J/[8_Z8_\ CW_UJSJ* -'^V/\ IC_X]_\
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M#1_MC_IC_P"/?_6JGK.J>;IEPOE8RO7=[_2HJJZI_P >$W^[0!M_VQ_TQ_\
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M :/]L?\ 3'_Q[_ZU']L?],?_ ![_ .M6=10!H_VQ_P!,?_'O_K4?VQ_TQ_\
M'O\ ZU9U% &C_;'_ $Q_\>_^M1_;'_3'_P >_P#K5G44 :/]L?\ 3'_Q[_ZU
M']L?],?_ ![_ .M6=10!H_VQ_P!,?_'O_K4?VQ_TQ_\ 'O\ ZU9U% &C_;'_
M $Q_\>_^M56QU78UU^ZSF8G[WL/:H*KVGWKC_KJ?Y"@#9_MC_IC_ ./?_6H_
MMC_IC_X]_P#6K.HH T?[8_Z8_P#CW_UJ/[8_Z8_^/?\ UJSJ* -'^V/^F/\
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M)'=3P>8  <X8 J2.O&16=X-\(P^%-&DM'D%[=W,KW%[=.@!N)7.68CTZ #L
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MX:=^%7_0]:/_ -_O_K4O_#3?PK_Z'K1_^_W_ -:CZQ1_G7WH/J&+_P"?,O\
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M1]9H?SK[T']G8W_GS+_P%_Y'I-%>;?\ #2'PQ_Z';2?^_P!_]:E_X:/^&/\
MT.VD_P#?[_ZU'UFA_P _%]Z#^SL;_P ^9?\ @+_R/2**\W_X:.^&7_0ZZ3_W
M^_\ K4O_  T;\,O^AUTK_O\ ?_6H^M4/^?B^]#_L[&_\^)_^ O\ R/1Z*\X_
MX:,^&?\ T.NE?]_O_K4O_#1GPS_Z'32O^_W_ -:CZU0_Y^+[T']FXW_GQ/\
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M<+_PO/P#_P!#7IW_ ']_^M1_PO/P#_T->G?]_?\ ZU'US#?\_8_>@_LG,?\
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M>\2_%G1O%6F-I=S;'P_H\]W=O?O)&51'6:)$"Y.<DG'MUK;^&?C[P1X.\.>
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M<-3JJG5A>3\DS?+\NS#$8:5?#U>6";O[S6RNWH?7W_#+GPG_ .A#TC_OR?\
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M"1I/_?H_XTO_  S5\+_^A(TG_OT?\:^-A^W'\3_^?C2O_ $?XTX?MP_$X_\
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M_:Z^(!_Y;:=_X"#_ !I?VUE/_/K_ ,E17^I_%/\ T$_^5)?Y'U%_PH#X=?\
M0H:;_P!^C_C1_P *!^'?_0HZ;_W[/^-?+P_:Y^(&?]=IW_@(/\:</VM_B ?^
M6VG?^ @_QH_MO*/^?7_DJ'_J=Q3_ -!/_E27^1]/_P#"@?AW_P!"CIO_ '[/
M^-+_ ,*"^'G_ $*.F_\ ?L_XU\PC]K;Q_G_7:=_X"#_&E_X:U\?_ //;3O\
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M9W/E7#EDNI 4"'S)%.9).@S\H[5AZ;I4^E3V4>ED6[6]OJ0MH=.DEBEMX Y
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M3^IJ]16M/#T:3YJ<$GY)(YZ^.Q>)CR5ZLI+LY-K\6</X^^"?@GXG7MM>>)=
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M%G>6?]!$?O1\\CK4HZ5]!C]A'XH@_P"JTC_P._\ L:>/V$_BA_SRTC_P._\
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M>E?^!G_V-3_9N,_Y]/[C1<093_T$P^]'A*]*D'6O=1^Q7\2!_P L]*_\#/\
M[&G#]BWXC@_ZO2__  ,_^QJ7EN,_Y]2^XT7$.4?]!,/O1X6.M.'6O=!^Q?\
M$;/^KTO_ ,#/_L:=_P ,8?$;_GGI?_@9_P#8U#RS&_\ /J7W&BXBRC_H*A_X
M$CPQ>M.KW,?L9?$4?\L]+_\  S_[&E_X8S^(O_//2_\ P,_^QI?V9C?^?4ON
M+7$>4?\ 05#_ ,"1X:.E.7I7N0_8T^(H'^KTO_P,_P#L:4?L;?$0?\L],_\
M S_[&I_LS&_\^I?<6N(\G_Z"H?\ @2/$!TI1UKW ?L;_ !$_YYZ9_P"!G_V-
M-F_8^^(-O&TCQZ9M49.+O_[&C^R\;?\ @R^XI<29/_T%0_\  D>*+TIR]:]N
M'['7Q#'_ "STS_P,_P#L:</V._B$/^6>F?\ @7_]C4O*\=_SYE]Q:XDR;_H*
MA_X$CQ&GIVKVS_ACSXA?\\],_P# O_[&G+^Q[\01_P L],_\"_\ [&D\KQW_
M #YE]Q2XER;_ *"H?^!(\3IPZ5[9_P ,?_$'_GGIG_@7_P#8TH_9 ^(&/]7I
MO_@7_P#8U+RO'?\ /F7W%_ZRY-_T%0_\"1XH.M/7I7M(_9!^( /^KTW_ ,"_
M_L:</V0_B /^6>F_^!?_ -C2_LK'?\^9?<6N)LE_Z"X?^!(\6'6GKUKV?_AD
M3Q__ ,\]-_\  O\ ^QIP_9&\?@_ZO3?_  +_ /L:3RK'?\^9?<5_K-DO_07#
M_P "1XP.M.KV<?LC^/L_ZO3?_ O_ .QIW_#)'C[_ )YZ;_X%_P#V-3_96._Y
M\R^XM<3Y+_T%P_\  D>,+TIXZ5[*/V2?'H_Y9Z;_ .!?_P!C3O\ ADOQ[_SS
MT[_P+_\ K4GE6/\ ^?,ON*7$^2_]!</_  )'F'A3^T_^$CTW^QM_]J^>GV;9
MUWYXK]&=*:5-%LVN IG%NAD$.2I;:,[<]L]*\.^ G[/MYX U*\UKQ$EM)J*(
M8[-(7\Q8P1\SYQ]XCCZ9]:]GU"\33_"DMQ(&94M,[47<S';@ #N2< #U-?H?
M#F7UL)1E*M=.;V[6_5_Y'X/Q[GF%S?&TZ6$M*--?$NK=G9/LOSN4-&GB\3Z;
M;ZO>07%BLA9A:WZA'C"L5Y7) Z9SZ-[D5J//9Z,D$<4)Q)Q&L*Y)P!_0#\J^
M3/!/PDO_ !=_PJ#1O$_AB_?3-)BUB/6+:\C=$C,CF2#S,$<-D$>X]J]D^ _A
M;6-$^%_A73-5MKRQN;*6ZC,<Y(DBB\V3RAD]MNW'MBOH^(?;X+ RJ8&7-4YH
M12M?253E;WZ*[UT5TWH?GT:5)U'S/373[[?D>K0ZE%-<K %=)6C,FUUQ@9Q3
M)=7BBNVMA'+)(N-VQ<@9JC.DMEKD4XAFN(EMO+WJNXDY[_E4;+*FM3W)ANQ&
MZIM$0X. .#7P.(SO'TH>SVFJO+)\C^#E;YNVLE:Z=NA<</3;OTY;[];[&I-J
MUO;R3I*QC:%0Y##J#Z>M<]J]]I^N^)8_#-]H5W<Q7NFO<O?F,"!4$BCR6<'<
M&)(; XPIJ[K-C<:A>K/% ,6@#*'',ISDCZ5YGXX\*>*-6^,\FL:);RV@?P5>
MV-MJ#<)#>/-&T:D]CQG\*^FR7&XO%X_$T,2N6G#X)<K7,KN[NW]EKEMUMS[2
M1G*G"$8RB]7OKL_ZU_#H=9JWP_.L:FL<ET+VU>^:^N)_M'D3P%%'D0CRU&^,
M'.0QS@G!K,T3P!XCTLV\UEJFB:1JMSJAO]:?3K4L+V'<2$^<D@G+9( Y/'OX
M]\(/AWJ>D^*O"DNE^#M<\,:G8V%S%XMU+4F;RM4D:$A0K%B)B9OG##H*9\(O
M@QJO@_5_A%KL?A^_L-9:35(O$-RQ?<(BS"!903@+C;M'TK[V5&,$U[1:>2[2
M\_+\4;K$5(QY.96]$^_3;^D]SZWHHHKPSR HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *KVGWKC_ *ZG^0JQ5>T^]<?]=3_(4 6*^7]7\17B? 3QM -5
MF76H_&\NGQH+D^>KOK$9BA'.06B=2%'\+#M7U!7/3?#KPI<>,8?%LOAC1I/%
M<$?E1:Z^GQ&^C3:5VK/MW@;688!Z,1WH \LMOC#XK7QCMN?[(;0'\83>%TM8
MK24705;=I$F,IFVYW  KY?([@USVA?M'^(;;0=%UW7KG0KK3-8\.:AK(&D6,
MS/82VLD2;7_?-YJL92N $(==N>I'T WA/1&;=_9%@'^UF_#BV3(N2NTS@X_U
MF"1OZX[US/@?X(>"O &ASZ;IWA[39&O+1++4;V:Q@^T:E$J[0MRZH/-&TXPV
M1CC% 'DWAOX]?$#Q!(-&GTK3M"\0KXP3P[+_ &I:(WE0-IWVO>T5M>SKY@/
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MJ(-Q!.% SP*T['P]I>F7*W%GIMG:7"VT=F)8($1Q A)CBR!G8NYL+T&3@<T
M?.ND_M _$H^$)-5UGPM9Z0M]_9":;J%[]E\E7O;M("[16VH7#/"BR*P<M$6.
M5P.H[C]GV6\EUWXK#4+VRU"]3Q48YKC3XS'"S+96JD!"[E2,8(+'!!YKN-.^
M%'@C1]'UC2;#P=H%EI6LEFU.QMM+@C@OBPPQG0*%D)!(.X'-:OASPIHG@[3Q
M8:#H^GZ)8C:!;:;:I;Q#:H1?E0 <*JJ/0*!VH U:DMO^/F+_ 'Q_.HZDMO\
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M.X$C;S0O_P!I:)M'D*6,=OJ+720I;1WR&;R6T==1\\!HSE=S&'.TC(SG/RT
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MC&*X<_LZFTUZTELHM"73K>[CFLVDLR+C1HTO9+DI98^6/>L@C.-H&P$[UP@
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M[2:WTNVB1/W\ -H(VC+ '(4J"C=,\ \<]*E6[T_^TUTU3%]M@B%RL(7E$)9
MPXP,X8?G7@>F_LK26!#M=6LNICPVFA1ZV+FZ2:W*V2V^U80_EM%N4OC@_,>X
M#5IW_P"SG!J%O*\?AGP9I5S<:,^DR0Z?8A(HT\]I-L;",,JR!W#XP03D9/-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>armp-20231231xex10d28001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20231231xex10d28001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "/ /H# 2(  A$! Q$!_\0
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M(%O=(!,QD^>9MI EC)RV#D_,N15*QUEH;:'P\^I2V5K9LFH:Q<63;99<DDO
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MK(D5XG9'#(ZG!5@01^%?0QX<PTE?G?X?Y'S$N*<7%M>SC^/^9^B'_"^?A_\
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M1HW1A@@@X-:8+%X3$Q<,*](]+6W,LPP6,PLE4Q:UEUO?;SU/T=^%WBZ+QSX
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*+-\ONWO?;YG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>armp-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2024 5:39:19 PM-->
<!--Modified on: 3/21/2024 5:39:19 PM-->
<xsd:schema targetNamespace="http://www.armatapharma.com/20231231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:armp="http://www.armatapharma.com/20231231" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" id="DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails">
        <link:definition>40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" id="DisclosureBalanceSheetDetailsOtherReceivablesDetails">
        <link:definition>40603 - Disclosure - Balance Sheet Details (Other receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40604 - Disclosure - Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" id="DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails">
        <link:definition>40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails">
        <link:definition>41102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>41103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails">
        <link:definition>41104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" id="StatementConsolidatedStatementsOfShareholdersDeficitEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" id="DisclosureEquityIncentivePlans">
        <link:definition>11001 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" id="DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails">
        <link:definition>40101 - Disclosure - Organization and Description of the Business (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" id="DisclosureLiquidityAndGoingConcernNarrativeDetails">
        <link:definition>40201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40301 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>40303 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" id="DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails">
        <link:definition>40402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" id="DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails">
        <link:definition>40403 - Disclosure - Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" id="DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails">
        <link:definition>40501 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" id="DisclosureBalanceSheetDetailsNarrativeDetails">
        <link:definition>40601 - Disclosure - Balance Sheet Details (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails" id="DisclosureConvertibleDebtNarrativeDetails">
        <link:definition>40701 - Disclosure - Convertible Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLongTermDebtDetails" id="DisclosureLongTermDebtDetails">
        <link:definition>40801 - Disclosure - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails" id="DisclosureStockholdersEquityDeficitNarrativeDetails">
        <link:definition>40901 - Disclosure - Stockholders' Equity (Deficit) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" id="DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails">
        <link:definition>40902 - Disclosure - Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" id="DisclosureEquityIncentivePlansNarrativeDetails">
        <link:definition>41001 - Disclosure - Equity Incentive Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" id="DisclosureEquityIncentivePlansRestrictedStockAwardDetails">
        <link:definition>41003 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" id="DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails">
        <link:definition>41004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails">
        <link:definition>41005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" id="DisclosureIncomeTaxesNarrativeDetail">
        <link:definition>41101 - Disclosure - Income Taxes (Narrative) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>41201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" id="DisclosureGrantAndAwardsNarrativeDetails">
        <link:definition>41301 - Disclosure - Grant and Awards (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" id="DisclosureLiquidityAndGoingConcern">
        <link:definition>10201 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10501 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" id="DisclosureBalanceSheetDetails">
        <link:definition>10601 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureConvertibleDebt" id="DisclosureConvertibleDebt">
        <link:definition>10701 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10801 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit" id="DisclosureStockholdersEquityDeficit">
        <link:definition>10901 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11201 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwards" id="DisclosureGrantAndAwards">
        <link:definition>11301 - Disclosure - Grant and Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" id="DisclosureEmployeeRetirementPlan">
        <link:definition>11401 - Disclosure - Employee Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30503 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" id="DisclosureBalanceSheetDetailsTables">
        <link:definition>30603 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables" id="DisclosureStockholdersEquityDeficitTables">
        <link:definition>30903 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" id="DisclosureEquityIncentivePlansTables">
        <link:definition>31003 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31203 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails">
        <link:definition>41002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" id="DisclosureEmployeeRetirementPlanNarrativeDetails">
        <link:definition>41401 - Disclosure - Employee Retirement Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantExpirationDate" id="armp_WarrantExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2016Member" id="armp_EquityIncentivePlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentBenefit" id="armp_ResearchAndDevelopmentBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="C3jStockPlan2016Member" id="armp_C3jStockPlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" id="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockOptionsMember" id="armp_CommonStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PropertyAndEquipmentUsefulLifeTableTextBlock" id="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryEquipmentMember" id="armp_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OfficeAndComputerEquipmentMember" id="armp_OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncomeTaxRateReconciliationPermanentDifferences1" id="armp_IncomeTaxRateReconciliationPermanentDifferences1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AnnualIncreaseInRentPercentage" id="armp_AnnualIncreaseInRentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceThreeMember" id="armp_ExercisePriceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceFourMember" id="armp_ExercisePriceFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceFiveMember" id="armp_ExercisePriceFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecuritiesPurchaseAgreementMember" id="armp_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" id="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeaseBaseRent" id="armp_OperatingLeaseBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeaseBaseRentEndOfLeaseTerm" id="armp_OperatingLeaseBaseRentEndOfLeaseTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LeaseAndRentalAbatementCreditPeriod" id="armp_LeaseAndRentalAbatementCreditPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetLeaseObligation" id="armp_DeferredTaxAssetLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="armp_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AwardReceivable" id="armp_AwardReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="GrantsAndAwardsPolicyTextBlock" id="armp_GrantsAndAwardsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceSixMember" id="armp_ExercisePriceSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CysticFibrosisFoundationMember" id="armp_CysticFibrosisFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThresholdDevelopmentAward" id="armp_ThresholdDevelopmentAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AwardAgreementInterruptionPeriod" id="armp_AwardAgreementInterruptionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardTable" id="armp_AwardTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardLineItems" id="armp_AwardLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardTextBlock" id="armp_AwardTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AwardAbstract" id="armp_AwardAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" id="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" id="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MedicalTechnologyEnterpriseConsortiumMember" id="armp_MedicalTechnologyEnterpriseConsortiumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquitySecuritiesMeasurementInput" id="armp_EquitySecuritiesMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SecuritiesPurchaseAgreementSecondTrancheMember" id="armp_SecuritiesPurchaseAgreementSecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecuritiesPurchaseAgreementFirstTrancheMember" id="armp_SecuritiesPurchaseAgreementFirstTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedLiabilitiesClinicalTrial" id="armp_AccruedLiabilitiesClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ProceedsFromExerciseOfWarrantsAndStockOptions" id="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsAndRestrictedStockAwardsMember" id="armp_StockOptionsAndRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceSevenMember" id="armp_ExercisePriceSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceEightMember" id="armp_ExercisePriceEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfTranches" id="armp_NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MaximumAllowanceForTenantImprovementsReceivable" id="armp_MaximumAllowanceForTenantImprovementsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="InnovivaStrategicOpportunitiesLlcMember" id="armp_InnovivaStrategicOpportunitiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaseAnnualRentToBePaidYearThree" id="armp_BaseAnnualRentToBePaidYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ExercisePriceNineMember" id="armp_ExercisePriceNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisePriceTenMember" id="armp_ExercisePriceTenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AnnualReductionOfStandbyLetterOfCredit" id="armp_AnnualReductionOfStandbyLetterOfCredit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" id="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="UnvestedRestrictedStockMember" id="armp_UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecuredTermLoanMember" id="armp_SecuredTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionPercentOfDiscountOnSharePrice" id="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShortTermVariableLeasePaymentAmount" id="armp_ShortTermVariableLeasePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ProceedsFromQualifiedFinancingPerAgreementBenchmark" id="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseFairValueOfLiabilities" id="armp_IncreaseDecreaseFairValueOfLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="UnbilledAwardReceivable" id="armp_UnbilledAwardReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" id="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TenantImprovementReceivableCurrent" id="armp_TenantImprovementReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ConvertibleDebtDisclosureTextBlock" id="armp_ConvertibleDebtDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LiquidityAndGoingConcernAbstract" id="armp_LiquidityAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProbabilitiesOfSettlementScenariosMember" id="armp_ProbabilitiesOfSettlementScenariosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleLoanPreModificationMember" id="armp_ConvertibleLoanPreModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleLoanPostModificationMember" id="armp_ConvertibleLoanPostModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" id="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" id="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedPaymentArrangementExpenseReversed" id="armp_ShareBasedPaymentArrangementExpenseReversed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentMeasurementInputForPeriod" id="armp_DebtInstrumentMeasurementInputForPeriod" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CreditAndSecurityAgreementMember" id="armp_CreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfLongLivedAssetsInGeographicalLocation" id="armp_PercentageOfLongLivedAssetsInGeographicalLocation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SharesIssuableUponConversionOfConvertibleLoanMember" id="armp_SharesIssuableUponConversionOfConvertibleLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncashInterestIncome" id="armp_NoncashInterestIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ArmataPharmaceuticalsInc.Member" id="armp_ArmataPharmaceuticalsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfDirectors" id="armp_NumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfBoardDirectors" id="armp_NumberOfBoardDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockVotingPercentageHeldPercentage" id="armp_CommonStockVotingPercentageHeldPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromTenantAllowances" id="armp_ProceedsFromTenantAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" id="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" id="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingLossCarryforwardsNotSubjectToExpiration" id="armp_OperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" id="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" id="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantAndAwardReceivableCurrent" id="armp_GrantAndAwardReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EmployeeStockPurchasePlan2016Member" id="armp_EmployeeStockPurchasePlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesIssuableUponConversionOfConvertibleDebt" id="armp_SharesIssuableUponConversionOfConvertibleDebt" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>armp-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2024 5:39:19 PM-->
<!--Modified on: 3/21/2024 5:39:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsOtherReceivablesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638466395566455690" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638466395566455690" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395566455690" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638466395566455690" xlink:to="us-gaap_OtherAssetsCurrent_638466395566455690" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638466395566455690" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638466395566455690" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_Goodwill_638466395566455690" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638466395566455690" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638466395566455690" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638466395566455690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638466395566455690" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638466395566465689" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638466395566465689" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638466395566465689" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638466395566465689" xlink:to="us-gaap_CommonStockValue_638466395566465689" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638466395566465689" xlink:to="us-gaap_AdditionalPaidInCapital_638466395566465689" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638466395566465689" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638466395566465689" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638466395566465689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638466395566465689" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638466395566465689" xlink:to="us-gaap_SecuredLongTermDebt_638466395566475693" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638466395566465689" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395566475693" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638466395566465689" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638466395566475693" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638466395566465689" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638466395566475693" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638466395566465689" xlink:to="us-gaap_LiabilitiesCurrent_638466395566475693" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638466395566475693" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395566475693" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_638466395566475693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638466395566475693" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_638466395566475693" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638466395566475693" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638466395566485691" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638466395566475693" xlink:to="us-gaap_OtherLiabilitiesCurrent_638466395566485691" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" xlink:to="us-gaap_InvestmentIncomeInterest_638466395566485691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638466395566485691" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395566485691" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638466395566485691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638466395566485691" xlink:to="us-gaap_InterestExpenseDebt_638466395566485691" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638466395566495691" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638466395566495691" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638466395566495691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638466395566495691" xlink:to="us-gaap_OperatingExpenses_638466395566495691" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638466395566495691" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638466395566495691" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638466395566495691" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638466395566495691" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638466395566495691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_ProfitLoss_638466395566495691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638466395566505689" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_OtherNoncashExpense_638466395566505689" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638466395566505689" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="armp_NoncashInterestIncome_638466395566505689" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395566505689" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638466395566505689" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638466395566505689" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638466395566505689" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638466395566505689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_ShareBasedCompensation_638466395566505689" order="10" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_638466395566515693" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395566515693" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395566495691" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638466395566515693" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395566515693" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395566515693" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638466395566515693" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395566515693" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638466395566515693" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="us-gaap_PaymentsOfFinancingCosts_638466395566525691" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638466395566525691" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638466395566525691" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638466395566525691" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638466395566525691" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638466395566525691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395566515693" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638466395566525691" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395566535690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395566535690" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638466395566535690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_638466395566535690" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638466395566535690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638466395566535690" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638466395566535690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638466395566535690" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638466395566535690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638466395566535690" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Details (Other receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="OtherReceivablesNetCurrent" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherReceivablesNetCurrent" xlink:to="armp_TenantImprovementReceivableCurrent_638466395566545691" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherReceivablesNetCurrent" xlink:to="armp_GrantAndAwardReceivableCurrent_638466395566545691" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_638466395566545691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638466395566545691" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="armp_AccruedLiabilitiesClinicalTrial_638466395566545691" order="3" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395566545691" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395566545691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395566545691" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638466395566555689" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395566555689" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638466395566555689" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_638466395566555689" order="6" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638466395566555689" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638466395566555689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638466395566555689" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638466395566565690" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638466395566565690" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_638466395566565690" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638466395566565690" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638466395566565690" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638466395566565690" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638466395566565690" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395566565690" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638466395566565690" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsGross_638466395566565690" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638466395566565690" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638466395566565690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638466395566565690" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="armp_DeferredTaxAssetLeaseObligation_638466395566575691" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsOther_638466395566575691" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638466395566575691" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638466395566565690" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638466395566575691" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395566575691" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638466395566575691" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638466395566575691" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638466395566575691" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_638466395566585690" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_638466395566585690" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638466395566585690" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638466395566585690" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncomeTaxRateReconciliationPermanentDifferences1" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="armp_IncomeTaxRateReconciliationPermanentDifferences1_638466395566585690" order="8" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638466395566585690" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638466395566585690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638466395566585690" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638466395566595689" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638466395566595689" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638466395566595689" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638466395566595689" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details) (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShortTermVariableLeasePaymentAmount" xlink:label="armp_ShortTermVariableLeasePaymentAmount_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="armp_ShortTermVariableLeasePaymentAmount_638466395566595689" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638466395566595689" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638466395566595689" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638466395566595689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638466395566595689" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638466395566595689" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395566605690" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638466395566595689" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395566605690" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>armp-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2024 5:39:19 PM-->
<!--Modified on: 3/21/2024 5:39:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfShareholdersDeficitEquity" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLiquidityAndGoingConcernNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureConvertibleDebtNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.armatapharma.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficitNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesNarrativeDetail" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureGrantAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.armatapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:title="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:title="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:title="definition: ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis to SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: IndefiniteLivedIntangibleAssetsByMajorClassAxis to IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain" xlink:title="definition: IncomeTaxAuthorityNameAxis to IncomeTaxAuthorityNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="ShortTermDebtTypeAxis" xlink:title="ShortTermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="ShortTermDebtTypeDomain" xlink:title="ShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShortTermDebtTypeAxis" xlink:to="ShortTermDebtTypeDomain" xlink:title="definition: ShortTermDebtTypeAxis to ShortTermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:title="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="EmployeeStockOwnershipPlanESOPPlanDomain" xlink:title="EmployeeStockOwnershipPlanESOPPlanDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="EmployeeStockOwnershipPlanESOPPlanDomain" xlink:title="definition: EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis to EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:title="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:title="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:title="definition: RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis to RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="DerivativeContractTypeDomain" xlink:title="definition: DerivativeInstrumentRiskAxis to DerivativeContractTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:label="AcceleratedShareRepurchasesDateAxis" xlink:title="AcceleratedShareRepurchasesDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:label="AcceleratedShareRepurchasesDateDomain" xlink:title="AcceleratedShareRepurchasesDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AcceleratedShareRepurchasesDateAxis" xlink:to="AcceleratedShareRepurchasesDateDomain" xlink:title="definition: AcceleratedShareRepurchasesDateAxis to AcceleratedShareRepurchasesDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Description of the Business (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="armp_ArmataPharmaceuticalsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfBoardDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_CommonStockVotingPercentageHeldPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_CreditAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="armp_LaboratoryEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="armp_OfficeAndComputerEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPreModificationMember" xlink:label="armp_ConvertibleLoanPreModificationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="armp_ConvertibleLoanPreModificationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPostModificationMember" xlink:label="armp_ConvertibleLoanPostModificationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="armp_ConvertibleLoanPostModificationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="armp_UnvestedRestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity (Deficit) (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfTranches" xlink:label="armp_NumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="armp_NumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSixMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceEightMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceNineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceTenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_WarrantExpirationDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Equity Incentive Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_EmployeeStockPurchasePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShareBasedPaymentArrangementExpenseReversed" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ShareBasedPaymentArrangementExpenseReversed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_C3jStockPlan2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="armp_CommonStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_EquitySecuritiesMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Narrative) (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" xlink:label="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_BaseAnnualRentToBePaidYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_MaximumAllowanceForTenantImprovementsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromTenantAllowances" xlink:label="armp_ProceedsFromTenantAllowances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ProceedsFromTenantAllowances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRent" xlink:label="armp_OperatingLeaseBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_OperatingLeaseBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_AnnualIncreaseInRentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_OperatingLeaseBaseRentEndOfLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LeaseAndRentalAbatementCreditPeriod" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_LeaseAndRentalAbatementCreditPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Grant and Awards (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardTable" xlink:label="armp_AwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="armp_AwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="armp_AwardTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="armp_CysticFibrosisFoundationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="armp_AwardTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="armp_AwardLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ResearchAndDevelopmentBenefit" xlink:label="armp_ResearchAndDevelopmentBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="armp_AwardLineItems" xlink:to="armp_ResearchAndDevelopmentBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="armp_AwardLineItems" xlink:to="armp_ThresholdDevelopmentAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardAgreementInterruptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="armp_AwardLineItems" xlink:to="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnbilledAwardReceivable" xlink:label="armp_UnbilledAwardReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="armp_AwardLineItems" xlink:to="armp_UnbilledAwardReceivable" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>armp-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2024 5:39:19 PM-->
<!--Modified on: 3/21/2024 5:39:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Long-Term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 12)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value; 217,000,000 shares authorized; 36,122,932 and 36,144,706 shares issued and outstanding at December 31, 2023 and 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and shareholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Grants Non Gaap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of convertible debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on convertible debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on convertible debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Shareholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock returned value shares issued net of tax withholdings .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholdings for taxes related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock returned shares issued net of tax withholdings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Returned Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholdings for taxes related to net share settlement of equity awards, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture of restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock upon vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Common Stock upon vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseFairValueOfLiabilities" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) fair value of liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Fair Value of Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of convertible debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NoncashInterestIncome" xlink:to="armp_NoncashInterestIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest income included in net income that result in no cash inflow</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_NoncashInterestIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest income</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Right of Use Asset And Liability, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) operating lease right-of-use and liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible debt, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of long-term debt, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for taxes related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants and stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Exercise Of Warrants And Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset obtained in exchange for operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents, and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LiquidityAndGoingConcernAbstract" xlink:to="armp_LiquidityAndGoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LiquidityAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity And Going Concern [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LiquidityAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleDebtDisclosureTextBlock" xlink:label="armp_ConvertibleDebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ConvertibleDebtDisclosureTextBlock" xlink:to="armp_ConvertibleDebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAbstract" xlink:label="armp_AwardAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAbstract" xlink:to="armp_AwardAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about award abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Awards</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardTextBlock" xlink:to="armp_AwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">represents about award text block.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retirement Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risks and Certain Other Risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-Process Research and Development ("IPR&amp;D")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translations and Transactions</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GrantsAndAwardsPolicyTextBlock" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about the grants and awards policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants And Awards Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Revenue and Other Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:to="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of useful lives of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets and Liabilities - Derivative Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes in Fair Value of Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrant Information</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of components of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Shares Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assumptions Used in the Black-Scholes Model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-Based Compensation Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) Income from Continuing Operations Before Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Statutory to Effective Tax Rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ArmataPharmaceuticalsInc.Member" xlink:to="armp_ArmataPharmaceuticalsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Armata Pharmaceuticals, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armata Pharmaceuticals, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ArmataPharmaceuticalsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Armata Pharmaceuticals, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_InnovivaStrategicOpportunitiesLlcMember" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innoviva Strategic Opportunities LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding equity (in percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt financing</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfDirectors" xlink:to="armp_NumberOfDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of directors during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Directors</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfBoardDirectors" xlink:to="armp_NumberOfBoardDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfBoardDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board directors during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfBoardDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board Directors</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CommonStockVotingPercentageHeldPercentage" xlink:to="armp_CommonStockVotingPercentageHeldPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Voting Percentage Held Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares (in percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuredTermLoanMember" xlink:to="armp_SecuredTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to secured term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SecuredTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured term loan</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CreditAndSecurityAgreementMember" xlink:to="armp_CreditAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CreditAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to credit and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CreditAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit And Security Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, interest rate, stated percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating segment</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of irrevocable letters of credit with financial institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Standby Letters of Credit included in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letters of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment Loss</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of long lived assets In geographical location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Long Lived Assets In Geographical Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LaboratoryEquipmentMember" xlink:to="armp_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OfficeAndComputerEquipmentMember" xlink:to="armp_OfficeAndComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OfficeAndComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProbabilitiesOfSettlementScenariosMember" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input used to determine value of probability of settlement scenarios.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probabilities of Settlement Scenarios [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probabilities of settlement scenarios</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Option Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DebtInstrumentMeasurementInputForPeriod" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Measurement Input For The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, measurement input, for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPreModificationMember" xlink:label="armp_ConvertibleLoanPreModificationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ConvertibleLoanPreModificationMember" xlink:to="armp_ConvertibleLoanPreModificationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ConvertibleLoanPreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to
Convertible Loan Pre Modification.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ConvertibleLoanPreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan Pre Modification [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ConvertibleLoanPreModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan Pre Modification</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPostModificationMember" xlink:label="armp_ConvertibleLoanPostModificationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ConvertibleLoanPostModificationMember" xlink:to="armp_ConvertibleLoanPostModificationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ConvertibleLoanPostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to
Convertible Loan Post Modification.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ConvertibleLoanPostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan Post Modification [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ConvertibleLoanPostModificationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Loan Post Modification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at September 30, 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net issuance of the Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Initial Recognition of modified Convertible Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial recognition of modified Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Amount Exchanged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount exchanged</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_UnvestedRestrictedStockMember" xlink:to="armp_UnvestedRestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_UnvestedRestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of Convertible Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted weighted shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:to="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of property and equipment not in use included in laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment Not in Use Included in Laboratory Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment not in use</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory and manufacturing equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and Computer Equipment [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Other Types [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land and Building [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_TenantImprovementReceivableCurrent" xlink:to="armp_TenantImprovementReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of current tenant improvement receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvement Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_TenantImprovementReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement allowance receivable (Note 12)</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GrantAndAwardReceivableCurrent" xlink:to="armp_GrantAndAwardReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of awards receivable current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and Award Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_GrantAndAwardReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant and award receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AccruedLiabilitiesClinicalTrial" xlink:to="armp_AccruedLiabilitiesClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AccruedLiabilitiesClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent  of discount on share price for conversion of debt into shares of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Conversion, Percent of Discount on Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount on share price for conversion</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from qualified financing per agreement benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Qualified Financing Per Agreement Benchmark</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from qualified financing per agreement benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement First Tranche [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement First Tranche [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement Second Tranche [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfTranches" xlink:label="armp_NumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfTranches" xlink:to="armp_NumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceThreeMember" xlink:to="armp_ExercisePriceThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Three [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.60</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFourMember" xlink:to="armp_ExercisePriceFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Four [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.87</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFiveMember" xlink:to="armp_ExercisePriceFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Five [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $2.87.</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSixMember" xlink:to="armp_ExercisePriceSixMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Exercise Price Five Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.25.</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSevenMember" xlink:to="armp_ExercisePriceSevenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Seven [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $3.25</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceEightMember" xlink:to="armp_ExercisePriceEightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Eight [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.00</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceNineMember" xlink:to="armp_ExercisePriceNineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price nine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price $5.00.</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceTenMember" xlink:to="armp_ExercisePriceTenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceTenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price ten.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceTenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price 1680.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_WarrantExpirationDate" xlink:to="armp_WarrantExpirationDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the terms related with expiration of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Expiration Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquityIncentivePlan2016Member" xlink:to="armp_EquityIncentivePlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Balance Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Balance Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards/units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for future grants under the 2016 Plan</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issuable upon conversion of convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Conversion Of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon the conversion of Convertible Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares reserved</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockOptionsAndRestrictedStockAwardsMember" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Restricted Stock Awards [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options And Restricted Stock Awards [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EmployeeStockPurchasePlan2016Member" xlink:to="armp_EmployeeStockPurchasePlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 2016 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, 2016</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period of share-based payment award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual increase in number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShareBasedPaymentArrangementExpenseReversed" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ShareBasedPaymentArrangementExpenseReversed" xlink:to="armp_ShareBasedPaymentArrangementExpenseReversed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for award reversed under share-based payment arrangement. Excludes amount capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense, Reversed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of share-based compensation award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of vested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock closing price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining period for recognition of compensation costs related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Vested and expected to vest at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercisable at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercised</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:to="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable at September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_C3jStockPlan2016Member" xlink:to="armp_C3jStockPlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_C3jStockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to C3J 2016 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_C3jStockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C3J Stock Plan 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Issued as Common Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Avg Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Issued as Common Stock (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CommonStockOptionsMember" xlink:to="armp_CommonStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CommonStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CommonStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquitySecuritiesMeasurementInput" xlink:to="armp_EquitySecuritiesMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure investment in equity security measured at fair value for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value input, equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards ("NOLs")</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards that are not subject to expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss not subject to expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and penalties pertaining to income tax examination recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxAssetLeaseObligation" xlink:to="armp_DeferredTaxAssetLeaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax asset lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_DeferredTaxAssetLeaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease accounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets after valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to debt extinguishment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Extinguishment, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of change in federal tax rate</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustment on convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Fair Value Adjustment on Convertible Debt, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustment on convertible debt</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncomeTaxRateReconciliationPermanentDifferences1" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncomeTaxRateReconciliationPermanentDifferences1" xlink:to="armp_IncomeTaxRateReconciliationPermanentDifferences1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the contribution of other permanent differences between reported income tax expense (benefit) and expected income tax expense (benefit) computed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation Permanent Differences 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" xlink:label="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" xlink:to="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office And Research And Development Space Los Angeles California [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_BaseAnnualRentToBePaidYearThree" xlink:to="armp_BaseAnnualRentToBePaidYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount for base rent to be paid in year three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base Annual Rent To Be Paid Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_BaseAnnualRentToBePaidYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base annual rent for 2024</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:to="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum allowance for tenant improvements receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Allowance For Tenant Improvements Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum allowance for tenant improvements</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromTenantAllowances" xlink:label="armp_ProceedsFromTenantAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromTenantAllowances" xlink:to="armp_ProceedsFromTenantAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromTenantAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromTenantAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Tenant Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromTenantAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant allowances</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRent" xlink:label="armp_OperatingLeaseBaseRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLeaseBaseRent" xlink:to="armp_OperatingLeaseBaseRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating lease base rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Base Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expected yearly base rent</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AnnualIncreaseInRentPercentage" xlink:to="armp_AnnualIncreaseInRentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in rent percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Increase in Rent Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in rent percentage</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:to="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of base rent for operating lease at the end of lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Base Rent, End OF Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Base rent at the end of lease term</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LeaseAndRentalAbatementCreditPeriod" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LeaseAndRentalAbatementCreditPeriod" xlink:to="armp_LeaseAndRentalAbatementCreditPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of lease and rental abatement credit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease And Rental Abatement Credit, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of lease and rental abatement credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense under operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letters of Credit Outstanding, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AnnualReductionOfStandbyLetterOfCredit" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual reduction of standby letter of credit..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Reduction Of Standby Letter Of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual reduction of standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShortTermVariableLeasePaymentAmount" xlink:label="armp_ShortTermVariableLeasePaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ShortTermVariableLeasePaymentAmount" xlink:to="armp_ShortTermVariableLeasePaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ShortTermVariableLeasePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short- term variable lease payment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ShortTermVariableLeasePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Variable Lease Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ShortTermVariableLeasePaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plus: estimated short-term variable lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: amount representing interest</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardTable" xlink:label="armp_AwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardTable" xlink:to="armp_AwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about award table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award [Table]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CysticFibrosisFoundationMember" xlink:to="armp_CysticFibrosisFoundationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CysticFibrosisFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cystic Fibrosis Foundation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CysticFibrosisFoundationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cystic Fibrosis Foundation [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical Technology Enterprise Consortium [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medical Technology Enterprise Consortium [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about award line items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ResearchAndDevelopmentBenefit" xlink:label="armp_ResearchAndDevelopmentBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ResearchAndDevelopmentBenefit" xlink:to="armp_ResearchAndDevelopmentBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ResearchAndDevelopmentBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate benefit incurred during the reporting period as a result of research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ResearchAndDevelopmentBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development benefit</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ThresholdDevelopmentAward" xlink:to="armp_ThresholdDevelopmentAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold amount of development award under the award agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Development Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of threshold development award</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardReceivable" xlink:to="armp_AwardReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of the balance sheet date of award receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award receivable</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAgreementInterruptionPeriod" xlink:to="armp_AwardAgreementInterruptionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Agreement, Interruption Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award agreement interruption period</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" xlink:to="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in expected revenue that is not accounted for under Topic 606, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease in Expected Revenue Not from Contract with Customer, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in expected revenue from grants</label>
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnbilledAwardReceivable" xlink:label="armp_UnbilledAwardReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_UnbilledAwardReceivable" xlink:to="armp_UnbilledAwardReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_UnbilledAwardReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unbilled award receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_UnbilledAwardReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unbilled award receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution to 401(k) plan</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>armp-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2024 5:39:19 PM-->
<!--Modified on: 3/21/2024 5:39:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfShareholdersDeficitEquity" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLiquidityAndGoingConcern" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureNetLossPerShare" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureConvertibleDebt" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLongTermDebt" roleURI="http://www.armatapharma.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficit" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlans" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureGrantAndAwards" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEmployeeRetirementPlan" roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsTables" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficitTables" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansTables" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLiquidityAndGoingConcernNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsOtherReceivablesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureConvertibleDebtNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.armatapharma.com/role/DisclosureLongTermDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficitNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesNarrativeDetail" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" roleURI="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureGrantAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="armp-20231231.xsd#DisclosureEmployeeRetirementPlanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638466395567265694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638466395567265694" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638466395567265694" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638466395567265694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638466395567265694" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638466395567265694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638466395567265694" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638466395567265694" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638466395567265694" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638466395567265694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638466395567265694" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638466395567275693" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638466395567275693" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638466395567275693" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638466395567275693" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638466395567275693" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638466395567275693" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638466395567275693" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638466395567275693" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638466395567275693" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638466395567275693" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638466395567275693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638466395567275693" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638466395567285693" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638466395567285693" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638466395567285693" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638466395567285693" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638466395567285693" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638466395567285693" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638466395567285693" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638466395567285693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638466395567285693" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638466395567295692" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638466395567295692" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638466395567295692" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638466395567295692" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638466395567295692" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638466395567295692" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638466395567295692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638466395567295692" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638466395567305695" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638466395567305695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_AssetsCurrentAbstract_638466395567305695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638466395567305695" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567305695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638466395567305695" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638466395567305695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638466395567305695" xlink:to="us-gaap_OtherAssetsCurrent_638466395567305695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638466395567305695" xlink:to="us-gaap_AssetsCurrent_638466395567305695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_RestrictedCashNoncurrent_638466395567305695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638466395567305695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638466395567305695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638466395567305695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638466395567315692" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_Goodwill_638466395567315692" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_OtherAssetsNoncurrent_638466395567315692" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638466395567305695" xlink:to="us-gaap_Assets_638466395567315692" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395567315692" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_638466395567315692" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638466395567315692" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638466395567315692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" xlink:to="us-gaap_OtherLiabilitiesCurrent_638466395567315692" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638466395567315692" xlink:to="us-gaap_LiabilitiesCurrent_638466395567325691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395567325691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638466395567325691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="us-gaap_SecuredLongTermDebt_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_SecuredLongTermDebt_638466395567325691" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638466395567325691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_Liabilities_638466395567325691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_CommitmentsAndContingencies_638466395567325691" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_StockholdersEquityAbstract_638466395567325691" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638466395567325691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638466395567325691" xlink:to="us-gaap_CommonStockValue_638466395567325691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638466395567325691" xlink:to="us-gaap_AdditionalPaidInCapital_638466395567335692" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638466395567325691" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638466395567335692" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638466395567325691" xlink:to="us-gaap_StockholdersEquity_638466395567335692" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638466395567315692" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638466395567335692" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638466395567335692" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638466395567335692" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638466395567335692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638466395567335692" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638466395567345693" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638466395567345693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638466395567345693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638466395567345693" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638466395567345693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638466395567345693" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638466395567345693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638466395567345693" xlink:to="us-gaap_OperatingExpenses_638466395567345693" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638466395567345693" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherExpensesAbstract_638466395567345693" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638466395567345693" xlink:to="us-gaap_InvestmentIncomeInterest_638466395567345693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638466395567345693" xlink:to="us-gaap_InterestExpenseDebt_638466395567345693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638466395567345693" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638466395567345693" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567345693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638466395567345693" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567345693" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_638466395567345693" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638466395567355693" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638466395567355693" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638466395567355693" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638466395567355693" xlink:to="us-gaap_EarningsPerShareBasic_638466395567355693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638466395567355693" xlink:to="us-gaap_EarningsPerShareDiluted_638466395567355693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638466395567355693" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638466395567355693" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638466395567355693" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638466395567355693" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567355693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638466395567355693" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567355693" xlink:to="us-gaap_StatementEquityComponentsAxis_638466395567365697" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638466395567365697" xlink:to="us-gaap_CommonStockMember_638466395567365697" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638466395567365697" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638466395567365697" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638466395567365697" xlink:to="us-gaap_RetainedEarningsMember_638466395567365697" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638466395567365697" xlink:to="us-gaap_EquityComponentDomain_638466395567365697" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567355693" xlink:to="us-gaap_StatementLineItems_638466395567365697" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockholdersEquity_638466395567365697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_SharesOutstanding_638466395567365697" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638466395567365697" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638466395567365697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638466395567365697" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_638466395567365697" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_638466395567365697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638466395567365697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638466395567365697" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_638466395567375695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638466395567375695" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638466395567375695" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638466395567375695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638466395567375695" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638466395567375695" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638466395567375695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638466395567375695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_NetIncomeLoss_638466395567375695" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_StockholdersEquity_638466395567375695" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638466395567375695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567365697" xlink:to="us-gaap_SharesOutstanding_638466395567375695" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638466395567385694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638466395567385694" xlink:to="us-gaap_ProfitLoss_638466395567385694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638466395567385694" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638466395567385694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_ShareBasedCompensation_638466395567385694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638466395567385694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_OtherNoncashExpense_638466395567385694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NoncashInterestIncome" xlink:label="armp_NoncashInterestIncome_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="armp_NoncashInterestIncome_638466395567385694" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567385694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638466395567385694" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638466395567385694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638466395567385694" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638466395567395694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638466395567395694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_638466395567395694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638466395567395694" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395567395694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638466395567385694" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638466395567395694" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638466395567395694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638466395567395694" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638466395567395694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638466395567395694" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638466395567395694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395567395694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638466395567395694" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638466395567395694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638466395567405694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt_638466395567405694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_PaymentsOfFinancingCosts_638466395567405694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638466395567405694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638466395567405694" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_638466395567405694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395567405694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638466395567405694" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638466395567405694" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638466395567525711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638466395567525711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638466395567525711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638466395567525711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384663955675257111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6384663955675257111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638466395567535694" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638466395567535694" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638466395567535694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638466395567535694" xlink:to="us-gaap_ContributionOfProperty_638466395567535694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638466395567535694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638466395567535694" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567535694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638466395567535694" xlink:to="us-gaap_RestrictedCashNoncurrent_638466395567535694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638466395567535694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638466395567535694" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638466395567535694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638466395567545684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638466395567545684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern" xlink:type="extended" xlink:title="10201 - Disclosure - Liquidity and Going Concern" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638466395567545684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAndGoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638466395567545684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638466395567545684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638466395567545684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638466395567545684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638466395567545684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10501 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638466395567555680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638466395567555680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" xlink:type="extended" xlink:title="10601 - Disclosure - Balance Sheet Details" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638466395567555680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638466395567555680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleDebt" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleDebtDisclosureTextBlock" xlink:label="armp_ConvertibleDebtDisclosureTextBlock_638466395567555680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="armp_ConvertibleDebtDisclosureTextBlock_638466395567555680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10801 - Disclosure - Long-Term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638466395567555680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_638466395567555680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit" xlink:type="extended" xlink:title="10901 - Disclosure - Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638466395567565679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638466395567565679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" xlink:type="extended" xlink:title="11001 - Disclosure - Equity Incentive Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638466395567565679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638466395567565679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638466395567565679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638466395567565679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11201 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638466395567565679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638466395567565679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwards" xlink:type="extended" xlink:title="11301 - Disclosure - Grant and Awards" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAbstract" xlink:label="AwardAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardAbstract" xlink:to="armp_AwardTextBlock_638466395567575677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan" xlink:type="extended" xlink:title="11401 - Disclosure - Employee Retirement Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638466395567575677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638466395567575677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638466395567575677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638466395567575677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638466395567575677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638466395567575677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638466395567585682" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638466395567585682" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638466395567585682" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638466395567585682" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638466395567585682" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_638466395567585682" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638466395567585682" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638466395567585682" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638466395567585682" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638466395567585682" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_638466395567585682" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638466395567585682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638466395567585682" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638466395567595678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638466395567595678" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638466395567595678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638466395567595678" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638466395567595678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638466395567595678" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638466395567595678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638466395567595678" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PropertyAndEquipmentUsefulLifeTableTextBlock" xlink:label="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_638466395567595678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="armp_PropertyAndEquipmentUsefulLifeTableTextBlock_638466395567595678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638466395567605678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638466395567605678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638466395567605678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638466395567605678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30503 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638466395567605678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638466395567605678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Balance Sheet Details (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638466395567605678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638466395567605678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638466395567605678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638466395567605678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders' Equity (Deficit) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638466395567615678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_638466395567615678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" xlink:type="extended" xlink:title="31003 - Disclosure - Equity Incentive Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638466395567615678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638466395567615678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638466395567615678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_638466395567615678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638466395567615678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638466395567615678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638466395567625678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638466395567625678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Description of the Business (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567625678" xlink:to="srt_OwnershipAxis_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638466395567625678" xlink:to="srt_OwnershipDomain_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ArmataPharmaceuticalsInc.Member" xlink:label="armp_ArmataPharmaceuticalsInc.Member_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638466395567625678" xlink:to="armp_ArmataPharmaceuticalsInc.Member_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567625678" xlink:to="dei_LegalEntityAxis_638466395567625678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638466395567625678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638466395567625678" xlink:to="dei_EntityDomain_638466395567625678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638466395567625678" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567635679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567625678" xlink:to="srt_RangeAxis_638466395567635679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395567635679" xlink:to="srt_RangeMember_638466395567635679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567635679" xlink:to="srt_MinimumMember_638466395567635679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567625678" xlink:to="us-gaap_StatementLineItems_638466395567635679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638466395567635679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638466395567635679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638466395567635679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfDirectors" xlink:label="armp_NumberOfDirectors_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="armp_NumberOfDirectors_638466395567635679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfBoardDirectors" xlink:label="armp_NumberOfBoardDirectors_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="armp_NumberOfBoardDirectors_638466395567635679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockVotingPercentageHeldPercentage" xlink:label="armp_CommonStockVotingPercentageHeldPercentage_638466395567635679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567635679" xlink:to="armp_CommonStockVotingPercentageHeldPercentage_638466395567635679" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LiquidityAndGoingConcernAbstract" xlink:label="armp_LiquidityAndGoingConcernAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAndGoingConcernAbstract_2" xlink:to="us-gaap_StatementTable_638466395567645690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567645690" xlink:to="srt_CounterpartyNameAxis_638466395567645690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638466395567645690" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567645690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567645690" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567645690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567645690" xlink:to="us-gaap_DebtInstrumentAxis_638466395567645690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638466395567645690" xlink:to="us-gaap_DebtInstrumentNameDomain_638466395567645690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638466395567645690" xlink:to="armp_SecuredTermLoanMember_638466395567645690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CreditAndSecurityAgreementMember" xlink:label="armp_CreditAndSecurityAgreementMember_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638466395567645690" xlink:to="armp_CreditAndSecurityAgreementMember_638466395567645690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567645690" xlink:to="us-gaap_SubsequentEventTypeAxis_638466395567645690" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638466395567645690" xlink:to="us-gaap_SubsequentEventTypeDomain_638466395567645690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638466395567645690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638466395567645690" xlink:to="us-gaap_SubsequentEventMember_638466395567645690" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567645690" xlink:to="us-gaap_StatementLineItems_638466395567655684" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567655684" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638466395567655684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567655684" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638466395567655684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567655684" xlink:to="us-gaap_DebtInstrumentFaceAmount_638466395567655684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567655684" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567655684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Significant Accounting Policies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638466395567655684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567655684" xlink:to="srt_ProductOrServiceAxis_638466395567655684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638466395567655684" xlink:to="srt_ProductsAndServicesDomain_638466395567655684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638466395567655684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638466395567655684" xlink:to="us-gaap_GrantMember_638466395567655684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567655684" xlink:to="srt_StatementGeographicalAxis_638466395567665684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638466395567665684" xlink:to="srt_SegmentGeographicalDomain_638466395567665684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638466395567665684" xlink:to="country_US_638466395567665684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567655684" xlink:to="us-gaap_StatementLineItems_638466395567665684" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_NumberOfOperatingSegments_638466395567665684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash" xlink:label="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash_638466395567665684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638466395567665684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_638466395567665684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_GoodwillImpairmentLoss_638466395567665684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_OtherAssetsCurrent_638466395567665684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638466395567665684" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PercentageOfLongLivedAssetsInGeographicalLocation" xlink:label="armp_PercentageOfLongLivedAssetsInGeographicalLocation_638466395567665684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567665684" xlink:to="armp_PercentageOfLongLivedAssetsInGeographicalLocation_638466395567665684" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567675674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567675674" xlink:to="srt_RangeAxis_638466395567675674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395567675674" xlink:to="srt_RangeMember_638466395567675674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567675674" xlink:to="srt_MinimumMember_638466395567675674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567675674" xlink:to="srt_MaximumMember_638466395567675674" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567675674" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567675674" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567675674" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567675674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LaboratoryEquipmentMember" xlink:label="armp_LaboratoryEquipmentMember_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567675674" xlink:to="armp_LaboratoryEquipmentMember_638466395567675674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndComputerEquipmentMember" xlink:label="armp_OfficeAndComputerEquipmentMember_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567675674" xlink:to="armp_OfficeAndComputerEquipmentMember_638466395567675674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567675674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567675674" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567675674" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567675674" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638466395567685680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567675674" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638466395567685680" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638466395567685680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure_638466395567685680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567685680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567685680" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567685680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567685680" xlink:to="us-gaap_FairValueInputsLevel3Member_638466395567685680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638466395567685680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" xlink:to="us-gaap_MeasurementInputTypeAxis_638466395567685680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638466395567685680" xlink:to="us-gaap_MeasurementInputTypeDomain_638466395567695679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567695679" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638466395567695679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProbabilitiesOfSettlementScenariosMember" xlink:label="armp_ProbabilitiesOfSettlementScenariosMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567695679" xlink:to="armp_ProbabilitiesOfSettlementScenariosMember_638466395567695679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567695679" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_638466395567695679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567695679" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638466395567695679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567695679" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638466395567695679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" xlink:to="srt_RangeAxis_638466395567695679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395567695679" xlink:to="srt_RangeMember_638466395567695679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567695679" xlink:to="srt_MinimumMember_638466395567695679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567695679" xlink:to="srt_MaximumMember_638466395567695679" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638466395567685680" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638466395567695679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentMeasurementInputForPeriod" xlink:label="armp_DebtInstrumentMeasurementInputForPeriod_638466395567695679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638466395567695679" xlink:to="armp_DebtInstrumentMeasurementInputForPeriod_638466395567695679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638466395567705674" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638466395567705674" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638466395567705674" xlink:to="us-gaap_FairValueInputsLevel3Member_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638466395567705674" xlink:to="us-gaap_FinancialInstrumentAxis_638466395567705674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638466395567705674" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPreModificationMember" xlink:label="armp_ConvertibleLoanPreModificationMember_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638466395567705674" xlink:to="armp_ConvertibleLoanPreModificationMember_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ConvertibleLoanPostModificationMember" xlink:label="armp_ConvertibleLoanPostModificationMember_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638466395567705674" xlink:to="armp_ConvertibleLoanPostModificationMember_638466395567705674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638466395567705674" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638466395567705674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638466395567705674" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638466395567715678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638466395567715678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan_638466395567715678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_638466395567715678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged" xlink:label="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged_638466395567715678" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638466395567715678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6384663955677156781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638466395567705674" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6384663955677156781" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638466395567715678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638466395567715678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638466395567715678" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638466395567725683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638466395567725683" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" xlink:to="us-gaap_StockOptionMember_638466395567725683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnvestedRestrictedStockMember" xlink:label="armp_UnvestedRestrictedStockMember_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" xlink:to="armp_UnvestedRestrictedStockMember_638466395567725683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" xlink:to="us-gaap_RestrictedStockMember_638466395567725683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleLoanMember" xlink:label="armp_SharesIssuableUponConversionOfConvertibleLoanMember_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" xlink:to="armp_SharesIssuableUponConversionOfConvertibleLoanMember_638466395567725683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638466395567725683" xlink:to="us-gaap_WarrantMember_638466395567725683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638466395567715678" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638466395567725683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638466395567725683" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638466395567725683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Details (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation_638466395567725683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment" xlink:label="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_638466395567725683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment_638466395567725683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567735680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567735680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567735680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567735680" xlink:to="us-gaap_MachineryAndEquipmentMember_638466395567735680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_638466395567735680" xlink:to="us-gaap_TechnologyEquipmentMember_638466395567735680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_638466395567735680" xlink:to="us-gaap_OfficeEquipmentMember_638466395567735680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638466395567735680" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_638466395567735680" xlink:to="us-gaap_FurnitureAndFixturesMember_638466395567735680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567735680" xlink:to="us-gaap_LandAndBuildingMember_638466395567735680" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LandAndBuildingMember_638466395567735680" xlink:to="us-gaap_LeaseholdImprovementsMember_638466395567735680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567735680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567735680" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638466395567745686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567735680" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638466395567745686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638466395567735680" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638466395567745686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Details (Other receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_TenantImprovementReceivableCurrent" xlink:label="armp_TenantImprovementReceivableCurrent_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_TenantImprovementReceivableCurrent_638466395567745686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_GrantAndAwardReceivableCurrent" xlink:label="armp_GrantAndAwardReceivableCurrent_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_GrantAndAwardReceivableCurrent_638466395567745686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_638466395567745686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableCurrent_638466395567745686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AccruedLiabilitiesClinicalTrial" xlink:label="armp_AccruedLiabilitiesClinicalTrial_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="armp_AccruedLiabilitiesClinicalTrial_638466395567745686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638466395567745686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_638466395567745686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638466395567755683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_1" xlink:to="us-gaap_StatementTable_638466395567755683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567755683" xlink:to="srt_CounterpartyNameAxis_638466395567755683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638466395567755683" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567755683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567755683" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567755683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567755683" xlink:to="us-gaap_DebtInstrumentAxis_638466395567755683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638466395567755683" xlink:to="us-gaap_DebtInstrumentNameDomain_638466395567755683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638466395567755683" xlink:to="armp_SecuredTermLoanMember_638466395567755683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567755683" xlink:to="us-gaap_StatementLineItems_638466395567755683" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="us-gaap_DebtInstrumentFaceAmount_638466395567755683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567755683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567755683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638466395567765680" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice" xlink:label="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice_638466395567765680" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark" xlink:label="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark_638466395567765680" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseFairValueOfLiabilities" xlink:label="armp_IncreaseDecreaseFairValueOfLiabilities_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="armp_IncreaseDecreaseFairValueOfLiabilities_638466395567765680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567755683" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638466395567765680" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638466395567765680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638466395567765680" xlink:to="us-gaap_DebtInstrumentAxis_638466395567765680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638466395567765680" xlink:to="us-gaap_DebtInstrumentNameDomain_638466395567765680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuredTermLoanMember" xlink:label="armp_SecuredTermLoanMember_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638466395567765680" xlink:to="armp_SecuredTermLoanMember_638466395567765680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638466395567765680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638466395567765680" xlink:to="srt_CounterpartyNameAxis_638466395567765680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638466395567765680" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567775678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567775678" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567775678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638466395567765680" xlink:to="us-gaap_DebtInstrumentLineItems_638466395567775678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_DebtInstrumentFaceAmount_638466395567775678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638466395567775678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_LongTermDebtFairValue_638466395567775678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638466395567775678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638466395567775678" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638466395567775678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638466395567775678" xlink:to="us-gaap_InterestExpenseDebt_638466395567775678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity (Deficit) (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638466395567785682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638466395567785682" xlink:to="srt_CounterpartyNameAxis_638466395567785682" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638466395567785682" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638466395567785682" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638466395567785682" xlink:to="us-gaap_StatementEquityComponentsAxis_638466395567785682" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638466395567785682" xlink:to="us-gaap_EquityComponentDomain_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638466395567785682" xlink:to="us-gaap_CommonStockMember_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638466395567785682" xlink:to="us-gaap_TypeOfArrangementAxis_638466395567785682" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638466395567785682" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638466395567785682" xlink:to="armp_SecuritiesPurchaseAgreementMember_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_638466395567785682" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember_638466395567785682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_638466395567785682" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember_638466395567785682" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638466395567785682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638466395567785682" xlink:to="us-gaap_ClassOfStockLineItems_638466395567785682" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638466395567785682" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638466395567795677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638466395567785682" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638466395567795677" order="2" use="optional" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638466395567785682" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638466395567795677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_NumberOfTranches" xlink:label="armp_NumberOfTranches_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638466395567785682" xlink:to="armp_NumberOfTranches_638466395567795677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638466395567785682" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638466395567795677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567795677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567795677" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638466395567795677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638466395567795677" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceThreeMember_638466395567805677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceFourMember_638466395567805677" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceFiveMember_638466395567805677" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceSixMember_638466395567805677" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceSevenMember_638466395567805677" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceEightMember_638466395567805677" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceNineMember" xlink:label="armp_ExercisePriceNineMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceNineMember_638466395567805677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ExercisePriceTenMember" xlink:label="armp_ExercisePriceTenMember_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638466395567795677" xlink:to="armp_ExercisePriceTenMember_638466395567805677" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567795677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567805677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567805677" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638466395567805677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567805677" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638466395567805677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate_638466395567805677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567805677" xlink:to="armp_WarrantExpirationDate_638466395567805677" order="3" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567815677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567815677" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567815677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567815677" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567815677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567815677" xlink:to="armp_EquityIncentivePlan2016Member_638466395567815677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567815677" xlink:to="us-gaap_AwardTypeAxis_638466395567815677" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638466395567815677" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567815677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567815677" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638466395567815677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567815677" xlink:to="us-gaap_RestrictedStockMember_638466395567815677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567815677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395567815677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395567815677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395567825678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_638466395567825678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395567825678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638466395567825678" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_SharesIssuableUponConversionOfConvertibleDebt" xlink:label="armp_SharesIssuableUponConversionOfConvertibleDebt_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="armp_SharesIssuableUponConversionOfConvertibleDebt_638466395567825678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567815677" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638466395567825678" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Equity Incentive Plans (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638466395567825678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567825678" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567825678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567825678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_638466395567825678" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567825678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_638466395567825678" xlink:to="armp_EquityIncentivePlan2016Member_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567825678" xlink:to="us-gaap_AwardTypeAxis_638466395567835680" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638466395567835680" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567835680" xlink:to="us-gaap_EmployeeStockOptionMember_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567835680" xlink:to="us-gaap_RestrictedStockMember_638466395567835680" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567835680" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_638466395567835680" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567825678" xlink:to="srt_RangeAxis_638466395567835680" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395567835680" xlink:to="srt_RangeMember_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567835680" xlink:to="srt_MinimumMember_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567835680" xlink:to="srt_MaximumMember_638466395567835680" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567825678" xlink:to="us-gaap_PlanNameAxis_638466395567835680" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638466395567835680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638466395567835680" xlink:to="us-gaap_PlanNameDomain_638466395567835680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638466395567835680" xlink:to="armp_EquityIncentivePlan2016Member_638466395567845673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EmployeeStockPurchasePlan2016Member" xlink:label="armp_EmployeeStockPurchasePlan2016Member_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638466395567835680" xlink:to="armp_EmployeeStockPurchasePlan2016Member_638466395567845673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567825678" xlink:to="us-gaap_StatementLineItems_638466395567845673" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638466395567845673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638466395567845673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638466395567845673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638466395567845673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShareBasedPaymentArrangementExpenseReversed" xlink:label="armp_ShareBasedPaymentArrangementExpenseReversed_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="armp_ShareBasedPaymentArrangementExpenseReversed_638466395567845673" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638466395567845673" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638466395567845673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638466395567845673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638466395567855674" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638466395567855674" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638466395567855674" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_SharePrice_638466395567855674" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638466395567855674" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638466395567855674" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638466395567855674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567845673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638466395567855674" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638466395567865673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638466395567865673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638466395567865673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638466395567865673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384663955678656731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384663955678656731" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638466395567865673" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638466395567865673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638466395567865673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638466395567865673" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638466395567875688" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638466395567875688" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638466395567875688" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638466395567875688" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638466395567875688" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638466395567875688" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638466395567875688" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638466395567875688" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638466395567875688" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638466395567875688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638466395567875688" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638466395567885673" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue" xlink:label="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue_638466395567885673" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638466395567885673" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638466395567885673" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638466395567885673" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567885673" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638466395567885673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567885673" xlink:to="us-gaap_AwardTypeAxis_638466395567885673" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638466395567885673" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567895677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638466395567895677" xlink:to="us-gaap_RestrictedStockMember_638466395567895677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567885673" xlink:to="us-gaap_PlanNameAxis_638466395567895677" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638466395567895677" xlink:to="us-gaap_PlanNameDomain_638466395567895677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_C3jStockPlan2016Member" xlink:label="armp_C3jStockPlan2016Member_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638466395567895677" xlink:to="armp_C3jStockPlan2016Member_638466395567895677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638466395567885673" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567895677" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638466395567895677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638466395567895677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638466395567895677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638466395567895677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638466395567895677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384663955678956771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384663955678956771" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638466395567895677" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638466395567905674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638466395567905674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638466395567905674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638466395567905674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384663955679056741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638466395567905674" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384663955679056741" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638466395567905674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395567905674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567905674" xlink:to="srt_RangeAxis_638466395567905674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395567905674" xlink:to="srt_RangeMember_638466395567915679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567915679" xlink:to="srt_MinimumMember_638466395567915679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395567915679" xlink:to="srt_MaximumMember_638466395567915679" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567905674" xlink:to="us-gaap_StatementClassOfStockAxis_638466395567915679" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638466395567915679" xlink:to="us-gaap_ClassOfStockDomain_638466395567915679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CommonStockOptionsMember" xlink:label="armp_CommonStockOptionsMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638466395567915679" xlink:to="armp_CommonStockOptionsMember_638466395567915679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567905674" xlink:to="us-gaap_MeasurementInputTypeAxis_638466395567915679" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638466395567915679" xlink:to="us-gaap_MeasurementInputTypeDomain_638466395567915679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567915679" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638466395567915679" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567915679" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638466395567915679" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567915679" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638466395567915679" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638466395567915679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638466395567915679" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638466395567915679" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567905674" xlink:to="us-gaap_StatementLineItems_638466395567925674" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567925674" xlink:to="armp_EquitySecuritiesMeasurementInput_638466395567925674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638466395567925674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567925674" xlink:to="us-gaap_IncomeStatementLocationAxis_638466395567925674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638466395567925674" xlink:to="us-gaap_IncomeStatementLocationDomain_638466395567925674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638466395567925674" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638466395567925674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638466395567925674" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638466395567925674" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567925674" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638466395567925674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638466395567925674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638466395567925674" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638466395567925674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Narrative) (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638466395567935686" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567935686" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638466395567935686" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638466395567935686" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638466395567935686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638466395567935686" xlink:to="us-gaap_DomesticCountryMember_638466395567935686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638466395567935686" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638466395567935686" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567935686" xlink:to="us-gaap_StatementLineItems_638466395567935686" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="us-gaap_OperatingLossCarryforwards_638466395567935686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="armp_OperatingLossCarryforwardsNotSubjectToExpiration_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="armp_OperatingLossCarryforwardsNotSubjectToExpiration_638466395567935686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638466395567935686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="us-gaap_UnrecognizedTaxBenefits_638466395567935686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638466395567935686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638466395567935686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567935686" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395567945676" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638466395567945676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638466395567945676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638466395567945676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638466395567945676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638466395567945676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638466395567945676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638466395567945676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638466395567945676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxAssetLeaseObligation" xlink:label="armp_DeferredTaxAssetLeaseObligation_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="armp_DeferredTaxAssetLeaseObligation_638466395567955679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsOther_638466395567955679" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsGross_638466395567955679" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638466395567955679" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638466395567945676" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638466395567955679" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="armp_DeferredTaxLiabilitiesRightOfUseAsset_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" xlink:to="armp_DeferredTaxLiabilitiesRightOfUseAsset_638466395567955679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638466395567955679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638466395567955679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638466395567955679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638466395567955679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638466395567955679" xlink:to="us-gaap_DeferredTaxLiabilities_638466395567955679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638466395567965674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638466395567965674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638466395567965674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638466395567965674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent_638466395567965674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638466395567965674" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent" xlink:label="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent_638466395567965674" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncomeTaxRateReconciliationPermanentDifferences1" xlink:label="armp_IncomeTaxRateReconciliationPermanentDifferences1_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="armp_IncomeTaxRateReconciliationPermanentDifferences1_638466395567965674" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6384663955679656741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_6384663955679656741" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638466395567965674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638466395567965674" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_638466395567975683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567975683" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638466395567975683" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638466395567975683" xlink:to="us-gaap_CashMember_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567975683" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567975683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638466395567975683" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember" xlink:label="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638466395567975683" xlink:to="armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638466395567975683" xlink:to="us-gaap_StatementLineItems_638466395567975683" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_638466395567975683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_BaseAnnualRentToBePaidYearThree" xlink:label="armp_BaseAnnualRentToBePaidYearThree_638466395567975683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_BaseAnnualRentToBePaidYearThree_638466395567975683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_MaximumAllowanceForTenantImprovementsReceivable_638466395567985678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ProceedsFromTenantAllowances" xlink:label="armp_ProceedsFromTenantAllowances_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_ProceedsFromTenantAllowances_638466395567985678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRent" xlink:label="armp_OperatingLeaseBaseRent_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_OperatingLeaseBaseRent_638466395567985678" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_AnnualIncreaseInRentPercentage_638466395567985678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_OperatingLeaseBaseRentEndOfLeaseTerm_638466395567985678" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_LeaseAndRentalAbatementCreditPeriod" xlink:label="armp_LeaseAndRentalAbatementCreditPeriod_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_LeaseAndRentalAbatementCreditPeriod_638466395567985678" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638466395567985678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_OperatingLeaseExpense_638466395567985678" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638466395568045688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_OperatingLeasePayments_638466395568045688" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_OperatingLeaseLiability_638466395568055711" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638466395568055711" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638466395568055711" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_638466395568055711" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AnnualReductionOfStandbyLetterOfCredit" xlink:label="armp_AnnualReductionOfStandbyLetterOfCredit_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="armp_AnnualReductionOfStandbyLetterOfCredit_638466395568055711" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395568055711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638466395567975683" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638466395568055711" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638466395568065695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638466395568065695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638466395568065695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638466395568065695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638466395568065695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638466395568065695" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638466395568065695" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ShortTermVariableLeasePaymentAmount" xlink:label="armp_ShortTermVariableLeasePaymentAmount_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="armp_ShortTermVariableLeasePaymentAmount_638466395568065695" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638466395568065695" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638466395568065695" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638466395568065695" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395568065695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638466395568065695" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Grant and Awards (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAbstract" xlink:label="AwardAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardTable" xlink:label="armp_AwardTable_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardAbstract" xlink:to="armp_AwardTable_638466395568075678" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_638466395568075678" xlink:to="srt_RangeAxis_638466395568075678" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638466395568075678" xlink:to="srt_RangeMember_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638466395568075678" xlink:to="srt_MaximumMember_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_638466395568075678" xlink:to="dei_LegalEntityAxis_638466395568075678" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638466395568075678" xlink:to="dei_EntityDomain_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638466395568075678" xlink:to="armp_CysticFibrosisFoundationMember_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_638466395568075678" xlink:to="srt_CounterpartyNameAxis_638466395568075678" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638466395568075678" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_638466395568075678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638466395568075678" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_638466395568075678" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_638466395568075678" xlink:to="armp_AwardLineItems_638466395568085683" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638466395568085683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ResearchAndDevelopmentBenefit" xlink:label="armp_ResearchAndDevelopmentBenefit_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_ResearchAndDevelopmentBenefit_638466395568085683" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_ThresholdDevelopmentAward_638466395568085683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_AwardReceivable_638466395568085683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_AwardAgreementInterruptionPeriod_638466395568085683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther" xlink:label="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther_638466395568085683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20231231.xsd#armp_UnbilledAwardReceivable" xlink:label="armp_UnbilledAwardReceivable_638466395568085683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_638466395568085683" xlink:to="armp_UnbilledAwardReceivable_638466395568085683" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Employee Retirement Plan (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638466395568095679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638466395568095679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523925070896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARMATA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1549568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5005 McConnell Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">665-2928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARMP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,148,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903119248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,523<span></span>
</td>
<td class="nump">$ 14,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,265<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">8,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,151<span></span>
</td>
<td class="nump">27,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,559<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">44,717<span></span>
</td>
<td class="nump">43,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">10,256<span></span>
</td>
<td class="nump">10,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,470<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">98,363<span></span>
</td>
<td class="nump">95,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">5,689<span></span>
</td>
<td class="nump">6,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">9,481<span></span>
</td>
<td class="nump">17,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,461<span></span>
</td>
<td class="nump">24,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">28,583<span></span>
</td>
<td class="nump">31,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt</a></td>
<td class="nump">58,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt</a></td>
<td class="nump">23,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">130,428<span></span>
</td>
<td class="nump">59,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 217,000,000 shares authorized; 36,122,932 and 36,144,706 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">276,393<span></span>
</td>
<td class="nump">275,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(308,819)<span></span>
</td>
<td class="num">(239,774)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' (deficit) equity</a></td>
<td class="num">(32,065)<span></span>
</td>
<td class="nump">36,080<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' (deficit) equity</a></td>
<td class="nump">$ 98,363<span></span>
</td>
<td class="nump">$ 95,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903156688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">217,000,000<span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,122,932<span></span>
</td>
<td class="nump">36,144,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,122,932<span></span>
</td>
<td class="nump">36,144,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906032576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 5,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">33,770<span></span>
</td>
<td class="nump">35,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,649<span></span>
</td>
<td class="nump">7,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">45,419<span></span>
</td>
<td class="nump">42,454<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,890)<span></span>
</td>
<td class="num">(36,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(2,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of convertible debt</a></td>
<td class="num">(21,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible debt extinguishment</a></td>
<td class="num">(3,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(28,155)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (69,045)<span></span>
</td>
<td class="num">$ (36,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">36,075,555<span></span>
</td>
<td class="nump">34,294,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,075,555<span></span>
</td>
<td class="nump">34,294,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523923425216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 227,983<span></span>
</td>
<td class="num">$ (202,857)<span></span>
</td>
<td class="nump">$ 25,397<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">27,112,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">44,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards, shares</a></td>
<td class="num">(5,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">38,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,917)<span></span>
</td>
<td class="num">(36,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">275,493<span></span>
</td>
<td class="num">(239,774)<span></span>
</td>
<td class="nump">36,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="nump">36,144,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Withholdings for taxes related to net share settlement of equity awards, shares</a></td>
<td class="num">(25,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(27,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Common Stock upon vesting of restricted stock units, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
<td class="num">(69,045)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 276,393<span></span>
</td>
<td class="num">$ (308,819)<span></span>
</td>
<td class="num">$ (32,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">36,122,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned shares issued net of tax withholdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned value shares issued net of tax withholdings .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903550064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (69,045)<span></span>
</td>
<td class="num">$ (36,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">3,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of convertible debt</a></td>
<td class="nump">21,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NoncashInterestIncome', window );">Non-cash interest income</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible debt extinguishment</a></td>
<td class="nump">3,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Change in right-of-use asset</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss from disposal of property and equipment</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">4,826<span></span>
</td>
<td class="num">(7,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Accrued compensation</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(13,451)<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(47,423)<span></span>
</td>
<td class="num">(32,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(8,144)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,134)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of issuance costs</a></td>
<td class="nump">29,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of long-term debt, net of issuance costs</a></td>
<td class="nump">24,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">53,988<span></span>
</td>
<td class="nump">44,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,569)<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">20,812<span></span>
</td>
<td class="nump">11,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">19,243<span></span>
</td>
<td class="nump">20,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">8,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseFairValueOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseFairValueOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NoncashInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income included in net income that result in no cash inflow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NoncashInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromExerciseOfWarrantsAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906262176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,523<span></span>
</td>
<td class="nump">$ 14,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 19,243<span></span>
</td>
<td class="nump">$ 20,812<span></span>
</td>
<td class="nump">$ 11,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906054960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;) together with its subsidiaries (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on </span>the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Armata&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;) is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s principal stockholder, <span style="font-family:'Times New Roman;">Innoviva Strategic Opportunities LLC (&#8220;Innoviva SO&#8221;), a wholly owned subsidiary of </span>Innoviva Inc. (&#8220;Innoviva&#8221;), owns 69.4% of the Company&#8217;s outstanding equity as of December 31, 2023. The Company also received $90.0 million in total debt financing from <span style="font-family:'Times New Roman;">Innoviva SO</span> during 2023 and in March 2024. Innoviva designees represent three out of eight Board of Directors seats during the year ended December 31, 2023, and cannot vote or take any action by written consent with respect to any shares of common stock held by Innoviva SO that represent, in the aggregate, more than 49.5% of the total number of shares of the Company&#8217;s Common Stock for voting on the matters related to election or removal of the Company&#8217;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the board of the Company in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#8217;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#8220;FDA&#8221;) of any of the Company&#8217;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809809744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_LiquidityAndGoingConcernAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2023, the Company had an accumulated deficit of $308.8 million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $13.5 million as of December 31, 2023, together with a $35.0 million loan received from Innoviva in March 2024, will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent Financing:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-family:'Times New Roman;font-style:italic;">2024 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">On March 4, 2024, the Company entered into a credit and security agreement (the &#8220;2024 Credit Agreement&#8221;) for a loan in an aggregate amount of </span><span style="font-family:'Times New Roman;">$35.0</span><span style="font-family:'Times New Roman;"> million with Innoviva SO. The 2024 loan bears interest at an annual rate of </span><span style="font-family:'Times New Roman;">14%</span><span style="font-family:'Times New Roman;"> and matures on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the loan is secured by substantially all of the assets </span><span style="background:#ffffff;">of the Company and the subsidiary guarantors</span><span style="font-family:'Times New Roman;">. Concurrently with the execution of the 2024 loan, we amended certain provisions of the Convertible Loan and Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 10, 2023, the Company entered into a credit and security agreement (the &#8220;Credit Agreement&#8221;) for a loan in an aggregate amount of $25.0 million (the &#8220;Loan&#8221;) with Innoviva SO. The Loan bears interest at an annual rate of 14% and matures on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. See Note 8, <i style="font-style:italic;">&#8220;Long Term debt&#8221;</i>, for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Convertible Credit Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company entered into a secured convertible credit and security agreement (the &#8220;Convertible Credit Agreement&#8221;) with Innoviva SO. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30.0 million (the &#8220;Convertible Loan&#8221;), which bears interest at a rate of 8.0% per annum and was scheduled to mature on January 10, 2024. Concurrently with the execution of the Credit Agreement, the Company amended certain provisions of the Convertible Credit Agreement to, among other changes, extend the term of the Convertible Loan to January 10, 2025. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The Convertible Credit Agreement provides for various conversion and repayment options, including the conversion of principal and accrued interest into the shares of the Company&#8217;s Common Stock upon a Qualified Financing (as defined below) and the Company&#8217;s option to repay the loan prior to maturity. See Note 7, </span><i style="font-style:italic;">&#8220;Convertible debt&#8221;</i>, for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LiquidityAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity And Going Concern [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LiquidityAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523810149888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The Company operates and manages its business as </span><span style="background:#ffffff;">one</span><span style="background:#ffffff;"> reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. The long-lived assets of </span><span style="background:#ffffff;">$12.4</span><span style="background:#ffffff;"> million, which represents </span><span style="background:#ffffff;">98.8%</span><span style="background:#ffffff;"> of the Company&#8217;s total long-lived assets, are maintained in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, convertible debt and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Convertible debt is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;padding-top:8pt;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2023 or 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">  IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2023 and 2022, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a result of the quantitative analysis. Consequently, no impairment loss was recognized as of December 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the Company recognized as other receivables in its consolidated balance sheets $1.5 million and $1.9 million, respectively, related to invoiced grant amounts that have not been received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2023 and 2022, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments</i><span style="color:#212529;background:#ffffff;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203;&#160;</i>(&#8220;ASU 2020-06&#8221;)<i style="font-style:italic;">.</i>&#160;&#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">contracts that may be settled in cash or shares impact the diluted earnings per share computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809364048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:29.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents include investments in a money market fund of zero and $0.5 million as of December 31, 2023 and 2022, respectively, which are carried at fair value and represent Level 1 financial instruments under the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company&#8217;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">models with assumptions and estimates such as volatility, expected term and risk-free interest rates. Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;">The Company estimated fair value of its Convertible Loan using the following inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:21.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21.01%-45.88%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0%-85%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 101.1%-123.6%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.2-1.5</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.62%-5.39%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Post Modification</b></p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net proceeds from issuance of the Convertible Loan  (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,031</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,757)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,602</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Convertible Loan exchanged  (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the determination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903090496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities at December 31, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,352,803</p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 99,666</p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,549,338</p></td></tr><tr style="height:15.35pt;"><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,024,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,031,807</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523813580768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,007</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 449</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,720</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,103)</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,617</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense totaled $1.0 million and $0.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. Property and equipment not in use was $8.1 million and $1.0 million as of December 31, 2023 and 2022, respectively, and are included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other receivables as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tenant improvement allowance receivable (Note 12)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,835</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,595</p></td></tr><tr><td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant and award receivable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,528</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,936</p></td></tr><tr><td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,363</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,531</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Payable and Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,678</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,021</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,650</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,083</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,706</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,689</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,034</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906054960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ConvertibleDebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Convertible Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2023, the Company received the Convertible Loan in the aggregated amount of $30.0&#160;million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of&#160;8.0% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Credit Agreement with Innoviva to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#8217;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;The Convertible Credit Agreement provides that if there is a financing from new investors of at least $30.0&#160;million (a &#8220;Qualified Financing&#8221;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Loan shall be converted into shares of the Company&#8217;s Common Stock, at a price per share equal to a&#160;15.0% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#8217;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was market value of $1.52&#160;(as may be appropriately adjusted for any stock split, combination or similar act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, <i style="font-style:italic;">Distinguish Liabilities from Equity</i>, due to the fact that the Convertible Loan will predominately be settled with the Company&#8217;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 10, 2023, in connection with the Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $1.8&#160;million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $3.9&#160;million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized a $23.6&#160;million loss as the change in fair value of the Convertible Loan from July 10, 2023 to December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ConvertibleDebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ConvertibleDebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523814069296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Long-Term Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">On July 10, 2023, the Company entered into the Credit Agreement with Innoviva. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25.0&#160;million at an interest rate of&#160;14.0% per annum and has a maturity date of January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#8217;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#8220;material adverse effect&#8221; as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#8217;s operating budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Loan was initially recognized at fair value of $21.2&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $3.8 million. Debt issuance costs and debt discount in the amount of $0.9&#160;million were amortized to interest expense using the effective interest method during the year ended December 31, 2023 . The Loan&#8217;s annual effective interest rate was&#160;27.31% as of December 31, 2023. The Company recognized $2.6 million interest expense for the year ended December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523808156496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Investment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">February 2022 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On February 9, 2022, the Company entered into the February 2022 Securities Purchase Agreement to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase&#160;9,000,000&#160;newly issued shares of the Company&#8217;s Common Stock, at a price of&#160;$5.00&#160;per share, and warrants to purchase up to&#160;4,500,000&#160;additional shares of Common Stock, with an exercise price of&#160;$5.00&#160;per share. The stock purchases occurred in&#160;two&#160;tranches. On February 9, 2022, Innoviva purchased&#160;3,614,792&#160;shares of Common Stock and warrants to purchase&#160;1,807,396&#160;shares of Common Stock for an aggregate purchase price of approximately&#160;$18.1&#160;million. On March 31, 2022, upon the Company&#8217;s stockholders voting in favor of the transaction, Innoviva purchased&#160;5,385,208&#160;shares of Common Stock and warrants to purchase&#160;2,692,604&#160;shares of Common Stock for an aggregate purchase price of&#160;$26.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Warrants issued to Innoviva expire in five years&#160;from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 31, 2023 and 2022, outstanding Common Stock warrants to purchase shares of Common Stock, all classified as equity financial instruments, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,183,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October 16, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 27, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 8, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 30, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 1,680.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,549,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023 and 2022, the Company had reserved shares of its Common Stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,352,803</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,368,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 570,570</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,549,338</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,402,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,512,459</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523913072784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is ten years, the exercise price is the Company&#8217;s closing price at the date of grant and the vesting period is usually four years<span style="white-space:pre-wrap;">. The Company also granted RSUs under the 2016 Plan that vest over four years.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to 5% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2023, there were 2,368,160 shares available for issuance under the 2016 Plan. The increase as of January 1, 2024 was 1,807,235 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has issued restricted stock awards (&#8220;RSAs&#8221;) under certain legacy option plans that generally vested&#160;<span style="-sec-ix-hidden:Hidden_1t18bwPO80umxL4QF2kQLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span>&#160;to&#160;four years&#160;based on service conditions. As of December 31, 2023, all RSAs were fully vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to its 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of 1% of the total number of shares of the Company&#8217;s Common Stock outstanding on December 31st of the preceding calendar year and 30,000 shares, subject to the ability of the Company&#8217;s Board of Directors to take action to reduce the size of the increase in any given year. There were no awards issued under ESPP. As of December 31, 2023, the Company had reserved 9,748 shares for future grants under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option activities during the year ended December 31, 2023 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,352,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 330,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516,353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,176,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 115</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The aggregate intrinsic value of options at December 31, 2023 is based on the Company&#8217;s closing stock price on that date of $3.24 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The weighted average grant date fair value of the options granted during 2023 was $1.97. The fair value of vested options during the year ended December 31, 2023 was $5.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2023 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27.11</p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39.53</p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (102,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.79</p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, there was $1.8 million of total unrecognized compensation expense related to unvested stock options, restricted stock awards and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately 1.7 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"><span style="font-size:7.35pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The assumptions used to estimate the options fair value were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.54% - 5.54%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.65% - 4.20%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">75.40% - 116.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">81.81% - 85.86%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.12 - 7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.50 - 7.00</p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2023, in connection with the resignation of its former chief executive officer, the Company amended the terms of certain of his awards. As a result, the Company reversed $0.6&#160;million previously recognized stock-based compensation expense related to his forfeited and unvested awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#8217;s consolidated statements of operations for the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,794</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,311</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,105</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523810378960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,228)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (863)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,689)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,917)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,525</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,103</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,192</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 929</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,660</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,452</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 86,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 80,861</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,818)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,043</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,510)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,043)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,120)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards at December&#160;31, 2023 are $167.6 million and $118.9 million for federal and state income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2028, respectively. The federal net operating loss carryforwards generated after 2017 of $113.1 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#8217;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately </span>$6.3 million during the year ending December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value adjustment on convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.9)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2023, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2019 or to California state income tax examinations for tax years ended on or before December 31, 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not have a liability for unrecognized tax benefits at December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2023 and 2022, the Company has no accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes have not been provided for undistributed earnings of the Company&#8217;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523808366800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced on January&#160;1, 2012 and in April 2020, the Company amended the lease (&#8220;2020 Lease Amendment&#8221;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, was approximately $1.9&#160;million, and base rent increases by&#160;3% annually and will be $2.5&#160;million by the end of the amended term. In addition, the Company received a&#160;six-month&#160;rent abatement in 2020. In accordance with authoritative guidance, the Company re-measured the lease liability in April 2020 to be&#160;$11.7&#160;million <span style="background:#ffffff;">using an</span> incremental borrowing rate of&#160;12.89% and related&#160;right of use asset was&#160;$11.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with the Company&#8217;s execution of the 2020 Lease Amendment, an irrevocable letter of credit in the amount of $1.2&#160;million was delivered to the landlord. Starting on February 1, 2022, and each&#160;year thereafter, the letter of credit will be reduced by&#160;20% of the then outstanding amount. As of December 31, 2023, the letter of credit was $0.7&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, California (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for&#160;</span><span style="background:#ffffff;">16 years</span><span style="background:#ffffff;">&#160;and runs through 2038. Monthly rent for 2022 and 2023 are fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately&#160;</span><span style="background:#ffffff;">$0.25</span><span style="background:#ffffff;">&#160;million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to&#160;</span><span style="background:#ffffff;">$7.3</span><span style="background:#ffffff;"> million, of which the Company received </span><span style="background:#ffffff;">$5.4</span><span style="background:#ffffff;"> million during the year ended December 31, 2023. The Company is responsible for construction costs over such allowance. Out of pocket expenses to be incurred by the Company are considered noncash lease payments, and included in the lease liability and the right-of-use asset when the amount can be reasonably estimated. As of November 16, 2022, the Company finalized the budget to complete the construction of the 2021 Lease. Accordingly, the Company re-measured the lease liability and related right-of-use asset as of November 30, 2022, using an incremental borrowing rate of </span><span style="background:#ffffff;">11.8%</span><span style="background:#ffffff;">. The re-measured lease liability of the 2021 Lease as of November 16, 2022 was&#160;</span><span style="background:#ffffff;">$37.0</span><span style="background:#ffffff;">&#160;million, and the related right of use asset was&#160;</span><span style="background:#ffffff;">$33.8</span><span style="background:#ffffff;">&#160;million</span>. During the year ended December 31, 2023, the budget was modified and the Company re-measured the lease liability. As a result, the lease liability and related right-of-use asset increased by approximately $2.7&#160;million, using an incremental borrowing rate of&#160;14.27%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the total amount of $5.0&#160;million to the landlord in 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,899</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,307</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,724</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,452</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,616</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,181</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 75,179</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plus: estimated short-term variable lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,729)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,064</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,481)</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28,583</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#222222;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Rent expense was $7.4 million and $6.3 million for the years ended December 31, 2023 and 2022, respectively. Total cash payments for operating leases as included in the consolidated statements&#160;of cash flows during the&#160;years ended December 31, 2023 and 2022 were $3.5 million and $2.7 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523810235504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant and Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardAbstract', window );"><strong>Grant and Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardTextBlock', window );">Grant and Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Grants and Awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MTEC Grant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which the Company received a $15.0 million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. <span style="background:#ffffff;">On September 29, 2022, the MTEC Agreement was modified to increase the total award by </span><span style="background:#ffffff;">$1.3</span><span style="background:#ffffff;">&#160;million to </span><span style="background:#ffffff;">$16.3</span><span style="background:#ffffff;">&#160;million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of </span>the Company's<span style="background:#ffffff;"> therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;</span><i style="font-style:italic;background:#ffffff;">Staphylococcus aureus</i><span style="background:#ffffff;">&#160;bacteremia infections. The MTEC Agreement specifies that the grant is paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement is effective through October 30, 2024.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $4.5 million and $5.5 million in grant revenue from the MTEC Agreement during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the Company had $1.5&#160;million and $1.9&#160;million as awards receivable from MTEC, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Award Agreement&#8221;) with Cystic Fibrosis Foundation (&#8220;CFF&#8221;), pursuant to which the Company received a Therapeutics Development Award of $5.0 million (the &#8220;CFF Award&#8221;). The CFF Award has funded a portion of the Company&#8217;s Phase 1b/2a clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa </i>(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;)<i style="font-style:italic;"> </i>phage candidate, AP-PA02, as a treatment for<i style="font-style:italic;"> </i>airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The CFF Award is payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The last milestone in the amount of $0.3 million was achieved in December 2023 and was received in January 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span>The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Award Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#8220;<i style="font-style:italic;">Significant Accounting Policies&#8221;</i>, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2023 and 2022, the Company recognized $0.3 and $1.0 million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about award abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>represents about award text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809355344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Retirement Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Employee Retirement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#8217;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $0.2 million and zero to the 401(k)&#160;plan for the&#160;years ended December 31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906119776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The Company operates and manages its business as </span><span style="background:#ffffff;">one</span><span style="background:#ffffff;"> reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. The long-lived assets of </span><span style="background:#ffffff;">$12.4</span><span style="background:#ffffff;"> million, which represents </span><span style="background:#ffffff;">98.8%</span><span style="background:#ffffff;"> of the Company&#8217;s total long-lived assets, are maintained in the United States.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risks and Certain Other Risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;">Concentration of Credit Risks and Certain Other Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company&#8217;s investment policy, to a concentration limit per issuer or sector.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#8217;s operating leases (Note 12).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;white-space:pre-wrap;"> Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, convertible debt and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Convertible debt is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;padding-top:8pt;margin:0pt 0pt 4pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2023 or 2022. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development ("IPR&amp;D")</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">  IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized in-process bacteriophage development programs for </span><i style="font-style:italic;">S. aureus</i> infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when a quantitative analysis of IPR&amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#8217;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#8217;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2023 and 2022, the Company performed the annual evaluation of its IPR&amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for <i style="font-style:italic;">S. aureus</i> infections was greater than its carrying value as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a result of the quantitative analysis. Consequently, no impairment loss was recognized as of December 31, 2023 and 2022. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) is determined based on the number of units granted and the closing price of the Company&#8217;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translations and Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Foreign Currency Translations and Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. <span style="background:#ffffff;">Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the quarterly </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">average exchange rate in effect during the </span>year.&#160;<span style="background:#ffffff;">Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#8217;s consolidated statement of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_GrantsAndAwardsPolicyTextBlock', window );">Grants Revenue and Other Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grants Revenue and Other Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines whether agreements are within the scope of Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from contracts with customers</i> (&#8220;ASC 606&#8221;) or other topics at the effective date of an agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;<i style="font-style:italic;">Collaborative Arrangements</i>&#160;(&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;<i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company also considers the guidance in ASC Topic 730,&#160;<i style="font-style:italic;">Research and Development&#160;</i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">.&#160;</i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the Company recognized as other receivables in its consolidated balance sheets $1.5 million and $1.9 million, respectively, related to invoiced grant amounts that have not been received. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Company&#8217;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;">Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2023 and 2022, as such, the comprehensive income (loss) for these periods was equal to the net loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. </span>Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.<span style="background:#ffffff;"> The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="color:#212529;font-style:italic;background:#ffffff;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments</i><span style="color:#212529;background:#ffffff;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203;&#160;</i>(&#8220;ASU 2020-06&#8221;)<i style="font-style:italic;">.</i>&#160;&#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">contracts that may be settled in cash or shares impact the diluted earnings per share computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In October 2023, the FASB issued ASU 2023-06, <i style="font-style:italic;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</i>. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#8217;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In November 2023, the FASB issued ASU 2023-07, <i style="font-style:italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.<span style="font-size:12pt;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GrantsAndAwardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about the grants and awards policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GrantsAndAwardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903294448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PropertyAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of useful lives of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5 &#8211; 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3 &#8211; 5 years</p></td></tr><tr><td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter of lease term or useful life</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PropertyAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PropertyAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906215120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract', window );"><strong>Fair Value of Financial Assets and Liabilities - Derivative Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:21.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">21.01%-45.88%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probabilities of settlement scenarios</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0%-85%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 101.1%-123.6%</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.2-1.5</p></td></tr><tr><td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.62%-5.39%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Changes in Fair Value of Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level 3 financial liabilities (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Pre Modification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Loan</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Post Modification</b></p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net proceeds from issuance of the Convertible Loan  (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Initial recognition of modified Convertible Loan (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,031</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,757)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,602</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Convertible Loan exchanged  (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,332)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 58,633</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the determination of fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523808397584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,352,803</p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 99,666</p></td></tr><tr><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20,549,338</p></td></tr><tr style="height:15.35pt;"><td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44,024,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,031,807</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523813958960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property and equipment as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,007</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 449</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,447</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,720</p></td></tr><tr><td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,103)</p></td></tr><tr><td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,617</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,678</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical trial expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,021</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,650</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,083</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,706</p></td></tr><tr><td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,689</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,034</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523808316064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 31, 2023 and 2022, outstanding Common Stock warrants to purchase shares of Common Stock, all classified as equity financial instruments, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,183,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October 16, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 993,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 27, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,867,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 16, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,807,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 8, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,692,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 30, 2027</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"> 1,680.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:26.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,549,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"><span style="font-size:11.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023 and 2022, the Company had reserved shares of its Common Stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,352,803</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,368,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 570,570</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,549,338</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,402,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,512,459</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,352,803</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,368,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 570,570</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,365,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,549,338</p></td></tr><tr><td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shares issuable upon the conversion of Convertible Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,293,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 46,402,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,512,459</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903456256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in the Black-Scholes Model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.54% - 5.54%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.65% - 4.20%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">75.40% - 116.96%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">81.81% - 85.86%</p></td></tr><tr><td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.12 - 7.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.50 - 7.00</p></td></tr><tr><td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,794</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,311</p></td></tr><tr><td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,105</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (in thousands)</b></p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,352,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 330,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (516,353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,165,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 429</p></td></tr><tr><td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,176,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 115</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock', window );">Schedule of restricted stock awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 129,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27.11</p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39.53</p></td></tr><tr><td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (102,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.79</p></td></tr><tr><td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.39</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809690272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">(Loss) Income from Continuing Operations Before Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Loss before income taxes consisted of the following components (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,228)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (863)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,689)</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69,045)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,917)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory to Effective Tax Rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments for tax effects of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal tax</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.9</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in valuation allowance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.2)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.3)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value adjustment on convertible debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.6)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.9)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5 </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(0.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 42,525</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,103</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,192</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 929</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease accounting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,660</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,452</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets before valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 86,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 80,861</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,818)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets after valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,043</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,510)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,043)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (91)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,120)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,077)</p></td></tr><tr><td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523808357456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future minimum annual lease payments under the Company&#8217;s noncancelable operating leases as of December&#160;31, 2023, are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,899</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,307</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,724</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,452</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,616</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 43,181</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 75,179</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plus: estimated short-term variable lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: amount representing interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,729)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of operating lease obligations </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,064</p></td></tr><tr><td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,481)</p></td></tr><tr><td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Noncurrent operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28,583</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523902396288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Total debt financing | $</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfDirectors', window );">Number of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfBoardDirectors', window );">Number of Board Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_CommonStockVotingPercentageHeldPercentage', window );">Total number of shares (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member', window );">Armata Pharmaceuticals, Inc. | Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Outstanding equity (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_CommonStockVotingPercentageHeldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_CommonStockVotingPercentageHeldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfBoardDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board directors during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfBoardDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=armp_ArmataPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523813683120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity and Going Concern (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (308,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (239,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.31%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Credit And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Credit And Security Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_CreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_CreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903454864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash', window );">Letters of credit | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">8,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">12,559<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PercentageOfLongLivedAssetsInGeographicalLocation', window );">Percentage of long-lived assets</a></td>
<td class="nump">98.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of irrevocable letters of credit with financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PercentageOfLongLivedAssetsInGeographicalLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of long lived assets In geographical location.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PercentageOfLongLivedAssetsInGeographicalLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903320528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809768000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract', window );"><strong>Fair Value of Financial Assets and Liabilities - Derivative Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809778896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details) - Fair Value, Inputs, Level 3<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Discount rate | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">21.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Discount rate | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">45.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Probabilities of settlement scenarios | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Probabilities of settlement scenarios | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">123.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected term | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected term | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentMeasurementInputForPeriod', window );">Debt instrument, measurement input, for the period</a></td>
<td class="nump">5.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DebtInstrumentMeasurementInputForPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DebtInstrumentMeasurementInputForPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=armp_ProbabilitiesOfSettlementScenariosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=armp_ProbabilitiesOfSettlementScenariosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903114480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Changes in Fair Value of Liabilities) (Details) - Fair Value, Inputs, Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Convertible Loan Pre Modification</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Net issuance of the Convertible Loan</a></td>
<td class="nump">$ 29,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(1,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged', window );">Amount exchanged</a></td>
<td class="num">(31,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss on extinguishment</a></td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Convertible Loan Post Modification</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan', window );">Initial recognition of modified Convertible Loan</a></td>
<td class="nump">35,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">23,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at September 30, 2023</a></td>
<td class="nump">$ 58,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=armp_ConvertibleLoanPreModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=armp_ConvertibleLoanPreModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=armp_ConvertibleLoanPostModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=armp_ConvertibleLoanPostModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903192816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">44,024,924<span></span>
</td>
<td class="nump">24,031,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">3,165,216<span></span>
</td>
<td class="nump">3,352,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember', window );">Shares issuable upon the conversion of Convertible Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">21,293,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">20,549,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=armp_SharesIssuableUponConversionOfConvertibleLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523814052768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment', window );">Property and equipment not in use</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of property and equipment not in use included in laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906150160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 24,380<span></span>
</td>
<td class="nump">$ 14,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(11,821)<span></span>
</td>
<td class="num">(11,103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">12,559<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">19,678<span></span>
</td>
<td class="nump">10,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,447<span></span>
</td>
<td class="nump">$ 3,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523813735552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Other receivables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_TenantImprovementReceivableCurrent', window );">Tenant improvement allowance receivable (Note 12)</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="nump">$ 6,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_GrantAndAwardReceivableCurrent', window );">Grant and award receivable</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 8,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GrantAndAwardReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of awards receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GrantAndAwardReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_TenantImprovementReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of current tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_TenantImprovementReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523814206496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 1,585<span></span>
</td>
<td class="nump">$ 1,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AccruedLiabilitiesClinicalTrial', window );">Accrued clinical trial expenses</a></td>
<td class="nump">3,021<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Liabilities, Current, Total</a></td>
<td class="nump">$ 5,689<span></span>
</td>
<td class="nump">$ 6,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AccruedLiabilitiesClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AccruedLiabilitiesClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906044288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,863)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark', window );">Proceeds from qualified financing per agreement benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">27.31%<span></span>
</td>
<td class="nump">27.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice', window );">Discount on share price for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseFairValueOfLiabilities', window );">Change in fair value of convertible debt</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible debt extinguishment</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent  of discount on share price for conversion of debt into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseFairValueOfLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseFairValueOfLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from qualified financing per agreement benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903484672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember', window );">Secured term loan | Innoviva Strategic Opportunities LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">27.31%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Recognized at fair value</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance cost</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of Debt Issuance Costs and Discounts</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523810162288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 09, 2022 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">3,614,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,807,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants | $</a></td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember', window );">Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,385,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,692,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523807140112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">20,549,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember', window );">Exercise Price $5.60</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Oct. 16,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember', window );">Exercise Price $2.87</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">993,139<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Feb. 11,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember', window );">Exercise Price $2.87.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">7,717,661<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember', window );">Exercise Price $3.25.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,867,912<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Jan. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember', window );">Exercise Price $3.25</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">4,285,935<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember', window );">Exercise Price $5.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,807,396<span></span>
</td>
<td class="nump">1,807,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Feb.  08,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember', window );">Exercise Price $5.00.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">2,692,604<span></span>
</td>
<td class="nump">2,692,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember', window );">Exercise Price 1680.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 1,680.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the terms related with expiration of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523909242304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Shares Reserved for Future Issuance) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">3,165,216<span></span>
</td>
<td class="nump">3,352,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares', window );">Employee stock purchase plan</a></td>
<td class="nump">9,748<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">19,365,847<span></span>
</td>
<td class="nump">20,549,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_SharesIssuableUponConversionOfConvertibleDebt', window );">Shares issuable upon the conversion of Convertible Loan</a></td>
<td class="nump">21,293,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">46,402,832<span></span>
</td>
<td class="nump">24,512,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock awards/units</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants under the 2016 Plan</a></td>
<td class="nump">2,368,160<span></span>
</td>
<td class="nump">570,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_SharesIssuableUponConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable upon conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_SharesIssuableUponConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523811991024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ShareBasedPaymentArrangementExpenseReversed', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,402,832<span></span>
</td>
<td class="nump">24,512,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of annual increase in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants under the 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">1,807,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member', window );">Employee Stock Purchase Plan, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of annual increase in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Additional awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember', window );">Stock Options And Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition of compensation costs related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants under the 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368,160<span></span>
</td>
<td class="nump">570,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ShareBasedPaymentArrangementExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award reversed under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ShareBasedPaymentArrangementExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523812046272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Summary of Stock Option Activity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Beginning</a></td>
<td class="nump">3,352,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">330,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited/Cancelled</a></td>
<td class="num">(516,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Ending</a></td>
<td class="nump">3,165,216<span></span>
</td>
<td class="nump">3,352,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at September 30, 2023</a></td>
<td class="nump">3,165,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at September 30, 2023</a></td>
<td class="nump">2,176,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning</a></td>
<td class="nump">$ 5.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest at September 30, 2023</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at September 30, 2023</a></td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at September 30, 2023</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2023</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited/Cancelled</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2023</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at September 30, 2023</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523810409200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Restricted stock award) (Details) - Restricted Stock Awards [Member] - C3J Stock Plan 2016 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">129,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/Cancelled (in shares) | shares</a></td>
<td class="num">(27,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and Issued as Common Stock (in shares) | shares</a></td>
<td class="num">(102,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Avg Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">39.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and Issued as Common Stock (in dollars per shares) | $ / shares</a></td>
<td class="nump">23.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_C3jStockPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_C3jStockPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903559248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details) - Common Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">75.40<span></span>
</td>
<td class="nump">81.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">5.54<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">116.96<span></span>
</td>
<td class="nump">85.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">7.00<span></span>
</td>
<td class="nump">7.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EquitySecuritiesMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EquitySecuritiesMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=armp_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906156624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 3,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="nump">$ 1,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906145920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss not subject to expiration</a></td>
<td class="nump">$ 113,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties pertaining to income tax examination recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards ("NOLs")</a></td>
<td class="nump">$ 167,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards ("NOLs")</a></td>
<td class="nump">$ 118,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523902410560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (68,182)<span></span>
</td>
<td class="num">$ (32,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(863)<span></span>
</td>
<td class="num">(4,689)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (69,045)<span></span>
</td>
<td class="num">$ (36,917)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523813841968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Deferred Tax Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 46,591<span></span>
</td>
<td class="nump">$ 42,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research and development</a></td>
<td class="nump">21,431<span></span>
</td>
<td class="nump">19,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxAssetLeaseObligation', window );">Lease accounting</a></td>
<td class="nump">13,899<span></span>
</td>
<td class="nump">13,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">86,767<span></span>
</td>
<td class="nump">80,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(75,166)<span></span>
</td>
<td class="num">(68,818)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">11,601<span></span>
</td>
<td class="nump">12,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(11,510)<span></span>
</td>
<td class="num">(12,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">In-process research and development</a></td>
<td class="num">(3,077)<span></span>
</td>
<td class="num">(3,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">14,678<span></span>
</td>
<td class="nump">15,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (3,077)<span></span>
</td>
<td class="num">$ (3,077)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxAssetLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxAssetLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523903189968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(9.30%)<span></span>
</td>
<td class="num">(28.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent', window );">Debt extinguishment</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in rate</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent', window );">Fair value adjustment on convertible debt</a></td>
<td class="num">(6.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncomeTaxRateReconciliationPermanentDifferences1', window );">Other</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of change in federal tax rate</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to debt extinguishment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustment on convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncomeTaxRateReconciliationPermanentDifferences1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the contribution of other permanent differences between reported income tax expense (benefit) and expected income tax expense (benefit) computed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncomeTaxRateReconciliationPermanentDifferences1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809964976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 26, 2022</div></th>
<th class="th"><div>Oct. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_BaseAnnualRentToBePaidYearThree', window );">Base annual rent for 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_MaximumAllowanceForTenantImprovementsReceivable', window );">Maximum allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ProceedsFromTenantAllowances', window );">Tenant allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLeaseBaseRent', window );">Operating lease expected yearly base rent</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AnnualIncreaseInRentPercentage', window );">Annual increase in rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_OperatingLeaseBaseRentEndOfLeaseTerm', window );">Base rent at the end of lease term</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_LeaseAndRentalAbatementCreditPeriod', window );">Period of lease and rental abatement credit</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense under operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="nump">38,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">44,717<span></span>
</td>
<td class="nump">43,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">12.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (decrease) operating lease right-of-use and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,451)<span></span>
</td>
<td class="nump">$ 3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember', window );">2021 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (decrease) operating lease right-of-use and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letter of credit</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AnnualReductionOfStandbyLetterOfCredit', window );">Annual reduction of standby letter of credit</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AnnualIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AnnualIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AnnualReductionOfStandbyLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual reduction of standby letter of credit..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AnnualReductionOfStandbyLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_BaseAnnualRentToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for base rent to be paid in year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_BaseAnnualRentToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LeaseAndRentalAbatementCreditPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of lease and rental abatement credit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LeaseAndRentalAbatementCreditPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_MaximumAllowanceForTenantImprovementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum allowance for tenant improvements receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_MaximumAllowanceForTenantImprovementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLeaseBaseRentEndOfLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent for operating lease at the end of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLeaseBaseRentEndOfLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromTenantAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromTenantAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523925074736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Future Minimum Lease Payments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 26, 2022</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 9,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">5,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">5,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">43,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">75,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ShortTermVariableLeasePaymentAmount', window );">Plus: estimated short-term variable lease payments</a></td>
<td class="nump">5,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(31,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease obligations</a></td>
<td class="nump">38,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(9,481)<span></span>
</td>
<td class="num">$ (17,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease obligations</a></td>
<td class="nump">$ 28,583<span></span>
</td>
<td class="nump">$ 31,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ShortTermVariableLeasePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short- term variable lease payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ShortTermVariableLeasePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523807172896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant and Awards (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2022</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Mar. 13, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 5,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember', window );">Medical Technology Enterprise Consortium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther', window );">Increase in expected revenue from grants</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_UnbilledAwardReceivable', window );">Unbilled award receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember', window );">Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ResearchAndDevelopmentBenefit', window );">Research and development benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardReceivable', window );">Award receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardAgreementInterruptionPeriod', window );">Award agreement interruption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_armp_ThresholdDevelopmentAward', window );">Amount of threshold development award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAgreementInterruptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAgreementInterruptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about award line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of award receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in expected revenue that is not accounted for under Topic 606, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ResearchAndDevelopmentBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate benefit incurred during the reporting period as a result of research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ResearchAndDevelopmentBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ThresholdDevelopmentAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold amount of development award under the award agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ThresholdDevelopmentAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_UnbilledAwardReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled award receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_UnbilledAwardReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809150992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plan (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution to 401(k) plan</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523809098880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (69,045)<span></span>
</td>
<td class="num">$ (36,917)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140523906215120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY_AW+=K9EJD"=X\WZI?YR\N7>< I\5G\/0K%\JQSTD$AF>,L%K?LZ1-9O]!
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M)?GADN"0<'6#_'S.F-B<J *V/P<Y_P]02P,$%     @ CX)U6%->;4LA!@
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M.FWC#6_L-MYH:;[E1D\O+D6C1,5+JED)WM&*-@4#-]:< C/P^>8*O'SQ"KP
MO &?5J)5M"G5^5R;E:W^O-BM\FZ["AY9Y8H59X"@*< 0$X_ZY?/5\;'ZW/B[
M=QKOG<:=/3+F="LE:S2@2AD_?>YL]2._OBVMUVI-"W8Q,;6CF-RPR>+''U "
MW_B<^T[&CEPE>U=)R/KBDJH5,)L&"OO _F[YAE;&=Z_76U-I9\K6_V:!2&PW
M;'/HCD<JRF*\ESK"&>UQ1D&<UY*M*2\!>S -2C'5819ZQ:2I@E.[M34='R#"
M.(D'L%TADB21'W6\1QT'47_H $I6,!/6VXIYT<7NPB09!M45RF*"_.B2/;HD
MB.Z3T+1Z1O@29VV4HQ@-$+I2.(51ZH>8[B&F08@?F=*2%[;YV 3UH4N==>,4
MPP$XCU">0#^V;(\M.Y&2ABRE?NQ2T5;.VM"7GH*&:1_.S(TBCN-\ -25(@D:
M"6*^!YJ'L]# I)HW=Z!BAM& M-0U$\M9:UZZ;??AS1TD490>0-GB]4@12&(_
M8 1[UH%!R.^;V5J*@BD%;,^CLMAVJ9)MS&31!=K+,M -,L1Q,@!]4NP8]0%7
MHB#J7X0H[WE5>:$A=V>C?)BGIZ2.@?5\AH(<LNM#XQ6^4S\JWBAUP/FD<#X"
MKF<@%*:@;1L*@"/.LGGF=DB?6)R1D0Z.>N)!T;.&@8K36UYQS?U=' 7YZVM'
M@N]E[=CGGK90F+?>%H5HS1  UO31\E97>[0H9&L:\:E N%05)]FPSWFD$CBZ
M63VCH3"EO=UA+$1MYP1JCP)>D"Y;I4DVQ.@AO@QG(QA[2D-A3GM*J+60W4E%
M+($8=.A3(7;I+(^R(2%[I% *T<C0@'K:0V'>^W T=9V"ZA*:.S&&%_S6;._I
M$87Y\7@..N60RW@HB1(G^*X8CK*4^(./>V+$86(<<OD!VF[RL-E4'">8]_SB
M,B#.3+<<>.$1(RB#(V6*>Z+$8:(TI\J-&9VX;2TEN_5R.7:I,,X2XD ,KO2-
MN8,/3HIA9OU--'<SS60][H>'-4F21D,__H]3(.Y)&(=)^(HMF<F:$FCZL$^J
M1Z\_+L\2F [GPE-2QS![,L;A8^"V5$^4*':/<HC " _[NT<NSM-X++M[]L1A
M]KP4=<VUG5&WQ]1"-+9B65,8P.#E'T(S@/ K+_2@97\6 .^=PG\W=.Q]3\$X
M"<Y+-RLJV4I4)9/J)_"R9$M></VJ.R&-9%20T[_Z-N4[63MVOV=W?(+=S>8;
M4E=:%%^FX 4\@\A,41)L:-6R-P"C= HAM/^ LI$R*=+JE9#\'U:^ 229(HRG
M.<%=YMC7*)JF,'D2YDK9^::[_6BUTN;!D@'5X(H5K+XUS/QTC]8)V1NQJ3U#
MK5EW(5KY=\ =%8A#:2>$CN/53Q,X/$V\+4MN6<J4M;W@F?'&G/37W)2Y%Z@[
M3N T(;G#"CZY.,K'^+>?%7!X5C #9ENW57<=NDMM+TZ7_F<$9AD:SL$^04SR
M-!WI0J2?%$AX4MBV2O75U4A<SI\1#)W[,H\<26 V<E8E_6Q PK.!T^*[//X&
M/Y!S#^D[-OK$/,?&^<$5NOW]XG<J[WBCS!2V-'KP+#5QD-N?!+8O6JR[6_5;
MH;6HN\<5HP:^%3#?+X6A@=V+O:C?_S"S^!=02P,$%     @ CX)U6)(5T!!X
M @  ,P<  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM5=%NTS 4_14K
M(+1)HTZ<)ATCC<0Z(7A JE8!SUYRVUAS[& [[>#KL9TT:D<&K40?&E_[GG//
M<>+K;"?5HZX #'JJN=#SH#*FN<%8%Q745$]D \*NK*6JJ;&AVF#=**"E!]4<
MDS!,<4V9"/+,SRU5GLG6<"9@J9!NZYJJG[? Y6X>1,%^XIYM*N,F<)XU= ,K
M,%^;I;(1'EA*5H/03 JD8#T//D0WB]3E^X1O#';Z8(R<DP<I'UWPN9P'H1,$
M' KC&*A];&$!G#LB*^-'SQD,)1WP<+QG_^B]6R\/5,-"\N^L--4\N Y0"6O:
M<G,O=Y^@]Y,XOD)R[?_1KLM-9@$J6FUDW8.M@IJ)[DF?^GTX $33%P"D!Y!3
M 7$/B+W13IFW=4<-S3,E=TBY;,OF!GYO/-JZ8<*]Q951=I59G,D74FC)64D-
ME.B6<BH*0"M'I]'%DBH0I@+#"LHOT5OT&F&D*SNK,VQL=<>!B[[2;5>)O%#I
M#HH)BJ,K1$(2C\ 7I\/),1Q;SX-Q,A@GGB\^W_B8MXYL.D[FCMJ-;F@!\\">
M)0UJ"T'^YE64AN_'G/XGLB/?\> [_AN[]5W7]OC8#ZMXO$(-56A+>0OH@@E4
M2LZITJ@!U;WFR[&MZ/BO/;]K$ML\G(11AK>'%O^1="1].DB?GB&]^PX1;4TE
M%?L%Y9C6CC YD$&B6>A_SP2?DGFD.AE4)^>K9EJWXXJ3/W3$:43(NY@\$SR:
M.)W.PG1<;SKH3<_7:_N_-E243&S&1*>GBAY-'!.-#UJ:NTZ^4+5A0B,.:PL-
M)S/+H;H6W05&-K[+/4AC>Z8?5O96 ^42[/I:2K,/7.,<[LG\-U!+ P04
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MQFV+@6$X"9'%+PX[C,*=>K:_>&R9'@7>"O19$Z(\1.6C$S%XO2A]"SV 6CV
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M TORQZ@-Z6&/X\$.L IA^,2O7NH I<N2/0>S"]E O$EJJ(\Z,, *&:KD$?I
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M@8#TZPWHV_4&5F@'EA6Q:;J>Y&51?* M1>FUI"T[T-$P93;FFX\QAPE+ &'
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M9"%52Z&NS#S*:QP?@#$1L]IITJEW$BE)#$Q^A\?OKE:-I/"2R2SH-)%J-7C
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M@V4M"6A T$IQ(6Y?"D/,R>70,,N8+=9HP0D?/7U^)E]^W6'5S_:N/J1OIQ<
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MK.F#A<8[T/U&:W?8^ ##)W#U'5!+ P04    " "/@G580?AJ/#\$  !##
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6S55VUOVS@,_BN"5PPM8,3O
MB9,E 9IUNSN@VXJV=_=9L9E$F&QYDMPT]^M'R8[K+&GN[<O=E]BDR$</)9)F
MIELAOZH-@";/!2_5S-EH74T\3V4;**@:B I*7%D)65"-HEQ[JI) <^M4<"_T
M_:%74%8Z\ZG5W<GY5-2:LQ+N)%%U45"Y6P 7VYD3.'O%/5MOM%%X\VE%U_
M^M?J3J+D=2@Y*Z!43)1$PFKF7 >316SLK<%O#+:J]TY,)$LAOAKAEWSF^(80
M<,BT0:#X>(+WP+D!0AK?6DRGV](X]M_WZ!]M[!C+DBIX+_CO+->;F9,Z)(<5
MK;F^%]N?H8TG,7B9X,K^DFUC&X8.R6JE1=$Z(X."E<V3/K?GT'-(_5<<PM8A
MM+R;C2S+&ZKI?"K%EDACC6CFQ89JO9$<*\VE/&B)JPS]]'Q!.2TS( \V VY
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MXF+.7PLET65H ]9GSL7V@0QTOZU<_@U02P,$%     @ CX)U6%YDQ2T0!0
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ME8L8*^ESC;<V>1; >>-<'!=L8'J]7_T#4$L#!!0    ( (^"=5C%HA D]04
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M ;DO=R 55J$B[V E:BQ<'0B_(UCF:+HY_UCV)(D)E^\0M07REA<5+9\($H&
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M>NZ.J&X86=I/07-IC,SMXXI1..+C 'B_D-+4#5R@^39X^6]02P,$%     @
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MH]A8S:[CCU8J15U(A]A45,18*@D=L:*IRC*B,Z/JQ'B/'8TU3:Q!L25R!D\
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M(42K?4:Q*)5+8!4P\6..;V=/;@O5JSB85UA20A%C%3"4?)N(KR04^'!6 S_
ME4,N JS_BC&!V4@4C&(@4R$T*$5H#CO,TT?PA%*E70-Y4B]# &%FFFJ2"CEK
M!1RW2$^Q4B*M>C9]Z4'("Y@7H*4HR@9:=RQ? 7 4GECK[S# V1WJ$?>YK4A-
M[#YPVU<K[HK<3Q)9UJ RE+%^&I,;L,:$PO&JEE_T+9;>*^\Y$V!\HV5K*X,R
M,-Z2(R\IE+V0<38<-.!@YL$5M>;<?.RZVF])L-1"EK/Q?L5V.W.XL8H9J NN
M EW <FLXW+BF>AY#!JPU: ]HMJG<>123 0DDP[9.!S0.2B'D21?;)D1MW#YT
M:(VC&>@,O-113^3J:,PXU.T8)) WY9!^8H4J!KQUMZZ5#9,C55$>-<>F()\"
M1ZD//^FE3Y"O!/W-PZVXF%T0!'1Y/CN?B)NR-#MRN'Y"JC$R> SN#3*[*=#B
M/-5"@M+T7:DAF'7-[QD")&)M.I1-@71O3 IPN&E65%E<=9ZRG9BTX9!1U<<&
MC E0.==DR1.34G%T.CD;=/VCL]X#7>Q9\4REHB =04%O:  C_8@P8OXE<6PU
ME(]5Q/D%LE7&##6(TXV/@_CY]7U,,YG2 -NS?#[YJ7O@8^=LL.8VQM:3Y?O:
M;^_N"*!F='@8PLV*?8L4"5/X$\_E^?+O>591M^W#O"H*?(98W>X\#:\[O7+6
M(QWO+#5A;JT-C8*U_X)%_8U_0/^H3[/Z!A,\O*I16Z=3\Y@+EQH3*RJ)]<5)
MT#.%MLY?O_7]^=\-\, U7.^X]ZH"*T 311"5JS:ZL![$8=*_&QK $W77S*H^
M LR!R$_F()IRVM,U/?)U9Z<QFV0:F+0T ",+QUY"0^&@5BC?%E<M/^TAV-)-
M9"%?H^^WSKSH+LC(/9,1N.IQ3@<G00[4M;Z7)Q'TM788Z7 V]L"V?^PM'C="
MXHSC\,Z[\((NJ$3F<9(R"%ZC(]0EO">+_2)NV3&$ NW/:<.%$.TR$F:U<!W0
M/NO12Q)6(\["VKIO:WY?W4=9@&_NZL%%R31;OA4?!BF&J %K3Q&J@'G'30P5
M@O1(*$H03$:@[$6JH>"9B/9#@Z;/[(S9!%AY6F%@'\.^5*UYF!P.UZO(,'F*
M:\L%MCR?Q6EYC Y1U]8':ARN*JEDVDY "*RE-NP+LJG*U2$3.;]J@^2:R'B$
MK.545"#U',9R*.UKXP96# #,*P11:?;4*:(TPR"&0=%)9GBFUV6&TY=(/ BS
MYM;H R,9QPF\(C''<W(5!XT$ZXBJ'-.8H5H8%C&@W%IGTJU.P:. 9ZE(\YCH
M4R2C'-B&E]9%T9U*.^KY;+U$1I 0!?<#7"F&E$T49#HH$+8=[Z?'MW<HQZ"Y
MGPR[)KJX,FG7JRFLQPOXC* 4)ZW;_\:[ID'A-/)MXVA&/$.[V:6FL&NGQ@V^
M?,0+HD#\O*?RPO,^I5<#*.H\;_RJ3P-/CP##+(B9M^OIWN?K=JN>H>9UHO08
M>F#:S*>G_5[>T;MQ1U3;4U%GIO!@KEX\6H.R\GMU=. X 7T6@=@TW3^7W]0>
MU1_:WC9G9O'<YB@ S7$PK0WH9LM0*5'PYGQP0'$KOBXB/>R! 07FU\ABY _2
MP5/1U:GC7XHF5^>>+"8UOOF^DF2RB">1^DP>=4FNA*XG-[]]E[ !N9[VB?=@
M=C_#MT$+D\0Z.N^8'<_(5'L<Q7ULNK]:' S QNIZ$P\TPM88L$1JL!$)1+C?
M6_B/4WA=AX>^ZDU[7UF1)1O^ENP%BX@?7-NG[>?JF_B5MEL>OW6#)(*A>&'4
M&EMGD]=GHWB>:6Z"+?F;[<J&8'.^S)1$3=,"O%];N%7?D(+V(_[U_P!02P,$
M%     @ CX)U6(<0L<## @  1@8  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULE97;;AHQ$(9?9;2MHE:*V .$T 20($G57$1"20\752_,[L!:\6%C
M>T/HTW?L7;:T"DBY87V8^>8?VS.,-]H\VA+1P8L4RDZBTKGJ(HYM7J)DMJ<K
M5+2STD8R1U.SCFUED!7!28HX2Y)A+!E7T70<UA9F.M:U$USAPH"MI61F.T>A
M-Y,HC78+]WQ=.K\03\<56^,#NF_5PM L[B@%EZ@LUPH,KB;1++V8#[Q],/C.
M<6/WQN S66K]Z">WQ21*O" 4F#M/8/1YQBL4PH-(QE/+C+J0WG%_O*-_#KE3
M+DMF\4J+'[QPY20:15#@BM7"W>O-%VSS.?.\7 L;?F'3V/:'$>2U=5JVSJ1
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MTCL_B\ T7:N9.%V%3K'4COI.&);4Z-%X ]I?:>UV$Q^@^^N8_@%02P,$%
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M'+Z\!1UJ>W@/UM^.\&B+ZK(V^I:1NT)4*V<;TFJ@FE"!(7I-6_8[8!X +<@
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MJ@T<'[+$%I>D6\2.];CA=R(&*T $^4*H\N'55M]B?)2H5--PB$AZ@12BVFS
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M2Q*AW'(]Z!$?CO1*[X 699H-2!*.S@AL\ P@I0?H"+%."BS9DH_ZD\8L+8U
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M^G6K%5@J? &^7UL('.0#3A#^7L;K_P%02P,$%     @ CX)U6,<O5<AK P
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MN,7;QQ(^FZ@T"O!^)83>"L9!_R&V^!=02P,$%     @ CX)U6$B#?\OA!
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M9YF;CO$=#,H2X/^AE&:YL ?4+^O^3U!+ P04    " "/@G58?OY@.B %
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M_3$>>E1UWZI^C%RX.\Y4&KPQN<\Y7E%!60&<SZ0TFQ_KH+[T3OX!4$L#!!0
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M@&L#]7[%F-P-=(#Z0VCR-U!+ P04    " "/@G58F@WT:PP#   O#0  &0
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MNT0/WG3OZSN%:!J5%VGY]'R%<)ZR'SE(]/VSQD&W"A*Y-:7V"5+J-"EU[+<
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MK:"S;GH33UW0@< LC5&C,3J+"HB&-&P@,,NP<6/8^&PJ8'RPL0,8C7P8[15
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M*5EN+M<8I9CK '5_R9A\&>@'-"?$\U]02P,$%     @ CX)U6()),:5Q @
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MN?T*G1\GL)!<NU^R];5C+"Y:;63=@5%!S81_TJ>N#WN >/P&(.D R6O \ U
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M+N'E2;Z<2)85A^$')M71NABN@(3 =8"Z'S$FMQ-]OJ[_3_'_ E!+ P04
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MJ+X#S1F]4?I6XK.E=QOS=G"H?9>3AEVQ[6OOO6GO_6_GG(IZMPRZXZ-:V>[
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M<FMS:&5E=',O<VAE970T-2YX;6R]F5UOVS84AO\*H15; @26*']GMH'$2K
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M(6BB+U<819BI%^3S!:5B=Z,<E.>TD_\ 4$L#!!0    ( (^"=5@KAPE;C@4
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M41CQ*_#^H;B]()N"'P&E0<H9^+;DC ?I)$IG5]*6!U',KL!'\ Y8@,T#2MC
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M&HCWIUG&WP[D!:H]B:/_ 5!+ P04    " "/@G58$C"^@-,#   7#@  &0
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M&^#S%>?J<:#/!NU9</8#4$L#!!0    ( (^"=5@']BS_SP8  +0O   9
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;,5:;6_;-A#^*X17#"V06"+]$J=+
M#"21@G5 NJ!!V@_#/C 2;0N51)>DG&38CQ\I*7IQ9#H:SEO0-++,>TC>HSOR
M.?'LD8OO<L680D])G,KSP4JI]4?'D<&*)50.^9JE^IL%%PE5^J-8.G(M& US
MHR1VB.M.G81&Z6!^EM^[%?,SGJDX2MFM0#)+$BJ>+UG,'\\'>/!RXTNT7"ES
MPYF?K>F2W3%UO[X5^I-3H811PE(9\10)MC@?7."//CDU!GF+KQ%[E(UK9*;R
MP/EW\^%3>#YPS8A8S )E(*C^LV%7+(X-DA['CQ)T4/5I#)O7+^C7^>3U9!ZH
M9%<\_A:%:G4^F U0R!8TB]47_O@K*R<T,7@!CV7^/WHLV[H#%&12\:0TUB-(
MHK3X2Y]*1S0,\'B' 2D-R+;!9(?!J#08;1F073V,2X/Q6X<T*0WRJ3O%W'/'
M>531^9G@CTB8UAK-7.3>SZVUOZ+4/"AW2NAO(VVGYOZ/+%+/Z%,:L-10AFYC
MFDKT_C,5@IH;']![CRD:Q?(#.D;W=QYZ_^X#>H<<)%=4,(FB%-VGD9)'^J:^
MOHGB6#\!\LQ1>GBF$R<HAW)5#(7L& I&-SQ5*XG\-&1AA[VWQYY8 !SME\HY
MY,4YE\2*^!M-A\C%1XBX9-PUH3WF63Q$H\)\U#4?N[G' JNY_W9S8G'&J'I2
M1CG>> ?>G>+!]V,3E"$*>*(SE:1YK+,G<\TZ1GAI130Y\*-<TX"=#W22DTQL
MV&#^\T]XZO[2Y>P";)J#F?RWF;O#Z9FS:7H4LD,?"*SE[7'E[;'5VU<\2;1O
M<Z<?H2NZCA2-T5T1<E^*[D*D%PITG:E,,/1)RHSJ*.ZBP=I57QH@P;P";-+@
M=#P=NV0V(FUB_=<-R7B"]>]IU;#EYTGEYXG5S]_RE42[DFZ8T"LC6@J:*A12
MQ=""1@)M:)QU.M6*V]>ID&!> 39K^ H/3T^V' K48\OIT\KI4ZO3KRO'(KY
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MACV"G6);=(RHV2RA+R$<CY9IEMD([G9(UZNPF8,WA2OM^=@(]S,Q-ZKS;M?
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M?[]K)V0I"J@?]H7X<<_Q.1??Z_%>R!>5 6AR*'*N)DZF=7GGNBK)H*#J1I3
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MIN7E":,]9FJ ?'^@5#S=J(.]YJAX^1]02P,$%     @ CX)U6/8YC:C6!
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M_TZJI_.]^?KXR_+KY.R]7'!.MQ7E^2]02P,$%     @ CX)U6/\GIW7C 0
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M'#\\\];4W2&?#7\RFKT!4$L! A0#%     @ CX)U6 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "/
M@G585G[82NX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "/@G58F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (^"=5C32X<8
MI@<  !HR   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "/@G584UYM2R$&  "D&0  &
M@('I#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ CX)U
M6)(5T!!X @  ,P<  !@              ("!0!8  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( (^"=5B/=UJ@GP0  ,<2   8
M      " @>X8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" "/@G585*TC.*T%  "*(P  &               @('#'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ CX)U6%[6)?4J!P  1R$  !@
M             ("!IB,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( (^"=5B>JF)$F@(   \(   8              " @08K  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "/@G58VJ')0@(#  #Q
M!@  &               @('6+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ CX)U6#RYB#Z-"0  FQL  !@              ("!#C$
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (^"=5A5?YY=
MBAP  #18   9              " @=$Z  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ CX)U6/P'P](C!P  4Q,  !D
M ("!DE<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "/
M@G589+OD:08#   .!P  &0              @('L7@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (^"=5A!^&H\/P0  $,,   9
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M970Q-RYX;6Q02P$"% ,4    " "/@G58JZO3C7D*   <'0  &0
M    @($W@@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M (^"=5C8C$*Y'0D  &D7   9              " @>>,  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ CX)U6-M-7'=3"0  T!<  !D
M             ("!.Y8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " "/@G58AQ"QP,,"  !&!@  &0              @('%GP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (^"=5@ 2@^(]AT
M #MC   9              " @;^B  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ CX)U6,<O5<AK P  O@<  !D              ("!
M[,   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "/@G58
MP^STQ74$  !?"P  &0              @(&.Q   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( (^"=5C)/QS^XP(  )$&   9
M      " @3K)  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ CX)U6,,O+9MM P  = D  !D              ("!5,P  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "/@G58RKE]\&T$  "4#0
M&0              @('XSP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( (^"=5A(@W_+X00  &4/   9              " @9S4  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ CX)U6'[^8#H@
M!0    \  !D              ("!M-D  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " "/@G58+PCA("X#  ",!P  &0
M@($+WP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (^"
M=5A-GGNZU@,  )D/   9              " @7#B  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ CX)U6(U\O1\8!   #!@  !D
M         ("!?>8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " "/@G584W3[?98#   4#0  &0              @(',Z@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (^"=5B:#?1K# ,  "\-
M   9              " @9GN  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ CX)U6*GNRW P @  &@4  !D              ("!W/$
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "/@G58'^=B
M9T0$  !;&0  &0              @(%#]   >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( (^"=5A9ORCW@@,  -@*   9
M  " @;[X  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MCX)U6%O0<"X-!   +18  !D              ("!=_P  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " "/@G58@DDQI7$"  !&!@  &0
M            @(&[  $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( (^"=5@"OOAPL ,  %L1   9              " @6,# 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ CX)U6"(_3$-Q @
M;@8  !D              ("!2@<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " "/@G58RAQEY9D"   S!P  &0              @('R
M"0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( (^"=5B2
M<W5:4 0  .<4   9              " @<(, 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ CX)U6'PV#8>2 P  7PX  !D
M     ("!21$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (^"=5ALC$-8V 0  $<9   9              "
M@0XK 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ CX)U
M6)!0X<IK P  8 L  !D              ("!'3 ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " "/@G58KCZJ;;X#   D$0  &0
M        @(&_,P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( (^"=5B*6J.^/0,  " ,   9              " @;0W 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ CX)U6.9&O4Q\ P  F0L
M !D              ("!*#L! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " "/@G58NSR8Z9H"  #V!@  &0              @(';/@$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( (^"=5BQE__L
M#@0   L/   9              " @:Q! 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ CX)U6#C.7TV( P  6@P  !D
M ("!\44! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "/
M@G58B\R+87P&  !>,   &0              @(&P20$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( (^"=5CG&MB;)P0  #86   9
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M970V,BYX;6Q02P$"% ,4    " "/@G58IXOW\S4#  #($P  #0
M    @ %D80$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (^"=5B7BKL<P
M !,"   +              "  <1D 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M (^"=5@:(,5%& 4  & I   /              "  :UE 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "/@G58=TMQA08"  #Q)   &@
M@ 'R:@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "/
M@G58_R>G=>,!  !L)   $P              @ $P;0$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     1@!& "$3  !$;P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>325</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Grant and Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantAndAwards</Role>
      <ShortName>Grant and Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Employee Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan</Role>
      <ShortName>Employee Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Description of the Business (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Organization and Description of the Business (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails</Role>
      <ShortName>Liquidity and Going Concern (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails</Role>
      <ShortName>Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails</Role>
      <ShortName>Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Balance Sheet Details (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Details (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details (Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Balance Sheet Details (Other receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails</Role>
      <ShortName>Balance Sheet Details (Other receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureConvertibleDebt</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stockholders' Equity (Deficit) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Shareholders' Equity (Shares Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Equity Incentive Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails</Role>
      <ShortName>Equity Incentive Plans (Restricted stock award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails</Role>
      <ShortName>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Income Taxes (Narrative) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail</Role>
      <ShortName>Income Taxes (Narrative) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Components of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Grant and Awards (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails</Role>
      <ShortName>Grant and Awards (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureGrantAndAwards</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Employee Retirement Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails</Role>
      <ShortName>Employee Retirement Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="armp-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockSharesOutstanding, us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:UnrecognizedTaxBenefits -  armp-20231231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  armp-20231231x10k.htm 9</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '41401 - Disclosure - Employee Retirement Plan (Narrative) (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. armp-20231231.xsd 369, https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30</Log>
  </Logs>
  <InputFiles>
    <File>armp-20231231.xsd</File>
    <File>armp-20231231_cal.xml</File>
    <File>armp-20231231_def.xml</File>
    <File>armp-20231231_lab.xml</File>
    <File>armp-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="armp-20231231x10k.htm">armp-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>armp-20231231x10k003.jpg</File>
    <File>armp-20231231x10k004.jpg</File>
    <File>armp-20231231x10k005.jpg</File>
    <File>armp-20231231x10k006.jpg</File>
    <File>armp-20231231x10k007.jpg</File>
    <File>armp-20231231x10k008.jpg</File>
    <File>armp-20231231x10k009.jpg</File>
    <File>armp-20231231x10k010.jpg</File>
    <File>armp-20231231x10k011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="478">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "armp-20231231x10k.htm": {
   "nsprefix": "armp",
   "nsuri": "http://www.armatapharma.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "armp-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "armp-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "armp-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "armp-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "armp-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "armp-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 272,
   "keyCustom": 53,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 30,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 10
   },
   "contextCount": 160,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 579,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 478,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity",
     "longName": "00300 - Statement - Consolidated Statements of Shareholders' (Deficit) Equity",
     "shortName": "Consolidated Statements of Shareholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "longName": "00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "10101 - Disclosure - Organization and Description of the Business",
     "shortName": "Organization and Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern",
     "longName": "10201 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10301 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurements",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShare",
     "longName": "10501 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails",
     "longName": "10601 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.armatapharma.com/role/DisclosureConvertibleDebt",
     "longName": "10701 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:ConvertibleDebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.armatapharma.com/role/DisclosureLongTermDebt",
     "longName": "10801 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit",
     "longName": "10901 - Disclosure - Stockholders' Equity (Deficit)",
     "shortName": "Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans",
     "longName": "11001 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxes",
     "longName": "11101 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11201 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.armatapharma.com/role/DisclosureGrantAndAwards",
     "longName": "11301 - Disclosure - Grant and Awards",
     "shortName": "Grant and Awards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:AwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:AwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan",
     "longName": "11401 - Disclosure - Employee Retirement Plan",
     "shortName": "Employee Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20302 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "30303 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables",
     "longName": "30503 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables",
     "longName": "30603 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables",
     "longName": "30903 - Disclosure - Stockholders' Equity (Deficit) (Tables)",
     "shortName": "Stockholders' Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables",
     "longName": "31003 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables",
     "longName": "31103 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "31203 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
     "longName": "40101 - Disclosure - Organization and Description of the Business (Narrative) (Details)",
     "shortName": "Organization and Description of the Business (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_sBfL2nm_uUqs1c4xDma_2Q",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
     "longName": "40201 - Disclosure - Liquidity and Going Concern (Narrative) (Details)",
     "shortName": "Liquidity and Going Concern (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
     "longName": "40301 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_item_ut51679BVkKDEZU2hHrXGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_item_ut51679BVkKDEZU2hHrXGg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "40303 - Disclosure - Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)",
     "shortName": "Significant Accounting Policies (Useful Lives of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "armp:PropertyAndEquipmentUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails",
     "longName": "40401 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
     "longName": "40402 - Disclosure - Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)",
     "shortName": "Fair Value Measurements (Company's Fair Value Measurements Using Level 3 Inputs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ",
      "name": "armp:DebtInstrumentMeasurementInputForPeriod",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ",
      "name": "armp:DebtInstrumentMeasurementInputForPeriod",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails",
     "longName": "40403 - Disclosure - Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)",
     "shortName": "Fair Value Measurement (Changes in Fair Value of Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
     "longName": "40501 - Disclosure - Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "shortName": "Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails",
     "longName": "40601 - Disclosure - Balance Sheet Details (Narrative) (Details)",
     "shortName": "Balance Sheet Details (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
     "longName": "40602 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)",
     "shortName": "Balance Sheet Details (Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails",
     "longName": "40603 - Disclosure - Balance Sheet Details (Other receivables) (Details)",
     "shortName": "Balance Sheet Details (Other receivables) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "armp:TenantImprovementReceivableCurrent",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "armp:TenantImprovementReceivableCurrent",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "40604 - Disclosure - Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)",
     "shortName": "Balance Sheet Details (Accounts Payable and Accrued Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
     "longName": "40701 - Disclosure - Convertible Debt (Narrative) (Details)",
     "shortName": "Convertible Debt (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "armp:IncreaseDecreaseFairValueOfLiabilities",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_mj_DWLuDI0Cq6OS1KhCggw",
      "name": "armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "armp:ConvertibleDebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails",
     "longName": "40801 - Disclosure - Long-Term Debt (Details)",
     "shortName": "Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
     "longName": "40901 - Disclosure - Stockholders' Equity (Deficit) (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Deficit) (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_ftqcXLn_pEaX9uiZCz_1XQ",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails",
     "longName": "40902 - Disclosure - Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)",
     "shortName": "Stockholders' Equity (Deficit) (Summary of Warrants Outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_d5V1utBQS0W089AQBKdTBg",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
     "longName": "40903 - Disclosure - Shareholders' Equity (Shares Reserved for Future Issuance) (Details)",
     "shortName": "Shareholders' Equity (Shares Reserved for Future Issuance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
     "longName": "41001 - Disclosure - Equity Incentive Plans (Narrative) (Details)",
     "shortName": "Equity Incentive Plans (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w",
      "name": "armp:ShareBasedPaymentArrangementExpenseReversed",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w",
      "name": "armp:ShareBasedPaymentArrangementExpenseReversed",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
     "longName": "41002 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "shortName": "Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
     "longName": "41003 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)",
     "shortName": "Equity Incentive Plans (Restricted stock award) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
     "longName": "41004 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "shortName": "Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ",
      "name": "armp:EquitySecuritiesMeasurementInput",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ",
      "name": "armp:EquitySecuritiesMeasurementInput",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
     "longName": "41005 - Disclosure - Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)",
     "shortName": "Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
     "longName": "41101 - Disclosure - Income Taxes (Narrative) (Detail)",
     "shortName": "Income Taxes (Narrative) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "armp:OperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "armp:OperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails",
     "longName": "41102 - Disclosure - Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)",
     "shortName": "Income Taxes ((Loss) Income from Continuing Operations Before Income Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "longName": "41103 - Disclosure - Income Taxes (Components of Deferred Tax Assets) (Details)",
     "shortName": "Income Taxes (Components of Deferred Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails",
     "longName": "41104 - Disclosure - Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)",
     "shortName": "Income Taxes (Reconciliation of Statutory to Effective Income Tax Rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "41201 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
     "longName": "41202 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "shortName": "Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
     "longName": "41301 - Disclosure - Grant and Awards (Narrative) (Details)",
     "shortName": "Grant and Awards (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "armp:AwardTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails",
     "longName": "41401 - Disclosure - Employee Retirement Plan (Narrative) (Details)",
     "shortName": "Employee Retirement Plan (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "armp-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current, Total",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r657"
     ]
    },
    "armp_AccruedLiabilitiesClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AccruedLiabilitiesClinicalTrial",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities clinical trial.",
        "label": "Accrued Liabilities Clinical Trial",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r144",
      "r498"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Total",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r657",
      "r846"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r528",
      "r772",
      "r773",
      "r774",
      "r830",
      "r847"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r339"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r692",
      "r702",
      "r728"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r695",
      "r705",
      "r731"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r696",
      "r706",
      "r723",
      "r732",
      "r736",
      "r744"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r383"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r443",
      "r642",
      "r643",
      "r766"
     ]
    },
    "armp_AnnualIncreaseInRentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AnnualIncreaseInRentPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in rent percentage.",
        "label": "Annual Increase in Rent Percentage",
        "terseLabel": "Annual increase in rent percentage"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AnnualReductionOfStandbyLetterOfCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AnnualReductionOfStandbyLetterOfCredit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual reduction of standby letter of credit..",
        "label": "Annual Reduction Of Standby Letter Of Credit",
        "terseLabel": "Annual reduction of standby letter of credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from computation of diluted weighted shares outstanding",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "armp_ArmataPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ArmataPharmaceuticalsInc.Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armata Pharmaceuticals, Inc.",
        "label": "Armata Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Armata Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Total",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r147",
      "r166",
      "r201",
      "r211",
      "r213",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r413",
      "r417",
      "r434",
      "r491",
      "r566",
      "r657",
      "r670",
      "r792",
      "r793",
      "r836"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current, Total",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r152",
      "r166",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r413",
      "r417",
      "r434",
      "r657",
      "r792",
      "r793",
      "r836"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688"
     ]
    },
    "armp_AwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award abstract.",
        "label": "Grant and Awards"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardAgreementInterruptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardAgreementInterruptionPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.",
        "label": "Award Agreement, Interruption Period",
        "terseLabel": "Award agreement interruption period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "armp_AwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award line items.",
        "label": "Award [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of award receivable.",
        "label": "Award Receivable",
        "terseLabel": "Award receivable"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award table.",
        "label": "Award [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "armp_AwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "AwardTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents about award text block.",
        "label": "Award Text Block",
        "terseLabel": "Grant and Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "armp_BaseAnnualRentToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "BaseAnnualRentToBePaidYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for base rent to be paid in year three.",
        "label": "Base Annual Rent To Be Paid Year Three",
        "terseLabel": "Base annual rent for 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "armp_C3jStockPlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "C3jStockPlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to C3J 2016 stock plan.",
        "label": "C3J Stock Plan 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r142",
      "r628"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r120"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r97",
      "r163"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r97"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r148",
      "r149",
      "r150",
      "r166",
      "r188",
      "r189",
      "r191",
      "r193",
      "r199",
      "r200",
      "r248",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r301",
      "r302",
      "r305",
      "r308",
      "r315",
      "r434",
      "r521",
      "r522",
      "r523",
      "r524",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r554",
      "r575",
      "r593",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r751",
      "r768",
      "r775"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r199",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r313",
      "r315",
      "r521",
      "r522",
      "r523",
      "r524",
      "r644",
      "r751",
      "r768"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r493",
      "r553"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r266",
      "r267",
      "r614",
      "r789"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total shares reserved",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r772",
      "r773",
      "r830",
      "r845",
      "r847"
     ]
    },
    "armp_CommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "CommonStockOptionsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time.",
        "label": "Common Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r554"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82",
      "r554",
      "r572",
      "r847",
      "r848"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 217,000,000 shares authorized; 36,122,932 and 36,144,706 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r494",
      "r657"
     ]
    },
    "armp_CommonStockVotingPercentageHeldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "CommonStockVotingPercentageHeldPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting rights of the total number of shares of the common stock of company on matters related to election or removal of board members.",
        "label": "Common Stock, Voting Percentage Held Percentage",
        "terseLabel": "Total number of shares (in percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Retirement Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risks and Certain Other Risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r131"
     ]
    },
    "us-gaap_ContributionOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContributionOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of Property",
        "terseLabel": "Property and equipment included in accounts payable",
        "documentation": "Value of property contributed in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "armp_ConvertibleDebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ConvertibleDebtDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for convertible debt.",
        "label": "Convertible Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible debt",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "armp_ConvertibleLoanPostModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ConvertibleLoanPostModificationMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to  \nConvertible Loan Post Modification.",
        "label": "Convertible Loan Post Modification [Member]",
        "terseLabel": "Convertible Loan Post Modification"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ConvertibleLoanPreModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ConvertibleLoanPreModificationMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to  \nConvertible Loan Pre Modification.",
        "label": "Convertible Loan Pre Modification [Member]",
        "terseLabel": "Convertible Loan Pre Modification"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r284",
      "r303",
      "r453",
      "r629",
      "r631"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "armp_CreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "CreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to credit and security agreement.",
        "label": "Credit And Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "armp_CysticFibrosisFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "CysticFibrosisFoundationMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cystic Fibrosis Foundation.",
        "label": "Cystic Fibrosis Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r77",
      "r78",
      "r122",
      "r124",
      "r171",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r444",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r769"
     ]
    },
    "armp_DebtInstrumentConversionPercentOfDiscountOnSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "DebtInstrumentConversionPercentOfDiscountOnSharePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent  of discount on share price for conversion of debt into shares of common stock.",
        "label": "Debt Instrument, Conversion, Percent of Discount on Share Price",
        "terseLabel": "Discount on share price for conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r283"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71",
      "r281",
      "r444",
      "r640",
      "r641"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, interest rate, stated percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r282"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Term Loan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r444",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r769"
     ]
    },
    "armp_DebtInstrumentMeasurementInputForPeriod": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "DebtInstrumentMeasurementInputForPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instruments, including, but not limited to, convertible and non-convertible debt for the period.",
        "label": "Debt Instrument, Measurement Input For The Period",
        "terseLabel": "Debt instrument, measurement input, for the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r171",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r444",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r48",
      "r51",
      "r68",
      "r69",
      "r71",
      "r73",
      "r110",
      "r111",
      "r171",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r444",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance cost",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r287",
      "r298",
      "r640",
      "r641"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r113"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r123",
      "r397"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "verboseLabel": "Deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r492"
     ]
    },
    "armp_DeferredTaxAssetLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "DeferredTaxAssetLeaseObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset lease obligation.",
        "label": "Deferred Tax Asset Lease Obligation",
        "terseLabel": "Lease accounting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets after valuation allowance",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry-forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r827"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "In-process research and development",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r828"
     ]
    },
    "armp_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "verboseLabel": "Employer contribution to 401(k) plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Total",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r203"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets and Liabilities - Derivative Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "verboseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r341",
      "r372",
      "r373",
      "r375",
      "r651"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688",
      "r724"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "terseLabel": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r186",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r428",
      "r429",
      "r488",
      "r504",
      "r632"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r188",
      "r191",
      "r192",
      "r193",
      "r197",
      "r428",
      "r429",
      "r488",
      "r504",
      "r632"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "U.S. federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r391",
      "r407"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r829"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in rate",
        "verboseLabel": "Effect of change in federal tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r825"
     ]
    },
    "armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to debt extinguishment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Debt Extinguishment, Percent",
        "terseLabel": "Debt extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "armp_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to fair value adjustment on convertible debt.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Fair Value Adjustment on Convertible Debt, Percent",
        "terseLabel": "Fair value adjustment on convertible debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r829"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income taxes, net of federal tax",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r829"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average remaining period for recognition of compensation costs related to unvested options",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "verboseLabel": "Unrecognized compensation cost related to unvested options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "documentation": "Information by name of employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares",
        "verboseLabel": "Employee stock purchase plan",
        "documentation": "The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "documentation": "Entities identify multiple employee stock ownership plans by unique name."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "armp_EmployeeStockPurchasePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "EmployeeStockPurchasePlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to 2016 Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan, 2016"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r138",
      "r156",
      "r157",
      "r158",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r249",
      "r250",
      "r317",
      "r376",
      "r377",
      "r378",
      "r403",
      "r404",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r452",
      "r512",
      "r513",
      "r514",
      "r528",
      "r593"
     ]
    },
    "armp_EquityIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "EquityIncentivePlan2016Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016 [Member]",
        "label": "Equity Incentive Plan 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "armp_EquitySecuritiesMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "EquitySecuritiesMeasurementInput",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value for the period.",
        "label": "Equity Securities Measurement Input",
        "terseLabel": "Fair value input, equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r692",
      "r702",
      "r728"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r689",
      "r699",
      "r725"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "armp_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight [Member].",
        "label": "Exercise Price $5.00"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member].",
        "label": "Exercise Price $2.87."
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member].",
        "label": "Exercise Price $2.87"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price nine.",
        "label": "Exercise Price $5.00."
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member].",
        "label": "Exercise Price $3.25"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exercise Price Five Member.",
        "label": "Exercise Price $3.25."
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price ten.",
        "label": "Exercise Price 1680.00"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member].",
        "label": "Exercise Price $5.60"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r431",
      "r458",
      "r459",
      "r460",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r431",
      "r460",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Changes in Fair Value of Liabilities",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r119"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount exchanged in financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Amount Exchanged",
        "terseLabel": "Amount exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Loss on extinguishment",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "armp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of initial recognition of modified convertible loan of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Initial Recognition of modified Convertible Loan",
        "terseLabel": "Initial recognition of modified Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Net issuance of the Convertible Loan",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at September 30, 2023",
        "periodStartLabel": "Balance at December 31, 2022",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r458",
      "r459",
      "r460",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r297",
      "r313",
      "r425",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r503",
      "r637",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency Translations and Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r732"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss from disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r786",
      "r787"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on convertible debt extinguishment",
        "terseLabel": "Loss on convertible debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r43",
      "r44"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r577"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r260",
      "r487",
      "r638",
      "r657",
      "r782",
      "r783"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r263",
      "r638"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r261",
      "r262",
      "r263",
      "r638"
     ]
    },
    "armp_GrantAndAwardReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "GrantAndAwardReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of awards receivable current.",
        "label": "Grant and Award Receivable, Current",
        "verboseLabel": "Grant and award receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "armp_GrantsAndAwardsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "GrantsAndAwardsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about the grants and awards policy.",
        "label": "Grants And Awards Policy Text Block",
        "terseLabel": "Grants Revenue and Other Awards"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r675",
      "r688"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "verboseLabel": "Impairment of in-process research and development",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r784"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "verboseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r40",
      "r104"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r105"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "verboseLabel": "In-Process Research and Development (\"IPR&amp;D\")",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r406"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r88",
      "r126",
      "r201",
      "r210",
      "r212",
      "r214",
      "r489",
      "r500",
      "r634"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesLossIncomeFromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r406"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r578"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r578"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r385",
      "r392",
      "r394",
      "r401",
      "r405",
      "r408",
      "r409",
      "r410",
      "r526"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "verboseLabel": "Interest and penalties pertaining to income tax examination recognized",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r387",
      "r388",
      "r394",
      "r395",
      "r400",
      "r402",
      "r520"
     ]
    },
    "armp_IncomeTaxRateReconciliationPermanentDifferences1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "IncomeTaxRateReconciliationPermanentDifferences1",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the contribution of other permanent differences between reported income tax expense (benefit) and expected income tax expense (benefit) computed",
        "label": "Income Tax Rate Reconciliation Permanent Differences 1",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "armp_IncreaseDecreaseFairValueOfLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "IncreaseDecreaseFairValueOfLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) fair value of liabilities.",
        "label": "Increase Decrease Fair Value of Liabilities",
        "terseLabel": "Change in fair value of convertible debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Compensation",
        "terseLabel": "Accrued compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "armp_IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in expected revenue that is not accounted for under Topic 606, classified as other.",
        "label": "Increase Decrease in Expected Revenue Not from Contract with Customer, Other",
        "terseLabel": "Increase in expected revenue from grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Lease Right of Use Asset And Liability, Net",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Increase (decrease) operating lease right-of-use and liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r765"
     ]
    },
    "armp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in operating lease right of use asset.",
        "label": "Increase (Decrease) in Operating Lease Right Of Use Asset",
        "negatedLabel": "Change in right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r687",
      "r696",
      "r706",
      "r723",
      "r732",
      "r736",
      "r744"
     ]
    },
    "armp_InnovivaStrategicOpportunitiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "InnovivaStrategicOpportunitiesLlcMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva Strategic Opportunities LLC [Member].",
        "label": "Innoviva Strategic Opportunities LLC [Member]",
        "terseLabel": "Innoviva Strategic Opportunities LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r748"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r748"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r748"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "In-process research and development",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r294",
      "r299",
      "r642",
      "r643"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r202"
     ]
    },
    "armp_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandAndBuildingMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land and Building [Member]",
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": []
    },
    "armp_LeaseAndRentalAbatementCreditPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "LeaseAndRentalAbatementCreditPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of lease and rental abatement credit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease And Rental Abatement Credit, Period",
        "terseLabel": "Period of lease and rental abatement credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "verboseLabel": "Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Standby letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Total",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r166",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r414",
      "r417",
      "r418",
      "r434",
      "r552",
      "r633",
      "r670",
      "r792",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity, Total",
        "totalLabel": "Total liabilities and shareholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r125",
      "r496",
      "r657",
      "r770",
      "r781",
      "r832"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and shareholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current, Total",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r141",
      "r166",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r414",
      "r417",
      "r418",
      "r434",
      "r657",
      "r792",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "verboseLabel": "Change in fair value of convertible debt",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "armp_LiquidityAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "LiquidityAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity And Going Concern [Abstract]",
        "label": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Recognized at fair value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "armp_MaximumAllowanceForTenantImprovementsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "MaximumAllowanceForTenantImprovementsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum allowance for tenant improvements receivable.",
        "label": "Maximum Allowance For Tenant Improvements Receivable",
        "terseLabel": "Maximum allowance for tenant improvements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r336",
      "r485",
      "r511",
      "r543",
      "r544",
      "r598",
      "r600",
      "r602",
      "r603",
      "r605",
      "r624",
      "r625",
      "r636",
      "r644",
      "r650",
      "r659",
      "r794",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "armp_MedicalTechnologyEnterpriseConsortiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "MedicalTechnologyEnterpriseConsortiumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Technology Enterprise Consortium [Member].",
        "label": "Medical Technology Enterprise Consortium [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r336",
      "r485",
      "r511",
      "r543",
      "r544",
      "r598",
      "r600",
      "r602",
      "r603",
      "r605",
      "r624",
      "r625",
      "r636",
      "r644",
      "r650",
      "r659",
      "r794",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Outstanding equity (in percent)",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r99",
      "r127",
      "r139",
      "r153",
      "r154",
      "r158",
      "r166",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r190",
      "r201",
      "r210",
      "r212",
      "r214",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r429",
      "r434",
      "r502",
      "r574",
      "r591",
      "r592",
      "r634",
      "r668",
      "r792"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r696",
      "r706",
      "r723",
      "r732"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "armp_NoncashInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "NoncashInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income included in net income that result in no cash inflow",
        "label": "Noncash Interest Income",
        "negatedLabel": "Non-cash interest income"
       }
      }
     },
     "auth_ref": []
    },
    "armp_NumberOfBoardDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "NumberOfBoardDirectors",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Board directors during the period",
        "label": "Number of Board Directors"
       }
      }
     },
     "auth_ref": []
    },
    "armp_NumberOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "NumberOfDirectors",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors during the period",
        "label": "Number of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "armp_NumberOfStandbyLettersOfCreditIncludedInRestrictedCash": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "NumberOfStandbyLettersOfCreditIncludedInRestrictedCash",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of irrevocable letters of credit with financial institutions.",
        "label": "Number of Standby Letters of Credit included in Restricted Cash",
        "verboseLabel": "Letters of credit"
       }
      }
     },
     "auth_ref": []
    },
    "armp_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of tranches.",
        "label": "Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "auth_ref": []
    },
    "armp_OfficeAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "OfficeAndComputerEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Computer Equipment [Member]",
        "label": "Office and Computer Equipment [Member]",
        "terseLabel": "Office and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And Research And Development Space Los Angeles California [Member].",
        "label": "2021 Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office and Computer Equipment [Member].",
        "terseLabel": "Office and computer equipment",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses, Total",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss), Total",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r210",
      "r212",
      "r214",
      "r634"
     ]
    },
    "armp_OperatingLeaseBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "OperatingLeaseBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease base rent.",
        "label": "Operating Lease Base Rent",
        "terseLabel": "Operating lease expected yearly base rent"
       }
      }
     },
     "auth_ref": []
    },
    "armp_OperatingLeaseBaseRentEndOfLeaseTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "OperatingLeaseBaseRentEndOfLeaseTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent for operating lease at the end of lease term.",
        "label": "Operating Lease Base Rent, End OF Lease Term",
        "terseLabel": "Base rent at the end of lease term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Net",
        "verboseLabel": "Rent expense under operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Noncurrent operating lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r449"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards (\"NOLs\")",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "armp_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards that are not subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss not subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Description of the Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r118",
      "r517",
      "r518"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other receivables",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r657"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpensesAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r657"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r694",
      "r704",
      "r730"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r697",
      "r707",
      "r733"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r685",
      "r697",
      "r707",
      "r733"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred offering costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments for taxes related to net share settlement of equity awards",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEmployeeRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "verboseLabel": "Employee Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r649"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "armp_PercentageOfLongLivedAssetsInGeographicalLocation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "PercentageOfLongLivedAssetsInGeographicalLocation",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of long lived assets In geographical location.",
        "label": "Percentage of Long Lived Assets In Geographical Location",
        "terseLabel": "Percentage of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "armp_ProbabilitiesOfSettlementScenariosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ProbabilitiesOfSettlementScenariosMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of probability of settlement scenarios.",
        "label": "Probabilities of Settlement Scenarios [Member]",
        "terseLabel": "Probabilities of settlement scenarios"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from issuance of convertible debt, net of issuance costs",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "armp_ProceedsFromExerciseOfWarrantsAndStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ProceedsFromExerciseOfWarrantsAndStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of warrants and stock options.",
        "label": "Proceeds From Exercise Of Warrants And Stock Options",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from sale of common stock, net of offering costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of issuance costs",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Proceeds from issuance of common stock and warrants",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r521"
     ]
    },
    "armp_ProceedsFromQualifiedFinancingPerAgreementBenchmark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ProceedsFromQualifiedFinancingPerAgreementBenchmark",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from qualified financing per agreement benchmark.",
        "label": "Proceeds from Qualified Financing Per Agreement Benchmark",
        "terseLabel": "Proceeds from qualified financing per agreement benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "verboseLabel": "Total debt financing",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "armp_ProceedsFromTenantAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ProceedsFromTenantAllowances",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Proceeds From Tenant Allowances",
        "terseLabel": "Tenant allowances"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r486",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r626",
      "r645",
      "r658",
      "r753",
      "r790",
      "r791",
      "r795",
      "r844"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r486",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r626",
      "r645",
      "r658",
      "r753",
      "r790",
      "r791",
      "r795",
      "r844"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r153",
      "r154",
      "r161",
      "r166",
      "r175",
      "r183",
      "r184",
      "r201",
      "r210",
      "r212",
      "r214",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r412",
      "r415",
      "r416",
      "r429",
      "r434",
      "r489",
      "r501",
      "r527",
      "r574",
      "r591",
      "r592",
      "r634",
      "r653",
      "r654",
      "r669",
      "r764",
      "r792"
     ]
    },
    "armp_PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of property and equipment not in use included in laboratory equipment.",
        "label": "Property and Equipment Not in Use Included in Laboratory Equipment",
        "terseLabel": "Property and equipment not in use"
       }
      }
     },
     "auth_ref": []
    },
    "armp_PropertyAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "PropertyAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of property and equipment including, but not limited to, laboratory equipment, office and computer equipment, and leasehold improvements.",
        "label": "Property and Equipment, Useful Life [Table Text Block]",
        "verboseLabel": "Schedule of useful lives of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Details",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r132",
      "r135",
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r143",
      "r499"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, Total",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Long-lived assets",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r490",
      "r499",
      "r657"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r132",
      "r135",
      "r497"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r319",
      "r336",
      "r367",
      "r368",
      "r369",
      "r461",
      "r485",
      "r511",
      "r543",
      "r544",
      "r598",
      "r600",
      "r602",
      "r603",
      "r605",
      "r624",
      "r625",
      "r636",
      "r644",
      "r650",
      "r659",
      "r662",
      "r788",
      "r794",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementsCompanySFairValueMeasurementsUsingLevel3InputsDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r319",
      "r336",
      "r367",
      "r368",
      "r369",
      "r461",
      "r485",
      "r511",
      "r543",
      "r544",
      "r598",
      "r600",
      "r602",
      "r603",
      "r605",
      "r624",
      "r625",
      "r636",
      "r644",
      "r650",
      "r659",
      "r662",
      "r788",
      "r794",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r689",
      "r699",
      "r725"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r284",
      "r303",
      "r453",
      "r630",
      "r631"
     ]
    },
    "armp_ResearchAndDevelopmentBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ResearchAndDevelopmentBenefit",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate benefit incurred during the reporting period as a result of research and development activities.",
        "label": "Research and development benefit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r690",
      "r700",
      "r726"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r691",
      "r701",
      "r727"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r686",
      "r698",
      "r708",
      "r734"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r762",
      "r767"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]",
        "terseLabel": "Restricted stock awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned shares issued net of tax withholdings.",
        "label": "Restricted Stock Returned Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Withholdings for taxes related to net share settlement of equity awards, shares"
       }
      }
     },
     "auth_ref": []
    },
    "armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned value shares issued net of tax withholdings .",
        "label": "Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Withholdings for taxes related to net share settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit), Total",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r112",
      "r495",
      "r515",
      "r516",
      "r525",
      "r555",
      "r657"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r249",
      "r250",
      "r376",
      "r377",
      "r378",
      "r403",
      "r404",
      "r419",
      "r421",
      "r422",
      "r424",
      "r427",
      "r512",
      "r514",
      "r528",
      "r847"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Grants Non Gaap",
        "terseLabel": "Revenue from grants",
        "verboseLabel": "Grant revenue",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r656"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "verboseLabel": "Schedule of Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation of Statutory to Effective Tax Rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "verboseLabel": "Schedule of Stock-Based Compensation Expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "(Loss) Income from Continuing Operations Before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.",
        "label": "Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used in the Black-Scholes Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r110",
      "r111",
      "r112",
      "r148",
      "r149",
      "r150",
      "r199",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r313",
      "r315",
      "r521",
      "r522",
      "r523",
      "r524",
      "r644",
      "r751",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Schedule of Warrant Information",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Long-term debt",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "armp_SecuredTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SecuredTermLoanMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to secured term loan.",
        "label": "Secured Term Loan [Member]",
        "terseLabel": "Secured term loan"
       }
      }
     },
     "auth_ref": []
    },
    "armp_SecuritiesPurchaseAgreementFirstTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SecuritiesPurchaseAgreementFirstTrancheMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement First Tranche [Member].",
        "label": "Securities Purchase Agreement First Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "armp_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member].",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "armp_SecuritiesPurchaseAgreementSecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SecuritiesPurchaseAgreementSecondTrancheMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement Second Tranche [Member]",
        "label": "Securities Purchase Agreement Second Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r540",
      "r541",
      "r542",
      "r599",
      "r601",
      "r604",
      "r606",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r646",
      "r662",
      "r795",
      "r844"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r216",
      "r635"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Total",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period of share-based compensation award",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "verboseLabel": "Restricted stock awards/units",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Avg Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and Issued as Common Stock (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and Issued as Common Stock (in dollars per shares)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for future grants under the 2016 Plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at September 30, 2023",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable at September 30, 2023",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "armp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeited in period intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Forfeited/Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited/Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance",
        "periodEndLabel": "Shares, Balance Ending",
        "periodStartLabel": "Shares, Balance Beginning",
        "verboseLabel": "Stock options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2023",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest at September 30, 2023",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Vested and expected to vest at September 30, 2023",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of annual increase in number of shares",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Additional awards",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r345",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r379",
      "r380",
      "r381",
      "r382"
     ]
    },
    "armp_ShareBasedPaymentArrangementExpenseReversed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ShareBasedPaymentArrangementExpenseReversed",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award reversed under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense, Reversed",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Common stock closing price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Expiration period of share-based payment award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable at September 30, 2023",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2023",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at September 30, 2023",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested options",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "armp_SharesIssuableUponConversionOfConvertibleDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SharesIssuableUponConversionOfConvertibleDebt",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails": {
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureShareholdersEquitySharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable upon conversion of convertible debt.",
        "label": "Shares Issuable Upon Conversion Of Convertible Debt",
        "terseLabel": "Shares issuable upon the conversion of Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "armp_SharesIssuableUponConversionOfConvertibleLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "SharesIssuableUponConversionOfConvertibleLoanMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issuable upon the conversion of Convertible Loan",
        "label": "Shares issuable upon the conversion of Convertible Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "armp_ShortTermVariableLeasePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ShortTermVariableLeasePaymentAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short- term variable lease payment amount.",
        "label": "Short-Term Variable Lease Payment Amount",
        "terseLabel": "Plus: estimated short-term variable lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r164"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r148",
      "r149",
      "r150",
      "r166",
      "r188",
      "r189",
      "r191",
      "r193",
      "r199",
      "r200",
      "r248",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r301",
      "r302",
      "r305",
      "r308",
      "r315",
      "r434",
      "r521",
      "r522",
      "r523",
      "r524",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r554",
      "r575",
      "r593",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r751",
      "r768",
      "r775"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r138",
      "r156",
      "r157",
      "r158",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r249",
      "r250",
      "r317",
      "r376",
      "r377",
      "r378",
      "r403",
      "r404",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r452",
      "r512",
      "r513",
      "r514",
      "r528",
      "r593"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r540",
      "r541",
      "r542",
      "r599",
      "r601",
      "r604",
      "r606",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r646",
      "r662",
      "r795",
      "r844"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "verboseLabel": "Organization and Description of the Business",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r486",
      "r519",
      "r539",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r663"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Shareholders' (Deficit) Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureConvertibleDebtNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfShareBasedCompensationExpenseDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail",
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusinessNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r486",
      "r519",
      "r539",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r663"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r693",
      "r703",
      "r729"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of Common Stock upon vesting of restricted stock units, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r24",
      "r48",
      "r112",
      "r291"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r81",
      "r82",
      "r112",
      "r521",
      "r593",
      "r608"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted stock awards (in shares)",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r81",
      "r82",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r81",
      "r82",
      "r112",
      "r351"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of Common Stock upon vesting of restricted stock units",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r81",
      "r82",
      "r112",
      "r528",
      "r593",
      "r608",
      "r669"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeiture of restricted stock awards",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r81",
      "r82",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r112"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "terseLabel": "Options",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "armp_StockOptionsAndRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "StockOptionsAndRestrictedStockAwardsMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Awards [Member].",
        "label": "Stock Options And Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfShareholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Attributable to Parent, Total",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total shareholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r101",
      "r556",
      "r572",
      "r594",
      "r595",
      "r657",
      "r670",
      "r770",
      "r781",
      "r832",
      "r847"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity (Deficit)",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r165",
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r317",
      "r426",
      "r596",
      "r597",
      "r612"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcernNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r454"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "verboseLabel": "Liquidity",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_TechnologyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyEquipmentMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member].",
        "terseLabel": "Laboratory and manufacturing equipment",
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals."
       }
      }
     },
     "auth_ref": []
    },
    "armp_TenantImprovementReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "TenantImprovementReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of current tenant improvement receivable.",
        "label": "Tenant Improvement Receivable, Current",
        "terseLabel": "Tenant improvement allowance receivable (Note 12)"
       }
      }
     },
     "auth_ref": []
    },
    "armp_ThresholdDevelopmentAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "ThresholdDevelopmentAward",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold amount of development award under the award agreement.",
        "label": "Threshold Development Award",
        "terseLabel": "Amount of threshold development award"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureFairValueMeasurementChangesInFairValueOfLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r297",
      "r313",
      "r425",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r503",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "armp_UnbilledAwardReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "UnbilledAwardReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantAndAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled award receivable.",
        "label": "Unbilled award receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r393"
     ]
    },
    "armp_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r129",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureIncomeTaxesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "armp_WarrantExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.armatapharma.com/20231231",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the terms related with expiration of warrants.",
        "label": "Warrant Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r193"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r193"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001558370-24-003706-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003706-xbrl.zip
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MOPKD'WYI[NFG;%@":Q"D[A;?*B UO$XNJ'[^8RWYF?3C5X4C:8;ST&H8/5V
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MQ7=T#;XC.,R"=$**ZZ8*LR$'VX/PAAIY5ZS>O,^"Y _[&&#=&PN=SFSQ7$:
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M%(:"$)C+CW@-6=P"U0JG17L  NMHW%H0Z38Y)6.'EC3CP?SP*GKA/^FEIVL
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M&:5^;(BPJ^9P^WX Y$ .-*G;\\)EDH4D3D2[%2(^>=<L1%RD4*R[]T3_>U:
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MK@<*AY;LE^0IBF,46A@G):C#]$,;*2CQ[A#1^>DX9TL1[_CG_P=02P,$%
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M12J+LZL9E$:@5Z9];O;4J?P:M4(=$#E6I4J <VXEX[M\DY^G:9*>)FE*_8[
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M\V_Y:?+X9GLC/8+>2Y/."8NQ>HTW)^K1B[!LV\\R)-"(GJ!,R'#)8U2C<!+
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M]6C<IM_#9>,Q3/M0O(Z@CV#C!.8*+@' )(Q) 7K"C:Y.?Z7I^87V!$>,7U^
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M6RB*I=T5\RX6\B9O/6NU<C!.GZ7'H[SBMH_$NZCVT&N<'P+==E1-QF:++X$
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M[6<AX+&,OD5M,) W8!N="]\P" NW#IN9&QWF@6R]Q"0:>PEXQ]"\NZO@T_X
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M[#BOGA^S&/7D]<1CDO#IW1.E^6GD95G(;$'4/N_IUFT9!\X%85*)-CH,VT2
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MVK['Z1>4G("U'WR)SX;5))HJ5P6-_ [P]NUJ>GTZ2S9>N'^CT3YB 3K5Y.9
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M2H,,2E7?T@@:_3%F\]<S^J!R!3U3<-N^#K][U925X_%:MQ;5(RHH<^ B<[P
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MI)3*738'F78G@&69>+\LNDQ=/7LY)J_!@T73!VP$T)&J#2N^TXP)10*@C];
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M0O8:TW";FR[?O9D3TAR\IJ)-^00/ER0T>-XGV>2]?H<U+:>F#Y*FX-5>E%Y
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M_YGFM]1/'F.XLI.?Q"F$.A=NW)8^ZR_06L%M2L1X_=.\[(]_,"'()*I 1JK
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M')V0.Q.8X8N_V?P,?_#X)1DIMAK*V_ J>U(Q<28%B.7[D'U&)G<=*_ =D&7
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M$XQS9/O$V:B1^EILCB$K*CUCFE3!ADBL?<A2K<,0/4RB.4!/P 'PC4[ =>N
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MQZ5]TN;GA>UYN=#;U= 44@T($7&[,R!Z7.\G3;U9 #3#\Y>O*/@1S=-H($Q
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M^7/3O]E\V,XQ(AY(B3:"M4-)9/KFD#3V2>K1X<X1:P0K 87G 62R%-7TN;?
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MAO@28+3)PAY%_3O RVY,"39?A@R^E&2:MK_-PI[0/KD,?!TC+/DC;1UU"'H
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MN_FK"F+IS.- O9FXG3P(V[+WR#W\=PQ=2&.N?@VP!NAKW,BOZ3%R5/886==
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MOWN  HH-[B) $?R3?L[4%\O]1%/QHR5@JPIJNG8]3ZCJ@QEI7XFLGXVQ; ^
M14!>EM&22EEH7:[A061[3)O6_<DU7?X] 0= >M==\;6YT_)K<XQ3:UJ/A385
M[0^LZSJQO  ?EY^;HF_@NXH18GBKB'.9TM?5W5)JRM;)@Y(-P?Z*$B5<D* 6
M4D#S<PP7Y!IR:=J89OF.=AZ'9MM8X[&JF@CB#(/D04VQ6AVZ.WHXMF+HQO-B
MXC4=/MHKH@72-1P'Q2#_K*_J</Y9<CC/ZK;2RJDS6EK]P-Z/[7N4U[$^S?.
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MZR_7PK&B]]0J:_2DJ:6 5EY5J/^<)F,*F_6'=)Y5&69C.\T8\)87;%RN</G
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M!D_!SI2BZ4X4:[5TLJ.WH@9,.3V2ZWV\:(B6+W7SH)/@\"[=L?@-D"NOP+W
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M]R=B62MNG!6^,P4I!?UN0!%+8A06E7>3MKXM2G%(?O2"AUBU%3!P1&CSZI%
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MLL]-I&*9^$[!$\ B03)\7=DA>9"-_$,ND;W9'E%&]:><)RGJ%V@*%100+=-
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M'N+5MM5X4FLJI\32)=\F0E]C[<XYG@E#,3=CMIIM<_?A,>@E']A0L5X :EA
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M;.WXN9[GGPK+ T(C92X;R8?L(C.J6O%T; %&L-_Y@WW,KPF-_ #0?:&1?1S
MLB,V.="!W+:I]W:T_Q/F&F:@NS9S;]06_5)OVFU/$@O!J(*;R/S.MUKPA5FO
M:;'7IOVM Y"/0"8/%:@#&9,N)8V1@@Q24HBE<ATTL>QM$^5&B]SH/FJ9A?XT
M/AMDSQLT!TW\6\-FGRD\EJ:II]E.9M;J/K! G)@-\58$7?\VI/.]IO&#<?H(
M9 [3-(V>V&*KLM$8\1:;!&8OVWC@?>L(G8&F^5K8L+LM5*.5:,=G0(RW%_E!
M=S $9>VIZX<UZPTES;%?TPPRYO0+#W=O$O=F^B$S3;1YLS7KUA-Z#8[\0*GU
M_BNQ(S9+#W>YJ-V!<!YNM@MZ34JUQS.NI0_EU&.IX+-FZ;15'!?]O-*&]^Y(
MB"?+Y60?175VK $IISW6!G'#M^;8#SL2?.>Q'0,2J]+W=,?L-_59+\S"QVCS
M?A;JQ1\MWYK:KR]]_YYP\)3-1Z4Q7XI'9DC(/SQ84@M*P_C8MSE[/Y3-?TM(
M>$KN([>%HA(U]7$[KR<X76GWFM.Y;^-^'Y3<?TM >,KU1[,[M5"_EZ,"&#4Y
M34MDE23W/6S&:<KUOR<@5J7^DHJ2[0G[,&1O$^F;A-""(8/['E[E:4K]OR4@
MO-L$Y'CV,6*EG@JCYET^G"A7U4E;^!XJXD3;!+X<$F\\@:(,)7)Z90N*0T65
MU<%"H!?JF$P953%4W436>%GS.;2&#]F'P:@I3)1G5LJF.?^=V?=*OX4W3/B8
MN/B4?JC'8W7B3K-:XSB?8:N3QW8F 8=)D I8_?:>%D=N*,2%[:,']QX9G%F0
M<^1SJ*>K!C*P'Z1(WC/*"$(:I $(O8-\*H,Y&B_Y7J\^I.K%<:,LA-(%49P4
MJJVZ_X*$_4<"OSS]O5P^"&E+NEW\)A_7"'<B_+ T(1D^8D(R[G$4XDL;P3W.
M)T_U2.^YC60^E)'KJ;!P^E#@'>8T?K YQ9=^IH?5/.@D]Y0D(?(T(-< DHI*
M!FC(!+(;D/7CA0G+M0MM!.48WWN<Z7+3=\*W*H$\Z$#W%Z?\K3RO0Q=8CP$5
MO3A)2R.YQ;=CO:'4Z,=*W6S*M^D]7T/%#VOQ'],J^.NQJGA+$/MB,=W.#I[N
MVYE::E1#@S8HM\\='EO3#+3'6R"1NDD\ZO=E@VT^2?TG;FJ8BX3O/'K?0L*/
M6N*]08!<ZQ34> ]E!5B/=Z>CA-83_6<\CN[D?T>M\%X(E"VK,[@9MP"+;F:\
M)E@)?N:_&G7?0>"KM0"[4@-'/F!K_-3-WI>L;)'-3&+5)G<[S P&O@/$B7NI
M'D5#K ZO>B5 ]5YZY'SOTGSFH3K0@38D>3 *"I%03U]TV\VNV1EU(J)<[@M\
M)U,QI%:_!/W7*IRP?.]T+GX[\[EN-\\C6^NKGLK.0XK/@_DT5A;CPGTQ.>\@
MR+?2AN_\@3/OHWSB//.1>B>_V^4\%+"YV'S<?N*3 Q;6V,5CN/YT)S[X3NGL
M=SQ\86*^R@G%JBNY]$)7'XZW[!0"42M:-QZBH[%H/;1J798M='V7 ?7GLM.F
MHYH,\<E#8+)QZ1%@$E]S5 ]=B3[M4;#5T%/64)_*3Z-%,9Z:WJ>'#WK5=WK'
M+S;NZXZ"W5[P.=2?/K:R6T.Q/TY]3TIFK*E'PW=L?LIJBCZT="'FNQQ> .+W
M@WCMTM.O+^0 TN^ ;,'T8OEG 3.=[(M<E,BNR+6L\O*:HJ)9ID$O"&\@.H<4
MH(@(R#L/D5]O*%53#;.L2AAGHC<YI679=#MM2;5V/@/A7.';T4K2=_&("[/#
M:+C*6;] Q(]C?@_UW:S9(>3_GJZKSP5!ASOD(/^<BUF%N^Z4S=^'2K6<DIZ-
M0X$<'%\.=E'_CQ*#'65A2/&4A;F8+D-@8--))DZY1G(A:X*Q>0$MM;U39?QV
M&9-GXW'+O)Y3N4L7\KQ"LES=LUMM&<[]Z-$HL,6HE&PO\MEAOWU7C4]2OG3F
M-VO&O%3].,KWL6,E9 ?QX^,#V<O(I<#MYF0@9,<0,M)\@+15(@[MD20,+HQ8
MX^;F^4&X%2I<9**"!\7R9:3A-PG;9D8@7E\E7FNES>\6KP8R1CD=8C\%1[30
M,!MX_$<2L^C G,KQ 7H4\K/'>E5^Z$^B_LQ*O:OX^81BMI\I@;B=M[B=QF6L
M5[MS)7PW>Q@MU*DTN9_'V*A^%@;MJR4M<!F_H9"=P&6<H>?R;?T6503X5!Y7
M>\6<482^7+OSFX0%+N,79__>+3Y9-"5@E([H$O)5KF@T>LUX.]-KEZ+R8F&.
M_%><^W&P;Y,N /VGE R?+ UQPCBIE)G</?7+Q2H;N^%C4O_Y*2;E?2<4?DQ'
M_%%QTE>79W^JN)TF3LI-PF@6:N>!4!W*]1N-E4//D4#2@CCISQ2R$\1)@PFO
M*8GB;9<%TG/A=LJV;@;CL\A$?+6$_1%QTIF(E^]3Z^ YQY8>2@56F$0$U)@7
MBN7'QED8LJ].1P0NXW<5M].XC(7*C:4:A4&N#?60OC XDV^GS\*@?;6D!2[C
M-Q2R$[B,K1M47-P*=U$6M!Z'HXQDI5*/@2T+7$;_BI<?4^N3H2'?3&K-NU%^
M/I:FM_56.-[WG1@%J?6S!;TB9T%F,DC>C_*/C_$;/:K?-$Y_X-$Y4NZ]M9$G
MJ-,_9M"J6:/V9-B[BPLH=#?1*A8OW/MO\>[TN1U?[07XE CX.ZP4GK-0VD9G
M*[:-P%E'J,'FS2@64Q+AD!H;A?QW='D@D*\(Y&[N!L+H4V'<$0*W>FTK_)1;
MW+6MJ%[OS,NC6:US%DFB0!#?%T\'0OBU0IA%!FV.Y7%/>T\/C6B\: [;S5Q'
MSHG&/,+- FMX;D*XS=E "+]8"&GBJ::K/= C#@J")$4"35.FUS9%J  \?3<1
M=3>/)L)F2RX+"R$<C9>-YR97/HMM/W^D'-($UZ',_=-%<><BBA_LX0MIFW'!
M3*/*L'8KQ(:ZMJA*SUIR\@=N73@3>0S2-M]&*/>D;8;M%E)KV9(RJO:L9C4]
M&NH9>!8&,A#((&USKL*X(VUC&M,GZ\EJQ-H W0FMU+2MA)_.(FT3"&*0MCE'
M(=R1MLG#4/UVGKN=M.]G5EPM13OSF\19I&T"(0S2-GX6PK>E;1+AQN/S?70Q
M&(%4,U&NC:(5?A[(H5_E,$C;G/;(&%>ZWM;#6'R6RQTM5FJRF<=T<1$1<N7!
MP)<>9=##^$L/MCGY412OK2.$M?L4SSYWT@*Z?9H\1*-WT?K<=TF(TQU5\2Y+
M<] "P3GJ5.><):Q!$P1_7+>L\(EB.RODVXN2$%&DS+B<*OBAV--S+@R1Q!"?
M6#[H9.?"M%%&'8QR89F]KY7;F=*CU4D-3NX:G1%N/GYJX_TTIC9KJ4Z-S=RP
M;=128ZG;NN\6*?QP9-_I3N\*=[DPX2+[;BXNZK>-O%8&O5%>4^Z-$#LN*EW?
MN3\^XR(;8C$CPT=48RM&8CWV<:[6[Q9@E,X.S?;89%,#-3%+Z]E -E_3QQM\
M?4D?;USZ47T<Z899F^5N%-. V,M&)$F: <8PI=!_R.G#4R#C"1F[OUU+19#?
M'$#$1ZUZ<?986+#Y7%<')9&+]6Y]ERIPHXSWS]US%/-R\J=3 I%0F#VB$HC8
MO@S5 2M C)XX:U'M]SK";3B=R&EW.&:53R[+[Q"=R(&NS ;ACNC*I/3I0U1M
MW8DLY(59:W9;>Z@D?>8"']D#\.SVJL\B(#Y-)Q^$_+QHW'*)S,W\].>GOFWV
M_$=F3R)%.O4V_H/LNL1609>Z[6:V6]7OU)()C=LV:M8?P&2:7M2EE1LSMI-R
MOY&A1G@N?HUO<=_A_N1^)B]YY84:OKZ;&SUP\UM4'[)\6P_=<:K)P[O9UAN=
M>>$_/_#"AV[_B;W3TNTN&H7,=C0RGO#C&W%[?M1X/GS@3<B$XZYE1KE8/)F^
M&]UFA<<V/RSHG?R>EY$;/O ^4P<*AE^7&X755+BOC]HQ83)3K(RXR*)M:M)7
M.O=\X*W&$.C0Z*:?JQTI;0Z3 N#)H;.+866@U/>PT+[G[2^U-[]2D#JOG4=%
M]>%)T9I"L]5[&/#M_EUKMB*O1&_P/JQBC2$V$:K^3CAOW4^^S$)%'2-EUV,/
MG?#:(WZNCWZ-+C_1_!H_2[5T$1KVQR$$$E4?^(;??^/_,(:YD+$6&H-Y:(8D
M<WC-L>Q_?FE DI R",FP;UY'KB+QU5<Z&@R7WV$_D=A0_!I2W#&%ORXVGJH/
MD!(R5>V:YZYBFOG+\PY\J>9>V,<J)]0'8R0OKO_;PJZ)P53@C&FH8Z#\]]+^
M!O]K8$75_^\O>K6!GB%^$'ZF_99K_"=#_C_L_$%> )BA#OO_7/RK5<W@CX8&
ME+57TK^O%54? ]E^[ S2^3E?7?QN@9X,&;7/9(A6Q/[.WS_)4S ) ?Y_;0<I
M11D"_;JGFL-?FU3=(A?F8VAHOY%CK\)1>]1+LO14';,KA)]EJN/E8!7XZT/T
M<CEI/_;:^Q7A%(<_$_T? C(:*-<B).GO7\Y0R 7A*T)A0Y61Q/R+I?_S\.#7
M3CK3E^,?I\A =!UF<3U$$C9H^/+__5>"9\._EH35MBF 7WNJZ7,;TV=?FKY[
MSR=2X$-SW9[((<.,'CY,0%5N-QEF8V*\%^TFPE&I&XGUV6X2<M%NKY?LL7&0
MY&/]^(4M,Z>:&/T&*<1'NE[7"F2BO1W,"..?O#+?4V4)7]NN%%M"EFFV4BVA
M^??/WFGY<;1A-X5,NU%L%84FDZID&:&3*:0J>8')5,OE8K-9K%;.9R[W.(K$
M\FBJRB63O<I<,3P;C227X_<HV_?.('FU&J KU60P7H5\Q27A>(?27K=AGL'T
M@#@:Z"1M$A)56=6O7=W@/I&HFJW'4:5S%<.OLA_,1Z_PDVV%8ZL[EXX,L$R5
MO-.V.?9_/\[,\(>9N<Z]7+51_M]_<3'V%^48=COP+*@WA$3&"2X:Q"J_<SF!
M40 )G$@>*ZN*=$F4+/=?4%54 ;K>9<N(&\?C^30;"S>T=&TV3(<RLU>&S;&A
M6QMB:R,^*>38/Q-R21=Q^_#UHPSTD8VAJ@+_\IH:5HQ$Q 27Z(I<''2Q(Y[L
M)G@QTA7#"3Z&;4T$1B7'U-AWM,1N5>12^'+Y08C)*J>;T]D32->[;)?;O%(K
MQ<5.1LHNA,S#_6U_\1C1%YT!AB>[>67L>5+J%<!PSH8R12-MA8&6-E-=?ON9
MB6ADFA]URG+[WL@L'KJC1+T\J9-\\^:5H61EH'7JVF TZ2;[W%.O8#9N!]W(
M\NTF]4;7?2/,=QEH!KQV__#*-O&Y'2@09U2TG5@7A=2]IQQVOK"=>_K-6@C@
M]9OL:]@M9][$<84IN8.C)VN*0':4BHUWYX[P%<__Q\MPY]&N<CFB?=JKP'9[
M/DGZ(^-Z..NJJT]B O.?"X2?:T 1STF5>T"65;.GSB].I-E2BF(!N0')FOV%
MBY,GO3PN-?J50KLY[*K/ [;.@N8,XYG=-3.7@$TX4"'3+C+-Q1CKO$V!)/Y=
M,AZ)K?R['7KPIRD=RN5D["H>/RF;7U4C+^K[5*723I68AE"K-EI,K=UHME.5
M%M.J,MB5:F%_R=8_7)BI-A@N^D/ZRU%(.:95$!B/O[7TM5*9%H-_YI+AR-)9
MH13[287#%A LIH2^_USP%X>0D8K7I\C*QWRYY&Y7+J?JC#F$3!\9>((V!1<X
M0&8@?K;$[/ 0/&)V+9%V8_BA0PDLR%U0.96<U6@.5+"SXAY7HIF8U;O1X:0L
MW,[RB4;IR7KN34C:Z+!!'W_ &4O'9#!SE)X/F";;8Q9*QK3(5D=M%MZFTZK4
MS&33S6WWYR6V9:%HKQ.1K/$.G^CP)UWNXO%I>+BB20Y_8W@HP@^+ VFN)-KM
M,0XJ*J/VI-I7WD81,I;=[N$^->D5^K.WBNM^*\<?GB+PI\DX4JRCZOL5_9GP
M_' 1>$5;?YY3U-*!8L<T&XY1I]E6^.Q-6Q8LJ:;4(])-J@Q3V-5FMR9ZH%>T
M@PS438K\VALK^A/P[X)WJY&J-(O$&?KC_:3$L;,DCF-D+K',V.NP3%]7QS8)
MO^J_IKJ#+3]I\'DLG20C!;IIC^B!=N@->>G/=XOIVE-TM?1TN%HE37.106IQ
MF!S"X3U6)L3S.KG;9-=_D5?:;_3X2[/LO)%4.X\=P2J'XX6)HM22K=2;9L6R
M7"@<CT8B>_7DUX0NIZ=H PZ00<3:)/M%/%2=UT;22(("S^8K%4MKWK?CN=C@
M351--<JI5HJI%<@?&:'=*F92I>8E4ZQDKDY'Z+?J/GL==BD+/X0Y$$U*)[*2
MJB_IPP"#,30HDJ(6B4$*@TR#$8= QX]?2_I)\1@'DI%$-R%QR6Z$B_>[@*3_
MHF(<8-%/A-GP5H*NH$?0=#H:3]C[[$ 5Y].16ID,NOQV*D\3A7K*2&HW[$0R
MX\^E;*%8F];QE?SFE8,0"TIB//?8SJ-!?!15E XWF3G^A5\3=(FWYN<BB:MD
MXC]O6_/T15KB9=?4(,W+-5V=$B >/S"WA;^HB*J.?5+Z,-HNG6X@TQ<958)+
M/[5OWIIZSIS( J_$[V G5F@9=RDG@7>X-EBMDQW#&>6O6,['ON@^9V7=53D<
MX<GS1_@I -P"\Z)3:"C2!WJ= PS=6G[2J+;B@P5['R['9M5>+U<LD-PS_R;H
M)KD0%XTDH['$R]!]8T"]KKIH.<L9<'6_N_LI:9>3"_Z[,T^?1H)UA?#'X^9]
M4N>OZ/L'M;X,#K-5'&?KS).E(T-"(@VUU?[W$9+$)PN)S]A<O&I<-:\88:S)
MZ@+S>=UZ,17UZJ_O!6SD=3$9H$@8XP.@H&?ZQ5\!L'T([".J]R-0Y4_-YYUX
MD'X,_@^JSL'^CBL)R:M$]"LDX;/#G)0DZ= PG']*&!B<)U,'U'BQ71+KXQ%4
M0-^J18VBWG_;>G&49:-,6<RHB@)EF4E-H6+!3\^%?A%9,_C/JMY29XJ'J*G"
MW?09\$JU#8MIOH4D542EMZ4_2ZK!I)0!E,D6&;^7):Q1A#JC5;VFJU-LO[U9
MX6QL+BU:1CO<KLX:S7"$;<=FF;>1)9/Z$#5F0V3"$-9C(KS6=!B:Z4 CR[V?
M3**::IA ?D3:*E5&"61D$C=WP\9=I]TL/Y:?)]4(UX/UMV4;6#86\T]^G+BM
MSJ1)0ES3,220!F0&SJ%HD1)=_#7V8*%QR>"?9(MH8.89:9C\$CS$PUMI]"A[
MQ47\Y]L<SKL?)T<AT58I'8(-W#WFM7Y2DZ6H8,7$12>W4/,W\MMP%R8ML#ZD
MI_XZO1"65(R;VE!5MM<!3>[FMA.M%TH":(WN^5"D)C;OWJ:;8K%HB$_R^]-\
M7R)]JS4ZXL=Q\5\&8V*KHA$J, HE@U?T $;'INR]'DH>[%;]?.$A8^QPRO P
M8?YY$M?^.&$+]Z&PY=,+OS:6,&FC/=HQS5F^A#J4&,W2#8NL8YHJ@Z\@8N@4
MP_ _>DX9#-;OI,PC)9K7WA5-'B;B44D2NR('$]T(+W+=! S'NGPXP?7BD.TG
MHEOKE(VV]91%]Z#9CFE/8DX7(FJJ-'!6C=8W$I@:"(FYXK0=4JTTR)9B8-)-
M.4GZM2M[8D(HJ*W'@H!RU;K"AZ9F^H%LC8AL7BFF>J7'N?#TQ,8JPO-C)]OL
M1=>V1O@[_'$'MMIN&W&VVQZ8)L$B'-]:,M+FGY<B?H>>:R'3WKT,@3AD1')H
M\YN<!_XJ\EGUB7[(BQR,!#9Z=DC0 ;5D=I7C#^-M3B3&@0]]R"_&03AVQ9\;
M#"I.#0[5!W N#DGC3D95&!P#XF]6MFW+S]G4G]Q5_ /ZTVXT\(FT\MUJN^-1
M+#B^1[6TU^LV018-'YZZ[>J""TO];O*Q:*9>!+Q=18CYV#15<;1O!]=+]U\R
M&M"9*6G0S?R;O6(Y4H[*T'8DA\M'8#G>8#D"&7",DFV3EA4FL^$L;D4&^HB-
MR8W"XW.8C18YXFCRKXA JE&NO7_S8F#M#K=VYPC=S7) 8OU.4PGHJG;!L:^K
M,F",[NY,O(/W^>FT/:[IVC ^GG?J@QE^5>05=%<>F@*3HG,!RJLP_P.7^);N
MD ,(+J$=(Z)G<# _^(OQQ/%,157@%7/LA9N#AOTB1(J*1,H>(--;,.(0BB,&
M/V?$('OHGKIK9#" F4%9#HT4=8:?!X&!YR3A'PR+I+Z P4BPCQ2[++MAR=#.
M9D38J$L)#P$Q4:Z8[<K,!VCL*M>T6?Z>;>KV+)?[K_8\:.W2?36CNS;XGV)M
MXQX3^9;0N.F0N$@I[/'VJJ'PXL;4PFG!RJ;,1J4.LHV;^FO*0'V/CW<"/L1.
MM>WF<Z5!44W\S<1"1 E@V>^3C3@ZW5QHO)#F"Y/RLO6O5AO@'#EQK< ^*=DI
M*W^8E-RILJ680*>[D73OSNTD0&RM!>=L^[YR>U<'HT0E9[T6"P72\6[IF TA
MK98DR%TMDC _. ?40VP9B'!(#)#EI81X1:<'G0OP@W=(R[: > R)5U:(G2$[
M1!D)_ZH,Z*6:#D5(\U@<;S^#-EHPF!_XR=C!8PQ+'.*@524[B-S]E.80F)OS
MF0%C6][IS<Z4_KJDE74_>,^\>]A7Q!?UGO"LR$WT>GPG&8_S,+([V: CH<,%
MALDD6?L)$E@8Z_+_>?+E-(VP=TN3B,L$YEJ#A/E]IZZ 5B'>CO6%9S$TZC<,
MVE?W)0@]0,-W<O8>/5=13ZIZSU'T/=:1(!^#?HQ,$\L*E#'X=54A8:*\8" .
M&1<,/6H;B+1P(0M,8.]CW5 *JV=X[>F6:XF%U)+MTM9FJ,7\(#_&?_%A')2[
MOB>BFP0ULDGP>,I!WZ\<[)$OQ1T:?UWM:1%UFAUE2^(2VCJB[)'="#]&BT48
M9(3\8ZS.#:OL4QV\YD &LOMYLKN1IW^R#!/U%V^0YK<)+ WN9/PLR !1Q )+
M#OZ2*'))9*?L_!9[P$IHYP_&&$LZ?HON&@^,\C$FSH)8<_PT;//(L ?,0%=G
MYM#]]0K;=6@'D;2[ :UT(F$_S_[:-SCZ,_?+O>S5"_8.S;V.F'#GVCW#=*]<
MBW(YOA?BF5W^^W>I\XU^:K.,78C?46Y!_I^SQ;"T&R$OMZUX@]CO%/3#2^K\
M13R2^OX"2KVE .K$)-M,#[\=<*\EBZDIII0EBGB@ZB=H[;9JR*%GG)=X7?2Q
MT5$S91VQ^=%3.)Z0J]URZO4\T0ZM_E'#?[*D7LR/XOAV;+WF?S?WFZU#B/R%
M#;ALA-+QIRT#*=#P!I$W9GQX:]W+4GLLYY\'Q>ZS41CM#"+?#8OW;Q,_6[R<
M:G7O; ER\5O8Y\N=A?BXH\_3P6?LL7N;+W&@/8S*D!_=PGDE8SR-,L^I(XA1
MY$ Q"E8-][?U*O9?"'E(Q?B!2PXDJ4)3*=@FD[4'4V4L ]*K\%CLWK@[.L/A
MB(N\2UZ0E\\0?C6)PQ0\3Y68$TPS:N,5H(@(R,1_)LUGR,6&<PJ3P9 ..$AZ
ML7HY_ .\M(;Q4>_Q<Y)AT5,EPYSTMV.^&6</-C!-2#H,$79A@I).5G@68$!3
MPLM-!L PL,TD7[GA)>SW(4WN*,YN('(G(CD?!7.0Z!]=E1D5*V\/8U>>@X4)
ML%R"8B)LY$=ON5;=!'H/X,>&JG,9+FA._0<79=I737*F1IR/D2KUO\C$5[-T
M5L%[,M:-'OCTD3ZV<V4:?C<@%V'$T=5BB8X86!(RG7'MRXY]JJXMBGT]10:E
MZJD5:W(R&'A4K1*KM2=C5HX)MS< --I"KF_<#TZI:E^"(G-\(?%J7^Z*C[PH
M-?Q5<K_<.,=+\&&NS[-;LRX>DL/K,\9JJ0=CZ(#"BYZW\&*O?O4*ZTI(:+\O
M>T%&W5[SI7M[[/(&^S9G&:<OT]4=_)6HZCITVX50M:_K9&%')3(P1:IER M7
M!':]]<HW?L>J0;;2-,>F0.:16<YN0R8>Q&&W;]6'M^W,8CSG[RM2-7QW4IDX
MFAW?0'OX%;0GHJL\P.N6@&8\"8Y4;*AM**P0XN+9@SFJ+9?+",1<B"I=+<%6
M05X8R%;V"JEDP]H_U /$=A/K#A7#-B-D/0/_1%=2EV_WHGAI5CS[1O_W7[$(
M'TW^$J%N>%='=.QN3 GRE^-PG JOY#F++1'VBF.S(0Z+W]5Q$D8GT69OY.\>
MW119Q5BKI.KGMYG];$^&KA(80]*;P,WG_]A7];4W'_[7FPM:OCSZ:I(I;P==
M4CHMW2;KNCB"8/C<&4P[C^G="^"?X0D<MMK%G"3M=O2(:D?B=87H%%6#-Y;B
M0"W,7C*$GY<4:V PP) EF"90AJ:S/P'?,56=L$;%.,<LI4J2KF'UB2G'MRRM
M_JKLXY*QM:QJVWQ15@WR$ WS [I7>_=1D NWA\;\(-?)I+:CYR3!& DLME^W
M5,]CU:!Z%U,#NPPT@H,D\L.05W'H,+'LCK>DZG)BJ>9JA&LUOY=T81IH.(";
M(RPV$#_KWXY Y>@*,;Z+'/U*Y>7@TYK7SBY1K+&DFA(4\0OD"X:<IX&1$%L7
M1?L,[)AS5GJX>Y.X-],/F6FBS9NM6;>>T&MP-+M@G,<8_UR$HMN"6*-!1DY6
M@7<QNUV/I.^3(^N&M3*(;[2R<N>FEKKXS?%745>$W,G^9C V9?S'L6IQ7\D%
M+.%:!KHX9+@HQ4/DDCF0"2\?@'P ']A=? AWN2CA0Z0[#S?;!;TFI=KC&=?2
MAW+JL508>/E0K.1V% =1Q%/ -^D(JY9)TP58-CR<L4+R+9@^QP<";"8[U5EE
M%)VTL88,QRZY2.(R&DYN\\>>\0N2L29M,QP),.KJY5>?8V,/<@W\N6=]QTQ>
M:J'KQ@',JDNQ[5UB.&':8U_T>&>$'GWP=B.,+49Y+_I"7FVJCG!L<W(UDK%Q
MZB#VN/%9IUH"^_$UK.073-,-)QC[[$;BRZOT;B+PC'TX'%.&D/Z$'TP%:8AI
M@;W_2V=3YPPKR555)LT:;I1=DOS5TJWS'$= KD4D#O>4,#*@;SK>)"2M!_=.
M9L^)7^[)4HY-Y5QS3^(GM %+W84E28BI3 V;2?NV8K&X+ 5SB-!89N-R6(\R
MY#3/8^H/OZ6M#SG*FGQ>WYZ\Z^CNPWO>OMC;XZT3EY"AR6#QG@.]O6'@IFX_
ME%?LAU2[YS34_SGH.%;/H?#.P'G*K $._'4(1B$J5== GF$1<P\'PNR(+8]E
M77*"GF\?N8K$_\.L_B03W3J)?O/X>6\M$3UN_C\;Y43NEUL'QEYL/)?2C2"&
MYZZHHEN=81MQ-H:OER4=6PCM CE/; ^8H4Y\HG^UJIF=3"=_8[!A%TM>:U/D
M?'7QNT6KNK!6R=CE6:OZ2.!ENH<.'J9NDGH7!9U.*G1\J\XJW7"<C8D)[$9'
M(8R3L]/[W5Z_)^&/(HB'PU$I"F+.'<>AXI;9?*EM("5T<DGG5BI=$LC939EJ
MI2546LTC:K./C.NE<U$83]^=(C:G'.^<2?50O:\(C6:A6*OF,D*CE2I6TD)%
MR!4SQ2.WM#E5&5_B*OP)O7L/T:<[NW\=N4XA$;X*G_:T-!],=VW3->;O%Y]2
ML=N-/]QKKV$3Y^:NKMYZ5N+7 AWL9ON%:VEJJ4:KV.5(<[O(=DN\??;&I0N^
MV?%E;:J LY:%TT+?!^<Q4$5]$G+X70Q.S/0_#=(!9GV@NJD;F&XWBQ6AV>PF
MV!C/)MX7-9 G.8MD5UL!@Y^!_WDD<BN%WT8>OTE.C#D?^ <J.U#9WU)EIQK(
M&.6 :*JZT8TDV6@D_F&UG?J&>OMH="+/89P'G;?^?D&,+GZ34XK/3%X"'1_H
M^'/#[($^9Z4A-*NE.R';;*5RN4RU7":9YFXD&DG&/J[OT]]0WY^$9FU%AX8J
MDP+4I@GZ?;HRO'-AY+O(&O;RPV<G5($A" S!N6'V(*66R2QZ4'>VC"S>K_<9
M+O,-5?XQJ+/VB$"K^TE" JT>:/5SP^PA>HNOZ:I&!@V-CWKR_/?3ZA^FSNK^
M[ZS.HV<G&H$Z#]3YN6'V$(45+@GY5*G6J&8$(5NLY)O=:"S,)Y,?U>WA[Z?;
MCTNJ$AP F>P2$"'M>1KH>U_)3J#O WU_;I@]1(E%RJ0>))436@_98C-3JC;;
M#0%K,B[&A3]<01/Y?DK_!/0J(X6T]NE#<\%DD4$V,5MZX._[2Y8"_1_H_W/#
M[$'U[L5N+,QRT0\5O <5[P'2 ^U\KK,+,.M+[4R\S6@YU;@56KEJHR'DB\U6
M(U5I-4DM2+4BU-O%UD-#*'W428]^/R?]=&0KVUV+2-_6_<U/A(F%$7J)KY!I
MXP-/#P>F3-J*ZG:'!OOD0*9FZ>(0&'9;%?M>3R^'( SPD] &AB8P-.>&V4,T
M9JP!\:.F4/JH-8E]/VOR0=JX=W]G11X[.Z$(%'F@R,\-LX<HJW@Y54GE!5HL
M3A+4[6:S6*VD*EG\=>FA66Q6<[F/ZOCX]]/QIR-;>?O, )+DM^R&;"0,2'G:
M1^>6;<<SJB+99T60:[ 1L62[[WE5@W;CW&\=&@06Q5]"%%B4/]:BI.KM5*55
M;*5:Q3L!JT3\L>1\<I= /VQ1ON&>W=/1K4ZZ^R.3]J&CU@%_(;N?/2O(3*JG
M6B;CY*S(SM]O;#'B@<7PEXP$%N-/M1B)7!&[SIEBJM3$ZLYVJK'^:[9KM1+]
ME&H\?-1B)+Z?P3@=V59117-UG TQ'$U+TV3Z&>@+AIQ&'U@(/TE;8"$""W%N
MF#U$U24SA50E+S2)PLMB9SB5;PBVPKLOM@JI3*;:KGS40B2_GX4X'=DR]*@
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M93NT76:+9GW<'J<#U3YG4X)].\4!*/G<[;R.EET:+:^-I.'Y,EUC/\ V+DZ
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MR':&[^$8OK];DF#1O'-K5;@%0^Z1*;;)53$3*AX73TW("+M/Q%_H2F2^G=K
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MOM%2_?N+_=%W*XV*W++X.NM?VNV+J1]B.*:O\NIB+W>+ZU^%I/J2G2I;- O
M>]$F=*Y1.5W"D!I)?B\"BZ:U6L;;4^E3#I]E5",+[]%=0_>_S5^R?F]_.:]7
M$UVH*,_FXPXO1>G3TOO+EM)92->;WI9L;WNIM8^T@W@Y E&YK'R\+<HBI:I'
M\AWR[3E/P\T%S5I>"UK0G;*03]/6F/3%&H7-PI/,S;FI%5V=+#%-?1%XX)-;
M:J.W<[R?1GU:3)7D+LSQ;>>=1>V]M=R9#(KO3^?RU$:NM8XG=A]L6*=E%V=6
M(K]1D+>8*4+M13YG 8T9/Y7RY[I)G$/K^C$3?BWG,%"RB>FB*I[;2[DM<K^R
M4O<97@[/)CXB,XW!C4M1NVZI5E74+0=O+L=^J!<^"P)UPYZXC"^T\AQ$0T8I
MZQOS62)Q:;U4T@2^E*,$(0Y/4I K6:;>!.G8V<D_".)8>ZXD , K7\XD<]EK
M\\-_?__Z-/,7N6R9>Z0W$5%=DYK&<C"=725MAWQ1(/UB>9-3?Z4B?6"("-%O
M;$O-V#6JGVA=<0$Z'MXZ4FV7-9UF6'7GJ'L"1_><^O4??CD]]Q_[0*:9>DXJ
M>4432(NU;@:Q*A?%9=-NS]_^U3IIK&G;.ELTRS/$'93%) "E-@CX3O:PN])P
M1AQ8<#?$GNV8*HND^V2GD.H#T9^A9M!=%*>R!%P_(_UDP_[Y=>VIM7AUD+39
MC=(#Z).V59&VDI[]/$J\=TVU-&U$[,Z-.> /:7HZ;6?Y(@\FX<(Y>)U(21;.
MEHAJ*9-LA#Y6(R@;EI)L17$A2#%YN^_+(E$Y1#9?T)(B.OU=.6.2+G"Q+DKV
M43A7O$(K:R?5#3JV%7*6G%*1CMU^D\X;:4J0-GUY7Z\UCP'>VX_<K7,7&=N-
M2#+30O3R/=_Y1?'*+XKM:O+>T0$NN[0M.S*B:L&?OWB>12>8LF@HYQB*"1/1
M@N[B_DX$0%.4REKKM[U-Q6T=P1/U]CG?/T?$U5@S71;O(021,CS/LS5>.O-2
M0P+[DFC-6]D#HA-+(%(7<!6E@C"O"G+F%K P$U/OLU&'GB>SQV!DD6*1_%I9
M=]P\ML+JX8/+82R(,?E[0Q^B\*'0+ZWNL>Z0%#<XDQ5?":36D,6_<WP$I$!\
M37U4\OK M >/W[EG2(7YP@3 ,)4T/6$RR&P"=QW<A.[<$0Y%-&0*DXD7%0RF
M]55@P<%7W*W2,*"[,X$O'L?-']($Q#Y<^.8??%JVPE^0\%=87N!V94-(?'$Y
MI$W*L?K' S<&P7Y)+_UK=F@_-YZ*UTF'[&O?(>L.\^<K8GQ?EN,6_)^$TWXN
M6D6W)CA: Q 8:T L*KFP#FB5YWXID9]O]E/?ACO0LUAX+NKG+]_\XG6:<9M]
M7"'7+!#3Y4\2=L-!&I!'AP<G\9=\3_)CC5@3CNY#3\\P+?-+]W90 8"L<J $
M>['J#$KAI8K=2#G"L*NFT;?0YFPZHFSY!,ASN4BW-W/0;I.A'"OEB"^28O#P
M:%?XVQ7^'BC'(!R,I<B47ZVFH9,X+ULD6KIBTA9BL82&22U7.7D+2.@2% OA
ML*SRF;#J9?9[-.N"/=A@"&UA+1WQV?H33E)O&Q1#4*A:,>EZ IK(N17XXM*<
MF2!>6;QS 7([CI/H@;]C@A@F0XD%HMI2(<,NDDZQA'Z#/H.23E'4>%Y.;1Q\
M_"H>[CZ8B#47I;QW&8RR$#5UP0%5.,J%"]! ]T?Y=@R;5].C8DLQ_<_+Q82X
M-F8/]5#0-"Q3(%["-U4@PNPPI18C87R\2!O>N1? >DJVAE7!M.N!SM/"K10Y
M[KK8P_<%S!CXDPY1*K@2+R?.^GN8-,+2Z0M5W<V1<X>P[H$[>X!AU9'Q##/Z
MY.0O,B7!EW7+'(D'=[1+Y-VR,Z$A4W<_6'&'>2<%K&299J,+9$%(13*\8[QN
M=&"\D>G2!/O1D2;MW<)U=E)IC;$FENUU>2TM;TR&?_4LP0F=5F@:<RO"JML#
ME<>[3IS"+"4UXM;;@JQ:R[DP26+%K@FV6MXF$WX[#Y+KS;4LIN(=2D1%(H0V
M+<@?H39R&AC>ND@X"=0P_)DP-&C.B:G9/@".@:KSNB2';!6*-5Q_@/4G[:@;
M$DT;=!3O.\]1E>4'4JN]0'Y)^;F-<Q5@LGBBA?XO>+C*7'8C$RN\@5\?'$2T
M1@-.*FN1QP>?*3-TZ[3\O:GW>G'%Z#LWGY.KTLU"'H<9N7NA__&G__UC]?:K
MXZ.#PR=/O_J3^ *?W:8S"!2J57WW<51IH4D@WPKUN\.#]X<0,!5':]\3C U<
M@KR55)1F;L*QOR&TY4)"I" IA^MRPB*)$)<B.>D6/C.XSNEH4$B ^?($']EZ
MQ)X!\(DW)!G2V#,AX6QS:98B,9-42[A78L*?\T98%3)*:U&^>0M#OI!QZ8IT
MV)I>TE\"#(OF>CU;)8E>E( ":9T\+)X^9 G HN;.R_3QR46'+/IZ5HL+Q!\B
MO:/CZ=Y%4X73(U:#T/RYGB_'ZU\D:=F^9"V\&;8;H0-:&#OU%=-:(E"2M*!P
M"0[DHSY8DVGH</&,F(D5;XNYU$J=,]FN:WYY@TMTO:+G @<D8!O&73D@)SYL
MM]-)^5U'YO#.VY+'>?O@?XSS5K2MMS^K9;8^7[;G_1R)/MTF+*^H]I!^>R_:
MK^$[92*N$<<+:[2$3&NC=A.8N)\='3S[=H!),!O*YQRKV>[OS\ :N(%97ISF
M][R*0 $JGO&K.WG6Z:_CD#,X[Y*V5G [.V&0$77_>WRB,W%R\)=L-&W)2VU5
M6L;I:R3KCT!#_&ZB\>"??>ZLM3VGTC#*R"B;-&>RQACB\29*Q/X\3'AM8-=3
MAH('6CER;W9^M:HH>H?""!4"/VGMZ+X6X3NOXO19,[KAMN)*#51=;<^.JZ:9
M=C#>,W &Z^[5E&G9;60"7;+3*F;Y[/E=4/F:)I+J'$_@^+R3]&.YEI% '#\5
M^+90F8K/XFY/]AW/5&HP&5%S"H8N>O"T%DTN\ #0YH,$'KC4*!UM,DK8<'=Y
MOFB&+&E^?OJ=EUCRQ-S.+JB84S]^FL7E!/?;-/&E7.5XZ_+FG@0S$-RRDZ?\
MT!_<GEX:(;+[P[.3?: KXU.]L61%+/.65Y/FJJE<% A\']+-SK5S$:Q;5F,7
MC;K1%O54 <G.S0B=10IY8+T=*3BW9%=<A70:\0X;'RW#[1,5(&"1:$Y1@X(B
M$&9?2<&!3\)LZ%+$"[XL]O(I^*OC;,&(\I^=%#&!:)9ECI]&,]O9;1AQ\!N
MX+QZ<=[7;W,CN"Y;ILPPG0M["(F%#?#:/QXP<*3W.E+JN976X1#SI-$^X84'
MYU.K-XS?\2GEL)M](JE5X9+BAB,0RD!A@C_&G97(W-3_?/%;)9YXYLV1C=#.
M5?Q,OT46?%\KQ*NT0J^O WL*X8%T#T84)QKB.>B6W00B>ICU>\W">9@%MX
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MHZ VNA&\AHNJN;'ILW_O@:/P&TE<N%-G^MZ$@?][/F8W7O&M<31^VBS!\%G
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MF%H@U/5^4HJ_M\"85W>+#AQQA=3ZP)EWCL&F&5$[/@WC,:B1J.BY__A:9$F
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M],A-GS3>GKYX'+J\W'\ 3F<D$T"^*GXK]"RI:#2X#WK=2N=>*C.Z47J#R14
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ML)N+02*=]T.DJ?6X/^L;8%[:,]1^*$'M^0<1U&IZ\2&T EAR^.>(9?";@;Z
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MB(>HA_',FKI8A4VJ7 /.%(.W5KL4\6P?GW8PK>C<P2S^ T]G?2]#5$BJ[3#
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M@7K']M"/D<LC4Q^'VU'<Z7TDHX 73@,!$2IA;$1N+,0Z*Q4_[WW9%_5\&26
M#/+EXJII$5CZX%;E(:2G!U^IR&[6]2*N1+,@ #4#-W 1BK1K+V @GW?KFA:X
MOH8Z2%*[T +C64*=2>6=&9ZYN91X D^PELKK1A'+&Z=E@*]IU)-6BI*?*KO4
M=WY]-%B[AY(H3/J0!.+IYX,[YZXKX%[O3U?->Y,1*;%^UU1@%-*84/M/9CFR
M('2%A<LY@Q*F5&^)$?5@T4?CY8)U\O4NDL=)C/BY5PY1'8-K9TN-'W5@LSQ\
M8HB74Q!UYW$-+&0*(X_?(A*M'(0(*\1_3XP@$[N&O*]!3>Q<^4^>[1_M']K)
M=.L,/HB:Z8;S7CN\_M.=&]-FAH=KA>G%/1C;OCSJ)85$"6)I>W["JWKTM[Q>
MNI%*;NWHX/ P&RE A:(I&MN1VFORSV4IOB8^^LZWZLEO?UI,]VE9H"(XX\*Q
MPR-4:1-7H-258O<^>.K=@J&+^]*(XKS. HN.0+ZRT7-W?=%"''T_*UH!@ITA
M8^UN6ILTH%MF[@EA2:PBH,'QL'$*B'GK;_ ES3Z!GPD^]_%'>0(>0Y.&,':B
M8:H+DG*+T"QXSZ7D7:47S8^^7KJ=M?4/GU)?6P:9EU 4N'L1<^;&7+G&:6_\
MO_WZWC#;J="&VM&J[V3/1+CAVGD6=9^Z'WISKVKJ*)330GU_F_DU@E]/93TN
M O<.,7DK&ZI[(>L%RW!V6WWVTLW1I>:HEG/\&!O@^-O# \H[ST.I*>G<1&\A
ME$S+RW(A.R9"!IFCL-$S*&MGG.>-.LY>Q'AP.VRQ.WG=G#"#+;5F>ET\A)S;
MOB@K?5&!T5B.F"KOO&/J7V.U"@^]W+QLW8JX8*='<9&#O;@19S>\3;<\^DY9
MR!D&() ($:3D\DF$-K!A; EAD6DA+DT=KD]..9M1:@&/QQ'T$%#P3*6W-OZ]
ME""2.I3\^OA %A8*E9HB[%WQ ;2H!)WF[35*4HM9]U.!=OBIUN<%KULU$\.O
M;5!WS+Q*=3Z=&DSAY.#@9/1Z\ISD#=7H]+JHET76N\3IZ.N#@Z^^(IK98'5'
MS^B&'0[ATT4*'6;MY*OL>%T^7K3FL\U27$(BFX@J@V%#=Y'4,TEC78E0JMPP
MSB%@:*.?\'$*DPJ?^SQTY\[!A63P<8R^=EOAT+Q6\PT$ BFW$3PUSVA9NH=?
MC0!<[^1?C*&6=1"3/SHX?K9OY/KR'(D.F6:!I.\K"!8()RK@R'.6OTHXN1P+
M]8!Z (\LTF0?FKE'_T=-???/_='%8O\Q&Z<-CS N]'9>1S3@##ZQG.<]VBOS
M(#D:K?I4JON]"__)R<'QZ(?*N7)-X9?]VC6P\H^^/LI"/U[H29?5<'R2G7R\
M%2Z+5*X<U;9ZZ@#'ASWM;U^_85O?NW(FYOE8WW@R-"X1O^96<E\+N\+34?;2
MY*9(R.X13/]$3DIXDN-N[*'F0_)0UI<-'E"(+PA_\FI5[NRGGC62[Y N'_W7
M<U._W1^==O1_&I7?3*?+-S0$X^6G8XS3<[J'I2JA@Z=H5H%,>FMPF/?<,<-D
M@\#U;3UP66FN<H$"LH?JBU<@4HBA;#FPF.0E[G^1):(GNQ+1KD3TI33,);CZ
M&S.>^>@D,7Y-LQ@\-<Y7+H!WEOX40N]N?^1K)?$G0T:T;S]A^ZY+D0^ AKEZ
MB\PB+JF$VK.1MY\%I@V?M/!O[= -@BGY(I9L-_JF?.IB4TLAQ#WU)*YRYG^/
MMI*2]<ZJ>P20:C5%>BS0=>AY(>OF73.THC_GUBZ*3NGTX15,^$U&<CF %PB/
M<."@I%(,B;^OB];B<8* BP14^?0Z)Q[%1.H^*M?$/<.3GUQL3U%S4W_:7I3R
MDOTOY4RHR-S_A@.8X#+!_&F,BC5TJ0<MUA;Z>"0(_6TYO?2N*9+N'H3"7 GY
MUB&Z84XJQ;^0SIHTH$UC]L:4&$'C$!@<KLO+QAU>706<YD71JS39!;M"U;GD
MY^(KA[8^$%14RR@!$+XO2\YKC^5AY&[I%!B;IA-,0L^+H7N=#:S.J29$6]4T
M$E=KKBFC+M*KUI8TYJUJG=F%T(1=B<9),M.9&QMSJ2VSYB"#<5-\6:9(V&:Y
MF*CXV<(X5FQQ;<G[/_5Y# -;46_RM*Z7[+R5XHTN-LQ_W.)&6)2^AXJ[Y1,]
MT#UW\ ]!(^87J<VY5[6]71P-1TMPBTW$<YGYSA<%$IK $2],-07G;"74A5ED
M0[V.?=!YJ;P6)_1"9PULL62CKD0[,*Z49:G^C,8+,;.?NXC15WK>/V,\R7!X
M%Q5_X8Z)M_DE_[-SASD9[=H"):6]MT4QE^\8X6(F.W@!8:C++*%ZR4#[Y?QK
M$YQQ#T B%^6C:;DX=8PQ48VS*W -*"K+ZB,Y9%35U!\QLEHEIVJT9L(8HZL]
ML _NCWX@5(%GZ[B 2!O2):J61)XUO:CM?!D0JK<^*0T/D2*HTV+&DUAAZ.[V
M.JO&<YE%S)?N9.5?3)@ PI03Q?B/0TH^,QV;D"X2$=^HADD.(O><<9E:E^&*
M./49\H/"?]<6UZ5[/)5O4P'9E:Z7]9]K()]@>CL]'OR!8W/R4-4,>UJ.^AQQ
M&^&9.)!;%39\<U5X1Q:'UVT239W/M(4JEG;OA^)N1!G6LS:9FII8&);:O,:,
MV7JCVGE):,WD0U94-4X3GC,Z,;R@/Y<]+]7^Z&7 PG*8JX!C"/+3HY<O3NUV
M"K!8\"SBM:?+?J-$O[%,IJX-0E;ZF30)L0,G6#6D\.W($S7EBDI>//\BHEGA
MMG0.5JFX_MH*4QBM_Z<J*AK++<@!.LQ*8]O,"[*N2S].V_Q&>MR\K#-&&#7!
M734 S]_D+1=$5=!U"OIBS@8[$Q9]T!7EOY;48%:=R]:(*=PS.\-!%<BH^*2^
M4X]6[;=E;5Q[%T+MJ(_%!1KIM%EXP&]XSE+:?.<]7FJKH#O)RNN2@YFTI8A=
MNJ'D%0Y+%^@ 822UXGC"BYK,77*XRDAEJM_O+RZU[FM+P]<$U>#A!7JCOWYZ
M6"G1S-LPD>RE'2!0=6VJ:T6%>_CZ%Z:2M6,-_R2LX<\3',?<;5C;VE%J!)X9
MX7SE3$E>C"451[X:Y/"Y:3@3 ]8TT_A2<_)G3XK4G!HLX8>?SGPS(W(0$JH'
M.QR9_W\'Q87=FOXD:_H<CF776=Y?#:IVLO[]17S0><E[]6X-]JC65TH=:<MW
MI^;W4D %ZX:WT32$ .'$ E^8MZMBFLP$A,'M%O-N,6]8S&=26:/W3*D!S=$*
M$ZEQ<FU8J8DIUK7F^[=B7QK]>4W-Z/VB:!6>Y,)3FN^(R%V,=V2PGY]U2?LY
MX=BA-S2Q\H:/BO3MO"R +["JZ^L#B;(UR8"RE@!3>M";B$J5\88(-C :UU@V
MZFZ=$Z0_X$IA3.4BBAR7PDL%*/EN5^YVY9V/&&!3I: 0NF/">>,WSG<_G?I]
M(WP/2.ZL+]!_(S6^DUTU>E>-OF<U>F=O_^#VUJV$3O2=5KW> S<0V%X7NH:\
M?5E3?B@"]J;U88\@:)(B>,@I#W@*(/\4!)4Z1R!G7,MM]ITLHK0B3RO3WS+G
M:&7(, 13E>IB_ZY7G2>4JR"N:\-8_=U+Y'<EV;YHB_IR<14**B2Z8JY_Y^?L
M]MVFZ /5'Z9GL<?6MU7=U#WR7V>\-3?48TJ3/W#-:QMN,;4R,"AY/<!&+^T\
MI'\3#<3=VOPD:S,VL][RA\63I':H,G9K3KU71J4,65,-Y]:_-'%$P2+#_*_B
M2IXA:'WY8;V*AQ.HK)>4;#.ELH%RGN5G?V^M+@C&D-'M!D1ST:#:PH-AT+1B
M*)DM]AQU*B*"DYN:=H7V&AB+G(*K-X@)LNA? @5'.A_A'/:RC_4U;&\0)Z/N
M&9F+\KEO<$>]S[B*HX)LDGB)]8N0.*G5_2C6RO\<O'D( ^-&3Z%W9+S H@D=
M4A]R-$=WOTK^"!(A+I$FD(^>AN/D*F_EAO_R2II%[WP9.%DVSJ]4V614+EI?
M$OK".N@75OS:J>A^-H>GO]#=@D4'[NB1]E"R.72$BNZR4U3IS+TC,7DW937=
M6ZSFJM]H7XN9!IP9=DN"75;\SN-_!^][MSX_V_IL&[8EP;9.BCE!H3UZU]0&
M[I;7;GG=(<]"Z0L1HUX[5IU1]'EL.CF># GM$8;ZXW\D7D^^6X.[-?CA:_ 7
MMP:OA3F(>!/JY(@00,\;=,OLWR1%L%M=GPWPY!?0>L'X0<3U]^4>.HLVQWD$
MT7KU]Q?;8Q#Z3C(N"NTG.@#I@X;R9$)MYC.,BT@E3*2,W98G.D#[!H:S-M*B
M;'3-4N\/,V%WIBK]_NBL]R<?$,88M0)WU\1%@**:%CTR^._*B:70(P1<0KG2
M \N%B@%'Z!\Z6H5Y=/"^[W$ELD5_$3[V.(?^PS'W%>.:%6Z=Y&8D5Q/2!;&.
M]B;X'EH:NTE;C@5]>G0X>O[RE]%9WBJ]S,FST:,??CI3L@;R*8%/!,,1()0U
M@EA+U.#X,=67(L+%T?<[QR,\2%[GU6HA>LGY(L\$B'*=ET(L$<24D6PF*_@"
M*6CD03CW 202H5V:13-!RTE4XB??=$A2]^!D\KC\<.F,?VY!W[A %U:L;A73
MI<0B#&[G!!!P-EK6E:T9%KD@QM?Y.U/C*\%B<YY*;<,[/MB;Y@I2%S4)DA9)
MZXE;2Z2XTDO9*[+$'^[&U\46.0":06:_7"!5)^VQB#]:MWPTJ<IL89J7D92J
MLPPR+;RDT;NC3:8KTL%W\D#K>SM&V^OM&I]4ZF.>M(].-Y8?IOL!V49\\G)_
M=&KH*&U@=3=$O]DX,'YQ&KN ]1C$$!K-$-:RI8NY5(PGO#]"-J=<ED(8CENX
M_T VU7VX=!]JILKW'[)#TH8"C#R3TX'>A^\SO<=G:GBY73_,1O2&3_U9Q<*>
M]V9<$?#2UA'U4(1"UOJB<V])@&<KJB6XXP7G"QL65+4C<$%U2[>_P#,N%V0"
ME6('[L8X@"YA/9TY"YC\^=6J0Q]!+9J-A5N5S2IT .AVW!_UGP3I5C7[GHW*
M#!55()S%8RYU4_-=0WA=>1W$']*E0W5/W[L^E68-ZT?AP= %;5+[ER>T-?.!
M[-FLD!.9K5@F0ZH==?Z*LDWW1]^C3\P>Q,-Q0XM8,,'K<V+?#O,RP"CYP_.S
MY)2+"%G9H]:S77;-+Y+WXZL=TFJ'M-HJ[\?F0T/Z/)5?/.[TS &GGQ8XWZ39
MW?=KT5]E=^BX@7Z$82A?_?)=W"WB'$6@+@%EALTH@+H/)@&^"_B*U>BM]S[#
M*,&(3TA(D9,ZQ \!7PCJ(SU;84(Y_F;H&1NYT0V/JF.=ZS+B=B8:6NMC+GZX
MR-4K5:Y+#)DW8JO<I'3O>^$!0BRP:3^Q>Z19QR#$I&M)Q]R][42(VJV*<KJ$
MR?174F&J@<>2LP9G)76AY7VU12R)5M;"N*DP6!0I>4TV4-3%16DEN$US05=0
M%X&XM>+4%_)HJG$R$^?'3+)0M&@I<\!TV]'B;@AB ?R/FPIA"V@+0J?JA310
MDK$%E[5C:>#M"EVD8L[P;A,:BF6G1&Y[PHKQ_)>?N[A3LVCM14FD!I*MROF9
M1;^*Z0M(&*11,O*MXI)):#E3E?)H?;HO^,LE/H=?)LXYS6L)J9+1> ]I[<0D
M TP_&.J,L4S:9KEO5U+&Y^8 I1T7E\2\,_#L!(8Z9S,J:=C,IX*U:V1*O >#
M*!&_B4K9##G<OK=65NVG1%O-;)Y/%M9NS)>^H0/72SO>&/67+ AV/-#9*K&@
MWP-OJ/*;=6B#M)O:]DU#\FYM4VT)J_#C<'L(WL!JKD%JXCXMW$&%PCX[N&E[
MKD0DD3LQ%]'S*I^3BJ#PG+J[NOHN[;JIK@X)U6^L[[D7;)&[H5R4VJ^\,* M
MF24L#)-.H;1!R%DZ5-+;TKUL-W[NX"BGYF(95*X6356T&O2/75RE>ETN0LG'
M355VLY0&Q**;5D#&L2:=W/"61/%N[>_6_N#:/[IE[6O&62/74>5<+BYKR32,
MYLU\&=PL 75?K,!5(\=6RC @.T,W ;V_3#'C%<D-N$_LCH+(6V^8ZXV1V\HJ
MO%+W=>-3I1O/ NI%*-?V739JW)Y#0ES_HIN3J?G)53%=5L6#WE2[,MY#W%/'
MWPPFR)@6 ]\K]\N%Y'G"DI<E&'G,"?I1-PZEB@(QX<!6)) =GN7\2CTHMQ_F
MV(C#V'=ZSNL>H<): W%1VM?:$%I9<2/_5:.J$7.7:U+.HER.V$@XDK5?9)QW
MI9(@ZC>-."MAF5K<-&EW,<*-O:C%6*=\</Q##":!*&R P,EX&6/@=AZS:D5%
ME8=0E;V+NEI"(:8%0.;Z90:?]&<PB[4AQ*&)I[%#L28P"5Z$.;.0/'CN4DE2
M5RJ=3O[$UJ#GZFA#:O8245'4NXVPK2VAVFK(Y")(F[ P:HEPS1^$11Q5<I%U
M\.]Q*V)WB/Z$96<N NZ6)!^J0:YQ/:QEHG,2%5:KI"J([:)B!W;PZMUN2V7[
M='D:LE](*HIB<OC&LO81M#_IKSGQJG]V44I-3EZ3T5]&95LI1G=61+J\A!B;
MM9^U7ILD'P'JBC,^IS!;]Y9C2?WN4,S3?(F5#AMHFU&P:IK%?_!-&JR]ZO1$
MS'J2U!/:*REOY7W[&1< W1ZXSF5R)(N=%*QS/QDQR6>/6B NXF 'C LEH6UT
M*U#<+Y\ 8$G/0QD(,"/[HW/G155Y6Y$C;V-J:\(I&RC7I19O_4&%C2!D'LNA
MA0FG46J56HO=7/A82/[-OX6!P4:4$%'70)#$=K&_.W8GW- 1&@'BRY0XZ,O5
M10O6UC&N()(W,N]N&A.^K[692,NXDL3,%Q*BA4T4-H[8+!M:OR2[+D6L\XTS
M4]SHE1Q6G='2JAMQDV]+T^9Y4QL!LVA"]$^-"0698<:7W5)3.)*EC,WX &L3
M;1(C6I.LBKX?P2I&SH(L%[H$4*]$4=_W:+AYG_05Y..B?4A8@GFO@OI?[MN/
M*'R8P#F&KU(FXO618L' 2M=>V[C&]P;9@VKN/J7T@>7#;=26:? GZY0M-Z+C
MJ3)0GH>JG+%=EHW"MK%,86J=X5-,X!GE#DU]ZYSUA6)T.F'%U^T?-RF:]R9M
MJ+&\]&BPQ0>+73BD^(&?\#NBB] +P-&43)!."_#C3:T/9HB:W!=/07=>6>=1
MA]0UNZSDAOB%M06-\X6+V&Y[\_5T<_TYP0+9\K.F9S+$*&*+L[*Y?SDS9M(L
MZF0.\N]8R>MOI<]:'C-1>@[9<&03#*VE#TG\R,W@H$O_N.VJ]1(TPV&C78UZ
MO6\%L4V;0NPZ3<]EDYY"#*]+4QJFE 4.B\ZM\(M155Y\H2H53W?5ZEVU^H%6
MJV^'.,$)_B7P%I^:9Z>LO<5G!#T-J&EPE;/"1L;>X'A2.1>1X7 G] 9V</14
MBQG3)(,Z]#Y=L8%FK#/J#I$'Z#-U"1BIUI;DVWRZ-!N9$'N%(/,]T*$W@==7
MN61-<*E2;&C C#*:ZA,<F NUYHR%$*2&0J/2\^:S<7FYA#=A<6;D%LF*OBXL
M9%G#NTJD*NKBWB>3Y1_FNL_Y$;&G:_%W9ELGLQR1S%K@3U\_K&6J FY[ND9>
M7(2N[D&Z9?=NC1-=@DSML$]D"_RQB*TD(A\\[ZR)GZ_Z0J)UNA7L"W=AR07F
M)5-?O0X$U!Z,84R.A)2R\+R23!B#5/RJ^J@PR7M)GYZU1%&+E/$+,+O_PUU]
M]+*@C\BB?SZ3G(J!7LY>_./E:1"Y)P "$V7K'DZQA 6"JDE"^B6N?E$4(8;/
MITA4BP_*2_OO"!JWUGR'S-T^AW:3E]>*A:1?K3!RK#>_>>"W*XAV4K:3Y:RC
M<]N+U>5*MO'CC>D&X+?Y1=DB7HG_RETACS?#U@TB(:F#5S?1\W"$!.'+NG#3
MUJ5.M?3Z,I#-\7S.1:_)N-\E4&R?<262V9L0 HSU1UM/>]D+1I#^50PVIUF#
MWVAX<V&M@W&/*S@QA&@-["SKS.U3I830'>H5YODC4F9[LP1 04>(NMTC$HSI
MWZ0$H E)^5*"$!_7BM0<^@>\S8$F,,_@%&5.1G#^ (N%-L(?8"4B#T"EH&RK
M5R8^?*$ZMH2%X)I<RSI R3Y=Q'AP47Q:6>)V0QA-U#U%3IBVR[QQLSV+L\%.
MJT _O^%:;Z[2'_3FC6LRDDPQY%Q Z7/;\^UUF(GP_MSF8?K8AE=V0V\Y\Q>1
M2_,B\=(9COWB]>1/H(A;"UY!ZA,,<G-F7-!Y/8KB(HW]W,7PJN60Z]W.[B+Y
MLNB('$R9,9$0>+KDT(P8MVZAV5(^C0\+5_='X2BX; P#-F^JDAVTU.H5+8M0
M#A#(-TUU>!.8DT/=Y&[N%U==2-GKWK1LBJ(8F["G9(I+)6#A:I$^A\9%, RD
ML1A4ZG3>U-ZC\M($&A67[]X_@H$K1T97C'$I"A_]7>V#8PGI!">&P<NYA0D<
M!;5*0XWIV]-KPN0'-5A]6DN% "QX@10^Y6RF<L*8] .SZJQ8#:?*@!RK\I8G
M[1;-OC;<B3LDARRYD!(?RT!J2,<5=R7-L\H=OE#+[/%BFTZ/5=* -I2CBX?&
M]ZO"%/'>U=.7EEMOTH6S8S"U913UJ<B=)!03A-_:F,3?C?CVU!"$Q%BB3Y'F
MP;0#RU=$#39A@E_>\X*A)K3(>4,+"3ZX90;:A92QIS_P]9Z&U/M9I.=AX-(7
MC^V"9]YU,1!B=5+<::SQ2%&S)"LJ)\BJ<T=8BZ2&="@M6"E=JBCY]+KLE+-1
M:@U9A#B$E%Q=5'HHFQ\ES\_6F%!"9C$26=6@%91%C9K:Q ?-IQD<9OV0D[?)
MDW'>"."DXR+ T!EB@*R]R=30WF!HOOH:O3XKP" S%82*XMMW)IPR, ?C);V0
M'GZ[__M)#B\&,T4FK%E.NJXILKOI8/""W4LQO6!\8QH%5[2R9CTE'I<!^[Z=
MN!1/'?O0AD<W\;KP?.&QW$]FDZIR65)&C"(.R"LKF"GFB$B 0P+'Z*R<&#QG
M6:'+3NJ37 <W:(4;%W91+W?,-PF)E[940'!4-9!FXG2;1NT_Z2XQGC*\=@M@
MD'_/HW%YQ1LI)4+E1E#8&)JN8\\<MP:Z> "]>3]+D,*(\X4>OQ2JVU:Z*OA!
M\= 8 \>OAT&]C\O"P&EMUJ31DIQ6P-<0PP!C(>QK7(D\OFV7>^G86$0G'_RJ
M)B 4=W=1W/ IW.".#D2F/6ZZ&$ZLH18BKOD=?F:MYZ$II2W$),7]&5*%[<59
MDZ83>3HO-J=AS-M^%2Z)YM>'($Z NRD)KW#%H0FR>!&V[9JT5SSDNKQ:*R'M
MV\OGBXQ?KS"D>\F[$#=YO(RX/9'(!OV>.*+!&N+Z20+[^#994G/RA>((S"+D
M7Y3Y6W11%[]>$*9*%]6DD@"'];]J%7GPFY_2FVA2_ZU42P%4*$!,EO0QW:'5
MPD7%Q:;+M(<UH?_KJ>F%O-V7621ZMBL2[8I$6RT2W:7X$OM/-+Q743HQVO%!
M))$9)W6T0LZ3<8+M7PNZ-IY;T8%0RBWI5:Y9N"@?0E-7R;D86T5M[;X6\6WA
MT2W@D2<)>QS)<<#&5K#%53_."/4F*?] ,Q$WL0?B)U$)1_!OUT4MZ825>]E1
M-L'2"$)CX7W6]<C'D 92=Q#@K 18ZM<%04CGLQ5,)2;YZ745<?$_+I:*,&MN
MI"VM1WO1="HX*+ S^KA1.]HB?^<<[\(-5U,1EJ&VQ#H=\'2JF/2JG,6:KA1R
MI2&+?Z.24..7*=#>!R"$*M:27"!,AX3BH+[\Z+UO>CV9UZYU9YHL"H@NPJDJ
MVK2BE_F/0X HQ4,YH869E>ZU==X$B!BCGTS4M B(8_W "^N"+1R]0B3+V!I"
M:S8O%J5P.UR9D+?$$=S+"=A/)='SB/$W5B$:V@GQQ_%WXVM$7Q\OU=Q,++(E
MMK>YN-AC]!%4UOLUBL0GB1<!LQ1ZN:J9O$T#/E!1UMR-VL4I993!#5P2Y.=G
M[/^R]Z[-;6-)MNA?8?3,F;#C0BK+KRJ7YTZ$2G9UN;M<Y6N[3\5\F@!)4$(;
M!-@ *9G]Z^_.E8^=&P IN1Z6/,TY9R;*(@GL1^[<^5BY4@3/47>+#7=%,)AT
M1>3!R(<)I"EAR=FU?%=*3\P\U]%K96BC&S/I0@LL:?M@$DST.HZL.N%ALV9E
MSF2<CL6";["EHKMQS,>6+\U"Y76BF>V6&(*[633J1"+:)I^K3P+1,-<FOB6C
MZT)U^;2XR:60"@QHO\U1>;FA'$KX++@+80BXAQ@RRW$/>@L;V3/:BT'@S4K'
M[X"C_":HZ9R""I-7,=9[%]SD.+"W>L^\#.L83BPGCA'S <]*4)/<I!8^LJ6=
M1+@Y[IBRD^UII68NF(KWK,K+98+ 8&@FE[$SC^/*QAKLG5A 8V5CVOA!ZL$X
M^)J0]%@G\1V/2EWA_6FE-&K&-_H<7>_(V5XP-XTC?(JO5.XP"LGYSL5V;9^:
MS7%UT:!A#)7Z*T$J\Y[M*')1M4['*0V'<F>PG%-BX5=D.2"+2'_VUS*ZPW-U
M'8FJ_4%:=8=M@O:AOP9727(QZ3I[@C8H$LX*16%[!P[V-V%:$9#P+O9L%3V9
MY)LY"%H$UZQ9'$DI)'(W,+&X9L#'+V!=R.?0^ 5A[8&78?(YN LNG\FC](ZP
M5BI9R<W#KQXQ?3QOOLWKW1N>LI( DJ[=K*D4T$(34> P=626A-)/36'==-IM
MY;WG^RK:DO+K2+[$5B&IX(S""JAE6,%LE%,35DR8] 5RN@;BFA#=I._#:>#V
MX1.N-/1R! T;7\U.P!!*Q-8G&>V:OQ8AE-.02C\K""L-R'<<@QB,,+7.U:=<
MF!;3'.G*(CU34=H8F0U1"3V:/Y<\T2[S'DW<0D50Q)T2IUREQ%=2V&A_.KDV
M@Z6<PNT\*<E8(.EZ!/H-+R>^!(6(9<+E=UY8#]<X&1("[I5A1@1"_&2R*#P"
MBT!EJPPOYN48<MMF(OJ@7ABC"_G*L.F1WW#(>W$G+M)W%/K/N8W0RX^T7#3S
M'>!)C/KV;ED/G=%2(UU+?Z:_SX/0O0]*Z4/J8_\H&8\W=C]E@"M4TO0HJ=_K
MI;L5TM:O"94ET^O-:BC@$;L]IT=&;(9Z2]W(4_7724F?ENN (7-1'!%J)XP9
M=Y@E;7S,01691[I[?E-0X<Q1?[>IE\7:R&O@I/*!7FW:E30]6:,Z41>;;@2G
M.[1&8LTW&^8%@W%8?>%+C7"*2C6".:UGZ "W5I'P[K8@6U 8156>&QE-OE/(
M+ ;#=12&O4DP6*K7 ?$2[:<2YJVDL?3(#40AC3[U!*'/=.LD =O0%P;URB#1
MNS,YRJW8<6&LIUJ$@4=#UN%%\(":S5SOC'OE-+;4>67AG\E/S159T#U40@0V
M]-8.GRZ 6QV;$\VGE&]9:;9D%+;2;K F%[#X6'92F#CXFE'N3-UR5EL+Y+!^
M**UJ)OR(EL<$(=KP%H?A3HI=C\M*I65<Y""/WF5V8(%RX6B2/M/I(?S]^$ Q
ME'@W,S?1*-MG-",D,=V+0EHPU:!C?#7/4UYC'"_523VY]?! /;,(S8GW/2KO
M+-MN>C9@9X6XIDJCUW\_N1;<\7]P4>78H]-$JW5NBG"+H!!F!FM@T,V8'P.\
M-3$&"""T3!F"K4"QC_84.&/V93)N/CNDIP[IJ3M:PR1WJGFI6KV3&_-.#%8F
MD0_\I7?HW;F-&@,^$SM07+VQYU=B)@PQ?#88@QW3PF<#5V\%QO3:L#ISA_ 7
MTL3^)#B9UJ7@QI1AY#;LO=/:NOB-TT-PD;1H6>]YL$'35^-D,QN72&)&"A1[
MN^($"O=+5AM[S,WHNQ3JG&CJ9^"UC/DWF50"XYT/'YQ\DTF$.AA>TAE(.$R(
MSVI3$T&GV2]9=).B^3;TK"9O\O4%U>A/_&I29M//OS=<,<O(OQO8J&I_C>#1
M^W9;+&T#)JX*,ZKSY)O1K/-!KK0F)W@UE,E;<BXG=<F(EBX_KYNN5*29M(1D
MDT/M7%3\M$*PK0U,U17JF;)Y$++EBN&ZX?3,DJ*%V']3I- A+ 7,. A9[K![
M(A'G/G2WTBQQK1@5:S!:5PTCQ8#WRK;MZ6/"/B:*QPPH&QUBIT:=JL&RW5VC
M2#M$NP-;<(^'%):ZCAAD7S:)G&GXRF*3MCS1%#7JNJ,]KZ+0I7G%T>,VEJC?
M&KF+@ES%-V3;##'@/:1/_:A36NVINMLS@O!V@H"73,%NTP9-PQU:.* I\>TN
M(M4()/JA8$J=%<6W@4VW5\O*P$$<##Y]6Z3TTI=I%0I"?NUEB;1E.(\MG:66
M^?.633LMY](/?DDQ!FT.WXNN:6HJN^$<_.!^TQO#"QF?!T),JE?9U')MTD,!
MTVCSMM0<.YW;0L@DV.[V7CJN/P;WE?K>BBX16E"OQDSX6(D8+V%4ORM6O]<K
M=@[7N /860;AQS>G+RR%0-):,'P1TZ,Q+"MD87O.S8B&AN\=S0HZ2M1X!4]B
M[YRQ$=">([/QI%8<AY8C'J>E88;ZMJ)$ISOYP,:AS'GJINY1U:Q<X-"-12NY
M]@Y\W"NB.(O^GVMR1,*XV&IV QV"1$/@2!3SWWPB]&1'RW#/E!21'NOA_-1H
MB^=M?J7@2 [^4;6>WHEQ286*I[*%[?K,;+ONGA2%R<8,B3RMR9&'4H3_6C9R
M$Q.27RK+/<1]E/MZ3;2>YPZ3H,#W*M_4X:<#Y/N.D&+_;N:F5",3FC<,4T4.
M1(ZI<G0GI'Z4[L>!]N'KY!B[+RL^-:8"W%H)@^%UI_:YP>R1,1-4@;HW^MM-
MUR\'$!+#)2Y(%%O$Q'DNS "QRIU"7F"&]$[&D"'REA3$2QA#K-A=5MF'EUS-
M%HHI9D7=63L97F]-/R?I@?U185.-/1;;/?IU&#(]CL51L3KFYA=='(-JA[T7
MFUK<(V/M8[]]F'Q!K7E>P0 P$EY::HY&;]- K*^US),+S;/K@Z&^A]GSO H%
MV8XRT=0D34E+QV?#]F^WRP VV]!) "5)L0UJ<RY(;:RA-I!UH0!5V/YF<YY@
M3!.*BT1]#+-=>T.)QQC'D;GYF%6LK+*#?H.C&Q=5. +SRZ85' 'LJR.P@DD%
M,8NO0J><2,R:8,N"5#%L*R/J3 WLB*6/Z7W9):6WN$,Q]8&MD:3,11IX8C[@
MWGB\<\( ET_$QDND1=SC8S'Z)J>3L8\9I,9H/SQJSSVOYKB>T Q@@D+0HSX#
MP*TM^"/4W;!Y,3!/4RJW7Y\64\X5)=_>.DM&C[1D'7PT;&2.#8\2%^HN+>&#
M"3U'TO01@O1Q_CH<RBBYL(3!3V+0)Z%Y,0VJI./-% 7R<P$ME/5H5N(:191"
M'T>D0LMX(8LW</L-ZT5I4J*$-O0W,Q*YZ1$Y!5:*R6($@M0Y7F4HCSE1^&6[
ML_/CH;-=X9.$#'3TD(SKE3W'2D_5'<[=#4P68?6)6B2F>3%T?U[[*('4[:F
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MA%S=&?V+#3!EHU=4# E"(D;O"BL0OP.,6C&,.GEK1M#M,>;UJ!/@*@6Y/V\
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MWWW;@FZS7)+Y'8N'QPBA7'73G?!DB:DN\NN\=>BL6W5M/;NRM#P'J5Z,*R1
MLJ37"GU9.]2.=XQ*PY!R4P2I+H,_(27:@VS'SNXHXWD1**^(SETT?8Z076S8
M-/ 1AGRF%%1QE"&3N.K=1K*>D(- ;RR.JGQ:5.SL_-341SB-I6>\ \N:7TQ2
M1+%IFB]ZCK6?JZ#E*PRXU_=J7Q>C/8&ANW 6WB5>])OH19\Y+YK4SMNX=2]-
M7Y:WW#,M[=RUET]",A?:>PSN?Z=XTN2V,BX6"1'0!637$D6^J6</;2;,/DF1
M@7#/2NO0F$]JE$P#CG&[[VR%)FU[MFJW#;]A360IG)7Y$,L8T<4@"C]:LD>+
M>*^L$QK_1A?"A5CXI."ZHV?):OZN3">_O<B[SS_X^.DS(LUX%@O2*'(0; H*
ML\&V0/7K;A,DC1I!J]4=-DLUW7"E4&$[E:YV\CQE,$E9%57OC=GP%.VT.O*Q
M9A I>3/7D"K+SEAH,,'%V/SE-.2,9)9HV'88CW-^E(_(B<=%RG\F2V&)4UN[
M&>E>\Y;DCYST[QF%AKS(8@N$-C'[^==,F4&!5P-CHSARWD/_Y-WH4LAJW9P:
M<H1"]8:\D'U;%A$]KC;K\>[%JOL@9E,,2)8*(>+P6R=CVGJ"$B&T;67P.5.N
M 7,C2'-$#JZVVUEH<QVWBNSURY?64N 8PT*DAA$%#@D4=IOB$&8;S/QL]MR0
MFH#5!9-X'[NZ:&C!;^LT&-K4TFM>Y"MYV72S-N6NU>%]T4:;U/C[7:MS3]4S
M'>OP^ETD#<JK2/[$K>G'7RZ(;8W6C[<%:M'Q1^L65^2<8K&W'(E)F5*,YD&6
MLR'MI/S#,3G)JL3Z_.7I'MSHF7SY[18*XQB[7HPMOCN@01_7!NI::E.#Y(ZM
M&U:3E!F0MM*<WX#2T:GM$*VLGP].QF?/G3(YWCQB-':LD4!T^N1UGW2X7QJ/
M7T(=XW=,5AO975EQDI[N=_7D/OVRUU[+TG&4F9UC^D9A:R!J:%JS^V:;MF56
MC>:JYNQ&V(IPC8?_MG.@QN$:H0-==G!:38MMP[M8VL.HFKT4PX\[P$8346X@
M[CX=WE$5]7D$K8X1-+,-RW1/G3*!QQ;39>4XB0R]0PP1MP07\>=C!W'9"*AB
M8(YB<JY@:MPX_9;=3!>PR?1VC_=A-A+7X</7CT)]D4F>QP\.29Y#DN=+2?*<
M7I_P'X<FW$-Q)FC2!T^X[R$]6,)>8+>O)5(BTJMF/ X<5<CQY$7_"<*QUUD,
M6*/ZXDWW*DEK"CNI>@<\+JD\35N%)7>SML\U';]S&1B+EJ2UM6T1I;97FY;B
M@>)+#.9XS8S4>Y0G=GV7T;=AD+ =^D30(*IFN@]KQF$-[<S;8U',UR,3O5<<
MGP<W@ 3%8U+HWP1$R2CH7)\7NTRO^]>9\P(Z-]B;-%S 2.DE9%?$D(B7$[)]
MTV?!!N:?^<FAMT1-'?-:[C$D'A2UO H#,JR:-K_BEJ.[X8LP#\,]28D*9)M\
M+VX9WO/)16R>UA\0BAWD#G8>XNB#)M(L<8D3BXPA8R=CU$FHQNBA!LC#-_:@
MBBR0D*[,E X21RY\(-9.D!H.HYTEK3<,OQ*=%=\14U\J/ Q:)/,N6(G, S>F
M"/2IUXFTX".EUV%_;3R<G@WS,:75\S %9[MI-3 ^4&I,7'??@V?VKK;O)D?A
MZR/?3,@.BTIB*AJV2H-1C'C5UR@_UQ-<!3..4C!O W?-XV^-N;M'J>C<FHCI
MDEC]^&1OR6K^+G:-<T$W8;03U ,!X:930ILFO$7DCEQ0#B_2?CK_0RX-B->.
M_1*Z0[X3\&J6:FL!00\X>7!$2N_DA!\R<GD8DV*:,'3]\&(,P#F]M:"R@K<*
MK&"A:2R(4K&^*B1]'Q]D?K-&L_.QKO,2')7&F#>00D"!'0_LZU/I91)?G%!-
M&YDN*4%P&$.7NAW;4?;@>O2XCLL4\>7F0R4GL=WL^M(?5-C?&,^]*[47]HVO
M0"U\!/95 SUABNC9F+0!N*TTYX"QM.RL?JE_[>C7"B!IB&YP)TR?B[_J'NOL
M_U:&U/R&_*CY]>RHN6H$TATC86,[W?>Z(ASC:5!2MQ7(?-/SWR>.KG2<@O)X
M\F4#5B;[N(+]AE"B'G4%N8*L#(+"]9J73;7A)"^2\QI9EY"9W3X[O#5!!3>M
MJTY(LS^U3+87\,UZZ!39N#7(4SGHH\DUL4SB=RFVON,4B)$B36>1:B6]V7.D
MQ)I/N\KN-^5B35MJ_^!&G=S8P>2P*J'F]CB9=R#]#QS[Y =4K1%5[>1'8N^F
M-3B+F D/D)G\+&V_1<*3F^@6T3-DX5O%TVG0I$=_+6<?*!B&L6U0)]Y<E-/2
M!\![]ZC@E"Y+/<\F W  A527NRA<;(.0A_7!O\H:])$$3:EGS:8EZEU^6-'-
MVE):P%%#Z&58Q;EHW_!?C30]S\A;#S<X%12@L&&;";Z3:LLX=3QRZ6E/3IU:
M#!2G,5BV;#Y]:DA0PMHY)_^B'DG<T*UU%#RV*>$B*Y*>L2:5:;_/O_UU\IW\
MXC1HF(</3AZ ICA]Z ?=0!MW-[GW?<NYE.^*ZKS<!,^_6,^.H?X6*,=QM:)=
MP>.9H9N! _>P607O>L%F&3$;H^]C4W,YPJO:]2%.YK'*MTN!CLR+WG)I H>+
M05%PVZ$N<9[X:(2F74:&7?> 9D$LS?H8AA9QL3@ =B7T[]I0Q"E1LZ;4]7%F
MBQ;A)#=;>C4!6,,S--Q3*%IA4<!8 8$"&HK8X[^2_- .Y):R;P2;(OB_&UCF
M_=ZD?:A5'EM3F[C:SM..93A/P3T@0-R<ZRN30<I?%XJ9R+QA7=9#\3N>?)^7
M%?JK:D]'RZ\-D& ]<6F+U69M]EO9?<BTV)>ZLY94DH.VT+'\B1J)*U0L$Q&C
MDF$O87=!3?[M^!WZ1H>[C4S6MMV$+[Z1'NH='<TLDAI<%<R\K(#8M71[A]ZA
M56N#3Z_L$=)BFD5";]#Z/#^7DCT]6[$AL .VH($N=^X.MVLMN ]HV46UD<:9
MW )F<M6T'^29><V943K6LWR5S[B9F)C'8UU@P9RMP4_%D(4G5O,KNN%48['*
MF=S[L2DG[_)56=_7I*E<'W\-(YB'&=Y+]=I]5+93Q\^*'4E J4BQ$[I;_@7U
MJX$B@<1L58F%\5'<"/D^XAYF>OT:B4YL&FOEI66%P]PS_\<@_8N%' 4JX@^N
MH1&NX-7Q3P8LD[7,UVOJEGF3?<$24C'<K]BA+S,%=W)(P1U2<'>T[^.N28O-
M[R<];:HYN=5MR4!!P'S+Y70C5JE-_3;NJE,M^J^!X]@)E+6X'(SKEK0+8NZ*
M7O3Q#BX=9713$E$V;S!SCZ$;@&&'.U^.+ +#/0QAGT5@<,I%1B\OV_D1:]_6
MK[3B:)E6A>.7BV).S1(R:5$( $-;7M)_ ZD%ZRH^3WZL%<ON%KB([EV8PGF;
M+YT]CIY<N53&\S]*(GR1-PFA25E3^9E0OH2-#BHK*+><4:94S?9+ :-]5JZ8
MVV8PKBLIX0:-1&_NA-6)Z]LY&@NVST8>QUTP9M3Y.>P:5=Q<$&T/YXW8]5(@
M&;?EBN4%E'[11BZU;&^_N3LCN(OVDA%NKR(D.DMR4IM:3)GU5CJIP<?1$AT_
M2V'D"2^KBZMJ&^4OW1Y9@5\8UT1$(AX<3$ B9N+4"HQ"<9FN0M$J WV<???D
MT[7_>5S2%60Z+7RV+GV@&CSHM43?VBQ5K\2!+^#1(E9?%!_&CL%PNX]3O>0'
M(T>LXF!H[#E$EA(ZH.B[J"#=392C8DGS<QPPZ[7$M&:WA-A4R-A$F<O:@D\0
MP2;*FBU!8*3K#?P<M!Z#OF#1A<K@.E>RP->.Z<JI!D@\*W\T,&H$A(9\GN "
MFRL&K#DQI5T?,%E %."FQI@'ER+<'E(P'MI2BD74<C:#WZ(^7#NER\%18+3(
M47?<#JP@QDOED2*GE<O^-).F983.K>1%!V\./53?<TD167(W*LD#"/*4#[V"
M4/LE>GV\.:M5:H/(#AB-'HT8O!/,, '&9+-^ F9B/+(4.U RUM$<='\A,#D'
MV$^Z';K=^/0@75$S=WO>>[%9YC57;YVF;7H%ZHEZ9]<2EG6]0FE'FBEB.?!K
MJOTH\CDWEJ5G,'<+^FFV"+2TL!CPWW8FY#I7[>#N\YA 4,#,Z!#ZZ)GW.-&2
M3*BE9UJLK8BU@$+<3$8.SS*.J>TM-0YM'@6@5X7@,F6$?(!N-(*AD5U3"<U;
MR E+L1I5_5OC=D[X#^'"#8[SC G+;()5'J[EBUVQT,F\<;VI957#J=B@EUTW
M&MCF3J,@)J!C3CR@HH"=,1 ^H!1 ^YGB^M/D!:E%_Y(C?C+P'W">SO(5N0"3
M__QJ>EL6/1;W==X&K7*231X^>/@8 .Z+<!Z?/D7E]!%,AT*''ZP1WHWQC[/)
MD\?A =29CX)+O.-$YX97T-03_L48;**/3A[&!PT>PD6?0=LB<I.)2@J/#E(_
M0U0O'/8J/DQD0TQCCB'_4FB+"*43)2MC&I9'29EZ@6 Z46YN5T5L,4'60+BM
MZEG!92<450G;UZPH>*!Q+:)B(XAZ51;4HG#32I=W4@C#%W")1]/\KE2<&DCP
M_.M[)(0R4)NVO[J3!C%&-%D5=R9#O88%><-]/@>\8@N7+2CK=E.NY;^%\RJS
M7JWH]R[]"X-/?]YR"A^KH6@Q,?Z4Q<B+(*=.PL.";U,9JE)5H#6$94^(2Z ;
M"I]1(%7'([QC:W:J@C'*B5.WVS"7*\I+()I\67;*L,F748-\=21$\33-01!F
M'XZ"P0J+7,H2$<!'W1&#7_+N0KX21(FRKHRKPC=ZRPO9U?L\[[4 L,31*I]]
MR!ET>5%4*R=9? K$<M F90!A@90@T^,ET%145C0QKTC"[:W+OLE!!1:P7<'%
MQADM]R$>Y_Z=SV:E_&!>Y&M1#&7'EH6 ,PG+2E]&I\PCY/ QM"8(,_X5?F#8
MFOCL57"6PQTP^T" -"+[C+BBI",HR4:&XE)9)-XSR_KI%R:+*H@DV.ZUA(1J
M#3><IB'772H9Z+V7N<(HPYG$GDF0^**P5>=J4OX1[0"S0HCL%LDUP=N%DT^H
MR=_[CN#8JK2N?1YCI-_^VP+_DZJ%3X]BO4"SY5)*9U_5R,TW]1\4P_JTV;""
M_B-OW>M&\ NG;Y37EPN)-ZWYDR@V#J(OZ6P$5HB(QJ_I(GAX $7SV80VP$54
MU)=EJZG37PK5QPS:(Y)<16,ZC2?8Y4IB$.> Y% Z]Z(N.75#4:'U10(T"3JU
ME. ,8VQAA#9!(N P.>X5R>\1\@-)X'OSX/T1(8G,!%[@_1X@#X0^5,N?5,G1
M%%%0S+$16Y,PV.#?R=J4*F]Z551RPR(_WQ8+T?@4G7$G#S.J[0*BF0"Q_$N1
M>/I%?<%\C3=YOSQD8G1" " B<\]77C';X,(**HM@4!?E*EBT^?+W//&?=+PE
M2?+DP8,'3QZD;3S.@MQ,VS*\YX>BNBS(DZ%WAHOV:/CBD^2LW8%C_ZE*C.XR
MOF.^O2CGX7!C.M\\?/ HF<^7EBU[>,B6';)EMU^P]D<;(#^(R?4N$GC\0C;O
M=S"Y?G^%I&*(OC&_RBA0NA^)6J4VHYF,1V8SPHW-SS?:%8!N5S#S$4R8'.BN
M*QA7Q<RK=%.IIQ4Q ^;<94*X(DY9[ -ST5R1)]NL0 2)](OOID)C/?OY_[YZ
M<73R+/PF3'@)7#-%%![ ;W8MQW.^#]HB>%]BKI ]T<R:*GHNR&XQWDI(IA9]
M;YR-I>5R4ULY,>K#$<@CVR/)UHECT\SZ1"\*%3][<=;# \(,ZAHD'H,A0L!_
MM0N,D8AQ1\7'<%0VW 8^6 FU@.6-,&"P-L>\!K^003='/"$F Z08KR+',OA.
M^;99+&![=7E%L6ETQN;Q62V2I'@4W46 ^GS#WT'$ NE8VH-V(UF&LC;@J\@#
M[01:1C![2]@&^D1V(EJEO?I V'OE"N440RN)^W,7PO D<A%&%^2JF$/XN 6%
MB%+L4A"I&<CQ=@%>>3P&#6G$)-F-)O:&88J6]YQ,+O80"RK@-[I\H6.V)*4.
MTDI<BFYMO26Z$3%$;HR)W J)ZN#X714XG?F40%@B?O13N)E<WOB[NG3CRN>/
M5K%G27 C3/$["4;<"7/O]KV\GT5)E>NEY$ )8B9N F+W2"&:%J<JH:9Q?LFL
M:26*T)D(H>^5EG-*+L=2D)NRHBH3=DH*[XJ(<X@SSOB OO^)<<& H%&N#'@(
M1DKS$^VPM0T%_D@=*7[:@J*9CVE%W6MB<AH^X=/'&0*W*MS.@=/!]/^IIX.V
MM/HE1E/A3!'9R 99SD71"A2BK!DES.A^GT^>]855ZU85A&' ASA9G[R7$*+H
M++PE^M&,KJN+*@$G<%59=Y&\&S>B1O-DUNGG+K7+&ZC)*(WUZ5?"I4"ZC&5C
M9ZBJD[@8@O6X3O@ 6(RLCG$ RGR54N.IZ\+20GXSD^SL#JGMP/&#C1?7B1;U
MQ!769"0]!C!%JD2UZIU2[CV-ZT^;>B.]JZ"O*<2KP;2PY^O9128=/2ZRP</B
M)/W _^C(FE<:CY[^-E_\A@[IK>:ZS@1Y7$PX';@5'%N"9+^]I)>H9*2(K_)N
M0I$U[C)E#6ZX_,D,9&9\LWI>T5WWT.^-NGA]J)LKM"\ZI0J=-Q?E?;8#SA[]
MA=44T0U2FDQA.:3;7@>-]XQR;B?/@L;09IG55JH*E,2A8AY6;9! G0W;S%XD
M- MS8 MJ%!8V.KXW2;8Y'))7]>RV.*H?_<5J'X+U1ZVJNH[*\,X>3?Y2YG7&
M%S4-,,.>A!M+A6@^X:9"ZXLBJ6:!:H&C2QJX"29<3LOZ4W.)+ (_\3$M\(,G
MU!YP\GTQ;3?!@.9/'C[%VC]%HD7='-K_1$K1UR\7$J/A8"?H-#G7/H?![JNJ
M[1$365%12QGVE+F8PPJPEG)O@]DN1(JC3X=T-C7UD>7[.3?'HRK5)E91EG%_
MTGJ1Q,Q[;_[QQ[/CR1LO@RIT),Y7#'NX9%$-3@+7K=.?)84TCZDY=!65VGG"
M[DE]BEH_3.-;?S8X$B6\]=Q\JI#]$NZ3,-0U!Z&1,>?E.GGVS3-6'7MV_Q5Y
MJ<7'R5FLR1#[XYP@^-&/R<7]9@ KV#EE>\-;3YX]>TC?>!]FA#+2/P=C (S>
M[KFP/OZ2UT[2'YR<>(UA5:A,S!(VHS-*_^_*1H%!/Z[G&1M@1*8[:YLI^<'3
MDGS&BYHJXZ/LL4687OU2@Y%%+_B\848"\2#%Y2J!BSG7DNAM-,8V'=.WLREC
M?"C!'##T,8$!9ELD^^WWU"UPS1#15!F$A7AXTX5X)P6L;S"T'\+%!BOK39!;
M7ICAW$^I0"J<K7QDRLYKC6B(V#B2L5^K<DY<+5W0UIP/#RL13"4NQ@V_I[5'
MD9/99S[]W//+_8&;,OM[@W66E/.:;CU$0#[?Z4OLFENR9/8;+QA_N)[D,/7B
MW_U/*>;Q+10'_=?@8_:=NZ8JR2HZ-5CLJQJ.T1JYT-_5"KHCJWV-#B;8.0@.
M),RBK(UML4*^TY$N@ERQ,U^/V5*EZQ6%^(A&U0[;NR(\*2* 7GX4#BK'_6#=
MQUY:][&$K'[3JL/)@R&+XGNJAS]Y</37C+R]<!6WZ+W%8W6?_W_98";ZZ3?T
M8]S^%%PT@FEEO><O,\DHNGN%RQFL."NE]'HG$<63)_?F]^URBO.UN9YR9>K)
MLT>/&4*R1(?LC#.?)H(+*H0GO71!=TG4K;(N,-2NBG"%4<>VJZNKXZZ8'9\W
MEU)HQUJ'5NL5^OR$/[Z-P";Y'8$DU^M5]^U77Y7RK>,<IBGC((^#!N4$KEW#
MY-3.99$Y68N@ >O7'YM@8(<Y5N101B,F,Z(14:@TK^ M/9F\GIW!(:\FIY=%
MO0E^;OJ(T\FS!P^>/HVAN6#3%*L+*FX1#'>PS_Z?D\F]1R</[D^>/GUR]/#9
MPV^D$D"B#/G8=&G!^C--"S>E.319^P32GC6KLG#(?YH%48F"G<*U-G T%&54
M(L0XL:%.<HR,\I\T'$32,0II1&+X3+>.T4XX&4I:)AR#MWP,OL@LYZ-#EO.0
MY;PC-8'AF?XJ85#[))8[ZW5#E(<SY&A(32AW5J/*66Z1VIW93H%#IHB0AUI#
M[PLFNJR%P(K.#]]N]FLB"/S7,P'],.9EMZKR[;=E36;<T33<.1^2:41M]N2;
MX\?\ !G?4';QPO"=&TXNGY3S__=/__/TX>,GT_GCK__GZ^F31__S.'_Z\'^F
M\P?A_TR+9\63AU\_R[]Y^B<6;_[%JW6Q/#E]6W8?OF=FZO]Y_.S!D\=?RY=^
MGS4;V,=[:GO">,0C/CV>T+@F,K _2+8024TW=2^QSG\W&\*2$I6$ELM-*,#.
M$+5UPG8]O%SAH85)=<'/(DC:%%5'X>MTKP=OG,ZP&:)\I/U#A%M7G>3!_<I!
M?AQC0=AQ8ED-X/"9Y%+[V?MC,\$ZG=Z40<3:%<2XHE;$8RO .HK"E5)<(\!M
MI*)0A*I<YYP#U>+7N#K\N&4AW(%3A21SV_2RFVV,_I:>N6K6 D+@%41S=JW2
M+-%1GN3FU(P;<.UXA$+L^T;O4V@_/RT%#'*=#CSS6%%K%9F^3]QYT42N!>;=
MS8B0<$EV*%O3E-!:$TX@Z-8<VT(K4N?K3<N0@)S@E[0%"XD!8VK\G^-SI11%
MT7)%=#K)S/6ULG%FOJM<C!-EG%-:A WI *>F10JSK\K@&\T-'<J-BJ1@4+'T
M1*A!4D*D(Y6P3?*0I'%Z/D?FD G^@)'4IF/4S\.W<\]<!964[2BK?W"YFEH@
MU<G[@G_,4('WB4RE4D-K9U)HO-3A.!$V_JAJ&A!8(,6_Y(T+NRR/B($HC>'\
M1#B3MP"W@M>7<\+E?WTOS_M1GO?.GK=?D_ 3.G')Q@^TO^R/_T 6KA$MN#^'
M?R?#+M3US-H6^KOCCTP3W63I?@46]',,]#NZ>9BFT_5[7"=E,7I\F,";.M0B
MLDQW!5=8U/ZDOL-))06Q82,8U8QA)[;2957?8QQ^ZFT+Y"Q>D!JL60"@';5Z
M[XS''_"CD;K0P^04@+XY<W&AX8LR+=U<D$?'5S/77=N=&"_[6"[?O[V'-_?U
MQ]O"!VG,*H:E7IYI@7+8!D:0^8T(&I$K9EI540,5RO;YN%?W5'TJV)$_5!].
MGCS[YG'X?]^(*<BN$,,ZU/>%HWH$?-*J*[[5_WC^.YQVC0&XO] P(=0TAB-"
MM&W6WR[*C\7<>YXC67%UJ'F*ZS;\[USGP+]\_/"8'-@_?>4_^DVSH&P;V002
M9L!!#!-X?G41G*NC<,YGY)I>M?E*!_]-1%\9[NC9TZ^?!;6PGOMQI5\::IO?
M9*;?P&D&,I)M*>/;FS>;Z5J,7(0_):WH845(;YTW0DI <#DE7T7Y-ZR$_H^%
MHDIL$,OU&<NU-F-F,HC9ABPDYH.(9@Y";2B.!NN&'[:+A,5GNW;.>WHX1J2E
M>QME6QA*XC@4&B5&3QH7K<K+9AU;!#'*]8GD\Z@9$>Q!Z*6R\NT!1X9L[9*F
ME, ))X,CP)O:&*G5K.ZG>! X=_PZADX8G_E.?_4/EKGG$69-9^$K.L-?00_<
MDDKZ%]!!3P>AT&OTT? 'GUU.M#0[G+X-V@56P5DMJ*6R5EF5M?:PX!"8HS9B
M,V# QH)G)>1 \E#EI: [N2L*SHA(^S*]S&.75T<P$72G>7,'R3Y(]DTD.[T+
M]'Y*H*K$=2/!A0@1$V"0PG[C->4P\FCFT@0#J\WM;G$T8X!RP(C.^M=S+).@
M@_"" /EKA0Z\*!;4?T]@KMRP@ (X:VKO'?Z("G8F90UW:2YW?U.SA> B#_Z^
M<A8 E\!;SA&DIW'4SP_'ZG"L;G1A@/VV*#[T3#] 91CQ0H;B.;+MC"5*@##L
M'F[K((,$JQ$0DH&;T+HG2&7%_$8Y 8O5Z"6J_#)X;B61FQ%>U$542:2!LV8+
MC2FXW$DXGOS4] 9B/#FQ5L>HK<;PU* UK[KBBL[P\>&\',[+]>?EK<21F=:R
M+:SUCK(4DKB^ ?/%"<G7PT$OU-V<FX19H<>"^+$X"E99*5U8<R0A-4!MD#-/
M%RCG!B$G;;!G(6^Z?$ U=C[HS7JX)PYR?[-[ A5"WC'0FR*\9D-!1JZBC 97
MC_ZT'T"@'!.<=2X.$N_$&5?S9M(UDO:(M/7X26=QUX,T'Z3YUTAS2UDTD!?Z
MNE/'2#LB7=80"W1"UG=!2O3D@V8:5E$P?$"VD153@90^MJ8(<ZG1"DN/P&^(
M21UD_B#S-Y#YGQ.N E<KX:##SNDTAKV+<B59F&CK  2)U N)>M-V68_LV5J:
M] G@AA3(5%/)AHXO&9*S-@MW3K,LE&9[6G@ @X,LN+>[AB[<<T7ZF^$: <.
M1LNME\G!]C^<H)N$H.K@R):7>2:*6%/$CHH@D\KB&>- FJN:^GD7.;<?#<-]
M\N#_J"8G8D"* P&#<9$+1:O/5\;>?*C59:E%BJ.@@C/K+">U1I6P) ;#2GO=
MQG(L](E1UX"6YK^),83SU09[OT<?RD-_^N]W+Q7<WR.*UX4PC'LD=A"SS!2-
M)F7*!9"2:UZ%F.;MT3CL.H9?&F;Z\0$S?<!,WQ',]/5]5&X-GO,K*^/? K?R
M5F+J02>2;?.]P?[.%/8'$^*G0EJA. B-4$8;*BI!?3Q[_/#DD:*$?Y]Y A M
M@G]R_/B13OSDP0UNM>NX8PYXA.OQ"'<12W#\.<'Y-Y"DVZMM?'C\[$E_](1K
MS3=SA.O)@VC0H9J.LIWS"%SE>-),C!_:];I!8P@Z&IS")K+MN?:MW+1*(\ID
MXN3_T*\DL0UX<G'. +X($>;HK'.=VIQZP_WV8\?E>^,3ZSB5..-N$8^87OX1
MAMC_ZT-F>U=>,&?\41>&)6?]Q]/\PS$QF72CA6YHO401NWQ.?"Q2>PE,)!H(
M2WS.LI%A 6;-LC!^!M=/Z'AR.CXIX\S?U-K.HV!^;R/Z!NG!95[A]>$9_W[R
MZ/A)&$)5P3 5_AKD?^A!@YWM[V"RTU%GN#UGY(2A)F ),]._T?R'MQ3E)0CL
MO4:IFO!OO%#M98SXT9/C!SIBWGCO"-"/@&X7&CRA((C8*/K;IB[PA^/)__*B
MYS'%D-P=U/D%A]"M^TSZ07C<67+_*"<^]/%X(P7>&'=Z=[[ELLR5B8.JSHJI
MS]'+-1)+ 3C1S^6BL9[CBKHE@SM/>GB/5%H8DQY)&\%=RX[:FN*C=<.B?]F0
M%2E4[KX0@FL+NO$L* Z--@>U!EV@J4(C*V*.B!3]2=<4#@L9/1^B.>#O1[X8
M9,U*=FT(ZKZ-T!+G(9%&7$S@741.JN$];V1ET#FQ/2?&Z<V$-FV:YZE JJT:
M Q0MBM=Z1[HBV6*>^-5%44/8V X@JW)&RH!_5[3+SEL,OJQ^3M6!&1--<@_M
MBCFXD^XJ,%"HI F=Q,++Z7+*N*$1MV[)HAV5/ /ZM57D."BTG3 ;_X?1C?O"
M%RK6:[C]MB,BH:>!]B/CFGF W7N4'HWC?0I2G+L(^I:JMW,I87';K:F;'&IX
MTB2X;<T2^4@ ,9VM@2"G,)^7N$\1(FW&N],"R^+<153CF90CDS$Y @URFM<?
MZ,C-.)8/'GFO5"K%P(<+KM9*@O =+HJ2 *00OVFMD*H& 2QIH?G>8B;E^AS6
M,_TQ#7KN^'5P ?**'J%AT@(E]E^)063?3H_..4N(G$2WJY# 14ED,I-M<./C
MK1_$"-6 VDU$&UTYPY+BX\O83I-N@EDXRN QM2]Q=Q6^TL+S)!(':&6^-F*R
MI& L?CN>+79&R#'QYU0NJ;@"@%XK1PYB<305#O^C<$WQH&*3BI\GY$$)XZ]K
M$4IRBZ;34BWCX-_?WNF:Z,\>WD?CH$^KY[@VMH^EN#.1_1M%\V\I@J_M',6:
M*I>N9\P-VFO=I4SK09!N6Y!@8"GWMB(41U #ON#N(&,'&;NIC*6P*E%;'8CT
MUTJ6";HEY3'T_']DSW)_Y//M00 / OAKE1P<W-YMR>00ZO27EVA--Z,N>NA&
MZ-U%=3V'/IRXS,%$)DKK[N(@=@>Q8[&[NBB,) 3!EQAB57_$.$*#WY-_#)].
MV9TO(9P'43J(TGY[7\M='%:,*T7N&(3X(#UW0WJ"R# ?!9IQ=^@S2/^@"*]T
MB*"B0^*[D&PXH1N!]!60HO(-57FY9,BCY2V5+&-=H)?RAEN:KPJ*IW(P\SE]
M[PZ)Y8.#5-X1J22$ZZ9$9D?;,6VZR<ZZBST(NW'<%A208<:^-!3>DP,*[X#"
MNU44WC44WL!3)/E&RC.CP8\T+4:%"/6@XF0!-R#GO)E +<IV,L^W87^/YI2V
M-3\^P7+UN.CZV!1?3I\F3G?HD6O3XY([C2D"M!.B)&'&53>4A.%ZQEYZ;CPJ
MT:<7OUG0 YYJ+QJ'+HKAF<C". -0N0M[2Q-I'7'#6U:R)-YZ<7JCGRMO)T9V
MY_%ZSBW)!B)#;;E]RVJZ[>&6YTT;&0<SSV&MO&1M1$%:KC"+  +&Y4D+K\C:
MB&0-.ER2B% BG#EWK'5VVU3@%FP+902KFT&.RZ71W'Y//4-Z&-9&<NB6&M^5
M12?O;4WI[#N5QQQ@0Y_\ON2PO[%SX)?'^/('X!X3-?OH^&%_6?_X!H;)Z\Y&
M$@!1E0V"N 1*)-Z.K0O/MFSD$5B%NILR#H\0(IZ[=5T(AS5X^2/X+JIP='G9
M5W,NF>.:4MMT# U#%]_E)0.B]DF"\?DXL3_S)O=N0-L1XO,-=\)B4]G&\/Y?
M )Z0G@N^&P&)D>M0J16!,=:F-FE3&CEK@#!;VYN12$;857HBP0<)(7:SB_T5
MQW=W2PP@U-0:L,]KT$KX;<]O18[/"94S,N+L)@_A>T)X/3)#=.OZRF4GMPNZ
M9DJHN0X?M]1#CG!3N@U5<3QY>4E=?1D2-KI+<DA4T^GSF'C!\&.;3EF(TI\2
M/CA<?<!DH5_+T'PRX;'B2PB.T4SP&O!95I&Y*/++DFN8 9\2:RK(YP%Q<8BA
MW95HA5-D2>[14Z? Z]!_C/7%OM,E[P?YNDWYTDA^>B/ZN\4<('S-[L9%,WZ[
MA3];>R&K]+G#+",'\;M-\7,]&'.U &CQLPG:#^*_VH+EK,2_D(BB=JB+<..3
MK(RRY^SASCD(WT'X6/BJ//C4%ZK]O'DODK17N4D)Y+6J,IL4)2)74X?6$(&'
M04I)KR+SOZQ1:!<[FI?UHLU=.4.#ASD(2?B1]/ZE"&&PA0]"?A!R%O)XJ0\\
M.\4B&<FC$D >I.<@/2P]KCFPMC22J(H5_J@'(N+E_(^#'!WD2.3(R 4@2;Y]
MZ+IHZ3^Z;;<N!"G9O^[R3NH'#_)TD">1)\DJJKD4["RRT<!<$-YUL/H/HK-+
M=.KBO*'L-<G*(K]LVIA"U5ZHSK(F5H21/'6"QT8^V_P"H+*!K#F(W$'DI!*%
M.RPH ')-O144] AV:H5E$-O"HJG*AFSS?9!&C^<0,&1&<9$Y%?//VD*PD=0#
M\NBBN3H@( _B&(WZ-=IQ0!HORE8E,0B->(K_V%!;^Y(\PJ+MT+S^-R(?/T<V
M3=.0ODF6M2/<286AT*VRBW[P(N&_0)@&64N'_6"X"*@G739_O,BL'UD:\[DY
MI0D*"\(#2%N3.IQDHDD0<!%C"K2RWC@X#!@TY0;"W[\XY9:H+S>D-()PO29N
M>V)$F)P2K\AV<D](*E^^/E6.RBS>;H1""+-*8EN;]473EDKRK)3-NTLUE<_?
ML80Q,0FQ9NCBCQ?.^WQR*PGB&V 2[QY^]ND!/WO S]XJ?C91D!XHD2(D "?-
MJ]T1P1YHHP<!,?9"Y90:H0<4!@R/A_ICB%=^?\C%9X$R[Z)T YQV-MLL-XQ3
MG8,=.6C/O)O\^Z,'WQQ_HV1H0^09XQ"OAYA-% 09+L-@G,X%Q-:'-?*G>T&,
MCLNOVGIFI<B@ K:A'574N[D>/?NH[XN;-JL=9?51:BENR6O]AJ^C1#3.P_"+
M5^&/DV\4QY3VX!52.;E07QO W,B=7\1^P_3=TS"%;5=BD+LX5]_&>?QL\U!.
MZL' OA[O#OR'H8!_=Z#@;X3P'EK;?5IKN^/)OS)SJK,^3AX>TU]&&@+LGHYW
M_U9M<00'\$__->'_^5G8)4^>0'\_P+T).Q'GE<0BG/#SMN :%&O.#0,]B-;[
MR"7WDGZU:JDNY(R45?!&-TLSW%^_?WD6C'EY4+3A03N7,R^7A:0BP:;N_+^?
M.!9-I1RLA5XM'2\Q%Q;%$<B[A!,OR'98Q;+CKXG7\:)Y822'&!TFI_>^R:**
M_@_H.*'^"+W[+T&XUY-?\G9!FQ-.JR[*6[TNWO#KCVF9WQ6K-=^5#Y\Q>RO[
M/.G"X)I<-G/V9OE*9)<*Y QHH,RS#[/X]Y/C1[8FX;O_?O+4_8&#->M":"0I
M8,@KA'^!PR_XS2T-/)QPHCG#O4KT9%S%P>_DMY$+12US<$V"/RWGKF>L6T^F
M7SW,LTGXZKQ94D?Z#,RX57  @L,5_A6>.BNFS5'L7$#?Z(JC K@97"1):S4
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MA_\Z7,:][U_/][$VB6H4)6KB?JV8E#N>8A)P"%Z, H0A#!4T'<+:L()/,X4
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M3=,9X$37Z(T,\=BID^_H2[(*)R=OCL,R:'*S(%WK>3YIT?\[*1K*^VT/J3/
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MRM<LS;9**?;8C@BUO89\"WG4.F-&X#YAH!VS^0W.*E01?1*S9T$+R&WU"7,
MN[6= CP1K9L25/VUC(U3+#'5U%*>Z=#7B !1)45]%O;F[>C%K[.H<V^=3UWG
M4Q])/O7>-*V6>TM=>3$96'9D'.1:<Z]!>1F-:*KX<$L7PN@&/2;T?X@1UU *
M,'RX'SVX\-Q12)>2A5"9N2@DD,UYVK&4N-8U6BM&3VO,9=6K=IFT**,&P\(#
MGE3$D!8U>0K!Z;:=QB;,  V] 6T&V\X0B86"S)F+;#[D3]59\.- F".9_-XP
MQBQP>GRF4A_Z<DPUZ\7OY9HH)Q7)>95*R4:#DIY ?:K7Z)#-V;1@7K@JPHH+
MB8B,G]&+LC;19X%]+7#.24S%-PEN7:!*2!X3T2 Z/$-RBK*JOLF4LR&5[H<)
M9;7KD?8'%%"]C]2HY$1]-JM8<FXC+]%L:^DW&$L3XH=H"4AC_0%@?%E$[BL7
MVONV?3_P"X788^[I,0>4RW#/I.%0!6F>3JBN:)8N+LH)GT?Z>..BO&H%:7S3
M.BG3ZNW/KHOOS>?2UU^;W?BB-.]QI8E:$.K:N.F-LK+MDY EGXS3AMW?$)<]
MU]8\X(MTTH?.S[[MN.&1EYH*X\TC7U *M=*<@JHZ@/:7;NWK@?Q4J%CP$VJC
MGO;(GW2!C0(-X2O6GNIC3[Y2/8GF$_'KF?4J."]R;$4=U,G,-YR4A)P^KB<Y
M]ZJT^ARL^]<F\TV_(#MGLD#IH="1)<3_S+?"C1NI*X+L\BRMSMDEFDBXLKOH
M;#4#@:G3CXIY6CA&GQD-NVFJ:C1R69L--R%5/8*T-HJ2T86Z:&:4_2NIS5;)
MU*%%:ZCT+FICVK.#<1,D2D5%*K9S$W6EGXQ1B3E;IY'"/66!@B%0==6>*PV1
M=BY(D5+*/QK*CQOD-FT"PO]D+TLC^I'&U15S0NO2M&HXCFTR&X"+NFZ8)0O"
M/>0VJAF% [RZY&6.@V!]QT47A71^]X!'^2,9N6G&<-,A;F?JC]U W!JC77W!
M904TFIVM[6WF#Y,XM3^W5 GJI.E<@"FMV?5.1,K4W.9+S3V\VY3&T,^G,[H>
M-'4[8A ]\X'4MZ#:]+J_2G@^Y!U;/$EO8,@72!@,NP7^6&/)\-SU!:?>-*-P
M35."*JM1KV'Z"]6(S%*BA027+"=>>_=N)QSG;O@7F>1OE&PK/$3*E3\ERM-#
M)08!7ES/I;\<U'2C%8=.@3M???N0$@>[1T_=&5Y<U-*!AFW>H:@^(C@$\1R'
MG2FTD&OE$IOW5\OZVJ O32I=B:9952]\LUQ&29',,]<4:?(T$/H:NTGH,WKM
M)U,HWWT/PBC3LN>*,R73.@)?74$508)CH?)[2OA[*W6IX=\R\*\B,;UY15:,
M5&M,^]>J;3_VC.U3E.4G*,>PX4)XZ9OG4>249TR!S6"?]E)J)"T<6+JA@V,N
M9U_A#J=H0.%S[<-(S*-O9+YNV(#94VYQ\)KR(LR7^/[LS;O7^*]12I:KWE(3
MYAD#T@5W9/HGAD );+K*Y:(<>F,-9BNP)M)@)RA0/9+TJA;1G_^.[QDVC I@
MEJKJUH=3/M[(F?H<<7RE9RRGC*CR*S<THV#W3N]07]J#_*^U"F72TH=<PILM
M+PT6UZ"GO<"*W$\_M;;BHMUD O...)7<[] Y'40=#%M(>"&C3D2<"8@Z[)D6
M!%5K4.K;^4=GQ930@1U(8G3;::-X;WM6X1;F^U3/J^")4$#8CG+T:HY:*CY3
M]&IA4S<7VG,4=++/A5;SDL[#$9FDMF2'.R[G>3(JI8>%.N;H] *G?N@=P,ZJ
M=$E)>SLD/,25C^9MR@=HKN4EX1=22J9>35:?J^)033CQ &'OL-PDI&2S$88W
M3^5*)!&!%+(9RVB-[)+S4](+#0>VOQ6V32PMR\ XF3L5DD1S_EJB0\61SH26
M61K22EH%_C,B9=),(5EX0A*0_3=U4-FA^VQ<E!F*P^+8B*P4EYJ:7+3-<45Y
ML!(ZWTVY'G9"!*59*7F/BJ]"W*\HCM8W\-XL'??\6Y$(9.XMW[7.7?.,W)2C
M,@F2X\,FMC*<KJ)<VIZV-S&(D+2K(")6HV4T[](W0DW'"JX&L09G08('5FQ-
M<&$*\W=XT>A:F[SAG(Q&=%'!>J=R#\KKQ[)C&KE"MDF,(3T<7>0CHG9%9W'8
M/T!.D.^)81R6TE@5Q)!G3I4-QV')R,KJ"UAA 4)O1;\2 7[IIZQ[0::[%1(K
M$#X@;$)ZA02SNO1KW+A1 @(@(=6)4)EMM; *W?IQ(3=.;E]#\$!P\1JS55>!
MZUY>%#'CJC/2N9+:V Q#E#,UU2)4>4B)-"9E+7UNMY(),$.W;67<\(N6L7J3
MCL37KT@MU-@%F'$O4PDA9SQT$_!N&ZDACBR7?@"EL*B:!&LXR*( U/P*6'8L
MLK6>2]B/-V;4A7;?/Y!?\54F(_?7R<AU,O*1)B.#,9>7;!4+E_:EZ(*I<]D(
M>!MPI\.@9=CPNTCS2:P AZH6R8$H8-<AJBH_D\ R_YHCYWP%!K]HP@#][H-[
M;46+$>IM"UXOR"XW1B,GJ%J6>LL&,?"\7D05NTK\/D2!FZHOXQ '1I8#M.K[
MJ-B\$Z3FN\@3Y<R7$U6N$3K7KM/BC/N[60,R;,@8-Y!LC54QQ*'US&C-+.,%
MZ X\BAWN+=C?(MQU!R?V$/WGHK18E3*]J*U+2F:4Z&':M+[5,.$$;9US4_[%
MC:>I%R'(Z:-"6$KI7E9*9$_]8I@\0_NZ8!,A&I((_6?89%OUNB(8W >5O(T[
M&(J@W0V'3C/C-'J_P)A\9&@S1C_[<1"\HF$2*D$*U.DE<W<0?LN\JI.C44,4
MH,9IJ 3VR$'-8_C2\L!J2:$C*%.QDZ(N+F +;9TGL8 UX^8)]P/M&H /HK/$
M25^U]%PO8L[0S2(6U2'[,[;P%8,A)FD H^Y_$8<7U AYB.,O9?^VC]D+TYE0
M6E*H8Q!'0CV!P6HMY"FC1]KKL.66J ,QH0 LBFO C.8=VF&KY6//=</!9Z\<
M.\?!G)&.AQ="ODIB9-'.7O9"+6C4P["4GIBQ<HZUBZ^H63FGT"OXIMETVUBV
MH"4>JGT=YJ3SX#)T63UDESP 4\Y;Y=,GIZ$#!O(![>>'H)V/^XU2A!+4_$F%
M\-%M\WEVJ>%DZU"'TAB?B(\B%=Y'TN:,-FL<RU8C+*J2IY@YFPDJ1FHPHZRF
M&U*>^NI,.$Q*6J3D/-/4<YA'IP%%;Q2C8M"1CQUX@XYX^,C3#6R>WJV6X6IL
MJ5D2?.L'PT-I@3J)0Z9\4&I137$@RS2N.6%UZ-MMTO!G66VH1+SJ[:>0IFL.
M_$!U.J[2A41]X_99A@!6;3^@U,EG[B> ?0! ]FV[._0<J1LA_1Y1PBWV*&I/
MBPKZUH>UFYY+IM1CWB1('5K8^"!:T2=U=-+1F2Q4OG>G&.Q*]P1P%G.HV0/3
M0_QCY?+Y7&XOB4 <YO!''ZF(T+)<^.7+NA\M QT2$L8W*-'^;*>:SD$[&7ML
MV8!7@)8PG"YR25L-B_"M%KQ>*%.79&T%ZH,['K6P0](HF M=YDU% ?L>/%;<
M4:)_25= 'H7;0I6?R21WQ&_I^OZ5";"33E>\("V%!*&*$PJS!)'])<,$O\:B
M[!%5[PJT8%F/8M4>9.H/HPM/6J'\WEJKY0*$&XXQ*A72=('ZP4=QK5 A1L_I
MS)[D "A/I@S5&OIFLM7"Y FZ9B ?]+2J:!)9VAY<9PS<9=5BFB6HG8#:I:3+
M0$F*>Y7E.VY^'L1 TUG=S$4[9^XDUQ.US&V_N!9\AN5CI78SY\)G,I'ACI)Z
MX:BDLU:R[D[#0JO3"2\UY6=($ISO34<1Y"M1$[JJ=,><.RWJIG7NYYMNS"68
M3_)=.;)47]>+E'UIO;F\9AA*97P#7)'_NTDHFJ_*A31-+@4$T@++ARQO9# &
M\%?_5*RX1J/A6]PBX.+@38@AQO7T'U&<%;K93T%XXV.8QL/R0X_S9M/>(SZ,
M'340T'62SFW>S7:MI.R;QVAO4IEY@#H&@M0N\F;97G<X<#N]:%FBW*&1#*$[
M1&6U\)X/JW(^,A*SBDOA OV >#!-E&DDEQ%LS(139QQ#'(3V:'+*]B)6+60'
MRX #YH$*%-"#H3Y4>5E^3+L GV51(,\W*!V0B;Q0(4D^)ZI>DH9F ^FA^HI>
M7RD!$"">$X0UD/D>6F45^=H!O[#Y=>;@#M8YN'4.[I'FX(Z5G%EA&ZKB6AIU
MY66:5!SE\6ZMKV_R?&XV_F5O<@-)#87XOI=2_UM5VQC,FWB4CS4ZTD<W8CD;
M>V@:85];<Z#5_S:@*Z4SGM8\^9 "96?NA6?C4\+BP76'&9&F'RWB&YRQ"N[M
M(5GIR]!<"=-J18$2>FR\2"%:V13\FC04O0W;0>9N9B7J%0B4DK!VV!"L7?"E
M9!N=@4G">$3-"1;<CP3>'X5^3>?$/MY.5&0RHRFW+)6+^^I"(JM10'@6"E%Q
MI&?SO+Q&Y:<[[/,2!$X!4EI6D"UV=$UQ0^L;FF.R(%SYG.RG!!:@.\.99T(H
MI4C.6AH,]@;OEA.9@OE:A2^@] TDQ3+LVQ3N54H"@$7D%>PLEW!V%AJD4(&K
M2?=(/Z-X1:.%"@2(/+'-P;.TGF>+5%!=HB2',=;+)M6D.PV*0,*;V)S$%-..
MA;NDAV5'E)8,IC<9.#<]4'ER$R9K)?HSGWJ,MHA#; J6H_Y;Z5*_9&GP>\),
M:$P'(?TAP((:O2CF*H7A"MW.":/HG9)%IH-<* #;)$2&DNE'SGB12I\K+^TF
MS&)#C@J^]RTV=&\"U6?;+9%Z=[^E#Q21>5D6B&1 S9G&*NC;8J0,[+QRF_1?
MIED='#Z?MQ>'E5:;Q,47NW)C!HV:4-^&XG9A?F5,]%&(;DIJ149.C0CO.TRE
MSAV"HA3%FX-3&"QP>"S:-9&T8Y;#K\^OXWUN9W622/1:"[2*,B9X/9K[SHC%
M4*IHN*@[FK7&["LXJ="_[-PMB]V3C")L3^LI0<>FT']8HR)2&%]21G>,C'YZ
M_?H-1>NVOETA';%J/.E0I,T;=[<D0=_Z**(3)_:<-1M82;5A##3V9FG--F=%
M'[++WU01OXTJ8A1V1;CQPK=7TZ/5'W9$-8HATHAU(%>7@;+2>=Z<1_5A5$0+
M>I:4,=V)67^<MJN0>RQ*(01NA0(%J4-7E2$Z9QJXIN"%R]R1,)@V'+<89-.B
M/8^"H$U]ZPF'$\N@\%O/=9G9UF,G/U)F1:"J'C.9XF]I3V/S0!&A448Z]::V
MBP&1OC26U*=%>O3@54))!".P%-D9D10BC8ES]N"XNT@YM!D:O47AJSA"*-2S
M3QC!A=V+9>ZP;Z"SV6!&3-D;GK=W&<O%L!4+-G^@V*4;&T66EU%DT"RT= 6#
M#G_JP]O=LNCZG2=B482<<"K&PZ"G+!F\H,0\&X/4EB@)3%3;1.]!F%I10W:;
MN%*CG9;14MV(NH'FO^$FG$'H2=&EFD-XXUO 1: =- B07@;)F/Q>MXR9-*OB
MLF?NV=+JN!H<552G2Y9(N-R#]W3NEN*?BE_IK4&B@Z(5LN&H)6/MH^ C*1$>
M2\<02ZDG#\09](;=L/5OOQF2%*B=SL![T \/+>+XS"[U]Z-.@.A7NR1Y1GYT
M=',C!^%>Z%[^<+# MO$C1FW(A_B:*!_V>O[LF+VPTY?'(7(.86=B0$-);KL9
MB)AFO:N#;=%6R$%+&A1:7'AKQ^P;&K-M+1E0I8CV1**LEB72I48\N^DT&_[^
MERM0"CUK0)\M:DNTB*GE9GE&0^6>6":$EOM^^\=E@0N%_^RQJVY=2H\>#CQ
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MMJQF5,)643.\$3<*:VW*YN!,OA*\@I3L Q'(X!%YZF:LA8116JG7$#YOX8<
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MTSJC>E8?6L?6/G.V"&_MH6YMU[AZEG&FQXV"FJ!G)!&X*=U>$F%46159$@X
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M /0L'S^+?Q'9@:0PV$9D@\T7A"ZNYYSI[]J8Y5AS70BP3RG<PG0\I;1)P.?
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MXC<*S9Z4,T 15L+%1"N-H[9@'DKM&D500M\3/%HS@NO6^).[[_PJNL\: 9<
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MZ>C@P^'6WN&'[2>[3Z:'.T\FH_%N=[].3BP \SYJY'3,E@%H5:\KLPTG/=N
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M:=AYLK*]F<>GO?:;?6\ASR7WA\0Y>\!E)^"ARVKV-JX1[5H6'Z9#0,69=[_
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M EG2,'$%\'N*!4_CNM_PTS_BCGCF')HYZR"9?P_X6)A>7C $/PEY9H1)D)&
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M\+$TFSUTO?[/Y,"^=S\C%HY +]^6:#CR0[JR)9S5K3['X&*I[!?%S9'?'Y5
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M=3:S6TW%IJ77UY-+B,FE#M[ E]VU80EJ+"#EKC0DYKUCFN"H053R@DQ0@1(
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M?.O6;U@7<OQD(_0,"7H.#, MB UJTLAR5)(8,32T(6"F8Y'P&Y;> SIY"**
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MF @Z-82>MDX-?'$6P;M8)!LFX6, %5-%@'X2'3</4[L,F%9&7 M>BW9R_2/
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MRLJ?D;Z:K]A*]:%:*O+G;S=M:2RB9IV0/B@P0C:67M"K[-=Q^%G8U4FJM.V
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M2;962]6KPW9Z66 :PV 4+-J@/\*<2Z+R:,L+!WOI#AY^_WC\OL=TAR_O5/D
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M&0;C$-=/A.)>9-^+['N1?0_!O<B^%]F_;63_!L+Q)2%O-EJQU^X@9E,0NZS
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M?CT,,BZ'+^6$Z&;;+6:[,>XE'R_JHUZ?/'JT:JBD!RL])??,8$TGV\V4)_6
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M9=DK)8=!TK\LE/!BMS^06F]NWW^W/A\7HU:#5:1Y)BP:L^U\*ZSEPB*\B4Z
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M6*O;AP9(6QE_3[76W3\8/;TA2Q"[H#_JH@3[D/?QE   6X#"(5Q53H21&8)
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MP_19/QLR,CEMY,E7MS-QX#&LK:D&Y;4F5F*MRAH71=0=G5S'DZ^)%=.MY48
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MNQ[@]MIKZ01W$/EQ=O-9J(B,0 *?Y.?$S@H#43$T4S)J5E*=NKM3DFFG^<W
ML15?=3Q/,J/.*H5$"A-@?CR'VEB0D'L#FP_B6-S5SN/W_QO3'23;06GA"$G*
M^C\.'#BH1%M8>6'D1#LO*-XQQ*45AX9JJWDQO^WV_(BVYP3V?>M[SAR(A<3)
MVKE$, PK53$F4ZN"3QF/D4J]GOL531I)IC8YBOE=33$PW]W#FH4"SB*1)#1(
M$C=2S&P6OP]#$\F:E4U'UM%$# P.@TY5@469:2K=J2BA/2H=0;KGBJ0,8&J'
M,[D>"9)H-)J*@0D?K420LR8:TX?,I(-K);WXS5P<"G4PDB 7 ^"A(E,>8'9N
MIJ+HJB(Y"U9&E$=I4)V.EQXA DY5&5F..(4'T8(_W<LA=-OBR<N&; MXCP!4
M#5L2\1JDR21FG;NK6V/FATB2Q43"[Y=\,'!:F=.$;0N2%C&J-'%!$#756)A
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MZCEQ]/0@72HXT6K0N#ONGH/83YTI9K])4+[P<2A2F$?S4Q\ZV-9CTA[DA!\
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MM;K._=I.!")I.[XCDO,3[6L./0!(!R-7[_+9RJIK:U"DSY9LMI!KBMJ,)N3
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M7D'!=+81/A]CV-L2LK9DNKG!KTT%-QD50;._L#[$B\18A [<ICID90D)X "
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MST%)3;\?%C*;8C7#S(OSR#+U\L951VYYX:[/W;K9Z<>+O8IRP 2+K^GL7N2
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MJF0>GW<8/!0+;@]YQ%Y]?GSLXH<.N6=2%8(9W-)!UQ8=;H\.'\Z<==M[>18
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MW>,(/$JD8'7T2TTI'Y3[]2GWSPI\[]*6"49(@15C<*KUUQHR]Q0<_0*%[=]
M:'GOZ#N8[W43K/&XN1+) 58II-5"/LWPP_N+T'!K:<&J.67"$E.ZOE#W,;G
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M6N8"!JB,OP@<<J]@E3F%/R7B5P+5B<P@#X#Y7RXR-R"?^Y]N(WN6ZN#/@$@
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M>2:A+JJI@%J1RP]:%+SEQ(KF',0>+ZO"3R+B!.AN]J(!;F8%5#$!74%6!W0
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M,147$^.4&!?&9#).)!(T%9_BJ1_.6SFOR#M7TLL5M=2ORW:GSJ_[;;44H])
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MS$^GP_GI#ZYQ+:YQ#[1V5E'Y>.; G]),(E6KI:92W,"6X.1Y?=2<)<S9,9G
M=)$EV--<X'8PQ>0DO=]]YT&#A@JTC_Y[56[M$_.>B=$CN<#L2G:E58+HG_CQ
MN\%;&@SYX^ZDI7!'B?=KX&\+;O^-BM;'D"&OV8:+"[E^;!-K+5*<;%.<1LIJ
MJL-</$7\93UK+U#-]JQ@=>5"-M[*RNQ@QN(MIZ(\E2*C.!E.TKIW?]XI:IRR
MQJN9'M\+_3]F9P30W]H9\<EXLTLQV:X..%F/H];S2U<ZOHS^4JY0V)"&%6,*
M4ULIC(59*['> /0G+H+^M_)5O:(;?*+)\%7M@X<Q<'%9=@M;(-Y+#U)R,[?
MN&8]T2[SL615A.(M#OO2)1,/XOXJ5'(':GP V^5-3RNV^DJ<X>0.KNO)G)K"
M-Q?4XNE&BM3SPG[&2H.DRNYSQEH1(.(F NWB<"=S-WYI-?[.G"-?1K.7UIZ5
MM]&8^CR9H51V.>A3A)C9K$;6YWI04Z;8MQB[D&$:Y')4F$T:9+D^<SI ):()
M/!&EZ3_RH-Y+).)FZOY]'?OK6  ',FD/2H5*;[6GF7YUSDAQ4E4H\P^J%C]
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M2$$7*OW6.MW36Y 4H%L<B\8I0 YD\N$!^\O\XM[PF[_#H7>&RQW/^'D@ZW>
M+E+:_HLFE%_X_KU)[0$!<::Y/_SYEV2!7?/A!O\_?G><L>QM$;QJ+0J0KT?R
MMF4;8J1DFC:GPM%;!\A=Y@"*I(HQ;THD_D3$7T2JP)?=M6]$LPL"75+!6\!F
M0_.]TFBDO3?(+D(ZS3;)"!!N\ <B&K'F(AQY#W:UB\PY(6)X5^U(:?AUR3+A
MDB60Z!U+XV4$A:D#!<F%0FCH_<=C ZR4U69RGE2P?K/&9JLC>Y">M8Z<]QU^
M+@JV @Q19U]H6UE.AXCDH(R',7G-</#%0Y<N1/4NV$M& =]QA?ID7*FD]I-8
MULPRL6:25&-BH8'7P$M%(/YU\%K+L,7+$NJS,/L(RT($['W'51IY  Y.-\5?
MW@_!;0#-[5\7Q9?<-H;@H_I\*::(4RO(J&*(H:!/CJ>96H;WUL!8U1]O57P3
M@&)2C[&M)VSD[2SDDK.]Z1=+51Z ^"Q D$\D\8#$'4 ">Z(>P[WO 1 /DKCM
M<.]7I?3GS@'[))?#R_+P+QO%ZU#8%Q[%>[GQ[1\5!S>_@@=&?&QZ^^O<T-+T
M8U9X:Z^68X9K.A1%P$0_N*LOQOEN?<++.5M=1+XK=]Q?$45$CI8,9XH"]!^)
MJHF\.FD82)F)2T"NF=UA29/;P8_2&W"*AH.W@2A+W8:4>FZTWW":*1'V:H M
M8]UY2C)KR1Z==D8HDU&<CD<)_"IER ZWOS45W,![_2"7*T4:/X-<TIN12+3T
M9DI>B=-<<TNEF2R] >1"07(AXT0TB9$OD,L'1.&GT@.KKD73$I&7VC(D'OYH
M(ED($<#\"GK_'1'Y]Z+H0Y(=HJKN3A=18IWW:=M'*:1=P=>:[0[K5>&LDHUL
M+9O!,"E6K3+%N"X+U3^HQOLP-V!6-D".D@HV:\,/S88U%XWNG%-=/E'77")Y
MEDO$EO%M:[E=4DQL;5GB:,1L8YVT,S"4P+ H=IV\O*L;4 _2NGDF^D=(*[M-
M516@8UBR6&S;L?G8&JCC6PC:"Y 6A;5+\?ZFLV1C1&-BES5NB)EP%B\4P*]1
MUA<T1)FEKF@[472EL&X;_!Q<:T17./5ABSZ4Z\^R13T\1/REL5%%PYQ+>A-@
M(=-I-!UR=9(%)"#QA*Z6$=NB(D(.X.0+G*'E32*=;EH\L\-BPRR=+]5[8K7@
M3M5+11/453+\'G;G]R:-R]N=UR -DZWB3(XH\6R6'2T2.[X@-15(&M3KI''O
M-J:;<L:M.4E!636!;*<9*GH!4!=$ V5.$1A.1YJ7%'9?6K)]+UH]6)0OTUA.
M,GE%,P$"F9D=_#!0T.6JG#"Z(:U%^$>(4JYF+"4&;-X>9W!L664KI?*^,JUU
M;V%T>ES"H8VT1QIYS2A BCC#(>BZWMNG>*7-9+=5>8>OY10W3#O3IH@H22>C
M /,>5N:#W#YB95Z)W.SJ6-?'J03+[,3.?";-)6,]^1KD-FI(&;75Q_:,O=NG
M\X-YGNJ.(;D!@1Q/8%'PS]]E>'H%J(_@YT.K_B(EE+F2W(REV'I=[G<R5:8D
M6Y/RJ.5,7[E,!>7#J'R@_]V63;;H8D>,\].EW!&3Z9JU*+3ZVQE ?^J-59-?
MQ'!$%3'0;K1U $MH)/+0;6R8$+3:-))%OUD27%+5OJKE>#MB?O0 NHI@<^JJ
MT$9*+@:S (&S/NY"'Y&/N3EQ<DX-U1>CN$KNK07345HMLM_=+<OMM#,U@,"C
M1(J,)FG\8?9](Q* EX 3IQ6G7\O8Z&H6IW@%D5Z!Y,/:>+NZ]6AC<6USY+UE
ML.>FJ%JE@=+J%[-L89?41M0*7PSS::?;,T5'*8R()LFK3(A_V"</@OEL ^8"
M!*,(^VV'),P>4UF6\P8KQ4N#&208:-%0T3A.1*EXZC6+YBK-%\Y@],=*QTZ;
MVY[Y'<)-4FW..=SE*^1?/I;S%U\9(MY^MFMU*/!0[."'1N%5WP'<AE6&T"=L
M6F;(_VN&6Q/LV<1 KK2;<8;.*DN;71FJ16X<>@'W+@IIZX5U8[@,OU(C@U#9
M38!+P'^\'B   #CV%''<[Q'?_XXBI^8%FV&\AOWPYY>ZC: D)N2"][;VZ"UR
MOD_%*7B[@38B2TY2+?"/&>&< /E9N$=^0M\(W#L!J[+<.#KZ'?_WGV@$2$U^
M'M$-#3;8-%$4'G[!;S@"&Y/X#T2B)<)!R)G@8[02R@*X"A!Y;&4#F$\E44"=
M3P+?"Q921=U?.5TW@-1 Q!I!T@_\*91Q[KSLS!^@]/.V M^FBP822^"EL0DD
M]:,'/$7@U;G+E]PN,G'3#,"ZR2[8G@594HE_S4A&@P@*^[I(8)^69I@12T-=
M6D0W, :V)?A_@WO0IE.)%]U?P&+ %$Q;L6 $Q=F )3J7!=_GU95YVY#,R!\P
M2].PQFT8\4)A./A;C=M*2WOI1=VN&]0;Y7/%3'E?;6*%HE)D:Q:1;XG'PZAB
MILC_$FP#%H.;AS;Q1V&\R>MAO$DHG]3O+=\$MZ8)#D>O<X8QUHP5(ZP3T@(3
ME]71IE[:E/'VYL=O2U0CL%F]>2IIG48]HMN%%9 % "<$S#G\@!<%%$)W$6>A
M1; =/@0P JJ#!N!3F,Z*EJ(-P@?:@+P49?<G$+\R1%=8P;(K]?*:B74R2YLI
M3\I+^N80I64FV10I691C^YG!+V:;[3J;_O%[JMG&>9 ><?J@C0"X#^I1 -BJ
M0YP>8P5ZKN939;O#GLU$ K\!D$/ 1F#'@\AA T^1R(NZ'6H0$.A[P"O@6]"(
MF?][K&61D.=?H_'!L_6^!!5J)I:*GS8W^#]'31M\HPHV0M*,7Y[E%#B5*X<)
M9$3- '=&/2&X*7CQ+T[9<#O3\T.EGOSV\[]\XXM$,A![(N/_B01^AM<1NDO8
M9"EP8T=]EMRO';=:\CY\I3>%"QA+TW\1.+3+_EV"7]V#4?A3(GXE4)VH N0!
M,/_+1>8&Y!/_TVUDGU?#5$BNRI$:YGX$M D40'&"); OU4$1XX(M+9[#U>.K
M/G>#G&?#37*)ZB8QBL^9U283K[:J0]DJS2!?^^&\S5\Y+5C9*M7#:99>%E=I
M?=[(##.S,0%'@ARO;'!43-S2MLYF,PN3WPV&)2[5&I/AE;%!$JON"R6#%?LC
MO=?F.MM9Q<VC/%XI#9J#$<V9#89+$X:JQ,WI*)<&*T//S.34P<Y(D9),]+J9
M3B;77I7DF9,*<KQ2F0BK!K\PQUBE"C"FU#$VC2E,&@D]DQJO9MI^8\QD8MA>
M,0P]V1O)%EB9.EUIVBDUEY37 M9A&MEAPMY.2EC:B?(=K]P8^76Q4BT7V#XC
M[^O8@NV-U)DSD/WD[*O,$ENI.LEV)CEA+<0M<5*'SPR]G6J,IB,[N:(Q<8PI
M?&U;Z@XR+2?^<+RRWDFTE]9 GV'T0+74&EFAJUFX,K3/3K.J9$@S;S+BIFQ*
M1GS.[O2T,VSR>.6"WC=&$[K680NC0H9KB9;41@-50_LLMFK=Y&0:FS %DU;U
MQB;9V1?<^8/'*^=;I8$+V&0F+P<3TQZM!6'<WS@^AN.570,K;./60I2S;'<[
M7[)"6D7>B-#;L5*NH&<F11:SQ<YL3L7+]1@%GXF'7M^D8IA5Q&95+$MPQ"Q9
M+^ZM;-H97G*\4D]FQ4QKB1'L;I\K%J320!%7,[ RM-&8P#8$+-OL,KNX3I+<
M,K/2][ O?&BC8B=.T87M>,STR2S%9*QZ=KV *\,;-1HQC% ;U2&;W9DI/4/F
M2IBZ<?M3GP"T%HO%JD.S@XGMA39L%$M,8HU:68>VNM:43E*5VQ++S3*SF3;0
MM+Z=ADM#>UVL8R6ET<OB6"&N,))(%SNR#);BX0W$=58C97E*RW9YD3%+HQ([
M<):&-K!/8]LB/VIW9:)?LQ:[U+XCI69P:6@#6:S'5"NE.(,MI_2FIRTI>CS<
M0+TLM %VD= W[4:'9_N2+;):2MFI,EH:VH IIFML@JKL97NG89/)D+:[@/+!
MTM &U$&NDEX:$XVM:&2RF-KT:ZT.>"H9W@ N-KLT%1/ TD)R(.]FW)SG9G!I
M: .\O6H)6*5ALO:N95N"VE%+; LN#6T@':]7Y?$^7V:SV#3/Q]N<.1V #5#A
M#2SYO+R;SNP]LYP!>WJZ7*Y:VQ9<&MH 5XREXNRL,61L8M@4DU-Z71NCI6$<
M4)7BG"S%\JRH4 6M8K=7@S18&GXH*^YS9J>PL9C=$A#+M-'+T;WT^ P >LOZ
M>+>O*PL6Z-:;O=R( R:Y<8HU3\0.P]82*[[;E0L)-MFJ$8E8;S,;G[G334'9
M&X:Q->6"D6ZPE&PD":DU/G-/DZ:5G*8I ,(^%:/8^GBT%/Y_]KZT255E2_1[
M_PIC=Y_7YT:47@;'?6[O"%2TG$><OA"(@"B",HCZZU]F I86U.Q8Q8WN?:JL
M%#+7E&M>12KH@MKRF>RN1T\>F4;16BFU 2W$I_"*\#U3ZE4I E]-EDR_M:"H
MC#Y+M:=4T 65W3!=C<S,I'DQ.P#GZF!BK@H%OY^BL<=E,I>>K[!57:X5B.9P
MS ^DH&NG5[%:P^UZ-F0(?;EH&K-Q89"&@M_/ILG>M+BN5Z/SU2@Z$Y;JKA<U
MI: KHF)K46L<?6S,M]D<P>\*/*%S5) XQQ(;1JUT-R.ZF"[OMF-&'0QFU($X
M?^9/?=T'Z/GV/N ))$ZKJ[_/.<3XK13'GE51HBM4]-S@*F>94TT'[W!:_>Z=
M/3+Z$]@7"J\ \U16>1W5J$ G"><]2(!^'NC?>&=$8@FL3[8P'^*;BMR:@KM+
MC_9PS22$GOWK4R8O/%H=V)KOM64;M05GU:M-;LXUY(JYY.J#7OW3PQT_G7 ,
MK%FX/V #-<2#+"YDN+O>FGW\(TH<6+U4ODPVEFF%F5<2PVJAGHUN-KCTZT_"
M%_7XR_,NF2B8[L.\^U>?+\,)SGB.NJ>]10!6#_H:0VO7>0+TW0EH!=POQ#.R
M?A\B@)ZXB"(8@)S]KY\(T ,FJT]>-\?+QJFJXP\9"X"X5?A84=<6D3*GHBGC
MJ*$RG@($9LK*\:=$,A9YH?\RHGY=B-CPGPO6J7R4/.L:^T@MI&J:[E/3^6RV
MG>E,Y0OC\RZ5$8]H,ZLUDXL)J\VPAJZNB,;&T)BQ_5KYR5X*'=5^[850@+/%
M\<]XP@@VP0;H/J:">,3FC#,@^;E(BB.1Y/W\:8'$B NENHQNYY5XKKH:+(;D
MSO["4+@O8YR:3)#Y[@5HJ?T-$8CTS4).%W=\JL@4NW%@BJU&1GUDPX%3:2SU
M0)!^P>0B/7;]N,F4<[)'@_K;N &"O]UX2;M#&5ZHQ*5+7M!AT 5(.(GCMZX3
M'Q7B&XY+4!)404>RS&EBX.;]'+IGH-\T*F^B3FCI]R/Z#XN;>'IL-QMIS%IL
MJO%6@9BWJE)@K.I+@<2W_4*FK>T]0>@_SAE,S3W+^:,4[VIPX7YGJ]#]0JM:
M3,SEQK@PZAGT;#KXN*/Z,]R#_NDYSGW'58T?^JKEBIRM*OD-;:6'_4*_U9+Z
MVJN^:@>^3O0*4!7,D8"Q!0!AASN-5ZXZ0'(12*_.;2=:3Q1X(9X#A-.T="C$
M32]0YH0EO>853MRWZ36O<**3+J?1G6;S*2AI'H4YMVXT!5P2;IQR'Z9T_R"Z
M\4/XWGUSC)<G*SC729!NY)O!H!^.Q BXHN"^([8,8!^L.$,T[B\J1WL2.'YZ
MK#1YNI"K-8$U-Z18'T:7/-P]N\VFREI<Y[-Q JNHZ]5(B0]E/M^Z'_5Z,"7X
M 64;2883F$6"CJ>(1ZX%;K-3J==')/4%[1H%%,^OXUR:.FY;UVDOL5+^L6^3
M\V*QG^U$YW*B(5,O-AIR2>$A8ECCF< C60A1RCGY)"^12'"V@<G-P3<=/(-?
M=6%B ?$#OP]%LO>LO; !>@D4F1)0.)T -Y)TY[. ;HUPT#T/B.?4]_Q3P88P
M*>V#T@&TTE2E[2S+#G?T-B.M:I72H][: $FB:GXZ\=)H'%74N5+@=?*Z.1L\
M1>BZQNT[<#E9MK!5=9;J8HLECS6(Z8C/[:Z96(K0A4WG=/.1&4SGR7Y\7.I-
MB7:_2KW47,43\J]U*D$(O)B^]9E<ZDOLZ[!Q-A)?:R!PH?O'TN&=!@&%KC-P
MLP'B#9B;I:,KT!"<_"P!CI>X2#+IT\2K8%GAY-@XB5N4<Z[M"Z.N1B-%Q.=U
M.CKGM&BY7&_E9#IYKE%7A[GM(OK?*\;P#YI\E2!CX>"K+^2EAX.OOALB,K%$
MB(<;P$/($#>#""Q$Q"T@(A%+)T-$W  B0M%T(XA(QQ+A0+Y;0$3($3>#B$QX
M1]P$(HA8B(@3(N*#LT+?\FN$HT+/?&1?6?,'8<!K"OSP_WYE?GT2'O%X+!Z_
MZ]&1KA_527IH'#88'3_OWA!RQH_AC+.XM<Y<-WFC0+D,8=P?5%YW^/Q,J+SE
M??F94 DYZ#-^B:MK%GWT&VP>. ZIX'R\\;HM_D.A\H9A?-=0"77QVQ 5M\T"
M-ZZ+_T Z^$9Z]4T=^=:5YI#4?Z@"3($#<9)P5_KO36'X,LKM;1WYQC774%']
MOE([5%1O!BC?BS#V<3;BLW&VY)E%PX_T==V4*+QY;:XMP%[/OLAHB.-0GPOU
MN5"?NT&>#O6YFP'*]R*,[Z_/?6?731BN#D0Y;+\-B\PM3OF6:+\XC^/Q6.*\
MNL^7N5R2=$'B3"%,=KQGR@[UG)L!RO<BC.^OY]#ND)UO>>.%BDX@SKN"OOB6
M^ XU'!^N2T"GE55#YD,-Y\8HV]]&ZC4\.N4Y_G]/Q,=(E[GC(B:G[=B]"+4S
MH?Y$VLH=DT$3#@'\X53P%:7ECE'_]Q"V<O[7#T?^R52:.Z:$'J=80N1O-!A7
MLPQ.G3PGB[>U'U-;'JD^ 5/K+ZH-'=3EPAFG7J]&API(_,'Y 0Z//QGQ7_O(
M'H6?2+>Y_&D.:!BU53QX882$TRL/YGN>OW4LP;;L.)=:9S-#NK@I&14\G2MO
MLE]H_OKI/KYNQ?D!33L]H9\WA^WR[+RUJTMUFC5I:R5&<]E=L;@UX.Q XM<?
M\H%,$ ]IC/2UB/TV//"9'J&G*!^X]KG_YV15 ??-]WD9SEE@F4[>X_Q-@M>&
M,W79H3O=\5 B&+'7A2-KOLCY%YD,X.=[+VO.C;9ZSDBDQ@=( R)7'U:7FU6!
M7MF#B<)6R*3%PEF>B5]_$C&2^+Z"X&27H:OGWS97?*#!-''48)I@527/Y592
MIC\OCD:ILI[0RVTB> P-['U]LF'I;]+V/GOP(,P,';'$GKKSLIIHL>6Q-B=*
MIEVNJ(MXHB@!ZDX!.9&*I?TSS+\)<5_CELM<YVXX^2WGI!?>.#]'T'P-XI^O
M6& 7Q0R:LP>3N6_?D7!NP^FFZ.CRLU->&EAP+:,)4:;A33\IZIIA!"A*^J)5
M$\1);3@O6M/,@!AG:%.SV0PRFTCL@4@FSZ<K??N[X^(%UJ<SA^Z(FS]G^WR=
MGT]J"AD?8N</FD/LH%3/Y4J:C"7-L2SE6*'!M"3 Y< <(F)DYINP^(EMGRNR
MP)7DU?UB[ KU0J=3RF]*UIY  [^VN>2)PTDDM'R_4S $DN??WT"SAT/)G.&$
M>31@S;G3G<R4PXEE>SH.N-+I,K]J--)3B\GMAMQPG*GOVD*+Q3&HN>,/B8!)
ME_\*N2&,=OS@:,>=:?P>]W]6Z3=:C=XHH\@Y>L74FCO+W!#ZR(82 FC]9 Q/
M?-\@R.7EPRU&2ZYH1/P\ @@#!;=T0>S50'A%-/2>5C4%H\+(G=:06ZVSV];D
MY'<#=D'?KN]JZ,+Q]OL,?I37%G C3)*$95;[(YE>C)>Y9:9I6],=NA%P#"B-
MK]P'-QZ%*6BZ* !RGOP[!V='*PKXB=XL93V,S%PY7?^GF'1?9&B7@"W]B:4#
M^+>>87?-^G+.SROM27G3)?I;?B&Q. YMO@2>?" 3_A2WTUE]W_X&#\,UH?%V
M(N,M@*$_:+YU,EHJ,Z5( >NO>&-:KX]+[ 0Q.S#?XK%,/ S:A$&;^\98&+3Y
MMM90E'R'M.7TQ<E4)V'BR=D7S"#R2;(JK)S6-EB9$1)U-LKJ#6LEMJ!D/;T9
M=&V'P+O+@<AOX_LY>SG0L3E% G-JHEEC1;@%>^H*]4(D2^GK84+K]GA,(&B[
M:U>:PWKFQNN%4A.1W-!B94X3N4=+$!.KG"+9\%2H8 A/)AX(_(RY;]?FDAL*
MH5V=GRX78[OZ4:]NQWU">-Q'R5'6K'1%6Z?J&,%'Z^ENK9D9$BUX4E1SA)W1
M7KNV+#E_S=%=\<T'BI+>JUC?0U'25LJ/[5)\AU5L,=5*+#"!V4CP<+ J*1'+
MA%5)YP\V7IU/+A>-O/I1KVF@?^(6O61\\D".O!F4;.'9DB%OYXVY('6'=2Z1
M+S84"IX-6N-QXK7D]!L/2_8$ TC0" !$1-@L!1[^8FJ1-?CX4L;X?>H! 5'+
M;\+@W\G,=LB;4B>T2]Q=#7[T+NM;3[5[F%J=8)U=KKK1DF(W.03*,GDAZ_O;
MZP?(U+XV YW+KK[VN4(C^JN"X8.VM27UHD:O/=2QZ&8Q2;5:8CQA25!<G-VV
MOL\+-*A)WXTSROU:S1\F]Y>,:?PI4T^B6R6[S.^P1:W97,OS,9/%;$CPYS:F
MO_W-F+F%&^1<9O*USQ7:Q%^X%/<S1MZTF>6\6DRRICFG%PK9RHV7?(FJ45 \
MG,-FOK9_S=4..$C(80P[C&'_"./Z@.A?M*+S14*R$OU^@EXE-H.!6#33Z0I0
MB^/0BB8>\%3R@4B%95YA##N,8?\D\_M ='S0SM93>KK<H+)S;/&8G32SU7S!
MVMA0H*"<8^RUW+@[ER5A#/N;6.,O4__;9G=O_E@>-VM= 6LPE7ES)58SC1&B
M?VAV P8(8]AA##N,85_-7G]75OD9!,FQ08X'Y)3/$]4&(9!VD4YNR>)P.-]Q
M/9:"D@/EE+_:; %9Y/\VX8O^^ 3,909FP9]_RR:@!/[3L_!.2)&R"MYB_L9]
MLT^Z4R'">6Z2B.RA);)&DSPT,:(YN#OT$T1(_"$""2PB&Q&$[(@&)WX($4@7
MG+I%':]2_Q@17M$,F"AOP!X\D254DIREX&D3^$+P@O^YB$+ITC"+Z+&[70K4
M1C;VG]*+I:)M!>&@5U -'95=UYIK1IK@8SJYZE'*\%'6L1+U)44T4%>L<[K.
M<HD,8*W.8YL1B$DZ'1^OMW'<AKU%"'] )K($F$ @B44N1BZ?N=4N1<:VJYQ$
M.$<[B4BPPZ-#9R(GZT\T#4G5HVO)Z3<<F:#&40Y9VYQQ'K*\L9K+KW3(1'_,
M ]@6 &@#W:J(I!=;U:X\3NHF(PP>A:[94Z?]7 L(\%@FY2/I6 3B\1A7:R?E
MQT.7BR:(0:CK1@1 $9, R?0.%%ZCB"MQP>O6\8][Z-NCZ>FR31[@J3,KLXGL
MK%?$N&*M:!JKLE3K4# 6[#=1(X"#%?!#[,>+G5O=5QN@'MPRD'&<JY>#=&&@
MQ#G]^=\@5S@+(A#!:]F4A?<S&B! <+$+AH"DZ%A0-/LW.N?I[=W#&D=^*DPL
M16B(P4+N"0#H2D=L03F'VW:A7M@%F\DJX$^NPCEFK5%!SD8[LS3324YKE7B9
MG=H+<-,+@%N6X+VF#D3<[9(5TG:][[AF$*\I"K<TA-_>#X?; +;(/U-'*5UP
MFRA"D.IM)*H(HOF;LTS-^P!9,\XGKN'DK#FPI-PU\!/73,.PO^!Q3-W;F/M"
MW#GF.P)F*2*62+T61)_(ZX"':^"!(B1%%V3>[U%H1/X>ZP(WC]H 2/\L@8(*
M">:W+BB <M;"LV?N_\Z-#4VQ3.$?L+> (UYN#"\\WGO]"> @^W^_9' 3,>+5
M5@!GQH)KSZ,7^Q#RHQ"!8[$4'F+B!C !6((,$7$#B,!CB5>'I82(N)QL2KY:
M$1)BXF.8>#NSR$/)^W2ERYTZ_8%3GU4QN>R1/^OI/;-.\#WQ_NKM>U]X/\'L
M< "0\XX,^^IL<,]_&*'6TD=G@H=B+A1SEQ)S;]'XK8$EE(3W)@E1Z"0"8R>A
M'+PU.>CWQ;Z&22?'S?_O,5Z_*O&NV&WZJZ3NC. Y$3C.+NG.A/R3R;0[)@08
M?HR@^.-'99XO%G#MS+X7.D!Z(3'B9&+NV@?U"_MKZ7S?9';&Y\MIB#<2F)[%
M.]WD)>^O3853Z]S"^0J,G[(Y<H86PK\0&)YTO]#NS@;#9G[6P3J3^7@Q7A<*
MTZ9TA9H=>F4!PBJIX%06Z@[>,*>"WIURJIO<4-=4)S/DQ5J>#38IU$NX,)ZO
M$H6::B5%QM8E%I7RX$3F(7F>0<S.)753K'NA[./$U<<;!MU*)TDW=AS;]RV%
M3I)(>3-RZ")Y<.^70A].C@,"2FHQ+#MC6@.,Z"]Y?-:.DH^I%HM*@XA4##]5
MW^QKV(E%)ZOR'BR^FQ">%W=M74.G>2OOZR*B)5/0!K7Z4LS27%,M)+*='+^[
MRJ"B-X7+<?IMT!!Z*5-E."S)TSEIDK&BCX0U5%IL A4K8]@#%C"R]A[,\)O@
MR#>2"FZU,.JM$/S-"9+S)-+?B"BY#2WEBWG\0-(T2PN;Z+#6@NXOA,=Y6V>J
MJ34%) U456+DJ;JCW(B#)V#X8>C3^>8^G7^N,S;Q1N34K:@\OM%# ;+H,5FO
M%^8#TF8$-2_:QF12(7,2FT1:3^J!C/OMIE-,; S].K?EUW%B+:%W)U2C+BR<
MX 3*S^A0W*ZLCOI,L<@T4CS5'7161,>$<@OH4&0F%C!H]G[</0=]V4N&8<$?
M#5@,O@!TBE >.H+N)>(?*DKWH"@=U_8&2)NV)2=X-K,4YIU9/LX0FE:S))M-
MH>@71CR0A+^!QNG4I._.I:%S*-1JOHE6<RQ)/J/88(\<G2KP>8;N)^*C7IS/
M\ERW!40-= Z1L=0W\PY== #L#3J-KNPC^I8=OK[29_<BTFQ6Z6V4]CI>IHN/
M1$)G5A9/J]0M:D9O)P8M5@DKWZ-Z95K>%OCB>)&("CF;35\D;/8#6?E:#J0P
M#>AJ_=0N)G5N0X?Z4AI06<B*FT1?6F+<;C74IQ4N-VZV@#AZ9VSMO'T.3]^H
M!NX3DI:L6IQ['E3Q?%#(S2L"IT-VG'K=9[SK'K[V')7<+SJ;B?@3<[D,EDD^
MK];^KZ,J]+UX@/UW-/VWIY@<G,JM?B>0O)"$J%/DSHG@Q;\YQ>:VAJ?S9F*D
MYP[ZO==M(!@B0!J1B;\B!S]#</A@"7O['$#LJ'>/^[7C]CW>AV\4V[N(@=UP
M"!R*H'\6X%?W8'$\EDJ<"54'H@^)OR?$_(>+3'4HK?Z[V\B]W)53A0)#.:I4
M<S_Z]0?UAH)MYV!'8\CJ>\KE#FOT7Z+58U '09#SV'Y'QW4^MS633&<A#>P^
MQ];HE00,5O*7\[;]RBJ[:!B;EIS!DIM^=YN7^9F4L5G"OU)>SMJ-@C'+TT5Y
MF9MUJ?KC;-MBT<#LXY6T5--9S9ZI<Z*@V.6F6<L,NQ)+LMCSE95)JH\9V[B&
M;;OIZG(T[FVF-ESI>WNY/Y5'F>Q\QC3$0E&*MA?%8IEBR8"WSU)3JIU?<G0G
MRNW6,RW#Z"+%QOUOWU8TI5D;]60FJ=8L<9(:%RL27.F'4K676228ILP(RR1M
M#_-&I4&YV93'*X>$660&2E^CDVE"GTRY'M=MP+0IW]OQJ5[)M@=4"BL65D)Z
MO19;25T"*WUOCS_FVP6&8QDF&BWDVG9.&T\%-T'B>.5&W:PKK8;$8OV1HM:*
MRRZ.32@V^>SMK(BEXG@Z(;("GA+9.(>+;":=GK").([CA)!*$Q/Q^;,7E?S,
MZ$WMVKPX2]!R02M-,S8%G2#/5RH=?%JGZ(TZ+Y*#=+&3Q(UI4@*4XEMI]V>S
M/KF@%&8U;1LYJBN4DW8@3?4%(=X0+6F%Y3;;H38OSYCV8R!-)8P*-AEW1PML
MM4T^9H8E?#JA(*7XWEYEY^L4C^5%6BX5*OKJD<V*A!1$4Y+0-^3NN->A*XN$
M.JG/,JNY+ 71E%K.%0I-LBK.BQECJ2AM?):B["#\CSIF-<WM'G'&4KNJT.>;
M\4':=A+LCE?NC'E]6%>Q*K9:,9LX+^PR(\T^P/^S2\]K.K=C4H-YI=U,T,F<
MLK"8E:Z:I,W"I<1I+[<7[W#*@/+.U]CO ;;^TX6S--*\8'?>#W7<W+](T-<R
M+P0KC'ME#VW6Z&HFIQS^/:<99ETSAP(X*Z])*D##Y&#G1F#[S:)%40-J2;(,
M1U97'<QB:#)-P3:IZ1?;;Z).MO#M !WZ_E4 T$][05.254.(H"O(&99LN=N/
M.-T?W<:J#_Z^D&_UC 3? :82/SWL_.R.93;@B_9[BL"./FB5KT6O[DT0@-V,
M96T"S\0ME[JV ?@Q!64;^4(?R6"J0@;'(4(H=1+4+M)P:2Q>X'8U":]I3)_8
M83FJ)::%G?3NZ0MGHRFWK:NFNQ_!=?@!227,07%*\%(:6Y"\-BK:M6P/ER!)
MI9[;"JC#I_$3VKG>3]OV+^WTUQ]$QU&G.?LA)9U^HXJL"I[>C^,Q(O&.S:,O
MNVMOJ&UN]U"0&28200827,<]J8\D9\26S2D47T@@J+R )*;AL#N45Q/966<9
M7D/=K )LQ&B'GVH*>#Y\K".M%]I$4$[)AH>X20&S[IVH<9?>&&8XP[ 62P^6
MSF7F8>FHI?L!LFRHP@ -1M041;.-\W8FWCN: IH3'_J3#B^?GH=\ZNET+S0H
MCN>CEK$$E@I6 59 H\[N6F;[YS4H/G_WX:,N*TDRAH=-#9_+[O=+AU/V^4R&
M?3YO!!')$!&W@(ADC'AUPGB(B8LU@\;"_NBW@ @\$7:J/RDF/MB4[DUUZ1LV
MI7M+,?F>1WY5!;CI(^_[L9&?[<=&DK%XYJ[[L0WA3!_Z:*;/LPS&+_6F#,7
MF7 >4 ,7U('P]AG\HH=Q].0[9E<GG?A$731?5U5_9A=E5V^\;Q(A/M];TQ78
MUT[3;,O&/"KJ AI%*\"P8T1'?9)/))VO?;YKI-\F@T=E?_=SNS+_MI-UR5@B
M_E<D^MXZ@:6E"VQA/L0W%;DUQ0A&C_9PS22$GOVQ$BA#-]DVS'M%(7'X6XW;
MR MK\2Q5MR9P!G@G#%V4U*5E^G(SGB^ #%P _%MRV;<-N/?9,\%I3/2%G,(9
M1D-T0NY/N<"H;/@P1N)^/R&9:R4ER2.Z:(]:#64HKA(-^Z/9P&A\I)/1VQ%X
M2T?3+I^?(G"4K;T0UKG>>IYA*C+'#Z*CU89NHQ&I"?]TYK].=E/?%@5?AY<3
MURJ#^@@OGYN'B2,>)H)X6%9OG(>KN55O)M9*#2Q9)I(3<3=+3HH?KHK\/ _7
MRRVE 50+#%M,^^U2N[H8YM063+1/^NNA+R&8WX'4FQ?,W*Z 58?51XQ>Q6FY
MO7DLU4;M"R*U.8]RM6I6R-*<M&'U5;N9; SM7W_B,<)?R?77E_3CBRI--,JE
M$R:1M09]S5#(WH.;XB:TORO[)R^IXOZD._ =>NQI[L"F+O-";\]W)Y*4\LAX
MQ$J)28;9%O-3D>DU4BOJ@BIL8?/("?G)T, :K9VR$936NCT%DC*5B,4#1.5W
M,DS.@]!6@]VH9,\>SK?:>K+J;Y)80O]PH_+/(S0Z4EH9>\E',8ZK&:5=1:!W
M X!0',B&C'^^P>FLDA]J@OPD67LQ>^,\K%E8D;(=98H<W9@JK?(24Z*[^ 6U
MTLT\U2ZUK%R%(82DH3;%>CR3EG[]2>.QM+]%Y;>R-<Z#T,=ZV=*,1ZG "'I4
MWQJX23#9"\K:';$3R6V[7,+ZG:U%"H\TW1A1 *&)6/I547N'?OB]Z0&,Q47D
M;UEU2D1.T2$L=,3_L'/?A2/^G;)WR(HSK+?,,JP\CYI,(KY8$8LR_\$&9&>[
M23VV[0*N/9'4%;9&LETN[X9TA:[C\97&#57K@E)7VJIML]G$&";:'-0:4W8A
MY;O@&L5B..$OC7SW)7HV1)[F!CT#(FUY5ZNT*G*=%F:U16-<*A@EX</-5#Z/
MR#[&=A9,A6O2Q5I[D._/6ZP%]+$_J=BY^BV%T9/O%SWY'-]>S)0Y ]]**V*I
MIDL5%N,FN\?*&NN6I<4%!3"N=G/=R3".S_N=Q3K17*0'@YP3]O3S[;D%\,5,
MF#,@LEN62]L*W4M@7'<TG><F%D6-+FB0CA]%JKC<;L#[!_7UHUE-D,6:]*8
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MW_#+Q=U%F[8@SC4B8T'1[(AA+< "V!$,D1CJ7?;FV?YV*(I3_@7(GE<L2*&
M'@]H#K(DGOK'@.2"RC4XIU&9*R@1&6M+P2$?!!WT;:?CF %A;L!BBPF*<YA3
M 'X -N-?EVX6\ZY.892B:#SZJ2$^[P4&NX09_KXQ1'O'I-DDG\2B ]+@4X-Y
ME>9:/ZYOC-NP%K6-X2Q3\SYPVL:@3R[<6B85CV%A1Y-;Z!I Q(BPQ\\M( */
MQ<.&)K> B$S81N,V$!&*IAM!1"B:;@01F;#IU4D1\<'6'F]JK=^PM<=;0OBR
M1_YJAX1]_YO$9_O?$&0L>=\--<[<_R9DDC/A_/T8?KF?S/@%=B ^RPYP,%CR
MKMGAI/UE?C(9I.^=##[<0R9([ET[R[DM&$"^\U/D_YX(:T'1EM 5?#+ROO8!
MKY$G$K].%O?1N4\QQC%S#^F0[TVC^W#T[(WTD)+*:PMA'V2NNL&&Y],=$7=1
MZB3_Q%MN8,P--_>-YE:LCM<LLTIO::/!E>.;WO%D'O(#DWG<L(<P"8Z*N._>
M!^/(?>"9+Z7F2:*D*O,M55RFR6B]GUJTG/%E^ .&DV<:]1K*B'N7$=^F9N6S
M(N*EK)93B8A6%AOD["X[Q#A^9;;Y"L^Q.^GR(J*AU]8#7<MUYO**3S<S&:-;
MXN TNB04$:F,O[G379F%14$5=$Y!JA W6<BJ;)@Z<FS=@[)_0V+M>FJ]'P@G
M:XV:N7;;RW>4S$3^OF%ER&4O(.BH(^8ZEG7)?*4C%^;;PKR?L,Q'<9VRI?P%
MU"$ 4?#H *&'E7$KORYH>::(-<UTIY]09R7;&:R:\K?".D7A;R@K[E]6W,#9
MOHF&]#ZYT1[S7:RA&.TY86$9SASGVT/"OKR.U#'$(9/(]B4L)T1'=,D41L,H
MG*Z,="02]S>TN'<74O?5[,302#R]D7@L6$@@6"::!7/_KB(US^IINOI1;]D5
M]5+>[*5E'H,EF^7)XZ8]C[95>TEJY9DQIYSI[QG2/Y<YE FA3/B"9^GJ1[TE
MF?!<LU*5/)=;29G^O#@:I<IZ0B^WKZ$'<<(N*8MQO<Q88J+3VS4;=L%L 9D
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M$4T488&;:)F6CMZ&_N"\_"$BB^#AVP?T!IB%%AD+@)?A]X3-4M;A0LA[2;0
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M!01F&>PR: /@7=QRJ6L;A&X%QE21<79J]2=O.9H'B[.N_M/5#K4A1LYITKQ
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MP]'$/QE.TXPHFBJ!)0>39(^V<[!K8<.A":EH<JC7! 9.GS/@^#EGR"+X="S
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M97&X,<]".HJ1'-/#FV XDT;^-ID=Z,[OC@%DD7?6L7Y4LZMEA28G3X: #KI
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M/J8Y5W-79_ HE,;^IJU+($W$7*+(8U9JR[;758HJCVS_I+'@==Y<LK.T>/V
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M#JX_3-WOP:$\:;O])RH>ZR@<GQW3_-Z9]CK7GX^-<U^NW5Q;$_2)WR/C2M*
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MZ9" &QWHDLX#;R;Q)$WVRP#6?0Y6&+#E$QO/ZC&[E.6EHT3(<F)\9K4L';.
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MACT&).6_!$\)O%G/J:=4+<W:FNW4(0&A.:Y-],D/XC1<M(EXX!BPY M81&Y
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MG"#7L!NW+C_FG24FN2ZW=J7J8<^(6*(Y?ZA)RPQ+&)$>[_A!K\1)14\S&!O
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M[.]EPF1'O)9/ BI*""M'=T9 <RC0P4I.3YAT_[]1./Z>JV=. EZX3:L35H;
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MOYPN1)Z_8C>,3 @2>3.7/7:W<7)0>W03&<PXSV\PNWFMI\CF/;C(YFL-#TG
M-27H%W552^B":3]TDW <6Y4-G$-H7 ET++Z>U\I!%I?F$B*+@\GB\DJATT1)
MT+:$$WR/Z *JK@)WX7.A;N0X7A_]/"R*Q=\/G6X]OK]T?-_H,-2_AA@9PDTD
M =V&AV*<!'@LRWJ9T#%L+R,P$\OX:KLCT3Z$[_B^@5!]9VPOH>NTXA$)R$Q:
M>V.V5=G"<.A*>YS7"6\S! *'PY)?JZ_MM$@ ?/MN]/HRNO* 2\[C."S0VALP
M69P6-\5PG*;ZI<KGT>N_CN][_[Y_X:A9]1YTP8*<N$W"$/310Q*0&K($'O>7
M/H8YD==Z3J@>&FM(Z%(!'7M_ W+OY<C93_.&_F$\_@_C"[^-5^\F[=-T[PCU
ME-\DEH<^;15K.&H@&/HPW)@Z/:!0#Y[NOBN]WH\.NT("3HXD=QXIDK$$@W]C
M\:(^QH*J-6N/P"UBU<E87'7^Q-*%CB!7S%0R"8 6%1\EQ1%-]MX1)[Y 90]?
MXQ(XL=$$1:$8$K!D-0#:W!G*Q\UBE<G:'L?:@T9_B.="W6>@QRRHQ.)_AHX3
MQ4A KM=O 6,2@/#PSR%&=HN0$ZVOC5.0W3>;BCCTHSP.9\S;K ..&6\]_[=\
MTKA7V_3.)6?0WH$+='2T]Q<XD!N'H_T-WJDRD7:]'NUQP"V7<W@D=>&HKOD6
M=,%F +JY4PNULP.1TPJJ_PCZ25P(2;@9[$,"F&K0X -N[V-A:8("/ :Z9/VO
MA&/NR2?A=PT/5N ]K7I"=?4Q9#(:#8^(:?D-1S7!VM[A? C4'8H(:$4Z3&BT
MX3@DEO4UEN-*LF-^!</N$12*R:;_B&,3#Y%F@_8U%4*GEYU)P,,YT&^R\2S'
M9,/S6J\+U:7'@)9L!^!D83@&)2A*QAYTBXQ]H/\H+OYW[J<_'^=^=Y=SBYN@
M (UA(72AS,C1O H=FQ(!;4L[@_<.+$%5CW-^M.Y(KQ-HCP.Q-0(+0Q$.^!1B
MY)$$.=-ZMT!NO:PY^^D[E8>'4J"UVQZ_JXA(>9S(BO>5R?#9:@)YRM4@II)I
MMR\D 5'?L4)'# ?'CI+^%#_X$D9TW)-=C968#S]\Y!]/WNOPW[BTUY/0LN2:
M(::3E0OS#]GY"*6;ZL2/]T'D(CA Q>Y+$/GXVL [TLM0<JA^! 6QY^0"HB![
MF5YV(B(Z2(#X81]\A/%WZ!;]X/-)X^QD<6" O$76R%D9M14F >]HCJW;%Q]%
M)QQGA028>PH=LV5G:X4U^Y)] 8NV7NH?Q8>&"(>TZN\N;'LY^4_\>'>_/I<J
M"/F"7';W\7'$L-/@HZ.T="(?99LV\?[OD_K\5W-+^@:7S6Q="3V!^R,VSR.*
ME9O4OI. Y)4#Y!>MX=UD2>33D&O>R2[WR68J&DSL=87&U.=6S;>#Z49\F.BO
MJ<U9)(IXN/>(FH_<]?*=6_";4&*(-.D\X]# >@C&1[=&%$&GQ\@Y"D%3DH#+
M K)$8I>-T9>%*EW1VAVE7TG?Y\<AJ_.]NL.M7*N*C3\M=[>*\G!5EATH-S]&
MMF41\)O+,VS\&W<F'F]:_X)'W!^&Z66]WFV"7%HUEH6Z+N_=+"]\Z\<5I7J9
MA_(,F^P+I1[73#)Y+5C:(Z"VE\SU3:]#<U?%Y+4&S$BR9\YDZOR#_=,#/*K?
M)90J4\#(G))7V/U[;X>F0^X2FYLLC\96C(/EZCRB,,N^>VD(TT.VL32K!:Y9
M!B;\'=^<=%]F65.?'*KRQ'!H@;_/6CFY._^YEVX9GR"W4481D_'K*0?/-U5'
MGDJ.%%R,<Y;T#)3Y2H?,0]"L&03N(J U**@=*:?T>+"+N8$0&6">+=B&+EH9
M,DLQG72"C=LH7B.P<,UB./*UXLLY-EWUS(HJ7<=3+1=K";*8J.)9R%VC!E<F
MX:EQHZR@HK<B5.&<G'8F?#1HSR?^NYLVDYN$9VZ@*>B\Q,(J"VK:3/$%0S=S
M.\0O20XA&?EU\:5LA^N2O_Q5B..A\,& D3SLZVL1GR7U.ZX_2E-'NH3SC2RN
MP0RWKCDM>M=\>%E"&R!:F6^K!Y5B^G#APT'DBG,=-_>3TEI/K8'JMLB),)GK
M1M]5O3E_INYHK8^;FN>U<F%[UQ]@&TE FVQ]E"I=4*'3MWE-@9%HU:UO[S V
MSP'V)5K.33A-JYQ_$MH1,>D L?N*) I@#7(H%W@A]K$7QYTO8#UX57=M/5V1
MY:D/+]PU.3^<DSEPU,L<Y175=B_UPD4;L/> [YIOZT7\X,PTS<IYQ+V1O%AL
M*.&*B,[=H_5W,X<^%1$:6(=D-$3H\.XM>"RQD^KU6>4.E:<J$6NN,U=[:?T_
MX%:<%_I@ >=3NYI@;PJJQ%+V7,=(@'VY6)NE6:R\%=^D K'W5F/->7#M=6P1
MQO/D!-!#5_GNYQ-&-3Y*\2'QJ0*379?>77 ,=@S,,7?E]3,GLUR7)[ZF!JNP
MJ=[>&[[99_')92Z!SQ(@?N?>5E>Q=M*-=W[:<*W!V\UEM3QQ]EY7)RPG*W9>
MF4F>.#VKJCDC9:4]))H@N= 85K7U*Y(A2BA:TZ;^:R_UE+,9VXH9%M8DXY8H
M=CAZ35>@T0Q+RVB*CGDL9WIN")]3:PR7EK8Y&H*G39GV$5]T=DJ;TRQOK6^@
MD/#%E4 3#B/PT.)B[G_ZW[?4?&^9OVZ;U PMUL;::'0_T@M*LVZ^A6?FP/7T
MYQ1JE_A[W1Z1WCD<'^>YY"&W)V-I*&P_\_#RK>PQSL*;EF]2RW!G!R-:1@Y(
M /AQMSIF_&L=:A\IC,%E"999?\>UUQF=WQZN26P]<K[4>MK?>,^6B,I!H-P:
M*[!BJ*FQVY'16F+\.8'+[TMQNQZACN.A;^-;*[5&YJVF[>'0N]UN:DS+Z5/2
M6+5RM)3$[>'\UI;$A;9NH0RL>-OSS_./TZQGV%3,7(-F;42,LITKO,>=?Z5U
MU^XYQK.-K#WI%\(9T'*6WKR'Y708?#)N^'4Z5PXSY%R4SUD*(4R2@+OL%AC3
M"+24,)/TW0')S5J\PK[I=ANO".IRD_IR>+MI+?[QK"M#4(94,ZA8G;J[ 9:I
MM#XDF7Q"QY1G_E%V*VS Z,Z'(;U4W?&A_KZ"7S_1E4N)EGNST&<P*?%._4;,
MQMO'=@]/UCW5\[%_)J@#5N^]-02F7UI"/;"1&0;5R.*DJ@"I+86W&8?-CRUK
M[ZP,N?08;FXVB'.D-,8N#]9-^VE&#A/X/N!3T)=22E8DBHLB\FJL+21OKWM)
MKF4]F0G[P"T:SYXM&[LA*)_,RZLIPG@J*-:'PZ"@*"_GYB..9:VL%*OODT1P
M<H+CS"3;9^>'TWJP9\Y9[6G?/A^JD8"6FD%EY8(6C$/T>Q+@=%1\"Y9S>#,_
MJ 4;L?BJX^M4P^=VB)$>RF!O 0HE=]'70K372E 3'Z:R30FU.Y>#]69 S/CO
MN1"/F]7#I_GW(3XGGX3M ME#1W>_J-#4YVL63#OAS"S=>+;*[<-O/YXKZD^\
MLF[E?=?$1?1ERB#$ESU?MV["M&D97M)K'7P-,SP5Z9&OEVNNENJ.UBEG9/C5
M@<"'K86L.)+9N90#?7AP\TV:WQ:O^SM_3=&>ZWP9@L7AO3!(OS:LA-"[R6*G
MMV\&:>3?34),,SEG"DPE..>.6BW[W8^+,W]'_W+>;D& !)P>^-17>]@USO=I
M;39MH<MOK-";.F^BR<IY/;D=G)=2HK QWU%R-[8ZMKX8DNAZ&^\Z:\-M ;%$
M(% ^105M]:@'=2;!V07\GH8P[UI3KMRY!)9;6*FH<+_WHBHM6VGU=1?:&@1G
M[H>*.I0TIF;7IX"OL5XT1I1+<4R_'":63>9]@G,0;O2I\OHYNY;:ZC%U#]0@
M.!1J#'JX^1)%M):31RKQ'NTJ9G$[_=#\J<X0)_-<[V_BB _5+^B3EZ[+O16/
MI<^/^Q4"*9Z2MTS)*BKXE*ZWNG>ZUDP:#8T)%<"$YE-'E09)*J9HV>L\J,WT
MO<!,=X12H!TI3D*S1!=BREI%D^Y%Z;.=<PBJ9=28>R].LY9TVQ&54U5J?\G,
ML2[)*.1ADFR22N.DC?.*MYRI373,3HLA KN:ME=5ERIJZ]_HEK>V8>"I;;";
M-#L=2WZ:F[Z3])Z\I^?=_]I8^7Z:D#RMJ<9*;F?CPLM\HZ(AVZSE^O<J.RFQ
M7K8X5'G(U;?V9Y>M0XK;-T].K9Y:]ERE1WK=NA_GS5;VY!LS?5FDQI7>^\.C
M@J^*#;S7BKE:;A6;OK5J?&(P^;:WDP2@)(AZE8F@-3$QXE/8,,$XM18>!J+?
M.5+1BM,?LFMN:HT]OR_VR>+$T[E/)AT4RS9)'=)CFNCB>*(XOM*JOUG20ZYI
M?/]<?<XZ[GN+)XUO;5BB^HKX7D0K-<$/4QFU@%E?1-@(M:L)O@377GI=,6FE
MQR^S(\UW[FLCF\KLQQ")E6&7X%>HS &4C:_:E;[2=?%B6F>PE=J>LC3YS7 7
MZUXRYQ&)7?FZXD%GX?)2O6A"C^V5ML1K$>W#-HJ> <^K9D)8[MMX9Z:%IO,)
MI?B\16MN+\ZGA[=@L:/P##]*X1]6 IZ/;6>EOTZC! AFL]T.0M$'-@F5T3$J
M[G&./A#.>-[#Z0LYC\4^2>4$;K=HXE3P_24NBF8O\9<ET]F:?[(;UWZ6;$\$
MA0R>?R,^N+C@I==?L?9ZH'1MGU,9=.]0*HG)MG9WV78(]' S/H+X:(X$1$@8
M$J\:"%5%=Y"G&9G'Y'$\M9@$"%3TEO41??;RHU<:DO9QQ 7_AF4#V^%U2IP,
MGDR!QE]RQ4FCO7.GR).,*GDR[A@D 8G#DOHLB^1Q8_BQT/8&V$OU0>!@Z5CG
MFBOV.?1G-A1C1V[G.YVG,1W3/- E0Q#^2BT)F*LEUFCN(Z=B#HI$B"%=&X[Q
MB4/8D997H>06EP>T=.<?4K.'_,'W>PFQM"2 1B&'X%ORT FJ<MC76D+NBW.>
M'+Z><S6T35V+(">E%;1PK 7[0TLPV%9H^T(.@0=% K HJ 5YB@=Q3T7NWM8F
M'*9/] H(E.RNB>"NX5LZ"<9BQ[;A!-^7X#%N]! ]+^'\/38.:-O7H2WH>KE\
M[!^JSP^*Q'X'^D+J6J#9QZ11$H ^GJ#)P]?,5R0Y"8/1:^%83^C/ BCF@>LQ
MX#(3EGU\ZX[A$!;T.RMAOL65EKO8P[/!5G/$BR)D'AC QSQ4B[6_@\[?!>$O
M'\<. ULB2$!O^UZNJB#9H=Z&8[+T+?]EVT;0(X\X3:*][-]ZH/8WT&]%?[J[
M6&8J1 R5;F%8\<_9WY7^E*W1XG)SV;8!] @:!Y" ;^__(8? Z>(_@A;N_>DO
M%6SUA[^\T$+RL)IC?/AZ/J)0U;O24JC:K#T8>JRH=HSO;N?::ZP5,?(N"0C'
MP0E/,MMG2<#B?"@98!5X>P7L10)$OFM;!NY66@A5^[5;DWU^(*N._Z&:@[T'
M_?G7^<$4.5;M38V#-(ECB-#Y@,NKAI:[CP\O!-\CDTTN-\IU./Z7:N@/,$<G
MX<<_SD'E?[K4^_(0OCC4NDC4?B6E[#HL>I06>L&J8T!W]NE[E9QZ*Z&C$N/*
MM5*L#GGP^GK)$[I\<.S5),2#A4RE"#FS7/]P>VNG.#%U)1]GBL\#+9B!\ *0
M/U)DAL\GE_PG$O!YU8.H;+B:X;&_+T3.K5+E<6[)$\^O5^1J-23R.J*CCQC(
MQ4E93HY/*;0+RKY- H2__"=%-LQO10+U;\V#76F\?2\YV3N20@3F.C()KS;Q
M]M,QTW^=IX*M$=#>;T=+.>_19,1#< PW43MU,/K6'YIDP9P_%6</+Q$,R(/P
M(W(9^M23 /[\OV.%_^6R=."-"K*$92P([40NV;]D"X6JR;WX!)FI6BA&9?HW
M,PM\Q\RH[_*#"0?IQ!/D>ULK/H'1!%G:MMX#KB0BK15Y0_WP(\AR__.Y*V\4
MN7:J#ONR*;E)@!IY7@V#;ZFV!-Z-MMS!'EX)OBVT+25$8*H_#GD,ZE 9P[5R
MVI"9T_AZ[SBD5XR(^L-O)[DBHJ3)U)  "C(YA2HM5XF\*6CP$0-YX*8D4X/_
M1;Z0A3;[IPM"QYD:/5H"WVDGEW$)=$::D'19P'EX&8&SQY-'= WR(_KS.)2H
M3#;*V(L5(T;6D N8G#O"DQRDY_0V#A3(\OXA.<D_?R<YH]+2<]4V$^0 C1$A
MVO\E^@;DD!1#2;1'_*U[^;>NV H/?'_[CS0OW"L=:5$D\A:CM8\8HO\1X(6C
MS%!1\CPK//MG(/IVGO#_[/;UX.H ?#:S513:UP#%*/RF CZ;I49^2OQ]X6"#
M^W>._!G!A/T_N-F^27Y&PY8U<6[X1-""-0C/Z_%' 4/P\: %FS_/+_RI"5Z0
M?F\'^M-E)MDE:#:K503:UPC%R/SI\HV:,-GE/RZ8A/@QD+>,W5[E-O?0E9SM
M!3">?"[2K6WIOVK[ N3(\AR^<RF'P/B;UWS<8WQ,SCZW(9'F=TVH-47^K@GD
M?MPAB)=<%?9_5 7ZC8H9>7<AE(-OD O7FUR,CX0(-DJA/=!3G\E9]/_S JAB
M%KJX%KI+?$CL[8#VOO[-K&*A+6R)!&#(LB1@R9:,C[SWN&^!'$'/ \BZP?]!
M%XHY]Q^4E8J1^5"$2K &V>T_),GUA$1S'Y%1[2L?FS)<'07O'PH1Z* 9\!KL
M7XA[2LS* Q4)LO VZ0-R@6\]82%>"C^\2E 7VI8F ?/S9$M"ME_'\55DCM/_
M$]XUG\HBJ(. F6G30.AW+UZ(.,J7JZ;F"4]\-<4$,SQ1XF<9W%%:T-I6G0-U
M&18Y(?$3>>=C@E?7?64QP>%=LVC"%<>90R9VW:KK+ZQ*+VF;*O':;1C*;X\M
M7&515<G7+U$<FQK94<N/WB+HJQK6EW!3I9NX3B.+P0W+JV_QD6B):3J\A/GP
MSBI[B2WJNGWL.%64,O\+Y3,GS,-[*-J]37X&WTZQ3/IL.>?OUTV<X.K&&9[5
M!+WNN,S"B=EYZ2.<X_/I@,EA^*)\2_8X>6/5XIO033#,MT&/9F4T7XC-0JR-
MUA3=3.Q8'M_T+\GV<'!Z!.)$ +^I652HHC^RK2Y3$J.6^'7.Z%--$PF(">ZX
M\JOC$0TO58'2Y_&FQ* 35XQZA=K76>X,K)]K'I%G^"+09/7=D8/=_,=/$K!\
M8D/KACT*[@=X\WS_,+@*.BW/4[L[6.[#=[5+L3YJ<QU7]=R]T%"^\ M_QL1)
MI'^GZ..1UDCC@I%8P?K=K9WQJJV-EGO#$T=2RT>;8BU[*CG10KR[E=SX1H3A
ML,/ CDDF2EED\!$L8V)JX[ERIM@D[,X5B:=T^P8Z%0[@I"FU*@SAH&4JJ;C=
M0[Y]PC>@SI/^1D&46+?H-O(LJ/Q.7[ N-G/<?'!CDUR_IPR^0Z@&S>7+A![Y
MH!:\'3Y[*)X]$0F*DC#4 <>AFC/O6?X\&$GRXIQ8^%5F.IF;1O.\B\OJP2\P
MZQN[_T'<F\=#W;W_XZ]224(+V6(JBA(2@VR3A"1$(L14*C'9]W5*2?80RIHM
M6:<PR#:5K;)E&S+6L>\SEC',]GV-ZK[O]_W[_#Z/[_)[?']_S"-S.M>YGM?S
MNLXYUWG-.>?U2'E%[T<VFWRW9$[_&LX ',G'XX^5CF0D+WFBI'T="ZM(#$ %
M!^MW;$S@W11UFC;Q_#$@X=V^ES/DZ,IQ8_:C+OG56O+1U8<4O\[I2"_(X"O<
M;(N"29*=^18JO8=(KE$?2H.>]'L[C+6F7'CRZ+N3CPV ZUHS".=PSZ'EJ?I2
M-+X_WSB&'9[G8/WY+3K[H2.OL.-Y&1P0NJBV:Y"JF634O>#GOO>MH*^RH;U;
MQZGC=2]:%AXI.L>9")VM=L_(2]>7\HOV* NU"DCK??6N^:")75II8LV:<X?M
M',V;S^H0>0DOY(C7CTH?Q/7A9M8]3>,I=\JBBVY<7.1YK1MUTNG)9-W>9.<&
MW[43NUPC;1&?448\ D[!)U?[?*Z?/)%GD#@OGA$ZJ13XOW%OV:ZJ'49-CW;I
M^7W$6_J17Y#SZ[&;#A_4TCG3#\XH>&P^+,9EF10@)]X)GK]_UJ8+NL;14&FI
M+GIVNW7TY?=[C4<(WH=#LS/)OOH_Y&[(A;%?+^]Z$_4]$M#9YAL>HS/K#9V^
M+7.FSDK/LLH?A\%HM#2.VH25&A?$T2EF_OW4>6^N$#\#]WRJ%MF_T"O@BZ2)
M18W4[(.%B<IEWKVYR;78F9G('LRH)4N#U>X//>[<G0_=[:W-NP46)[]++)74
M/:PZO^UF^H 7OR*_&!0[ ^%244W7RVZVSMDMVG7@1D%[DHBWQ-'F1^R' _U]
M/!K<W-UEKDX8SS0-7NY?[,%9P*#EUY1NG%Q10M];4G!'F*D9)_5XJRZEXX6/
M=:^1:V7( 9.]&N45/6F::2WO_<^+.D_TPFKZ/*UI'3?IY6]OD@W=TCAGWS>_
MLT3X5,TE9J=&/%QG/RRNOMS#?3?BL[KB5.+Z1Q7HVU;\;O=R-$>>!KM%DW--
M\8</WV[:"&G?O!\/X[3M( =:.ML'DPKB\3U%[!_4KMI_/M_&JD*0>&"=SL/3
M7$QU+S?-J*&\,I!*'DA*72)XU,:;5UGXFDW[C7FBGM?RDU?J$#LG7LI[AG@Z
M[EPHP7T]/?GRT$[!%V\6(1I6<<1M=]1.D>^<)M'>V$&JEC<WA'6&HTC.X:09
MRPDP,9:SO'8]P:CJ?:3O-WOS1FV/ARH[QC.EG+3\-6W(GJ,V0=23'@ZEK>(:
MSA.O3'3$8JX)".<E]<T+-X?F6HLW#Y486/67<Z>6+]<.7HK<7NW?_+;4%#NC
MI5<H.66_6G[M!1&90-1NZ+<)+BT]8.MS?-9JUB>0:S KY/NGITXW8]N4]JS%
M=E;H&CP>VOO>']MOWXI9VEMUIWLQ3O=@C$>(,[:JI+/"F>?D-RWNI.+%VO6J
M@=7WI7F?V]QC)A-LD)K%.&)W9F:RV=XGZ\/E%*VB16%P/D-]D^YGKZ]LS0%7
M18(:NS[DJN^Q<]D9*?'3T/BV#]#'TV5%%2>R4W=UJ1VUM9+"HAP&OATGQ?=V
M3O+QD/BO<50\NKS8?J77AN1B&)ZM[.KMJ0A#"[X<$_"<P%@-BZQ!G-:I$8+!
MF''$<F+=)S717C=(\(JM\ FL38_*-7?GA[=2Z==#N<2CDHZ6A!_0]Y>XKRKX
M6<%\OI:_G%R"[UM#2VZ?[456=0JXCQ0M*;<:?VU<:0IX.63) XY9N]CE8AE
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M IE&DGL@A$:K?:!([1\1T%U>:F#H;F(BP2 <^]R9"JH2(<D1P&[UZN]:.QG
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M*O<"G\__X X/K-]6';.A>MZ<9+"/C- E6J60.*R^*U/.SAU]9O195_J"DU9
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MH6$!BV$!C\X/ Z6(LH9'0/=9UG];=3Z#R; M8N[[6__V70?Y!H9-+Y VB##
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M%3L.=YYS$+XJ#-3?G#T8_3A BYO,_.P!-A52X?"5).!%#J9"Z[>3D-9/9OM
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MQPTT%B_52S'BNF=!D1B;LVUTU!.WE-(R<#T8'7]<WO1);ABNTKD!049#>RO
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M20#IJ8<!BT!P[O9XNED M)4#?0]P(L )307(N\.1WZ#$T%4S+ C1"Q#FM/^
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M&%E%/K&N,X&MV&$Q9)-2:W2Q5KV'%I)=%ZT@,'"U-AF'E<O"55R*05P(9SZ
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M4A?;%_C".GPU-0OVIS6>'4T/=Y4GK[_KK9A_=$[0")6VE6+)U^M0&L"+4GF
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M&F)8\R]2]L@E/""&!]KAAM#_W9Q-)X4F1%1NO5 H2H+@D+^F75@GZ(3*3XG
M>](\H3[5M@1%MURQA=-*>1TI>ZSN/%]Y_TM9K%2H-^GK8-)#0[ ?/ZN[L*Y3
MC_F^\E25_>/K:*W[6:O7<I]6.\_9:*H]]C+I--.+Q,B3-^9:4A[V!#$F)F2R
M:=*\\V:^<E2F>AN;B:%;XB[Z0&-@.J%3Y3L=A#(%'B0&)K&P[[>]-N^]I"XD
M9JC]P='S4"XS>5E(OL @WL4C*4;#UQ3E.7A8)-Q-B$+V\R&5,[S\8-L(=J>D
M<2.2F?0FJEV,)O)26PL]8L5G-[]H^DON5XIXE](FG=AW%\2TZ96%'D6TC48D
M"%U+.BU5UA&V?H!16M8MI>SHO9T&AO7JZ$:''UB1!PQQDB'G*CD3\^Q7K+1>
M,)C<4U*Q.S1H(STSGFCGBE!A13^NL6EGZK-U.CX1BI5Z$]RIR\!.JR$E N:\
M/VND_[*LUIBAHLE-N$2DH.>^KT;B[*EH?VM3[V?HOBF.W]]M#\L/4R]O"M6O
M"-R<;7^GQ]K+%K-DS$*Q+[VN0HH'XOJ0BEOYD UE-4^?!#.<,[9&_3OOV'DS
M2#?\<%5RA%"K[RH]_/M:MQ]BJW?"F]J%]2!DFN$ZAR%_AW[X7[JB07N&>. \
M1)ZSVNJ$21\/<.AAK[VK,N)P?E"#P,5Z%X*9+M?$2@V_'VPDTX^[%:W'F9B\
ML,?YHT41L8=:BW&S&?%48+$\[R5X7,$6&_[#_4K^]O2$KS<[5;"I@7N"U56/
MYJK&C8!U-35OUX#A %)+QB/G'4%"J3*^MPWVJDPFM\Q%1<N?J+N.Y)?J+%I-
MB7]6D1A;')':<:?9WJD06 ];.F"K"&QC0>U9]'($.ZH91<U-90\EZ:2HTQ>*
M*.UPS N/3*@._X!)(FUV&!><2;>.4V5@19J.$-NO%1^K8U_QJ=*]/\_);#S0
M-A"1P8S.<NX*=4X]_+Y]<'QK:&>^T7F.'3MBQ [F=%=.L.<7FS 9Z>[/,XG.
M5=TRS.33[3F0:S3=WJNI-594.&"#GLA3@\X85P@[%PM.!S]QQ0/\W#9XX'$3
M]/2^T MS5<R=$=&Y6H+WKOQ,UI;YT=XV$9"5!3\R//!P5OM$ YP/-EV:/Y'C
M(H)\ES7 Z4\43M"R+9?BQ+$U_-7O(10$Y 3& \>\ U>P'ULD-Z'G'@_2IN2;
MV=,5:HO<%4M/=AJLZYPWF-U*K<-F*CU9<+YH)],"0OC7Q.;92WCKSYE:I,AD
M2/C32DC(R96 II_?"/UR58(T9-,EYY#BXO)1J5T+B=?QTK7F[!D_5:1*NF_.
M1H7WT-3&X+NG\J1!^P(LGTGW7PR:O ;72#SX6H78!>^))J4UE'K#8#/^_=24
M"<-?/]5%NCU,&--]-E,_^T%_I2;9#+R2FM\%YP!C[B*9WF!N+#K*&L=KV3Q:
MFU%0[&Q4]Y=,9J<:0<SO<(O5+T"8+&9LM_((I><[I5K6I[M^M5]XKF 7B)AY
M:CFSZB" 0X--*,0>_I9)H2S3(6]:RO!*TJYU&+73FV"RMSV?E7Q-^/)U,WB1
M3%UZ%^T6!K)[\RUR/']Y]*#IK0F7/AM7GK)#XI,7%X\3M6L%B^VR-"=+Q3,W
ME*!$^D+.M-G,K9'UV!UK?H:EW>T]S^J4N>F (3@]UQ>";2U$R4!H=A5W'S7Z
M?S'Z>N/*/OE-E@[?O==^C^R6]RCM4K'A31['0Y2D+R\V2 XE+-==B6EM4?J$
M $7L09ZAQDN;+#86N\?M> >5LEYE]7^!>]'U);%]4I>'Y>. +1F%O580[8S=
M.,G=FCOGB4=ON$1&ZG_JBJ,D73GH\[3V2CT2*C".KPQ,JAD[-MY8.5("\_4B
MI*Y7% >_,8PRO5GG:LI;%9F047$0T]B2_S%U'P],[N'4+'UQG1P:>$"#]8CD
M-UQ2_&^X!#QK=9P*CL/21;<1^ALOX@0@.UT%0VJ,,UZ9OX%\BO<!?SI6"$(O
M+A(P+SU&=M3QL)MF%D-_TYNFXNA]F]"=>[[O<NC\[C=P=<))'7R>RSYI;[".
MJ#O9<=Z-F_,R;U"0)[W@M0'V5+);RN_?\>J<V+(1QDYHP+?MER2FP)UB%I7I
MVS"' C/4GHVSQO==@3)SW&58(/R'\R $84.'!Q@U,*)69)#!^8\$Q-?/A1-J
M:&[F6K?R49HO6(*OC\(13#@-0[67\XAJ/T8\H!H0A >"Y"#H(M"B/5H8%X*E
MP /D+G@ >=_7!]3?<LBEWP$9*(0LB&.B\\)7X7\>!&D=0YA@:4[I<.<7\<!2
M >H0DN[_0R4[' ] "7#SL]4)AXYW*1R39C2 C1#& [G2@[(=SJ1%<7Z//BX0
MG)U;@+#T2@"G/4\7G.$(#S!]%P:%9GZ*T*QH?"I4>Y>]J2QE\]4"^5[?2^-B
MJOC\<YJR??Z*O -Z%"&EMY*NEMK*=<465XV7YB0U^S5>.^4L5V,PR?%#ZZLQ
M /^#C6@-RDP G(*( URG.03+*/H"6A/_'*W_['N_])U^T$Y:XB3F"1YXE]\V
M<,9"R*6']ZO%N_2"/;F8FCAH(QP+U/)Z.(9G6'+?=I^CVHHD!C6?F@1'Y"J,
MEDMM%-<Z^'>?^<$N:5.^[2V>2,QDNC9O_>V,2P'MVB7+1=7"Y*>*>%-YJ8"(
M-/4A\$RM,>HF#QP(VDE=;Z)87$=DE",U-!)K^ZP74[+>O8Z!^O'!#306K6YY
MQ:.<:I%,44U<9;V0"S%W:FH#43/M>E,8:-W-@=X!B_6KF?$H]V8($QH/F++.
MUL6TC[M.==%-3E]GX6"F]_3[/CW-X=":9!Z^%K7L3IU;-%D(&A./1;FA0T7N
M%8SN"!5J^8"BY(0=IR22L<TS"#:KRS-J9R#($VCHP LGHU&OS"5RJ6L&GL27
MKA2>O#2O700GEOCQ0E@QYQ T+4$PN].HW92&)=(&_UA+9Y#4$T\>NQ,7C<>T
MPF--B@@/?[8%OSGB9(-PNY7:#*Z:$MXK8MN?=_B5;,;K*4'6^0WH%Q]_5#A$
M.,-^F-#W/2F:_N47HOF <0/7MI?GE"X(/UC]_K9U)%1Y([?!V"[?H11KB9I9
M*VQG9DVT*!A#Z4JO\NX(%O*SB#W+*%1.U3&5&6Z0_\#%:)L:&MTDFXNYB_;'
M ^<&WG(G,NF-/I_,>CUS??+=&VM/HN@'YU%]!'-F<Y::#[-BK>Z3O3<F>HA5
MO#E\+7!V]]JY4L]:%Q)E38][&EDFV5.X@3EQ)']XE8YYEXIDC%F01H*.HZ.C
M\^JN-7>('O"T:&4ACES2C),4F^)6JG!@"4?&V>%$1J6%L]TJ>I[?NZW)]XHL
MQ@!R4V?QAOORMH7RA/"<L4Y.RX38Z<Y&X?4^B1(:O5+UZG5F4W7VX?"$W.+\
M 0??QKR=LF0ID'4,,Z35"!&C&V(J.[MQ=YP^\*5+4R8(00R/+14GAO38H-./
M1N"'&1_1:HC'D&!.'J34^%2:ZP^?G"QS7[*WQ>;ONMC7*585?6@9[N-("/AI
MX#?\Y'/(8\SP:;"DE'?G6%T3E*IBPJ8D;:'[R(1">"2-(5D;G"LST5,3HT,
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MM]#R\YLQ=U>@K1^*C;2N^\A#VB"6=\?IZ(3<A=7 U[?V];1/I/:JT_<<=?'
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M)I9?59=$&:0AI3O4</V+,04I5SLK5A%&ARX]$_X!O2B=XAY!?2+%H>LQZV+
M+2+)M<?0S1WSDDZYPZ_?,WF\LY4^LSCJ<,_U$$P[<#U%QZP*V7#+8WRBTF16
M]/G>(+KM3!,/-&N@XO& 3TLL'@AA3\:%,N*!+]YX8#D!TD9+*"Y4P_' 0A,>
M0'Y%XX'MYUTX?YPP9F ,/OXM" ?! RN5A*;W 5X%/1N%V(&.BS>XT(]Z(#]>
M6&&8H#AY#<SU;?BA' Q'C0?.K+F^3\9@SC F)Z&GD^\@!-R/28)@P@X\_\9
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M-SU9[%6W?8N$:_\8F&3003V(1<"RLD:N^$"TG<:D@/TJV&&1!("_>EGU+S$
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M)9D=%4PA,ZY$P!>5^D;$*:PV:O;Y;/Z%_5F[AV)[2F9X<YXDO?VRP=H&?9\
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M+]:&XQ<M.CB<-=R]9%UIP>"8X:D:4T+HINKG=3LTRQ.?T6P'AVJ;M0:# [$
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MMPKE\MMYT?>6'<5\E-TOR-5M;&P-7@-^M<YQ?ZDK\UGTBR>,E!M5\RW%7KO
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M=R,&Q:E7*KUM*98&?6HT,4CXC=J[Z+YX1SX>DJ8\>F)V,E.$JG'^A/P75_=
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MEZ0#9,Z%W[XZ</=2I0JD%.S00S37=\<>5!7-G\XW_/A:\PTD^K;?/K9N?XN
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M<@@5DXT-C1UZRK4/]P^OXV*D!T;S/>=3<Z#K)7KQF..\3SI$GP%X_6TN@%M
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M$I[W;P%]QR%Q+X(5"*$Y_)@Q^#^G 3!R-&UA>Z04JYHDG;^][_,CHIYR9&C
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MIZO\$$#[AYWJSEG -P22U/0-+*#N/:38QH6D<U3]89XFU<8-\GN6Y\]QX5O
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M41FY$X% _U%^_!]/GA]S_P)02P,$%     @ DH)U6*6((?-=*@$ 9S$! !@
M  !A<FUP+3(P,C,Q,C,Q>#$P:S P-2YJ<&>\NF507%'3+CH$]Q#<28"0(,'=
M0Y#!!G>7X.YNP2UX@FL&&P9W#18@N SN$BS,H(/?O%]=J5MUZM2]WZDZO=?S
M:_5>U4\OZ>ZU]_/B\R;@I:(<4 Z \@( 0/GW )Y7 #( U!<O_M/^"=J_AHZ%
MCHZ&AHZ#B8F!A8>#AX>+@XN+3_#J)3X!$0$N[DNRET3$)*2DI'B$Y!1D)!2O
M2$A)_C,("NJ_=]#0L='1L4GP<?%)_G_+<R^ " NE!M4$%>4-X 41"BH1RO,
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M2FFI_YI5>K)H.<!=HJEGVS1)I"6>O=$P[^/>*V#US@!W,VE>^^40\"E=!N-
M,U6C?OW $^'6/Y/TAFO?^7#H;L/8L4EQN4#>],$M:64'/RNR.)PZD<")_^_N
MW%;0'K.^0$:O.(!M@G#]NII^.6MP)AEU?.N/9^S9Z96^>;C?3O)O;*(,G]0B
M57);EV\)KD$-YY'@F*N<D#B#3W"33:"+.Y;".:.46G< 4>_F]:3P8!#O%N>R
M.VXRT8HMS)\$(I8=8+1J@HD.ROQX-:S:D\>Z*(]QZ]T55Q*K<:VIKKNW/SO2
MT=-OVD=WNJ6THG1&J->5"%UTRF3^U'C^T,.$$IKCRH7I+**;@S3=DH!"D!MZ
M"/H!?<>K$IIZZ6+]XGUJ46_+3-S':[7"NEUW$=U\>\G&N>R0@1!"VV4TG6<
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M445><@%I?1D+_-4J<++VUCP?@RB'X_LF<6;7.:$%VF77BT>VQ7$EDT3?WHU
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M(7:'<T&84$!_J7?5V#A?PVG6N#R.1L85:XPI=8*-^K93PSA@*[_(BWW&MVJ
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MX>)59Y*)/4WS+3][*%FB/5UP39$+1_.D5Y]G2W$RT8<L$[\E^"7PK/#FFMU
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M5=>-X =-]^*3TZ2RPV?;QAS/;O3*E\R1;UK5D::)W3ZD45$9@QP$?X>=ZYX
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ME8?_O!5I_++4%=PD6IX2 ]/@;_OZ!X;GCYA9U7%YY$8:7B.NP>X)R[HL(T\
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MO917WY-L"WU'X0[7E FI05TJC@Q*K,XNPOSMF^];R%CN=0X_0EBN,^;W4I\
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M1'OV"_+8LT>":@9<@_,$('*3&;_L9YC&O;4I$>+2-<@2</WY+5@=3$%OIR'
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M\32?3-#<@'0/'G6%>JC<K0!&U078RK+H^44[[.<3( A4'!_ 8+P/8I=XJ<*
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M/YVS>=$4EZC]M\:3F^?;CP^KOH5)S*$XYJK4W$47;.<EE[3+F27)E*#+AM!
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M4IZ]$:H0YVM\7.'+-.QP6OY^)C+*<=#\5&V_.(8'**GIM8937']P40=?/'T
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MNRXE=^!;$XVS;-R<TB)'DWO->WZG22:U[";B43^_VV9WS92^O;F&C<F<C/5
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M8[*F$VLRF LVSJ_9<(-FR:-5QO.:;(_<I_(Y8L[FS#"]U:4(>OE_2TL!*PH
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M"*5@/\+/+U*>'RRA4 I*ZPKA)* D< [ ]V:-?'CMKWI2$"@9=UTUNNMMT84
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M^OW$2Y.V=/5A/_W^XL\H]D?VTC4NN04-/RJ'WTG6/W#PPKUX)4^?KT9=T5K
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MP+>O-L\^$CY9XEK\*2FA29F<;."99Y$8X[/J7FFSP0Z/]#-R/[?I)DV&=ZL
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M<FT.\"7>3 \^ !(H#?8GA7[B.S-2Y1DTQ$P9V^91Q9&I,2,)75MEV56ON]]
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M+=,6-\?!1T'"WYB,"ZBKA<K/'5&S/V"SBS.!V9=\C\;]4<(]M-'E93_)Y/G
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ML"VSLFUY;O:H3U40D_TI[3YSC9D\FH,Y@Q@MS'E\?WQP#J<(X:PP-3]9V.D
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M/R[LW4%Z"C3H][Q5K-GWF4O+W<"DL4A8RYG_3>&GTB,3\.9DI:E:"+586\!
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MOLHU[YY8VGB+1.9\D?AL'#.=2QMZA/_P79=Z^J4T]N 5KLI0WT9=%&O:?KR
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M?4XQKTW9P)PDQOA']L(U#2T$F^97U;Z;_3NQT__+["^QO[U& !4(2+X\" K
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MH0A'7XOKI:GI^ZI_WR(;_P=02P,$%     @ DH)U6 +6^C0S=   T8<  !@
M  !A<FUP+3(P,C,Q,C,Q>#$P:S Q,"YJ<&?LO&=<4]VZ+SH1$!$D]%ZDHX@(
M@E2)B#01 1&0+M)!FK0H@2!5.H* TJL@+4J5WGOO$J2$*B604$*$D!S>?=8Y
M^^SW76OOM<^]^]S[X8SD^9#,D?E[^O-_QA@SQ!_$)8#VH9JF&D!R 0!(SE\
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M3I (/)A3)@(M5XA E]XI*ZRO''J'"'Q5A)TP&%4;&9A4,VD*"C=L65U23W*
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M\6RV4#<RE4!2GM+WN13.:7I@_;SGI=9H:U/.79N!MI!TZ_$Y_-0))@*<542
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MCO9-3[:X!>P^(@+TL*6/B]3-5_$/JS$/C-Z$A;]X9'>J5MFA^DJ?-/R%L0Q
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MS%284'Q]JDD8SKPS6OT1WDB9XQS -W9DNO8SWF3K2F'%@PIF@#1^BW)%./C
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MY=48>)LE)X'3$N+9A? F N&-*LL:5>'H^X[%ICO<Q@G+J%W0L#$35QJ'P:M
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MP,OCP_NYPGMV;TIJK">Z)0V\ ;VH/D]24%"0KUQQ$G;ESM.*?\*F\*30A$.
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MR29>/,IUJ-IOQA@5\*7HR[82&RJP#84!9SYU=MQDLT#UDNHZ5HAUV)B^^L;
M\Q  >I"#%(7+#OE9^+1KY"!>PB!VB"O.,<.YQ@Y2YL74G\[!A\*<X*EP(2ZU
MJ _K=7@ V\1KZ\5^M5D(%0K6#\\K]/>#$$M7-<N.U?,[F+P5^V,0P2 ^PDBR
M*\9 XI,8"*"@@:CK,3E:B<.P-%7+9IJE3CT+U7B:Y>8:WZ>J8J1<Z&#^$2DJ
MKQGB?Q"6 8VKRX$9F2!7Z2(]DJ>@PWOO4C)>>'_=[W_(-6L<&3A] V"'J*)N
M44R73/_3[+'G/W[-1W>UVN==(6W:X7PV8P5$LHP+M):C%!Z*JQ.+0M5O6N+K
MM%)L#/9-OQ(0:&_F>UIIHC7/0#-*O. P:'MQ^\^B$G9J\!NL8/F 4YW,)6A:
M0D*R7/RKI))[/ZZ$! Z Q2=:V;&6(3<(^2HCY?/VU"UC[I-1$FI*/?QIY/\A
M2X2E#_$2W_7$GCGDM03%^ _-]9[80''T^0$KXJC>VA2.43/$^#L@34Y\"STY
MI:'KE-,$O6Z/@Y?<[CUDY)Z?O0'4CT/;H^)<,H?D8F5C%&1=$7$EEW?:%D$D
M6F4C0VO08P\/)?>A44'7;VL-54H$, 7^*G-,YHO662E1<M&(W,U(CA;OE%'N
MX/:0W^U4H<;,(0HD@#][3]"O8%!1EL")OVP9%H45KVF)AEB_.?/G?@#GHI5U
M[\ MJUK*(@M_XR-)K37A/"\<Y#A)L[PCEYCK6>K8;M3S&5QA3;;'%#$P)OT)
MW&S^T2%4A.?C]_K'GWG^I.?6:UGDBE($CLRO,J'^^NAXH&!>0>[9SS186 7,
M;FL)\^C:23L0'Z%?24SX.9(8;OL:;2YQ_?U"RJ\GTFM,V/I%(YHMI=K2N<')
MEKLZR-V3(L7-3H-9XRU)]$L\IL\A@ZJ S4"6P!FF\T'1NV"V297IQ@/) ?AU
M0IGS/>*R$2ZS)4V@MS # +>#D<?N&P>=)70SGN4$TX FF-E8S8 \%>J4+5C$
M*N9#_5JBOKIPMZ2(V)A^RV)_%R^#38B_PQM?-SB7N>]>ZFA&& XZH6#"1#V&
M=0I*GY_9]S@*CP\W=WP<DVXLF_JX]1C*GN5!$BKFW'PK(UYQ;<)[5RIRO1?9
MSKIW-_IA7RUIT[T$@7:F.>,\8$_.U*?KE/MB#[\1?N@YT-ZH0R@Z0)NO"67-
M^%$1L)C]6H>FKL:6Q@R&\+YY7]LX:M?H+=NXT.%^ .5<"Y(B=I4[JC^(N*F6
M$NS<;U;2$]NI7ZSJ5+*J.6/P$_:=AN\]Q_=4WPI&K;YDO]0[![)G>@&"B,.N
M=? U%^;+K_Y[V;9PI9S2U1Q?XZ=-Z4_EN'S?;'%*Z)-5+1&J)@OZ6U[E,UNA
M?/I!!-:TJU %FK+%W1<60\YW]UJ:#5*$@N-Q&I.]U],F:7%&,9EG2;!.<724
M%FIK-:?D!F#OI,27U._L?*=?UY?%P[PQ955KY^,&V:A*"&HK\-U995"#<$)S
M+EKP+"QV?E70,2D1/X+S14$#L/G=>,AR'?=EFK'#5?K[^7FKPS5H>W5U/>8'
M^">I>B(]U9I$_?>2+!T%4-=7XE%;@!;@[B2BM,\=M0?MEILG:/"L4(X]U:_4
M)4,-QKERQ-PGB=!X^L=]\-$O 3U/%69E&@7=,K#L-[.?+24FYKMF$0D-NN1-
M<W"SODT?7^LM=3SNM 4F5!)%X'QF0TOTB7.E/.F5"PSJ9QSUOG+/6H94?E$4
M86J3GJ%BJ4_X49NY)9Q9;WRH&6N%L2O%VF"\JL!JAFVM#8VS1LHG<9;=MJXL
MY4+O\&Y!V&!Q)2Z#+1MQ[4-8CVT7^X#KANEI$K6SY!HX#R3[PG\I2(#XG>A^
MT<O0W<7T0 ,9?KC/W:)D1[P,3-=&?ERV*NI.>/XB&UM[!_JT.?;<+2J/U6#J
M8#.;_Y5:5(P/%]?@(G<I(?"7@P$F#=F(A@V.2_8KT:*P>0*H^9B277ICS:"<
M*M=$!%12HNRU:LP<@0GNG\D'[0%J9[YR:U%2?-))C,YF0]&-"1Y+UG'6[8G+
MSXZ_545'<JO':VX-[S7R;<4Y2'<@1,/5^M;H%2PWD@[&.G8ZU8%V#L+Q/P;K
M^II[P]5-5=X&^3[PA/F\(P%L=,JCPZS0D^&-!ZY/H]3F&D>PM.VGRP9_ZBI7
MGL:_C5*6F97G(2/)8)9C0?]D)PODQ:JBUQ*[F7H1&:A?D2>ZA@@P[ "K),Q-
MGS$C-5_>(%Z/K6P50+A5=H3JL:$1%"%RFK<8%0]<VF_%UME>'V;1UM5F6DS*
M7W^I^I8K1NM;HN+06S8"O?(:A[[\AI7\/BTL>PWPHKFNPA(CV7<,]@4A0A^D
M&=23L]1!#0'$>(^#Z;B\M1Y.J-QQ#;^%O@KF:/8G*)54V-,&--E%9"$(&:#
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MVA:')[UM EOK$";RM=9+T)D 6WS>D$2^M)PXTP]E?D03IR%Z282$.P+8Y"N
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M-^X[JH473Q=LLY]W<;V4,UJP[X0P6/GV3FHBN\)VB@]9/UP7AI];WS6[R6)
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MB!9'"C\L'?,RWA6LU.2;8_*BE-C>MJ>1G(NJNZSQ*9TZ_U ,;U$)U_%B#K$
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MJ5FUDRV3[AH['2(.0VDN0F/E%*V1K[]SB":M+ABC]!9/B<:*/E?6QWH*W-[
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M9:J3USBEI;5$0/21F]O1TF,RQ]\GO/(M O,*\K7+Z;C,[+Z-F>?CG,$GM6&
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ME1>$X!B:&=5!]U9;H1B:T5J<4\;S?Q+[B?@/8C5F(%T-S3L9*P8';B?X/['
M) D6.*"QDNH[>^98IK*%!4@JAV9(!F&3N#ARC3$P&:^<Q ;B[\</GD;K<VW[
MM70=.V!Z.[' ;]XA+H]!:[N_<7A'G&0'3;,XXMJ$*<[*I<D_,S8Y"EDW_#M
M3,^_436,."G$L)II@?;Y+2 +IA> FQ$PF,\YV>0?.$"_/KFASW[W"F<\7*^
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MX//_Y""CZ?M9P&S<B:#L&P86^XARB[D,B,B.\>4M,CBE7ZT)" GH1>YWAT>
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MBT94BDTK:BC+HG3](%@->9,6@>]U."R% F=605"22'E4"+69JLR  &!-,FF
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M4%+9Z7]\.00=C,"73X:>MTJ:4X&-A-W>X:QRX5$ZV1%O:+2!);: HA$A&((
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M"_H'C4%+ $-JN-#J4 Q.MMOCV5U$ZI)R/D"R@P7#UA3MX)L4)OWKMP44*)V
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M^(MT,._ M!N#T0,TP"&6&,V O :IPC@X7 1K,RI@)"0 A<\Z]<"W_4!"(J'
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MJ!+0'4!G7^ZOW'1/EBVWG!"7Y5>[416V\<TA:2:H7.SN.#VC-/>/3(.AE)X
MG8MIM:R<P='*/OIA2Q,#T^$E>NI.CW8?C:@[6GSP*'NLKR$WL392O.W%L<VG
MZ\N./RO+9/_H$?K8'#FE\/13"PM/B[+HBSME:IHUD4-B\2'-<RYEB&.A!26>
MIGZ53Q.>W'Q](V N/NF0H,V3B$<MG.=?3B:MLT4>&],1-"Q*OUTJ=\5)/,#L
MKN2*UN?GZ(X;R;FZVF_NQ"ZZE1A:A$Y$BGWQ.#0V5]XY:MHBJ!HK=O=BWLD7
M-GG<\'C[V](]Q4<S)O#"=__B]Z*-1B64 =AZ+P-R\GILX[]]P^EOHJVA;P8T
M?T<N1\]<YEO34X<<!0_+;0I]6T9FANJO35]7^Q]\(,J0*])/7PF&([OO+D4M
M1$O).^(Y-Z17JG;?9F7E$>G.<(V4_]1Z'Z7U8J$W4M1^):Z(_*K$2-"*N%]<
M#?<N33RL$Q_5KIU0+'6WX(1BIGC4ZSR>9IR) JQ1_)HO[8"X:X-$ING"73:^
MK^ACT[(NK_I@^[,U;SX:R':M-N!L13<^*/'WZ!_R:R?]3/ITMA3VI&3=J+(O
M"^UI/323H6<B($Z4*0^LON3_;DRL97?^GK/<K9)"HF^W8EDG;_N)3_![&E;%
M\ELU2&2(O! .L_1*W$N=M/N\VRQE,F8@N:_O:7+N0!==N=9&^F&IC?J IDNA
MC)WYG._I);R[KPAJWJW$:)\=\5[WPL0=^A$*7Y8]K_PZ[.)4 H[3',<6]<;L
MO4_$O:R!VI-C=1-\-5P-0[O23M1\#'U0 [<W\QIGWZ?.?F5D:N>C)^OO:DNO
MM6L9%9>U+0P-%^=2+A[+>8U[,)%=H.E2\\IQ$)53B,J9<59_)(L\]%Y)#9<*
M-R L!3XJT/%HCW86FG,2?WF _[YKRG'"A0/VRX^KW=)DRWJ/:?.XU6CK?I(M
M3W"I ,2;E>1Q3_@)HIFAV9?.-"[G=PVN=RVJW\ <T3J2)S^H/CC_/A6?7]-=
MFU@:?8SYWU<8D)::$0;DA]8P.9EDMF%-:'\Y"8L*.-*U'LZ]+BX[CTM :;J6
MW11TV5''^I9?;"F== 9*?37:07M6B'F)#@(>.!^V2SM(^HE31IK41.OTB#OQ
MYU2^4K3:(P))V>D3@Y1\:;;0.3V,^$X[$D+&?"QP<5XV'<;&._B>CQDW(FH\
M\T-)1*NPF_K)]I2,\J):D0?-?HS]D/;4@KL+#(<:Z]1\J#)BQ<98F. D'G<N
M5 +!/_O\'#.\7!B0+XZ1%Q&5)MD)-Y'W$B4%SYF]REF1GZX1PYW.S/+C[9/Q
M]_V".>;FS&D7F3TR#(/.KHZ.UE!:>&YKF&1<98M+B7V$[R^C\Y H=0('"#./
MG:KA:)):PP>SNJ-IP@IISP=,>\M%R<]5VXYP1,C?D<*S*J,2![OS6CN<:SS-
M"VF>RG#GT,SV//.<OF3]L@Z$M^920DMN1M=HFIP517G>,'P"A3Z*\G%^5E+(
MHD=OJ<#4'+Y1- HNG_*QPC9 (OMU;LA3%(;0L4C$X6'UL"-3Q/^KO?<.BGKI
M^@='0<D2)*=!@B!1),<!0:)$49* @D@<<DZ#(#F#@(* 2)(L,.0P2,XY2)(D
M.8[ ,###L(/>>Y_WN;^MK:W=K:W:JOWC6T53W:=/?_K$ZI[3P'!HX8'PH&S?
MSN.)4K^S)977+_K%OQ=(=?="8_KDV0&N1D!RM/[2)2!*V^NH7<>K46L4&Y^^
M;3$CVTI+R5Z/XNFQ#!4W$6,5XA%(H;7T'N(!R34AG3]OPF[[T7SR*N(RGSBV
MPW\Q6?V2U?C'0OM=5%"Z]CM=K3Y\M.^4;0:7NF+:]+/SF6,4+-]-G3RR6/.7
M2W0Y0QY3\JJGKX?#CFG1K%#R..1U>G&A,)A_I[.!.6N5Y/6H(Z^?F)2:58*)
MNF(<BP*CPTY0T0!!SPE5*OA0YA,2[+C*9-71$!#BZ.[L:NEHX4I\X,HW(&-.
M&/Y]6*,;0/% R6Y3/2ZN>,7$3 '.GP77?W28&<Z;+1F;)!:VMS')QQG)$EVS
M5IHU0-Q#F!(/)MD$E!,@$U9W@!3H!X>L=[,1"^:+AE,'!]DOJ!\=K=5ZS;0%
M?JJ9!G%UX[TQG"P(>VL<6S-G<F*TB5YTU" Y_![M;],E(MRH/[J5FV[4R6.=
M\NMDDB9LM]=/0/^A+/<H9%G"#EA+2D0J/&]A]9[U2-3;W.3CF6^MZUA2.ZS*
M=_L'\#"@&++*Q*# S&MQ*QGLEB2=])C]%X(L?$Y)S6\OA*%;9-]H<>^F"(0:
M%"U\$'FN&;P\ WXTC1 V!=:D&M;6D0>^>(CHD'WNM,>I,!X]G:BQNG!M%V35
MTU5(X$@Z7[4=-7S.@K)W3%E%?<H4&BMR^SKJ,(L^G>397%1"^9 KWWX_H:JN
M=%KIJ96B46J>LLVSY[,=K44>,%2;=C-D)>J+GU:.[6QY2!_$?DM4@TW5IKX&
M?D<N]FG=BVB/C\'#5#FKI$&Z K%-NFEEQ<O#^%L^[*)Q[L[V2>E.XTJ91IVD
M!QP>$KU=<A+2A"W2OMCH<*]\]I;CGHI?.1E?Z]C<1Q.'%@J2)D]3[TZ?6P6K
MP]?MS,BD_4NV9FM#XL+7Z*W'1("4ALV#<>^^<@^1V8,K0W&(]8Y;NU2_Z'U1
MM0&C$.N7 (ZY-5?]B*YOJ&D?Q_[%F3-C]7YC*8ZI@;/5%5"[:@!S390S<ZEE
MN0W]9-:<O0@/8$5"6T()5S+TV3-=PH2$'_77QIH7$9GPJ:15#> RVH.9K0K.
M@<FP<K]QT9G\'AIC*>1PS9SPT]U;E*N\-)R)=FUX:D>"]]]RU[6#00)9Z_[4
M9L]*[:6M#(V,SNQG3:AW>GWNK.;)OI=\LI.0^1FHR70/NCR6.THA8.2THV$*
M79[*'25ELMEYC/UT!\F6IS(EQ_&,O+!_D[,>YS'9T.1Q[3R9@*I(/IG.N^]6
M4*X6:ATF8!3O]F6Z5$52US*[_3?I;2*%;K6G.RI7U8(?C]XJN/5NUFE+U^"<
MZW,2WRVF>\I&\F/OW NYO'8T\V.AVX^_%L1"^[QV%+YG3^24<G#MZ.HRJ4F.
MZ<9"/UC[C(WQ\;'&K^7E&AFE:*]M:3'=BQK+E-3ENM<_EJYI^NZ#Q70>'Y:S
M0BYW2AUY%:>K#L%YTFZ%]P@EIYLQ_2 JO% 1Q.%0CJ")V!._N2I@"D]L\"8#
MP-_9%!_;(:#?C# L4EK.3_U+F_'C<2 9#VF*X7G<%U/2::K=GYC%G0E,>?,E
MX%;M&9"S,TL7TU5^@G4=LY[K*-$C&)J)].M.'YH(CM* 6X6AS4I^V)S2FZ2&
MB4@(ST3[EIF:A"B=Z)G,IS "[ :;S"XJX,&(^*DF$N]5)OTV^KMA^9V>-G8Y
M\^DVY;E^U/%?UX(V"AP6!KV!(2=@]6^0RNFNJ%+@\V:-A^,=<ZR3V74\4ICS
M&P+-*A(O-%5VDLQ&*9T$W\EL',B:GM^3Q60YHV,([Y5Z>J"URD\RQ+0;?!DR
M7F-F&=)EGN[SCO5)J*E:RYOQZ_W D5!Z8; F+T'H_ PMMH3BD9)A,509G=DZ
M<*DP7DZ0+E0]$[VG=^8"Z/L(D.MRU8\I7C3<\B0WY35ZZ[&]U./:1$4WO#.H
M:E'>:%TK]J2(@(7#)<L]SA;=4$!F?M^[U%Y64HV2\M6R]8]M<DUPK[HR0Q_<
MR<@P?_ B3H:VP:</ 9&:4P\0DV@$A9XS>G ^'DN<G34FX39AY4P<9<=/?'&\
MRA/O4@]8+^]?IMOESV^J"J(6]1'_.IY3G9P=3W9+/]%"IPTLI7G?->'QV#[#
MXQ9HIKKW\E$5XP'WLF%$#\MT"')8':[<43Y;8'9H61 KDD5B+;A)9JI.G>'4
MITK!TD:\3,#[H/WC=:GIG#:Z-0?6]LD4CB]Z^7.)56,/H#D;56O^C#D\UC;A
MGS:'^DSW8$LRL&*A\1,I*2GU#!$1'K,]8S-"P]+=LUA#@;&M,]V\Z]UWO3EQ
MRJ6?;;R55OVRE5::&E;]H9K$4;LEY&!:!S.$DB;KT.J_?=1.["9]9"9I>_X:
MM@H+AS#LO8(/1T"+@<2L)C:(AH!/\,]UM;Q"0QYHF-L+"M>I"F$2Q\Y9J[ 6
M(K12:C?]":9P!>RQ^'B"U\'!]=6A< S==;+KP=62)[W#1A<D2V<Y5AS^LHCZ
MU.TGB1FRJCR7@'3]<0V11H]%]5W_WJ=[LB?=%^Z@GJ>1Y3:G9:"=0LS#)IPN
MWJL3J/53(*-P/V3V^O2RQ/A^;*GLV]G#EAM^;VA3^[\K>3H,RPB:6KFC7+QL
M94"ZHBWT4^XDYD#:WJ5TDKO4(:]@S8JD]28+.K?QBK^N%_F]/"R/\B- Z7M9
MK2"BEBZTNNE)T6RN7A#MBI$?P)HYE=='NH]43:@F-H!>%GASLB;9?GBP<0RQ
M5PHH HA?G45S"6BS6658I*B)6]ZI T&/2;:C'+;7#;XE_;1_YQSX_<X;UD#9
M]A%I3^<OR.L0BFT,TT23B#.8>&Q^BSXLQ8%5T&'^071/ZUZ/I3D^RWJ35BNL
MYB(L HPF+]R!D3:I+@.)D$-NU:-^"MX<U9VYXQ*LPDF]"6D4'632G72=M@%#
MF7AP1#!*P SIVP6&N);U4N<P9SD6F90._GP6UV34+OQI.9=03CI>TJ/\YB%-
M8 NGU^*2_K>#8'T@B4@YD<+RGE+;J1F<NI&CR6.+J?1;%KBRFZ<I^B?W6M!J
MYBT7@.PO?RNMV M[T_,91^/D&IMW*@%1'Z>')!?W&F_&%7IA#%KHD3E/#VO?
M5*NZ-;MVT/NE5'(T=EWS)*-3' AD3"$*E&#7?^,UA_" MU25>56I:(6*U9J1
M50L 25S5D3F(<%Q1'[-9\DGI Z$AC00>Y9]%8(F%J09C,-%*:A -(NXP)?FP
MW&3:G32<_@+=H%3YJB9*W8"?A>RLLF<LC+87G'W+YY4VWCPS YPZ:^6 =*OA
M1Y)+;9IICB/39'5;$&Y"0^B3X)ZE6!(;?:I#K597-#_R$388(S!YSC$Y%9,W
M-Z,A#'%?(+O)L_=Q=;;1","M[H@\B[J H[<E$^<PLN:7 #^()&#QKPMK.(1'
MF*L+S#[9A>6_+Z@5T?^?_]%3'QKB6NP5MO(L.,<:\=4T/SI,OS%VW8+2<DB7
MS("',;H>!]C7K!O/&LI+>5-&4T)DV#2IE(IH[BG2UG.I0AU/9_+GNH>-&?AI
M^:D8^%F-/^F-H%6=0T0R7*R=OA0JZB@3TU5E14SQP8* ]7X\#]7SP-7Q0I$I
M+X;EO;6+K!!W?U>S]*>Q;6/W2NR?S=R)Q!,$T%4DKLFSW#9-&V5+-*2*8'!1
M=E33OAX(:&4"E$EZT7:I#B[PM:"*YY0=TIC+V"0SU!R$/WU::QR]2*:QRY\\
MGUE8^"B"21)-SMXN7X60/RJUOJU4H7Y[JY^PN[X5]QW["5OF@HO@<_ZP%:0T
M2?FVM@WSG?2. -*JL=RF^+X59TM6.*/=_9W&3T^2QIH'WTG&M]Z7D<_G@W*'
MX*J0-WS1"=9_@C^?P^U2W;"]F#<WZ2W$3??1@J"M2>)=K7J*X%919&RBV4#I
MV*D^;)A&$B_R6"#,R*'Z;IP%HE3R&!EDG-ODZGS'Q>B1X-D+EQAHS&(;SY?#
M\FAH' D2U3G=D+?K(2HY(9H6$S*P8?O\T1K9PZ3)4&4FN^^107DJ-U2Z2-4L
MC!]N9W]6(CJ5U^D>JXB]-O;.4M/7V-T_R81O%(._6YBI?)M@O%QY!=:VE_/.
M$NQ=XWQ<Y</,L QA) VY!! O96[?B-.;=N<I/)Y3K_FE5]P;_TMPF>QZB>M,
M6*DGA(#/+8J)?EN*SW;89-+AKIA/QD))$6H=DKTL1XLSHN_(T?0$P![#**#1
M=^N>>1"7ZUI7PD;9)(Y(*2-OH1I?WS9WOU;S02,:NN]B?B3I5>1.D;]ZKS]-
M\US&[5GU;FIFN?XH+Y#!2TP1_N/#K:05$E$28PWOX.KJOC4B+G9&7WUZD"7L
M[2KFE0P0@\Z"EPS/]J\XU!Y&+4LAX]H/KMOJF+93I(<W=<R>X46>Z2_'[;V!
M9ZU@@QP(X59:6-A>^8G$8QUU3W/%W[5Q?ZX"CF]6=:PX36P7N;_T!K$/_D(W
MWN]XF6=&JI]"T(@:M"_[$3:]>-B?=768H3 &.NB]!-";(2T/0H#'K#; TY^7
M@!B_2T".GP.R>F6COOJPO ,2ELDYN1RD_G9LM]3!(M-=OOYM@!M7B1SNJL1*
M77DHL+J@*RXR4WI<FC-_<9,Z+00%=>[U-7\FS)T7NU?/EKWW_( F6$/ JF66
M;216/ZWO0>H47U_9P3T>?H3MQA3LL/\20 C:5/R'E=>D(:#_L!)^":@^[5+!
M,!HC!Q8W03-5VV.;._@5LD[)=V)U.]SF:N0D-UC@SP\OFEMX&"&Y-B D -15
MD?(R,/;X$O!+SUV!=6@CP AE ^]!N6+HPI:U+O ;E"_.0*M7974Z#XLQ;TW8
MKF OCU#>VX'K70+ZNY(N 8$XEX#(@O*]-;CV/_]!VX*@E9> L]-+0&*.XXFO
MS"4@:_%,.J[Z$K#\'D-U"1B)R84LYF"$88<#$$(LNDICD(-1[)*0N0$_@)3#
MZ*8_S&7":CT[V2X! O1:&$ </.^B(!4R#$,GDUZ8#,,V+@$8+;8]$/*U64C6
M,9L-Z'03BX( 6DBL;?B<_#@+]0O2U<('K+7J9(6LKJI= EK),<)PE!M:!\M-
M#-9A Y218YB)?MC&(D8MZA*@+X3E^.J()ZD?'5>%Y?0#AAK+:=S54<9O5@>!
M1)!-Y;\Y[0A8 %)BAP#I]:]XPR+0#Y>^0B 9BP ;VA92_6#Q-P"?89-E+-@I
ML=2E83TH 0Q=P;+G!0&]UL7Y'V@G#V&8MS&<F L@O#PF;*\;#L($")>CKP%7
M-;'Y8<?J)8#O^'=3':7/=_7ZY1GW/:=A,FQN?PE 9YK]] ^Z!%1YMI-[4V#=
M.54>F*LCCNL\SB<+0U>U?/4S$T[LVF'*:+M55Q38[_&#DLR U'IYG M\SVY8
MM1H(/!Q1@#$5AJ&O7TU@S/MG IX+@Q7@/VA\Q:*1'D +&4G*^VO;!A>)(9MJ
M8[ _6* P#'8K5NC3L4O (3XD1@8"CHNPPAAO09"XH*Y41(WA[S<M?^GIGY=W
MF!U=4>5,/0.:0=K%T(*7@&R>/PS:0)8_RM)!1E)_3R+RB_:BNH4#,NPO@-VJ
M,.1X*F("^0ZRUO(!BZ\"MK/=&N3H )OF/8(4S2M? N2!5_">[V#HNI=3+PA\
M]/^&=^UP&/.VF><WO G=>WEP]KB3<RO,-5)X0=R<PHH\:.=X^,_BS7C^7OS3
M%:US_$M 7^+5<\".2"M0:-;Q71O(;PD#'@YED8 V'U^=B5RM_HPK8&:1_ @#
M>XP5,4&,\ '2?A&KBD=S?[5A-0]@?PN")L<EX%,<NE#@ERST$A#JCK2[!#Q\
MG7H)"(A#8FD1[QU.8]XN"/SF-4EY+Q5.BY4H?S$L -W(JSJCEGY*EX#,<T?,
MM2MMJ$C^2QN>K)C]AUT@T@H2"CN^NP7Y6R&ZVQW/;[O!4,=8A= "UFAUV$/*
MQR&'Q) 8KHL*#&O6F6/^)6")]LJDS$GHHU&7@%X=L^W4VY 198P>=J,,(.W2
M:"P3V5+JOS?*MB4;!?*3B.S3U\*WB6QU4L0*UUHYTMXQ/.MH3N//JGLAV*6%
MZY-#'44SJD-O\6+YQ\STP3:F,6IAF$)GL0M<R)HJ).$D#"VTV!YW?OMX^(J]
M5 S=T7+W!<&YU=7N7;V+3'I5X37EKQ4#:V@Z'D"FMV#(FZ"NN+V/!1A_R,\O
MY2?*5V^B8.T$MSHZK@BVG"7+"!G)RO]+5(=AMR";6N.@@^E+@&G+4RSLWY!A
MEP 9Z"(:!ZMB9K.7@!7RJSD\_Z!:_0ZK6>57L&JOQ/T#ZW8<TNH@#'3,99/U
MEQ0,+V+I:F/I_A8"*PP]:H4&C1B''9)=X5H>P+)ZX9&!E=5@K*R"+4%'.UA9
M5;@$Z(GG8((@OW*QLHI=+5:QIB\(Z;'+O03L7.TP""V)!5H!*SLPLPN?,^N
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M0SE?Y.*%>TO#>V)SA7*5^]W"Y_V2ADO MWU?9+3I3;T-0JIE[[)G:W<72O;
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M[6:@-*?AQ2=I;\LOD#:A_$UMK[".B!7U!?(RX7Z59(Y8(BZ'8'8:L1'^E:I
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MZ7@)A-]MTH*&73I/#/@(,NB!"RW3CO$4*CW$!>NWD:F()-CA8@B4S]+-A,%
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MF1V6Z%5KAFM2T_@ F2BM$>$+_M89X]G/LQF7@$:_NG9!#[-T$+_!LL^U5@"
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MMOM]E7A.R&^X/U\=R3'W>N?8D+6+#,Q:0H/$"67[Y=G>O_-OS59]^:8MT!?
M#=DUD>XGSGI1<\2BQ<_Y2U\P7[!:4YQVEZ?5'F*):I3"+WWIS]I1$'9"0N[
M=F3EM5(G]'Y9GLN\D.ZCWW;?/@VQ8*!4^76T4-VA?J1[>D6>C:-=B>U!8478
M+?#SW/3\!Y(1],HVU_=Z]727U:+O 7Y4PC>"2TXTE)5J$W@WQLW35,=W*3KQ
M#=H^U*AHLX<HW%UZFY"08&Q$M.F9\+P[M]-F;:Z']<.+MRSZ7(DOHDF7W1P[
M](D@AS9C0&K3[_,$)PN6^XDT+8UUHC5?Y\&&HNUUGULFMXN(R!XX:;@%4!TJ
M(!UUFS(Z\Y8R=^?9AYGO!OJGX7MD=[L2<"9\8WYW;7S>IB;5DVQ8ID1(Z]J
M;B_M:ZQ;K53I0=_C@S9*W5_Y,8:/TV/IR"_RO)Z6UTDRX4>3@-)%IM7$IPFE
MJKQ-455OO\1Y7M'EM8F7&KI232:9"EG\ GQ*QM>&G&1U+(PN,N9TDSKN760L
M;X&K<9S$WJ;\6$%(O*;@U7_ TJLB-QLI1LP=S=7#PESJNZ)!V*T=VZ<4OD#T
MI<2O.HJ#/5'TU9-N0/Y!*VKR0G-8/;9/]: 4'%/]]6@F+_Q^G/G%?D;@!4\W
M+^BUB?@"U\3Q)8#4[)O3K/UL%%:D%6.\$"/0Q['AD:%"O^[3MDHPR'5J?[U(
MX7L)EX#!8MN?*8T!U=0C-NI)P41&(A4U!F*TKX+Q/*: WM^7XO,#9;IFW 9-
MOY]YC&HYLOM6(BX![!%W&9<20DF^B1],IX%3DO._;Q^IVEFS-**$=838[2O.
MY']R%7<-[%NQ"TA'PVN:?#%T^]9\PGDF8FVG-5,VN%9R35!.#:D[@F>1;YP8
M@1]4GY,<S <)>*&66TKA1-T-,>.;*2XVSP0-NIEJPY])0"^L7C3R$SLW?C48
M'+ G_@+R)FM+" ,P%S(GY:D)E*9JU!*PA=8I51,F"9Y5NM0%-'MO_/A@6;+U
M)..1_0('F-6L8KX;EW<0Y\RY=RT$A_.GUQQ1YN>FHFZ$8V5=Y=BNM)S;)8!L
M"Y$J.-^<MY"/-,C/G/J$Z])ZX_5\/7L@H)=-Q*(-=BTNU ^T>B'*EL_1'4DA
MZJ_$X)\$A9F'_E"XA[-Q4R53SO5CW\P&>Z"/6;B[B="W<ZH?Q=YDL6,3WB5?
M.^MGD$\)<XHK[B@7LNBE2HIFE6_5]+I;H&)&YGEO$5L:B9+2OB ]_(IGL\K:
ME-H)JKH;L_*RJ*G&2&I^.[5J?E'#V;Q2I$]D0D@ID4+6*8@U1YIDWB)MH.KB
M?<[8B2/UHO&<C?Z3G=O0%O!:YWBW-WF#X=34^GQ%5/\C'8ID1NXE[E#+3Z3V
MF.]C!]5$Q61MZ]L_'E5GBH1D]0L WU,-W;_VG#%3 J?P>NF"S3/]N8!Q*T?G
MZHZ<P0CC6S=Q7"17HZ>C%% 2)?0G0SDO+9</;JEZ<E1W)&XB IXG"'N4.YA'
MAY@MQ/2L)O1(WR)1SPD8$KUMO(68W8]9SMK](D)[\'K4GE?(4K9?*ERZ2XGV
M@9!FF2KPUX"+EO"U76<;T?N#O!4SQMV\)<S*!N^$ODK@?G21!_R<4&B?U?VD
MDS\30D'W,/PV0\\WAPSG'Y\/\Y-$WRR#@>KU=2B3SN2/HF//75%3BH3&F=YL
MTN=3I0 EOI5K@ B TGR.]9F6=)Q"+WJ[)(TZ73C?4!AER"'XWA/*K=G^L<QY
MY"=\/$G_RR="]<\V?8BA&NKL/:7OM _KPWTX@0++6E5CN]"?!#8V-XJNJQB8
MZP$R"]XLXOPJUM.^P>-_6Q,:DQ/4-D7YHJ^?D?M3:->2'-.AT,Z;9T;X'ULV
M1VL#RY.!]X]EF[4V='7DZ%)-Z<<$S.MC_1^,Z35(%9!<QQP>!<V[>$N?K$>1
M$F])@INAHN?^#1Q0 O#M!S?=8_1MRU83Y1A=[#0C 86WDBWM+04-YSHL7=E#
M6'6:XV[$XK&?"D^/NIWQK;[9Y<O$CZQ4'"G4X[Z?2_R"3)PYV2,2$/,BAL&E
M*W*&\XZ2]\[9A,O65-4<D3=?=N*"_HN(U1O75VF['UM$/XWDNIXKJ1%3']UI
MY4@>\_!NSSNPM@M@-9"4Y<F/MBF53+&:D!RGY80<W/N0%OR#1EBIP>= 0=@R
MZ2AFVMD5P7%4=C?4F\'5Y3"0=57\FA.^3I>+<Z)JR_G3=ZE;?E,>>S[!MO/O
MW_7DX+X0?2#.>21BBUW-S20+.^&Q=BM'RBKQ1&659,.YCT)D$M*96H6?25C;
MICS3&'B\\CV/Z!4CGG[XJK0BMQ/*)KLQ58I-F2!?H8N+D(Z6Z=,>MM13(E0'
MXPT'"9R1B</O<\;MQ#K&G8S:D")%.6I9_#-E!P)&GXEC[1NJ;NETZZ$V]GL_
M4V[R4<91I$0G)>JM!FEQ4L9OSOHW\5$^$QU5G*N,( R1:D$H26UD&=4_ LC?
MB*DN8FUWI%3[6/3Y!E&7>'<M4&T0#GHKG$6+]#A0F 0_G@6/)7LM)R^Y;T@E
MJO0UV9/>&0W&Z6&9&J2\-NCU9'DXS(\J>^M<*;7@FLV+(<2>KW!J4K$0]6NA
MQ\-L@NP9 QW'&V^,A381-**7 *NTKED#T2)O+8K*O>=[M&RT=.+'@\^Q.(.6
MB4:CI\?264P1^T0SO0D8[Y<&4VS1AY2*65QM/RF4#"/F_A]\6>____[7[W+F
M?P-02P,$%     @ DH)U6-CN\Z5]'P  T,X  !D   !A<FUP+3(P,C,Q,C,Q
M>&5X,3!D,C@N:'1M[5UY<]M&EO\JO9K-#%E%\9+MZ/"X2I:5C*K&L4I6-C6U
MM7\T@2;9,0A@<(AB/OV^H[O1 $F)U,06;3.5V"$)-/IXQ^^=>/U?AX>7\53&
M@0K%/V[?_U.$25#.5%R((%.R@&_GNIB*VR1-92S>JRS3423>9CJ<*"$&_>[+
M[F X[/8/#]^\AK$NS$U)?"J.>L-!;]@?OA#]EZ=')Z?]@;A^+UJ_WEZTZ>IW
M'RYN_W5]R8^]_O7M/Z\NQ,%AK_?;T46O]^[V'?_PH@OWW68RSG6ADUA&O=[E
M+P?B8%H4Z6FO-Y_/N_.C;I)->K<WO6DQBU[THB3)53<LPH,WK_$;^%/)\,WK
MF2JD"*8RRU7Q]X-?;W\Z/(8K"EU$ZLWKGOV;KQTEX>+-ZU#?B;Q81.KO!S.9
M371\6"3IZ5$_+<[@SA[\W+CF_G"NPV)Z.NCW?SA+91CJ>'(8J7%Q^K)[?%Q]
ME>G)U'V7\-).,Q7)0M\I'-L;-8B4S$Y'23$]:SY@U9VIO6^<Q,7A6,YTM#C]
MVZV>J5S\HN;B)IG)^&\=_@;^SE6FQW\[HZMS_8>"H6%YA;HO#F6D)S XSO6,
MUW]JECZJ/81O&\)/]'&N:'6C) KAVLO[J1[I FEE>/RZ-X)]2[_0+/'J-1.]
MTSG,*M+%XG2JPU#%</U?_W(\[!^=O>[AM=_W- .0 "KSYBGPOR'__<B<X5<]
MFX@\"_Y^(+-9>@@RX&@ _]ZK^T$_'![W^X/N[^GD0,@(^/#G3*93'1S8T4*=
MIY%<G.HXTK$Z'$5)\.ELRB3UXZ![= */,#PP?-$]&1A>_)*;\>@&G&<S";+F
M&F3-3 :J+'0@H[PCKN*@NV-3??&R?R1^CE0<)$J<WZFX5.(92.OEAJ3U7F8Z
MEB)4D;A1BXZX.!<G_>')\,^?<F."_6Y_LSD^%\O^7N:%'B^V(M-R C>)HWY'
M((]^WG/?>GY?T4:^ PTM;C1BB_!TMR:W.[M(;/2B>[0AI_^FA,R42 ']Y( H
MBT0$23S6V4PD92:2\5CAGT+-TBA9$&(EI/J0Z!6M8JH$KG[8=ZLOU\R UA*J
M(,DD8JS#((F2[/0O??IGZ5?45:=E'*H,_V_I9WK$:9Y$&B'113(#-+UXW2L?
MV0.:ZN"L+70L<.H6\.'"_T<'2EQG*M=PJ 5(PB1+\7$*_B\NLB2*5-81"O8I
M0&@H/JJT4+,1[-I+P^X[LAN7;HKO8/:;;TH'K S:%5 GLUP J!?C) ,2H,W2
MN8A4 3\).<F4(@+9D06?VPEMOM;/@!J^5OU&7^D8B?[TZ-6JA0S7+&0ELO2>
M@'9:;?B^@YKTH"6[YRFK<E82TT2<@)B*5ME-@RX;2[RE6QA<UT9(T.T/4E=7
MG.<;RI%%4H)\!=-_I 1<FR9@CX\BA1PG8,D23F!"S#@&>!8'6D9"CL=29SG*
M*OS!"#TAX[ :+5/PK$*$.@,1$"U0RM.U4ZW&XO)>!24)A@_C,<PR:PS5%?^"
M<8B]\<90W24PZP6JAW&)4RUS..<\%P6<!CU7@D"(28#"]73A/,D^T2)JXU[>
M!R M19D:"9-F&BZ99QKO1SV4HS@QLWF;@-:W'][12I+E9>^([*');B-CW5'%
M"1!'6&9XT+1U3<WKK;8C6KHM9$"[2!2BXP+^$[@3"5SHW]W!*UH:;E#Q1$Y4
MIR('^ %8T7SJB-H [G0E*@\01Z(UGRKZ"6Z#V8JTS/(2H ,>;PJD%&N9 ?V%
M=Q(F,U%MF+$LQ QY!X8&50&00O%::($A$!_P-1*.(WD4?/0E_.O.EM<"5 @/
M8K<9_(AH)=(!D0F-KO+EC=K+]>].K@^?*M<_R@CH=Q.I7B$J27)H"?IUF,!'
M@*Q%3L,ZX9Y*C7*2B%3&<0E;^ ?P$"D$&.J_AR?]#D@A8*A,+-#L,2+2$#12
MS.#'LQPX9E+"P##> G6("&$ YJ6\'/T.TT,1+-,T2^Y@^%"%98#BRK+;OTO@
M>G8^3V'Y('1R$O=9<[Z9NM-JCER>)3.6]*A$\._1HI+/*$F*')AREJHX)\F(
M'V8HT5DWS.0"QY,A$B2,9R W"$X% BD'OK;(VQ/Z#XWZ67E[S\P[P<Q'3V7F
MMTE<YIOP\K\\X*5@!PAU 84#ZZ$V-#R*[#C&6<8 YD8X-C$W!F) /P*:NF,+
M"*C7*BW_CH0X$@1&CD/CD_)"CB*=3V$(GXT>IGCB(^1H@)*A@5B&:\TT"R #
ML-.69TM+U#$H5QE%Q(@@ O"&1!SU?\!Y-R56!]W'TZ2<L$*5LZ3D!=+BI 4F
MO'.A@NDBN3"F \C0W#20E*%"2Q*H;ILU\PG-T(^&DV8DX :PFUU,,S?32,*U
M(4@;(TK&(%Q@,B1,$:K,ISJ8\K:@Q,R,3 9YE&0 \NP)>;0 ^$B1M.>[ZEN^
MM-> HVB3.B*?2D_H\WDAQ< D1@IN4N*]S& N@Y=VKF:2493,+>"GK^!>GK8N
M! 6C5+[AP<,WZ!$&/"; 9/=TPRP)-:!^WNYEX6[$\ZY(YJ?(P)2"8B<O'Y7F
M)O9(<<3^EY;N?[;.X:@I_SG-[%@C&7R: (_$8</:\:*?]1],2 B?3)K"?.[;
MW8);BF3&P5I_ SGH:K[QX[#-"&\*-'DX CC_Z5".03*<RF@N%[E1-L?'W>&+
M'\Y&Q),F*-MO1&Z_H7AP@W8W<^+N, KYNF''BZ?"CDO U6 IG\_)"["1?RA/
M4&&"H,[0T XD>WU\#5!WX-9]19,,C&W0AX!4DI2D,'DJ5IH,P_[@E3 SO(I1
M*^"8UQ'<NR/>$YS+%EY[T%5I"0H40<M+-IM Y6:JZ1QR.X :"K8H+X#Z=F7-
M'U)V)F[LJA:W,&^^RR",.W1]@)V7L>H.DC@D.05T07",H!U\6^BX3$ITY6=W
MZ)6TWD #HD#E,R@TF$+'@%*C"(%>;LW0L<YRC ,P\@#ZR7*9Z6K'0V/'$EWR
M5-4]0!"=DY<O4/;"V@* D&EPJ=&7E7T")',GHU)M=(X\L]J#R9,5P(:'A(2<
M5XAHG6QD^U@/$%6A#KS";:);&M[<L<_DV?/#XJ3 A>%=YOLJ)&+ )/FG$&/2
MYV*N%)T*W0-C?PEOU5Z7/(\N>?ED$U;%:@P@^S^Q8E.9 6WJ%)G#(/J1&188
M+03] 9\R,@GEG=01:9^F;940U,]5C$YZ98,&>6<=EYDG"#@DX)X5IJ[S8E/,
M('>NH1G:D*L\37JU#ZSA.]JSSS?(/J^>RC[GQ>%OR!&7+A"R"2/=^OH0-8%%
M"!+&A^&,%K:.B P@''$ 8#6,H"A- 1*R\VL@C&B<W1_(B_B+%]]A>P)TS52G
MZ!PFMH.]ZS!3H=-"HR^FX.@*,!OK'.:@YC6!+/.]=_1;9(8?G\H,MX;R-@Q;
M_TI.O+BB6./_:<0EZZ9(B)"'W%Q3>4=1;-A %79<1!HX0X$&X!\Z+.81AB44
M?6;8%=KX+G""YTD#?HGA_HA4"#^T'NA#^L>_ ,_E.L1 9!=L'.:S.QM,?G Q
M*X*LF9J '1=A$-1@P$S)'"$A^A'S,ICZ8W9J\V&$F<K%<BB(M%X09!@['0&_
MENB)# 'Q&F=<F5+LAJ!AY=:T +?V1)J;3-/(&(XV&D0WR_M:?&=7#)YSL_0/
M@ HF+/9V)%%G+]:>1ZP=/SED"[R=H3[<%",[N\^!9)N;DMNA*H <*D"6>F1C
ME0 '/JJ 1>ANG?8.T^F/P\]-ITL;\7E(U7QU\$96(HC_>I#L:CH(DW9JEI7%
M@_E*9818[@*QG&A1]&S,H3,5)7-V-A#6+*8 4L-2N92K4$G&@["YDNF@7>4
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M%/#PN+.2DF$<VA&XB>>29FJFRQF<6LZN(Y-H9,ZP\J"<N=8'^B'G+J]7%R#
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M!^M3,Z^:[^SI7G5<./H74$L#!!0    ( )*"=5AF>+39W @  (,L   8
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M7PDZ^V8C !_!FICA9125"A%02Z<;6LVD-E".Y\O0EHZ@H=]+R,;0]/X7JB0
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MP!@:3X^EUK((_:ZI1.W- ;27#X\JA5NY*STJP)U$WZ/Z'Y7'9ZG8K_+<IXK
M1RY<G@D4S\'&-R>*8P-;8LMU3\U;:WIV;<W3AOBG8KM+62>[+8UB[/*F2LX$
M7;L:7GIYMCK1)/  &3&7Q$[SW,;SE==VS=#*6[OU-X(EF3*G3O8DU4R%Y%IR
MVL#\VUZW=YM+ZB'/OD.L7S3:-Y<'_P)02P,$%     @ DH)U6!1OY SO!@
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MTD.P81"X4+&D+#JW1CY++$F%;8OW_ 4!/ACC"O$=9\X%8+BU K*K'08+,X(
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MX3G<*[CG<&F'"E[^-N 0'B$=W(\+'SMRMP4@2T\9M2"'@],5V@;CTU%'G?Q
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MMD-:%;8CHNIN=U6SH9CB5CQT-8[1L>7PWTX'E$KH OY!726J9V02N81;CIG
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MQ#XFWH(_XR)-7O\O4$L! A0#%     @ D8)U6'!#K91*%   (-0  !$
M         ( !     &%R;7 M,C R,S$R,S$N>'-D4$L! A0#%     @ D8)U
M6"Z] EH@$@   0@! !4              ( !>10  &%R;7 M,C R,S$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( )&"=5C_<)L'OS$  '4. P 5
M  "  <PF  !A<FUP+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "1@G58
M>;3W."1W  !<K < %0              @ &^6   87)M<"TR,#(S,3(S,5]L
M86(N>&UL4$L! A0#%     @ D8)U6+\Y.N]640  J,<% !4
M ( !%=   &%R;7 M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( )&"=5B9
MOB.R.&T# /(T'0 5              "  9XA 0!A<FUP+3(P,C,Q,C,Q>#$P
M:RYH=&U02P$"% ,4    " "1@G58+-1TB5+!  !>W   &
M@ $)CP0 87)M<"TR,#(S,3(S,7@Q,&LP,#,N:G!G4$L! A0#%     @ D8)U
M6(U(Y,\2T@  &/(  !@              ( !D5 % &%R;7 M,C R,S$R,S%X
M,3!K,# T+FIP9U!+ 0(4 Q0    ( )*"=5BEB"'S72H! &<Q 0 8
M      "  =DB!@!A<FUP+3(P,C,Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4
M" "2@G58(53L8UT'  #R!P  &               @ %L30< 87)M<"TR,#(S
M,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @ DH)U6(+N2HQ4!@  YP8  !@
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M,2YJ<&=02P$"% ,4    " "2@G58V.[SI7T?  #0S@  &0
M@ &1I @ 87)M<"TR,#(S,3(S,7AE>#$P9#(X+FAT;5!+ 0(4 Q0    ( )*"
M=5@'4C8 .@0  *D<   8              "  47$" !A<FUP+3(P,C,Q,C,Q
M>&5X,C%D,2YH=&U02P$"% ,4    " "2@G58P*290(D%   #'0  &
M        @ &UR @ 87)M<"TR,#(S,3(S,7AE>#(S9#$N:'1M4$L! A0#%
M  @ DH)U6&9XM-G<"   @RP  !@              ( !=,X( &%R;7 M,C R
M,S$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( )*"=5C$WWK-_P@  #LO   8
M              "  8;7" !A<FUP+3(P,C,Q,C,Q>&5X,S%D,BYH=&U02P$"
M% ,4    " "2@G586C$V#8$&  ".'0  &               @ &[X @ 87)M
M<"TR,#(S,3(S,7AE>#,R9#$N:'1M4$L! A0#%     @ DH)U6!1OY SO!@
MNB$  !@              ( !<N<( &%R;7 M,C R,S$R,S%X97@S,F0R+FAT
M;5!+ 0(4 Q0    ( )*"=5BA-*)*4@L  .LY   7              "  9?N
M" !A<FUP+3(P,C,Q,C,Q>&5X-&0Y+FAT;5!+ 0(4 Q0    ( )*"=5B_VK5U
MK1@  !Z=   6              "  1[Z" !A<FUP+3(P,C,Q,C,Q>&5X.3<N
9:'1M4$L%!@     8 !@ > 8  /\2"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>armp-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:armp="http://www.armatapharma.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="armp-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_ftqcXLn_pEaX9uiZCz_1XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zg5utsGBa0WpBXEonilgjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ygs2ZPk4X0u6vTMLhKW83w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wxAcBPHiMEauon7dJRUqsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pnWhyf4Eu02IKHMaDDg0eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JojKduK3ZEKIWxJbgigbMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DWvEXjElOkq1isfN-8Jmcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OMmauNLPakaOiKtpaNXVNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_No_HAmgL8EWAhkjjyjrUKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_i7XUFu_B10mLUKIJzKfMTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_uL_pp_97UEyeShgihirvbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OUfmlLp-ykK4CLqXmY3zwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_ZFDHBJzLP0GHlHUMt2FQew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_q0GtuKNJvE-SBmuEJbJm6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_1q8OCMCB00i-LLEH5pkdLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Cx9LlceetkeHRu-h_tXn_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:C3jStockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_sL46fLP8U0Cmr7LIx9jlSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ylEWFQLG5kiObFZVsEjhXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_NeQe2I2uKUmdVatAsYayIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_oTLYGAZfJ0aCfMIzYcDvAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_15_2020_To_6_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_MA9PVOA_T0GwtfbjiWZ8PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_v4Q6NyrSfkq9XoHpzL1dIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_3nc2z43Z7UGKrOWYMeqg2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_REZg-uX-1EKwp-ERlgSV_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_wkZ_l3MDG06ZzDCA_d-g9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A6LMOqmIk0W80NtUZ42iYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7rH9B56et06bczua6JeANw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xqoolKPjOkiiQNt83POWzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_-vi_PXcqgkGHr5XNE2CtDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_fGX9O5gmiU6OnmLCkIvOIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_1GHmaB3J8k2Q9CUoft7lLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n_Dh4or6E0Sk6Dr2xnxPkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_sBfL2nm_uUqs1c4xDma_2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_GYmMI98-LUq4vo-3aWzwDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Te5w4AY0_02NlOunnmW1LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_BOYj4BFoD02NQ0BXyjD2Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ptpXGjY7OUuRjoPo1n6BLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2022-11-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WMYo7GLLwEe8FdOQJ86O9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vc4GxSB8DkissaxivoExGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsInc.Member_BsIuyO6JukO_7P1mhHHqVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">armp:ArmataPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_hIBa8orrkkC3OY4OCziUrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_VjefCaiPsUS7e-BdlXj-7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_sJyIDh6BPkGLuZGEzoAROA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_W3KAPH27bUOTG34yisjgIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">armp:OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_C8m8rkPr3kO2_d83rkvc0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPostModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_4FazMg1MoUW2z0CAQf8ezg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_TrUOd3F28EaQGoWWyXJpuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:CreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_dpQ0qLj7T0mpc0O2hZcCzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_d5V1utBQS0W089AQBKdTBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_sJ5c5RHAEEuMXqt3TUVkIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_XmFAWm3wPEyeDD2bMVjmxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_pXWFLLYcXEmSfXZV4q_7FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_0FkAKCIhMkeJG_58ABDppQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_tyr5b_wy9ECTpratVa4vhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_RXIGKVqz6EWLhEi53nl4sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_w_tgP8EIkkGCdbFSjG9OBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_Zq7tR4QDd0qlIGHQ77DS4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_AxXerjEGLUa8RmPTJVbwoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_veV6l1wDOE6rGIRVVof-6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_pMc1sqe3X0KGAnGFAEcYPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_rcx6iUYUmUmx_O6MTosjtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_FHVNbN2hzEOd40sdvSt3oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_EWq8FVfJaUe4RYQsqoDOaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:SharesIssuableUponConversionOfConvertibleLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6Zjp426i-0Ws_0siDNehrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_om6vLPiiz0SKnHyQ-isXPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_SYddo8Ixd0SHaimuYPVT7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_nxls9YDyCkOu7B6yakefXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">armp:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WsPyfLbv_Uq8yEsOaJ4xVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6DKSiFkyFkW5utHfv7wgDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_QB0XCwT_Y0acqtRcKca_zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbcT0OlsRk2u09atbDRY2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_J8WtBYCv8U2tTw_Q8rPekw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_15_2024_x3SUHrPdAUmw1TrhlAZLHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_79MM9fi5r0mpadFpZPg7sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_BXtfSrwb30eZ5SWw-b7Zuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_5dm2L74wiEGYYudTedh7mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_4KHIn5trmUGr81rnUbSvxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_kwVoHQWl5EakS1pp8Dn91w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_doi9Uq0Yh0K8BJ8ETe-s1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_l7DZ4uAjHkSVG38MOoqUEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_FHhuhYDYgkSEqnz0dDB17g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_8VpuTm72C0OqZUC8eh9aAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QOYAQImRME-BHccqHOTQxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-13</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_lPXHo7biDEeQ7_vk8pbcAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_MuuXgJmTa0iJw2pEu82wXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_mj_DWLuDI0Cq6OS1KhCggw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-29</startDate>
            <endDate>2022-09-29</endDate>
        </period>
    </context>
    <context id="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_O-jDsojMjkyI7AvWBhYrOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPostModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">armp:ConvertibleLoanPreModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_iZsH0I5d9UyGDhfUVO7qAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_eys6RJJzYEKEN14qoaYnug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_5gtvl7giZEGwZQOlYfq5Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QO_xn3VwYkyovdqWx605rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wizMKQKiNEejMmObIFsIeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_LCqVjfMIO06J26dfzj6dGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Fq3iw-UGaEOhlQJp0l-z4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_gq2pn8IK_0adzHKv0TJgmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_azF0LYLH0Eq4EiRxHIMZRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_HNJuosHgFUer-rys1t2UBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_TJiIyKEV50aTZhkCduAAZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_qhslJqPSVkGxmdvKQT37fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">armp:CommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pukUqhbV7Ei-VqpNu2EWAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_4ewXEPeSJk66n83-o6k-PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TbUu3jFyVUu5rQXxMkwPXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_Vx583tTlMEyE357MszS1Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mHtBiNhPKE6hrpyOdzp9qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_hUTioPDLnkObuSOBkhrCew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tsvjujuR6UaiVETAvUn3jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_Ge-QKxFKqUWwu7oL5XxJ8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_83RZzW5ygkaAS8MPk5N2xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">armp:ProbabilitiesOfSettlementScenariosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_czlMXp6LS0CZBIy4EFMggg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_3pWA20zXBEiKjqY55V5Qxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Wv6oSPAXP0CJ0UiTo6AKQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_yQKRGpMabkGpnWs-0mIn_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-13</instant>
        </period>
    </context>
    <context id="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_QVyakBDhtUmt0Ago8wBrDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-13</startDate>
            <endDate>2020-03-13</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg">
        <measure>armp:Y</measure>
    </unit>
    <unit id="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg">
        <measure>armp:item</measure>
    </unit>
    <unit id="Unit_Standard_tranche_1k3oA3frkU6EqwnuCcyDiw">
        <measure>armp:tranche</measure>
    </unit>
    <unit id="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      id="Hidden_ul9qV3wcdUCnzSphGpbNgw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      id="Hidden_es_KXy1iHU6d1i8SNShtAg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      id="Hidden_teD6KMncE0i22w8XvQgfrQ">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Hidden_awY-qMH9ckyLpRHsEO2jAA"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36144706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Hidden_nRF0d8lHNEuOXDFsaUyGeg"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36122932</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Hidden_H4ZU_MC1IUm4pyKZsAUYAw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Hidden_5FzrqHRRckSxwzPY14KzNA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Hidden_bbzUoNAPc0SY4-z24H0urw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Hidden_ajDNRs2kdUyVeVQJ-vTaAw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:UnrecognizedTaxBenefits>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_ZYoQRtcKfkyCr07DiomEhA_2_1">0000921114</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_j81Yf9iRy0ezxDq0RZejFA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc__zZJQDv_4USQGfBuetlIcg_6_1">false</dei:AmendmentFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_sL46fLP8U0Cmr7LIx9jlSg"
      id="Hidden_1t18bwPO80umxL4QF2kQLg">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_0Mi1m77GB063RpBPwhB-Cw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_jrMmLRfNHUSh_ozg0Q0aSw_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_S8wQ_5hqMEKwG8RLjuzbqg">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_ELsvI0OkU0eKBBodSCDBSw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_2hIgdxn8UUmtonNkUqOfnw">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_XSUn2DJUlEudPnQ4dJAMeA_3_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_wDxR9oXZXEuM37HqnnP9TA">001-37544</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_xPkdkdeE20GNNupSWU7F6g">ARMATA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_ftKtrFtqlE2n7VeX6HTsVA_0_0">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_PGqROT7gy0W3M6wObbFIHw_0_2">91-1549568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_ao7IULcQmkenafuP5sIrfw">5005 McConnell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_AHVvza2nOUeIB2TidociLg">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_D6xdyTsU3UOwRS340U6wCg">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_sC8JVhRVXUSMZMzqO41beQ">90066</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_ZGpf9pld5Eu6cyXFyoGJlQ">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_t1JKX5QHLEaTkW2-4PcSVg">665-2928</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_ttaDihYj_UOy13df_9ZItA">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_whw7u4grk06lRHZz305I1g_1_2">ARMP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc__wcVeWGvvUmPrph7mxXQgw_1_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_O-3yJtp3BEuDAtRNQaDRJQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_9ai0PTex0UWNKVQak8NFuA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_xWXQnaTH7U6fEzc-kfRsVw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_42miyy3aCEGZ6Q1hO0jQaQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_xmsXoCMri0Gkj378lO_MAQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_Jt7hKuWldUmlGzgI_zsHkw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_w1aUh5le2kKexNCsjkCzAw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_n6PUqm0l6EKJaaRUEFfsWg">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_Ych_fuQhKUCymx2WNdO3Vg">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_dBBdK9QrckeahzXgvXZBVw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_J8WtBYCv8U2tTw_Q8rPekw"
      decimals="-5"
      id="Narr_UQ4BW9kuJ0uCi2RTDlXJPA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_15_2024_x3SUHrPdAUmw1TrhlAZLHg"
      decimals="INF"
      id="Narr_u-lKavz7gEeS9XOwNk5qUw"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36148539</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_S7O8UBKuJUm1wYZFcD_KYQ">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_Q1rp7hCmwEq2gB3JHSyJ6g">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Narr_ILKMJoKr4ku-H1HpBYzwtw">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_HwJolcMe4kC95OpuPE-EIA_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">13523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_1guyLgwUbEK93D_fifA0rQ_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">14852000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_MJ2kK-n4OE-jTf8tDPthvg_6_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2265000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_QNrhSnbaKUCScPYclix7Lg_6_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3664000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_RDY0wp7Tb0CRWpVMlIbHbg_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3363000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_PjJD-89i70eCFFOaXdgKgw_7_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">8531000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_R5aeKtq9uEK_jZN7ZRBSbA_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">19151000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_9LqzIeDCmECJopjX_4tThw_8_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">27047000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_mI30TSs0qEmLQHOddPvgOA_9_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5720000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_3ZzJLbNRAEKEOXGN75Mq-w_9_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5960000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_OYm-VQnhUkqfcll4SQchFw_10_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12559000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_jD_4EyKJ90SUFbiBrgUxdA_10_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3617000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_KSHz9m2EVUiU_ukO7hPAow_11_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">44717000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_HYYkNRIykkyxQYZ2dQKX0A_11_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">43035000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_J2ADdtSVNESPP6VEM8EOWw_12_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_sCT54DBGI0evn7Hj5OgUFQ_12_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_EBdGj06VWUai_OWJfqgNNg_13_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3490000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_tRr6PwvYL0CWO5ieM4uhNA_13_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3490000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_jsLS4Z1IL0eg_HQtYbFjgA_14_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2470000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_w9eFLGJJwE2J-JWPJ4jWng_14_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2429000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_p_G9HI7dE0Oq36H1Pn4rXQ_15_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">98363000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_p00RJ6wdyE2a_Ug25jnzWw_15_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">95834000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc__1P0PCGVME6QnFnrVjTIdQ_19_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5689000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_6-NGHdo310e8y_Z_0oo6UA_19_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">6034000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_uKpy37Pd3k6VuqU6T4GfIQ_20_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">768000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_c2VV8jB9B0SEdpncFSkGZw_20_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1828000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_HeIouCtNUk2w_8Z9blrH7w_21_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">9481000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_WpR_cLZT10uZwAiefZgDNA_21_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">17011000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_yCqioTM5BUmHLADsrzfdcg_22_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">523000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_aAWqNydpo06ztfoCUUXNOQ_23_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">16461000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_3kQDxd8JvUO_rTEAL78VfA_23_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">24873000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_IrnblRI1NkKp6eL1VB9H1Q_24_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">28583000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_qz7HhLetm02lDlJAv-veoQ_24_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">31804000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_r_xL0yl1IUW0C-h-IKLZ7g_25_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">58633000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_gPjQJw2tyk-ZuWhuEd9sUQ_26_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">23674000</us-gaap:SecuredLongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_KLKw88lnzUS-Me_wZGuFpw_27_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_hEo75vfPGk-Ttmvp6Fvxiw_27_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_yFFMbkWDy0uOEW1Xc0XVmQ_28_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">130428000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_r5ih07YY3UiJ2nw08XakOw_28_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">59754000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Narr_5ee0RZ4FvkShTfAb33a2UQ"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Narr_bU2je1C1LE2MWDP8CV89Xw"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Narr_QMMj2u40PkCc5uMaMmvF6Q"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Narr_ZPdagx63akyLhaWCYF-rew"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Narr_lcUOkxT_Rka8eLtd42bDNQ"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36122932</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Narr_GscygrkL0k6jHyljJvvkWQ"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36122932</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Narr_3LaYvntUV0-hd1zZ11j38Q"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36144706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Narr_MMyB1hqmZ0GWCVmToBdhoQ"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36144706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_k5HOoJbbvkmzuGtP6YrMDw_32_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">361000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc__y1a4qPexU6E7L_i1zEUgA_32_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">361000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_QhUQ-x1NDki52DJ-7oL9MQ_33_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">276393000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_zsvwN6zEB0mq7_NnMIwHrQ_33_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">275493000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_5QVwu-3vvUG0NQJh7NasBQ_34_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-308819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_iCOtdQWQFE2HxMfay4e_TQ_34_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-239774000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_i0JyosD9J0KL-rVoPA1b1A_35_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-32065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_NQjxGggYdkSWeqFt3HREqQ_35_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">36080000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ewvTBi5jpUWiPFCAnBrjCQ_36_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">98363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_obY7LVToz0-jOcNEzs4tnQ_36_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">95834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_kErPigWsr0GY9VTyq_3SsQ_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">4529000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_q4NmdBToHk6W65EQz_fm2A_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5508000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_n2vRtSotEk6RueR0ihkgCg_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">33770000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_dhLwg6m-gEutbtZlPvELBg_7_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">35017000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_Iwh99PikH0a1SIn0u-ENAQ_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_jP-Bt5E0eEWEbO0XcS25gw_8_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">7437000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_zLwHR6BdqECj1WBv7ZMgLg_9_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">45419000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_6YhBgeVl6ECmOc0YBvW-2w_9_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">42454000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_4EWa8k8PK0atFNg-2nCzag_10_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-40890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_Qrgkf8UbZkyyHeFmn-ei8g_10_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36946000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_0g9OvhyVUkeSHp8igxWybA_12_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">179000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_NzfejvYxAUKSkjZD1wLDpA_12_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">29000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_NaABziuv0Eual17Cc7_pbw_13_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2626000</us-gaap:InterestExpenseDebt>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_3zXyYgrmfECRhwL06dIEZw_14_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-21845000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_omhqtJc5MUe5LaMhEHtgjw_15_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-3863000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_04V-AS5NIEWJcorHC3Qwgw_16_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-28155000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_ZqlB71iXC0uB9nYx8fsWLg_16_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_0j-B70OzE0WUtLx2skJ6AQ_17_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_dvuU2fZsz0-SoYVJnBcUiw_17_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36917000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Tc_ikhzAcZbsU2r8UF9hoUdIQ_19_3"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">-1.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Tc_ikhzAcZbsU2r8UF9hoUdIQ_19_3_2"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="2"
      id="Tc_pzJPjzFnAUqsZafVqDkM6Q_19_6"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="2"
      id="Tc_pzJPjzFnAUqsZafVqDkM6Q_19_6_2"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_1Y4Irtaye06BF2_u_CN8nQ_20_3"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36075555</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Tc_1Y4Irtaye06BF2_u_CN8nQ_20_3_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36075555</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Tc_M3vajBIUTk6M1GbMnqJazA_20_6"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">34294124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="INF"
      id="Tc_M3vajBIUTk6M1GbMnqJazA_20_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">34294124</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ"
      decimals="INF"
      id="Tc_8YaGWH-6YES3TIYeN1jWGQ_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">27112299</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_y2syrQ7dvUmMfwdB4Ok8hQ"
      decimals="-3"
      id="Tc_HbspwTHot0yYZGfLI-ncFA_6_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DWvEXjElOkq1isfN-8Jmcw"
      decimals="-3"
      id="Tc_LVOxuVOA9k-L3XJFHYb4Mg_6_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">227983000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JojKduK3ZEKIWxJbgigbMw"
      decimals="-3"
      id="Tc_5IYMloMuU0SGRR4HYEAQSQ_6_11"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-202857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw"
      decimals="-3"
      id="Tc_jTMhnvK-FEKzxlLCVpi6fg_6_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">25397000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"
      decimals="INF"
      id="Tc_Bu6NiW9FpkuB74Fe42MeIg_7_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"
      decimals="-3"
      id="Tc_hidDlrU-4kG5yaFF6d7DZA_7_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">90000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ"
      decimals="-3"
      id="Tc_sQxrdgFbTU6aeHE98s3x3w_7_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">44301000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_sXIN8F-je0WKCGykmvhbdw_7_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">44391000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"
      decimals="INF"
      id="Tc_ulFG2lXrNkORXDLVEJuXnA_8_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">5511</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ"
      decimals="-3"
      id="Tc_7MsBDwV8OkyYK3xRgv28-g_8_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">21000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_t7XfR_qUhkS-xYn8va9PJA_8_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">21000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"
      decimals="INF"
      id="Tc_m1rTOAkXlU6CRXafab8b0Q_9_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">369</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fAJ8ZrWMs0Sjdfj1vsty8g"
      decimals="INF"
      id="Tc_8qG-ATfQNEeHw0f_uaiWMg_10_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">38287</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ"
      decimals="-3"
      id="Tc_XQHQ4KzOSUe9zh11KHnwvA_10_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">125000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_6FSqAb6pVE6B8SuRWCjsJw_10_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">125000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rIqBdklT2U6bhdRf6L_DAQ"
      decimals="-3"
      id="Tc_7XjsNR0PbUSwv4ywpAXApg_11_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_s1fS0AF9RUSb1CVKh172ng_11_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3105000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_vc4GxSB8DkissaxivoExGQ"
      decimals="-3"
      id="Tc_36gsRjvdtkSV2M5byWBg2A_12_11"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36917000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_82qH6W3gLk6Y8-4XFPvg8w_12_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36917000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g"
      decimals="INF"
      id="Tc_HpFM7r_rV0m_oF2955bcSw_13_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36144706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uiyD2qpxAUWos8skjfYq4g"
      decimals="-3"
      id="Tc_m2jZFKh4Bki_E-snbi9zlQ_13_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pnWhyf4Eu02IKHMaDDg0eg"
      decimals="-3"
      id="Tc_mHdHfelzxUaOOlXMFEW3qQ_13_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">275493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wxAcBPHiMEauon7dJRUqsA"
      decimals="-3"
      id="Tc_ApkrQuHBoEaw1JRexENq7A_13_11"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-239774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc__x5v_fHcF0-YWaC-QgULxw_13_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">36080000</us-gaap:StockholdersEquity>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ"
      decimals="INF"
      id="Tc_xC5Z8gpVskuupHDUfOCAOA_14_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">25933</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA"
      decimals="-3"
      id="Tc_JZXmuA9YUk6IhxMUUNleTw_14_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">43000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_gkviz6yiBEa3SAXFPW_hIQ_14_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">43000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ"
      decimals="INF"
      id="Tc_ORr_cfWDUkiAuoosWzyrNw_15_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">27341</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ"
      decimals="INF"
      id="Tc_siOgJjO-gEOOBPN_TCqH0Q_16_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA"
      decimals="-3"
      id="Tc_2u7zxwSnu0igooU_U17w1w_16_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_UX3QbH0wzEee09FgmBv3og_16_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fcIBUDgjWUCPAkPigUaMUQ"
      decimals="INF"
      id="Tc_v-bvUdah2UK8eO-t8ikMCg_17_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">30000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kf7Hq01UHUiel62bZwrlSA"
      decimals="-3"
      id="Tc_adbrhKGO2EKX6F3XbES2jg_18_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_V9nxxsIXTUe0xHiW2dcC7Q_18_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WMYo7GLLwEe8FdOQJ86O9A"
      decimals="-3"
      id="Tc_Dbx97IZhUUe_9KQGt_aLTg_19_11"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_ztBOi0ZRBkCZumyyxaAZbA_19_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-69045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg"
      decimals="INF"
      id="Tc_T9fMsaJZx0q1t4k687pIZA_20_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">36122932</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vm4fIaNPW0CwN1EJmqmANg"
      decimals="-3"
      id="Tc_QRv2kKoNcEiKYBUQnw2t0w_20_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ygs2ZPk4X0u6vTMLhKW83w"
      decimals="-3"
      id="Tc_Q4DKz-9cIUSrPiQVLTht3g_20_8"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">276393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zg5utsGBa0WpBXEonilgjQ"
      decimals="-3"
      id="Tc_SUN0NAlQAECL_Ut9x6UR8A_20_11"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-308819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_HEJPaaMswkussmk01ZAe1A_20_14"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-32065000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_aNnkUMzjd0uIW_RNq9NB9w_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-69045000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_I924XYNp2kmq_C2Y9R0iTg_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36917000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_xT_0YYMlbUqbjummqZW4nA_6_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">972000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_h7NBVp9NDUm7xXrNH5STkQ_6_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">892000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_ksAvlh9hwE66YEmR6XN2PQ_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">938000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_88G3I7-suEm7g6otEGbmtw_7_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3105000</us-gaap:ShareBasedCompensation>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_CfHZc2OUyU6xbhucf3nlFw_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">21845000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_czPYShq-uU6u5F9IgvseCw_9_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2573000</us-gaap:OtherNoncashExpense>
    <armp:NoncashInterestIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_jWWOEXo4-Uavi2cKk4pUpg_10_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">22000</armp:NoncashInterestIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_XGDSNkiM_E6z6DhS12m3KQ_11_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-3863000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_gbMxU_pYSkSHWInZoJXCmw_12_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-1018000</armp:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_MaPepDEVj0CTqK15WYkaDg_13_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-81000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_GdV25Ri7bkWqS0hxYdpYSw_15_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-4826000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_1QqztPN-W0yF9FrErAV43Q_15_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">7662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_aD9MvyY-10OMy4QGZMqXKA_16_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">39000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_u2olmD4iukymydwnHp4x6g_16_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3665000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_MXWfU-_pG0qhkPG9TI_23g_17_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-1060000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_iOB-Iin4_kOAogaf6HFXpw_17_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">793000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_4pKTl-ji-ku6hxvEoL4Q9A_18_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-13451000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_VXn7sMCNVkeHwTo-GcSAXw_18_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3643000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_2932icMxkkaPgT2btTnihQ_19_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-47423000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_oZan2Pxhu0-phN15p8qWFw_19_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-32481000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_n-rBRyRin0GYNZGothVvVw_21_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">8144000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_M5x0caPGNk2IjBYTgUDTUg_21_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_IO6J3CEEEk6qb3OyyloCew_22_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">10000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_jpuunE7H_0exAeL30Kpznw_23_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-8134000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_tnbpim781EO6kGR9EF1a0w_23_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-2211000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_MCIenzzxeEqMKpKIcNraAw_25_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">29101000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_Qby56i_fCEu8E-pqDSsNCA_26_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">24925000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_ADt_QaL96UKMwltpkGwqUw_27_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">500000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_z-Aqbli8KUqFkupJ8WwMMw_28_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">44391000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_4rrN0q6L1kKvfTI5g_ndWw_29_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">43000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_wQyvzBBCaEySw_ggPQ-whA_30_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_pM2AQLpZ00KE9umU_0hhFQ_30_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">125000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_iDaTT3g-20KJOFtU5TUK_A_31_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">53988000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_asQU-OAL8EW8trLgWs7x5A_31_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">44016000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_tYN6DDdsEkG5f-7oUTxxSQ_32_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-1569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_TsBGJ368TU-YO6_Qu8Gq7w_32_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">9324000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_9HTepAQdoUCNd8Qz_7jsNw_33_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">20812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_V6718eDEh0iPeJL2raNGzw"
      decimals="-3"
      id="Tc_6u3dsKFlXUKglBAT6rJvyg_33_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_rKJbHAkfYk-Y9F9H7G6mPQ_34_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">19243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_7Kla8Uns0kq5cl-xBtJKSg_34_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">20812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_bl8Og0tqb0aSPhwBni-09w_36_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_BWXvE5cdVUuhCEUSr_eAGA_36_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">8669000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_Z79sOTG7n0uZymS9Bf4Drg_37_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">217000</us-gaap:ContributionOfProperty>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_fK1Pkbw-jUumc-LdKOxUaA_37_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">78000</us-gaap:ContributionOfProperty>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_gT3cngBAXEeCqBGFSbEMHA_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">13523000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_WrBiyC6bT02-utD2vSj1_w_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">14852000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_1UF43Ml_CEaVTPcYWkJI1w_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5720000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_DdawSWriz0q_l6uvZ-E3CQ_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5960000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_MkKGqpq0lkeHAOGmmb4nuQ_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">19243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_W1NWOAxB3U-rlKXZfCWxFw_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">20812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_L5IxKZ12R0Wsxj4x-PNmNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Organization and Description of the Business &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Armata Pharmaceuticals,&#160;Inc. (&#x201c;Armata&#x201d;) together with its subsidiaries (the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company focused on &lt;/span&gt;the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Armata&#x2019;s common stock, par value $0.01 per share (the &#x201c;Common Stock&#x201d;) is traded on the NYSE American exchange under the ticker symbol &#x201c;ARMP&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s principal stockholder, &lt;span style="font-family:'Times New Roman;"&gt;Innoviva Strategic Opportunities LLC (&#x201c;Innoviva SO&#x201d;), a wholly owned subsidiary of &lt;/span&gt;Innoviva Inc. (&#x201c;Innoviva&#x201d;), owns 69.4% of the Company&#x2019;s outstanding equity as of December 31, 2023. The Company also received $90.0 million in total debt financing from &lt;span style="font-family:'Times New Roman;"&gt;Innoviva SO&lt;/span&gt; during 2023 and in March 2024. Innoviva designees represent three out of eight Board of Directors seats during the year ended December 31, 2023, and cannot vote or take any action by written consent with respect to any shares of common stock held by Innoviva SO that represent, in the aggregate, more than 49.5% of the total number of shares of the Company&#x2019;s Common Stock for voting on the matters related to election or removal of the Company&#x2019;s board members or amending the bylaws of the Company to reduce the maximum number of directors or setting the number of directors who may serve on the board of the Company in accordance with the voting agreement. The voting agreement expires on the earlier of the fifth anniversary of the agreement&#x2019;s effective date, January 26, 2021, or the approval by the Food and Drug Administration (the &#x201c;FDA&#x201d;) of any of the Company&#x2019;s product candidates for marketing and commercial distribution. Innoviva SO and Innoviva are related parties of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="2"
      id="Narr_VzI-WDpzmUOnyjPxPd0PDQ"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_OwnershipAxis_armp_ArmataPharmaceuticalsInc.Member_BsIuyO6JukO_7P1mhHHqVw"
      decimals="3"
      id="Narr_XPriai903EOLPJF5e8edAg"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.694</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_3_1_2024_To_3_31_2024_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_sBfL2nm_uUqs1c4xDma_2Q"
      decimals="-5"
      id="Narr_dCCbzYbAaE-oTxGvoHrWDA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">90000000.0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw"
      decimals="-5"
      id="Narr_4pZ4S3_zn0iQ40xA2207YA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">90000000.0</us-gaap:ProceedsFromRelatedPartyDebt>
    <armp:NumberOfDirectors
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw"
      decimals="INF"
      id="Narr_MfUBRp8OMEiinZHHqWF-eQ"
      unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg">3</armp:NumberOfDirectors>
    <armp:NumberOfBoardDirectors
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_F6xmUj29g0eP0yZ3QjVcYw"
      decimals="INF"
      id="Narr_4BNVsMLvIU-JJP7WUWJTAw"
      unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg">8</armp:NumberOfBoardDirectors>
    <armp:CommonStockVotingPercentageHeldPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_InnovivaStrategicOpportunitiesLlcMember_srt_RangeAxis_srt_MinimumMember_3pWA20zXBEiKjqY55V5Qxw"
      decimals="3"
      id="Narr_iyXPyFzyJU-6Ac0Ge-fnVw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.495</armp:CommonStockVotingPercentageHeldPercentage>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_dp-fShiMP0eBXRBEZFPHiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Liquidity and Going Concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations. As of December 31, 2023, the Company had an accumulated deficit of $308.8 million. The Company expects to continue to incur substantial losses, and its transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. The existing cash and cash equivalents of $13.5 million as of December 31, 2023, together with a $35.0 million loan received from Innoviva in March 2024, will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recent Financing:&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;i style="font-family:'Times New Roman;font-style:italic;"&gt;2024 Credit Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman;"&gt;On March 4, 2024, the Company entered into a credit and security agreement (the &#x201c;2024 Credit Agreement&#x201d;) for a loan in an aggregate amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;$35.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt; million with Innoviva SO. The 2024 loan bears interest at an annual rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;14%&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt; and matures on June 4, 2025. Principal and accrued interest are payable at maturity. Repayment of the loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the loan is secured by substantially all of the assets &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;of the Company and the subsidiary guarantors&lt;/span&gt;&lt;span style="font-family:'Times New Roman;"&gt;. Concurrently with the execution of the 2024 loan, we amended certain provisions of the Convertible Loan and Credit Agreement to, among other things, conform certain terms relating to permitted indebtedness and permitted liens.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2023 Credit Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 10, 2023, the Company entered into a credit and security agreement (the &#x201c;Credit Agreement&#x201d;) for a loan in an aggregate amount of $25.0 million (the &#x201c;Loan&#x201d;) with Innoviva SO. The Loan bears interest at an annual rate of 14% and matures on January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors. See Note 8, &lt;i style="font-style:italic;"&gt;&#x201c;Long Term debt&#x201d;&lt;/i&gt;, for additional details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2023 Convertible Credit Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 10, 2023, the Company entered into a secured convertible credit and security agreement (the &#x201c;Convertible Credit Agreement&#x201d;) with Innoviva SO. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30.0 million (the &#x201c;Convertible Loan&#x201d;), which bears interest at a rate of 8.0% per annum and was scheduled to mature on January 10, 2024. Concurrently with the execution of the Credit Agreement, the Company amended certain provisions of the Convertible Credit Agreement to, among other changes, extend the term of the Convertible Loan to January 10, 2025. Repayment of the Convertible Loan is guaranteed by the Company&#x2019;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; The Convertible Credit Agreement provides for various conversion and repayment options, including the conversion of principal and accrued interest into the shares of the Company&#x2019;s Common Stock upon a Qualified Financing (as defined below) and the Company&#x2019;s option to repay the loan prior to maturity. See Note 7, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;&#x201c;Convertible debt&#x201d;&lt;/i&gt;, for additional details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While the Company believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#x2019;s ability to achieve the development and commercialization goals would be adversely affected.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-5"
      id="Narr_8NWxce0Ea0uNdlku7lfLyg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-308800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-5"
      id="Narr_Q9qL4FoZFEGfELB3LF3RSQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">13500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ"
      decimals="-5"
      id="Narr_J6LoZnvwmU-H0xXce8EnYg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">35000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ"
      decimals="-5"
      id="Narr_mhkULyAqIUy-ctHnvhuM8g"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">35000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_4_2024_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember__ZlBmQp7X0-i_vcXfFgHtQ"
      decimals="2"
      id="Narr_qeD66OwnvEuWTQPqoYpIsA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA"
      decimals="-5"
      id="Narr_oQtaqTSKUkeL3zVheLOvJA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_CreditAndSecurityAgreementMember_a_OqJId5JUewt1zUw5QNMA"
      decimals="2"
      id="Narr_6jLt2qL8N0CeY4Y694yEHg"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"
      decimals="-5"
      id="Narr_I-tnsCmT-EmD8pGs_iJ3KQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"
      decimals="3"
      id="Narr_-FyhnJzJAUibj5jsOT0RKQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_lZo5xR6ftEaEDlhWMPxviA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. The long-lived assets of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$12.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, which represents &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;98.8%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s total long-lived assets, are maintained in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;"&gt;Concentration of Credit Risks and Certain Other Risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company&#x2019;s investment policy, to a concentration limit per issuer or sector.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#x2019;s operating leases (Note 12).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;"&gt; Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, convertible debt and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Convertible debt is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;padding-top:8pt;margin:0pt 0pt 4pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2023 or 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized in-process bacteriophage development programs for &lt;/span&gt;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If and when a quantitative analysis of IPR&amp;amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#x2019;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#x2019;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December&#160;31, 2023 and 2022, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections was greater than its carrying value as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;a result of the quantitative analysis. Consequently, no impairment loss was recognized as of December 31, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) is determined based on the number of units granted and the closing price of the Company&#x2019;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Foreign Currency Translations and Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. &lt;span style="background:#ffffff;"&gt;Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the quarterly &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;average exchange rate in effect during the &lt;/span&gt;year.&#160;&lt;span style="background:#ffffff;"&gt;Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#x2019;s consolidated statement of operations. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants Revenue and Other Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether agreements are within the scope of Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) or other topics at the effective date of an agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;&lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;&#160;(&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;&lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also considers the guidance in ASC Topic 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&#160;&lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;.&#160;&lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, the Company recognized as other receivables in its consolidated balance sheets $1.5 million and $1.9 million, respectively, related to invoiced grant amounts that have not been received. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2023 and 2022, as such, the comprehensive income (loss) for these periods was equal to the net loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. &lt;/span&gt;Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.&lt;span style="background:#ffffff;"&gt; The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="color:#212529;font-style:italic;background:#ffffff;"&gt;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments&lt;/i&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;&lt;/span&gt;This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In August 2020, the FASB issued &#x200b;ASU 2020-06&#x200b;, &#x200b;&lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x200b;&#160;&lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&#160;&#x200b;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;contracts that may be settled in cash or shares impact the diluted earnings per share computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#x2019;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. This ASU requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_wDsCt_VBFk217ghwrRdpgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission for financial reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Any reference in the condensed consolidated financial statements to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_HeWgQQd_Y0SCs3pSgprThw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the convertible debt, stock-based compensation expense, accruals for research and development costs, the valuation of deferred tax assets, impairment of goodwill and intangible assets and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_n0dEE8M36EeYqJzxIdMiyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; reportable operating segment, which is the business of developing a pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating resources and evaluating financial performance. The long-lived assets of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$12.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, which represents &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;98.8%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of the Company&#x2019;s total long-lived assets, are maintained in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Narr_gOsnGYsqFUyz-mk5KNXVlQ"
      unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw"
      decimals="-5"
      id="Narr_LAmyUUOAgEWWv14sjDdXjg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12400000</us-gaap:PropertyPlantAndEquipmentNet>
    <armp:PercentageOfLongLivedAssetsInGeographicalLocation
      contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_US_tXkX4clMfE2XCNsdTfLeBw"
      decimals="3"
      id="Narr_mEEFsKnvSEiaEEHnJWaPbg"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.988</armp:PercentageOfLongLivedAssetsInGeographicalLocation>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_lIyZUHbfsEuOmYh8-hUqfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times';font-style:italic;font-weight:bold;background:#ffffff;"&gt;Concentration of Credit Risks and Certain Other Risks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. As of December 31, 2023 and 2022, cash, cash equivalents and marketable securities were invested primarily in money market funds and U.S. treasury securities through highly rated financial institutions. Investments are restricted, in accordance with the Company&#x2019;s investment policy, to a concentration limit per issuer or sector.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Other receivables represents amounts due from Medical Technology Enterprise Consortium (Note 13) and reimbursement for tenant improvements (Note 12).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_nXZCqhPWlU6hb5hAL6tjnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist primarily of deposits with commercial banks and financial institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_w1Ultbpcs0WQkmEZ-BKuAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company defines restricted cash as cash and cash equivalents that cannot be withdrawn or used for general operating activities. The restricted cash consists of two irrevocable letters of credit with financial institutions related to the Company&#x2019;s operating leases (Note 12).&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Narr_mUjp_UPVPkOot9xi17Y2KA"
      unitRef="Unit_Standard_item_ut51679BVkKDEZU2hHrXGg">2</armp:NumberOfStandbyLettersOfCreditIncludedInRestrictedCash>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_YTy8lB1a3k6c4kBMT61S6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;"&gt; Financial instruments include cash equivalents, prepaid expenses and other receivables, restricted cash, accounts payable and accrued liabilities, accrued compensation and other current liabilities, convertible debt and long-term debt. The carrying amounts of the above assets and liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. Convertible debt is accounted at fair value. Long-term debt was accounted at fair value at inception and its subsequent fair value is not significantly different from its amortized basis, as effective interest rate is considered at market.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <armp:PropertyAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_YIRC0XMeq0KRLZ25s0_Vcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</armp:PropertyAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_lW6jZ9UquEKGNZUEVUTOlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:0pt 0pt 4pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement, or sale of an asset, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5 &#x2013; 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3 &#x2013; 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_teD6KMncE0i22w8XvQgfrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_jbHZbiIKKEK3TqCEcKkYWw"
      id="Narr_aSKXF4vFXk2HV-zlZwLzyg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_LaboratoryEquipmentMember_REZg-uX-1EKwp-ERlgSV_Q"
      id="Narr_P4ZB37EvNkWOcE5lV8YlHQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_v4Q6NyrSfkq9XoHpzL1dIw"
      id="Narr_EDIpSZXuqEyVTDw-Haydyg">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndComputerEquipmentMember_3nc2z43Z7UGKrOWYMeqg2w"
      id="Narr_zCoxQqko30CUZXADKRF0wQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_A6oWH4USHUyexNBiBGQMUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;padding-top:8pt;margin:0pt 0pt 4pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the carrying values of the assets to future net undiscounted cash flows that the assets or the asset groups are expected to generate. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. No impairment losses on long-lived assets have been recorded for the years ended December&#160;31, 2023 or 2022. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Narr_nKyLOtfPKke6twSYZ5qRlw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Narr_8PyNJFWSnkm-YgDz0RqYpw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_YY4dDxIND0mIm5qBVzaNbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized in-process bacteriophage development programs for &lt;/span&gt;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections that the Company acquired through a business combination. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each&#160;year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If and when a quantitative analysis of IPR&amp;amp;D assets is required based on the result of the optional qualitative assessment, the estimated fair value of IPR&amp;amp;D assets is calculated based on the income approach, which includes discounting expected future net cash flows associated with the assets to a net present value. The fair value measurements utilized to perform the impairment analysis are categorized within Level 3 of the fair value hierarchy. Management judgment is required in the forecast of future operating results that are used in the Company&#x2019;s impairment analysis. The estimates the Company uses are consistent with the plans and estimates that it uses to manage its business. Assumptions utilized in the Company&#x2019;s income approach model include the discount rate, timing of clinical studies and regulatory approvals, the probability of success of its research and development programs, timing of commercialization of these programs, forecasted sales, gross margin, selling, general and administrative expenses, capital expenditures, as well as anticipated growth rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December&#160;31, 2023 and 2022, the Company performed the annual evaluation of its IPR&amp;amp;D assets for impairment. The Company used multi-period excess earnings method, a variation of the discounted cash flow approach. Management assumptions included expected revenue forecast, estimated expenses, rate of success, and a discount rate. The fair value of the bacteriophage development programs for &lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt; infections was greater than its carrying value as &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;a result of the quantitative analysis. Consequently, no impairment loss was recognized as of December 31, 2023 and 2022. &lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Narr_JkjSjdtfzEOsjpcXvYz2Zg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Narr_TIduGVW8PkuW1PmPnjJFYA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_xHrSl4y0q0qb6mbDnWz3rg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over the fair value of net assets acquired in an acquisition. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations. The Company performed quantitative analysis of goodwill impairment and noted no impairment as of December 31, 2023 and 2022.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Narr_k6OtbhePZEqrvOYXbZ97zw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Narr_qmBDKq_BWEiipoW_ojxt_w"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_-2C0UMoWFky6ovvkIvEsZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services). Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial.&#160;Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_Otstt6lBRkWGpdf0kSoiNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;Compensation expense related to stock options granted to employees and non-employees is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period. To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected term, expected volatility, expected dividend yield of stock and risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s own stock price as well as stock volatility of similar publicly traded peer companies. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the U.S. Securities and Exchange Commission Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The fair value of restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) is determined based on the number of units granted and the closing price of the Company&#x2019;s Common Stock as of the grant date. The Company accounts for forfeitures in the period they occur. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_gS2tYVl-WEmZgRZMMSY68A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Foreign Currency Translations and Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. &lt;span style="background:#ffffff;"&gt;Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the date of transaction or historical rates. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the quarterly &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;average exchange rate in effect during the &lt;/span&gt;year.&#160;&lt;span style="background:#ffffff;"&gt;Foreign currency translation gains and losses are recorded as other income (expense) in the Company&#x2019;s consolidated statement of operations. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently&#160;re-measured&#160;at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the consolidated statements of operations. Nonmonetary assets and liabilities are not subsequently&#160;re-measured.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <armp:GrantsAndAwardsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_2GhINmvQFUmbbky4mxe7cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grants Revenue and Other Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines whether agreements are within the scope of Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;) or other topics at the effective date of an agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also determines if grants and awards are in scope of ASC Topic 808,&#160;&lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;&#160;(&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20,&#160;&lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also considers the guidance in ASC Topic 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&#160;&lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;.&#160;&lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, the Company recognized as other receivables in its consolidated balance sheets $1.5 million and $1.9 million, respectively, related to invoiced grant amounts that have not been received. &lt;/p&gt;</armp:GrantsAndAwardsPolicyTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_GYmMI98-LUq4vo-3aWzwDQ"
      decimals="-5"
      id="Narr_Q0vQhMi9t0yX9geUmCprvQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Te5w4AY0_02NlOunnmW1LA"
      decimals="-5"
      id="Narr_fV0HC6WXjk6T7Bv66hOBAw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_yLl7iKPewkK9Iav3QO6FVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines if an arrangement contains a lease at inception. The Company currently has only operating leases. The Company recognizes a right-of-use operating lease asset and associated short- and long-term operating lease liability on its consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term.&#160;The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company&#x2019;s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available as of the lease inception date or at the date of remeasurement in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_s3S2nmIbA0KPQqQAsiZnyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. Temporary &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;differences include the differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities and net operating loss and tax credit carryforwards. The effect on deferred taxes of a change in tax rates is recognized in income (expense) in the period that includes the enactment date. The Company evaluates the likelihood that deferred tax assets will be recovered from future taxable income. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_4XwBZOwRxESRRKFd3aUbNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:8pt 0pt 4pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"&gt;Comprehensive income (loss) is composed of net loss and other comprehensive income (loss). The Company did not have other comprehensive income (loss) for the years ended December 31, 2023 and 2022, as such, the comprehensive income (loss) for these periods was equal to the net loss. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_alnktxrIB0We0KClP0-P0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin:12pt 0pt 4pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of Common Stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the Common Stock warrants, Convertible Loan, unvested restricted stock awards and restricted stock units, and stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the&#160;two-class&#160;method required for participating securities. &lt;/span&gt;Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements.&lt;span style="background:#ffffff;"&gt; The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_MSRPOu_IgEWkfiePea5CfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="color:#212529;font-style:italic;background:#ffffff;"&gt;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&#160;on Financial Instruments&lt;/i&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;&lt;/span&gt;This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023, which did not have an impact on its consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In August 2020, the FASB issued &#x200b;ASU 2020-06&#x200b;, &#x200b;&lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x200b;&#160;&lt;/i&gt;(&#x201c;ASU 2020-06&#x201d;)&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&#160;&#x200b;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;contracts that may be settled in cash or shares impact the diluted earnings per share computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;i style="font-style:italic;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/i&gt;. This ASU aligns the requirements in the ASC to the removal of certain disclosure requirements set out in Regulation S-X and Regulation S-K, announced by the SEC. The effective date for each amended topic in the ASC is either the date on which the SEC&#x2019;s removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. Early adoption is prohibited. The Company is currently evaluating the impact of adopting ASU 2023-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. This ASU requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_HIQsz7pArkWZksAD9bAUKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.27;padding-top:12pt;margin:0pt 0pt 4pt 0pt;"&gt;4. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 12pt 0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:29.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3:&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash equivalents include investments in a money market fund of zero and $0.5 million as of December 31, 2023 and 2022, respectively, which are carried at fair value and represent Level 1 financial instruments under the fair value hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;The Company&#x2019;s Convertible Loan (Note 7) is measured at fair value and remeasured at each measurement period, with changes in fair value recorded as other income (expense) in the consolidated statement of operations. The Company estimates the fair value of its Convertible Loan using a weighted probability model of various debt settlement scenarios during its term discounted to the reporting date. Conversion option scenarios are valued using option pricing &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;"&gt;models with assumptions and estimates such as volatility, expected term and risk-free interest rates. Level 3 fair value inputs include probability and timing of various settlement scenarios and selection of comparable companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;The Company estimated fair value of its Convertible Loan using the following inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:21.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21.01%-45.88%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probabilities of settlement scenarios&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0%-85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 101.1%-123.6%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.2-1.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.62%-5.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the changes in the fair value of the Company&#x2019;s Level 3 financial liabilities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Loan&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Pre Modification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Loan&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Post Modification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Net proceeds from issuance of the Convertible Loan  (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial recognition of modified Convertible Loan (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Convertible Loan exchanged  (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the determination of fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7).&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Narr__riT5gd9bU-on919MpslWw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-5"
      id="Narr_BB3H78SZMUOfEYLG43BO4Q"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_1MMPp0Q__0afmeehCm6CPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;width:21.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:21.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;21.01%-45.88%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probabilities of settlement scenarios&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0%-85%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 101.1%-123.6%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.2-1.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:78.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.62%-5.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_bjYR57IthUSFXlFcsx41wQ"
      decimals="2"
      id="Narr_FfCrkkswzEyIOb4f4Y5BlQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">21.01</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_Ge-QKxFKqUWwu7oL5XxJ8Q"
      decimals="2"
      id="Narr_N9SFlfHskUSxx-CM-02CGg"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">45.88</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_Vx583tTlMEyE357MszS1Mw"
      decimals="2"
      id="Narr_yT5JWTAchEKAurhbONU-SQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_armp_ProbabilitiesOfSettlementScenariosMember_83RZzW5ygkaAS8MPk5N2xQ"
      decimals="2"
      id="Narr_fvKnd7F3lkGRRaLS-agdYw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">85</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_4ewXEPeSJk66n83-o6k-PQ"
      decimals="2"
      id="Narr_soj4pzDVLUiS1kNFJ4EwgA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">101.1</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputOptionVolatilityMember_hUTioPDLnkObuSOBkhrCew"
      decimals="2"
      id="Narr_Nc1mCOW-gUqq6nDI9CGckQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">123.6</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_TbUu3jFyVUu5rQXxMkwPXg"
      decimals="1"
      id="Narr_96nBpaTRT0KTcJJxKRuX7A"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.2</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tsvjujuR6UaiVETAvUn3jg"
      decimals="1"
      id="Narr_VAiClTdxBEyMjA5YEmkhuA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">1.5</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_pukUqhbV7Ei-VqpNu2EWAQ"
      decimals="2"
      id="Narr_H4QHojlvIUatjSbGeSUpYA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">4.62</armp:DebtInstrumentMeasurementInputForPeriod>
    <armp:DebtInstrumentMeasurementInputForPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mHtBiNhPKE6hrpyOdzp9qA"
      decimals="2"
      id="Narr_w4R4zivZU0ak1lrsrdpWFg"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">5.39</armp:DebtInstrumentMeasurementInputForPeriod>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_2AeqMltGfkeSv8O4BgfkGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table presents a summary of the changes in the fair value of the Company&#x2019;s Level 3 financial liabilities (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Loan&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Pre Modification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convertible Loan&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Post Modification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Net proceeds from issuance of the Convertible Loan  (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Initial recognition of modified Convertible Loan (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,602&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Convertible Loan exchanged  (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 58,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:16.2pt;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) The Convertible Loan is carried at fair value in the consolidated balance sheets. As such, the principal and accrued interest are included in the determination of fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The Company concluded that the amendment to the Convertible Loan was an extinguishment for accounting purposes and the amount exchanged was the relative fair value allocated to the Convertible Loan at the extinguishment date (Note 7).&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q"
      decimals="-3"
      id="Tc_XyWKsMBtGkaymYEAHn5zUw_3_2"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">29226000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q"
      decimals="-3"
      id="Tc_d84T2QZGM027gkA8c4Adiw_4_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">35031000</armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfModifiedConvertibleLoan>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q"
      decimals="-3"
      id="Tc_DtOParW_lkSmcazU-TfpFQ_5_2"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-1757000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_pD0BUBudPUGCeexn2U5N9Q"
      decimals="-3"
      id="Tc_8kQ1wRIKnUaitrQjIHen2w_5_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">23602000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q"
      decimals="-3"
      id="Tc_z1Maa7XXgkOc_thYe0Pxtw_6_2"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-31332000</armp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAmountExchanged>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPreModificationMember_GzF6uHV_v0GW-LPFnBwm-Q"
      decimals="-3"
      id="Tc_P38hzPsmtU-Ay6ZG3sC1nA_7_2"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3863000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_armp_ConvertibleLoanPostModificationMember_C8m8rkPr3kO2_d83rkvc0A"
      decimals="-3"
      id="Tc_LpPI_VfHSkSmZ8KY66nD6A_8_5"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">58633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_lLOoxg9SYEarGooqc63O5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding securities at December 31, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 99,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares issuable upon the conversion of Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15.35pt;"&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,024,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,031,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_wJnX5QmyJ0qK8srs4UINvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 99,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares issuable upon the conversion of Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:70.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15.35pt;"&gt;&lt;td style="vertical-align:top;width:70.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44,024,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,031,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_rcx6iUYUmUmx_O6MTosjtg"
      decimals="0"
      id="Tc_ChIov5RWiEmN8wnbAiWDkg_2_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3165216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_om6vLPiiz0SKnHyQ-isXPQ"
      decimals="0"
      id="Tc_sjbMgpG9d0Gnkj9aWT1vgw_2_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3352803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_FHVNbN2hzEOd40sdvSt3oQ"
      decimals="0"
      id="Tc_ulsiy61NkkmBQb_GFIDbQg_3_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_UnvestedRestrictedStockMember_nxls9YDyCkOu7B6yakefXw"
      decimals="0"
      id="Tc_d3QF1u17U0GGwixMihMh0g_3_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_SYddo8Ixd0SHaimuYPVT7A"
      decimals="0"
      id="Tc_X5sd5uUDc0m_hpWbp8mW6Q_4_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">99666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_armp_SharesIssuableUponConversionOfConvertibleLoanMember_EWq8FVfJaUe4RYQsqoDOaw"
      decimals="0"
      id="Tc_FtIzoj8MQEm7neXCovi5zg_5_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">21293861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_pMc1sqe3X0KGAnGFAEcYPQ"
      decimals="0"
      id="Tc_avijUnDlbU2f6Njnz-kGaQ_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">19365847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_6Zjp426i-0Ws_0siDNehrA"
      decimals="0"
      id="Tc_LnHJPBReA0ebBGF-8oj9Vg_6_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">20549338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_L7-Yo3Wmqk2VbMGTfyU4jA_7_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">44024924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Tc_uHBrT1WRe0W9CvV2oahT7Q_7_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">24031807</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_h78xaErIU0GWpsbPpg0z9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Balance Sheet Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,103)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense totaled $1.0 million and $0.9 million for the&#160;years ended December 31, 2023 and 2022, respectively. Property and equipment not in use was $8.1 million and $1.0 million as of December 31, 2023 and 2022, respectively, and are included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Other receivables as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tenant improvement allowance receivable (Note 12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant and award receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,531&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Payable and Accrued Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_meUu0WB0FkSC_QjRoV_sKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 14,720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,103)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_wkZ_l3MDG06ZzDCA_d-g9w"
      decimals="-3"
      id="Tc_sZc4w4GCQEGIQv1WSEnqwQ_2_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">19678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_-vi_PXcqgkGHr5XNE2CtDg"
      decimals="-3"
      id="Tc_8npSlT3q3ky1HlLMkFEnyA_2_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">10007000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xqoolKPjOkiiQNt83POWzg"
      decimals="-3"
      id="Tc_0mSIUllSpEGJ9cFb2mIDew_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n_Dh4or6E0Sk6Dr2xnxPkA"
      decimals="-3"
      id="Tc_vGGN-RKk00aB3oV1rBpqjA_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_A6LMOqmIk0W80NtUZ42iYQ"
      decimals="-3"
      id="Tc_J0CCIWiv_EOIQNyXU9X9lA_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_fGX9O5gmiU6OnmLCkIvOIA"
      decimals="-3"
      id="Tc_f8_2gsIBdkSBR0r7l8p5gg_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">449000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_7rH9B56et06bczua6JeANw"
      decimals="-3"
      id="Tc_CzvQVTucWk-bF56W6AVZbg_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_1GHmaB3J8k2Q9CUoft7lLA"
      decimals="-3"
      id="Tc_GofmZfpVUUelUTPUJlht_g_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_YLGHTiNLCUyuFPVfB8HBWA_6_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">24380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_EXZyHkfmNE6kYYLV-A7ehA_6_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">14720000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_EZrS6XB6UECNbaRFHT0fLg_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11821000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_FY_FGoxjAUyRvYqDUX9wtw_7_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11103000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_S_3WG2Exd0eGSKIkGIbA4g_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12559000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_zGut-b3y4kGhQB2zPgQCDQ_8_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3617000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_EkUuJ6cYNkKt7LcFT37ITw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_DTy1WO_fnEKDxbnzmV9i6w"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-5"
      id="Narr_UophDDJE-EmNW6l_DrCG3g"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">900000</us-gaap:Depreciation>
    <armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-5"
      id="Narr_HpJkJA4dM0iehEDMot1NtQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">8100000</armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment>
    <armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-5"
      id="Narr_ucs7I0c58kax5yBxockfZQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000000.0</armp:PropertyAndEquipmentNotInUseIncludedInLaboratoryEquipment>
    <armp:TenantImprovementReceivableCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_rWCCYAzSOkyvCgQT7EHbgw_2_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1835000</armp:TenantImprovementReceivableCurrent>
    <armp:TenantImprovementReceivableCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_KreKgAG9bES9mhfvQRsFTA_2_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">6595000</armp:TenantImprovementReceivableCurrent>
    <armp:GrantAndAwardReceivableCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_I2EdQsIZHkimkupidC4qwA_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1528000</armp:GrantAndAwardReceivableCurrent>
    <armp:GrantAndAwardReceivableCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_RMeRtgYXGkur2RLbPQwNOA_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1936000</armp:GrantAndAwardReceivableCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ibK1zzq4fEuz7vqSY8W4zA_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3363000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_ALpNsBNPMUG7E18muUR8lQ_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">8531000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_kri3--87jUOh5lx5jDdrQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical trial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_bm1f63X8PUWSPYmtvNtcUw_2_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1585000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_sLvnH_xCak2oOy1rPBvehQ_2_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1678000</us-gaap:AccountsPayableCurrent>
    <armp:AccruedLiabilitiesClinicalTrial
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_PW1zF8Z49E2GH7bvfqL8Bw_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3021000</armp:AccruedLiabilitiesClinicalTrial>
    <armp:AccruedLiabilitiesClinicalTrial
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_V-R20RMprk-MMbZ44krzFg_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2650000</armp:AccruedLiabilitiesClinicalTrial>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_bzShjxBIx0CxFSvtr8aNbA_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1083000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_LIFj1k_L_kCjhzyMITvc1g_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1706000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ahLfU21lR06rMUUbHH92sQ_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5689000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="-3"
      id="Tc_TixAidWwoEKs1d_MiVkPAw_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">6034000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <armp:ConvertibleDebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_zMKvBapKlEmCvLyKZ2UwbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Convertible Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 10, 2023, the Company received the Convertible Loan in the aggregated amount of $30.0&#160;million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears interest at a rate of&#160;8.0% per annum and was scheduled to mature on January 10, 2024. The Convertible Credit Agreement was amended on July 10, 2023, in connection with the Credit Agreement with Innoviva to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Convertible Loan principal and accrued interest are payable at maturity. Repayment of the Convertible Loan is guaranteed by the Company&#x2019;s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&#160;The Convertible Credit Agreement provides that if there is a financing from new investors of at least $30.0&#160;million (a &#x201c;Qualified Financing&#x201d;), the outstanding principal amount of and all accrued and unpaid interest on the Convertible &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Loan shall be converted into shares of the Company&#x2019;s Common Stock, at a price per share equal to a&#160;15.0% discount to the lowest price per share for Common Stock paid by investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file a registration statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender&#x2019;s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was market value of $1.52&#160;(as may be appropriately adjusted for any stock split, combination or similar act).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, &lt;i style="font-style:italic;"&gt;Distinguish Liabilities from Equity&lt;/i&gt;, due to the fact that the Convertible Loan will predominately be settled with the Company&#x2019;s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its consolidated balance sheet, with changes in fair value recorded as other income (expenses) in the consolidated statements of operations during each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 10, 2023, in connection with the Credit Agreement with Innoviva, as discussed below, the Company amended the terms of the Convertible Credit Agreement, to, among other changes, extend the maturity of the Convertible Loan to January 10, 2025. The Company concluded that the amendment was an extinguishment for accounting purposes. The Company recognized a $1.8&#160;million gain as the change in fair value of the Convertible Loan before the extinguishment date, July 10, 2023. The Company estimated fair value of the combined transaction, the Loan and the Convertible Loan, before and after modification and calculated an extinguishment loss of $3.9&#160;million, which was recognized as other income (expense) in the consolidated statement of operations for the year ended December 31, 2023. The Company recognized a $23.6&#160;million loss as the change in fair value of the Convertible Loan from July 10, 2023 to December 31, 2023.&lt;/p&gt;</armp:ConvertibleDebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"
      decimals="-5"
      id="Narr_Uc5OB2Q4P0W_ZHrGn2e1Ig"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"
      decimals="3"
      id="Narr_6rKSJtAAHkaGL8-TTvHF8w"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark
      contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_mj_DWLuDI0Cq6OS1KhCggw"
      decimals="-5"
      id="Narr_vhTOgLBQYkSE_RngOs6GDg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">30000000.0</armp:ProceedsFromQualifiedFinancingPerAgreementBenchmark>
    <armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice
      contextRef="Duration_1_10_2023_To_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_czlMXp6LS0CZBIy4EFMggg"
      decimals="4"
      id="Narr_LiKjvvIJHkmHByuCIODHgA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.150</armp:DebtInstrumentConversionPercentOfDiscountOnSharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_1_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember__qvLrOfx6E6yXpBcKvJ0QA"
      decimals="2"
      id="Narr_IcliGnlNJk-Qxez13-t0wA"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">1.52</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g"
      decimals="-5"
      id="Narr_Akpnq0rFa026DeZWNRNS2w"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1800000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g"
      decimals="-5"
      id="Narr_4jIr2Fq13kSjIoBSSzDRRQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <armp:IncreaseDecreaseFairValueOfLiabilities
      contextRef="Duration_7_10_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_O-jDsojMjkyI7AvWBhYrOw"
      decimals="-5"
      id="Narr_Om_uwqDlc0eYbI4mS6ZMLA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">23600000</armp:IncreaseDecreaseFairValueOfLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_DxBbFZ6NhUeSHBUGk_Sziw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Long-Term Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;"&gt;On July 10, 2023, the Company entered into the Credit Agreement with Innoviva. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25.0&#160;million at an interest rate of&#160;14.0% per annum and has a maturity date of January 10, 2025. Principal and accrued interest are payable at maturity. Repayment of the Loan is guaranteed by the Company&#x2019;s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a &#x201c;material adverse effect&#x201d; as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company&#x2019;s operating budget.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Loan was initially recognized at fair value of $21.2&#160;million and subsequently recognized at the amortized cost net of debt issuance costs and debt discount of $3.8 million. Debt issuance costs and debt discount in the amount of $0.9&#160;million were amortized to interest expense using the effective interest method during the year ended December 31, 2023 . The Loan&#x2019;s annual effective interest rate was&#160;27.31% as of December 31, 2023. The Company recognized $2.6 million interest expense for the year ended December 31, 2023.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA"
      decimals="-5"
      id="Narr_iwZviXkaDEmYVNgqmKdKiA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA"
      decimals="4"
      id="Narr_5QBVBpbumE61yaOpfjYUVw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA"
      decimals="-5"
      id="Narr_tUxFfqcQM0iq5gu7lhZTaw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">21200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_EOD6WXUvMEGJWz7MVQlkjA"
      decimals="-5"
      id="Narr_rNefiGGW7E2_oHbRpd8YOQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_7_10_2023_To_7_10_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_9dt6Sr53V0Gv0pnrhurE6g"
      decimals="-5"
      id="Narr_vF0w3byII06yq-1P8XcoiQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">900000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_DebtInstrumentAxis_armp_SecuredTermLoanMember_TrUOd3F28EaQGoWWyXJpuQ"
      decimals="4"
      id="Narr_htFcvQ944k-ApGS_LfJszQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.2731</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_vk7qhJae0E6NlIpxlgYP1g"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_D-wCcyU-Rkae7U5CRpx6HA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Stockholders&#x2019; Equity (Deficit)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Private Investment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;February 2022 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;On February 9, 2022, the Company entered into the February 2022 Securities Purchase Agreement to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase&#160;9,000,000&#160;newly issued shares of the Company&#x2019;s Common Stock, at a price of&#160;$5.00&#160;per share, and warrants to purchase up to&#160;4,500,000&#160;additional shares of Common Stock, with an exercise price of&#160;$5.00&#160;per share. The stock purchases occurred in&#160;two&#160;tranches. On February 9, 2022, Innoviva purchased&#160;3,614,792&#160;shares of Common Stock and warrants to purchase&#160;1,807,396&#160;shares of Common Stock for an aggregate purchase price of approximately&#160;$18.1&#160;million. On March 31, 2022, upon the Company&#x2019;s stockholders voting in favor of the transaction, Innoviva purchased&#160;5,385,208&#160;shares of Common Stock and warrants to purchase&#160;2,692,604&#160;shares of Common Stock for an aggregate purchase price of&#160;$26.9&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Warrants issued to Innoviva expire in five years&#160;from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 31, 2023 and 2022, outstanding Common Stock warrants to purchase shares of Common Stock, all classified as equity financial instruments, are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,183,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 8, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2023 and 2022, the Company had reserved shares of its Common Stock for future issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,368,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 570,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46,402,832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,512,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_ftqcXLn_pEaX9uiZCz_1XQ"
      decimals="INF"
      id="Narr_n6ackrKCXE6eVoRhWZUGbA"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ"
      decimals="2"
      id="Narr_BofIdizhzEisdyhJU1HUhw"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ"
      decimals="INF"
      id="Narr_H2xAt9MD_EyvlSuL8SXigg"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">4500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ"
      decimals="2"
      id="Narr_1o1WLoiM_0WLlhC8I9H1Zg"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:NumberOfTranches
      contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_Izgxv6Mc7EWI9xXie2TBsQ"
      decimals="INF"
      id="Narr_joYSyJHOV0q9eWoHYns8pg"
      unitRef="Unit_Standard_tranche_1k3oA3frkU6EqwnuCcyDiw">2</armp:NumberOfTranches>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ"
      decimals="INF"
      id="Narr_Cki5zso_nUWxHFLElwJbqg"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3614792</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_AxXerjEGLUa8RmPTJVbwoA"
      decimals="INF"
      id="Narr_KZQt-CdA1Um6W_MJi7M1sw"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1807396</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_J6XtDq89NEOF9pHRjIXDTQ"
      decimals="-5"
      id="Narr_vIlMNi1TF0K0V_v18d3IEA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">18100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w"
      decimals="INF"
      id="Narr_OfJfSDlG7k2G-n0I5Vx7zA"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">5385208</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_Zq7tR4QDd0qlIGHQ77DS4g"
      decimals="INF"
      id="Narr_0sGrVV-hAEmcBYR4QZYq0Q"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2692604</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_BCzanV0zD0q1Bt5ssZnP7w"
      decimals="-5"
      id="Narr_tAaUeDMgY0OkzCdUv_zG2Q"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">26900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_5OKBdTgKlE2K5IiOBqK8nA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 31, 2023 and 2022, outstanding Common Stock warrants to purchase shares of Common Stock, all classified as equity financial instruments, are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,183,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,807,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;February 8, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,692,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;March 30, 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2023 and 2022, the Company had reserved shares of its Common Stock for future issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,368,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 570,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46,402,832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,512,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_d5V1utBQS0W089AQBKdTBg"
      decimals="INF"
      id="Tc_JvuGaIs3CEq0WQJSB7269g_2_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1183491</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_veV6l1wDOE6rGIRVVof-6Q"
      decimals="2"
      id="Tc_EI7KV1sTGUyYBgSSRIJL3g_2_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_79MM9fi5r0mpadFpZPg7sg"
      id="Tc_znkQz7hVs06ZkGEyIuKQIg_2_7">2023-10-16</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA"
      decimals="INF"
      id="Tc_zd4PRgGtTkGC5QCkUXgU1Q_3_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">993139</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_tyr5b_wy9ECTpratVa4vhQ"
      decimals="INF"
      id="Tc_iDGGw3rt-EGfulG_dgQ7vw_3_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">993139</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_DW-w-Qj9aku4ao3kn9SEoA"
      decimals="2"
      id="Tc_5VAX9kPDj0aPN7RJc-8LeQ_3_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_kwVoHQWl5EakS1pp8Dn91w"
      id="Tc_6O93pFdzgUiX8nUzDrvldQ_3_7">2025-02-11</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg"
      decimals="INF"
      id="Tc_9seWtEuGBEO3mZGgbO3JNg_4_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">7717661</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_RXIGKVqz6EWLhEi53nl4sw"
      decimals="INF"
      id="Tc_dt1alc3ECEmDkSTMSLr8-w_4_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">7717661</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_woENh8B4nUmXW42eBwqZtg"
      decimals="2"
      id="Tc_mSMgxEhSm0GPfARC5d9onQ_4_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_doi9Uq0Yh0K8BJ8ETe-s1g"
      id="Tc_oHRMHkbJeEW-dFGoUnicgg_4_7">2025-03-27</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q"
      decimals="INF"
      id="Tc_LrzTQGPJN0mfr0GCiGNXow_5_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1867912</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_XmFAWm3wPEyeDD2bMVjmxg"
      decimals="INF"
      id="Tc_YP6QY2qP5EuP5c3ntrlFuw_5_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1867912</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_YD7IU7VS4UmTthxHgr7I0Q"
      decimals="2"
      id="Tc_vtknHfSyTUGRincWFwkL1g_5_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_BXtfSrwb30eZ5SWw-b7Zuw"
      id="Tc_fDGKZlEou0CMJRE1ZmI1rw_5_7">2026-01-26</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ"
      decimals="INF"
      id="Tc_PHXk1HBpJkC4esqlmO3qhQ_6_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">4285935</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_pXWFLLYcXEmSfXZV4q_7FQ"
      decimals="INF"
      id="Tc_UrnDtQepMUGmpu1ZyWmTjA_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">4285935</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_CzEN23w3DUm5zHuhwET0wQ"
      decimals="2"
      id="Tc_mjqmC8fSw0CF3h4oBmj9HQ_6_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_5dm2L74wiEGYYudTedh7mQ"
      id="Tc_VVkzE7tYxEKzziCPAUi4VQ_6_7">2026-03-16</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg"
      decimals="INF"
      id="Tc_GgtpLLzxIUeH26JlVN_krQ_7_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1807396</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_w_tgP8EIkkGCdbFSjG9OBw"
      decimals="INF"
      id="Tc_NT-wpB0PdU67vXjlA8RLag_7_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1807396</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_XF2mmBG9r0WfwLhEwTmBjg"
      decimals="2"
      id="Tc_-g6KCRVWwUqWgBKi4PhXeA_7_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_l7DZ4uAjHkSVG38MOoqUEw"
      id="Tc_Z3FEsqYFdEStJl8cqykxlQ_7_7">2027-02-08</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg"
      decimals="INF"
      id="Tc_7axIpjJJHkiYH4oM0HmVtQ_8_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2692604</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_0FkAKCIhMkeJG_58ABDppQ"
      decimals="INF"
      id="Tc_h854TUdSWUSF_XRbhd-klQ_8_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2692604</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_1e2KJmApR0e4bFDOC01BMg"
      decimals="2"
      id="Tc_KPOYFyNQq0aN_Q7-NUE-IQ_8_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceNineMember_4KHIn5trmUGr81rnUbSvxA"
      id="Tc_QAkTh9UgR0K1Sd_tI8IAfw_8_7">2027-03-30</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA"
      decimals="INF"
      id="Tc_f3jAI87UzUCJHhbylLyfqQ_9_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_sJ5c5RHAEEuMXqt3TUVkIg"
      decimals="INF"
      id="Tc_m4K4dzV9LE6gPTB-GOlMaQ_9_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTenMember_HOY6ELr740yNRkdR-XnYMA"
      decimals="2"
      id="Tc_UWNkIu1tr0-ScPKmLsUJdQ_9_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">1680.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc__csDiGg9PkiKsCh00y4kjg_10_0"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">19365847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_89ivu3M3akiKpdKWQvAVpQ_10_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">20549338</us-gaap:ClassOfWarrantOrRightOutstanding>
    <armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_KK9zb-CsCE-P83n-eGO1MQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,368,160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 570,570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,365,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,549,338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon the conversion of Convertible Loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,293,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 46,402,832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 24,512,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_zYfBI2uqX0m-Th9isM8V6A_2_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3165216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_AwZe2QpP9kqefDPx4AEC6w_2_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3352803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_1q8OCMCB00i-LLEH5pkdLQ"
      decimals="INF"
      id="Tc_-m5xQmxm4E-vtteZZEx-SA_3_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Cx9LlceetkeHRu-h_tXn_w"
      decimals="INF"
      id="Tc_40RI5WwSmU-2ObuJoaY0sw_3_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_w7AAPtcEy0-YC6FINVeLGw_4_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">9748</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_sUL1ED2IcUCUZj7ycGiPlw_4_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">9748</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_i7XUFu_B10mLUKIJzKfMTQ"
      decimals="INF"
      id="Tc_6NpVz9clRECxLky1vk9aYA_5_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2368160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_uL_pp_97UEyeShgihirvbQ"
      decimals="INF"
      id="Tc_ZOiBnQW0zEuyzAFXhF4T_A_5_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">570570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_DIkP-9UNNkWSBLEIktbJZQ_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">19365847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_Q6HSe5cfmkSe8AMtjGQWxg_6_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">20549338</us-gaap:ClassOfWarrantOrRightOutstanding>
    <armp:SharesIssuableUponConversionOfConvertibleDebt
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_pjZ5n3ztjESlQQ3WTymJRA_7_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">21293861</armp:SharesIssuableUponConversionOfConvertibleDebt>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_PtIXlQWHCUGy8oZ4q1jYFA_8_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">46402832</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_ldzxS32sVEKmJFrUi5IXgA_8_4"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">24512459</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_zU7XkKRP5E6ClmuUqrnt3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Award Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains a 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#x2019;s Board of Directors to its employees, directors and officers and to consultants. The term of the options granted is ten years, the exercise price is the Company&#x2019;s closing price at the date of grant and the vesting period is usually four years&lt;span style="white-space:pre-wrap;"&gt;. The Company also granted RSUs under the 2016 Plan that vest over four years.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2016 Plan, the number of shares authorized for issuance is automatically increased by a number equal to 5% of the total number of shares of the Company&#x2019;s capital stock outstanding on December 31st of the preceding calendar year, or a lesser number of shares determined by the Board annually beginning from January 1, 2017 until January 1, 2026. As of December 31, 2023, there were 2,368,160 shares available for issuance under the 2016 Plan. The increase as of January 1, 2024 was 1,807,235 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has issued restricted stock awards (&#x201c;RSAs&#x201d;) under certain legacy option plans that generally vested&#160;&lt;span style="-sec-ix-hidden:Hidden_1t18bwPO80umxL4QF2kQLg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&#160;to&#160;four years&#160;based on service conditions. As of December 31, 2023, all RSAs were fully vested.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Pursuant to its 2016 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), the Company may grant or provide for the grant of rights to purchase shares of its Common Stock. The number of shares of its Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each calendar year by the lesser of 1% of the total number of shares of the Company&#x2019;s Common Stock outstanding on December 31st of the preceding calendar year and 30,000 shares, subject to the ability of the Company&#x2019;s Board of Directors to take action to reduce the size of the increase in any given year. There were no awards issued under ESPP. As of December 31, 2023, the Company had reserved 9,748 shares for future grants under the ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock option activities during the year ended December 31, 2023 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 330,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (516,353)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,176,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The aggregate intrinsic value of options at December 31, 2023 is based on the Company&#x2019;s closing stock price on that date of $3.24 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The weighted average grant date fair value of the options granted during 2023 was $1.97. The fair value of vested options during the year ended December 31, 2023 was $5.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Restricted stock awards and restricted stock unit award activities during the year ended December 31, 2023 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27.11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and Issued as Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (102,325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2023, there was $1.8 million of total unrecognized compensation expense related to unvested stock options, restricted stock awards and restricted stock units, which the Company expects to recognize over the weighted average remaining period of approximately 1.7 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.25pt;margin:0pt;"&gt;&lt;span style="font-size:11.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.35pt;margin:0pt;"&gt;&lt;span style="font-size:7.35pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The assumptions used to estimate the options fair value were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.54% - 5.54%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.65% - 4.20%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;75.40% - 116.96%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;81.81% - 85.86%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.12 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July 2023, in connection with the resignation of its former chief executive officer, the Company amended the terms of certain of his awards. As a result, the Company reversed $0.6&#160;million previously recognized stock-based compensation expense related to his forfeited and unvested awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The tables below summarize the total stock-based compensation expense (reversal) included in the Company&#x2019;s consolidated statements of operations for the periods presented (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,105&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_ZFDHBJzLP0GHlHUMt2FQew"
      id="Narr_orqEdv7ij0emLZwNIwJ1Rw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_q0GtuKNJvE-SBmuEJbJm6w"
      id="Narr_6kE8Pe4kek-zgrcjgwxvCA">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OMmauNLPakaOiKtpaNXVNg"
      decimals="2"
      id="Narr_ADJ3Op8lUkK5YLFNB-xx1g"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_No_HAmgL8EWAhkjjyjrUKA"
      decimals="INF"
      id="Narr_BoP6md_oj0Ornq2OxsoUbw"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2368160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_armp_EquityIncentivePlan2016Member_OUfmlLp-ykK4CLqXmY3zwg"
      decimals="INF"
      id="Narr_xmi8Gzc7GUGT46MSqZsNZw"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1807235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_ylEWFQLG5kiObFZVsEjhXw"
      id="Narr_6iKiBLlDxEu8YWFWQQgWoA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ"
      decimals="2"
      id="Narr_Xh2cXAws6UaeUm5E472HaQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ"
      decimals="INF"
      id="Narr_Rp0IDHWw3kGGWBS-ki5OiA"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_hlvfvDB420KnvqZl4YicDQ"
      decimals="INF"
      id="Narr_PngyjB_YzEy9gqMKIHrQxQ"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_armp_EmployeeStockPurchasePlan2016Member_dpQ0qLj7T0mpc0O2hZcCzw"
      decimals="INF"
      id="Narr_0hkEPHUXhk6W4bIVh2RWLA"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">9748</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_ZZlf1kNE-kao-JJNQCiE6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,352,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 330,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (516,353)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,165,216&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:53.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,176,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="INF"
      id="Tc_kQzNgNE_tEuqf-CBzGGysQ_8_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3352803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="2"
      id="Tc_2CNYLpxqFEqwXdl_K36u_w_8_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      id="Tc_Din5Q_Jbok2ItwJKnm45Gg_8_7">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Tc_rmQMefdMYkGuh9X2b9Etow_9_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">330266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Tc__XINCCIoi06tbigC_eOUQg_9_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">2.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Tc_EJcqOO8huUCzYaYb9NzReQ_10_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Tc_sQOVZ9liCEqUMPzutx2rZw_10_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_d62utLWZiEmbpCp9Pwuhzw_10_10"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="INF"
      id="Tc_N9_zPNpkckKRdJxT2Wycmg_11_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">516353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Tc_S9o79hA3e0WqcshNNbI_dg_11_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">4.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_Sl_i8ox0JUe5N_-_rOuqfQ_11_10"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000</armp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_7df3xEfKkE2CHuef5qClgw_12_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3165216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="2"
      id="Tc_BtKTfwrAN02c-N8TMP9Y2Q_12_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_DygDbwI4z0Kwf7Q5m0eUxg_12_7">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_Q1BIsiykOkegTYNa5DGOlA_12_10"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_7r7RV0nLd0SzCLxo6fT6YQ_13_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">3165216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="2"
      id="Tc_ugV-sVRYr0-xmd7QQf45ug_13_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_dgEQIwJcz0mMPPvikbUB0w_13_7">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_iDnG6_ttkEml3QCbpcIAMA_13_10"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="INF"
      id="Tc_DG2gu5WW5Eq5xXXfGt88Kg_14_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">2176275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="2"
      id="Tc_r7r8JOABk0mHBdPBLDFuxw_14_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tc_VkHJbPMTe0OUKkPqfL9OZw_14_7">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_k5LO2e3wGE6y3GYYkzaV_A_14_10"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA"
      decimals="2"
      id="Narr_a59dCoSHRUe2d884bvy41w"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">3.24</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="2"
      id="Narr_mynwKHdNtUeXHeTtVnhWCQ"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_SjJ_5BjVG0aGMGtsqJgMSA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_uZFiB-Sj8US6hMK4J_hwmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 129,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 27.11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and Issued as Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (102,325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg"
      decimals="INF"
      id="Tc_x0dFNI1ebkq5FMnu6fUwrg_4_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">129666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_RTjXYPDjS0SdkbmbvFFhPg"
      decimals="2"
      id="Tc_gQU__jUQX02Wpc1jR-3H7Q_4_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">27.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="INF"
      id="Tc__g9LUa06cECgd9u-H2uYlQ_5_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="2"
      id="Tc_PImw2S_umEWmeHkRrUL7vA_5_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="INF"
      id="Tc_H6NNFkX3wUenDfwsddK3Cg_6_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">27341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="2"
      id="Tc_azJnZWUGGUO7cATXSq2Stg_6_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">39.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="INF"
      id="Tc_Rui5c_9pekSjD4U2ooMugw_7_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">102325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_9FoXMNpfBEaPnF5BSCczgQ"
      decimals="2"
      id="Tc_0HaE7FcDUEW54ZV4cBcaTQ_7_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">23.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA"
      decimals="INF"
      id="Tc_mq5uDVAVJEiyFcGbm5-eCw_8_2"
      unitRef="Unit_Standard_shares_BzOXdBth9Ea2_IzgyhNgnQ">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_armp_C3jStockPlan2016Member_jKVxlRv4JEGH25rUqucEnA"
      decimals="2"
      id="Tc_JeBfx5Wgp0azqYrhKaCbPQ_8_5"
      unitRef="Unit_Divide_USD_shares_x5coYjnpSESTbYg2UfVTwg">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_vMPvUgd1bE6qVAlYHir0IA"
      decimals="-5"
      id="Narr_GuAAXAp3_Ua3LqS0uUE38A"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_4FazMg1MoUW2z0CAQf8ezg"
      id="Narr_5tXGh2cg80m3coZGwMBV1g">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_4D-uspOQ_0K_54ON_zQtRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.54% - 5.54%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.65% - 4.20%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;75.40% - 116.96%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;81.81% - 85.86%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.12 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_5gtvl7giZEGwZQOlYfq5Ow"
      decimals="2"
      id="Narr_wmevCVvk9UKiacX-ZqxERA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">5.54</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_LCqVjfMIO06J26dfzj6dGQ"
      decimals="2"
      id="Narr_NJQlOint00mhWRIRLmYCnQ"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">2.65</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_azF0LYLH0Eq4EiRxHIMZRQ"
      decimals="2"
      id="Narr_Pk-aMLBeBEagx_rqRP6OYw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">4.20</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_iZsH0I5d9UyGDhfUVO7qAw"
      decimals="2"
      id="Narr_FxHaeDdYs0OQzlxelQvRhw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">75.40</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_QO_xn3VwYkyovdqWx605rg"
      decimals="2"
      id="Narr_-ZlQ9wpc-0aaMsIzKeEzXw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">116.96</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_Fq3iw-UGaEOhlQJp0l-z4Q"
      decimals="2"
      id="Narr_xk7RIQuCKU2e6snPfN498g"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">81.81</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_HNJuosHgFUer-rys1t2UBg"
      decimals="2"
      id="Narr_z2zf3yRJI0WSyu3eHEEOZA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">85.86</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_eys6RJJzYEKEN14qoaYnug"
      decimals="2"
      id="Narr_gynRtPP0UU-PXMOh_mgDTg"
      unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg">0.12</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_wizMKQKiNEejMmObIFsIeA"
      decimals="2"
      id="Narr_W0_SmUKaPEGMRXDWkQ_u4Q"
      unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg">7.00</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_gq2pn8IK_0adzHKv0TJgmg"
      decimals="2"
      id="Narr_1nTCTdY41kWSmv5Pm8XXCA"
      unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg">5.50</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_TJiIyKEV50aTZhkCduAAZQ"
      decimals="2"
      id="Narr_bHfAGpyx50aXNvHtL53GMg"
      unitRef="Unit_Standard_Y_fj0VpBU_ik-tU54mq2mJcg">7.00</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_2O1IsRbS7UCbUL5lyytkAQ"
      decimals="0"
      id="Tc_UT6Tic0SjkuXfvYEnhKA5w_6_3"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_StatementClassOfStockAxis_armp_CommonStockOptionsMember_qhslJqPSVkGxmdvKQT37fQ"
      decimals="0"
      id="Tc_b_8ZlXNgAk-Zxf4gIuE6Dg_6_5"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0</armp:EquitySecuritiesMeasurementInput>
    <armp:ShareBasedPaymentArrangementExpenseReversed
      contextRef="Duration_7_1_2023_To_7_31_2023_1ZxqjQ4bzUil2-ClQA3E1w"
      decimals="-5"
      id="Narr_JE3xAa8veUqSKllIulsTqA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">600000</armp:ShareBasedPaymentArrangementExpenseReversed>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_2RzU8_6c60-X3sc7XkLEaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1,311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,105&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 8pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WsPyfLbv_Uq8yEsOaJ4xVA"
      decimals="-3"
      id="Tc_cI7k62InlkyAGp83-NW7mQ_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_QB0XCwT_Y0acqtRcKca_zg"
      decimals="-3"
      id="Tc_OrMvXroCSkiqc8P99sTIaA_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6DKSiFkyFkW5utHfv7wgDA"
      decimals="-3"
      id="Tc_0J1uDvFoDUG0Pt8SW5njIw_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbcT0OlsRk2u09atbDRY2w"
      decimals="-3"
      id="Tc_SsfYU5BWg0Ce-ZEIteZY-Q_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1311000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-3"
      id="Tc_U06PJdHxRk-Rnwp3oJjskA_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-3"
      id="Tc_aez6if4rJUuf5SVzPOwFtQ_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_LeXJkQ3T-UCGccyCxiNfVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Loss before income taxes consisted of the following components (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (863)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,689)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,917)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation and amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease accounting &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets before valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 86,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 80,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,818)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,510)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,043)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,678)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,120)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net operating loss carryforwards at December&#160;31, 2023 are $167.6 million and $118.9 million for federal and state income tax purposes, respectively. Federal and state net operating loss carryforwards are available to offset future taxable income, if any, and will begin to expire in 2026 and 2028, respectively. The federal net operating loss carryforwards generated after 2017 of $113.1 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s net operating loss carryforwards may be subject to a substantial annual limitation as a result of ownership changes that have occurred or could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit or eliminate the amount of net operating loss carryforwards that can be utilized to offset future taxable income. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. In general, an 'ownership change' as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not undergone an ownership change analysis pursuant to Internal Revenue Code Section 382 as of December 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain.  Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company's history of operating losses, management has determined that it is more likely than not that the Company&#x2019;s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. The Company increased its valuation allowance by approximately &lt;/span&gt;$6.3 million during the year ending December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments for tax effects of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Debt extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value adjustment on convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction, state of California and certain foreign jurisdictions. As of December 31, 2023, the Company is no longer subject to U.S. federal income tax examinations for tax years ended on or before December 31, 2019 or to California state income tax examinations for tax years ended on or before December 31, 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or credit carryforward.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have a liability for unrecognized tax benefits at December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s policy is to classify interest and penalties on uncertain tax positions as a component of tax expense. As of December&#160;31, 2023 and 2022, the Company has no accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income taxes have not been provided for undistributed earnings of the Company&#x2019;s consolidated foreign subsidiary because the parent entity would not be required to include the distribution into income as the amount would be tax free.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Tax Cuts and Jobs Act subjects a U.S. stockholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740 No. 5. Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election either to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_bchizV5oC0yJr1vlBQgdRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Loss before income taxes consisted of the following components (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (863)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,689)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69,045)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,917)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_xnODQD3KD0iTaAlpfa3G8A_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-68182</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Tc_QVVFfOD7b0SMcitnUv7tvA_3_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-32228</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_o9QZ1Q8BoUKj4oLwd8pJjA_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-863</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Tc_e9ev-dLbXEa9vBC4bywm5g_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-4689</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="0"
      id="Tc_IGTj6ZCUyke5hg4PFWhw3A_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-69045</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="0"
      id="Tc_gOlv_B-13U2wT9ZcWOCKPg_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">-36917</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_BQAahEPCvkOaSNZfkCDpCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 46,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 42,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Depreciation and amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease accounting &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,907&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets before valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 86,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 80,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (68,818)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets after valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-use asset &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,510)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,043)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,678)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,120)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_w4N46GNWd0OIYvyfOOE6HQ_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">46591</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_BApsfpcOZUOZsMI0olA8zA_4_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">42525</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_3h6uzoGPlEWTgt7GdaAmiQ_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">21431</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_liUauk4bl0W5xitDnnOoEA_5_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">19103</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_4Y6bIWiMqU6xXHy7N20Dxw_6_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2083</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_cjWwGM78gUWaBdWxzHVBLA_6_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3192</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc__TTlAuA_9UCx-anwwhxhrA_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">856</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_YiphiFVp3EOdDD6Ir8xKrg_7_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">929</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <armp:DeferredTaxAssetLeaseObligation
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_YJW4Sg1YSEiodXcnTCjiNw_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">13899</armp:DeferredTaxAssetLeaseObligation>
    <armp:DeferredTaxAssetLeaseObligation
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_4GOeTRZc9Emn8-kabmmPHA_8_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">13660</armp:DeferredTaxAssetLeaseObligation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_IBBA5UOsm0O8yaiFz1QRDA_9_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1907</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_4IgqeCTT5UKz_o7pcSMAtg_9_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1452</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_1wcA_W7AoUyUvulGlKVV6A_10_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">86767</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_8g2_d_o3yEa4yLsbU-fFcA_10_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">80861</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_fS5L0G9AxkWpDkzKflFU2w_11_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">75166</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_HDAgU5xm4UGi-MghDixlvg_11_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">68818</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_RmXfWRVvkE-6UNKvV_EMBA_12_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11601</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_ETJXSkZB50-STNOCP_VaIw_12_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12043</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <armp:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_QMnFoWsaEEmI7_uquhULhA_15_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11510</armp:DeferredTaxLiabilitiesRightOfUseAsset>
    <armp:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_m3w3ElQaFESzMlvl4AhqoQ_15_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">12043</armp:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_JNkj3inayEer3J42pxx_XQ_16_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_oJd85LUEEEKiZ2tN69lakA_16_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_OWDAIzd53k63sEd1xsRRIw_17_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">91</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_cu7RORLe-0y0pCMZ_SJxKA_18_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">14678</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_CBRjMdqz3Eq8Zk5YLLgNmg_18_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">15120</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="0"
      id="Tc_BraSibnmYU-CZkZKm3gLgw_19_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2022_Qw4a7vB9YEGxIsK18CJxBw"
      decimals="0"
      id="Tc_xubY7l4pIU2HcJIPe2RM3Q_19_6"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3077</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_ptpXGjY7OUuRjoPo1n6BLg"
      decimals="-5"
      id="Narr_upf7NmSQMU-DqYz3G8_IYA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">167600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_BOYj4BFoD02NQ0BXyjD2Vw"
      decimals="-5"
      id="Narr_8SL2Dgihf0yyqOwvEAX9vw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">118900000</us-gaap:OperatingLossCarryforwards>
    <armp:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-5"
      id="Narr_p3ticoh-QEWGPXRedpft0w"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">113100000</armp:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_BkWosntCZUC6bp5OOQmiHw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">6300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_2rts5phxuUuxja-znn-6pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adjustments for tax effects of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Debt extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fair value adjustment on convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(0.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_oOcnS8p5AkCPIpbLNfPUuw_3_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_sq59wBoaUUK-Ie2Xaf8itw_3_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_61A09QBsREyfFPbesCyrAw_5_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_iStdUXlIJkiTfwNhxNULPw_5_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_DUACe0bo4EuXkMaO9MwVbQ_6_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_KuqTckBfuU6GI3YLMcNylA_6_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_tveWsydA3UaKiH88q5dbCw_7_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.093</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_fpJEKgHWmke7iJu-cP_WfQ_7_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.286</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_7iUfD1FT1UGVf_VEXbXMOA_8_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.012</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_ZBoa1PlXmky0JK_MvRE4IA_8_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.000</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtExtinguishmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_gt2wEz84CkKqPSkA6JEoCQ_9_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_3QwFt-FP-EeY-ZjdJ-uprA_9_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_asEgsXJzfUquLHkVnLVMNQ_10_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.066</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent>
    <armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_K1RVTeIivU-O2d7DA0GoyQ_10_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.000</armp:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueAdjustmentOnConvertibleDebtPercent>
    <armp:IncomeTaxRateReconciliationPermanentDifferences1
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_CRk97ZvfXk-3tK9AcPAoDw_11_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">-0.019</armp:IncomeTaxRateReconciliationPermanentDifferences1>
    <armp:IncomeTaxRateReconciliationPermanentDifferences1
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_8OQ1f8XvokqBfIcXzLrBoA_11_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.005</armp:IncomeTaxRateReconciliationPermanentDifferences1>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="3"
      id="Tc_k4t0Qwkk30u4xv1une-ZNA_12_2"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="3"
      id="Tc_fKVQE8rBv0q4N3bD3UHUyQ_12_4"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_uIkFw4EnvECztjdgQV6ssA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced on January&#160;1, 2012 and in April 2020, the Company amended the lease (&#x201c;2020 Lease Amendment&#x201d;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, was approximately $1.9&#160;million, and base rent increases by&#160;3% annually and will be $2.5&#160;million by the end of the amended term. In addition, the Company received a&#160;six-month&#160;rent abatement in 2020. In accordance with authoritative guidance, the Company re-measured the lease liability in April 2020 to be&#160;$11.7&#160;million &lt;span style="background:#ffffff;"&gt;using an&lt;/span&gt; incremental borrowing rate of&#160;12.89% and related&#160;right of use asset was&#160;$11.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Concurrent with the Company&#x2019;s execution of the 2020 Lease Amendment, an irrevocable letter of credit in the amount of $1.2&#160;million was delivered to the landlord. Starting on February 1, 2022, and each&#160;year thereafter, the letter of credit will be reduced by&#160;20% of the then outstanding amount. As of December 31, 2023, the letter of credit was $0.7&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, California (the &#x201c;2021 Lease&#x201d;). The 2021 Lease payment start date was May 1, 2022 and the total lease term is for&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;16 years&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;and runs through 2038. Monthly rent for 2022 and 2023 are fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.25&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$7.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, of which the Company received &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$5.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million during the year ended December 31, 2023. The Company is responsible for construction costs over such allowance. Out of pocket expenses to be incurred by the Company are considered noncash lease payments, and included in the lease liability and the right-of-use asset when the amount can be reasonably estimated. As of November 16, 2022, the Company finalized the budget to complete the construction of the 2021 Lease. Accordingly, the Company re-measured the lease liability and related right-of-use asset as of November 30, 2022, using an incremental borrowing rate of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;11.8%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. The re-measured lease liability of the 2021 Lease as of November 16, 2022 was&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$37.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million, and the related right of use asset was&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$33.8&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million&lt;/span&gt;. During the year ended December 31, 2023, the budget was modified and the Company re-measured the lease liability. As a result, the lease liability and related right-of-use asset increased by approximately $2.7&#160;million, using an incremental borrowing rate of&#160;14.27%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the total amount of $5.0&#160;million to the landlord in 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum annual lease payments under the Company&#x2019;s noncancelable operating leases as of December&#160;31, 2023, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 43,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 75,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Plus: estimated short-term variable lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: amount representing interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,729)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of operating lease obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 38,064&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,481)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Noncurrent operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="color:#222222;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Rent expense was $7.4 million and $6.3 million for the years ended December 31, 2023 and 2022, respectively. Total cash payments for operating leases as included in the consolidated statements&#160;of cash flows during the&#160;years ended December 31, 2023 and 2022 were $3.5 million and $2.7 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#x2019;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#x2019;s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on its consolidated results of operations or financial position.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <armp:OperatingLeaseBaseRent
      contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA"
      decimals="-5"
      id="Narr_l6gfYzCbaEqz0KcE0hRyLg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1900000</armp:OperatingLeaseBaseRent>
    <armp:AnnualIncreaseInRentPercentage
      contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA"
      decimals="4"
      id="Narr_pp5PuOONlEC83TvvVsc37w"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.03</armp:AnnualIncreaseInRentPercentage>
    <armp:OperatingLeaseBaseRentEndOfLeaseTerm
      contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA"
      decimals="-5"
      id="Narr_gGttgN8k1k2Aerxv9m5lSA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2500000</armp:OperatingLeaseBaseRentEndOfLeaseTerm>
    <armp:LeaseAndRentalAbatementCreditPeriod
      contextRef="Duration_4_1_2020_To_4_30_2020_kj1uyOfbXEK3B8FpVr_clA"
      id="Narr_1ufPUiN1yEmUwGN9-_7l1Q">P6M</armp:LeaseAndRentalAbatementCreditPeriod>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag"
      decimals="-5"
      id="Narr_QzD3XIogpku7YAA2HRlqbQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag"
      decimals="4"
      id="Narr_P6YR06LqgUma7ssdHbDoag"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.1289</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_4_30_2020_UNFte8RVoE6ZrpjTKZgoag"
      decimals="-5"
      id="Narr_bEwGKMT4zEu9QjLLpY4h2Q"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">11000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ"
      decimals="-5"
      id="Narr_MjNOJztpO0yiBsNBQMsdsg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <armp:AnnualReductionOfStandbyLetterOfCredit
      contextRef="As_Of_4_30_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_7kTQIwZHy0GF_raLc16bKQ"
      decimals="2"
      id="Narr_fxSPU-EPO0KxVvGXeYiPaw"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.20</armp:AnnualReductionOfStandbyLetterOfCredit>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_12_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_CashMember_hIBa8orrkkC3OY4OCziUrg"
      decimals="-5"
      id="Narr_KkULLBxvjk2dqOFmEbf36Q"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">700000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"
      id="Narr_43AsfAWYvUq4ec08l7hf0A">P16Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <armp:BaseAnnualRentToBePaidYearThree
      contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"
      decimals="-4"
      id="Narr_LhkVSvCGvUqNoPj4sLAbIA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">250000</armp:BaseAnnualRentToBePaidYearThree>
    <armp:MaximumAllowanceForTenantImprovementsReceivable
      contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"
      decimals="-5"
      id="Narr_0spqDFJ_dUe6e9o-7V47Pw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">7300000</armp:MaximumAllowanceForTenantImprovementsReceivable>
    <armp:ProceedsFromTenantAllowances
      contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"
      decimals="-5"
      id="Narr_cDTcRFFGv0mDlW5U1f6sjg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5400000</armp:ProceedsFromTenantAllowances>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_11_30_2022_sJyIDh6BPkGLuZGEzoAROA"
      decimals="3"
      id="Narr_MS0IBZaglUyAl1EpScpDLA"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.118</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ"
      decimals="-5"
      id="Narr_MORI1LzvSkm0f9FUfOgvmA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">37000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_26_2022_U1W3mab9Y0-IQHao3EiKSQ"
      decimals="-5"
      id="Narr_2x912IcoJE-3E-hD_QC_dw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">33800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_W3KAPH27bUOTG34yisjgIw"
      decimals="-5"
      id="Narr_bqaMoVGCP06pl9dbPOiV8A"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2700000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_armp_OfficeAndResearchAndDevelopmentSpaceLosAngelesCaliforniaMember_VjefCaiPsUS7e-BdlXj-7g"
      decimals="4"
      id="Narr_pI6NwauBr0e0W5Sef2z-0g"
      unitRef="Unit_Standard_pure_FkY1xKiQh02Ur-V1ot2eVw">0.1427</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="As_Of_10_28_2021_Mn28IUDEGUyLE4ndCmMAHw"
      decimals="-5"
      id="Narr_09EYEYQGW0qUA7R6xtUD6w"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb__HwMVQt_SUGZlReAe5S9uQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum annual lease payments under the Company&#x2019;s noncancelable operating leases as of December&#160;31, 2023, are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 43,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 75,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Plus: estimated short-term variable lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: amount representing interest &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,729)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of operating lease obligations &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 38,064&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,481)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Noncurrent operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 28,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_VNSN0z3W6U6oJE3R_mpH0w_3_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">9899000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ABFMPcHiGEGohesU_WRFPw_4_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5307000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_Z1eFkDbSNkOELn5OVd0k-A_5_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ilZZ8XOg306JTWvID1X4Kw_6_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5452000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_rDs1qGKMok6Led2AMMYRWQ_7_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_enWczY-igUqx00DSujairg_8_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">43181000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_sU_pF9Nj30SDrbAWB9y7_w_9_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">75179000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <armp:ShortTermVariableLeasePaymentAmount
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_r6P5bZpnI0e_8Vmw6OsV5Q_10_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5386000</armp:ShortTermVariableLeasePaymentAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ixMNj6j_fkiMwTfsR6798Q_11_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">31729000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_lESde4s8DUyDm4U9J1CYZg_12_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">38064000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_5AGGTjvh6k2uxnvrm7X4Sw_13_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">9481000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ArvY5oTVc0e2EwTwKPYN9w"
      decimals="-3"
      id="Tc_ddaWr_7ewEybxJK--Xyemw_14_3"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">28583000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_yqnLNrq0lkyp24QOLRnD5g"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">7400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-5"
      id="Narr_Q7B2Sxz7_0KL0kbhhqTUTw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">6300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_5XYN55ifbEqzC3R8cB3keA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">3500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-5"
      id="Narr_gjUM4bBtCEmuwBAYuLnMjA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">2700000</us-gaap:OperatingLeasePayments>
    <armp:AwardTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_pniofC5Gc0u7y_RvLAAJZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Grants and Awards &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;MTEC Grant&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 15, 2020, the Company entered into a Research Project Award agreement (the &#x201c;MTEC Agreement&#x201d;) with the Medical Technology Enterprise Consortium (&#x201c;MTEC&#x201d;), pursuant to which the Company received a $15.0 million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. &lt;span style="background:#ffffff;"&gt;On September 29, 2022, the MTEC Agreement was modified to increase the total award by &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$16.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase&#160;1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of &lt;/span&gt;the Company's&lt;span style="background:#ffffff;"&gt; therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Staphylococcus aureus&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;&#160;bacteremia infections. The MTEC Agreement specifies that the grant is paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The MTEC Agreement is effective through October 30, 2024.&#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue in the statement of operations when related costs are incurred. The Company recognized $4.5 million and $5.5 million in grant revenue from the MTEC Agreement during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the Company had $1.5&#160;million and $1.9&#160;million as awards receivable from MTEC, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CFF Therapeutics Development Award&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 13, 2020, the Company entered into an award agreement (the &#x201c;Award Agreement&#x201d;) with Cystic Fibrosis Foundation (&#x201c;CFF&#x201d;), pursuant to which the Company received a Therapeutics Development Award of $5.0 million (the &#x201c;CFF Award&#x201d;). The CFF Award has funded a portion of the Company&#x2019;s Phase 1b/2a clinical trial of the&#160;&lt;i style="font-style:italic;"&gt;Pseudomonas aeruginosa &lt;/i&gt;(&#x201c;&lt;i style="font-style:italic;"&gt;P. aeruginosa&lt;/i&gt;&#x201d;)&lt;i style="font-style:italic;"&gt; &lt;/i&gt;phage candidate, AP-PA02, as a treatment for&lt;i style="font-style:italic;"&gt; &lt;/i&gt;airway infections in people with cystic fibrosis (&#x201c;CF&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The CFF Award is payable to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement. The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The last milestone in the amount of $0.3 million was achieved in December 2023 and was received in January 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an &#x201c;Interruption&#x201d;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the &#x201c;CF Field&#x201d;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company&#x2019;s material failure to achieve certain development milestones. The Company&#x2019;s payment obligations survive the termination of the Award Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, &#x201c;&lt;i style="font-style:italic;"&gt;Significant Accounting Policies&#x201d;&lt;/i&gt;, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. During year ended December 31, 2023 and 2022, the Company recognized $0.3 and $1.0 million as credits to research and development expenses related to the CFF Award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred. &lt;/p&gt;</armp:AwardTextBlock>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_6_15_2020_To_6_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_MA9PVOA_T0GwtfbjiWZ8PQ"
      decimals="-5"
      id="Narr_KHtbM5MY00CXZmt1pd_YjA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">15000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <armp:IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther
      contextRef="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A"
      decimals="-5"
      id="Narr_teRIoIVhRE-xv6Mdt_e2aw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1300000</armp:IncreaseDecreaseInExpectedRevenueNotFromContractWithCustomerOther>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_9_29_2022_To_9_29_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_-a5u5QsY5kmcuYTP_00H_A"
      decimals="-5"
      id="Narr_rfXfATVMjUij8rSKfGTRWg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">16300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_NeQe2I2uKUmdVatAsYayIg"
      decimals="-5"
      id="Narr_2eTMhhGH7USUgKaruyEXMA"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">4500000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_oTLYGAZfJ0aCfMIzYcDvAw"
      decimals="-5"
      id="Narr_GFA39qi0d02vgl0asrqh9A"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5500000</us-gaap:RevenueNotFromContractWithCustomer>
    <armp:UnbilledAwardReceivable
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_FHhuhYDYgkSEqnz0dDB17g"
      decimals="-5"
      id="Narr_wdKqkaY25E695sXaLyc1BQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1500000</armp:UnbilledAwardReceivable>
    <armp:UnbilledAwardReceivable
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_8VpuTm72C0OqZUC8eh9aAg"
      decimals="-5"
      id="Narr_iun91xu4HE6PvvF20M9G-A"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1900000</armp:UnbilledAwardReceivable>
    <armp:ThresholdDevelopmentAward
      contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QOYAQImRME-BHccqHOTQxA"
      decimals="-5"
      id="Narr_nNjZaAyRgUK4U3_R1baM_Q"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">5000000.0</armp:ThresholdDevelopmentAward>
    <armp:AwardReceivable
      contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_yQKRGpMabkGpnWs-0mIn_g"
      decimals="-5"
      id="Narr_KiaaWRpTRkKD9Or07vkcmg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000000.0</armp:AwardReceivable>
    <armp:AwardReceivable
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Wv6oSPAXP0CJ0UiTo6AKQA"
      decimals="-5"
      id="Narr_d6TouCqvLU-BSD1Kpi0WAQ"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">300000</armp:AwardReceivable>
    <armp:AwardAgreementInterruptionPeriod
      contextRef="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_QVyakBDhtUmt0Ago8wBrDA"
      id="Narr_HeehXC6TxkSNDZEIkj7djg">P360D</armp:AwardAgreementInterruptionPeriod>
    <armp:ResearchAndDevelopmentBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_lPXHo7biDEeQ7_vk8pbcAQ"
      decimals="-5"
      id="Narr_0HeIiKgQt0SUUkzjbRniGg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">300000</armp:ResearchAndDevelopmentBenefit>
    <armp:ResearchAndDevelopmentBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_MuuXgJmTa0iJw2pEu82wXw"
      decimals="-5"
      id="Narr_oaq6l1JOjEas7bVhMU-bnw"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">1000000.0</armp:ResearchAndDevelopmentBenefit>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      id="Tb_x6SMmGWp2EeARuROBbPitQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Employee Retirement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s employees participate in an employee retirement plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986, as amended. All of the Company&#x2019;s employees who meet minimum eligibility requirements are eligible to participate in the plan. The Company did match contributions of $0.2 million and zero to the 401(k)&#160;plan for the&#160;years ended December 31, 2023 and 2022.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_UiCogkF3l0WPMUCLZuXAgQ"
      decimals="-5"
      id="Narr_U1wfrjz0M0yjmitzHMOSwg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_nlDaCqg9WkGZZ7Jr5rJR2w"
      decimals="-5"
      id="Narr_j2fVdGA4Z0aZCpWx1PEgzg"
      unitRef="Unit_Standard_USD_OrVoLtesKUiSQYaqvByQdg">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w"
      id="Narr_fZaPi8HP90aSsvtSj3MBsw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w"
      id="Narr_6ltz8xwErEyCM8VmZXZm4Q">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w"
      id="Narr_nkHY5MRF90CIXmxzws1HtA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_RT8U7wac7UyGg_ghaMpj_w"
      id="Narr_rR3ogs6PTku9xk4rIvyhVg">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
